02788000000000577000450099100020000070000020000270600020000470100020000609100090
00081300048000171510028000650350010000934800056001034800052001590300029002119300
00500240117000600245085000500251935001000256031000300266032000200269036000600271
04200020027720000020027906500090028112200030029004800140029304800140030704800240
03210490031003450490031003760490030004070490027004370490046004640490046005100490
02600556049002600582049003900608049003900647049003300686049003100719049002100750
04900310077104300720080204300720087404300720094654003880101854004020140654003960
1808541000602204#1#0#i#1#20110406#Revista Brasileira de Hematologia e Hemoterapi
a#Rev. bras. hematol. hemoter#1516-8484#Associação Brasileira de Hematologia e H
emoterapia e da#Sociedade Brasileira de Transplante de Medula Óssea#Rev. Bras. H
ematol. Hemoter.#RBHH#other#decs#1516-8484#33#1#20111#1#0#20110200#22#^les^hSuma
rio#^lpt^hSumário#^len^hTable of Contents#^lpt^cRBHH050^tArtigo Especial#^len^cR
BHH050^tSpecial article#^lpt^cRBHH140^tRelato de Caso#^len^cRBHH140^tCase Report
#^lpt^cRBHH160^tImagens em Hematologia Clínica#^len^cRBHH160^tImages in Clinical
 Hematologic#^lpt^cRBHH190^tEditoriais#^len^cRBHH190^tEditorials#^lpt^cRBHH330^t
Comentários Científicos#^len^cRBHH330^tScientific Commentaries#^len^cRBHH340^tOr
iginal Articles#^len^cRBHH350^tReview Articles#^len^cRBHH360^tForum#^len^cRBHH37
0^tMemory Lectures#^les^tRev. Bras. Hematol. Hemoter.^vvol.33^nno.1^cSão Paulo^m
feb.^a2011#^lpt^tRev. Bras. Hematol. Hemoter.^vvol.33^nno.1^cSão Paulo^mfev.^a20
11#^len^tRev. Bras. Hematol. Hemoter.^vvol.33^nno.1^cSão Paulo^mFeb.^a2011#^t<a 
rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Cr
eative Commons License" style="border-width:0" src="http://i.creativecommons.org
/l/by-nc/3.0/80x15.png" /></a> Todo el contenido de esta revista, excepto dónde 
está identificado, est&#225; bajo una <a rel="license" href="http://creativecomm
ons.org/licenses/by-nc/3.0/">Licencia Creative Commons</a>^les#^t<a rel="license
" href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Commo
ns License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc/3.0
/80x15.png" /></a> Todo o conteúdo deste periódico, exceto onde est&#225 identif
icado, est&#225; licenciado sob uma <a rel="license" href="http://creativecommon
s.org/licenses/by-nc/3.0/">Licen&#231;a Creative Commons</a>^lpt#^t<a rel="licen
se" href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Com
mons License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc/3
.0/80x15.png" /></a> All the contents of this journal, except where otherwise no
ted, is licensed under a <a rel="license" href="http://creativecommons.org/licen
ses/by-nc/3.0/">Creative Commons Attribution License</a>^len#BY-NC##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a01.htm#S#o#1#1#text#1#20
110411#115512#v33n1a01.htm#36##
00862000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000200092049000800094158000300102030002900105
03100030013403200020013706500090013901400070014803500100015512300020016523700270
0167012011100194010004100305070006100346070005600407002001300463#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#h#2#1#text#1#ed#en#br1.1#1#4.0#ILUS#1#R
BHH190#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f1^l2#1516-8484#1#10.5581/
1516-8484.20110001#The evolution of the "Revista Brasileira de Hematologia e Hem
oterapia" to meet the challenges of a new era^len#^rND^1A01 A02^nCármino Antonio
 de^sSouza#Universidade Estadual de Campinas^iA01^cCampinas^sSP^pBrazil#Associaç
ão Brasileira de Hematologia e Hemoterapia^iA02#v33n1a01.htm##
00869000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000200092049000800094158000300102030002900105
03100030013403200020013706500090013901400070014803500100015512300020016523700270
0167012011800194010004100312070006100353070005600414002001300470#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#f#3#1#text#1#ed#en#br1.1#1#4.0#ILUS#1#R
BHH190#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f1^l2#1516-8484#1#10.5581/
1516-8484.20110001#<b>The evolution of the "Revista Brasileira de Hematologia e 
Hemoterapia" to meet the challenges of a new era</b>^len#^rND^1A01 A02^nCármino 
Antonio de^sSouza#Universidade Estadual de Campinas^iA01^cCampinas^sSP^pBrazil#A
ssociação Brasileira de Hematologia e Hemoterapia^iA02#v33n1a01.htm##
00991000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000200105049000800107158000300115
03000280011803100030014603200020014906500090015101400070016003500100016712300020
01772370027001790120111002060100041003170700063003580700058004210020013004790080
08900492#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a01.htm#S#l#4#1#text#1#^m
Feb.^a2011#ed#en#br1.1#1#4.0#ilus#1#RBHH190#nd#Rev. bras. hematol. hemoter#33#1#
20110200#^f1^l2#1516-8484#1#10.5581/1516-8484.20110001#The evolution of the "Rev
ista Brasileira de Hematologia e Hemoterapia" to meet the challenges of a new er
a^len#^rND^1A01 A02^nCármino Antonio de^sSouza#^iA01^1Universidade Estadual de C
ampinas^cCampinas^sSP^pBrazil#^iA02^1Associação Brasileira de Hematologia e Hemo
terapia#v33n1a01.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttex
t&pid=S1516-84842011000100001##
00343000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704011400070002001300184#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#5#1#text#32#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIALS</b></font></p>
     ^cY#v33n1a01.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#6#2#text#32#<p>&nbsp;</p>     ^cY#v33
n1a01.htm##
00443000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704021400070002001300284#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#7#3#text#32#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>The evolution of the 
"Revista Brasileira de Hematologia e Hemoterapia" to meet the challenges of a ne
w era</b></font></p>     ^cY#v33n1a01.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#8#4#text#32#<p>&nbsp;</p>     ^cY#v33
n1a01.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#9#5#text#32#<p>&nbsp;</p>     ^cY#v33
n1a01.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704012100071002001300192#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#10#6#text#32#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>C&aacute;rmino Antonio de Souza</b></f
ont></p>     ^cY#v33n1a01.htm##
00457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704022700071002001300298#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#11#7#text#32#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Universidade Estadual de Campinas  - UNIC
AMP, Campinas (SP), Brazil. President, Associa&ccedil;&atilde;o Brasileira de He
matologia e Hemoterapia</font></p>     ^cY#v33n1a01.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011500071002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#12#8#text#32#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></font></
p>     ^cY#v33n1a01.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#13#9#text#32#<p>&nbsp;</p>     ^cY#v3
3n1a01.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#14#10#text#32#<p>&nbsp;</p>     ^cY#v
33n1a01.htm##
01375000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704114400072002001301216#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#15#11#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The "Revista Brasileira de Hematologia e
 Hemoterapia" (RBHH) is the only journal in our specialty south of the equator a
nd one of two hematology and transfusion medicine journals in Latin America. It 
is the result of the progression from the old "Boletim da Sociedade Brasileira d
e Hematologia e Hemoterapia" and it is in its 12th year of existence. In this pe
riod our journal evolved naturally, but this development was less than what the 
scientific community wants and needs. Data presented by "Scopus" (<a href="http:
//www.scimagojr.com" target="_blank">www.scimagojr.com</a>) show the remarkable 
evolution of scientific publications in our field within the international setti
ng. We publish at a pace similar to the Chinese and more than India and all othe
r emerging countries. In just ten years the number of indexed publications in Br
azil grew about 10-fold, that is at a rate of 15-20% per annum. Moreover, it is 
important to note that only about 20% of these publications are linked to intern
ational trails; i.e., 80% are wholly Brazilian publications. </font></p>     ^cY
#v33n1a01.htm##
01591000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704136000072002001301432#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#16#12#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">All this is great, but still small. In s
pite of being the world's eighth largest economy, Brazilian Hematology and Trans
fusion Medicine is in 16<sup>th</sup> place in the ranking of indexed publicatio
ns. There is no doubt, as the supplements on our two annual congresses (SBTMO an
d Hemo-ABHH) have demonstrated for several years now, as have data from European
 and North American Congresses, in particular the American Society of Hematology
 (ASH) that qualified national scientific production grows in the wake of the gr
owth of the country because of increasing support from government grant agencies
 such as Conselho Nacional de Desenvolvimento Cient&iacute;fico e Tecnol&oacute;
gico (CNPq), Funda&ccedil;&atilde;o de Amparo &agrave; Pesquisa do Estado de S&a
tilde;o Paulo (FAPESP) etc, and postgraduate programs, among many other reasons.
 In the last ten years or so, the RBHH has shown a very positive trend both quan
titatively and qualitatively. The number of submissions has grown significantly 
and the publication indicators such as number of papers submitted and accepted, 
the time between submission and acceptance, the expansion of the editorial board
, number of publications annually, the quality of the publication, submission on
-line etc. are improving constantly. </font></p>     ^cY#v33n1a01.htm##
00853000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704062200072002001300694#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#17#13#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The presentation of the journal improved
 greatly and it is more pleasing for both readers and authors. But all this is l
ittle and is not enough. A reassessment of national scientific journals of Coord
ena&ccedil;&atilde;o de Aperfei&ccedil;oamento de Pessoal de N&iacute;vel Superi
or (CAPES) was a true "cold shower" for the vast majority of periodicals, includ
ing the RBHH. The editors reacted and there is a consensus that perhaps the deva
luation was exaggerated, but undoubtedly this serves as a warning to make change
s and improvements.</font></p>     ^cY#v33n1a01.htm##
01564000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704133300072002001301405#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#18#14#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">As everyone knows, 2010 was the first ye
ar of the formal foundation of the ABHH. Many challenges appeared during the mer
ging process with "what should be done with the RBHH" being one of these very im
portant decisions. After discussions within the Board of Directors, Editorial Po
licy Board, Executive and Scientific Editors, and many conversations and consult
ations with colleagues who have vast experience in publications in Europe, USA a
nd Latin America, we believe that the RBHH has an important role in the continue
d education of the Hematology and Transfusion Medicine community, but that it sh
ould move towards offering a real and valid publishing option for physicians, he
alth professionals and scientists working in this area. Thus a process to identi
fy problems and find employees who could assist us in this transformation began.
 A working committee was created of technical advisors together with the editori
al staff of the journal including professionals from Scientific Electronic Libra
ry Online (SciELO), Biblioteca Virtual em Sa&uacute;de (BIREME), a native Englis
h-speaking translator, the companies Trasso (which has worked with the marketing
 and publishing of the RBHH for several years) and GN1 (specialized in indexing 
in PubMed.</font></p>     ^cY#v33n1a01.htm##
00972000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704074100072002001300813#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#19#15#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Additionally, it was decided that the jo
urnal should have its own Digital Object Identifier (DOI) - a number used to uni
quely identify electronic documents - among other things. It was decided that al
l articles published in 2010 (Volume 32) should be translated to English in orde
r to index the journal in PubMed Central, thereby gaining international visibili
ty with access to the articles. In this process the authors are not being reques
ted to translate their articles, just to check and approve the final text. Even 
so, the biggest challenges have been saved for 2011. It will not be easy and we 
are not totally sure of being successful in this venture. </font></p>     ^cY#v3
3n1a01.htm##
00771000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704054000072002001300612#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#20#16#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Basically this editorial is the way I fo
und to communicate a request to the Brazilian Hematology and Transfusion Medicin
e community. Volume 33 (2011) must be the best ever. There will be two versions 
of all regular issues (six per year): one printed in English and the other, an e
lectronic edition, in both English and Portuguese. All papers should be submitte
d and published in English, as this, we believe, is central to being accepted by
 PubMed and ISI. </font></p>     ^cY#v33n1a01.htm##
01885000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704165400072002001301726#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#21#17#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The structure of the journal is being ca
refully reviewed and adjusted to comply, when possible, with all the requirement
s for future indexing in the most important databases of the world. Through the 
directors of the association and other researchers, contact was made with many c
olleagues in countries of the northern hemisphere and Latin America asking them 
to submit papers and participate in the peer review process. Nationally, we invi
ted colleagues, who can decisively contribute to this process, to participate in
 this transformation. What we know is that we must be more competent and accurat
e in all phases of the complex editing process. Only then will we have a competi
tive and respected scientific journal. Indeed, Brazil has a significant number o
f doctors, health professionals and researchers who can and should publish in th
e RBHH and I know that the success of this decision depends on the scientific co
mmunity as I know, as a professor and academic that we always try to publish in 
the best journals. This is natural and correct. But this time, we may decide to 
be only observers of our history or, who knows, to change the history. An intern
ationally distributed journal of hematology and transfusion medicine can create 
scientific opportunities not only for Brazilians, but for many emerging countrie
s around the world. Within the new global scenario, Brazil is becoming a promine
nt player within the scientific setting; we have much participation and Brazilia
n Universities are being recognized as some of the world's best, we cannot passi
vely wait. </font></p>     ^cY#v33n1a01.htm##
00778000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704054700072002001300619#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#22#18#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The ABHH would like to catalyze this ine
xorable advance in Brazilian Hematology and Transfusion Medicine. The RBHH can b
e the scientific vehicle of this ongoing transformation that will be carried on 
by our young researchers guided by our medical colleagues, professors and scient
ists. Let's invest in these changes because we believe in them. I urge everyone 
to participate. Prepare your manuscript, submit to the RBHH, participate in this
 challenge that is ours.</font></p>     ^cY#v33n1a01.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#23#19#text#32#<p>&nbsp;</p>     ^cY#v
33n1a01.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#24#20#text#32#<p>&nbsp;</p>     ^cY#v
33n1a01.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018600072002001300258#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#25#21#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img src
="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b>    ^
cY#v33n1a01.htm##
00277000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004600072002001300118#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#26#22#text#32#<br>   C&aacute;rmino A
ntonio de Souza    ^cY#v33n1a01.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#27#23#text#32#<br>   Centro de Hemato
logia e Hemoterapia de Campinas, Universidade Estadual de Campinas - Unicamp    
^cY#v33n1a01.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012000072002001300192#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#28#24#text#32#<br>   Rua Carlos Chaga
s, 450, Cidade Universit&aacute;ria "Prof. Zeferino Vaz" Distrito de Bar&atilde;
o Geraldo    ^cY#v33n1a01.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004800072002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#29#25#text#32#<br>   13083-878 - Camp
inas (SP), Brazil    ^cY#v33n1a01.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003700072002001300109#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#30#26#text#32#<br>   Phone: 55 19-352
1 8740    ^cY#v33n1a01.htm##
00316000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008500072002001300157#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#31#27#text#32#<br>   <a href="mailto:
carmino@unicamp.br">carmino@unicamp.br</a></font></p>     ^cY#v33n1a01.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009100072002001300163#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#32#28#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Submitted: 1/24/2011    ^cY#v33n1a01.htm
##
00276000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004500072002001300117#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#33#29#text#32#<br>   Accepted: 1/2420
11</font></p>     ^cY#v33n1a01.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#34#30#text#32#<p>&nbsp;</p>     ^cY#v
33n1a01.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#35#31#text#32#<p>&nbsp;</p>     ^cY#v
33n1a01.htm##
00455000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022400072002001300296#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a01.htm#S#p#36#32#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" target="_b
lank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_blank">ww
w.scielo.br/rbhh</a> </font></p>     ^cY#v33n1a01.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a02.htm#S#o#1#1#text#1#20
110411#115513#v33n1a02.htm#36##
00826000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000200092049000800094158000300102030002900105
03100030013403200020013706500090013901400070014803500100015512300020016523700270
0167012002900194010003800223070010900261070005700370002001300427#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#h#2#1#text#1#ed#en#br1.1#1#4.0#ILUS#2#R
BHH190#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f3^l3#1516-8484#1#10.5581/
1516-8484.20110002#A new era, a new journal^len#^rND^1A01 A02^nFrederico Luiz^sD
ulley#Universidade de São Paulo^iA01^1Faculdade de Medicina^2Departamento de Clí
nica Médica^cSão Paulo^sSP^pBrazil#Sociedade Brasileira de Transplante de Medula
 Óssea^iA02#v33n1a02.htm##
00833000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000200092049000800094158000300102030002900105
03100030013403200020013706500090013901400070014803500100015512300020016523700270
0167012003600194010003800230070010900268070005700377002001300434#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#f#3#1#text#1#ed#en#br1.1#1#4.0#ILUS#2#R
BHH190#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f3^l3#1516-8484#1#10.5581/
1516-8484.20110002#<b>A new era, a new journal</b>^len#^rND^1A01 A02^nFrederico 
Luiz^sDulley#Universidade de São Paulo^iA01^1Faculdade de Medicina^2Departamento
 de Clínica Médica^cSão Paulo^sSP^pBrazil#Sociedade Brasileira de Transplante de
 Medula Óssea^iA02#v33n1a02.htm##
00955000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000200105049000800107158000300115
03000280011803100030014603200020014906500090015101400070016003500100016712300020
01772370027001790120029002060100038002350700111002730700059003840020013004430080
08900456#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a02.htm#S#l#4#1#text#1#^m
Feb.^a2011#ed#en#br1.1#1#4.0#ilus#2#RBHH190#nd#Rev. bras. hematol. hemoter#33#1#
20110200#^f3^l3#1516-8484#1#10.5581/1516-8484.20110002#A new era, a new journal^
len#^rND^1A01 A02^nFrederico Luiz^sDulley#^iA01^1Universidade de São Paulo^2Facu
ldade de Medicina^3Departamento de Clínica Médica^cSão Paulo^sSP^pBrazil#^iA02^1
Sociedade Brasileira de Transplante de Medula Óssea#v33n1a02.htm#Internet^ihttp:
//www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100002##
00343000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704011400070002001300184#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#5#1#text#32#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIALS</b></font></p>
     ^cY#v33n1a02.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#6#2#text#32#<p>&nbsp;</p>     ^cY#v33
n1a02.htm##
00361000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704013200070002001300202#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#7#3#text#32#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>A new era, a new jour
nal</b></font></p>     ^cY#v33n1a02.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#8#4#text#32#<p>&nbsp;</p>     ^cY#v33
n1a02.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#9#5#text#32#<p>&nbsp;</p>     ^cY#v33
n1a02.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011100071002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#10#6#text#32#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Frederico Luiz Dulley</b></font></p>  
   ^cY#v33n1a02.htm##
00521000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704029100071002001300362#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#11#7#text#32#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Departamento de Cl&iacute;nica M&eacute;d
ica, Faculdade de Medicina, Universidade de S&atilde;o Paulo - USP S&atilde;o Pa
ulo (SP), Brazil. President, Sociedade Brasileira de Transplante de Medula &Oacu
te;ssea</font></p>     ^cY#v33n1a02.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011500071002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#12#8#text#32#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></font></
p>     ^cY#v33n1a02.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#13#9#text#32#<p>&nbsp;</p>     ^cY#v3
3n1a02.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#14#10#text#32#<p>&nbsp;</p>     ^cY#v
33n1a02.htm##
00630000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704039900072002001300471#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#15#11#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Recently we completed 30 years of hemato
poietic stem cell transplantation in Brazil. We have over 50 transplant centers,
 totaling approximately 320 beds and more than 20,000 transplants have been perf
ormed. We have the third largest bone marrow donor registry in the world, with a
round two million donors registered.</font></p>     ^cY#v33n1a02.htm##
00787000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704055600072002001300628#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#16#12#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Over the years, the 'Boletim da Sociedad
e Brasileira de Hematologia e Hemoterapia', which began in 1973, has accompanied
 all these changes. It became a journal with scientific articles in 1984 (ISSN) 
and changed in 1999 to 'Revista Brasileira de Hematologia e Hemoterapia' (RBHH).
 In 2000 the journal was indexed by SciELO, in 2008 by Scopus and now in 2011 we
 will have the first issue published in English, thus improving international vi
sibility of our Brazilian works. </font></p>     ^cY#v33n1a02.htm##
00496000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704026500072002001300337#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#17#13#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Moreover, this is the official publicati
on of the Brazilian Society of Bone Marrow Transplantation, where many transplan
t groups have published their clinical and laboratory studies.</font></p>     ^c
Y#v33n1a02.htm##
00509000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704027800072002001300350#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#18#14#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">We are very fortunate that Professor Mil
ton Artur Ruiz set his body and mind during long years of his life improving thi
s journal to where today we are proud to publish works related to our area.</fon
t></p>     ^cY#v33n1a02.htm##
00476000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704024500072002001300317#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#19#15#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">It was not without help that the journal
 has evolved because many other doctors have helped by sending their articles, g
iving suggestions and supporting the RBHH.</font></p>     ^cY#v33n1a02.htm##
00551000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704032000072002001300392#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#20#16#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The RBHH, in 2010, edited a special issu
e in which the Brazilian guidelines for hematopoietic stem cell transplantation 
were published. This important publication counted on the participation of all t
ransplant centers across the country.</font></p>     ^cY#v33n1a02.htm##
00773000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704054200072002001300614#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#21#17#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Finally, I would like to congratulate th
e President of the Associa&ccedil;&atilde;o Brasileira de Hematologia e Hemotera
pia, Professor C&aacute;rmino Antonio de Souza, who with his friendship and unde
rstanding always encouraged the development of the RBHH. The Sociedade Brasileir
a de Transplante de Medula &Oacute;ssea fully supports the initiative to interna
tionalize the journal with the objective of promoting and improving Brazilian tr
ansfusion medicine.</font></p>     ^cY#v33n1a02.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010600072002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#22#18#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Congratulations to all!</font></p>     ^
cY#v33n1a02.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#23#19#text#32#<p>&nbsp;</p>     ^cY#v
33n1a02.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#24#20#text#32#<p>&nbsp;</p>     ^cY#v
33n1a02.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018600072002001300258#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#25#21#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img src
="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b>    ^
cY#v33n1a02.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003600072002001300108#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#26#22#text#32#<br>   Frederico Luiz D
ulley    ^cY#v33n1a02.htm##
00357000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012600072002001300198#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#27#23#text#32#<br>   Departamento de 
Cl&iacute;nica M&eacute;dica da Faculdade de Medicina da Universidade de S&atild
e;o Paulo - USP    ^cY#v33n1a02.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005900072002001300131#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#28#24#text#32#<br>   Av. Dr. En&eacut
e;as Carvalho de Aguiar, 155    ^cY#v33n1a02.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005600072002001300128#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#29#25#text#32#<br>   05403-900 - S&at
ilde;o Paulo (SP), Brazil    ^cY#v33n1a02.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003700072002001300109#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#30#26#text#32#<br>   Phone: 55 11 306
1 5544    ^cY#v33n1a02.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007900072002001300151#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#31#27#text#32#<br>   <a href="mailto:
onco@csf.com.br">onco@csf.com.br</a></font></p>     ^cY#v33n1a02.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009100072002001300163#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#32#28#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Submitted: 2/14/2011    ^cY#v33n1a02.htm
##
00277000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004600072002001300118#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#33#29#text#32#<br>   Accepted: 2/15/2
011</font></p>     ^cY#v33n1a02.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#34#30#text#32#<p>&nbsp;</p>     ^cY#v
33n1a02.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#35#31#text#32#<p>&nbsp;</p>     ^cY#v
33n1a02.htm##
00455000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022400072002001300296#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a02.htm#S#p#36#32#text#32#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" target="_b
lank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_blank">ww
w.scielo.br/rbhh</a> </font></p>     ^cY#v33n1a02.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a03.htm#S#o#1#1#text#1#20
110411#115513#v33n1a03.htm#34##
00821000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000200092049000800094158000300102030002900105
03100030013403200020013706500090013901400070014803500100015512300020016523700270
0167012004300194010003200237070010400269070004900373002001300422#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#h#2#1#text#1#ed#en#br1.1#1#4.0#ILUS#3#R
BHH190#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f3^l3#1516-8484#1#10.5581/
1516-8484.20110003#The AIBE and the new phase of the RBHH^len#^rND^1A01 A02^nÂng
elo^sMaiolino#Universidade Federal do Rio de Janeiro^iA01^1Departamento de Clíni
ca Médica^cRio de Janeiro^sRJ^pBrazil#Associazione Italo-Brasiliana Di Ematologi
a^iA02#v33n1a03.htm##
00828000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000200092049000800094158000300102030002900105
03100030013403200020013706500090013901400070014803500100015512300020016523700270
0167012005000194010003200244070010400276070004900380002001300429#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#f#3#1#text#1#ed#en#br1.1#1#4.0#ILUS#3#R
BHH190#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f3^l3#1516-8484#1#10.5581/
1516-8484.20110003#<b>The AIBE and the new phase of the RBHH</b>^len#^rND^1A01 A
02^nÂngelo^sMaiolino#Universidade Federal do Rio de Janeiro^iA01^1Departamento d
e Clínica Médica^cRio de Janeiro^sRJ^pBrazil#Associazione Italo-Brasiliana Di Em
atologia^iA02#v33n1a03.htm##
00950000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000200105049000800107158000300115
03000280011803100030014603200020014906500090015101400070016003500100016712300020
01772370027001790120043002060100032002490700106002810700051003870020013004380080
08900451#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a03.htm#S#l#4#1#text#1#^m
Feb.^a2011#ed#en#br1.1#1#4.0#ilus#3#RBHH190#nd#Rev. bras. hematol. hemoter#33#1#
20110200#^f3^l3#1516-8484#1#10.5581/1516-8484.20110003#The AIBE and the new phas
e of the RBHH^len#^rND^1A01 A02^nÂngelo^sMaiolino#^iA01^1Universidade Federal do
 Rio de Janeiro^2Departamento de Clínica Médica^cRio de Janeiro^sRJ^pBrazil#^iA0
2^1Associazione Italo-Brasiliana Di Ematologia#v33n1a03.htm#Internet^ihttp://www
.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100003##
00343000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704011400070002001300184#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#5#1#text#30#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIALS</b></font></p>
     ^cY#v33n1a03.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#6#2#text#30#<p>&nbsp;</p>     ^cY#v33
n1a03.htm##
00376000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704014700070002001300217#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#7#3#text#30#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>The AIBE and the new 
phase of the RBHH </b></font></p>     ^cY#v33n1a03.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#8#4#text#30#<p>&nbsp;</p>     ^cY#v33
n1a03.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#9#5#text#30#<p>&nbsp;</p>     ^cY#v33
n1a03.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011100071002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#10#6#text#30#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>&Acirc;ngelo Maiolino</b></font></p>  
   ^cY#v33n1a03.htm##
00487000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704025700071002001300328#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#11#7#text#30#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Departamento de Cl&iacute;nica M&eacute;d
ica, Universidade Federal do Rio de Janeiro - UFRJ, Rio de Janeiro (RJ) Brazil. 
President Associazione Italo-Brasiliana Di Ematologia</font></p>     ^cY#v33n1a0
3.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011500071002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#12#8#text#30#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></font></
p>     ^cY#v33n1a03.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#13#9#text#30#<p>&nbsp;</p>     ^cY#v3
3n1a03.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#14#10#text#30#<p>&nbsp;</p>     ^cY#v
33n1a03.htm##
00699000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704046800072002001300540#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#15#11#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The Associa&ccedil;&atilde;o &Iacute;tal
o-Brasileira de Hematologia (Italian-Brazilian Association of Hematology - AIBE)
 was founded on 04/02/2004 in the city of Genoa, Italy. The primary objectives o
f the AIBE are to promote the integration of the hematology service of both coun
tries through an exchange of healthcare professionals and the development of res
earch of common interest.</font></p>     ^cY#v33n1a03.htm##
00582000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704035100072002001300423#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#16#12#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Since its inception, the AIBE chose the 
Revista Brasileira de Hematologia e Hemoterapia (RBHH) as its official vehicle f
or the publication of scientific articles. For us, it is a great pleasure to par
ticipate in this new phase of the journal, its internationalization.</font></p> 
    ^cY#v33n1a03.htm##
00574000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704034300072002001300415#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#17#13#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The AIBE can be a powerful tool in this 
process, as publishing the journal in English and its future indexing by Pubmed 
will increase, without any doubt whatsoever, the interest of colleagues and Ital
ian researchers in publishing their articles in the journal.</font></p>     ^cY#
v33n1a03.htm##
00848000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704061700072002001300689#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#18#14#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">It is important to note that at present 
Italy is ranked second in the world in the number of scientific publications in 
the field of hematology. The Italian members, who helped found the AIBE are also
 in the leadership and participate in several cooperative groups that develop hi
ghly important research protocols. Today, cooperation and multicenter studies ar
e of fundamental importance in the development of medical science and Italy has 
a long tradition and has advanced greatly in recent years in the development of 
these studies.</font></p>     ^cY#v33n1a03.htm##
00485000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704025400072002001300326#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#19#15#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The AIBE and the RBHH are partners in th
is process and we believe that there will be a great synergy in actions that und
oubtedly will lead to great steps forward for both.</font></p>     ^cY#v33n1a03.
htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#20#16#text#30#<p>&nbsp;</p>     ^cY#v
33n1a03.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#21#17#text#30#<p>&nbsp;</p>     ^cY#v
33n1a03.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018600072002001300258#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#22#18#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img src
="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b>    ^
cY#v33n1a03.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003600072002001300108#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#23#19#text#30#<br>   &Acirc;ngelo Mai
olino    ^cY#v33n1a03.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006700072002001300139#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#24#20#text#30#<br>   Hospital Univers
it&aacute;rio Clementino Fraga Filho    ^cY#v33n1a03.htm##
00285000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005400072002001300126#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#25#21#text#30#<br>   Rua Professor Ro
dolpho Paulo Rocco, 255    ^cY#v33n1a03.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011800072002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#26#22#text#30#<br>   Servi&ccedil;o d
e Hematologia, 4Âº andar, sala 4A12, Cidade Universit&aacute;ria, Ilha do Fund&a
tilde;o    ^cY#v33n1a03.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005300072002001300125#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#27#23#text#30#<br>   21941-913 - Rio 
de Janeiro (RJ) Brazil    ^cY#v33n1a03.htm##
00292000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006100072002001300133#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#28#24#text#30#<br>   Phone: 55 21 - 2
5622462 Mobile: 55 21-81116663    ^cY#v33n1a03.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009300072002001300165#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#29#25#text#30#<br>   <a href="mailto:
maiolino@hucff.ufrj.br">maiolino@hucff.ufrj.br</a></font></p>     ^cY#v33n1a03.h
tm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009100072002001300163#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#30#26#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Submitted: 2/14/2011    ^cY#v33n1a03.htm
##
00277000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004600072002001300118#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#31#27#text#30#<br>   Accepted: 2/14/2
011</font></p>     ^cY#v33n1a03.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#32#28#text#30#<p>&nbsp;</p>     ^cY#v
33n1a03.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#33#29#text#30#<p>&nbsp;</p>     ^cY#v
33n1a03.htm##
00454000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022300072002001300295#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a03.htm#S#p#34#30#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" target="_b
lank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_blank">ww
w.scielo.br/rbhh</a></font></p>     ^cY#v33n1a03.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#o#1#1#text#1#20
110411#115515#v33n1a04.htm#68##
01090000000000445000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000200092049000800094158000300102030002900105
03100030013403200020013706500090013901400070014803500100015512300020016523700270
01670120066001940100026002600100023002860100027003090700066003360700099004020700
12100501117000600622072000300628002001300631#v33n1#V:\SciELO\serial\rbhh\v33n1\m
arkup\v33n1a04.htm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ILUS#4#RBHH330#nd#Rev. Bras.
 Hematol. Hemoter.#33#1#20110200#^f4^l5#1516-8484#1#10.5581/1516-8484.20110004#H
ematopoietic stem cell transplantation for Hodgkin's disease^len#^rND^1A01^nPoli
ana^sPatah#^rND^1A02^nLuis^sFayad#^rND^1A03^nMarcos de^sLima#Hospital Sírio Liba
nês^iA01^1Cancer Center^cSão Paulo^sSP^pBrazil#The University of Texas^iA02^1M.D
. Anderson Cancer Center^2Department of Lymphoma and Myeloma^pUSA#The University
 of Texas^iA03^1M.D. Anderson Cancer Center^2Department of Stem Cell Transplanta
tion and Cell Therapy^pUSA#other#10#v33n1a04.htm##
01097000000000445000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000200092049000800094158000300102030002900105
03100030013403200020013706500090013901400070014803500100015512300020016523700270
01670120073001940100026002670100023002930100027003160700066003430700099004090700
12100508117000600629072000300635002001300638#v33n1#V:\SciELO\serial\rbhh\v33n1\m
arkup\v33n1a04.htm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ILUS#4#RBHH330#nd#Rev. Bras.
 Hematol. Hemoter.#33#1#20110200#^f4^l5#1516-8484#1#10.5581/1516-8484.20110004#<
b>Hematopoietic stem cell transplantation for Hodgkin's disease</b>^len#^rND^1A0
1^nPoliana^sPatah#^rND^1A02^nLuis^sFayad#^rND^1A03^nMarcos de^sLima#Hospital Sír
io Libanês^iA01^1Cancer Center^cSão Paulo^sSP^pBrazil#The University of Texas^iA
02^1M.D. Anderson Cancer Center^2Department of Lymphoma and Myeloma^pUSA#The Uni
versity of Texas^iA03^1M.D. Anderson Cancer Center^2Department of Stem Cell Tran
splantation and Cell Therapy^pUSA#other#10#v33n1a04.htm##
01221000000000469000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000200105049000800107158000300115
03000280011803100030014603200020014906500090015101400070016003500100016712300020
01772370027001790120066002060100026002720100023002980100027003210700068003480700
10100416070012300517117000600640072000300646002001300649008008900662#v33n1#V:\Sc
iELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#l#4#1#text#1#^mFeb.^a2011#oa#en#br1
.1#1#4.0#ilus#4#RBHH330#nd#Rev. bras. hematol. hemoter#33#1#20110200#^f4^l5#1516
-8484#1#10.5581/1516-8484.20110004#Hematopoietic stem cell transplantation for H
odgkin's disease^len#^rND^1A01^nPoliana^sPatah#^rND^1A02^nLuis^sFayad#^rND^1A03^
nMarcos de^sLima#^iA01^1Hospital Sírio Libanês^2Cancer Center^cSão Paulo^sSP^pBr
azil#^iA02^1The University of Texas^2M.D. Anderson Cancer Center^3Department of 
Lymphoma and Myeloma^pUSA#^iA03^1The University of Texas^2M.D. Anderson Cancer C
enter^3Department of Stem Cell Transplantation and Cell Therapy^pUSA#other#10#v3
3n1a04.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S151
6-84842011000100004##
00354000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012500070002001300195#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#5#1#text#54#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>SCIENTIFIC COMMENTARY</b>
</FONT></p>     ^cY#v33n1a04.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#6#2#text#54#<p>&nbsp;</p>     ^cY#v33
n1a04.htm##
00398000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704016900070002001300239#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#7#3#text#54#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Hematopoietic stem ce
ll transplantation for Hodgkin's disease</b></font></p>     ^cY#v33n1a04.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#8#4#text#54#<p>&nbsp;</p>     ^cY#v33
n1a04.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#9#5#text#54#<p>&nbsp;</p>     ^cY#v33
n1a04.htm##
00400000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704017000071002001300241#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#10#6#text#54#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Poliana Patah<sup>I</sup>; Luis Fayad<
sup>II</sup>; Marcos de Lima<sup>III</sup></b></font></p>     ^cY#v33n1a04.htm##
00396000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704016600071002001300237#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#11#7#text#54#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Cancer Center, Hospital S&iac
ute;rio   Liban&ecirc;s, S&atilde;o Paulo (SP), Brazil    ^cY#v33n1a04.htm##
00364000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704013400071002001300205#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#12#8#text#54#<br>        <sup>II</sup
>Department of Lymphoma and   Myeloma, The University of Texas   M.D. Anderson C
ancer Center,   USA       ^cY#v33n1a04.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704016100071002001300232#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#13#9#text#54#<br>     <sup>III</sup>D
epartment of Stem Cell Transplantation   and Cell Therapy, The   University of T
exas M.D. Anderson Cancer Center, USA</font></p>     ^cY#v33n1a04.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011500072002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#14#10#text#54#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></font><
/p>     ^cY#v33n1a04.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#15#11#text#54#<p>&nbsp;</p>     ^cY#v
33n1a04.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#16#12#text#54#<p>&nbsp;</p>     ^cY#v
33n1a04.htm##
01291000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704106000072002001301132#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#17#13#text#54#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Autologous stem cell transplantation (aH
SCT) has been considered the "gold standard" treatment following salvage chemoth
erapy for relapsed or refractory Hodgkin's lymphoma. The first randomized trial 
comparing conventional chemotherapy and aHSCT was published in 1993.<sup>(1)</su
p> Forty patients received BCNU, etoposide, cytarabine, and melphalan (BEAM)  as
 conditioning regimen followed by aHSCT or "mini-BEAM" in the chemotherapy arm. 
The results indicated the superiority of transplantation. The European Group for
 Blood and Marrow Transplantation published a confirmatory randomized study (n =
 161 patients), in which dexa-BEAM was chosen for the chemotherapy control arm.<
sup>(2)</sup> With a median follow-up of 3 years, event-free survival (EFS) was 
55% versus 34% for the transplant and chemotherapy arms, respectively, reinforci
ng the recommendation that high-dose chemotherapy with aHSCT rescue should be th
e treatment of choice for relapsed or refractory disease.</font></p>     ^cY#v33
n1a04.htm##
01107000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704087600072002001300948#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#18#14#text#54#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Several models have been employed to pre
dict outcomes in patients with relapsed/refractory Hodgkin's lymphoma who underg
o high-dose chemotherapy followed by aHSCT. Moskowitz et al. proposed the use of
 three factors: complete remission &lt; 1 year, presence of B-symptoms and extra
nodal disease at the time of relapse. Patients with 0-1 risk factors had an EFS 
of 83%, while patients with 2 and 3 factors had EFS of 27% and 10%, respectively
.<sup>(3)</sup> More recently, functional studies to assess chemosensitivity (FI
; PET scan, Ga67 scan) performed before transplant have become excellent prognos
tic tools.<sup>(4,5)</sup> Persistence of positive FI before aHSCT identifies a 
group of patients who will have a worse outcome than those with negative FI afte
r finishing salvage chemotherapy.</font></p>     ^cY#v33n1a04.htm##
01660000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704142900072002001301501#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#19#15#text#54#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Chemosensitive disease has better outcom
es with autologous transplants, given the higher relapse and toxicity rates amon
g chemorefractory patients. Several approaches have been proposed to overcome th
is barrier, including tandem transplants. In this approach, patients are submitt
ed to two sequential autologous transplants, usually within one to three months.
 An investigation by the German Hodgkin Lymphoma Study Group enrolled 43 primary
 refractory or very unfavorable relapse patients. Patients received salvage chem
otherapy with ifosfamide, etoposide and woxorubicin (IVA), underwent stem cell c
ollection and two tandem transplants.<sup>(6)</sup> Conditioning regimen for the
 first aHSCT consisted of CBV plus mitoxantrone, while the second transplant was
 with cytarabine 6 g/m<sup>2</sup>, melphalan 140 mg/m<sup>2</sup> and total bod
y irradiation of 12 Gy, or busulfan 12 mg/kg. Four patients had no response to s
alvage therapy, seven patients received only one transplant and 32 patients comp
leted the initially planned treatment. Among the 24 patients with unfavorable re
lapses, 20 achieved complete remission and among the 19 patients with induction 
failure, ten were in remission. The 2-year survival from the date of progression
 was 65% for the whole study population, while it was 74% for the 32 patients wh
o completed the treatment.</font></p>     ^cY#v33n1a04.htm##
01795000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704156400072002001301636#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#20#16#text#54#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The Groupe d'Etude des Lymphomes de l'Ad
ulte (GELA) treated 245 patients with relapsed disease - 150 of which had primar
y refractory or very high-risk disease - with a protocol including IVA or MINE f
or salvage, and single or tandem autologous transplants.<sup>(7)</sup> Patients 
with standard risk received the first transplant only, while primary refractory 
or very high-risk patients proceeded to tandem transplants. The first conditioni
ng regimen included cyclophosphamide, carmustine, etoposide and mitoxantrone, wh
ile the second transplant, performed 45 to 90 days after the first, used total b
ody irradiation at 12 Gy, cytarabine and melphalan, or busulfan-based preparativ
e regimen, similar to the German study. With a median follow-up of 51 months, in
 an intention to treat analysis, 5-year progression-free and overall survival we
re 46% and 57% for high-risk patients, and 73% and 85% for the standard risk gro
up, respectively. In addition, the 5-year overall survival for patients with che
motherapy-resistant disease was 46% (as opposed to an expected rate of 30% obser
ved in previous studies). These results would suggest that patients who do not r
espond well to salvage chemotherapy or for early (occurring less than 1 year aft
er achievement of remission), unfavorable relapses, tandem transplants may be su
perior to standard single aHSCT. There are several unresolved controversies surr
ounding this issue, however, and this recommendation is not universally accepted
.</font></p>     ^cY#v33n1a04.htm##
01153000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704092200072002001300994#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#21#17#text#54#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Allogeneic transplants have been explore
d in younger patients who relapse following aHSCT, but are still considered expe
rimental and should be performed within a clinical trial. There is still controv
ersy as to whether a graft-versus Hodgkin's disease effect exists. However, long
-term survival rates of 10-40% have been reported for selected patients. For tho
se without matched related or unrelated donors, several centers are investigatin
g haploidentical (mismatched related) or unrelated cord blood transplantation. O
utcomes are better for chemosensitive patients, especially for those that achiev
e complete remission prior to transplant.<sup>(8-10)</sup> Non-transplant option
s include everolimus, and the immunotoxin, brentuximab vedotin drugs that have r
ecently been shown to have activity in relapsing/refractory Hodgkin's lymphoma.<
/font></p>     ^cY#v33n1a04.htm##
00531000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704030000072002001300372#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#22#18#text#54#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In summary, patients with relapsed disea
se should be referred for transplantation. Hodgkin's lymphoma, however, remains 
a challenging disease for the minority of patients that are not cured after init
ial chemotherapy.</font></p>     ^cY#v33n1a04.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#23#19#text#54#<p>&nbsp;</p>     ^cY#v
33n1a04.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010000072002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#24#20#text#54#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY#v33
n1a04.htm##
00569000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704032400074002001300398#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#25#21#text#54#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Linch DC, Winfield D, G
oldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with aut
ologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease:
 Results of a BNLI randomised trial. Lancet. 1993;341(8852):1051-4.    ^cY#v33n1
a04.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#26#22#text#54#</font></p>     ^cY#v33
n1a04.htm##
00851000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704060600074002001300680#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#27#23#text#54#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Schmitz N, Pfistner B, 
Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, M&uuml;ller 
P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V; 
German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Gr
oup for Blood and Marrow Transplantation. Aggressive conventional chemotherapy c
ompared with high-dose chemotherapy with autologous haemopoietic stem-cell trans
plantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. La
ncet. 2002;359(9323):2065-71.    ^cY#v33n1a04.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#28#24#text#54#</font></p>     ^cY#v33
n1a04.htm##
00596000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704035100074002001300425#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#29#25#text#54#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Moskowitz CH, Nimer SD,
 Zelenetz AD, Trippett T, Hedrick EE, et al. A 2-step comprehensive high-dose ch
emoradiotherapy second-line program for relapsed and refractory Hodgkin disease:
 analysis by intent to treat and development of a prognostic model.  Blood. 2001
;97(3):616-23.    ^cY#v33n1a04.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#30#26#text#54#</font></p>     ^cY#v33
n1a04.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704031200074002001300386#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#31#27#text#54#4#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Jabbour E, Hosing C, Ay
ers G, Nunez R, Anderlini P, Pro B, et al.  Pretransplant positive positron emis
sion tomography/gallium scans predict poor outcome in patients with recurrent/re
fractory Hodgkin lymphoma. Cancer. 2007;109(12):2481-9.    ^cY#v33n1a04.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#32#28#text#54#</font></p>     ^cY#v33
n1a04.htm##
00579000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704033400074002001300408#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#33#29#text#54#5#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Moskowitz AJ, Yahalom J
, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, et al. Pretransplantation 
functional imaging predicts outcome following autologous stem cell transplantati
on for relapsed and refractory Hodgkin lymphoma. Blood. 2010; 116(23):4934-7.   
 ^cY#v33n1a04.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#34#30#text#54#</font></p>     ^cY#v33
n1a04.htm##
00691000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704044600074002001300520#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#35#31#text#54#6#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Josting A, Rudolph C, M
apara M, Glossmann JP, Sieniawski M, Sieber M, et al. Cologne high-dose sequenti
al chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large 
multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 
2005;16(1):116-23. Erratum in: Ann Oncol. 2008;19(8):1515. Sieniawski, M &#91;co
rrected to Sieniawski, M&#93;    ^cY#v33n1a04.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002100072002001300093#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#36#32#text#54#.</font></p>     ^cY#v3
3n1a04.htm##
00799000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704055400074002001300628#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#37#33#text#54#7#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Morschhauser F, Brice P
, Ferm&eacute; C, Divin&eacute; M, Salles G, Bouabdallah R, Sebban C, Voillat L,
 Casasnovas O, Stamatoullas A, Bouabdallah K, Andr&eacute; M, Jais JP, Cazals-Ha
tem D, Gisselbrecht C; GELA/SFGM Study Group. Risk-adapted salvage treatment wit
h single or tandem autologous stem-cell transplantation for first relapse/refrac
tory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the
 GELA/SFGM study group. J Clin Oncol. 2008;26(36):5980-7.    ^cY#v33n1a04.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#38#34#text#54#</font></p>     ^cY#v33
n1a04.htm##
00599000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704035400074002001300428#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#39#35#text#54#8#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Thomson KJ, Peggs KS, S
mith P, Cavet J, Hunter A, Parker A,  et al. Superiority of reduced-intensity al
logeneic transplantation over conventional treatment for relapse of Hodgkin's ly
mphoma following autologous stem cell transplantation. Bone Marrow Transplant. 2
008;41(9):765-70.    ^cY#v33n1a04.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#40#36#text#54#</font></p>     ^cY#v33
n1a04.htm##
00750000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704050500074002001300579#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#41#37#text#54#9#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Sureda A, Robinson S, C
anals C, Carella AM, Boogaerts MA, Caballero D,  et al. Reduced-intensity condit
ioning compared with conventional allogeneic stem-cell transplantation in relaps
ed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party
 of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;
26(3):455-62. Co&ccedil;mment in: J Clin Oncol. 2008;26(24):4045-6; author reply
 4046-7.    ^cY#v33n1a04.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#42#38#text#54#</font></p>     ^cY#v33
n1a04.htm##
00648000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704040200075002001300477#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#43#39#text#54#10#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Anderlini P, Saliba R
, Acholonu S, Giralt SA, Andersson B, Ueno NT, et al. Fludarabine-melphalan as a
 preparative regimen for reduced-intensity conditioning allogeneic stem cell tra
nsplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. And
erson Cancer Center experience. Haematologica. 2008;93 (2):257-64.    ^cY#v33n1a
04.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002100072002001300093#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#44#40#text#54# </font></p>     ^cY#v3
3n1a04.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#45#41#text#54#<p>&nbsp;</p>     ^cY#v
33n1a04.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#46#42#text#54#<p>&nbsp;</p>     ^cY#v
33n1a04.htm##
00418000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018700072002001300259#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#47#43#text#54#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img src
="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b>     
^cY#v33n1a04.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002800072002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#48#44#text#54#<br>   Poliana Patah   
 ^cY#v33n1a04.htm##
00302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007100072002001300143#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#49#45#text#54#<br>   Hospital S&iacut
e;rio Liban&ecirc;s, Centro de Oncologia    ^cY#v33n1a04.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005100072002001300123#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#50#46#text#54#<br>   Rua Dona Adma Ja
fet, 91 - Bela Vista    ^cY#v33n1a04.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005700072002001300129#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#51#47#text#54#<br>   01308-050 - S&at
ilde;o Paulo ( SP), Brazil    ^cY#v33n1a04.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003700072002001300109#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#52#48#text#54#<br>   Phone: 55 11 315
5-0200    ^cY#v33n1a04.htm##
00320000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008900072002001300161#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#53#49#text#54#<br>   <a href="mailto:
polipatah@gmail.com ">polipatah@gmail.com </a></font></p>     ^cY#v33n1a04.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009100072002001300163#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#54#50#text#54#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Submitted: 1/25/2011    ^cY#v33n1a04.htm
##
00277000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004600072002001300118#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#55#51#text#54#<br>   Accepted: 1/25/2
011</font></p>     ^cY#v33n1a04.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#56#52#text#54#<p>&nbsp;</p>     ^cY#v
33n1a04.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#57#53#text#54#<p>&nbsp;</p>     ^cY#v
33n1a04.htm##
00455000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022400072002001300296#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a04.htm#S#p#58#54#text#54#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" target="_b
lank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_blank">ww
w.scielo.br/rbhh</a> </font></p>     ^cY#v33n1a04.htm##
00757000000000349000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730100018000890100
02000107010001400127010001700141010001800158810000600176012014900182030000700331
06500090033806400050034703100040035203200050035601400070036186500090036800200130
0377035001000390801000700400#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.h
tm#S#c#59#1#text#10#1#^rND^sLinch^nDC#^rND^sWinfield^nD#^rND^sGoldstone^nAH#^rND
^sMoir^nD#^rND^sHancock^nB#^rND^sMcMillan^nA#et al#Dose intensification with aut
ologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease:
 Results of a BNLI randomised trial^len#Lancet#19930000#1993#341#8852#1051-4#201
10200#v33n1a04.htm#0099-5355#Lancet##
01219000000000481000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100018000900100
01600108010001600124010001800140010001600158010002000174010001800194010001600212
01000180022801000150024601000160026101000140027701000210029101000200031201000150
03320110038003470110076003850120199004610300007006600650009006670640005006760310
00400681032000500685014000800690865000900698002001300707035001000720801000700730
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#c#60#2#text#10#2#^rND^s
Schmitz^nN#^rND^sPfistner^nB#^rND^sSextro^nM#^rND^sSieber^nM#^rND^sCarella^nAM#^
rND^sHaenel^nM#^rND^sBoissevain^nF#^rND^sZschaber^nR#^rND^sMüller^nP#^rND^sKirch
ner^nH#^rND^sLohri^nA#^rND^sDecker^nS#^rND^sKoch^nB#^rND^sHasenclever^nD#^rND^sG
oldstone^nAH#^rND^sDiehl^nV#German Hodgkin's Lymphoma Study Group#European Group
 for Blood and Marrow Transplantation^dLymphoma Working Party#Aggressive convent
ional chemotherapy compared with high-dose chemotherapy with autologous haemopoi
etic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a 
randomised trial^len#Lancet#20020000#2002#359#9323#2065-71#20110200#v33n1a04.htm
#0099-5355#Lancet##
00764000000000337000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100020000730100016000930100
01900109010001800128010001800146810000600164012018600170030000600356065000900362
06400050037103100030037603200020037901400070038186500090038800200130039703500100
0410801000600420#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.htm#S#c#61#3#
text#10#3#^rND^sMoskowitz^nCH#^rND^sNimer^nSD#^rND^sZelenetz^nAD#^rND^sTrippett^
nT#^rND^sHedrick^nEE#et al#A 2-step comprehensive high-dose chemoradiotherapy se
cond-line program for relapsed and refractory Hodgkin disease: analysis by inten
t to treat and development of a prognostic model^len#Blood#20010000#2001#97#3#61
6-23#20110200#v33n1a04.htm#0006-4971#Blood##
00744000000000349000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100016000900100
01500106010001500121010001900136010001300155810000600168012014600174030000700320
06500090032706400050033603100040034103200030034501400070034886500090035500200130
0364035001000377801000700387#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.h
tm#S#c#62#4#text#10#4#^rND^sJabbour^nE#^rND^sHosing^nC#^rND^sAyers^nG#^rND^sNune
z^nR#^rND^sAnderlini^nP#^rND^sPro^nB#et al#Pretransplant positive positron emiss
ion tomography/gallium scans predict poor outcome in patients with recurrent/ref
ractory Hodgkin lymphoma^len#Cancer#20070000#2007#109#12#2481-9#20110200#v33n1a0
4.htm#0008-543X#Cancer##
00765000000000349000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100020000730100017000930100
02100110010002000131010001600151010001900167810000600186012015100192030000600343
06500090034906400050035803100040036303200030036701400070037086500090037700200130
0386035001000399801000600409#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.h
tm#S#c#63#5#text#10#5#^rND^sMoskowitz^nAJ#^rND^sYahalom^nJ#^rND^sKewalramani^nT#
^rND^sMaragulia^nJC#^rND^sVanak^nJM#^rND^sZelenetz^nAD#et al#Pretransplantation 
functional imaging predicts outcome following autologous stem cell transplantati
on for relapsed and refractory Hodgkin lymphoma^len#Blood#20100000#2010#116#23#4
934-7#20110200#v33n1a04.htm#0006-4971#Blood##
00887000000000361000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100017000900100
01600107010002000123010002000143010001600163810000600179012017800185030001000363
06500090037306400050038203100030038703200020039001400070039206100840039986500090
0483002001300492035001000505801001000515#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a04.htm#S#c#64#6#text#10#6#^rND^sJosting^nA#^rND^sRudolph^nC#^rND^sMapara
^nM#^rND^sGlossmann^nJP#^rND^sSieniawski^nM#^rND^sSieber^nM#et al#Cologne high-d
ose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results
 of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)^
len#Ann Oncol#20050000#2005#16#1#116-23#Erratum in: Ann Oncol. 2008;19(8):1515. 
Sieniawski, M [corrected to Sieniawski, M].#20110200#v33n1a04.htm#0923-7534#Ann 
Oncol##
01134000000000457000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100022000730100015000950100
01500110010001600125010001600141010002100157010001600178010001700194010002000211
01000220023101000210025301000150027401000150028901000220030401000220032601100220
03480120221003700300013005910650009006040640005006130310003006180320003006210140
00700624865000900631002001300640035001000653801001300663#v33n1#V:\SciELO\serial\
rbhh\v33n1\markup\v33n1a04.htm#S#c#65#7#text#10#7#^rND^sMorschhauser^nF#^rND^sBr
ice^nP#^rND^sFermé^nC#^rND^sDiviné^nM#^rND^sSalles^nG#^rND^sBouabdallah^nR#^rND^
sSebban^nC#^rND^sVoillat^nL#^rND^sCasasnovas^nO#^rND^sStamatoullas^nA#^rND^sBoua
bdallah^nK#^rND^sAndré^nM#^rND^sJais^nJP#^rND^sCazals-Hatem^nD#^rND^sGisselbrech
t^nC#GELA/SFGM Study Group#Risk-adapted salvage treatment with single or tandem 
autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymp
homa: results of the prospective multicenter H96 trial by the GELA/SFGM study gr
oup^len#J Clin Oncol#20080000#2008#26#36#5980-7#20110200#v33n1a04.htm#0732-183X#
J Clin Oncol##
00802000000000349000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100018000730100016000910100
01500107010001500122010001600137010001600153810000600169012017300175030002300348
06500090037106400050038003100030038503200020038801400070039086500090039700200130
0406035001000419801002300429#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.h
tm#S#c#66#8#text#10#8#^rND^sThomson^nKJ#^rND^sPeggs^nKS#^rND^sSmith^nP#^rND^sCav
et^nJ#^rND^sHunter^nA#^rND^sParker^nA#et al#Superiority of reduced-intensity all
ogeneic transplantation over conventional treatment for relapse of Hodgkin's lym
phoma following autologous stem cell transplantation^len#Bone Marrow Transplant#
20080000#2008#41#9#765-70#20110200#v33n1a04.htm#0268-3369#Bone marrow transplant
##
00947000000000361000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730100018000890100
01600107010001800123010002000141010001900161810000600180012024800186030001300434
06500090044706400050045603100030046103200020046401400070046606100670047386500090
0540002001300549035001000562801001300572#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a04.htm#S#c#67#9#text#10#9#^rND^sSureda^nA#^rND^sRobinson^nS#^rND^sCanals
^nC#^rND^sCarella^nAM#^rND^sBoogaerts^nMA#^rND^sCaballero^nD#et al#Reduced-inten
sity conditioning compared with conventional allogeneic stem-cell transplantatio
n in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Wo
rking Party of the European Group for Blood and Marrow Transplantation^len#J Cli
n Oncol#20080000#2008#26#3#455-62#Coçmment in: J Clin Oncol. 2008;26(24):4045-6;
 author reply 4046-7#20110200#v33n1a04.htm#0732-183X#J Clin Oncol##
00842000000000349000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100019000750100016000940100
01800110010001700128010001900145010001500164810000600179012022100185030001400406
06500090042006400050042903100030043403200020043701400070043986500090044600200130
0455035001000468801001400478#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a04.h
tm#S#c#68#10#text#10#10#^rND^sAnderlini^nP#^rND^sSaliba^nR#^rND^sAcholonu^nS#^rN
D^sGiralt^nSA#^rND^sAndersson^nB#^rND^sUeno^nNT#et al#Fludarabine-melphalan as a
 preparative regimen for reduced-intensity conditioning allogeneic stem cell tra
nsplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. And
erson Cancer Center experience^len#Haematologica#20080000#2008#93#2#257-64#20110
200#v33n1a04.htm#0390-6078#Haematologica##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#o#1#1#text#1#20
110411#115516#v33n1a05.htm#75##
00808000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000200092049000800094158000300102030002900105
03100030013403200020013706500090013901400070014803500100015512300020016523700270
0167012007300194010003400267070008700301117000600388072000300394002001300397#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#h#2#1#text#1#oa#en#br1.1#1#
4.0#ILUS#5#RBHH330#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f6^l7#1516-848
4#1#10.5581/1516-8484.20110005#Molecular polymorphisms of human blood groups: a 
universe to unravel^len#^rND^1A01^nLuiz Carlos de^sMattos#Faculdade de Medicina 
de São José do Rio Preto^iA01^cSão José do Rio Preto^sSP^pBrazil#other#12#v33n1a
05.htm##
00822000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000200092049000800094158000300102030002900105
03100030013403200020013706500090013901400070014803500100015512300020016523700270
0167012008700194010003400281070008700315117000600402072000300408002001300411#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#f#3#1#text#1#oa#en#br1.1#1#
4.0#ILUS#5#RBHH330#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f6^l7#1516-848
4#1#10.5581/1516-8484.20110005#<b>Molecular polymorphisms of human blood groups<
/b>: <b>a universe to unravel</b>^len#^rND^1A01^nLuiz Carlos de^sMattos#Faculdad
e de Medicina de São José do Rio Preto^iA01^cSão José do Rio Preto^sSP^pBrazil#o
ther#12#v33n1a05.htm##
00935000000000421000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000200105049000800107158000300115
03000280011803100030014603200020014906500090015101400070016003500100016712300020
01772370027001790120073002060100034002790700089003131170006004020720003004080020
01300411008008900424#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#l#4
#1#text#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#ilus#5#RBHH330#nd#Rev. bras. hematol. h
emoter#33#1#20110200#^f6^l7#1516-8484#1#10.5581/1516-8484.20110005#Molecular pol
ymorphisms of human blood groups: a universe to unravel^len#^rND^1A01^nLuiz Carl
os de^sMattos#^iA01^1Faculdade de Medicina de São José do Rio Preto^cSão José do
 Rio Preto^sSP^pBrazil#other#12#v33n1a05.htm#Internet^ihttp://www.scielo.br/scie
lo.php?script=sci_arttext&pid=S1516-84842011000100005##
00352000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012300070002001300193#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#5#1#text#59#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>SCIENTIFIC COMMENTS</b></
font></p>     ^cY#v33n1a05.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#6#2#text#59#<p>&nbsp;</p>     ^cY#v33
n1a05.htm##
00405000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704017600070002001300246#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#7#3#text#59#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Molecular polymorphis
ms of human blood groups: a universe to unravel</b></font></p>     ^cY#v33n1a05.
htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#8#4#text#59#<p>&nbsp;</p>     ^cY#v33
n1a05.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#9#5#text#59#<p>&nbsp;</p>     ^cY#v33
n1a05.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011100071002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#10#6#text#59#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Luiz Carlos de Mattos</b></font></p>  
   ^cY#v33n1a05.htm##
00431000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704020100071002001300272#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#11#7#text#59#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Faculdade de Medicina de S&atilde;o Jos&e
acute; do Rio Preto - FAMERP S&atilde;o Jos&eacute; do Rio Preto (SP), Brazil</f
ont></p>     ^cY#v33n1a05.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011500071002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#12#8#text#59#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></font></
p>     ^cY#v33n1a05.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#13#9#text#59#<p>&nbsp;</p>     ^cY#v3
3n1a05.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#14#10#text#59#<p>&nbsp;</p>     ^cY#v
33n1a05.htm##
00707000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704047600072002001300548#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#15#11#text#59#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The discovery of the ABO blood group sys
tem by Karl Landsteiner in 1900 resulted in the description of the first human g
enetic polymorphism and the birth of Immunohematology.<sup>(1)</sup> In the deca
des that followed, new blood group systems were characterized and the frequencie
s of their common and rare phenotypes were established in almost all populations
 and ethnic groups.<sup>(2)</sup></font></p>     ^cY#v33n1a05.htm##
01059000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704082800072002001300900#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#16#12#text#59#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Immunohematology takes advantage of red 
blood cell agglutination methods to demonstrate the extensive phenotypic polymor
phisms of these systems and explain their patterns of Mendelian inheritance. The
 development of new serological methods and reagents reached its peak with the i
ntroduction of automation in immunohematology.<sup>(3)</sup> The resulting advan
ces have clearly established the importance of these polymorphic systems in tran
sfusion medicine, in the genesis of newborn hemolytic diseases, in autoimmune an
emia and, in some cases, in solid organ transplantation.<sup>(4)</sup> The immun
ohematology methods broke barriers and are even being used in other areas, such 
as to understand and teach genetics, biochemistry and immunology.</font></p>    
 ^cY#v33n1a05.htm##
01086000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704085500072002001300927#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#17#13#text#59#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In recent years, immunohematology has be
en experiencing technological advances in the molecular characterization of bloo
d group system polymorphisms. The genes that control the expression of blood gro
up antigens have been cloned and sequenced and the molecular basis of their poly
morphisms identified.<sup>(5)</sup> These advances have improved the classificat
ion of genotypes and phenotypes of blood groups in patients who recently receive
d transfusions, who have positive direct Coombs tests and, in some situations, w
here rare sera are not available. Moreover, they have allowed the determination 
of fetal Rh status from maternal blood plasma and the investigation of atypical 
inheritance patterns that are unexplainable by classical Mendelian genetics.<sup
>(6,7)</sup></font></p>     ^cY#v33n1a05.htm##
01262000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704103100072002001301103#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#18#14#text#59#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In this issue of the Journal of Hematolo
gy and Hemotherapy, Visentainer et al. present the results of a pioneer molecula
r evaluation of the polymorphisms of the Rh, Kell, Duffy and Kidd blood group sy
stems in volunteer blood donors and candidate bone marrow donors of both genders
 from northwestern Parana State, Brazil. The authors used conventional and molec
ular methods to define common and rare allele frequencies. They demonstrated tha
t the observed genotypic proportions did not deviate from those expected for pop
ulations that comply with the principles of the theorem of Hardy-Weinberg equili
brium. They compared their results to those reported in the State of Sao Paulo a
nd stressed that the differences found for the Rh, Duffy and Kidd systems result
 from the distinct predominance of European ancestry in southern Brazil. The res
ults reflect the careful selection of casuistic and the choice of methods to ass
ess molecular polymorphisms.</font></p>     ^cY#v33n1a05.htm##
01041000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704081000072002001300882#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#19#15#text#59#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The range of phenotypes in humans are a 
direct result of genetic variations which act together with environmental and be
havioral factors to produce diversity.<sup>(8)</sup> Based on the population imp
act, genetic polymorphisms can be grouped as two types: transient and balanced. 
A transition polymorphism has a restricted distribution, occurs at low frequenci
es and as it does not seem to offer advantage to carriers, gradually tends to be
come extinct. On the other hand, a balanced polymorphism, as it offers an appare
nt selective advantage, tends to gradually increase in frequency in populations.
<sup>(9)</sup> Both types of polymorphisms are present in genes that control the
 blood group antigen expression.<sup>(10)</sup></font></p>     ^cY#v33n1a05.htm#
#
00853000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704062200072002001300694#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#20#16#text#59#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The identification of gene polymorphisms
, which control the blood group antigen expression, contributes to the understan
ding of the biological significance of blood group systems. In addition to assis
ting in the characterization of allelic variations, the identification of gene p
olymorphisms allows us to estimate the processes involved in the formation of di
fferent populations (the founder effect, genetic drift, migration, etc.). Thus, 
blood group gene polymorphisms are valuable predictors of genomic ethnic ancestr
y.<sup>(8,10)</sup></font></p>     ^cY#v33n1a05.htm##
00881000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704065000072002001300722#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#21#17#text#59#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Population studies are often used to inv
estigate the biological significance of blood group polymorphisms in respect to 
susceptibility to disease and other pathophysiological conditions. Results from 
these investigations provide additional data for clinical analysis and preventiv
e and therapeutic measures. The association between maternal immunization and ne
wborn hemolytic diseases as well as resistance to malaria caused by <i>Plasmodiu
m vivax</i> observed in carriers of the Duffy negative phenotype &#91;Fy(a-b-)&#
93; illustrate these conditions.<sup>(11)</sup></font></p>     ^cY#v33n1a05.htm#
#
01182000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704095100072002001301023#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#22#18#text#59#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The molecular basis of blood group polym
orphisms is well understood. However, environmental factors that contribute to t
he appearance of polymorphisms are still unclear. The absence of polymorphisms i
n some blood group genes suggests that the maintenance of conserved sequences is
 important but not indispensable from the biological point of view. For example,
 the <i>FUT1</i> gene (19q13.3) that controls the expression of the H type 2 ant
igen in hematopoietic tissue is monomorphic, but its absence in the Bombay pheno
type appears to offer no biological disadvantage. In contrast, the variability o
bserved in other genes, for example, the <i>FUT2</i> gene (19q13.3) supports the
 concept that blood group polymorphisms in the population are maintained by bala
nced selection mechanisms. However, the bases of this form of selection are stil
l unknown.<sup>(10,12)</sup></font></p>     ^cY#v33n1a05.htm##
00796000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704056500072002001300637#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#23#19#text#59#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Studies such as the one by Visentainer e
t al. are aligned to the contemporary interest in understanding the significance
 of polymorphisms in biological systems and populations and contribute to elucid
ate the results of evolutionary pressure that created and maintain genetic, geno
typic and phenotypic variability of human blood group systems. The gene polymorp
hisms of the human blood groups are very diverse and are an attractive research 
field. This is a universe to be unraveled.</font></p>     ^cY#v33n1a05.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#24#20#text#59#<p>&nbsp;</p>     ^cY#v
33n1a05.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010000072002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#25#21#text#59#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY#v33
n1a05.htm##
00407000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704016200074002001300236#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#26#22#text#59#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Owen R. Karl Landsteine
r and the first human marker locus. Genetics. 2000; 155(3):995-8.    ^cY#v33n1a0
5.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#27#23#text#59#</font></p>     ^cY#v33
n1a05.htm##
00402000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704015700074002001300231#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#28#24#text#59#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Daniels G, Reid ME. Blo
od groups: the past 50 years. Transfusion. 2010;50(2):281-9.    ^cY#v33n1a05.htm
##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#29#25#text#59#</font></p>     ^cY#v33
n1a05.htm##
00403000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704015800074002001300232#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#30#26#text#59#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Butch SH. Automation in
 the transfusion service. Immunohematology. 2008;24(3):86-92.    ^cY#v33n1a05.ht
m##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#31#27#text#59#</font></p>     ^cY#v33
n1a05.htm##
00421000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704017600074002001300250#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#32#28#text#59#4#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Avent ND. Large scale b
lood group genotyping - clinical implications. Br J Haematol. 2008;144(1):3-13. 
   ^cY#v33n1a05.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#33#29#text#59#</font></p>     ^cY#v33
n1a05.htm##
00413000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704016800074002001300242#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#34#30#text#59#5#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Daniels G. The molecula
r genetics of blood group polymorphism. Hum Genet. 2009; 126(6):729-42.    ^cY#v
33n1a05.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#35#31#text#59#</font></p>     ^cY#v33
n1a05.htm##
00481000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704023600074002001300310#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#36#32#text#59#6#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Denomme GA, Flegel WA. 
Applying molecular immunohematology discoveries to standards of practice in bloo
d banks: now is the time. Transfusion. 2008;48(11):2461-75.    ^cY#v33n1a05.htm#
#
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#37#33#text#59#</font></p>     ^cY#v33
n1a05.htm##
00418000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704017300074002001300247#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#38#34#text#59#7#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Anstee DJ. Red cell gen
otyping and the future of pretransfusion testing. Blood. 2009;114(2):248-56.    
^cY#v33n1a05.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#39#35#text#59#</font></p>     ^cY#v33
n1a05.htm##
00434000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704018900074002001300263#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#40#36#text#59#8#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Mielke JH, Konigsberg L
W, Relethford JH. Human biological variation. New York: Oxford University Press;
 2006. 418p.    ^cY#v33n1a05.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#41#37#text#59#</font></p>     ^cY#v33
n1a05.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704020500074002001300279#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#42#38#text#59#9#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Rahim NG, Harismendy O,
 Topol EJ, Frazer KA. Genetic determinants of phenotypic diversity in humans. Ge
nome Biology. 2008;9(4):215.    ^cY#v33n1a05.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#43#39#text#59#</font></p>     ^cY#v33
n1a05.htm##
00599000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704035300075002001300428#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#44#40#text#59#10#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Klein J, O'Huigin, Bl
ancher A. Evolution of blood group antigen polymorphism. In: Blancher A, Klein J
, Socha WW, editors. Molecular biology and evolution of blood group and MHC anti
gens in primates: primates blood group and MHC antigens. Berlin: Springer-Verlag
: 1997. p.305-21.    ^cY#v33n1a05.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#45#41#text#59#</font></p>     ^cY#v33
n1a05.htm##
00411000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704016500075002001300240#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#46#42#text#59#11#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Anstee DJ. The relati
onship between blood groups and disease. Blood. 2010;115(23):4635-43.    ^cY#v33
n1a05.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#47#43#text#59#</font></p>     ^cY#v33
n1a05.htm##
00555000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704030900075002001300384#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#48#44#text#59#12#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Henry SM, Samuelsson 
B. ABO polymorphisms and their putative biological relationships with disease. I
n: King MJ. Human blood cells: consequences of genetic polymorphisms and variati
ons.  London: Imperial College Press; 2000. p.15-103.    ^cY#v33n1a05.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#49#45#text#59#</font></p>     ^cY#v33
n1a05.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#50#46#text#59#<p>&nbsp;</p>     ^cY#v
33n1a05.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#51#47#text#59#<p>&nbsp;</p>     ^cY#v
33n1a05.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018600072002001300258#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#52#48#text#59#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img src
="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b>    ^
cY#v33n1a05.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003600072002001300108#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#53#49#text#59#<br>   Luiz Carlos de M
attos    ^cY#v33n1a05.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011100072002001300183#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#54#50#text#59#<br>   Departamento de 
Biologia Molecular, Faculdade de Medicina de S&atilde;o Jos&eacute; do Rio Preto
    ^cY#v33n1a05.htm##
00281000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005000072002001300122#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#55#51#text#59#<br>   Avenida Brigadei
ro Faria Lima, 5416    ^cY#v33n1a05.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007500072002001300147#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#56#52#text#59#<br>   15090-000  - S&a
tilde;o Jos&eacute; do Rio Preto (SP) Brazil    ^cY#v33n1a05.htm##
00289000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005800072002001300130#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#57#53#text#59#<br>   Phone: 55 17 320
1-5857 Fax: 55 17 3229-1777    ^cY#v33n1a05.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009100072002001300163#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#58#54#text#59#<br>   <a href="mailto:
luiz.carlos@famerp.br">luiz.carlos@famerp.br</a></font></p>     ^cY#v33n1a05.htm
##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009100072002001300163#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#59#55#text#59#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Submitted: 1/18/2011    ^cY#v33n1a05.htm
##
00277000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004600072002001300118#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#60#56#text#59#<br>   Accepted: 1/25/2
011</font></p>     ^cY#v33n1a05.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#61#57#text#59#<p>&nbsp;</p>     ^cY#v
33n1a05.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#62#58#text#59#<p>&nbsp;</p>     ^cY#v
33n1a05.htm##
00454000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022300072002001300295#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a05.htm#S#p#63#59#text#59#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" target="_b
lank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_blank">ww
w.scielo.br/rbhh</a></font></p>     ^cY#v33n1a05.htm##
00495000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100014000730120054000870300
00900141065000900150064000500159031000400164032000200168014000600170865000900176
002001300185035001000198801000900208#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a05.htm#S#c#64#1#text#12#1#^rND^sOwen^nR#Karl Landsteiner and the first human
 marker locus^len#Genetics#20000000#2000#155#3#995-8#20110200#v33n1a05.htm#0016-
6731#Genetics##
00512000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100015000900120
03600105030001200141065000900153064000500162031000300167032000200170014000600172
865000900178002001300187035001000200801001200210#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a05.htm#S#c#65#2#text#12#2#^rND^sDaniels^nG#^rND^sReid^nME#Blood 
groups: the past 50 years^len#Transfusion#20100000#2010#50#2#281-9#20110200#v33n
1a05.htm#0041-1132#Transfusion##
00463000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730120042000890300
01700131710000200148065000900150064000500159031000300164032000200167014000600169
865000900175002001300184#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S
#c#66#3#text#12#3#^rND^sButch^nSH#Automation in the transfusion service^len#Immu
nohematology#2#20080000#2008#24#3#86-92#20110200#v33n1a05.htm##
00514000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730120062000890300
01400151065000900165064000500174031000400179032000200183014000500185865000900190
002001300199035001000212801001400222#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a05.htm#S#c#67#4#text#12#4#^rND^sAvent^nND#Large scale blood group genotyping
: clinical implications^len#Br J Haematol#20080000#2008#144#1#3-13#20110200#v33n
1a05.htm#0007-1048#Br J Haematol##
00502000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730120055000900300
01000145065000900155064000500164031000400169032000200173014000700175865000900182
002001300191035001000204801001000214#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a05.htm#S#c#68#5#text#12#5#^rND^sDaniels^nG#The molecular genetics of blood g
roup polymorphism^len#Hum Genet#20090000#2009#126#6#729-42#20110200#v33n1a05.htm
#0340-6717#Hum Genet##
00591000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100018000730100017000910120
10900108030001200217065000900229064000500238031000300243032000300246014000800249
865000900257002001300266035001000279801001200289#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a05.htm#S#c#69#6#text#12#6#^rND^sDenomme^nGA#^rND^sFlegel^nWA#App
lying molecular immunohematology discoveries to standards of practice in blood b
anks: now is the time^len#Transfusion#20080000#2008#48#11#2461-75#20110200#v33n1
a05.htm#0041-1132#Transfusion##
00504000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730120065000900300
00600155065000900161064000500170031000400175032000200179014000700181865000900188
002001300197035001000210801000600220#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a05.htm#S#c#70#7#text#12#7#^rND^sAnstee^nDJ#Red cell genotyping and the futur
e of pretransfusion testing^len#Blood#20090000#2009#114#2#248-56#20110200#v33n1a
05.htm#0006-4971#Blood##
00502000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710160017000730160021000900160
02100111018003100132066000900163062002400172065000900196064000500205020000400210
865000900214002001300223#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S
#c#71#8#text#12#8#^rND^sMielke^nJH#^rND^sKonigsberg^nLW#^rND^sRelethford^nJH#Hum
an biological variation^len#New York#Oxford University Press#20060000#2006#418#2
0110200#v33n1a05.htm##
00564000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730100020000890100
01600109010001700125012005900142030001500201710000200216065000900218064000500227
031000200232032000200234020000400236865000900240002001300249#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a05.htm#S#c#72#9#text#12#9#^rND^sRahim^nNG#^rND^sHari
smendy^nO#^rND^sTopol^nEJ#^rND^sFrazer^nKA#Genetic determinants of phenotypic di
versity in humans^len#Genome Biology#2#20080000#2008#9#4#215#20110200#v33n1a05.h
tm##
00721000000000313000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100015000750100015000900100
01800105012005000123016001800173016001500191016001600206018011900222066000700341
062001600348065000900364064000500373014000700378865000900385002001300394#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a05.htm#S#c#73#10#text#12#10#^rND^sKlein^
nJ#^rND^sO'Huigin#^rND^sBlancher^nA#Evolution of blood group antigen polymorphis
m^len#^rED^sBlancher^nA#^rED^sKlein^nJ#^rED^sSocha^nWW#Molecular biology and evo
lution of blood group and MHC antigens in primates: primates blood group and MHC
 antigens^len#Berlin#Springer-Verlag#19970000#1997#305-21#20110200#v33n1a05.htm#
#
00497000000000277000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100017000750120054000920300
00600146065000900152064000500161031000400166032000300170014000800173865000900181
002001300190035001000203801000600213#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a05.htm#S#c#74#11#text#12#11#^rND^sAnstee^nDJ#The relationship between blood 
groups and disease^len#Blood#20100000#2010#115#23#4635-43#20110200#v33n1a05.htm#
0006-4971#Blood##
00632000000000277000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100016000750100020000910120
07900111016001500190018007600205066000700281062002300288065000900311064000500320
014000700325865000900332002001300341#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a05.htm#S#c#75#12#text#12#12#^rND^sHenry^nSM#^rND^sSamuelsson^nB#ABO polymorp
hisms and their putative biological relationships with disease^len#^rND^sKing^nM
J#Human blood cells: consequences of genetic polymorphisms and variations^len#Lo
ndon#Imperial College Press#20000000#2000#15-103#20110200#v33n1a05.htm##
00272000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00400098#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#o#1#1#text#1#20
110411#115518#v33n1a06.htm#124##
00853000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000200096049000800098158000300106
03000290010903100030013803200020014106500090014301400070015203500100015912300020
01692370027001710120095001980100030002930700098003231170006004210720003004270020
01300430#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#h#2#1#text#1#oa
#en#br1.1#1#4.0#ILUS#TAB#6#RBHH330#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200
#^f7^l9#1516-8484#1#10.5581/1516-8484.20110006#Sickle cell disease: from the beg
inning until it was recognized as a public health disease^len#^rND^1A01^nPaulo C
esar^sNaoum#Academia de Ciência e Tecnologia de São José do Rio Preto^iA01^cSão 
José do Rio Preto^sSP^pBrazil#other#28#v33n1a06.htm##
00867000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000200096049000800098158000300106
03000290010903100030013803200020014106500090014301400070015203500100015912300020
01692370027001710120109001980100030003070700098003371170006004350720003004410020
01300444#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#f#3#1#text#1#oa
#en#br1.1#1#4.0#ILUS#TAB#6#RBHH330#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200
#^f7^l9#1516-8484#1#10.5581/1516-8484.20110006#<b>Sickle cell disease</b>: <b>fr
om the beginning until it was recognized as a public health disease</b>^len#^rND
^1A01^nPaulo Cesar^sNaoum#Academia de Ciência e Tecnologia de São José do Rio Pr
eto^iA01^cSão José do Rio Preto^sSP^pBrazil#other#28#v33n1a06.htm##
00980000000000433000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100038000400105121000200109049000800111
15800030011903000280012203100030015003200020015306500090015501400070016403500100
01711230002001812370027001830120095002100100030003050700100003351170006004350720
00300441002001300444008008900457#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a
06.htm#S#l#4#1#text#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#6#RBHH330#nd#Rev. 
bras. hematol. hemoter#33#1#20110200#^f7^l9#1516-8484#1#10.5581/1516-8484.201100
06#Sickle cell disease: from the beginning until it was recognized as a public h
ealth disease^len#^rND^1A01^nPaulo Cesar^sNaoum#^iA01^1Academia de Ciência e Tec
nologia de São José do Rio Preto^cSão José do Rio Preto^sSP^pBrazil#other#28#v33
n1a06.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516
-84842011000100006##
00352000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012300070002001300193#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#5#1#text#92#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>SCIENTIFIC COMMENTS</b></
font></p>     ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#6#2#text#92#<p>&nbsp;</p>     ^cY#v33
n1a06.htm##
00453000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704022400070002001300294#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#7#3#text#92#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Sickle cell disease: 
from the beginning until it was recognized as a                           public
 health disease</b></font></p>     ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#8#4#text#92#<p>&nbsp;</p>     ^cY#v33
n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#9#5#text#92#<p>&nbsp;</p>     ^cY#v33
n1a06.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704010700071002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#10#6#text#92#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Paulo Cesar Naoum</b></font></p>     ^
cY#v33n1a06.htm##
00440000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704021000071002001300281#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#11#7#text#92#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Academia de Ci&ecirc;ncia e Tecnologia de
 S&atilde;o Jos&eacute; do Rio Preto, S&atilde;o Jos&eacute; do Rio Preto (SP), 
Brazil</font></p>     ^cY#v33n1a06.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011500071002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#12#8#text#92#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></font></
p>     ^cY#v33n1a06.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#13#9#text#92#<p>&nbsp;</p>     ^cY#v3
3n1a06.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#14#10#text#92#<p>&nbsp;</p>     ^cY#v
33n1a06.htm##
01490000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704125900072002001301331#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#15#11#text#92#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Sickle cell disease in Brazil, when expl
ained in medical, genetic, social or anthropological terms, has a strong relatio
nship with the introduction of Black Africans in our country. In 1932, Nina Rodr
igues a Brazilian historian, researched about the origin of the African slaves t
hat came to Brazil. He used data obtained from the customs department of the por
t in Salvador, Bahia. This researcher concluded that almost all of the African s
laves were from two regions on the west coast of Africa: the Mina Coast (approxi
mately the region of Benin, Togo and Ghana) and Angola.<sup>(1)</sup> Recent stu
dies using mitochondrial DNA analysis, performed by Sales in 2004, showed that 5
8.8% of the Brazilian Black people originate from Central West Africa which incl
udes Angola, and 32.1% come from West Africa that includes some regions that are
 believed to have belonged to the Mina Coast.<sup>(2)</sup> Molecular analysis o
f Hb S haplotypes were made by several Brazilian researchers in different region
s of the country.<sup>(3-8)</sup> These analyses enable the African origin of Br
azilian Black people to be tracked by means of beta S globin gene (<a href="#tab
1">Table 1</a>).</font></p>     ^cY#v33n1a06.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#16#12#text#92#<p><a name="tab1"></a><
/p>     ^cY#v33n1a06.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#17#13#text#92#<p>&nbsp;</p>     ^cY#v
33n1a06.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008000072002001300152#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#18#14#text#92#<p align="center"><img 
src="/img/revistas/rbhh/v33n1/a06tab01.jpg"></p>     ^cY#v33n1a06.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#19#15#text#92#<p>&nbsp;</p>     ^cY#v
33n1a06.htm##
00670000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704043900072002001300511#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#20#16#text#92#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Studies showed that the Bantu and Benin 
haplotypes are prevalent however the frequencies vary according to the region st
udied. These results reveal a heterogeneous employment of slave workers in the n
ortheastern states of Brazil with incredibly similar results obtained in the cit
ies of Rio de Janeiro and Salvador, as well as in Bel&eacute;m and Campinas.</fo
nt></p>     ^cY#v33n1a06.htm##
00759000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704052800072002001300600#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#21#17#text#92#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Knowledge of the Hb S haplotypes of pati
ents with sickle cell anemia is an important molecular marker of the severity of
 disease, the clinical and hematological repercussions, as well as of the Hb Fet
al concentrations in these patients.<sup>(9,10)</sup> Thus, this article aims at
 emphasizing the necessity of associating sickle cell disease with its evolution
 in Brazilian science, setting it in the context of Brazilian public health poli
cies.</font></p>     ^cY#v33n1a06.htm##
03691000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704346000072002001303532#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#22#18#text#92#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The first article published in Brazil in
 which the cases were probably of sickle cell disease was made by Doctor Cruz Jo
bim in Rio de Janeiro.<sup>(11)</sup> This paper had a social basis because the 
author emphasized that "it is a very specific illness that mostly affects poor b
lack people". After the effectively scientific publication about the clinic char
acteristics of sickle cell disease described in 1910 by Herrick<sup>(12)</sup> a
nd the discovery of the distortion of sickled cells that was made by Emmel in 19
17,<sup>(13)</sup> there was a gap of almost thirty years with few scientific ad
vances in sickle cell disease. So a special mention must be made of Accioly who,
 in 1947, suggested in a scientific article published in Brazil that sickle cell
 anemia must be the homozygous condition of the gene that causes the sickling ph
enomenon.<sup>(14)</sup> The genetic interest about sickle cell disease in the B
razilian population called the attention of the geneticists Tondo and Salzano. T
hese two researchers studied abnormal hemoglobins in the Brazilian Indian popula
tion in 1960<sup>(15)</sup> and the Brazilian Black people in 1962,<sup>(16)</su
p> in particular Hb S. In 1965, Araujo studied the prevalence of hemoglobinopath
ies in patients of Hospital das Cl&iacute;nicas in S&atilde;o Paulo and conclude
d that the sickle cell trait (Hb AS) was the most prevalent abnormal hemoglobin,
 especially in the black people.<sup>(17)</sup> However, only in 1969, Marinho p
resented a dissertation to the Brazilian Medical Academy about the clinical char
acteristics of sickle cell disease of patients from the Instituto de Hematologia
 Arthur Siqueira Cavalcanti (currently HEMORIO) in Rio de Janeiro.<sup>(18)</sup
> The scientific setting that suggested that sickle cell disease is of importanc
e to public health stimulated Naoum et al.<sup>(19)</sup> to carry out a scienti
fic study to detect abnormal hemoglobins in the state of S&atilde;o Paulo. Durin
g the period from 1978 to 1982 they analyzed 18 thousand individuals from 19 cit
ies that were characterized as important medical centers in the state of S&atild
e;o Paulo. Among the different abnormal hemoglobins that were identified, the si
ckle cell trait was prevalent in 1.6% of the total population (White and Black);
 the frequency of sickle cell trait in black individuals was 9.0%, while in whit
e people it was 0.96%. This scientific experience stimulated the author of this 
article to create an educational program on the laboratorial identification of h
emoglobinopathies, especially sickle cell disease, aimed at healthcare professio
nals in several Brazilian regions. With significant collaboration of Claudia Reg
ina Bonini Domingos, Ivan de Lucena Angulo and other colleagues, courses were st
arted in 1980 and were offered for 25 years without interruption. In 1981, Hutz 
carried out one of the most complete studies on the natural history of sickle ce
ll anemia in Brazil.<sup>(20)</sup> She used the data of 409 patients registered
 in the HEMORIO in Rio de Janeiro; the results of this study are medical referen
ces until today. In this same period two pioneer researches were performed to id
entify Hb S in newborn babies. The first study was made in 1976 by Ramalho et al
. in newborns from Campinas<sup>(21)</sup> and the second study was made in 1986
 by Ruiz et al. with newborns from Santos.<sup>(22)</sup></font></p>     ^cY#v33
n1a06.htm##
01348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704111700072002001301189#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#23#19#text#92#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The gradual development in the diagnosis
 of the sickle cell disease stimulated Ramalho to publish a book about the impor
tance of this disease to public health in Brazil.<sup>(23)</sup> The possibility
 that this disease may be a real problem in public health caused both scientific
 and political measures. One pioneer study was organized in the 1990s by Bandali
se et al. in Campinas, the results of which were published in 2004.<sup>(24)</su
p> The Campinas experience made the local government of the city establish the f
irst screening program of newborns in Brazil to detect sickle cell anemia.<sup>(
25)</sup> Special mention must go to Jos&eacute; Nelio Januario who, in 1993, fo
unded the N&uacute;cleo de A&ccedil;&otilde;es e Pesquisas em Apoio ao Diagn&oac
ute;stico (NUPAD) in Belo Horizonte, MG. During 17 years NUPAD analyzed more tha
n four million blood samples of newborns with the purpose of identifying sickle 
cell disease and other important diseases, such as congenital hypothyroidism, ph
enylketonuria and cystic fibrosis.</font></p>     ^cY#v33n1a06.htm##
01182000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704095100072002001301023#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#24#20#text#92#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">The result of all this effort over many 
years with scattered and diverse studies on the general aspects of sickle cell d
isease was compensated in 2001 with the publication of a decree by the Health Mi
nistry of Brazil that established the National Newborn Screening Program.<sup>(2
6)</sup> The immediate success of this program caused the Health Ministry of Bra
zil to extend it to the government healthcare plan in 2005.<sup>(27,28)</sup> In
 2010, during the V Brazilian Symposium of Sickle Cell Disease and other Hemoglo
binopathies, in Belo Horizonte, MG, with the support of the Health Ministry of B
razil, it was revealed that about 3500 newborns are born every year with sickle 
cell disease in Brazil and that 200 thousand are born with the sickle cell trait
. The highest prevalence of newborns with sickle cell disease occurs in Bahia (<
a href="#tab2">Table 2</a>).</font></p>     ^cY#v33n1a06.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#25#21#text#92#<p><a name="tab2"></a><
/p>     ^cY#v33n1a06.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#26#22#text#92#<p>&nbsp;</p>     ^cY#v
33n1a06.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008000072002001300152#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#27#23#text#92#<p align="center"><img 
src="/img/revistas/rbhh/v33n1/a06tab02.jpg"></p>     ^cY#v33n1a06.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#28#24#text#92#<p>&nbsp;</p>     ^cY#v
33n1a06.htm##
00821000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704059000072002001300662#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#29#25#text#92#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">To complete this article it is also very
 important to recognize the effort that many Brazilian researchers have dedicate
d to study sickle cell disease and other hemoglobinopathies in different regions
 of Brazil, as well as the associations of sickle cell anemia formed by patients
 and collaborates, and scientific societies, in particular the Brazilian Society
 of Hematology and Hemotherapy and the Brazilian College of Hematology, recently
 merged as the Brazilian Association of Hematology and Hemotherapy.</font></p>  
   ^cY#v33n1a06.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#30#26#text#92#<p>&nbsp;</p>     ^cY#v
33n1a06.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010000072002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#31#27#text#92#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY#v33
n1a06.htm##
00404000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704015900074002001300233#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#32#28#text#92#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Rodrigues N. Os african
os no Brasil. S&atilde;o Paulo: Editora Nacional; 1932. 408 p.    ^cY#v33n1a06.h
tm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#33#29#text#92#</font></p>     ^cY#v33
n1a06.htm##
00571000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704032600074002001300400#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#34#30#text#92#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Sales A, Richards M, La
reu MV, Scozzari R, Coppa A, Torroni A, et al. The African diaspora: mitochondri
al DNA and the Atlantic Slave Trade. Am J Human Genet. 2004;74(3):522-4. Comment
 in: Am J Hum Genet. 2004;75(3):522-4; author reply 524-6</font></p>     ^cY#v33
n1a06.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704030100074002001300375#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#35#31#text#92#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">3.  Adorno EV, Zanette A, 
Lyra I, Souza CC, Santos LF, Menezes JF, et al.  The beta-globin gene cluster ha
plotypes in sickle cell anemia patients from Northeast Brazil: a clinical and mo
lecular view. Hemoglobin. 2004;28(3):267-71.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#36#32#text#92#</font></p>     ^cY#v33
n1a06.htm##
00580000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704033500074002001300409#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#37#33#text#92#4#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Figueiredo MS, Kerbauy 
J, Gon&ccedil;alves MS, Arruda VR, Saada ST, Sonati MF,  et al. Effect of alpha-
thalassemia and beta globin gene cluster haplotypes on the hematological and cli
nical features of sickle cell anemia in Brazil. Am J Hematol. 1996;53(2):72-6.  
  ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#38#34#text#92#</font></p>     ^cY#v33
n1a06.htm##
00543000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704029800074002001300372#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#39#35#text#92#5#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Fleury MK. Determina&cc
edil;&atilde;o dos hapl&oacute;tipos do cluster da globina beta em pacientes com
 anemia falciforme no Rio de Janeiro &#91;tese&#93;. Rio de Janeiro: Universidad
e Federal do Rio de Janeiro; 2000. 182 p.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#40#36#text#92#</font></p>     ^cY#v33
n1a06.htm##
00495000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704025000074002001300324#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#41#37#text#92#6#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Wagner S, Friedrish J, 
Job F, Hutz MH. Caracteriza&ccedil;&atilde;o molecular de pacientes com anemia f
alciforme de Porto Alegre. Rev Bras Genet. 1996:19(Suppl):244 (abstract).    ^cY
#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#42#38#text#92#</font></p>     ^cY#v33
n1a06.htm##
00456000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704021100074002001300285#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#43#39#text#92#7#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Zago MA, Figueiredo MS,
 Ogo SH. Bantu beta S cluster haplotype predominant among Brazilian blacks. Am J
 Phys Anthropol. 1992;88(3):295-8.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#44#40#text#92#</font></p>     ^cY#v33
n1a06.htm##
00578000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704033300074002001300407#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#45#41#text#92#8#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Bezerra MA, Santos MN, 
Ara&uacute;jo AS, Gomes YM, Abath FG, Bandeira FM. Molecular variations linked t
o the grouping of beta- and alpha-globin genes in neonatal patients with sickle 
cell disease in the State of Pernambuco, Brazil. Hemoglobin.2007;31(1):83-8.    
^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#46#42#text#92#</font></p>     ^cY#v33
n1a06.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704027100074002001300345#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#47#43#text#92#9#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Steinberg MH, Hsu H, Na
gel RL, Milner PF, Adams JG, Benjamin L, et al. Gender and haplotype effects upo
n hematological manifestations of adult sickle cell anemia. Am J  Hematol. 1995;
 48(3):175-81.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#48#44#text#92#</font></p>     ^cY#v33
n1a06.htm##
00427000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704018100075002001300256#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#49#45#text#92#10#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Naoum PC, Naoum FA. D
oen&ccedil;a das c&eacute;lulas falciformes. S&atilde;o Paulo:  Sarvier; 2004. 2
24 p.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#50#46#text#92#</font></p>     ^cY#v33
n1a06.htm##
00433000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704018700075002001300262#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#51#47#text#92#11#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Cruz Jobim JM. As mol
&eacute;stias que mais afligem a classe pobre do Rio de Janeiro. Rev M&eacute;d 
Flum. 1835.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#52#48#text#92#</font></p>     ^cY#v33
n1a06.htm##
00446000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704020000075002001300275#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#53#49#text#92#12#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Herrick JB. Peculiar 
elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arc
h Int Med 1910;6:517-20.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#54#50#text#92#</font></p>     ^cY#v33
n1a06.htm##
00469000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704022300075002001300298#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#55#51#text#92#13#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Emmel VE. A study of 
the erythrocytes in a case of severe anemia with elongated sickle shaped red blo
od corpuscles. Arch Intern Med. 1917;20:586-98.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#56#52#text#92#</font></p>     ^cY#v33
n1a06.htm##
00390000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704014400075002001300219#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#57#53#text#92#14#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Accioly J. Anemia fal
ciforme. Arq Fac Med Univ Bahia. 1947; 2:169-98.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#58#54#text#92#</font></p>     ^cY#v33
n1a06.htm##
00417000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704017100075002001300246#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#59#55#text#92#15#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Tondo CV, Salzano FM.
 Hemoglobin types of Caingang Indians of Brazil. Science. 1960;132:1893-94.    ^
cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#60#56#text#92#</font></p>     ^cY#v33
n1a06.htm##
00427000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704018100075002001300256#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#61#57#text#92#16#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Tondo CV, Salzano FM.
 Abnormal hemoglobins in a Brazilian Negro population. Am J Hum Genet. 1962;14:4
01-9.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#62#58#text#92#</font></p>     ^cY#v33
n1a06.htm##
00446000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704020000075002001300275#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#63#59#text#92#17#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Araujo JT. Hemoglobin
as anormais em S&atilde;o Paulo, m&eacute;todos de estudo, incid&ecirc;ncia. J B
ras Med. 1965;9:1264-83.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#64#60#text#92#</font></p>     ^cY#v33
n1a06.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704019700075002001300272#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#65#61#text#92#18#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Marinho HM. Hemoglobi
nopatia S - doen&ccedil;a eritrofalc&ecirc;mica. Rio de Janeiro: Academia Nacion
al de Medicina; 1969.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#66#62#text#92#</font></p>     ^cY#v33
n1a06.htm##
00496000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704025000075002001300325#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#67#63#text#92#19#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Naoum PC, Mattos LC, 
Cury PR. Prevalence and geographic distribution of abnormal hemoglobins in State
 of S&atilde;o Paulo, Brazil. Bull Pan Am Health Organ. 1984;18(2):127-38.    ^c
Y#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#68#64#text#92#</font></p>     ^cY#v33
n1a06.htm##
00522000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704027600075002001300351#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#69#65#text#92#20#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Hutz MH. Hist&oacute;
ria natural da anemia falciforme em pacientes da regi&atilde;o metropolitana do 
Rio de Janeiro &#91;tese&#93;. Porto Alegre: Universidade Federal do Rio Grande 
do Sul; 1981. 270 p.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#70#66#text#92#</font></p>     ^cY#v33
n1a06.htm##
00459000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704021300075002001300288#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#71#67#text#92#21#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Ramalho AS, Nassim-Jo
rge R, Oliveira JA, Pereira DA. Hemoglobina S em rec&eacute;m-nascidos brasileir
os. J Pediatr (Rio J). 1976; 41:9-10.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#72#68#text#92#</font></p>     ^cY#v33
n1a06.htm##
00580000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704033400075002001300409#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#73#69#text#92#22#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Ruiz MA, Guerra CC, N
aoum PC. Detec&ccedil;&atilde;o de hemoglobinas anormais em sangue de cord&atild
e;o de rec&eacute;m-nascidos na cidade de Santos, SP, atrav&eacute;s de eletrofo
rese em gel de &aacute;gar amido. Bol Soc Bras Hematol Hemot. 1986;8(1): 8-13.  
  ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#74#70#text#92#</font></p>     ^cY#v33
n1a06.htm##
00506000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704026000075002001300335#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#75#71#text#92#23#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Ramalho AS. As hemogl
obinopatias heredit&aacute;rias. Um problema de sa&uacute;de p&uacute;blica no B
rasil. Ribeir&atilde;o Preto: Editora Sociedade Brasileira de Gen&eacute;tica; 1
986.    ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#76#72#text#92#</font></p>     ^cY#v33
n1a06.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704025500075002001300330#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#77#73#text#92#24#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Brandalise S, Pinheir
o V, Gabetta CS, Hambleton I, Searjeant G. New-born screening for sickle cell di
sease in Brazil: the Campinas experience. Clin J Lab Haematol. 2004;26(1):15-9. 
   ^cY#v33n1a06.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#78#74#text#92#</font></p>     ^cY#v33
n1a06.htm##
00722000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704047600075002001300551#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#79#75#text#92#25#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">25.  Campinas. Prefeitura
 Municipal de Campinas.  Programa de triagem neonatal para anemia falciforme &#9
1;Internet&#93;. Campinas (SP): PMC; 1997. &#91;citado 2010 Jul 27&#93;. Dispon&
iacute;vel em: <a href="http://2009.campinas.sp.gov.br/saude/programas/anemia_fa
lciforme/nota_tecnica.htm" target="_blank">http://2009.campinas.sp.gov.br/saude/
programas/anemia_falciforme/nota_tecnica.htm</a></font></p>     ^cY#v33n1a06.htm
##
01029000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704078300075002001300858#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#80#76#text#92#26#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Brasil. Minist&eacute
;rio da Sa&uacute;de. Portaria GM/MS nº 822/GM em 6 de junho de 2001. Estabelece
 a obrigatoriedade de que os hospitais e demais estabelecimentos de aten&ccedil;
&atilde;o &agrave; sa&uacute;de de gestantes, p&uacute;blicos e particulares, pr
ocedam a exames visando o diagn&oacute;stico e terap&ecirc;utica de anormalidade
s no metabolismo do rec&eacute;m-nascido, bem como prestar orienta&ccedil;&atild
e;o aos pais &#91;Internet&#93;. Bras&iacute;lia, DF: MS; 2001. &#91;citado 2010
 Jan 21&#93;. Dispon&iacute;vel em: <a href="http://dtr2001.saude.gov.br/sas/POR
TARIAS/Port2001/GM/GM-822.htm" target="_blank">http://dtr2001.saude.gov.br/sas/P
ORTARIAS/Port2001/GM/GM-822.htm</a></font></p>     ^cY#v33n1a06.htm##
00906000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704066000075002001300735#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#81#77#text#92#27#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Brasil. Minist&eacute
;rio da Sa&uacute;de. Portaria GM/MS nº 1391, 16 de agosto de 2005. Institui no 
&acirc;mbito do Sistema &Uacute;nico de Sa&uacute;de, as diretrizes para a Pol&i
acute;tica Nacional de Aten&ccedil;&atilde;o Integral &agrave;s Pessoas com Doen
&ccedil;a Falciforme e outras Hemoglobinopatias &#91;Internet&#93;. Bras&iacute;
lia, DF: MS; 2005. &#91;citado 2010 Set 15&#93;. Dispon&iacute;vel em: <a href="
http://dtr2001.saude.gov.br/sas/PORTARIAS/Port2005/GM/GM-1391.htm" target="_blan
k">http://dtr2001.saude.gov.br/sas/PORTARIAS/Port2005/GM/GM-1391.htm</a></font><
/p>     ^cY#v33n1a06.htm##
00902000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704065600075002001300731#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#82#78#text#92#28#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Brasil. Minist&eacute
;rio da Sa&uacute;de. Secretaria de Aten&ccedil;&atilde;o &agrave; Sa&uacute;de.
 Departamento de Aten&ccedil;&atilde;o Especializada. Manual de Educa&ccedil;&at
ilde;o em Sa&uacute;de,  Autocuidado na Doen&ccedil;a Falciforme &#91;Internet&#
93; . Bras&iacute;lia: Editora do Minist&eacute;rio da Sa&uacute;de; 2008. &#91;
citado 2010 Out 15&#93;. Dispon&iacute;vel em: <a href="http://bvsms.saude.gov.b
r/bvs/publicacoes/manual_educacao_saude_volume1.pdf" target="_blank">http://bvsm
s.saude.gov.br/bvs/publicacoes/manual_educacao_saude_volume1.pdf</a></font></p> 
    ^cY#v33n1a06.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#83#79#text#92#<p>&nbsp;</p>     ^cY#v
33n1a06.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#84#80#text#92#<p>&nbsp;</p>     ^cY#v
33n1a06.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018600072002001300258#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#85#81#text#92#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img src
="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b>    ^
cY#v33n1a06.htm##
00263000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003200072002001300104#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#86#82#text#92#<br>   Paulo Cesar Naou
m    ^cY#v33n1a06.htm##
00323000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009200072002001300164#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#87#83#text#92#<br>   Academia de Ci&e
circ;ncia e Tecnologia de S&atilde;o Jos&eacute; do Rio Preto    ^cY#v33n1a06.ht
m##
00292000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006100072002001300133#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#88#84#text#92#<br>   Rua Bonf&aacute;
 Natale, 1860  - Santos Dumont    ^cY#v33n1a06.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007500072002001300147#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#89#85#text#92#<br>   15020-130 - S&at
ilde;o Jos&eacute; do Rio Preto (SP), Brazil    ^cY#v33n1a06.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003800072002001300110#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#90#86#text#92#<br>   Phone.: 55 17 32
33 4490    ^cY#v33n1a06.htm##
00316000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008500072002001300157#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#91#87#text#92#<br>   <a href="mailto:
a.c.t@terra.com.br">a.c.t@terra.com.br</a></font></p>     ^cY#v33n1a06.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009100072002001300163#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#92#88#text#92#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Submitted: 1/26/2011    ^cY#v33n1a06.htm
##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004400072002001300116#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#93#89#text#92#<br> Accepted: 1/31/201
1</font></p>     ^cY#v33n1a06.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#94#90#text#92#<p>&nbsp;</p>     ^cY#v
33n1a06.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#95#91#text#92#<p>&nbsp;</p>     ^cY#v
33n1a06.htm##
00454000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022300072002001300295#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a06.htm#S#p#96#92#text#92#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" target="_b
lank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_blank">ww
w.scielo.br/rbhh</a></font></p>     ^cY#v33n1a06.htm##
00428000000000241000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710160019000730180027000920660
01000119062001700129065000900146064000500155020000400160865000900164002001300173
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#c#97#1#text#28#1#^rND^s
Rodrigues^nN#Os africanos no Brasil^lpt#São Paulo#Editora Nacional#19320000#1932
#408#20110200#v33n1a06.htm##
00732000000000349000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100015000730100018000880100
01600106010001800122010001500140010001700155810000600172012007300178030001700251
71000020026806500090027006400050027903100030028403200020028701400060028906100650
0295865000900360002001300369#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.h
tm#S#c#98#2#text#28#2#^rND^sSales^nA#^rND^sRichards^nM#^rND^sLareu^nMV#^rND^sSco
zzari^nR#^rND^sCoppa^nA#^rND^sTorroni^nA#et al#The African diaspora: mitochondri
al DNA and the Atlantic Slave Trade^len#Am J Human Genet#2#20040000#2004#74#3#52
2-4#Comment in: Am J Hum Genet. 2004;75(3):522-4; author reply 524-6#20110200#v3
3n1a06.htm##
00736000000000349000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100017000900100
01400107010001600121010001700137010001800154810000600172012012800178030001100306
06500090031706400050032603100030033103200020033401400070033686500090034300200130
0352035001000365801001100375#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.h
tm#S#c#99#3#text#28#3#^rND^sAdorno^nEV#^rND^sZanette^nA#^rND^sLyra^nI#^rND^sSouz
a^nCC#^rND^sSantos^nLF#^rND^sMenezes^nJF#et al#The beta-globin gene cluster hapl
otypes in sickle cell anemia patients from Northeast Brazil: a clinical and mole
cular view^len#Hemoglobin#20040000#2004#28#3#267-71#20110200#v33n1a06.htm#0363-0
269#Hemoglobin##
00767000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090005000647080003000691180002000720100021000740100017000950100
02000112010001700132010001600149010001700165810000600182012014700188030001300335
06500090034806400050035703100030036203200020036501400050036786500090037200200130
0381035001000394801001300404#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.h
tm#S#c#100#4#text#28#4#^rND^sFigueiredo^nMS#^rND^sKerbauy^nJ#^rND^sGonçalves^nMS
#^rND^sArruda^nVR#^rND^sSaada^nST#^rND^sSonati^nMF#et al#Effect of alpha-thalass
emia and beta globin gene cluster haplotypes on the hematological and clinical f
eatures of sickle cell anemia in Brazil^len#Am J Hematol#19960000#1996#53#2#72-6
#20110200#v33n1a06.htm#0361-8609#Am J Hematol##
00539000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090005000647080003000691180002000720160017000740180112000910460
01500203050003900218045000900257044000500266020000400271865000900275002001300284
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#c#101#5#text#28#5#^rND^
sFleury^nMK#Determinação dos haplótipos do cluster da globina beta em pacientes 
com anemia falciforme no Rio de Janeiro^lpt#Rio de Janeiro#Universidade Federal 
do Rio de Janeiro#20000000#2000#182#20110200#v33n1a06.htm##
00643000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090005000647080003000691180002000720100016000740100019000900100
01300109010001500122012008000137030001500217065000900232064000500241031000300246
03200080024902000040025706100090026186500090027000200130027903500100029280100150
0302#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#c#102#6#text#28#6#^
rND^sWagner^nS#^rND^sFriedrish^nJ#^rND^sJob^nF#^rND^sHutz^nMH#Caracterização mol
ecular de pacientes com anemia falciforme de Porto Alegre^lpt#Rev Bras Genet#199
60000#1996#19#^sSuppl#244#abstract#20110200#v33n1a06.htm#0100-8455#Rev Bras Gene
t##
00593000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090005000647080003000691180002000720100015000740100021000890100
01400110012007000124030002000194065000900214064000500223031000300228032000200231
014000600233865000900239002001300248035001000261801002000271#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a06.htm#S#c#103#7#text#28#7#^rND^sZago^nMA#^rND^sFigu
eiredo^nMS#^rND^sOgo^nSH#Bantu beta S cluster haplotype predominant among Brazil
ian blacks^len#Am J Phys Anthropol#19920000#1992#88#3#295-8#20110200#v33n1a06.ht
m#0002-9483#Am J Phys Anthropol##
00754000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090005000647080003000691180002000720100018000740100017000920100
01700109010001600126010001600142010001900158012016100177030001100338065000900349
06400050035803100030036303200020036601400050036886500090037300200130038203500100
0395801001100405#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#c#104#8
#text#28#8#^rND^sBezerra^nMA#^rND^sSantos^nMN#^rND^sAraújo^nAS#^rND^sGomes^nYM#^
rND^sAbath^nFG#^rND^sBandeira^nFM#Molecular variations linked to the grouping of
 beta- and alpha-globin genes in neonatal patients with sickle cell disease in t
he State of Pernambuco, Brazil^len#Hemoglobin#20070000#2007#31#1#83-8#20110200#v
33n1a06.htm#0363-0269#Hemoglobin##
00709000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090005000647080003000691180002000720100020000740100013000940100
01600107010001700123010001600140010001800156810000600174012009500180030001300275
06500090028806400050029703100030030203200020030501400070030786500090031400200130
0323035001000336801001300346#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.h
tm#S#c#105#9#text#28#9#^rND^sSteinberg^nMH#^rND^sHsu^nH#^rND^sNagel^nRL#^rND^sMi
lner^nPF#^rND^sAdams^nJG#^rND^sBenjamin^nL#et al#Gender and haplotype effects up
on hematological manifestations of adult sickle cell anemia^len#Am J Hematol#199
50000#1995#48#3#175-81#20110200#v33n1a06.htm#0361-8609#Am J Hematol##
00455000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730160016000760160016000920180
03500108066001000143062000800153065000900161064000500170020000400175865000900179
002001300188#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#c#106#10#te
xt#28#10#^rND^sNaoum^nPC#^rND^sNaoum^nFA#Doença das células falciformes^lpt#São 
Paulo#Sarvier#20040000#2004#224#20110200#v33n1a06.htm##
00445000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730100021000760120067000970300
01300164710000200177065000900179064000500188865000900193002001300202#v33n1#V:\Sc
iELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#c#107#11#text#28#11#^rND^sCruz Jobi
m^nJM#As moléstias que mais afligem a classe pobre do Rio de Janeiro^lpt#Rev Méd
 Flum#2#18350000#1835#20110200#v33n1a06.htm##
00497000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730100018000760120089000940300
01300183710000200196065000900198064000500207031000200212014000700214865000900221
002001300230#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#c#108#12#te
xt#28#12#^rND^sHerrick^nJB#Peculiar elongated and sickle-shaped red blood corpus
cles in a case of severe anemia^len#Arch Int Med#2#19100000#1910#6#517-20#201102
00#v33n1a06.htm##
00555000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730100016000760120109000920300
01600201065000900217064000500226031000300231014000700234865000900241002001300250
035001000263801001600273#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S
#c#109#13#text#28#13#^rND^sEmmel^nVE#A study of the erythrocytes in a case of se
vere anemia with elongated sickle shaped red blood corpuscles^len#Arch Intern Me
d#19170000#1917#20#586-98#20110200#v33n1a06.htm#0003-9926#Arch Intern Med##
00439000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730100017000760120022000930300
02300115710000200138065000900140064000500149031000200154014000700156865000900163
002001300172#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#c#110#14#te
xt#28#14#^rND^sAccioly^nJ#Anemia falciforme^lpt#Arq Fac Med Univ Bahia#2#1947000
0#1947#2#169-98#20110200#v33n1a06.htm##
00513000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730100016000760100018000920120
05100110030000800161065000900169064000500178031000400183014000800187865000900195
002001300204035001000217801000800227#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a06.htm#S#c#111#15#text#28#15#^rND^sTondo^nCV#^rND^sSalzano^nFM#Hemoglobin ty
pes of Caingang Indians of Brazil^len#Science#19600000#1960#132#1893-94#20110200
#v33n1a06.htm#0036-8075#Science##
00530000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730100016000760100018000920120
05700110030001500167065000900182064000500191031000300196014000600199865000900205
002001300214035001000227801001500237#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a06.htm#S#c#112#16#text#28#16#^rND^sTondo^nCV#^rND^sSalzano^nFM#Abnormal hemo
globins in a Brazilian Negro population^len#Am J Hum Genet#19620000#1962#14#401-
9#20110200#v33n1a06.htm#0002-9297#Am J Hum Genet##
00507000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730100017000760120070000930300
01100163065000900174064000500183031000200188014000800190865000900198002001300207
035001000220801001100230#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S
#c#113#17#text#28#17#^rND^sAraujo^nJT#Hemoglobinas anormais em São Paulo, método
s de estudo, incidência^lpt#J Bras Med#19650000#1965#9#1264-83#20110200#v33n1a06
.htm#0047-2077#J Bras Med##
00452000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730160018000760180047000940660
01500141062003000156065000900186064000500195865000900200002001300209#v33n1#V:\Sc
iELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#c#114#18#text#28#18#^rND^sMarinho^n
HM#Hemoglobinopatia S: doença eritrofalcêmica^lpt#Rio de Janeiro#Academia Nacion
al de Medicina#19690000#1969#20110200#v33n1a06.htm##
00631000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730100016000760100017000920100
01500109012009700124030002500221065000900246064000500255031000300260032000200263
014000700265865000900272002001300281035001000294801002500304#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a06.htm#S#c#115#19#text#28#19#^rND^sNaoum^nPC#^rND^sM
attos^nLC#^rND^sCury^nPR#Prevalence and geographic distribution of abnormal hemo
globins in State of São Paulo, Brazil^len#Bull Pan Am Health Organ#19840000#1984
#18#2#127-38#20110200#v33n1a06.htm#0085-4638#Bull Pan Am Health Organ##
00525000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730160015000760180097000910460
01300188050004200201045000900243044000500252020000400257865000900261002001300270
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#c#116#20#text#28#20#^rN
D^sHutz^nMH#História natural da anemia falciforme em pacientes da região metropo
litana do Rio de Janeiro^lpt#Porto Alegre#Universidade Federal do Rio Grande do 
Sul#19810000#1981#270#20110200#v33n1a06.htm##
00595000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730100018000760100022000940100
01900116010001800135012004800153030001000201066000600211065000900217064000500226
031000300231014000500234865000900239002001300248035001000261801001000271#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#c#117#21#text#28#21#^rND^sRamal
ho^nAS#^rND^sNassim-Jorge^nR#^rND^sOliveira^nJA#^rND^sPereira^nDA#Hemoglobina S 
em recém-nascidos brasileiros^lpt#J Pediatr#Rio J#19760000#1976#41#9-10#20110200
#v33n1a06.htm#0022-3476#J Pediatr##
00634000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730100015000760100017000910100
01600108012014600124030002700270710000200297065000900299064000500308031000200313
032000200315014000500317865000900322002001300331#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a06.htm#S#c#118#22#text#28#22#^rND^sRuiz^nMA#^rND^sGuerra^nCC#^rN
D^sNaoum^nPC#Detecção de hemoglobinas anormais em sangue de cordão de recém-nasc
idos na cidade de Santos, SP, através de eletroforese em gel de ágar amido^lpt#B
ol Soc Bras Hematol Hemot#2#19860000#1986#8#1#8-13#20110200#v33n1a06.htm##
00483000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730160018000760180094000940620
04100188065000900229064000500238865000900243002001300252#v33n1#V:\SciELO\serial\
rbhh\v33n1\markup\v33n1a06.htm#S#c#119#23#text#28#23#^rND^sRamalho^nAS#As hemogl
obinopatias hereditárias: Um problema de saúde pública no Brasil. Ribeirão Preto
^lpt#Editora Sociedade Brasileira de Genética#19860000#1986#20110200#v33n1a06.ht
m##
00634000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730100020000760100018000960100
01800114010001900132010001900151012008200170030002000252710000200272065000900274
064000500283031000300288032000200291014000500293865000900298002001300307#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a06.htm#S#c#120#24#text#28#24#^rND^sBrand
alise^nS#^rND^sPinheiro^nV#^rND^sGabetta^nCS#^rND^sHambleton^nI#^rND^sSearjeant^
nG#New-born screening for sickle cell disease in Brazil: the Campinas experience
^len#Clin J Lab Haematol#2#20040000#2004#26#1#15-9#20110200#v33n1a06.htm##
00608000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730170033000760180056001090610
00900165066001300174062000400187065000900191064000500200110000900205109001200214
037008200226865000900308002001300317#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a06.htm#S#c#121#25#text#28#25#Prefeitura Municipal de Campinas#Programa de tr
iagem neonatal para anemia falciforme^lpt#Internet#Campinas^eSP#PMC#19970000#199
7#20100727#2010 Jul 27#http://2009.campinas.sp.gov.br/saude/programas/anemia_fal
ciforme/nota_tecnica.htm#20110200#v33n1a06.htm##
00855000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730170028000760180326001040610
00900430066001300439062000300452065000900455064000500464110000900469109001200478
037006500490865000900555002001300564#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a06.htm#S#c#122#26#text#28#26#Brasil^dMinistério da Saúde#Portaria GM/MS nº 8
22/GM em 6 de junho de 2001: Estabelece a obrigatoriedade de que os hospitais e 
demais estabelecimentos de atenção à saúde de gestantes, públicos e particulares
, procedam a exames visando o diagnóstico e terapêutica de anormalidades no meta
bolismo do recém-nascido, bem como prestar orientação aos pais^lpt#Internet#Bras
ília^eDF#MS#20010000#2001#20100121#2010 Jan 21#http://dtr2001.saude.gov.br/sas/P
ORTARIAS/Port2001/GM/GM-822.htm#20110200#v33n1a06.htm##
00745000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730170028000760180215001040610
00900319066001300328062000300341065000900344064000500353110000900358109001200367
037006600379865000900445002001300454#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a06.htm#S#c#123#27#text#28#27#Brasil^dMinistério da Saúde#Portaria GM/MS nº 1
391, 16 de agosto de 2005: Institui no âmbito do Sistema Único de Saúde, as dire
trizes para a Política Nacional de Atenção Integral às Pessoas com Doença Falcif
orme e outras Hemoglobinopatias^lpt#Internet#Brasília^eDF#MS#20050000#2005#20100
915#2010 Set 15#http://dtr2001.saude.gov.br/sas/PORTARIAS/Port2005/GM/GM-1391.ht
m#20110200#v33n1a06.htm##
00711000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090005000657080003000701180003000730170007000760170090000830180
06600173061000900239066000900248062003100257065000900288064000500297110000900302
109001200311037007600323865000900399002001300408#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a06.htm#S#c#124#28#text#28#28#Brasil#Ministério da Saúde^dSecreta
ria de Atenção à Saúde. Departamento de Atenção Especializada#Manual de Educação
 em Saúde, Autocuidado na Doença Falciforme^lpt#Internet#Brasília#Editora do Min
istério da Saúde#20080000#2008#20101015#2010 Out 15#http://bvsms.saude.gov.br/bv
s/publicacoes/manual_educacao_saude_volume1.pdf#20110200#v33n1a06.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#o#1#1#article#1
#20110411#115521#v33n1a07.htm#162##
03716000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000290011203100030014103200020014406500090014601400090015503500100016423700270
01740120087002010100039002880100034003270100027003610100036003880100032004240100
03100456010002900487010004300516010003000559010004600589070007700635083201000712
08500100272208500310273208500520276308500390281508500240285408500230287808500240
29010850024029250850032029491170006029810720003029871120009029901110010029991140
00903009113001103018002001303029#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a
07.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#7#RBHH340#nd#Rev. Bras. Hema
tol. Hemoter.#33#1#20110200#^f10^l14#1516-8484#10.5581/1516-8484.20110007#Autolo
gous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma^len
#^rND^1A01^nAfonso José Pereira^sCortez#^rND^1A01^nFrederico Luiz^sDulley#^rND^1
A01^nRosaura^sSaboya#^rND^1A01^nAlfredo^sMendrone Júnior#^rND^1A01^nUlisses^sAmi
go Filho#^rND^1A01^nFabio Luiz^sCoracin#^rND^1A01^nValéria^sBuccheri#^rND^1A01^n
Camila da Cruz Gouveia^sLinardi#^rND^1A01^nMilton Artur^sRuiz#^rND^1A01^nDalton 
de Alencar Fischer^sChamone#Universidade de São Paulo^iA01^1Faculdade de Medicin
a^cSão Paulo^sSP^pBrazil#^len^aBACKGROUND: Hodgkin's lymphoma has high rates of 
cure, but in 15% to 20% of general patients and between 35% and 40% of those in 
advanced stages, the disease will progress or will relapse after initial treatme
nt. For this group, hematopoietic stem cell transplantation is considered one op
tion of salvage therapy. OBJECTIVES: To evaluate a group of 106 patients with Ho
dgkin's lymphoma, who suffered relapse or who were refractory to treatment, subm
itted to autologous hematopoietic stem cell transplantation in a single transpla
nt center. METHODS: A retrospective study was performed with data collected from
 patient charts. The analysis involved 106 classical Hodgkin's lymphoma patients
 who were consecutively submitted to high-dose chemotherapy followed by autologo
us transplants in a single institution from April 1993 to December 2006. RESULTS
: The overall survival rates of this population at five and ten years were 86% a
nd 70%, respectively. The disease-free survival was approximately 60% at five ye
ars. Four patients died of procedure-related causes but relapse of classical Hod
gkin's lymphoma after transplant was the most frequent cause of death. Univariat
e analysis shows that sensitivity to pre-transplant treatment and hemoglobin < 1
0 g/dL at diagnosis had an impact on patient survival. Unlike other studies, B-t
ype symptoms did not seem to affect overall survival. Lactic dehydrogenase and s
erum albumin concentrations analyzed at diagnosis did not influence patient surv
ival either. CONCLUSION: Autologous hematopoietic stem cell transplantation is a
n effective treatment strategy for early and late relapse in classical Hodgkin's
 lymphoma for cases that were responsive to pre-transplant chemotherapy. Refract
ory to treatment is a sign of worse prognosis. Additionally, a hemoglobin concen
tration below 10 g/dL at diagnosis of Hodgkin's lymphoma has a negative impact o
n the survival of patients after transplant. As far as we know this relationship
 has not been previously reported.#^ddecs^i1#^tm^len^kHodgkin's lymphoma^i1#^tm^
len^kHematopoietic stem cell transplantation^i1#^tm^len^kAutologous transplantat
ion^i1#^tm^len^kDoxorubicin^i1#^tm^len^kBleomycynm^i1#^tm^len^kVinblastine^i1#^t
m^len^kDacarbazine^i1#^tm^len^kStudy retrospective^i1#other#23#20100923#9/23/201
0#20101112#12/11/2010#v33n1a07.htm##
03761000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000290011203100030014103200020014406500090014601400090015503500100016423700270
01740120094002010100039002950100034003340100027003680100036003950100032004310100
03100463010002900494010004300523010003000566010004600596070007700642083204800719
08500100276708500310277708500520280808500390286008500240289908500230292308500240
29460850024029700850032029941170006030260720003030321120009030351110010030441140
00903054113001103063002001303074#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a
07.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#7#RBHH340#nd#Rev. Bras. Hema
tol. Hemoter.#33#1#20110200#^f10^l14#1516-8484#10.5581/1516-8484.20110007#<b>Aut
ologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma<
/b>^len#^rND^1A01^nAfonso José Pereira^sCortez#^rND^1A01^nFrederico Luiz^sDulley
#^rND^1A01^nRosaura^sSaboya#^rND^1A01^nAlfredo^sMendrone Júnior#^rND^1A01^nUliss
es^sAmigo Filho#^rND^1A01^nFabio Luiz^sCoracin#^rND^1A01^nValéria^sBuccheri#^rND
^1A01^nCamila da Cruz Gouveia^sLinardi#^rND^1A01^nMilton Artur^sRuiz#^rND^1A01^n
Dalton de Alencar Fischer^sChamone#Universidade de São Paulo^iA01^1Faculdade de 
Medicina^cSão Paulo^sSP^pBrazil#^len^a<b>BACKGROUND:</b> Hodgkin's lymphoma has 
high rates of cure, but in 15% to 20% of general patients and between 35% and 40
% of those in advanced stages, the disease will progress or will relapse after i
nitial treatment. For this group, hematopoietic stem cell transplantation is con
sidered one option of salvage therapy. <b>OBJECTIVES:</b> To evaluate a group of
 106 patients with Hodgkin's lymphoma, who suffered relapse or who were refracto
ry to treatment, submitted to autologous hematopoietic stem cell transplantation
 in a single transplant center. <b>METHODS:</b> A retrospective study was perfor
med with data collected from patient charts. The analysis involved 106 classical
 Hodgkin's lymphoma patients who were consecutively submitted to high-dose chemo
therapy followed by autologous transplants in a single institution from April 19
93 to December 2006. <b>RESULTS:</b> The overall survival rates of this populati
on at five and ten years were 86% and 70%, respectively. The disease-free surviv
al was approximately 60% at five years. Four patients died of procedure-related 
causes but relapse of classical Hodgkin's lymphoma after transplant was the most
 frequent cause of death. Univariate analysis shows that sensitivity to pre-tran
splant treatment and hemoglobin &lt; 10 g/dL at diagnosis had an impact on patie
nt survival. Unlike other studies, B-type symptoms did not seem to affect overal
l survival. Lactic dehydrogenase and serum albumin concentrations analyzed at di
agnosis did not influence patient survival either. <b>CONCLUSION:</b> Autologous
 hematopoietic stem cell transplantation is an effective treatment strategy for 
early and late relapse in classical Hodgkin's lymphoma for cases that were respo
nsive to pre-transplant chemotherapy. Refractory to treatment is a sign of worse
 prognosis. Additionally, a hemoglobin concentration below 10 g/dL at diagnosis 
of Hodgkin's lymphoma has a negative impact on the survival of patients after tr
ansplant. As far as we know this relationship has not been previously reported.#
^ddecs^i1#^tm^len^kHodgkin's lymphoma^i1#^tm^len^kHematopoietic stem cell transp
lantation^i1#^tm^len^kAutologous transplantation^i1#^tm^len^kDoxorubicin^i1#^tm^
len^kBleomycynm^i1#^tm^len^kVinblastine^i1#^tm^len^kDacarbazine^i1#^tm^len^kStud
y retrospective^i1#other#23#20100923#9/23/2010#20101112#12/11/2010#v33n1a07.htm#
#
03892000000000697000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103038000400108121000200112049000800114
15800030012203000280012503100030015303200020015606500090015801400090016703500100
01762370027001860120087002130100039003000100034003390100027003730100036004000100
03200436010003100468010002900499010004300528010003000571010004600601070007900647
08320590072608500100278508500310279508500520282608500390287808500240291708500230
29410850024029640850024029880850032030121170006030440720003030501120009030531110
01003062114000903072113001103081002001303092008008903105#v33n1#V:\SciELO\serial\
rbhh\v33n1\markup\v33n1a07.htm#S#l#4#1#article#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#
ilus#tab#7#RBHH340#nd#Rev. bras. hematol. hemoter#33#1#20110200#^f10^l14#1516-84
84#10.5581/1516-8484.20110007#Autologous hematopoietic stem cell transplantation
 in classical Hodgkin's lymphoma^len#^rND^1A01^nAfonso José Pereira^sCortez#^rND
^1A01^nFrederico Luiz^sDulley#^rND^1A01^nRosaura^sSaboya#^rND^1A01^nAlfredo^sMen
drone Júnior#^rND^1A01^nUlisses^sAmigo Filho#^rND^1A01^nFabio Luiz^sCoracin#^rND
^1A01^nValéria^sBuccheri#^rND^1A01^nCamila da Cruz Gouveia^sLinardi#^rND^1A01^nM
ilton Artur^sRuiz#^rND^1A01^nDalton de Alencar Fischer^sChamone#^iA01^1Universid
ade de São Paulo^2Faculdade de Medicina^cSão Paulo^sSP^pBrazil#^len^aBACKGROUND:
 Hodgkin's lymphoma has high rates of cure, but in 15 percent to 20 percent of g
eneral patients and between 35 percent and 40 percent of those in advanced stage
s, the disease will progress or will relapse after initial treatment. For this g
roup, hematopoietic stem cell transplantation is considered one option of salvag
e therapy. OBJECTIVES: To evaluate a group of 106 patients with Hodgkin's lympho
ma, who suffered relapse or who were refractory to treatment, submitted to autol
ogous hematopoietic stem cell transplantation in a single transplant center. MET
HODS: A retrospective study was performed with data collected from patient chart
s. The analysis involved 106 classical Hodgkin's lymphoma patients who were cons
ecutively submitted to high-dose chemotherapy followed by autologous transplants
 in a single institution from April 1993 to December 2006. RESULTS: The overall 
survival rates of this population at five and ten years were 86 percent and 70 p
ercent, respectively. The disease-free survival was approximately 60 percent at 
five years. Four patients died of procedure-related causes but relapse of classi
cal Hodgkin's lymphoma after transplant was the most frequent cause of death. Un
ivariate analysis shows that sensitivity to pre-transplant treatment and hemoglo
bin < 10 g/dL at diagnosis had an impact on patient survival. Unlike other studi
es, B-type symptoms did not seem to affect overall survival. Lactic dehydrogenas
e and serum albumin concentrations analyzed at diagnosis did not influence patie
nt survival either. CONCLUSION: Autologous hematopoietic stem cell transplantati
on is an effective treatment strategy for early and late relapse in classical Ho
dgkin's lymphoma for cases that were responsive to pre-transplant chemotherapy. 
Refractory to treatment is a sign of worse prognosis. Additionally, a hemoglobin
 concentration below 10 g/dL at diagnosis of Hodgkin's lymphoma has a negative i
mpact on the survival of patients after transplant. As far as we know this relat
ionship has not been previously reported.#^ddecs^i1#^tm^len^kHodgkin's lymphoma^
i1#^tm^len^kHematopoietic stem cell transplantation^i1#^tm^len^kAutologous trans
plantation^i1#^tm^len^kDoxorubicin^i1#^tm^len^kBleomycynm^i1#^tm^len^kVinblastin
e^i1#^tm^len^kDacarbazine^i1#^tm^len^kStudy retrospective^i1#other#23#20100923#9
/23/2010#20101112#12/11/2010#v33n1a07.htm#Internet^ihttp://www.scielo.br/scielo.
php?script=sci_arttext&pid=S1516-84842011000100007##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#5#1#article#135#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLE</b><
/font></p>     ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#6#2#article#135#<p>&nbsp;</p>     ^cY
#v33n1a07.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704019000074002001300264#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#7#3#article#135#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Autologous hemato
poietic stem cell transplantation in classical Hodgkin's lymphoma</b></font></p>
     ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#8#4#article#135#<p>&nbsp;</p>     ^cY
#v33n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#9#5#article#135#<p>&nbsp;</p>     ^cY
#v33n1a07.htm##
00580000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704034600075002001300421#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#10#6#article#135#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Afonso Jos&eacute; Pereira Cortez;
 Frederico Luiz Dulley; Rosaura Saboya; Alfredo Mendrone J&uacute;nior; Ulisses 
Amigo Filho; Fabio Luiz Coracin; Val&eacute;ria Buccheri; Camila da Cruz Gouveia
 Linardi; Milton Artur Ruiz; Dalton de Alencar Fischer Chamone</b></font></p>   
  ^cY#v33n1a07.htm##
00409000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017500075002001300250#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#11#7#article#135#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Faculdade de Medicina, Universidade d
e S&atilde;o Paulo - USP, S&atilde;o Paulo (SP), Brazil</font></p>     ^cY#v33n1
a07.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#12#8#article#135#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></fon
t></p>     ^cY#v33n1a07.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#13#9#article#135#<p>&nbsp;</p>     ^c
Y#v33n1a07.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#14#10#article#135#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v33n1a07.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#15#11#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
33n1a07.htm##
00626000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039100076002001300467#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#16#12#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>BACKGROUND:</b> Hodgkin's lymphom
a has high rates of cure, but in 15% to 20% of general patients and between 35% 
and 40% of those in advanced stages, the disease will progress or will relapse a
fter initial treatment. For this group, hematopoietic stem cell transplantation 
is considered one option of salvage therapy.    ^cY#v33n1a07.htm##
00482000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024700076002001300323#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#17#13#article#135#<br>   <b>OBJECTIVE
S:</b> To evaluate a group of 106 patients with Hodgkin's lymphoma, who suffered
 relapse or who were refractory to treatment, submitted to autologous hematopoie
tic stem cell transplantation in a single transplant center.    ^cY#v33n1a07.htm
##
00558000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032300076002001300399#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#18#14#article#135#<br>   <b>METHODS:<
/b> A retrospective study was performed with data collected from patient charts.
 The analysis involved 106 classical Hodgkin's lymphoma patients who were consec
utively submitted to high-dose chemotherapy followed by autologous transplants i
n a single institution from April 1993 to December 2006.    ^cY#v33n1a07.htm##
00919000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068400076002001300760#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#19#15#article#135#<br>   <b>RESULTS:<
/b> The overall survival rates of this population at five and ten years were 86%
 and 70%, respectively. The disease-free survival was approximately 60% at five 
years. Four patients died of procedure-related causes but relapse of classical H
odgkin's lymphoma after transplant was the most frequent cause of death. Univari
ate analysis shows that sensitivity to pre-transplant treatment and hemoglobin &
lt; 10 g/dL at diagnosis had an impact on patient survival. Unlike other studies
, B-type symptoms did not seem to affect overall survival. Lactic dehydrogenase 
and serum albumin concentrations analyzed at diagnosis did not influence patient
 survival either.    ^cY#v33n1a07.htm##
00772000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053700076002001300613#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#20#16#article#135#<br>     <b>CONCLUS
ION:</b> Autologous hematopoietic stem cell transplantation is an effective trea
tment strategy for early and late relapse in classical Hodgkin's lymphoma for ca
ses that were responsive to pre-transplant chemotherapy. Refractory to treatment
 is a sign of worse prognosis. Additionally, a hemoglobin concentration below 10
 g/dL at diagnosis of Hodgkin's lymphoma has a negative impact on the survival o
f patients after transplant. As far as we know this relationship has not been pr
eviously reported.</font></p>     ^cY#v33n1a07.htm##
00516000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028100076002001300357#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#21#17#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Hodgkin's lymphoma;
 Hematopoietic stem cell transplantation; Autologous transplantation; Doxorubici
n; Bleomycynm; Vinblastine; Dacarbazine; Study retrospective</font></p> <hr size
="1" noshade>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#22#18#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#23#19#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#24#20#article#135#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></p>     ^
cY#v33n1a07.htm##
02408000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704217300076002001302249#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#25#21#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Classical Hodgkin's lymphoma (cHL) i
s a disease that has one of the highest cure rates of all human cancers with lon
g survival when patients are submitted to first-line treatment protocols which i
nvolve multiple chemotherapeutic agents with or without radiation such as the AB
VD protocol. The ABVD protocol consists of four to six 28-day cycles of doxorubi
cin 25 mg/m<sup>2</sup>, bleomycin 10 mg/m<sup>2</sup>, vinblastine 6 mg/m<sup>2
</sup> and dacarbazine 375 mg/m<sup>2</sup> on days one and 15 of each cycle. Th
e four drugs, administered intravenously, have few immediate toxic effects.<sup>
(1)</sup> More intense treatment protocols, such as escalated BEACOPP, an associ
ation of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, proca
rbazine and prednisone, promote a higher initial remission rate and increased di
sease-free survival in patients in advanced stages of disease. However the toxic
 effects and treatment-related mortality are higher.<sup>(2)</sup> Early stages 
of the disease allow treatment with few cycles of chemotherapy and low dose radi
ation, thereby minimizing long-term side effects.<sup>(3)</sup> Despite the effe
ctiveness of existing regimens, it has been reported in the literature that abou
t 20% of patients in early disease stage and 35% to 40% of patients with advance
d disease will have disease progression or relapse after the initial treatment.<
sup>(4)</sup> It is well known that these patients will not have good survival w
hen treated with conventional chemotherapy in particular those considered primar
y refractory patients and that have early relapse, i.e. within 12 months of init
ial treatment.<sup>(5)</sup> In order to improve treatment outcomes for this gro
up of patients, autologous hematopoietic stem cell transplantation (HSCT) has be
en used in refractory and relapsed cHL cases. Today there is ample documentation
 of the effectiveness of this approach<sup>(6)</sup> particularly in two randomi
zed studies, the British National Lymphoma Investigation (BNLI)<sup>(7)</sup> an
d Germany's Lymphoma Study Group (GHSG).<sup>(8)</sup></font></p>     ^cY#v33n1a
07.htm##
00713000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047800076002001300554#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#26#22#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Except for response to treatment of 
the disease prior to HSCT, no other predictive factor was found with an impact o
n survival in all the publications analyzed.<sup>(9)</sup> With data from a sing
le treatment center in Brazil, the objective of this study was to evaluate patie
nt survival and to identify possible predictors of survival, major treatment-rel
ated toxic effects and causes of death.</font></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#27#23#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#28#24#article#135#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Methods</b></font></p>     ^cY#v3
3n1a07.htm##
00922000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068700076002001300763#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#29#25#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This is a retrospective study with d
ata obtained from patient charts. Analysis involved 106 patients with cHL who we
re consecutively submitted to high-dose chemotherapy followed by autologous HSCT
 in a single institution from April 1993 to December 2006. Patients were followe
d up until December 2007, i.e. twelve months after concluding enrolment in the s
tudy; thus the mean follow up time was 47.5 months (12-178 months). For all pati
ents, the bone marrow had no evidence of infiltration by cHL at HSCT as proven b
y histopathological studies of samples obtained from at least one posterior ilia
c crest.</font></p>     ^cY#v33n1a07.htm##
00833000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059800076002001300674#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#30#26#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">After diagnosis patients were submit
ted to conventional treatment protocols with the MOPP protocol (six 28-day cycle
s of mechlorethamine 6 mg/m<sup>2</sup>, vincristine 1.4 mg/m<sup>2</sup>, proca
rbazine 100 mg/m<sup>2</sup> on the first day and prednisone 40 mg/m<sup>2</sup>
 for five days on days one and eight of each cycle), with ABVD or an association
 of both being used in 97 patients (91.5%). Involved-field radiotherapy was used
 as adjuvant treatment for 65% of patients with extensive tumor mass ("bulky").<
/font></p>     ^cY#v33n1a07.htm##
00652000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041700076002001300493#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#31#27#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Complete remission was defined as th
e absence of tumor for at least four weeks after the completion of chemotherapy 
pre-HSCT while partial remission was defined as a reduction in over 50% of the v
olume of the regions affected by the tumor for at least four weeks after chemoth
erapy without the appearance of new tumor-related lesions.</font></p>     ^cY#v3
3n1a07.htm##
00613000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037800076002001300454#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#32#28#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Patients were stratified as responde
rs to treatment used prior to HSCT when they attained a reduction of more than 5
0% of the initial tumor in the pre-transplant period (61.9% of cases) and refrac
tory for those who had less than 50% reduction in tumor involvement in the pre-H
SCT period (38.1%).</font></p>     ^cY#v33n1a07.htm##
01788000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704155300076002001301629#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#33#29#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Of the responders, 54 patients were 
in second complete remission (85%), four in second partial remission, four in th
ird complete remission and one in first partial remission. Pre-HSCT high-dose sa
lvage chemotherapy was performed in 45 patients (42.4%) using regimens based on 
ifosfamide with etoposide (53.33%), cytarabine with dexamethasone (22.22%) and i
fosfamide with gemcitabine (24.44%); 61 patients (57.54%) did not receive salvag
e chemotherapy. The mobilization of hematopoietic stem cells was attained in 83 
patients (78%) with cyclophosphamide 60 mg/kg on two consecutive days followed b
y granulocyte colony stimulating factor (G-CSF) at doses of 6 to 17 mcg/kg. For 
25 patients (22%), mobilization failed and collection was achieved by multiple b
one marrow aspirations. The resulting cells were cryopreserved for use to rescue
 bone marrow function after conditioning. The conditioning protocols used were B
EAM (BCNU 300 mg/m<sup>2</sup> on D-1, cytarabine 400mg/m<sup>2</sup> from D-2 t
o D-5, etoposide 200 mg/m<sup>2</sup> from D-2 to D-5 and melphalan 140 mg/m<sup
>2</sup> on D-6) in 55.38% of patients and CVB (BCNU 300 mg/m<sup>2</sup> on D-7
, etoposide 200 mg/m<sup>2</sup> on D-6 to D-3 and cyclophosphamide 60 mg/m<sup>
2</sup> on D-2 and D-1) in 27.35% of patients. MVB (a regime that substituted cy
clophosphamide for melphalan at a dose of 140 mg/m<sup>2</sup> on D-1) was used 
for 12.26% of the patients and 4.71% received other conditioning regimens.</font
></p>     ^cY#v33n1a07.htm##
00998000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076300076002001300839#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#34#30#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The World Health Organization toxici
ty grading scale, graduated from 0 to 4<sup>(10)</sup> was used to study the tox
ic effects of HSCT. The first day of two consecutive days with leukocyte counts 
above 1 x 10<sup>9</sup> cells/L or granulocytes above 0.5 x 10<sup>9</sup> cell
s/L, or platelets greater than 20 x 10<sup>9</sup> cells/L without transfusion w
ithin the previous seven days was considered the time of bone marrow engraftment
. Death that occurred before D+100 after infusion of cryopreserved bone marrow c
ells was considered transplant related. A CD34 cell count by flow cytometry was 
used to quantify hematopoietic precursor cells harvested and infused in the pati
ent.</font></p>     ^cY#v33n1a07.htm##
00851000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061600076002001300692#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#35#31#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This study was approved by the Ethic
s Committee for the Analysis of Research Projects (CAPPESQ) of the Hospital of t
he Medicine School, Universidade de S&atilde;o Paulo (number 0332/09 and Resolut
ion 196/96 of the National Health Council). Survival was analyzed using the Kapl
an-Meier method<sup>(11)</sup> with multivariate analysis by the Cox model to ev
aluate prognostic factors for survival. Statistical significance was considered 
for a p-value &lt; 0.05. Calculations of percentages, means and medians were use
d when necessary.</font></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#36#32#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#37#33#article#135#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>     ^cY#v3
3n1a07.htm##
00787000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055200076002001300628#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#38#34#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Autologous HSCT for cHL accounted fo
r about 7% of 2067 indications for transplantation performed up to December 2006
 at Hospital das Cl&iacute;nicas and about 20% of all autologous transplants in 
this period. The main characteristics of this transplant population are listed i
n <a href="#tab1">Table 1</a>. The overall survival rates of this population at 
five and ten years were 86% and 70%, respectively. The disease-free survival was
 approximately 60% at five years.</font></p>     ^cY#v33n1a07.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#39#35#article#135#<p><a name="tab1"><
/a></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#40#36#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#41#37#article#135#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a07tab01.jpg"></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#42#38#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00775000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054000076002001300616#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#43#39#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> A median of 2.6 x 10<sup>6</sup> CD
34<sup>+</sup> cells per kg of body weight was collected utilizing mobilization 
with a median time to engrafting of 12 days. There was no difference in survival
 in relation to the conditioning regimens employed (p=0.17). The mobilization of
 hematopoietic precursor cells in peripheral blood collection was unsuccessful f
or about a quarter of patients, so for these harvesting was by bone marrow aspir
ation.<sup>(12)</sup></font></p>     ^cY#v33n1a07.htm##
00678000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044300076002001300519#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#44#40#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Univariate analysis (<a href="#tab2"
>Table 2</a>) shows that sensitivity to pre-HSCT treatment and hemoglobin &lt; 1
0 g/dL at diagnosis had an impact on patient survival. Unlike other studies, B-t
ype symptoms did not affect overall survival. Lactic dehydrogenase and serum alb
umin concentrations analyzed at diagnosis did not influence patient survival eit
her.</font></p>     ^cY#v33n1a07.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#45#41#article#135#<p><a name="tab2"><
/a></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#46#42#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#47#43#article#135#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a07tab02.jpg"></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#48#44#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00509000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027400076002001300350#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#49#45#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Four patients had died by D+100 afte
r HSCT (3.74%). The causes were severe systemic infection in three cases and one
 case of bronchiolitis probably due to the use of a chemotherapeutic agent.</fon
t></p>     ^cY#v33n1a07.htm##
01044000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080900076002001300885#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#50#46#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Relapse of cHL after HSCT was the mo
st frequent cause of death. Of the 24 deaths after D+100, cHL as a cause, that i
s, progression after ASCT, accounted for 13 cases (54%). Septicemia was the caus
e of death in four patients (6.6%). One patient died of acute myocardial infarct
ion, one from pneumonia, one by bleeding of the colon followed by hypovolemic sh
ock, one by systemic aspergillosis and one had respiratory failure of undefined 
cause. In two cases the exact cause of death was not identified. Myelodysplastic
 syndrome (MDS), classified as multilineage dysplasia, diagnosed two years after
 the HSCT, was considered a late treatment-related complication of one patient w
ho was still alive at the end of the study period.</font></p>     ^cY#v33n1a07.h
tm##
00647000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041200076002001300488#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#51#47#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Fever was the most frequent complica
tion in the first 100 days after HSCT, present in 91.5% of patients. Fever witho
ut identified focus (38.7%), proven bacterial infection (27.37%), catheter infec
tion (11.3%), sepsis (6.6%), systemic candidiasis (3.77%), aspergillosis (1.88%)
 and cytomegalovirus infection (1.88%) were reported.</font></p>     ^cY#v33n1a0
7.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#52#48#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#53#49#article#135#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p>     ^cY
#v33n1a07.htm##
00758000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052300076002001300599#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#54#50#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Patients with cHL refractory to trea
tment and those that suffer relapse are problematic; on comparing current treatm
ent strategies, autologous HSCT provides the best results for these individuals.
 In this study, the overall survival at five years was around 80% with evidence 
of low toxicity and procedure-related mortality. <a href="#fig1">Figure 1</a> sh
ows the overall survival curve after autologous HSCT of patients diagnosed with 
cHL.</font></p>     ^cY#v33n1a07.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#55#51#article#135#<p><a name="fig1"><
/a></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#56#52#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#57#53#article#135#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a07fig01.jpg"></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#58#54#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
01153000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091800076002001300994#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#59#55#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Today this group of patients can be 
treated, from a practical standpoint, with conventional chemotherapy followed by
 high dose chemotherapy and autologous or allogeneic HSCT, as well as with exper
imental therapies, often involving specific monoclonal antibodies and/or palliat
ive radiotherapy. High-dose chemotherapy gives different results when applied to
 patients with minimal disease compared to patients with extensive areas of tumo
r; survival at three years ranges from 70% in the former group compared to only 
15% for patients of the latter.<sup>(13)</sup> Primary refractory cases and thos
e with early relapse, i.e. within 12 months of initial treatment, do not respond
 well to conventional treatment;<sup>14</sup> Bonadonna et al. reported less tha
n 15% of these patients had disease-free survival at five years.<sup>(15)</sup><
/font></p>     ^cY#v33n1a07.htm##
00561000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032600076002001300402#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#60#56#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The use of conventional salvage ther
apy achieved cure rates of less than 20% in the various series of published case
s.<sup>(16)</sup> The results of this study showed that patients with relapsed a
nd refractory cHL benefit from autologous HSCT.</font></p>     ^cY#v33n1a07.htm#
#
00859000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062400076002001300700#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#61#57#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In regard to prognostic factors, ser
um hemoglobin concentrations below 10 g/dL at diagnosis had a negative impact on
 survival; this has not been reported in any other publications and should thus 
be confirmed in future studies (<a href="#fig2">Figure 2</a>). The worse outcome
s correlated with the presence of B-type symptoms as reported by other authors w
as not confirmed in our study. However, response to pre-transplant chemotherapy 
was the main determinant of improved survival after HSCT, as illustrated in <a h
ref="#fig3">Figure 3</a>.</font></p>     ^cY#v33n1a07.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#62#58#article#135#<p><a name="fig2"><
/a></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#63#59#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#64#60#article#135#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a07fig02.jpg"></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#65#61#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#66#62#article#135#<p><a name="fig3"><
/a></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#67#63#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#68#64#article#135#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a07fig03.jpg"></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#69#65#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
01210000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704097500076002001301051#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#70#66#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Refractory cases could benefit from 
a more intense initial approach, as a more precise diagnosis can be attained tod
ay through studies using positron emission tomography.<sup>(17,18)</sup> Sureda 
et al., on analyzing 494 cHL patients submitted to HSCT by the Spanish Lymphoma 
Study Group, also noted that chemosensitivity is an important variable that dete
rmines response to HSCT. These authors even suggested that refractory patients s
hould be treated more aggressively in the early stages of treatment.<sup>(19)</s
up> The group at Seattle's Fred Hutchinson Cancer Research Center, in a study pu
blished in 2008 that analyzed 167 patients with refractory cHL submitted to HSCT
, failed to define any predictors of survival in this group. They concluded, how
ever, that HSCT can be performed in refractory patients, but only one in three p
atients will survive more than five years.<sup>(9)</sup></font></p>     ^cY#v33n
1a07.htm##
00772000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053700076002001300613#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#71#67#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Due to the high number of CD30 cells
 expressed in cHL, this is considered a promising disease for targeted monoclona
l therapy with the use of anti-CD30 antibodies. Some forms of humanized antibodi
es have been tested in clinical trials but showed low response rates and caused 
grade II and III pulmonary and hepatic toxicity and suppression of bone marrow f
unction when used as therapy in isolation,<sup>(20)</sup> thus they give worse o
utcomes than HSCT.</font></p>     ^cY#v33n1a07.htm##
01015000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704078000076002001300856#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#72#68#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Radiotherapy may be useful as adjuva
nt therapy in the treatment of localized relapse, but without a complete cure be
ing expected. Lymphomas are malignant tumors  that are highly sensitive to radio
therapy, especially cHL.<sup>(21)</sup> Allogeneic transplants, even with reduce
d conditioning doses, should be reserved for selected refractory cases and patie
nts that relapse after autologous transplants because the higher mortality rate 
in cHL patients makes indication a difficult decision.<sup>(22)</sup> Survival d
oes not seem to be higher than in autologous transplants due to the high rate of
 procedure-related mortality, in spite of the biological graft-versus-lymphoma e
ffect.<sup>(23)</sup></font></p>     ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#73#69#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#74#70#article#135#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Conclusion</b></font></p>     ^cY
#v33n1a07.htm##
00887000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065200076002001300728#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#75#71#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We believe that autologous HSCT is a
n effective treatment strategy for early and late relapse in cHL cases that are 
responsive to pre-HSCT chemotherapy, giving an overall survival rate of greater 
than 80% at five years. Patients are tolerant to the BEAM and CVB conditioning r
egimens and in our series of patients the mortality rate within one hundred days
 of HSCT was 3.74%. Patients who are refractory to primary treatment do not exhi
bit the same response as those who responded to pre-HSCT chemotherapy, and thus 
refractory to treatment is a sign of worse prognosis.</font></p>     ^cY#v33n1a0
7.htm##
00732000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049700076002001300573#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#76#72#article#135#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The presence of hemoglobin concentra
tions below 10 g/dL at diagnosis of cHL is a negative impact factor on the survi
val of patients after HSCT. We did not find any mention of this relationship in 
the literature but according to the sample in this study we believe that the hem
oglobin level at diagnosis may be a possible predictive factor of poor prognosis
, which should be taken into account when indicating HSCT.</font></p>     ^cY#v3
3n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#77#73#article#135#<p>&nbsp;</p>     ^
cY#v33n1a07.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#78#74#article#135#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY
#v33n1a07.htm##
00630000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704038100078002001300459#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#79#75#article#135#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Canellos GP, Anders
on JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of adv
anced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J
 Med. 1992;327(21):1478-84. Comment in: N Engl J Med. 2002;346(18):1417-8. N Eng
l J Med. 1993;328(14):1045; author reply 1045-6.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#80#76#article#135#</font></p>     ^cY
#v33n1a07.htm##
00841000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704059200078002001300670#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#81#77#article#135#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Diehl V, Franklin J
, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, D&ouml
;rken B, M&uuml;ller-Hermelink HK, D&uuml;hmke E, Loeffler M; German Hodgkin's L
ymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared w
ith COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348(24):2386-95
. Erratum in: N Engl J Med. 2005;353(7):744. Dosage error in article text. Comme
nt in: N Engl J Med. 2003 ;349(12):1186-7; author reply 1186-7. N Engl J Med. 20
03 ;348(24):2375-6.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#82#78#article#135#</font></p>     ^cY
#v33n1a07.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026500078002001300343#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#83#79#article#135#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Engert A, Pl&uuml;t
schow A, Eich HT, Lohri A, D&ouml;rken B, Borchmann P, et al. Reduced treatment 
intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;36
3(7):640-52.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#84#80#article#135#</font></p>     ^cY
#v33n1a07.htm##
00644000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704039500078002001300473#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#85#81#article#135#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Straus DJ, Portlock
 SC, Qin J, Myers J, Zelenetz AD, Moskowitz A et al. Results of a prospective ra
ndomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine 
(ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, an
d IIIA nonbulky Hodgkin disease. Blood. 2004;104 (12):3483-89.    ^cY#v33n1a07.h
tm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#86#82#article#135#</font></p>     ^cY
#v33n1a07.htm##
00495000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024600078002001300324#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#87#83#article#135#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Bartlett NL. Therap
ies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches incl
uding immunotherapy. Hematology Am Soc Hematol Educ Program. 2005:245-51.    ^cY
#v33n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#88#84#article#135#</font></p>     ^cY
#v33n1a07.htm##
00413000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016400078002001300242#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#89#85#article#135#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Ansell SM, Armitage
 JO. Management of Hodgkin lymphoma. Mayo Clin Proc. 2006;81(3):419-26.    ^cY#v
33n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#90#86#article#135#</font></p>     ^cY
#v33n1a07.htm##
00574000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032500078002001300403#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#91#87#article#135#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Linch DC, Winfield 
D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with
 autologous bone-marrow transplantation in relapsed and resistant Hodgkin's dise
ase: results of a BNLI randomised trial. Lancet. 1993;341 (8852):1051-4.    ^cY#
v33n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#92#88#article#135#</font></p>     ^cY
#v33n1a07.htm##
00855000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704060600078002001300684#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#93#89#article#135#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Schmitz N, Pfistner
 B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, M&uuml;l
ler P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl
 V; German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the Europea
n Group for Blood and Marrow Transplantation. Aggressive conventional chemothera
py compared with high-dose chemotherapy with autologous haemopoietic stem-cell t
ransplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial
. Lancet. 2002;359(9323):2065-71.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#94#90#article#135#</font></p>     ^cY
#v33n1a07.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030200078002001300380#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#95#91#article#135#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Gopal AK, Metcalfe 
TL, Gooley TA, Pagel JM, Petersdorf SH, Bensinger WI, et al. High-dose therapy a
nd autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the
 Seattle experience. Cancer. 2008;113(6):1344-50.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#96#92#article#135#</font></p>     ^cY
#v33n1a07.htm##
00438000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704018800079002001300267#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#97#93#article#135#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Miller AB, Hoogst
raten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 19
81;47(1):207-14.    ^cY#v33n1a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#98#94#article#135#</font></p>     ^cY
#v33n1a07.htm##
00432000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704018200079002001300261#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#99#95#article#135#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Kaplan EL, Meier 
P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;
53:457-81.    ^cY#v33n1a07.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#100#96#article#135#</font></p>     ^c
Y#v33n1a07.htm##
00585000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704033400080002001300414#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#101#97#article#135#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Canales MA, Fern
&aacute;ndez-Jim&eacute;nez MC, Mart&iacute;n A, Arrieta R, Caballero MD, D&iacu
te;ez J, et al. Identification of factors associated with poor peripheral blood 
progenitor cell mobilization in Hodgkin's disease. Haematologica. 2001;86(5):494
-8.    ^cY#v33n1a07.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#102#98#article#135#</font></p>     ^c
Y#v33n1a07.htm##
00578000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704032700080002001300407#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#103#99#article#135#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Lazarus HM, Rowl
ings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, et al. Autotransplants for 
Hodgkin's disease in patients never achieving remission: a report from the Autol
ogous Blood and Marrow Transplant Registry. J Clin Oncol. 1999;17 (2):534-5.    
^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#104#100#article#135#</font></p>     ^
cY#v33n1a07.htm##
00613000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036100081002001300442#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#105#101#article#135#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Lavoie JC, Conn
ors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, et al. High-dose chemothe
rapy and autologous stem cell transplantation for primary refractory or relapsed
 Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancou
ver. Blood. 2005;106(4):1473-8.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#106#102#article#135#</font></p>     ^
cY#v33n1a07.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#107#103#article#135#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Bonadonna G, Sa
ntoro A, Gianni AM, Viviani S, Siena S, Bregni M, et al. Primary and salvage che
motherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. 
Ann Oncol. 1991;2 Suppl 1:9-16.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#108#104#article#135#</font></p>     ^
cY#v33n1a07.htm##
00416000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016400081002001300245#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#109#105#article#135#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Aisenberg AC. P
roblems in Hodgkin's disease management. Blood. 1999,93(3):761-79. Review.    ^c
Y#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#110#106#article#135#</font></p>     ^
cY#v33n1a07.htm##
00721000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704046900081002001300550#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#111#107#article#135#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Rigacci L, Vito
lo U, Nassi L, Merli F, Gallamini A, Pregno P, Alvarez I, Salvi F, Sancetta R, C
astagnoli A, Versari A, Biggi A, Gregianin M, Pelosi E, Chisesi T, Bosi A, Levis
 A; Intergruppo Italiano Linfomi. Positron emission tomography in the staging of
 patients with Hodgkin's lymphoma. A prospective multicentric study by the Inter
gruppo Italiano Linfomi. Ann Hematol. 2007; 86(12):897-903.    ^cY#v33n1a07.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#112#108#article#135#</font></p>     ^
cY#v33n1a07.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025100081002001300332#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#113#109#article#135#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Juweid ME. Util
ity of positron emission tomography(PET) scanning in managing patients with Hodg
kin lymphoma. Hematology Am Soc Hematol Educ Program. 2006:259-65, 510-1. Review
.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#114#110#article#135#</font></p>     ^
cY#v33n1a07.htm##
01101000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704084900081002001300930#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#115#111#article#135#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19 Sureda A, Arranz
 R, Iriondo A, Carreras E, Lahuerta JJ, Garc&iacute;a-Conde J, Jarque I, Caballe
ro MD, Ferr&agrave; C, L&oacute;pez A, Garc&iacute;a-Lara&ntilde;a J, Cabrera R,
 Carrera D, Ruiz-Romero MD, Le&oacute;n A, Rif&oacute;n J, D&iacute;az-Mediavill
a J, Mataix R, Morey M, Moraleda JM, Alt&eacute;s A, L&oacute;pez-Guillermo A, d
e la Serna J, Fern&aacute;ndez-Ra&ntilde;ada JM, Sierra J, Conde E; Grupo Espa&n
tilde;ol de Linformas/Transplante Aut&oacute;logo de M&eacute;dula Osea Spanish 
Cooperative Group. Autologous stem-cell transplantation for Hodgkin's disease: r
esults and prognostic factors in 494 patients from the Grupo Espa&ntilde;ol de L
infomas/Transplante Aut&oacute;logo de M&eacute;dula Osea Spanish Cooperative Gr
oup. J Clin Oncol. 2001;19(5):1395-404.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#116#112#article#135#</font></p>     ^
cY#v33n1a07.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030600081002001300387#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#117#113#article#135#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Schnell R, Diet
lein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, et al. Treatment of ref
ractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti- CD30
 monoclonal antibody. J Clin Oncol. 2005;23(21):4669-78.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#118#114#article#135#</font></p>     ^
cY#v33n1a07.htm##
00955000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704070300081002001300784#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#119#115#article#135#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Aleman BM, Raem
aekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde 
P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lu
gtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Car
rie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna
 A, Henry-Amar M; European Organization for Research and Treatment of Cancer Lym
phoma Group. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl
 J Med. 2003;348(24):2396-406. Comment in: N Engl J Med. 2003;348(24):2375-6. N 
Engl J Med. 2003;349(12):1187-8; author reply 1187-8.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#120#116#article#135#</font></p>     ^
cY#v33n1a07.htm##
00555000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030300081002001300384#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#121#117#article#135#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Anderson JE, Li
tzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, et al. Allogeneic, synge
neic, and autologous marrow transplantation for Hodgkin's disease: the 21-year S
eattle experience. J Clin Oncol. 1993;11(12):2342-50.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#122#118#article#135#</font></p>     ^
cY#v33n1a07.htm##
00749000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704049700081002001300578#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#123#119#article#135#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Sureda A, Robin
son S, Canals C, Carella AM, Boogaerts MA, Caballero D, et al. Reduced-intensity
 conditioning compared with conventional allogeneic stem-cell transplantation in
 relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Workin
g Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol
. 2008;26(3):455-62. Comment in: J Clin Oncol. 2008;26(24):4045-6; author reply 
4046-7.    ^cY#v33n1a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#124#120#article#135#</font></p>     ^
cY#v33n1a07.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#125#121#article#135#<p>&nbsp;</p>    
 ^cY#v33n1a07.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#126#122#article#135#<p>&nbsp;</p>    
 ^cY#v33n1a07.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018600078002001300264#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#127#123#article#135#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b
>    ^cY#v33n1a07.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004600078002001300124#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#128#124#article#135#<br> Afonso Jos&e
acute; Pereira Cortez    ^cY#v33n1a07.htm##
00395000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704015800078002001300236#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#129#125#article#135#<br> Disciplina d
e Hematologia e Hemoterapia,  Departamento de Cl&iacute;nica M&eacute;dica,  Fac
uldade de Medicina,  Universidade de S&atilde;o Paulo    ^cY#v33n1a07.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006200078002001300140#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#130#126#article#135#<br> Rua Leandro 
Dupret, 204, sala 93, Vila Clementino    ^cY#v33n1a07.htm##
00291000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005400078002001300132#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#131#127#article#135#<br> 04025-010 - 
S&atilde;o Paulo (SP), Brazil    ^cY#v33n1a07.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#132#128#article#135#<br> Phone: 55 11
 55750562    ^cY#v33n1a07.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#133#129#article#135#<br> <a href="mai
lto:afonsocortez@globo.com">afonsocortez@globo.com</a></font></p>     ^cY#v33n1a
07.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#134#130#article#135#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted: 9/23/2010    ^cY#v33n1a
07.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003300078002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#135#131#article#135#<br> Accepted: 12
/11/2010    ^cY#v33n1a07.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010900078002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#136#132#article#135#<br> Conflict-of-
interest disclosure: The authors declare no competing financial interest</font><
/p>     ^cY#v33n1a07.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#137#133#article#135#<p>&nbsp;</p>    
 ^cY#v33n1a07.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#138#134#article#135#<p>&nbsp;</p>    
 ^cY#v33n1a07.htm##
00460000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022300078002001300301#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a07.htm#S#p#139#135#article#135#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" targ
et="_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_bla
nk">www.scielo.br/rbhh</a></font></p>     ^cY#v33n1a07.htm##
00835000000000361000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100019000960100
01800115010001600133010001700149010002000166810000600186012009400192030001300286
06500090029906400050030803100040031303200030031701400080032006101000032886500090
0428002001300437035001000450801001300460#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a07.htm#S#c#140#1#article#23#1#^rND^sCanellos^nGP#^rND^sAnderson^nJR#^rND
^sPropert^nKJ#^rND^sNissen^nN#^rND^sCooper^nMR#^rND^sHenderson^nES#et al#Chemoth
erapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with AB
VD^len#N Engl J Med#19920000#1992#327#21#1478-84#Comment in: N Engl J Med. 2002;
346(18):1417-8. N Engl J Med. 1993;328(14):1045; author reply 1045-6#20110200#v3
3n1a07.htm#0028-4793#N Engl J Med##
01139000000000433000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100018000920100
02200110010001600132010001600148010002100164010001500185010001800200010001600218
01000270023401000160026101000180027701100380029501201080033303000130044106500090
04540640005004630310004004680320003004720140008004750610177004838650009006600020
01300669035001000682801001300692#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a
07.htm#S#c#141#2#article#23#2#^rND^sDiehl^nV#^rND^sFranklin^nJ#^rND^sPfreundschu
h^nM#^rND^sLathan^nB#^rND^sPaulus^nU#^rND^sHasenclever^nD#^rND^sTesch^nH#^rND^sH
errmann^nR#^rND^sDörken^nB#^rND^sMüller-Hermelink^nHK#^rND^sDühmke^nE#^rND^sLoef
fler^nM#German Hodgkin's Lymphoma Study Group#Standard and increased-dose BEACOP
P chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease^len#N Engl
 J Med#20030000#2003#348#24#2386-95#Erratum in: N Engl J Med. 2005;353(7):744. D
osage error in article text. Comment in: N Engl J Med. 2003 ;349(12):1186-7; aut
hor reply 1186-7. N Engl J Med. 2003 ;348(24):2375-6#20110200#v33n1a07.htm#0028-
4793#N Engl J Med##
00698000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100019000930100
01500112010001500127010001600142010001900158810000600177012008000183030001300263
06500090027606400050028503100040029003200020029401400070029686500090030300200130
0312035001000325801001300335#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.h
tm#S#c#142#3#article#23#3#^rND^sEngert^nA#^rND^sPlütschow^nA#^rND^sEich^nHT#^rND
^sLohri^nA#^rND^sDörken^nB#^rND^sBorchmann^nP#et al#Reduced treatment intensity 
in patients with early-stage Hodgkin's lymphoma^len#N Engl J Med#20100000#2010#3
63#7#640-52#20110200#v33n1a07.htm#0028-4793#N Engl J Med##
00831000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940100
01300113010001500126010001900141010001900160810000600179012022300185030000600408
06500090041406400050042303100040042803200030043201400080043586500090044300200130
0452035001000465801000600475#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.h
tm#S#c#143#4#article#23#4#^rND^sStraus^nDJ#^rND^sPortlock^nSC#^rND^sQin^nJ#^rND^
sMyers^nJ#^rND^sZelenetz^nAD#^rND^sMoskowitz^nA#et al#Results of a prospective r
andomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine
 (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, a
nd IIIA nonbulky Hodgkin disease^len#Blood#20040000#2004#104#12#3483-89#20110200
#v33n1a07.htm#0006-4971#Blood##
00532000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770120110000960300
03900206710000200245065000900247064000500256014000700261865000900268002001300277
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#c#144#5#article#23#5#^r
ND^sBartlett^nNL#Therapies for relapsed Hodgkin lymphoma: transplant and non-tra
nsplant approaches including immunotherapy^len#Hematology Am Soc Hematol Educ Pr
ogram#2#20050000#2005#245-51#20110200#v33n1a07.htm##
00526000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940120
03500113030001500148065000900163064000500172031000300177032000200180014000700182
865000900189002001300198035001000211801001500221#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a07.htm#S#c#145#6#article#23#6#^rND^sAnsell^nSM#^rND^sArmitage^nJ
O#Management of Hodgkin lymphoma^len#Mayo Clin Proc#20060000#2006#81#3#419-26#20
110200#v33n1a07.htm#0025-6196#Mayo Clin Proc##
00761000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930100
02000111010001400131010001700145010001800162810000600180012014900186030000700335
06500090034206400050035103100040035603200050036001400070036586500090037200200130
0381035001000394801000700404#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.h
tm#S#c#146#7#article#23#7#^rND^sLinch^nDC#^rND^sWinfield^nD#^rND^sGoldstone^nAH#
^rND^sMoir^nD#^rND^sHancock^nB#^rND^sMcMillan^nA#et al#Dose intensification with
 autologous bone-marrow transplantation in relapsed and resistant Hodgkin's dise
ase: results of a BNLI randomised trial^len#Lancet#19930000#1993#341#8852#1051-4
#20110200#v33n1a07.htm#0099-5355#Lancet##
01223000000000481000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01600112010001600128010001800144010001600162010002000178010001800198010001600216
01000180023201000150025001000160026501000140028101000210029501000200031601000150
03360110038003510110076003890120199004650300007006640650009006710640005006800310
00400685032000500689014000800694865000900702002001300711035001000724801000700734
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#c#147#8#article#23#8#^r
ND^sSchmitz^nN#^rND^sPfistner^nB#^rND^sSextro^nM#^rND^sSieber^nM#^rND^sCarella^n
AM#^rND^sHaenel^nM#^rND^sBoissevain^nF#^rND^sZschaber^nR#^rND^sMüller^nP#^rND^sK
irchner^nH#^rND^sLohri^nA#^rND^sDecker^nS#^rND^sKoch^nB#^rND^sHasenclever^nD#^rN
D^sGoldstone^nAH#^rND^sDiehl^nV#German Hodgkin's Lymphoma Study Group#European G
roup for Blood and Marrow Transplantation^dLymphoma Working Party#Aggressive con
ventional chemotherapy compared with high-dose chemotherapy with autologous haem
opoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease
: a randomised trial^len#Lancet#20020000#2002#359#9323#2065-71#20110200#v33n1a07
.htm#0099-5355#Lancet##
00739000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100019000930100
01700112010001600129010002100145010002000166810000600186012012300192030000700315
06500090032206400050033103100040033603200020034001400080034286500090035000200130
0359035001000372801000700382#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.h
tm#S#c#148#9#article#23#9#^rND^sGopal^nAK#^rND^sMetcalfe^nTL#^rND^sGooley^nTA#^r
ND^sPagel^nJM#^rND^sPetersdorf^nSH#^rND^sBensinger^nWI#et al#High-dose therapy a
nd autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the
 Seattle experience^len#Cancer#20080000#2008#113#6#1344-50#20110200#v33n1a07.htm
#0008-543X#Cancer##
00579000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100021000960100
01700117010001700134012004200151030000700193065000900200064000500209031000300214
032000200217014000700219865000900226002001300235035001000248801000700258#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#c#149#10#article#23#10#^rND^sMi
ller^nAB#^rND^sHoogstraten^nB#^rND^sStaquet^nM#^rND^sWinkler^nA#Reporting result
s of cancer treatment^len#Cancer#19810000#1981#47#1#207-14#20110200#v33n1a07.htm
#0008-543X#Cancer##
00535000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960120
05800111030001600169065000900185064000500194031000300199014000700202865000900209
002001300218035001000231801001600241#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a07.htm#S#c#150#11#article#23#11#^rND^sKaplan^nEL#^rND^sMeier^nP#Nonparametri
c estimation from incomplete observations^len#J Am Stat Assoc#19580000#1958#53#4
57-81#20110200#v33n1a07.htm#0162-1459#J Am Stat Assoc##
00751000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100028000970100
01600125010001700141010002000158010001400178810000600192012011800198030001400316
06500090033006400050033903100030034403200020034701400060034986500090035500200130
0364035001000377801001400387#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.h
tm#S#c#151#12#article#23#12#^rND^sCanales^nMA#^rND^sFernández-Jiménez^nMC#^rND^s
Martín^nA#^rND^sArrieta^nR#^rND^sCaballero^nMD#^rND^sDíez^nJ#et al#Identificatio
n of factors associated with poor peripheral blood progenitor cell mobilization 
in Hodgkin's disease^len#Haematologica#20010000#2001#86#5#494-8#20110200#v33n1a0
7.htm#0390-6078#Haematologica##
00770000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01600116010001500132010001900147010001800166810000600184012014700190030001300337
06500090035006400050035903100030036403200020036701400060036986500090037500200130
0384035001000397801001300407#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.h
tm#S#c#152#13#article#23#13#^rND^sLazarus^nHM#^rND^sRowlings^nPA#^rND^sZhang^nMJ
#^rND^sVose^nJM#^rND^sArmitage^nJO#^rND^sBierman^nPJ#et al#Autotransplants for H
odgkin's disease in patients never achieving remission: a report from the Autolo
gous Blood and Marrow Transplant Registry^len#J Clin Oncol#19990000#1999#17#2#53
4-5#20110200#v33n1a07.htm#0732-183X#J Clin Oncol##
00798000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01900114010001600133010001800149010001800167810000600185012018600191030000600377
06500090038306400050039203100040039703200020040101400070040386500090041000200130
0419035001000432801000600442#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.h
tm#S#c#153#14#article#23#14#^rND^sLavoie^nJC#^rND^sConnors^nJM#^rND^sPhillips^nG
L#^rND^sReece^nDE#^rND^sBarnett^nMJ#^rND^sForrest^nDL#et al#High-dose chemothera
py and autologous stem cell transplantation for primary refractory or relapsed H
odgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouve
r^len#Blood#20050000#2005#106#4#1473-8#20110200#v33n1a07.htm#0006-4971#Blood##
00725000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01700115010001700132010001500149010001600164810000600180012010600186030001000292
06500090030206400050031103100020031603200100031801400050032886500090033300200130
0342035001000355801001000365#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.h
tm#S#c#154#15#article#23#15#^rND^sBonadonna^nG#^rND^sSantoro^nA#^rND^sGianni^nAM
#^rND^sViviani^nS#^rND^sSiena^nS#^rND^sBregni^nM#et al#Primary and salvage chemo
therapy in advanced Hodgkin's disease: the Milan Cancer Institute experience^len
#Ann Oncol#19910000#1991#2#^sSuppl 1#9-16#20110200#v33n1a07.htm#0923-7534#Ann On
col##
00511000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790120045000990300
00600144065000900150064000500159031000300164032000200167014000700169061000700176
865000900183002001300192035001000205801000600215#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a07.htm#S#c#155#16#article#23#16#^rND^sAisenberg^nAC#Problems in 
Hodgkin's disease management^len#Blood#19990000#1999#93#3#761-79#Review#20110200
#v33n1a07.htm#0006-4971#Blood##
01109000000000481000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01500112010001500127010001900142010001600161010001700177010001500194010001800209
01000200022701000170024701000150026401000190027901000160029801000170031401000140
03310100015003450110029003600120154003890300012005430650009005550640005005640310
00300569032000300572014000800575865000900583002001300592035001000605801001200615
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#c#156#17#article#23#17#
^rND^sRigacci^nL#^rND^sVitolo^nU#^rND^sNassi^nL#^rND^sMerli^nF#^rND^sGallamini^n
A#^rND^sPregno^nP#^rND^sAlvarez^nI#^rND^sSalvi^nF#^rND^sSancetta^nR#^rND^sCastag
noli^nA#^rND^sVersari^nA#^rND^sBiggi^nA#^rND^sGregianin^nM#^rND^sPelosi^nE#^rND^
sChisesi^nT#^rND^sBosi^nA#^rND^sLevis^nA#Intergruppo Italiano Linfomi#Positron e
mission tomography in the staging of patients with Hodgkin's lymphoma: A prospec
tive multicentric study by the Intergruppo Italiano Linfomi^len#Ann Hematol#2007
0000#2007#86#12#897-903#20110200#v33n1a07.htm#0939-5555#Ann Hematol##
00560000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120101000960300
03900197710000200236065000900238064000500247014000700252014000600259061000700265
865000900272002001300281#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S
#c#157#18#article#23#18#^rND^sJuweid^nME#Utility of positron emission tomography
(PET) scanning in managing patients with Hodgkin lymphoma^len#Hematology Am Soc 
Hematol Educ Program#2#20060000#2006#259-65#510-1#Review#20110200#v33n1a07.htm##
01528000000000589000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01700111010001800128010001900146010002200165010001600187010002000203010001500223
01000150023801000230025301000170027601000170029301000220031001000140033201000150
03460100025003610100016003860100015004020100019004170100015004360100025004510100
02100476010002700497010001600524010001500540011008900555012020800644030001300852
06500090086506400050087403100030087903200020088201400090088486500090089300200130
0902035001000915801001300925#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.h
tm#S#c#158#19#article#23#19#^rND^sSureda^nA#^rND^sArranz^nR#^rND^sIriondo^nA#^rN
D^sCarreras^nE#^rND^sLahuerta^nJJ#^rND^sGarcía-Conde^nJ#^rND^sJarque^nI#^rND^sCa
ballero^nMD#^rND^sFerrà^nC#^rND^sLópez^nA#^rND^sGarcía-Laraña^nJ#^rND^sCabrera^n
R#^rND^sCarrera^nD#^rND^sRuiz-Romero^nMD#^rND^sLeón^nA#^rND^sRifón^nJ#^rND^sDíaz
-Mediavilla^nJ#^rND^sMataix^nR#^rND^sMorey^nM#^rND^sMoraleda^nJM#^rND^sAltés^nA#
^rND^sLópez-Guillermo^nA#^rND^sde la Serna^nJ#^rND^sFernández-Rañada^nJM#^rND^sS
ierra^nJ#^rND^sConde^nE#Grupo Español de Linformas/Transplante Autólogo de Médul
a Osea Spanish Cooperative Group#Autologous stem-cell transplantation for Hodgki
n's disease: results and prognostic factors in 494 patients from the Grupo Españ
ol de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group^len
#J Clin Oncol#20010000#2001#19#5#1395-404#20110200#v33n1a07.htm#0732-183X#J Clin
 Oncol##
00750000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01600114010001900130010002100149010001700170810000600187012012100193030001300314
06500090032706400050033603100030034103200030034401400080034786500090035500200130
0364035001000377801001300387#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.h
tm#S#c#159#20#article#23#20#^rND^sSchnell^nR#^rND^sDietlein^nM#^rND^sStaak^nJO#^
rND^sBorchmann^nP#^rND^sSchomaecker^nK#^rND^sFischer^nT#et al#Treatment of refra
ctory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti- CD30 m
onoclonal antibody^len#J Clin Oncol#20050000#2005#23#21#4669-78#20110200#v33n1a0
7.htm#0732-183X#J Clin Oncol##
01572000000000637000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100021000960100
01700117010001800134010002200152010001800174010001800192010001500210010001800225
01000250024301000160026801000140028401000180029801000200031601000210033601000160
03570100019003730100018003920100016004100100025004260100016004510100019004670100
01400486010001700500010001500517010002000532010001900552010001500571010002000586
01100740060601200640068003000130074406500090075706400050076603100040077103200030
0775014000900778061010200787865000900889002001300898035001000911801001300921#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.htm#S#c#160#21#article#23#21#^rND
^sAleman^nBM#^rND^sRaemaekers^nJM#^rND^sTirelli^nU#^rND^sBortolus^nR#^rND^svan '
t Veer^nMB#^rND^sLybeert^nML#^rND^sKeuning^nJJ#^rND^sCarde^nP#^rND^sGirinsky^nT#
^rND^svan der Maazen^nRW#^rND^sTomsic^nR#^rND^sVovk^nM#^rND^svan Hoof^nA#^rND^sD
emeestere^nG#^rND^sLugtenburg^nPJ#^rND^sThomas^nJ#^rND^sSchroyens^nW#^rND^sDe Bo
eck^nK#^rND^sBaars^nJW#^rND^sKluin-Nelemans^nJC#^rND^sCarrie^nC#^rND^sAoudjhane^
nM#^rND^sBron^nD#^rND^sEghbali^nH#^rND^sSmit^nWG#^rND^sMeerwaldt^nJH#^rND^sHagen
beek^nA#^rND^sPinna^nA#^rND^sHenry-Amar^nM#European Organization for Research an
d Treatment of Cancer Lymphoma Group#Involved-field radiotherapy for advanced Ho
dgkin's lymphoma^len#N Engl J Med#20030000#2003#348#24#2396-406#Comment in: N En
gl J Med. 2003;348(24):2375-6. N Engl J Med. 2003;349(12):1187-8; author reply 1
187-8#20110200#v33n1a07.htm#0028-4793#N Engl J Med##
00747000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
02000115010001600135010001700151010001800168810000600186012011900192030001300311
06500090032406400050033303100030033803200030034101400080034486500090035200200130
0361035001000374801001300384#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a07.h
tm#S#c#161#22#article#23#22#^rND^sAnderson^nJE#^rND^sLitzow^nMR#^rND^sAppelbaum^
nFR#^rND^sSchoch^nG#^rND^sFisher^nLD#^rND^sBuckner^nCD#et al#Allogeneic, syngene
ic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Sea
ttle experience^len#J Clin Oncol#19930000#1993#11#12#2342-50#20110200#v33n1a07.h
tm#0732-183X#J Clin Oncol##
00952000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01600113010001800129010002000147010001900167810000600186012024800192030001300440
06500090045306400050046203100030046703200020047001400070047206100660047986500090
0545002001300554035001000567801001300577#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a07.htm#S#c#162#23#article#23#23#^rND^sSureda^nA#^rND^sRobinson^nS#^rND^s
Canals^nC#^rND^sCarella^nAM#^rND^sBoogaerts^nMA#^rND^sCaballero^nD#et al#Reduced
-intensity conditioning compared with conventional allogeneic stem-cell transpla
ntation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymph
oma Working Party of the European Group for Blood and Marrow Transplantation^len
#J Clin Oncol#20080000#2008#26#3#455-62#Comment in: J Clin Oncol. 2008;26(24):40
45-6; author reply 4046-7#20110200#v33n1a07.htm#0732-183X#J Clin Oncol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#o#1#1#article#1
#20110411#115525#v33n1a08.htm#205##
02886000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000290011203100030014103200020014406500090014601400090015503500100016423700270
01740120058002010100038002590100036002970100031003330100035003640100034003990100
02700433070009400460070007100554083147700625085001002102085002402112085004002136
08500220217608500380219811700060223607200030224211200090224511100100225411400090
2264113001002273002001302283#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.h
tm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#8#RBHH340#nd#Rev. Bras. Hematol.
 Hemoter.#33#1#20110200#^f15^l20#1516-8484#10.5581/1516-8484.20110008#Oral care 
in Brazilian bone marrow transplant centers^len#^rND^1A01^nFernanda de Paula^sEd
uardo#^rND^1A01^nLetícia Mello^sBezinelli#^rND^1A01^nNelson^sHamerschlak#^rND^1A
01^nClaudia Toledo^sAndrade#^rND^1A01^nLeonardo Raul^sMorelli#^rND^1A02^nLuciana
^sCorrêa#Hospital Israelita Albert Einstein^iA01^1Bone Marrow Transplant Center^
cSão Paulo^sSP^pBrazil#Unversidade de São Paulo^iA02^1Dentistry School^cSão Paul
o^sSP^pBrazil#^len^aBACKGROUND: Oral care is a fundamental procedure for the suc
cess of the hematopoietic stem cell transplantation, particularly regarding the 
control of oral infectious diseases. Information about oral care protocols and t
he inclusion of dental professionals in transplantation medical staff is poorly 
known. OBJECTIVE: The aim of this study was to carry out a survey about the prot
ocols of Brazilian dental professionals with regard to oral care of HSCT patient
s. METHODS: A questionnaire was mailed to 36 Brazilian transplant centers with q
uestions about basic oral care protocols, the indication of specific mouthwashes
, antibiotic therapy regimens, laser therapy, and treatment of oral mucositis an
d graft-versus-host disease. All the respondent centers (n = 12) have dentists a
s members of the HSCT medical staff. RESULTS: The majority indicate non-alcoholi
c chlorhexidine (n = 9; 75.0%) and sodium bicarbonate (n = 5; 41.7%) as routine 
mouthwashes. Laser therapy was frequently indicated (n= 9; 75.0%), mainly in the
 prevention of oral mucositis and in oral pain control. In the post-transplant p
eriod, antibiotic therapy was only indicated for invasive dental treatments (n= 
8; 66.7%). Several treatments for graft-versus-host disease were mentioned witho
ut a trend towards establishing a standard protocol. CONCLUSION: Basic oral care
 constitutes regular assessment in the routine treatment of hematopoietic stem c
ell transplantation patients in Brazilian centers.#^ddecs^i1#^tm^len^kOral healt
h^i1#^tm^len^kBone marrow transplantation^i1#^tm^len^kMucositis^i1#^tm^len^kGraf
t-versus-host disease^i1#other#37#20100526#5/26/2010#20100510#10/5/2010#v33n1a08
.htm##
02945000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000290011203100030014103200020014406500090014601400090015503500100016423700270
01740120065002010100038002660100036003040100031003400100035003710100034004060100
02700440070009400467070007100561083151200632085001002144085002402154085005702178
08500220223508500380225711700060229507200030230111200090230411100100231311400090
2323113001002332002001302342#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.h
tm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#8#RBHH340#nd#Rev. Bras. Hematol.
 Hemoter.#33#1#20110200#^f15^l20#1516-8484#10.5581/1516-8484.20110008#<b>Oral ca
re in Brazilian bone marrow transplant centers</b>^len#^rND^1A01^nFernanda de Pa
ula^sEduardo#^rND^1A01^nLetícia Mello^sBezinelli#^rND^1A01^nNelson^sHamerschlak#
^rND^1A01^nClaudia Toledo^sAndrade#^rND^1A01^nLeonardo Raul^sMorelli#^rND^1A02^n
Luciana^sCorrêa#Hospital Israelita Albert Einstein^iA01^1Bone Marrow Transplant 
Center^cSão Paulo^sSP^pBrazil#Unversidade de São Paulo^iA02^1Dentistry School^cS
ão Paulo^sSP^pBrazil#^len^a<b>BACKGROUND:</b> Oral care is a fundamental procedu
re for the success of the hematopoietic stem cell transplantation, particularly 
regarding the control of oral infectious diseases. Information about oral care p
rotocols and the inclusion of dental professionals in transplantation medical st
aff is poorly known. <b>OBJECTIVE:</b> The aim of this study was to carry out a 
survey about the protocols of Brazilian dental professionals with regard to oral
 care of HSCT patients. <b>METHODS:</b> A questionnaire was mailed to 36 Brazili
an transplant centers with questions about basic oral care protocols, the indica
tion of specific mouthwashes, antibiotic therapy regimens, laser therapy, and tr
eatment of oral mucositis and graft-versus-host disease. All the respondent cent
ers (n = 12) have dentists as members of the HSCT medical staff. <b>RESULTS:</b>
 The majority indicate non-alcoholic chlorhexidine (n = 9; 75.0%) and sodium bic
arbonate (n = 5; 41.7%) as routine mouthwashes. Laser therapy was frequently ind
icated (n= 9; 75.0%), mainly in the prevention of oral mucositis and in oral pai
n control. In the post-transplant period, antibiotic therapy was only indicated 
for invasive dental treatments (n= 8; 66.7%). Several treatments for graft-versu
s-host disease were mentioned without a trend towards establishing a standard pr
otocol. <b>CONCLUSION:</b> Basic oral care constitutes regular assessment in the
 routine treatment of hematopoietic stem cell transplantation patients in Brazil
ian centers.#^ddecs^i1#^tm^len^kOral health^i1#^tm^len^kBone m<strong>arr</stron
g>ow transplantation^i1#^tm^len^kMucositis^i1#^tm^len^kGraft-versus-host disease
^i1#other#37#20100526#5/26/2010#20100510#10/5/2010#v33n1a08.htm##
03043000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103038000400108121000200112049000800114
15800030012203000280012503100030015303200020015606500090015801400090016703500100
01762370027001860120058002130100038002710100036003090100031003450100035003760100
03400411010002700445070009600472070007300568083150500641085001002146085002402156
08500400218008500220222008500380224211700060228007200030228611200090228911100100
2298114000902308113001002317002001302327008008902340#v33n1#V:\SciELO\serial\rbhh
\v33n1\markup\v33n1a08.htm#S#l#4#1#article#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#ilus
#tab#8#RBHH340#nd#Rev. bras. hematol. hemoter#33#1#20110200#^f15^l20#1516-8484#1
0.5581/1516-8484.20110008#Oral care in Brazilian bone marrow transplant centers^
len#^rND^1A01^nFernanda de Paula^sEduardo#^rND^1A01^nLetícia Mello^sBezinelli#^r
ND^1A01^nNelson^sHamerschlak#^rND^1A01^nClaudia Toledo^sAndrade#^rND^1A01^nLeona
rdo Raul^sMorelli#^rND^1A02^nLuciana^sCorrêa#^iA01^1Hospital Israelita Albert Ei
nstein^2Bone Marrow Transplant Center^cSão Paulo^sSP^pBrazil#^iA02^1Unversidade 
de São Paulo^2Dentistry School^cSão Paulo^sSP^pBrazil#^len^aBACKGROUND: Oral car
e is a fundamental procedure for the success of the hematopoietic stem cell tran
splantation, particularly regarding the control of oral infectious diseases. Inf
ormation about oral care protocols and the inclusion of dental professionals in 
transplantation medical staff is poorly known. OBJECTIVE: The aim of this study 
was to carry out a survey about the protocols of Brazilian dental professionals 
with regard to oral care of HSCT patients. METHODS: A questionnaire was mailed t
o 36 Brazilian transplant centers with questions about basic oral care protocols
, the indication of specific mouthwashes, antibiotic therapy regimens, laser the
rapy, and treatment of oral mucositis and graft-versus-host disease. All the res
pondent centers (n = 12) have dentists as members of the HSCT medical staff. RES
ULTS: The majority indicate non-alcoholic chlorhexidine (n = 9; 75.0 percent) an
d sodium bicarbonate (n = 5; 41.7 percent) as routine mouthwashes. Laser therapy
 was frequently indicated (n= 9; 75.0 percent), mainly in the prevention of oral
 mucositis and in oral pain control. In the post-transplant period, antibiotic t
herapy was only indicated for invasive dental treatments (n= 8; 66.7 percent). S
everal treatments for graft-versus-host disease were mentioned without a trend t
owards establishing a standard protocol. CONCLUSION: Basic oral care constitutes
 regular assessment in the routine treatment of hematopoietic stem cell transpla
ntation patients in Brazilian centers.#^ddecs^i1#^tm^len^kOral health^i1#^tm^len
^kBone marrow transplantation^i1#^tm^len^kMucositis^i1#^tm^len^kGraft-versus-hos
t disease^i1#other#37#20100526#5/26/2010#20100510#10/5/2010#v33n1a08.htm#Interne
t^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-8484201100010000
8##
00354000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012100074002001300195#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#5#1#article#164#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLES</b>
</font></p>     ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#6#2#article#164#<p>&nbsp;</p>     ^cY
#v33n1a08.htm##
00394000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704016100074002001300235#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#7#3#article#164#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Oral care in Braz
ilian bone marrow transplant centers</b></font></p>     ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#8#4#article#164#<p>&nbsp;</p>     ^cY
#v33n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#9#5#article#164#<p>&nbsp;</p>     ^cY
#v33n1a08.htm##
00543000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704030900075002001300384#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#10#6#article#164#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Fernanda de Paula Eduardo<sup>I</s
up>; Let&iacute;cia Mello Bezinelli<sup>I</sup>; Nelson Hamerschlak<sup>I</sup>;
 Claudia Toledo Andrade<sup>I</sup>; Leonardo Raul Morelli<sup>I</sup>; Luciana 
Corr&ecirc;a<sup>II</sup></b></font></p>     ^cY#v33n1a08.htm##
00413000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017900075002001300254#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#11#7#article#164#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Bone Marrow Transplant Ce
nter, Hospital Israelita Albert Einstein, S&atilde;o Paulo (SP), Brazil    ^cY#v
33n1a08.htm##
00363000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012900075002001300204#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#12#8#article#164#<br>   <sup>II</sup>
Dentistry School, Unversidade de  S&atilde;o Paulo (FOUSP), S&atilde;o Paulo (SP
), Brazil</font></p>     ^cY#v33n1a08.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#13#9#article#164#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></fon
t></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#14#10#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#15#11#article#164#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v33n1a08.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#16#12#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
33n1a08.htm##
00619000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038400076002001300460#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#17#13#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>BACKGROUND:</b> Oral care is a fu
ndamental procedure for the success of the hematopoietic stem cell transplantati
on, particularly regarding the control of oral infectious diseases. Information 
about oral care protocols and the inclusion of dental professionals in transplan
tation medical staff is poorly known.    ^cY#v33n1a08.htm##
00412000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017700076002001300253#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#18#14#article#164#<br>   <b>OBJECTIVE
:</b> The aim of this study was to carry out a survey about the protocols of Bra
zilian dental professionals with regard to oral care of HSCT patients.    ^cY#v3
3n1a08.htm##
00610000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037500076002001300451#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#19#15#article#164#<br>   <b>METHODS:<
/b> A questionnaire was mailed to 36 Brazilian transplant centers with questions
 about basic oral care protocols, the indication of specific mouthwashes, antibi
otic therapy regimens, laser therapy, and treatment of oral mucositis and graft-
versus-host disease. All the respondent centers (n = 12) have dentists as member
s of the HSCT medical staff.    ^cY#v33n1a08.htm##
00752000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051700076002001300593#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#20#16#article#164#<br>   <b>RESULTS:<
/b> The majority indicate non-alcoholic chlorhexidine (n = 9; 75.0%) and sodium 
bicarbonate (n = 5; 41.7%) as routine mouthwashes. Laser therapy was frequently 
indicated (n= 9; 75.0%), mainly in the prevention of oral mucositis and in oral 
pain control. In the post-transplant period, antibiotic therapy was only indicat
ed for invasive dental treatments (n= 8; 66.7%). Several treatments for graft-ve
rsus-host disease were mentioned without a trend towards establishing a standard
 protocol.    ^cY#v33n1a08.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019100076002001300267#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#21#17#article#164#<br>   <b>CONCLUSIO
N:</b> Basic oral care constitutes regular assessment in the routine treatment o
f hematopoietic stem cell transplantation patients in Brazilian centers.</font><
/p>     ^cY#v33n1a08.htm##
00428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019300076002001300269#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#22#18#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Keywords: Oral health; Bone marrow t
ransplantation; Mucositis; Graft-versus-host disease</font></p> <hr size="1" nos
hade>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#23#19#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#24#20#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#25#21#article#164#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></p>     ^
cY#v33n1a08.htm##
00760000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052500076002001300601#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#26#22#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In the last decades, the number of h
ematopoietic stem cell transplantations (HSCT) has increased significantly aroun
d the world.<sup>(1)</sup> HSCT has shown an important increase since 1990, main
ly due to indications for different diseases, use in the older population, and i
ncrease in penetrability into the standard target population.<sup>(2,3)</sup> An
nually, it is estimated that 50,000-60,000 HSCT are performed worldwide.<sup>(4)
</sup></font></p>     ^cY#v33n1a08.htm##
01124000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088900076002001300965#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#27#23#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">HSCT centers have adopted multidisci
plinary teams in order to guarantee the success of treatment and to increase the
 patient's quality of life during and after transplantation.<sup>(5)</sup> The d
ental professional is one of the members of this team, who has the responsibilit
y of preventing oral infections during periods of neutropenia and to reduce oral
 side effects associated with HSCT.<sup>(6)</sup> Oral care guidelines are const
antly published in order to establish universal protocols for HSCT patients, mai
nly concerning the prevention and control of oral infectious diseases and oral m
ucositis.<sup>(7,8)</sup> However there are some discrepancies in the oral care 
treatment, especially involving oral mouthwashes, the adoption of antibiotic the
rapy and alternative therapies for oral mucositis.</font></p>     ^cY#v33n1a08.h
tm##
01129000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704089400076002001300970#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#28#24#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In Brazil, bone marrow, peripheral b
lood stem cells, and umbilical cord transplants have been adopted in private and
 public hospitals. At present there are 36 active HSCT hospitals accredited by t
he Brazilian Association for Organ Transplantation (BAOT).<sup>(9)</sup> In thes
e centers, there are also increasing trends towards extending this therapy to mo
re patients, in particular children with hematological diseases.<sup>(10)</sup> 
The number of HSCT over the last three years represents about 7.9 transplants fo
r every one million in the population.<sup>(9)</sup> In <a href="#tab1">Table 1<
/a> there is a brief comparison between the status of HSCT in Brazil, Argentina,
 South Africa, Australia, and the United States, as well as the data of the Euro
pean Group for Blood and Marrow Transplantation (EBMT).</font></p>     ^cY#v33n1
a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#29#25#article#164#<p><a name="tab1"><
/a></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#30#26#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#31#27#article#164#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a08tab01.jpg"></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#32#28#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00916000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068100076002001300757#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#33#29#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although there is an evident increas
e in the number of HSCT and presence of well-established HSCT centers, a multi-p
rofessional approach is not routine in some Brazilian hospitals. In this context
 oral care may probably be neglected or restricted to nursing. As oral care tren
ds in Brazilian HSCT patients are not known, it was decided to conduct a survey 
of the main HSCT centers in this country by means of a questionnaire with open -
 and closed - ended questions regarding the oral care protocols adopted by these
 centers. Obtained data were then compared with those described in the literatur
e.</font></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#34#30#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#35#31#article#164#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Methods</b></font></p>     ^cY#v3
3n1a08.htm##
00402000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016700076002001300243#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#36#32#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The study was approved by the Clinic
al Research Ethics Committee of our institution.</font></p>     ^cY#v33n1a08.htm
##
01390000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704115500076002001301231#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#37#33#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A questionnaire was prepared, contai
ning both open - and closed - ended questions regarding the following subjects: 
presence of a dentist as a permanent member of the multidisciplinary team; prese
nce of professionals other than the physicians; existence of previous oral healt
h evaluations as prerequisite for the HSCT; delay of HSCT caused by oral disease
s; oral care protocols mainly with regard to the use of mouthwashes, laser thera
py, and antibiotic therapy; and protocols for oral graft-versus-host-disease (GV
HD). The questions are shown in <a href="#tab2">Table 2</a>. Some of these quest
ions were based on the survey carried out by Guggenheimer et al. of US organ tra
nsplant centers.<sup>(18)</sup> The subjects of the questions was selected consi
dering some dental procedures that are not well explained in the literature, suc
h as antibiotic therapy, mouthwashes, GVHD protocols, and adjuvant or alternativ
e therapies. The questionnaire was mailed to the 36 coordinators of HSCT centers
 accredited by the BAOT. Replies were tabulated and analyzed as percentages.</fo
nt></p>     ^cY#v33n1a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#38#34#article#164#<p><a name="tab2"><
/a></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#39#35#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#40#36#article#164#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a08tab02.jpg"></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#41#37#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#42#38#article#164#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>     ^cY#v3
3n1a08.htm##
01175000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704094000076002001301016#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#43#39#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Twelve (33.3%) questionnaires were r
eturned. <a href="#tab3">Table 3</a> shows the regional distribution of the cent
ers that answered the questionnaire, as well as the number of HSCT in each Brazi
lian region, according to national registry data. The main HSCT centers are in t
he Southeast; the State of S&atilde;o Paulo has the highest number of HSCT (21.5
 transplants per million inhabitants in 2008).<sup>(11)</sup> The majority of th
e centers that answered the questionnaire were located in the southeastern regio
n (Six in the State of S&atilde;o Paulo, and two in the State of Rio de Janeiro)
. These centers in addition to the other four located in the southern and centra
l regions are responsible for 47.0% of the HSCT performed in Brazil. The questio
nnaires were answered by dental professionals (n = 7; 58.3%) and by HSCT coordin
ators (n = 5; 41.7%).</font></p>     ^cY#v33n1a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#44#40#article#164#<p><a name="tab3"><
/a></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#45#41#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#46#42#article#164#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a08tab03.jpg"></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#47#43#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00679000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044400076002001300520#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#48#44#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Apart from the physicians and nursin
g staff, all the centers have dentists, nutritionists, and psychologists (n = 12
; 100.0%) as members of the multidisciplinary team. Nursing assistants (n = 9; 7
5.0%) and physiotherapists (n = 10; 83.35) were frequently mentioned. Occupation
al (n = 7; 58.3%) and Speech (n = 3; 25.0%) therapists were less frequently repo
rted.</font></p>     ^cY#v33n1a08.htm##
01174000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093900076002001301015#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#49#45#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#tab4">Table 4</a> shows th
e basic oral protocols mentioned by the centers. All the centers performed denta
l evaluations before HSCT as a prerequisite for the transplant. Nine (75.0%) cen
ters reported delay in HSCT due to dental problems. Oral hygiene guidance was th
e most emphasized (n = 5; 41.7%) but recommendations to use ultrasoft toothbrush
es and dental floss (n = 3; 25.0%) were also mentioned. Some oral rinses, includ
ing antifungal and fluoride solutions were also stated. One center reported prop
hylactic tooth extraction before HSCT. On the question about the indication of s
odium bicarbonate solution, this was recommended by five (41.7%) centers as mout
hwash. Justifications for this indication were the maintenance of salivary pH, o
ral antisepsis mainly against fungal infections, and for the prevention/treatmen
t of oral mucositis.</font></p>     ^cY#v33n1a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#50#46#article#164#<p><a name="tab4"><
/a></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#51#47#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#52#48#article#164#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a08tab04.jpg"></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#53#49#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
01055000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082000076002001300896#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#54#50#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#tab5">Table 5</a> shows th
e types of mouthwashes mentioned by the centers. Specific mouthwashes were indic
ated by all the centers. The most common mouthwash was non-alcoholic chlorhexidi
ne digluconate (n = 9; 75.0%) as either a commercial or manipulated formula. Ben
zidamine was indicated in the case of oral mucositis by one center (8.3%). The c
ombination of rifamycin, diphenhydramine hydrochloride with antiseptic rinse and
 topical anesthetics was mentioned as a mouthwash for cases of dental infections
, such as abscesses and gingivitis. Dry mouth mouthwashes were mentioned by only
 two centers (16.7%). Chamomile and malva tea were briefly mentioned (n = 2; 16.
7%) as mouthwashes and beverages indicated for tissue repair.</font></p>     ^cY
#v33n1a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#55#51#article#164#<p><a name="tab5"><
/a></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#56#52#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#57#53#article#164#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a08tab05.jpg"></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#58#54#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00726000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049100076002001300567#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#59#55#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#tab6">Table 6</a> shows th
e frequency of answers to questions about laser therapy and antibiotic therapy. 
Laser therapy was not used only by three centers (25%), thus it was routine (n= 
6; 50.0%) or sporadic (n = 3; 25.0%) treatment. The recommendation of antibiotic
 therapy during dental treatment in the post-transplant period was implemented o
nly in invasive procedures by eight centers (66.7%).</font></p>     ^cY#v33n1a08
.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#60#56#article#164#<p><a name="tab6"><
/a></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#61#57#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#62#58#article#164#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a08tab06.jpg"></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#63#59#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00741000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050600076002001300582#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#64#60#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The results of GVHD protocols are su
mmarized in <a href="#tab7">Table 7</a>. For acute GVHD (aGVHD), some centers (n
 = 4; 33.3%) mentioned specific protocols, which were variable. On the other han
d, the majority of the centers (n = 9; 75.0%) showed specific protocols for chro
nic GVHD (cGVHD), which were also variable and involved rinses and application o
f corticosteroid gels, in particular clobetasol, and laser therapy.</font></p>  
   ^cY#v33n1a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#65#61#article#164#<p><a name="tab7"><
/a></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#66#62#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#67#63#article#164#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a08tab07.jpg"></p>     ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#68#64#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#69#65#article#164#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p>     ^cY
#v33n1a08.htm##
01221000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704098600076002001301062#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#70#66#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">At present HSCT is considered one of
 the most promising therapies for malignant hematological diseases, with an incr
ease in the survival rate in the countries with a significant number of HSCT cas
es.<sup>(4)</sup> In Brazil, there has been a rapid increase in the number of th
ese transplants and at present transplants exceed South Africa, Argentina, and A
ustralia/New Zealand in absolute numbers (<a href="#tab1">Table 1</a>). In this 
scenario, it was seen that the multidisciplinary team in Brazilian HSCT centers 
seems to be consolidated, with a permanent multi-professional approach. The ques
tionnaire adopted in this study was sufficient for this analysis though it was a
dapted from an international reference<sup>(18)</sup> focused on transplant cent
ers in general. It was useful for this study since it contains global questions 
regarding oral care for the majority of transplantation situations.</font></p>  
   ^cY#v33n1a08.htm##
00786000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055100076002001300627#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#71#67#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This survey reveals that the dental 
professional makes a regular assessment of the oral cavity and consistently prac
tices oral hygiene techniques. This was a surprise considering the barriers to t
he implementation of oral care for cancer patients and in transplant centers tha
t exist worldwide, such as gaps in knowledge, inconsistent or absent oral care a
ssessment, diverse oral care regimens and practices, and lack of interdisciplina
ry collaboration.<sup>(19)</sup></font></p>     ^cY#v33n1a08.htm##
02129000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704189400076002001301970#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#72#68#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Despite the fact that the Brazilian 
dentist is integrated into the HSCT medical team, some barriers were indirectly 
detected in this survey. Although the respondent centers represent only 33.3% of
 the Brazilian bone marrow transplantation centers, they are responsible for 47.
0% of HSCT performed in Brazil and constitute a representative sample of the hea
lth systems in the main Brazilian regions. Diverse oral care regimens and practi
ce were mentioned by the centers. This diversity has also previously been report
ed by US HSCT centers.<sup>(20,21)</sup> Some agreement was found as regards the
 adoption of oral care regimens, such as dental evaluation before HSCT, oral hyg
iene guidance and monitoring during transplants. These are considered "good clin
ical practices"<sup>(6)</sup> and fundamental for successful HSCT, particularly 
considering that these actions provide an efficient control of oral infections.<
sup>(22,23)</sup> However, other oral therapies that were very frequently mentio
ned in this survey have been questioned, such as the indication of sodium bicarb
onate solution for HSCT patients. Bicarbonate of soda solution has been used as 
an antiseptic mouthwash and/or in the prevention and treatment of oral mucositis
. It is considered a potent cleaning agent, enhancing the removal of oral debris
,<sup>(24)</sup> but it may lead to irritation of the oral mucosa when used for 
long periods or in incorrect concentrations. Due to this potential toxicity, and
 based on some clinical trials that have shown no efficacy of the salt solutions
 in the treatment of oral mucositis,<sup>(24-26)</sup> the indication of this ri
nse for critical patients has not been encouraged. It is believed that the large
 scale adoption of this saline solution in Brazil is due to its low cost and eas
y manipulation.</font></p>     ^cY#v33n1a08.htm##
01075000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084000076002001300916#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#73#69#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Among the specific mouthwashes, non-
alcoholic chlorhexidine solution was the most frequently mentioned. This highlig
hts the permanent oral care management in infection control by the majority of t
he centers. In addition to its indication as an oral antiseptic, chlorhexidine h
as also been used in the treatment of oral mucositis, but without proven success
.<sup>(25,26)</sup> By means of the questionnaire it was not possible to detect 
the objective reasons (whether it was because of the desirable action against or
al mucositis or as a broad spectrum mouthwash against oral infections) for the u
se of chlorhexidine by dentists. A more comprehensive study must be conducted to
 elucidate the dental professional's judgment on the indication of chlorhexidine
.</font></p>     ^cY#v33n1a08.htm##
01509000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704127400076002001301350#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#74#70#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Other specific mouthwashes were infr
equently mentioned, such as benzidamine and rifamycin added to Benadryl&reg;, an
d natural agents (chamomile and malva tea). The indications of benzidamine mouth
washes in the oral cavity, particularly for HSCT patients, have been seriously d
iscussed. An evidence-based study demonstrated no efficacy of this anti-inflamma
tory drug in the treatment of oral mucositis.<sup>(26)</sup> Rifamycin with Bena
dryl&reg; solution is similar to that described by Dodd et al.<sup>(24)</sup> as
 a "magic solution". This mouthwash was indicated in the present survey only for
 oral infections and not for oral mucositis. This latter indication seems to be 
ineffective according to the literature.<sup>(24,26)</sup> Chamomile and Malva t
ea have antimicrobial, anti-oxidant, anti-inflammatory, and analgesic effects<su
p>(27,28)</sup> that have been applied for oral mucosa repair. The efficacy of t
hese plants on healing in HSCT patients is controversial, particularly in relati
on to chamomile, which has been more extensively studied.<sup>(25)</sup> Althoug
h these rinses were rarely mentioned, they signal a trend to empirical indicatio
n of mouthwashes for HSCT patients.</font></p>     ^cY#v33n1a08.htm##
01624000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704138900076002001301465#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#75#71#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Prophylactic antibiotic therapy for 
dental treatment in HSCT patients has been discussed in the literature.<sup>(29,
30)</sup> Some of these reports established a protocol for antibiotic administra
tion based on the neutrophil counts in the myeloablative period before HSCT. Mor
imoto et al.<sup>(29)</sup> recommend oral cephalosporin administration for HSCT
 patients with low neutrophil counts (1000/mm<sup>3</sup> or less) when tooth ex
traction or scaling is necessary before the transplant. In a situation in which 
the neutrophil count is very low (100-150/mm<sup>3</sup>), the same authors indi
cate intravenous antibiotic therapy for invasive dental treatment. In the post-t
ransplant period, there are no reports that describe the antibiotic protocol dur
ing dental treatment. In the present survey the majority of the centers recommen
d prophylactic antibiotics only for invasive dental treatment, which is in agree
ment with the general rules established for HSCT patients as regards to infectio
n control in the post-transplant period.<sup>(23,31)</sup> Prophylactic antibiot
ics for all dental procedures should be carefully reconsidered when the patient 
has venous access devices or presents late complications, such as GVHD and disor
ders in the liver, lung, muscles, and endocrine system.<sup>(31)</sup></font></p
>     ^cY#v33n1a08.htm##
01328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109300076002001301169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#76#72#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Another finding in this survey was a
 trend towards the indication of laser therapy for oral mucositis. Although ther
e are few evidence-based studies confirming the efficacy of laser therapy in ora
l mucositis control, HSCT guidelines to dental professionals recommend the indic
ation of laser in HSCT centers with adequate equipment and qualified professiona
ls.<sup>(7,8)</sup> Studies have demonstrated some clinical evidence of low ener
gy laser in the reduction of the incidence<sup>(32)</sup> and severity<sup>(33,3
4)</sup> of oral mucositis in HSCT patients. In the present survey, 50.0% of the
 centers used laser therapy routinely in oral care and 25.0% sporadically when p
ain control in the oral cavity is necessary, which may indicate that there is a 
consensus in Brazilian centers as regards the adoption of laser as an adjuvant t
herapy. Further investigations must be conducted to identify the parameters used
 for laser as well as the level of efficacy and cost/benefits of this therapy in
 HSCT centers.</font></p>     ^cY#v33n1a08.htm##
01403000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704116800076002001301244#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#77#73#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Treatment protocols for oral cGVHD w
ere adopted in the majority of Brazilian centers. These protocols were quite var
iable but mainly involved corticoids and laser therapy. Clobetasol gel was the m
ost indicated, probably due to its high potency, improved absorption, and the fa
ct that it needs to be applied only twice a day.<sup>(35)</sup> One center menti
oned beclamethasone rinse and topical nistatin, which indicates concern about th
e risk of oral candidiasis inherent to topical corticoid therapies.<sup>(35)</su
p> Laser therapy was the second most frequently mentioned modality for oral cGVH
D treatment. A clinical report observed pain reduction and the efficacy of CO<su
b>2</sub> laser as symptomatic treatment for oral cGVHD in four patients.<sup>(3
6)</sup> Low-energy laser therapy with a diode laser was also reported as a suit
able adjunct to immunosuppressive therapy of cGVHD.<sup>(37)</sup> Because there
 were only two single clinical reports describing the advantages of laser therap
y for cGVHD in five patients, further studies must be conducted to confirm this 
efficacy.</font></p>     ^cY#v33n1a08.htm##
00634000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039900076002001300475#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#78#74#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The low frequency of protocols for o
ral aGVHD may be due to the fact that this morbidity is self-limiting,<sup>(35)<
/sup> with oral symptoms partially reduced by systemic therapy. Additionally, th
e frequency of oral aGVHD is lower than that of oral cGVHD and frequently confou
nded with oral mucositis.<sup>(35)</sup></font></p>     ^cY#v33n1a08.htm##
01179000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704094400076002001301020#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#79#75#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In conclusion, this survey indicates
 the trends in oral management of HSCT patients in Brazilian transplant centers.
 All the treatment modalities mentioned in the questionnaires were found in the 
literature; some of them are controversial, others considered standard protocols
. Great heterogeneity was detected in the opinions as regards the treatment of o
ral mucositis and GVHD, as well as a trend towards the adoption of alternative t
herapies, such as laser therapy. Apart from this, it seems that the dental profe
ssional is an active member of the multi-professional team in HSCT centers and t
hat the basic oral care constitutes a regular part of the routine treatment of H
SCT patients. A comprehensive study is necessary to detect details of the protoc
ols, particularly in regards to the frequency of application and doses in the ma
jority of the treatments.</font></p>     ^cY#v33n1a08.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#80#76#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b> Acknowledgments</b></font></p>  
   ^cY#v33n1a08.htm##
00485000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025000076002001300326#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#81#77#article#164#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We thank the coordinators and dental
 professionals of Brazilian HSCT centers that answered the questionnaires, for t
he essential contribution they made to this survey.</font></p>     ^cY#v33n1a08.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#82#78#article#164#<p>&nbsp;</p>     ^
cY#v33n1a08.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#83#79#article#164#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY
#v33n1a08.htm##
00688000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704043900078002001300517#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#84#80#article#164#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Gratwohl A, Baldome
ro H, Schwendener A, Rocha V, Apperley J, Frauendorfer K,Niederwieser D; Joint A
ccreditation Committee of the International Society forCellular Therapy; Europea
n Group for Blood and Marrow Transplantation. The EBMT activity survey 2007 with
 focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Tran
splant. 2009;43(4):275-91.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#85#81#article#164#</font></p>     ^cY
#v33n1a08.htm##
00847000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704059800078002001300676#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#86#82#article#164#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. International Bone 
Marrow Transplant Registry. Autologous bone and marrow transplant registry. Repo
rt on the state of the art in blood and marrow transplantation - the IBMTR/ABMTR
 summary slides with guide. IBMTR/ABMTR Newsletter  &#91;Internet&#93;. 2000  &#
91;cited 2010 Jan 12&#93;;7 (1):3-10. Available from: <a href="http://www.cibmtr
.org/ReferenceCenter/Newsletters/Documents/Newsletter_Spring200.pdf" target="_bl
ank">http://www.cibmtr.org/ReferenceCenter/Newsletters/Documents/Newsletter_Spri
ng200.pdf</a></font></p>     ^cY#v33n1a08.htm##
00552000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030300078002001300381#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#87#83#article#164#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Ballen KK, King RJ,
 Chitphakdithai P, Bolan CD Jr, Agura E, Hartzman RJ, et al. The national marrow
 donor program 20 years of unrelated donor hematopoietic cell transplantation. B
iol Blood Marrow Transplant. 2008;14(9 Suppl):2-7.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#88#84#article#164#</font></p>     ^cY
#v33n1a08.htm##
00770000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704052100078002001300599#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#89#85#article#164#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Pasquini, MC, Wang 
Z, Schneider L. Current use and outcome of hematopoietic stem cell transplantati
on: part I- CIBMTR Summary Slides, 2007. CIBMTR Newsletter  &#91;Internet&#93;. 
2007  &#91;cited 2010 Jan 12&#93;;13(2):5-8. Available from: <a href="http://www
.cibmtr.org/ReferenceCenter/Newsletters/Documents/Newsletter_Aug2007.pdf" target
="_blank">http://www.cibmtr.org/ReferenceCenter/Newsletters/Documents/Newsletter
_Aug2007.pdf</a></font></p>     ^cY#v33n1a08.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027900078002001300357#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#90#86#article#164#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Hacker ED. Quantita
tive measurement of quality of life in adult patients undergoing bone marrow tra
nsplant or peripheral blood stem cell transplant: a decade in review. Oncol Nurs
 Forum. 2003;30(4):613-29.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#91#87#article#164#</font></p>     ^cY
#v33n1a08.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029700078002001300375#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#92#88#article#164#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Epstein JB, Raber-D
rulacher JE, Wilkins A, Chavarria MG, Myint H. Advances in hematologic stem cell
 transplant: an update for oral health care providers. Oral Surg Oral Med Oral P
athol Oral Radiol Endod. 2009;107(3):301-12.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#93#89#article#164#</font></p>     ^cY
#v33n1a08.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025600078002001300334#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#94#90#article#164#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Peterson DE, Bensad
oun RJ, Roila F; ESMO Guidelines Working Group. Management of oral and gastroint
estinal mucositis: ESMO clinical recommendations. Ann Oncol. 2009;20 Suppl 4:174
-7.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#95#91#article#164#</font></p>     ^cY
#v33n1a08.htm##
00698000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704044900078002001300527#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#96#92#article#164#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Keefe DM, Schubert 
MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire 
DB, Hutchins RD, Peterson DE; Mucositis Study Section of the Multinational Assoc
iation of Supportive Care in Cancer and the International Society for Oral Oncol
ogy. Updated clinical practice guidelines for the prevention and treatment of mu
cositis. Cancer. 2007;109(5):820-31.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#97#93#article#164#</font></p>     ^cY
#v33n1a08.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022800078002001300306#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#98#94#article#164#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Associa&ccedil;&ati
lde;o Brasileira de Transplante de Org&atilde;os. T&iacute;tulo do que foi consu
ltado. Registro Brasileiro de Transplante. 2009;2(2):6.    ^cY#v33n1a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#99#95#article#164#</font></p>     ^cY
#v33n1a08.htm##
00578000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704032700080002001300407#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#100#96#article#164#10#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. de Castro CG Jr,
 Gregianin LJ, Brunetto AL.  &#91;Clinical and epidemiological analysis of bone 
marrow transplantation in a pediatric oncology unit&#93;. J Pediatr (Rio J). 200
3;79(5):413-22. Portuguese. Comment in: J Pediatr (Rio J). 2003;79(5):383-4.    
^cY#v33n1a08.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#101#97#article#164#</font></p>     ^c
Y#v33n1a08.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704023400080002001300314#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#102#98#article#164#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">11.  Associa&ccedil;
&atilde;o Brasileira de Transplante de Org&atilde;os. T&iacute;tulo do que foi c
onsultado. Registro Brasileiro de Transplante. 2008;2(2):15-16.    ^cY#v33n1a08.
htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#103#99#article#164#</font></p>     ^c
Y#v33n1a08.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#104#100#article#164#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Nivison-Smith I
, Bradstock KF, Dodds AJ, Hawkins PA, Ma DD, Moore JJ, et al. Hematopoietic stem
 cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow
 Transplant. 2007;13(8):905-12.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#105#101#article#164#</font></p>     ^
cY#v33n1a08.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029200081002001300373#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#106#102#article#164#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Jacobs P, Wood 
L. Immunohematopoietic stem cell transplantation: introduction and 35 years of d
evelopment in South Africa - the historical and scientific perspective. Bone Mar
row Transplant. 2008;42 Suppl 1:S125-S132.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#107#103#article#164#</font></p>     ^
cY#v33n1a08.htm##
00610000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035800081002001300439#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#108#104#article#164#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Fundaci&oacute;
n para combater la Leucemia.  &#91;home page&#93;. Buenos Aires, Argentina; 2009
.  &#91;cited 2010 Jan 20&#93;. Available from:  <a href="http://www.fundaleu.or
g/programa_transplante.php" target="_blank">http://www.fundaleu.org/programa_tra
nsplante.php</a></font></p>     ^cY#v33n1a08.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024000081002001300321#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#109#105#article#164#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Confer D, Robin
ett P. The US National Marrow Donor Program role in unrelated donor hematopoieti
c cell transplantation. Bone Marrow Transplant. 2008;42 Suppl 1:S3-S5.    ^cY#v3
3n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#110#106#article#164#</font></p>     ^
cY#v33n1a08.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028500081002001300366#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#111#107#article#164#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Gratwohl A, Bal
domero H, Schwendener A, Gratwohl M, Apperley J, Frauendorfer K, et al. The EBMT
 activity survey 2008 impact of team size, team density and new trends. Bone Mar
row Transplant. 2010;246(2):174-91.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#112#108#article#164#</font></p>     ^
cY#v33n1a08.htm##
00775000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704052300081002001300604#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#113#109#article#164#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. National Marrow
 Donor Program. Bone Marrow and Cord Blood Donation and Transplantation. Registr
y Transplant Data  &#91;Internet&#93;. Washington, DC: Last Update: February 9, 
2011.  &#91;cited 2010 Dec 12&#93;. Available from: <a href="http://bloodcell.tr
ansplant.hrsa.gov/RESEARCH/Transplant_Data/Registry_Tx_Data/index.html" target="
_blank">http://bloodcell.transplant.hrsa.gov/RESEARCH/Transplant_Data/Registry_T
x_Data/index.html</a></font></p>     ^cY#v33n1a08.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#114#110#article#164#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Guggenheimer J,
 Mayher D, Eghtesad B. A survey of dental care protocols among US organ transpla
nt centers. Clin Transplant. 2005;19(1):15-8.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#115#111#article#164#</font></p>     ^
cY#v33n1a08.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021300081002001300294#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#116#112#article#164#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. McGuire DB. Bar
riers and strategies in implementation of oral care standards for cancer patient
s. Support Care Cancer. 2003; 11(7):435-41.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#117#113#article#164#</font></p>     ^
cY#v33n1a08.htm##
00488000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023600081002001300317#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#118#114#article#164#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Ezzone S, Jolly
 D, Replogle K, Kapoor N, Tutschka PJ. Survey of oral hygiene regimens among bon
e marrow transplant centers. Oncol Nurs Forum. 1993;20(9):1375-81.    ^cY#v33n1a
08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#119#115#article#164#</font></p>     ^
cY#v33n1a08.htm##
00488000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023600081002001300317#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#120#116#article#164#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Poe SS, Larson 
E, McGuire D, Krumm S. A national survey of infection prevention practices on bo
ne marrow transplant units. Oncol Nurs Forum. 1994;21(10):1687-94.    ^cY#v33n1a
08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#121#117#article#164#</font></p>     ^
cY#v33n1a08.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026400081002001300345#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#122#118#article#164#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. McGuire DB, Cor
rea ME, Johnson J, Wienandts P. The role of basic oral care and good clinical pr
actice principles in the management of oral mucositis. Support Care Cancer. 2006
;14 (6):541-7.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#123#119#article#164#</font></p>     ^
cY#v33n1a08.htm##
00734000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704048200081002001300563#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#124#120#article#164#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Center for Dise
ase Control and Prevention, Infectious Disease Society of America, and the Ameri
can Society of Blood and Marrow Transplantation. Guidelines for preventing oppor
tunistic infections among hematopoietic stem cell transplant recipients. Recomme
ndations of CDC, the  Infectious Disease Society of America, and the American So
ciety of Blood and Marrow Transplantation. Cytotherapy. 2001;3(1):41-54.    ^cY#
v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#125#121#article#164#</font></p>     ^
cY#v33n1a08.htm##
00588000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033600081002001300417#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#126#122#article#164#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Dodd MJ, Dibble
 SL, Miaskowski C, MacPhail L, Greenspan D, Paul SM, et al. Randomized clinical 
trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-
induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90(1):
39-47.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#127#123#article#164#</font></p>     ^
cY#v33n1a08.htm##
00556000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030400081002001300385#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#128#124#article#164#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Potting CM, Uit
terhoeve R, Op Reimer WS, Van Achterberg T. The effectiveness of commonly used m
outhwashes for the prevention of chemotherapy-induced oral mucositis: a systemat
ic review. Eur J Cancer Care (Engl). 2006;15(5):431-9.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#129#125#article#164#</font></p>     ^
cY#v33n1a08.htm##
00617000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036500081002001300446#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#130#126#article#164#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Clarkson JE, Wo
rthington HV, Eden OB. Interventions for treating oral mucositis for patients wi
th cancer receiving treatment. Cochrane Database Syst Rev. 2007;18(2):CD001973. 
Update in: Cochrane Database Syst Rev. 2010;(8):CD001973. Update of: Cochrane Da
tabase Syst Rev. 2004;(2):CD001973.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#131#127#article#164#</font></p>     ^
cY#v33n1a08.htm##
00512000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026000081002001300341#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#132#128#article#164#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. G&uuml;rb&uuml;
z I, Ozkan AM, Yesilada E, Kutsal O. Anti-ulcerogenic activity of some plants us
ed in folk medicine of Pinarbasi (Kayseri, Turkey). J Ethnopharmacol. 2005;101(1
-3):313-8.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#133#129#article#164#</font></p>     ^
cY#v33n1a08.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023200081002001300313#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#134#130#article#164#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. McKay DL, Blumb
erg JB. A review of the bioactivity and potential health benefits of chamomile t
ea (Matricaria recutita L.). Phytother Res. 2006;20(7):519-30.    ^cY#v33n1a08.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#135#131#article#164#</font></p>     ^
cY#v33n1a08.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021800081002001300299#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#136#132#article#164#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Morimoto Y, Niw
a H, Imai Y, Kirita T. Dental management prior to hematopoietic stem cell transp
lantation. Spec Care Dentist. 2004;24(6):287-92.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#137#133#article#164#</font></p>     ^
cY#v33n1a08.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030600081002001300387#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#138#134#article#164#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Yamagata K, Oni
zawa K, Yanagawa T, Hasegawa Y, Kojima H, Nagasawa T, et al. A prospective study
 to evaluate a new dental management protocol before hematopoietic stem cell tra
nsplantation. Bone Marrow Transplant. 2006;38(3):237-42.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#139#135#article#164#</font></p>     ^
cY#v33n1a08.htm##
00772000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704052000081002001300601#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#140#136#article#164#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Rizzo JD, Winga
rd JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, et al. Recommended screening a
nd preventive practices for long-term survivors after hematopoietic cell transpl
antation: joint recommendations of the European Group for Blood and Marrow Trans
plantation, the Center for International Blood and Marrow Transplant Research, a
nd the American Society of Blood and Marrow Transplantation. Biol Blood Marrow T
ransplant. 2006;12 (2):138-51.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#141#137#article#164#</font></p>     ^
cY#v33n1a08.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031400081002001300395#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#142#138#article#164#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Antunes HS, de 
Azevedo AM, da Silva Bouzas LF, Ad&atilde;o CA, Pinheiro CT, Mayhe R, et al. Low
-power laser in the prevention of induced oral mucositis in bone marrow transpla
ntation patients: a randomized trial. Blood. 2007;109(5):2250-5.    ^cY#v33n1a08
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#143#139#article#164#</font></p>     ^
cY#v33n1a08.htm##
00605000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035300081002001300434#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#144#140#article#164#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Cowen D, Tardie
u C, Schubert M, Peterson D, Resbeut M, Faucher C, et al. Low energy Helium-Neon
 laser in the prevention of oral mucositis in patients undergoing bone marrow tr
ansplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Ph
ys. 1997;38(4):697-703.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#145#141#article#164#</font></p>     ^
cY#v33n1a08.htm##
00582000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033000081002001300411#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#146#142#article#164#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Eduardo FD, Bez
inelli L, Luiz AC, Correa L, Vogel C, Eduardo CP. Severity of oral mucositis in 
patients undergoing hematopoietic cell transplantation and an oral laser phototh
erapy protocol: a survey of 30 patients. Photomed Laser Surg. 2009;27(1):137-44.
    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#147#143#article#164#</font></p>     ^
cY#v33n1a08.htm##
00421000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016900081002001300250#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#148#144#article#164#35#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Schubert MM, Co
rrea ME. Oral graft-versus-host disease. Dent Clin North Am. 2008;52(1):79-109. 
   ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#149#145#article#164#</font></p>     ^
cY#v33n1a08.htm##
00496000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024400081002001300325#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#150#146#article#164#36#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Elad S, Or R, S
hapira MY, Haviv A, Galili D, Garfunkel AA, et al. CO2 laser in oral graft-versu
s-host disease: a pilot study. Bone Marrow Transplant. 2003;32(10):1031-4.    ^c
Y#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#151#147#article#164#</font></p>     ^
cY#v33n1a08.htm##
00559000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030700081002001300388#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#152#148#article#164#37#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Chor A, de Azev
edo AM, Maiolino A, Nucci M. Successful treatment of oral lesions of chronic lic
henoid graft-vs.-host disease by the addition of low-level laser therapy to syst
emic immunosuppression. Eur J Haematol. 2004;72(3):222-4.    ^cY#v33n1a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#153#149#article#164#</font></p>     ^
cY#v33n1a08.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#154#150#article#164#<p>&nbsp;</p>    
 ^cY#v33n1a08.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#155#151#article#164#<p>&nbsp;</p>    
 ^cY#v33n1a08.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018700078002001300265#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#156#152#article#164#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/rbhh/v33n1/seta.jpg" border="0" ></a> <b>Correspondence:</
b>    ^cY#v33n1a08.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#157#153#article#164#<br>   Luciana Co
rr&ecirc;a    ^cY#v33n1a08.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005300078002001300131#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#158#154#article#164#<br>   Disciplina
 de Patologia Geral da FOUSP    ^cY#v33n1a08.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007200078002001300150#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#159#155#article#164#<br>   Av. Prof. 
Lineu Prestes, 2227 Cidade Universit&aacute;ria    ^cY#v33n1a08.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005600078002001300134#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#160#156#article#164#<br>   05508-000 
- S&atilde;o Paulo (SP), Brazil    ^cY#v33n1a08.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003700078002001300115#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#161#157#article#164#<br>   Phone: 55 
11 3091-7884    ^cY#v33n1a08.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007700078002001300155#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#162#158#article#164#<br>   <a href="m
ailto:lcorrea@usp.br">lcorrea@usp.br</a></font></p>     ^cY#v33n1a08.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#163#159#article#164#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted: 5/26/2010    ^cY#v33n1a
08.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#164#160#article#164#<br>   Accepted: 
10/5/2010    ^cY#v33n1a08.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011100078002001300189#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#165#161#article#164#<br>   Conflict-o
f-interest disclosure: The authors declare no competing financial interest</font
></p>     ^cY#v33n1a08.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#166#162#article#164#<p>&nbsp;</p>    
 ^cY#v33n1a08.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#167#163#article#164#<p>&nbsp;</p>    
 ^cY#v33n1a08.htm##
00460000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022300078002001300301#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a08.htm#S#p#168#164#article#164#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" targ
et="_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_bla
nk">www.scielo.br/rbhh</a></font></p>     ^cY#v33n1a08.htm##
00922000000000373000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100019000950100
02100114010001500135010001800150010002200168010002200190011007900212011005200291
01201010034303000230044406500090046706400050047603100030048103200020048401400070
0486865000900493002001300502035001000515801002300525#v33n1#V:\SciELO\serial\rbhh
\v33n1\markup\v33n1a08.htm#S#c#169#1#article#37#1#^rND^sGratwohl^nA#^rND^sBaldom
ero^nH#^rND^sSchwendener^nA#^rND^sRocha^nV#^rND^sApperley^nJ#^rND^sFrauendorfer^
nK#^rND^sNiederwieser^nD#Joint Accreditation Committee of the International Soci
ety forCellular Therapy#European Group for Blood and Marrow Transplantation#The 
EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellul
ar therapies^len#Bone Marrow Transplant#20090000#2009#43#4#275-91#20110200#v33n1
a08.htm#0268-3369#Bone marrow transplant##
00784000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750110094000770120114001710300
02300285710000200308061000900310065000900319064000500328110000900333109001200342
031000200354032000200356014000500358037008500363865000900448002001300457#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#170#2#article#37#2#Internatio
nal Bone Marrow Transplant Registry. Autologous bone and marrow transplant regis
try#Report on the state of the art in blood and marrow transplantation: the IBMT
R/ABMTR summary slides with guide^len#IBMTR/ABMTR Newsletter#2#Internet#20000000
#2000#20100112#2010 Jan 12#7#1#3-10#http://www.cibmtr.org/ReferenceCenter/Newsle
tters/Documents/Newsletter_Spring200.pdf#20110200#v33n1a08.htm##
00758000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100015000940100
02400109010001900133010001500152010001900167810000600186012010100192030002900293
06500090032206400050033103100030033603200040033901400040034386500090034700200130
0356035001000369801002900379#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.h
tm#S#c#171#3#article#37#3#^rND^sBallen^nKK#^rND^sKing^nRJ#^rND^sChitphakdithai^n
P#^rND^sBolan^nCD Jr#^rND^sAgura^nE#^rND^sHartzman^nRJ#et al#The national marrow
 donor program 20 years of unrelated donor hematopoietic cell transplantation^le
n#Biol Blood Marrow Transplant#20080000#2008#14#^s9#2-7#20110200#v33n1a08.htm#10
83-8791#Biol Blood Marrow Transplant##
00753000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100014000960100
01900110012010800129030001800237710000200255061000900257065000900266064000500275
11000090028010900120028903100030030103200020030401400040030603700830031086500090
0393002001300402#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#172#4
#article#37#4#^rND^sPasquini^nMC#^rND^sWang^nZ#^rND^sSchneider^nL#Current use an
d outcome of hematopoietic stem cell transplantation: part I- CIBMTR Summary Sli
des, 2007^len#CIBMTR Newsletter#2#Internet#20070000#2007#20100112#2010 Jan 12#13
#2#5-8#http://www.cibmtr.org/ReferenceCenter/Newsletters/Documents/Newsletter_Au
g2007.pdf#20110200#v33n1a08.htm##
00625000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120161000940300
01700255065000900272064000500281031000300286032000200289014000700291865000900298
002001300307035001000320801001700330#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a08.htm#S#c#173#5#article#37#5#^rND^sHacker^nED#Quantitative measurement of q
uality of life in adult patients undergoing bone marrow transplant or peripheral
 blood stem cell transplant: a decade in review^len#Oncol Nurs Forum#20030000#20
03#30#4#613-29#20110200#v33n1a08.htm#0190-535X#Oncol Nurs Forum##
00747000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100026000950100
01700121010002000138010001500158012009100173030004900264065000900313064000500322
03100040032703200020033101400070033386500090034000200130034903500100036280100490
0372#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#174#6#article#37#
6#^rND^sEpstein^nJB#^rND^sRaber-Drulacher^nJE#^rND^sWilkins^nA#^rND^sChavarria^n
MG#^rND^sMyint^nH#Advances in hematologic stem cell transplant: an update for or
al health care providers^len#Oral Surg Oral Med Oral Pathol Oral Radiol Endod#20
090000#2009#107#3#301-12#20110200#v33n1a08.htm#1079-2104#Oral Surg Oral Med Oral
 Pathol Oral Radiol Endod##
00645000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100020000960100
01500116011003000131012008500161030001000246065000900256064000500265031000300270
032001000273014000600283865000900289002001300298035001000311801001000321#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#175#7#article#37#7#^rND^sPete
rson^nDE#^rND^sBensadoun^nRJ#^rND^sRoila^nF#ESMO Guidelines Working Group#Manage
ment of oral and gastrointestinal mucositis: ESMO clinical recommendations^len#A
nn Oncol#20090000#2009#20#^sSuppl 4#174-7#20110200#v33n1a08.htm#0923-7534#Ann On
col##
00958000000000397000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100019000930100
01700112010001600129010001800145010002600163010002100189010001800210010001900228
01000190024701101340026601200870040003000070048706500090049406400050050303100040
0508032000200512014000700514865000900521002001300530035001000543801000700553#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#176#8#article#37#8#^rND^s
Keefe^nDM#^rND^sSchubert^nMM#^rND^sElting^nLS#^rND^sSonis^nST#^rND^sEpstein^nJB#
^rND^sRaber-Durlacher^nJE#^rND^sMigliorati^nCA#^rND^sMcGuire^nDB#^rND^sHutchins^
nRD#^rND^sPeterson^nDE#Mucositis Study Section of the Multinational Association 
of Supportive Care in Cancer and the International Society for Oral Oncology#Upd
ated clinical practice guidelines for the prevention and treatment of mucositis^
len#Cancer#20070000#2007#109#5#820-31#20110200#v33n1a08.htm#0008-543X#Cancer##
00502000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750110047000770120033001240300
03500157710000200192065000900194064000500203031000200208032000200210020000200212
865000900214002001300223#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S
#c#177#9#article#37#9#Associação Brasileira de Transplante de Orgãos#Título do q
ue foi consultado^lpt#Registro Brasileiro de Transplante#2#20090000#2009#2#2#6#2
0110200#v33n1a08.htm##
00714000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100020001020100
01900122012010200141030001000243066000600253065000900259064000500268031000300273
03200020027601400070027806100610028586500090034600200130035503500100036880100100
0378#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#178#10#article#37
#10#^rND^sde Castro^nCG Jr#^rND^sGregianin^nLJ#^rND^sBrunetto^nAL#Clinical and e
pidemiological analysis of bone marrow transplantation in a pediatric oncology u
nit^len#J Pediatr#Rio J#20030000#2003#79#5#413-22#Portuguese. Comment in: J Pedi
atr (Rio J). 2003;79(5):383-4.#20110200#v33n1a08.htm#0022-3476#J Pediatr##
00508000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110047000790120033001260300
03500159710000200194065000900196064000500205031000200210032000200212014000600214
865000900220002001300229#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S
#c#179#11#article#37#11#Associação Brasileira de Transplante de Orgãos#Título do
 que foi consultado^lpt#Registro Brasileiro de Transplante#2#20080000#2008#2#2#1
5-16#20110200#v33n1a08.htm##
00741000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100020001020100
01600122010001800138010001300156010001600169810000600185012008400191030002900275
06500090030406400050031303100030031803200020032101400070032386500090033000200130
0339035001000352801002900362#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.h
tm#S#c#180#12#article#37#12#^rND^sNivison-Smith^nI#^rND^sBradstock^nKF#^rND^sDod
ds^nAJ#^rND^sHawkins^nPA#^rND^sMa^nDD#^rND^sMoore^nJJ#et al#Hematopoietic stem c
ell transplantation in Australia and New Zealand, 1992-2004^len#Biol Blood Marro
w Transplant#20070000#2007#13#8#905-12#20110200#v33n1a08.htm#1083-8791#Biol Bloo
d Marrow Transplant##
00666000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950120
15200109030002300261065000900284064000500293031000300298032001000301014001000311
865000900321002001300330035001000343801002300353#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a08.htm#S#c#181#13#article#37#13#^rND^sJacobs^nP#^rND^sWood^nL#Im
munohematopoietic stem cell transplantation: introduction and 35 years of develo
pment in South Africa - the historical and scientific perspective^len#Bone Marro
w Transplant#20080000#2008#42#^sSuppl 1#S125-S132#20110200#v33n1a08.htm#0268-336
9#Bone marrow transplant##
00520000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170036000790610010001150660
01300125067001000138065000900148064000500157110000900162109001200171037004900183
865000900232002001300241#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S
#c#182#14#article#37#14#Fundación para combater la Leucemia#home page#Buenos Air
es#Argentina#20090000#2009#20100120#2010 Jan 20#http://www.fundaleu.org/programa
_transplante.php#20110200#v33n1a08.htm##
00614000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950120
10000113030002300213065000900236064000500245031000300250032001000253014000600263
865000900269002001300278035001000291801002300301#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a08.htm#S#c#183#15#article#37#15#^rND^sConfer^nD#^rND^sRobinett^n
P#The US National Marrow Donor Program role in unrelated donor hematopoietic cel
l transplantation^len#Bone Marrow Transplant#20080000#2008#42#^sSuppl 1#S3-S5#20
110200#v33n1a08.htm#0268-3369#Bone marrow transplant##
00739000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
02100116010001800137010001800155010002200173810000600195012008300201030002300284
06500090030706400050031603100040032103200020032501400070032786500090033400200130
0343035001000356801002300366#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.h
tm#S#c#184#16#article#37#16#^rND^sGratwohl^nA#^rND^sBaldomero^nH#^rND^sSchwenden
er^nA#^rND^sGratwohl^nM#^rND^sApperley^nJ#^rND^sFrauendorfer^nK#et al#The EBMT a
ctivity survey 2008 impact of team size, team density and new trends^len#Bone Ma
rrow Transplant#20100000#2010#246#2#174-91#20110200#v33n1a08.htm#0268-3369#Bone 
marrow transplant##
00644000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170087000790180029001660610
00900195066001500204065000900219064001700228110000900245109001200254037009000266
865000900356002001300365#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S
#c#185#17#article#37#17#National Marrow Donor Program^dBone Marrow and Cord Bloo
d Donation and Transplantation#Registry Transplant Data^len#Internet#Washington^
eDC#20110209#February 9, 2011#20101212#2010 Dec 12#http://bloodcell.transplant.h
rsa.gov/RESEARCH/Transplant_Data/Registry_Tx_Data/index.html#20110200#v33n1a08.h
tm##
00597000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100016001010100
01800117012007200135030001600207065000900223064000500232031000300237032000200240
014000500242865000900247002001300256035001000269801001600279#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a08.htm#S#c#186#18#article#37#18#^rND^sGuggenheimer^n
J#^rND^sMayher^nD#^rND^sEghtesad^nB#A survey of dental care protocols among US o
rgan transplant centers^len#Clin Transplant#20050000#2005#19#1#15-8#20110200#v33
n1a08.htm#0902-0063#Clin Transplant##
00562000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120089000970300
02000186065000900206064000500215031000300220032000200223014000700225865000900232
002001300241035001000254801002000264#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a08.htm#S#c#187#19#article#37#19#^rND^sMcGuire^nDB#Barriers and strategies in
 implementation of oral care standards for cancer patients^len#Support Care Canc
er#20030000#2003#11#7#435-41#20110200#v33n1a08.htm#0941-4355#Support Care Cancer
##
00655000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01800110010001600128010001900144012007300163030001700236065000900253064000500262
03100030026703200020027001400080027286500090028000200130028903500100030280100170
0312#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#188#20#article#37
#20#^rND^sEzzone^nS#^rND^sJolly^nD#^rND^sReplogle^nK#^rND^sKapoor^nN#^rND^sTutsc
hka^nPJ#Survey of oral hygiene regimens among bone marrow transplant centers^len
#Oncol Nurs Forum#19930000#1993#20#9#1375-81#20110200#v33n1a08.htm#0190-535X#Onc
ol Nurs Forum##
00637000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01700109010001500126012008800141030001700229065000900246064000500255031000300260
032000300263014000800266865000900274002001300283035001000296801001700306#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#189#21#article#37#21#^rND^sPo
e^nSS#^rND^sLarson^nE#^rND^sMcGuire^nD#^rND^sKrumm^nS#A national survey of infec
tion prevention practices on bone marrow transplant units^len#Oncol Nurs Forum#1
9940000#1994#21#10#1687-94#20110200#v33n1a08.htm#0190-535X#Oncol Nurs Forum##
00667000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01700114010001900131012010600150030002000256065000900276064000500285031000300290
032000200293014000600295865000900301002001300310035001000323801002000333#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#190#22#article#37#22#^rND^sMc
Guire^nDB#^rND^sCorrea^nME#^rND^sJohnson^nJ#^rND^sWienandts^nP#The role of basic
 oral care and good clinical practice principles in the management of oral mucos
itis^len#Support Care Cancer#20060000#2006#14#6#541-7#20110200#v33n1a08.htm#0941
-4355#Support Care Cancer##
00798000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110042000790110038001210110
05300159012023600212030001200448710000200460065000900462064000500471031000200476
032000200478014000600480865000900486002001300495#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a08.htm#S#c#191#23#article#37#23#Center for Disease Control and P
revention#Infectious Disease Society of America#American Society of Blood and Ma
rrow Transplantation#Guidelines for preventing opportunistic infections among he
matopoietic stem cell transplant recipients. Recommendations of CDC, the Infecti
ous Disease Society of America, and the American Society of Blood and Marrow Tra
nsplantation^len#Cytotherapy#2#20010000#2001#3#1#41-54#20110200#v33n1a08.htm##
00816000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
02000111010001800131010001900149010001500168810000600183012012200189030004900311
06500090036006400050036903100030037403200020037701400060037986500090038500200130
0394035001000407801004900417#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.h
tm#S#c#192#24#article#37#24#^rND^sDodd^nMJ#^rND^sDibble^nSL#^rND^sMiaskowski^nC#
^rND^sMacPhail^nL#^rND^sGreenspan^nD#^rND^sPaul^nSM#et al#Randomized clinical tr
ial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-in
duced mucositis^len#Oral Surg Oral Med Oral Pathol Oral Radiol Endod#20000000#20
00#90#1#39-47#20110200#v33n1a08.htm#1079-2104#Oral Surg Oral Med Oral Pathol Ora
l Radiol Endod##
00678000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100021000970100
02000118010002400138012013000162030001800292710000200310061000500312065000900317
064000500326031000300331032000200334014000600336865000900342002001300351#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#193#25#article#37#25#^rND^sPo
tting^nCM#^rND^sUitterhoeve^nR#^rND^sOp Reimer^nWS#^rND^sVan Achterberg^nT#The e
ffectiveness of commonly used mouthwashes for the prevention of chemotherapy-ind
uced oral mucositis: a systematic review^len#Eur J Cancer Care#2#Engl#20060000#2
006#15#5#431-9#20110200#v33n1a08.htm##
00711000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100022000980100
01500120012009100135030002700226710000200253065000900255064000500264031000300269
032000200272061012500274865000900399002001300408#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a08.htm#S#c#194#26#article#37#26#^rND^sClarkson^nJE#^rND^sWorthin
gton^nHV#^rND^sEden^nOB#Interventions for treating oral mucositis for patients w
ith cancer receiving treatment^len#Cochrane Database Syst Rev#2#20070000#2007#18
#2#CD001973. Update in: Cochrane Database Syst Rev. 2010;(8):CD001973. Update of
: Cochrane Database Syst Rev. 2004;(2):CD001973#20110200#v33n1a08.htm##
00651000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01800111010001600129012009800145030001700243065000900260064000500269031000400274
032000400278014000600282865000900288002001300297035001000310801001700320#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#195#27#article#37#27#^rND^sGü
rbüz^nI#^rND^sOzkan^nAM#^rND^sYesilada^nE#^rND^sKutsal^nO#Anti-ulcerogenic activ
ity of some plants used in folk medicine of Pinarbasi (Kayseri, Turkey)^len#J Et
hnopharmacol#20050000#2005#101#1-3#313-8#20110200#v33n1a08.htm#0378-8741#J Ethno
pharmacol##
00594000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950120
10400114030001400218065000900232064000500241031000300246032000200249014000700251
865000900258002001300267035001000280801001400290#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a08.htm#S#c#196#28#article#37#28#^rND^sMcKay^nDL#^rND^sBlumberg^n
JB#A review of the bioactivity and potential health benefits of chamomile tea (M
atricaria recutita L.)^len#Phytother Res#20060000#2006#20#7#519-30#20110200#v33n
1a08.htm#0951-418X#Phytother Res##
00620000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100014000970100
01400111010001600125012007100141030001800212065000900230064000500239031000300244
032000200247014000700249865000900256002001300265035001000278801001800288#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#197#29#article#37#29#^rND^sMo
rimoto^nY#^rND^sNiwa^nH#^rND^sImai^nY#^rND^sKirita^nT#Dental management prior to
 hematopoietic stem cell transplantation^len#Spec Care Dentist#20040000#2004#24#
6#287-92#20110200#v33n1a08.htm#0275-1879#Spec Care Dentist##
00760000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01800114010001800132010001600150010001800166810000600184012011600190030002300306
06500090032906400050033803100030034303200020034601400070034886500090035500200130
0364035001000377801002300387#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.h
tm#S#c#198#30#article#37#30#^rND^sYamagata^nK#^rND^sOnizawa^nK#^rND^sYanagawa^nT
#^rND^sHasegawa^nY#^rND^sKojima^nH#^rND^sNagasawa^nT#et al#A prospective study t
o evaluate a new dental management protocol before hematopoietic stem cell trans
plantation^len#Bone Marrow Transplant#20060000#2006#38#3#237-42#20110200#v33n1a0
8.htm#0268-3369#Bone marrow transplant##
00979000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01800113010001400131010001900145010001600164810000600180012032700186030002900513
06500090054206400050055103100030055603200020055901400070056186500090056800200130
0577035001000590801002900600#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.h
tm#S#c#199#31#article#37#31#^rND^sRizzo^nJD#^rND^sWingard^nJR#^rND^sTichelli^nA#
^rND^sLee^nSJ#^rND^sVan Lint^nMT#^rND^sBurns^nLJ#et al#Recommended screening and
 preventive practices for long-term survivors after hematopoietic cell transplan
tation: joint recommendations of the European Group for Blood and Marrow Transpl
antation, the Center for International Blood and Marrow Transplant Research, and
 the American Society of Blood and Marrow Transplantation^len#Biol Blood Marrow 
Transplant#20060000#2006#12#2#138-51#20110200#v33n1a08.htm#1083-8791#Biol Blood 
Marrow Transplant##
00744000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100021000970100
02600118010001500144010001900159010001500178810000600193012012400199030000600323
06500090032906400050033803100040034303200020034701400070034986500090035600200130
0365035001000378801000600388#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.h
tm#S#c#200#32#article#37#32#^rND^sAntunes^nHS#^rND^sde Azevedo^nAM#^rND^sda Silv
a Bouzas^nLF#^rND^sAdão^nCA#^rND^sPinheiro^nCT#^rND^sMayhe^nR#et al#Low-power la
ser in the prevention of induced oral mucositis in bone marrow transplantation p
atients: a randomized trial^len#Blood#20070000#2007#109#5#2250-5#20110200#v33n1a
08.htm#0006-4971#Blood##
00813000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01800111010001800129010001700147010001700164810000600181012015900187030002900346
06500090037506400050038403100030038903200020039201400080039486500090040200200130
0411035001000424801002900434#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.h
tm#S#c#201#33#article#37#33#^rND^sCowen^nD#^rND^sTardieu^nC#^rND^sSchubert^nM#^r
ND^sPeterson^nD#^rND^sResbeut^nM#^rND^sFaucher^nC#et al#Low energy Helium-Neon l
aser in the prevention of oral mucositis in patients undergoing bone marrow tran
splant: results of a double blind randomized trial^len#Int J Radiat Oncol Biol P
hys#19970000#1997#38#4#697-703#20110200#v33n1a08.htm#0360-3016#Int J Radiat Onco
l Biol Phys##
00730000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01500116010001600131010001500147010001800162012015400180030002000334710000200354
06500090035606400050036503100030037003200020037301400070037586500090038200200130
0391#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#202#34#article#37
#34#^rND^sEduardo^nFD#^rND^sBezinelli^nL#^rND^sLuiz^nAC#^rND^sCorrea^nL#^rND^sVo
gel^nC#^rND^sEduardo^nCP#Severity of oral mucositis in patients undergoing hemat
opoietic cell transplantation and an oral laser phototherapy protocol: a survey 
of 30 patients^len#Photomed Laser Surg#2#20090000#2009#27#1#137-44#20110200#v33n
1a08.htm##
00536000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980120
03500115030001900150065000900169064000500178031000300183032000200186014000700188
865000900195002001300204035001000217801001900227#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a08.htm#S#c#203#35#article#37#35#^rND^sSchubert^nMM#^rND^sCorrea^
nME#Oral graft-versus-host disease^len#Dent Clin North Am#20080000#2008#52#1#79-
109#20110200#v33n1a08.htm#0011-8532#Dent Clin North Am##
00698000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100012000930100
01800105010001500123010001600138010002000154810000600174012006300180030002300243
06500090026606400050027503100030028003200030028301400070028686500090029300200130
0302035001000315801002300325#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.h
tm#S#c#204#36#article#37#36#^rND^sElad^nS#^rND^sOr^nR#^rND^sShapira^nMY#^rND^sHa
viv^nA#^rND^sGalili^nD#^rND^sGarfunkel^nAA#et al#CO2 laser in oral graft-versus-
host disease: a pilot study^len#Bone Marrow Transplant#20030000#2003#32#10#1031-
4#20110200#v33n1a08.htm#0268-3369#Bone marrow transplant##
00706000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100021000930100
01800114010001500132012015800147030001500305065000900320064000500329031000300334
032000200337014000600339865000900345002001300354035001000367801001500377#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a08.htm#S#c#205#37#article#37#37#^rND^sCh
or^nA#^rND^sde Azevedo^nAM#^rND^sMaiolino^nA#^rND^sNucci^nM#Successful treatment
 of oral lesions of chronic lichenoid graft-vs.-host disease by the addition of 
low-level laser therapy to systemic immunosuppression^len#Eur J Haematol#2004000
0#2004#72#3#222-4#20110200#v33n1a08.htm#0902-4441#Eur J Haematol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#o#1#1#article#1
#20110411#115527#v33n1a09.htm#165##
02852000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000290011203100030014103200020014406500090014601400090015503500100016423700270
01740120120002010100043003210100027003640100028003910100032004190100039004510100
03800490010003000528010004500558070005900603070006100662083127500723085001001998
08500210200808500340202908500240206308500190208705800090210605800390211511700060
2154072000302160112000902163111000902172114000902181113001102190002001302201#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#h#2#1#article#1#oa#en#br1.1
#1#4.0#ILUS#TAB#9#RBHH340#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f21^l25
#1516-8484#10.5581/1516-8484.20110009#Genetic polymorphisms of Rh, Kell, Duffy a
nd Kidd systems in a population from the State of Paraná, southern Brazil^len#^r
ND^1A01^nGláucia Andréia Soares^sGuelsin#^rND^1A01^nAna Maria^sSell#^rND^1A02^nL
ilian^sCastilho#^rND^1A01^nViviane Lika^sMasaki#^rND^1A01^nFabiano Cavalcante de
^sMelo#^rND^1A01^nMargareth Naomi^sHashimoto#^rND^1A01^nLoide Souza^sHirle#^rND^
1A01^nJeane Eliete Laguila^sVisentainer#Universidade Estadual de Maringá^iA01^cM
aringá^sPR^pBrazil#Universidade Estadual de Campinas^iA02^cCampinas^sSP^pBrazil#
^len^aBACKGROUND: Red blood group genes are highly polymorphic and the distribut
ion of alleles varies among different populations and ethnic groups. AIM: To eva
luate allele polymorphisms of the Rh, Kell, Duffy and Kidd blood group systems i
n a population of the State of Paraná METHODS: Rh, Kell, Duffy and Kidd blood gr
oup polymorphisms were evaluated in 400 unrelated blood or bone marrow donors fr
om the northwestern region of Paraná State between September 2008 and October 20
09. The following techniques were used: multiplex-polymerase chain reaction geno
typing for the identification of the RHD gene and RHCE*C/c genotype; allele-spec
ific polymerase chain reaction for the RHD&#936; and restriction fragment length
 polymorphism polymerase chain reaction for the RHCE*E/e, KEL, FY-GATA and JK al
leles. RESULTS: These techniques enabled the evaluation of the frequencies of Rh
, Kell, Duffy and Kidd polymorphisms in the population studied, which were compa
red to frequencies in two populations from the eastern region of São Paulo State
. CONCLUSION: The RHCE*c/c, FY*A/FY*B, GATA-33 T/T, JK*B/JK*B genotypes were mor
e prevalent in the population from Paraná, while RHCE*C/c, FY*B/FY*B, GATA-33 C/
C, JK*A/JK*B genotypes were more common in the populations from São Paulo.#^ddec
s^i1#^tm^len^kGenotype^i1#^tm^len^kPolymorphism, genetic^i1#^tm^len^kBlood group
^i1#^tm^len^kBrazil^i1#UEM^dLIG#Fundação Araucária do Estado do Paraná#other#23#
20100704#4/7/2010#20101121#11/21/2010#v33n1a09.htm##
02894000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000290011203100030014103200020014406500090014601400090015503500100016423700270
01740120127002010100043003280100027003710100028003980100032004260100039004580100
03800497010003000535010004500565070005900610070006100669083131000730085001002040
08500210205008500340207108500240210508500190212905800090214805800390215711700060
2196072000302202112000902205111000902214114000902223113001102232002001302243#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#f#3#1#article#1#oa#en#br1.1
#1#4.0#ILUS#TAB#9#RBHH340#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f21^l25
#1516-8484#10.5581/1516-8484.20110009#<b>Genetic polymorphisms of Rh, Kell, Duff
y and Kidd systems in a population from the State of Paraná, southern Brazil</b>
^len#^rND^1A01^nGláucia Andréia Soares^sGuelsin#^rND^1A01^nAna Maria^sSell#^rND^
1A02^nLilian^sCastilho#^rND^1A01^nViviane Lika^sMasaki#^rND^1A01^nFabiano Cavalc
ante de^sMelo#^rND^1A01^nMargareth Naomi^sHashimoto#^rND^1A01^nLoide Souza^sHirl
e#^rND^1A01^nJeane Eliete Laguila^sVisentainer#Universidade Estadual de Maringá^
iA01^cMaringá^sPR^pBrazil#Universidade Estadual de Campinas^iA02^cCampinas^sSP^p
Brazil#^len^a<b>BACKGROUND:</b> Red blood group genes are highly polymorphic and
 the distribution of alleles varies among different populations and ethnic group
s. <b>AIM:</b> To evaluate allele polymorphisms of the Rh, Kell, Duffy and Kidd 
blood group systems in a population of the State of Paraná <b>METHODS:</b> Rh, K
ell, Duffy and Kidd blood group polymorphisms were evaluated in 400 unrelated bl
ood or bone marrow donors from the northwestern region of Paraná State between S
eptember 2008 and October 2009. The following techniques were used: multiplex-po
lymerase chain reaction genotyping for the identification of the RHD gene and RH
CE*C/c genotype; allele-specific polymerase chain reaction for the RHD&#936; and
 restriction fragment length polymorphism polymerase chain reaction for the RHCE
*E/e, KEL, FY-GATA and JK alleles. <b>RESULTS:</b> These techniques enabled the 
evaluation of the frequencies of Rh, Kell, Duffy and Kidd polymorphisms in the p
opulation studied, which were compared to frequencies in two populations from th
e eastern region of São Paulo State. <b>CONCLUSION:</b> The RHCE*c/c, FY*A/FY*B,
 GATA-33 T/T, JK*B/JK*B genotypes were more prevalent in the population from Par
aná, while RHCE*C/c, FY*B/FY*B, GATA-33 C/C, JK*A/JK*B genotypes were more commo
n in the populations from São Paulo.#^ddecs^i1#^tm^len^kGenotype^i1#^tm^len^kPol
ymorphism, genetic^i1#^tm^len^kBlood group^i1#^tm^len^kBrazil^i1#UEM^dLIG#Fundaç
ão Araucária do Estado do Paraná#other#23#20100704#4/7/2010#20101121#11/21/2010#
v33n1a09.htm##
02981000000000661000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103038000400108121000200112049000800114
15800030012203000280012503100030015303200020015606500090015801400090016703500100
01762370027001860120120002130100043003330100027003760100028004030100032004310100
03900463010003800502010003000540010004500570070006100615070006300676083127500739
08500100201408500210202408500340204508500240207908500190210305800090212205800390
21311170006021700720003021761120009021791110009021881140009021971130011022060020
01302217008008902230#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#l#4
#1#article#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#9#RBHH340#nd#Rev. bras. hem
atol. hemoter#33#1#20110200#^f21^l25#1516-8484#10.5581/1516-8484.20110009#Geneti
c polymorphisms of Rh, Kell, Duffy and Kidd systems in a population from the Sta
te of Paraná, southern Brazil^len#^rND^1A01^nGláucia Andréia Soares^sGuelsin#^rN
D^1A01^nAna Maria^sSell#^rND^1A02^nLilian^sCastilho#^rND^1A01^nViviane Lika^sMas
aki#^rND^1A01^nFabiano Cavalcante de^sMelo#^rND^1A01^nMargareth Naomi^sHashimoto
#^rND^1A01^nLoide Souza^sHirle#^rND^1A01^nJeane Eliete Laguila^sVisentainer#^iA0
1^1Universidade Estadual de Maringá^cMaringá^sPR^pBrazil#^iA02^1Universidade Est
adual de Campinas^cCampinas^sSP^pBrazil#^len^aBACKGROUND: Red blood group genes 
are highly polymorphic and the distribution of alleles varies among different po
pulations and ethnic groups. AIM: To evaluate allele polymorphisms of the Rh, Ke
ll, Duffy and Kidd blood group systems in a population of the State of Paraná ME
THODS: Rh, Kell, Duffy and Kidd blood group polymorphisms were evaluated in 400 
unrelated blood or bone marrow donors from the northwestern region of Paraná Sta
te between September 2008 and October 2009. The following techniques were used: 
multiplex-polymerase chain reaction genotyping for the identification of the RHD
 gene and RHCE*C/c genotype; allele-specific polymerase chain reaction for the R
HD&#936; and restriction fragment length polymorphism polymerase chain reaction 
for the RHCE*E/e, KEL, FY-GATA and JK alleles. RESULTS: These techniques enabled
 the evaluation of the frequencies of Rh, Kell, Duffy and Kidd polymorphisms in 
the population studied, which were compared to frequencies in two populations fr
om the eastern region of São Paulo State. CONCLUSION: The RHCE*c/c, FY*A/FY*B, G
ATA-33 T/T, JK*B/JK*B genotypes were more prevalent in the population from Paran
á, while RHCE*C/c, FY*B/FY*B, GATA-33 C/C, JK*A/JK*B genotypes were more common 
in the populations from São Paulo.#^ddecs^i1#^tm^len^kGenotype^i1#^tm^len^kPolym
orphism, genetic^i1#^tm^len^kBlood group^i1#^tm^len^kBrazil^i1#UEM^dLIG#Fundação
 Araucária do Estado do Paraná#other#23#20100704#4/7/2010#20101121#11/21/2010#v3
3n1a09.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S151
6-84842011000100009##
00354000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012100074002001300195#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#5#1#article#138#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLES</b>
</font></p>     ^cY#v33n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#6#2#article#138#<p>&nbsp;</p>     ^cY
#v33n1a09.htm##
00463000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704023000074002001300304#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#7#3#article#138#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Genetic polymorph
isms of Rh, Kell, Duffy and Kidd systems in a population from the State of Paran
&aacute;, southern Brazil</b></font></p>     ^cY#v33n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#8#4#article#138#<p>&nbsp;</p>     ^cY
#v33n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#9#5#article#138#<p>&nbsp;</p>     ^cY
#v33n1a09.htm##
00627000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704039300075002001300468#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#10#6#article#138#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Gl&aacute;ucia Andr&eacute;ia Soar
es Guelsin<sup>I</sup>; Ana Maria Sell<sup>I</sup>; Lilian Castilho<sup>II</sup>
; Viviane Lika Masaki<sup>I</sup>; Fabiano Cavalcante de Melo<sup>I</sup>; Marga
reth Naomi Hashimoto<sup>I</sup>; Loide Souza Hirle<sup>I</sup>; Jeane Eliete La
guila Visentainer<sup>I</sup></b></font></p>     ^cY#v33n1a09.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015600075002001300231#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#11#7#article#138#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Universidade Estadual de 
Maring&aacute;  UEM, Maring&aacute; (PR), Brazil    ^cY#v33n1a09.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#12#8#article#138#<br>   <sup>II</sup>
Universidade Estadual de Campinas  UNICAMP, Campinas (SP), Brazil</font></p>    
 ^cY#v33n1a09.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#13#9#article#138#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></fon
t></p>     ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#14#10#article#138#<p>&nbsp;</p>     ^
cY#v33n1a09.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#15#11#article#138#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v33n1a09.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#16#12#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
33n1a09.htm##
00456000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022100076002001300297#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#17#13#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>BACKGROUND:</b> Red blood group g
enes are highly polymorphic and the distribution of alleles varies among differe
nt populations and ethnic groups.     ^cY#v33n1a09.htm##
00392000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015700076002001300233#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#18#14#article#138#<br>   <b>AIM:</b> 
To evaluate allele polymorphisms of the Rh, Kell, Duffy and Kidd blood group sys
tems in a population of the State of Paran&aacute;    ^cY#v33n1a09.htm##
00868000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063300076002001300709#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#19#15#article#138#<br>   <b>METHODS:<
/b> Rh, Kell, Duffy and Kidd blood group polymorphisms were evaluated in 400 unr
elated blood or bone marrow donors from the northwestern region of Paran&aacute;
 State between September 2008 and October 2009. The following techniques were us
ed: multiplex-polymerase chain reaction genotyping for the identification of the
 RHD gene and RHCE*C/c genotype; allele-specific polymerase chain reaction for t
he RHD</font><i>&#936;</i><font size="2" face="Verdana, Arial, Helvetica, sans-s
erif"> and  restriction fragment length polymorphism polymerase chain reaction f
or the RHCE*E/e, KEL, FY-GATA and JK alleles.     ^cY#v33n1a09.htm##
00499000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026400076002001300340#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#20#16#article#138#<br>   <b>RESULTS:<
/b> These techniques enabled the evaluation of the frequencies of Rh, Kell, Duff
y and Kidd polymorphisms in the population studied, which were compared to frequ
encies in two populations from the eastern region of S&atilde;o Paulo State.    
 ^cY#v33n1a09.htm##
00516000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028100076002001300357#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#21#17#article#138#<br>   <b>CONCLUSIO
N:</b> The RHCE*c/c, FY*A/FY*B, GATA-33 T/T, JK*B/JK*B genotypes were more preva
lent in the population from Paran&aacute;, while RHCE*C/c, FY*B/FY*B, GATA-33 C/
C, JK*A/JK*B genotypes were more common in the populations from S&atilde;o Paulo
. </font></p>     ^cY#v33n1a09.htm##
00409000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017400076002001300250#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#22#18#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Genotype; Polymorph
ism, genetic; Blood group; Brazil</font></p> <hr size="1" noshade>     ^cY#v33n1
a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#23#19#article#138#<p>&nbsp;</p>     ^
cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#24#20#article#138#<p>&nbsp;</p>     ^
cY#v33n1a09.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#25#21#article#138#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></p>     ^
cY#v33n1a09.htm##
00617000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038200076002001300458#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#26#22#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">According to the International Socie
ty for Blood Transfusion (ISBT), there are currently 308 red blood cell antigens
 classified into 30 blood group systems.<sup>(1) </sup>The genes of all these sy
stems have been cloned except for one: the gene responsible for the P1/P2 polymo
rphism.<sup>(2,3)</sup></font></p>     ^cY#v33n1a09.htm##
00710000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047500076002001300551#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#27#23#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Knowledge of the molecular basis of 
these genes enabled the development of molecular biology typing methods, the ide
ntification of new mutations, an understanding of polymorphisms and the discover
y of new alleles. Genes of red blood cell groups are highly polymorphic and the 
distribution of allelic frequencies in these systems varies between different re
gions of the world.<sup>(4,5) </sup></font></p>     ^cY#v33n1a09.htm##
00509000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027400076002001300350#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#28#24#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The red blood cell groups are compos
ed of numerous antigens, of which the main ones are: ABO, Rh, Kell, Duffy, Kidd 
and MNS. ABO and Rh are the most important systems in transfusion medicine.</fon
t></p>     ^cY#v33n1a09.htm##
00549000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031400076002001300390#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#29#25#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Rh system is the most complex of
 all blood group systems with 50 well-established antigens currently known. The 
antigens of this system are encoded by two genes located on chromosome 1: <i>RHD
</i> and <i>RHCE</i>.<sup>(5)</sup></font></p>     ^cY#v33n1a09.htm##
00909000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067400076002001300750#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#30#26#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Kell system consists of 31 antig
ens, including six pairs of antithetical antigens. The Kell protein is associate
d with other proteins on the red blood cell membrane.<sup>(6)</sup> The classic 
Kell antigen (KEL1) is important in transfusion medicine: anti-K antibodies can 
cause severe or even fatal transfusion reactions and perinatal hemolytic disease
 (PHD). The gene encoding the antigens of this system (<i>KEL</i>) is located on
 chromosome 7q33 and its expression occurs in erythroid cells and in some tissue
s, such as the brain, lymphoid organs, the heart and muscles.<sup>(7)</sup></fon
t></p>     ^cY#v33n1a09.htm##
00657000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042200076002001300498#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#31#27#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Duffy gene (<i>FY</i> or <i>DARC
</i>), the first human gene recognized as being autosomal, consists of two exons
, and its locus is on chromosome 1q22-q23. Fy<sup>a</sup> and Fy<sup>b</sup> are
 encoded by the <i>FY*A</i> and <i>FY*B</i> alleles, and are responsible for the
 Fy (a+b-), Fy (a-b+) and Fy (a+b+) phenotypes.<sup>(8,9)</sup></font></p>     ^
cY#v33n1a09.htm##
00532000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029700076002001300373#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#32#28#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The common phenotypes of the Kidd bl
ood group system &#91;Jk (a+b-), Jk (a-b+) and Jk (a+b+)&#93; are encoded by two
 codominant alleles: <i>JK*A</i> and <i>JK*B</i>, located in the 18q12,3 region.
<sup>(10-12)</sup></font></p>     ^cY#v33n1a09.htm##
00529000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029400076002001300370#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#33#29#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The aim of the present study was to
 evaluate allele polymorphisms of the Rh, Kell, Duffy and Kidd blood group syste
ms in a population from the northwestern region of the State of Paran&aacute;, s
outhern Brazil.</font></p>     ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#34#30#article#138#<p>&nbsp;</p>     ^
cY#v33n1a09.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#35#31#article#138#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Methods</b></font></p>     ^cY#v3
3n1a09.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008900076002001300165#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#36#32#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Donors</font></p>     ^cY#v33n1a09.h
tm##
00771000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053600076002001300612#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#37#33#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">After receiving approval from the Hu
man Research Ethics Committee and after signing informed consent terms, peripher
al blood was randomly collected from 400 voluntary blood and bone marrow donors 
from the city of Maring&aacute; in the northwest of Paran&aacute; State. Of thes
e 400 donors, 217 were male and 183 female, with a mean age of 31.16 ± 11.34 yea
rs (20-42 years). The donors were of mixed ethnic origin, but predominantly of C
aucasian descent.</font></p>     ^cY#v33n1a09.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#38#34#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Genomic DNA extraction</font></p>   
  ^cY#v33n1a09.htm##
00598000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036300076002001300439#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#39#35#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">To obtain the DNA, 5 mL of periphera
l blood was collected in EDTA and centrifuged (2500 rpm for 10 min) to obtain th
e Buffy-coat. The DNA was extracted using the EZ-DNA (Biological Industries&reg;
, Kibbutz Beit Haemek, Israel) extraction kit following the manufacturer's proto
col.</font></p>     ^cY#v33n1a09.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011600076002001300192#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#40#36#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">RHD, RHDY and RHCE*C/c genotyping</f
ont></p>     ^cY#v33n1a09.htm##
02236000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704200100076002001302077#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#41#37#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Genotyping of the alleles of the Rh 
system was performed according to the protocol previously described in the liter
ature,<sup>(13)</sup> with some modifications: For the amplification of the <i>R
HCE*C/c</i> alleles and to test for the presence of the <i>RHD</i> gene, the PCR
 (polymerase chain reaction)-multiplex technique was used. This technique amplif
ies <i>RHCE*C/c</i> alleles and tests for the presence of <i>RHD</i> through the
 analysis of the exon 7 and intron 4 of this gene. Detection of a 37-bp duplicat
ion in the <i>RHD</i> gene known as <i>RHD</i></font>&#936;<font size="2" face="
Verdana, Arial, Helvetica, sans-serif"> or <i>RHD</i> pseudogene, was achieved u
sing the AS-PCR (allele-specific polymerase chain reaction) technique with a pai
r of specific primers for this genetic region and a pair of primers (HGH - human
 growth hormone) as an internal control. For both reactions (PCR-multiplex and A
S-PCR), 200 ng of DNA, 50 pmol of each primer, 2 nmol of each dNTP, 1.0 U of Taq
 DNA polymerase (Invitrogen Life Technologies&reg;, Grand Island, NY, USA) and b
uffer to make up a final volume of 50 &#181;L were used. The PCR-multiplex ampli
fication cycles were performed in a System 9700 PCR thermocycler (Applied Biosys
tems&reg;, Foster City, CA, USA) and consisted of: denaturation at 95ºC for 15 m
inutes and 30 cycles of one minute at 94ºC, one minute at 65ºC and 3.5 minutes a
t 72ºC, followed by extension for ten minutes at 72ºC. For AS-PCR, the amplifica
tion cycles consisted of: denaturation at 95ºC for five minutes and 28 cycles of
 one minute at 94ºC, one minute at 60ºC and one minute at 72ºC, followed by exte
nsion for seven minutes at 72ºC. The analysis of the PCR products obtained was p
erformed after electrophoresis in 2% agarose gel, stained with SYBR Green (Invit
rogen Life Technologies&reg;, Grand Island, NY, USA) in a micro cube SSP gel sys
tem (One Lambda&reg;, San Diego, CA, USA).</font></p>     ^cY#v33n1a09.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012300076002001300199#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#42#38#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">RHCE*E/e, KEL, FY-GATA and JK genoty
ping</font></p>     ^cY#v33n1a09.htm##
01911000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704167600076002001301752#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#43#39#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>RHCE*E/e, KEL*1/KEL*2, FY*A/FY*B-
GATA</i> and <i>JK*A/JK*B</i> genotyping was performed by the RFLP-PCR (restrict
ion fragment length polymorphism-polymerase chain reaction) technique according 
to protocols previously described in the literature,<sup>(14,15)</sup> with some
 modifications. The PCR reaction used 200 ng of DNA, 50 pmol of each primer, 2 n
mol of each dNTP, 1.0 U of Taq DNA polymerase (Invitrogen Life Technologies&reg;
, Grand Island, NY, USA) and buffer to make up a final volume of 50 &#181;L. The
 amplification cycles were performed in a System 9700 PCR thermocycler (Applied 
Biosystems&reg;, Foster City, CA, USA) and consisted of: denaturation at 95ºC fo
r 15 minutes and 35 cycles of twenty seconds at 94ºC, twenty seconds at 62ºC and
 twenty seconds at 72ºC, followed by extension for ten minutes at 72ºC. The prod
ucts obtained from the <i>RHCE*E/e, KEL*1/KEL*2, FY*A/FY*B-GATA</i> and <i>JK*A/
JK*B</i> PCR were digested overnight with their respective restriction enzymes (
MBI Fermentas&reg;, Canada): <i>Mnl</i> I, <i>Bsml, Ban </i>I, <i>Sty</i> I and 
<i>Mnl</i> I, in final volumes of 20 &#181;L, using 10 &#181;L of PCR product an
d 10 &#181;L of the enzyme/buffer mixture, following the protocol recommended by
 the manufacturer. Analysis of mutations in the GATA-box region was performed af
ter electrophoresis in 6% polyacrylamide gel stained with silver. Three percent 
agarose gel stained with SYBR Green (Invitrogen Life Technologies&reg;, Grand Is
land, NY, USA) was used to evaluate the other alleles (<i>RHCE*E/e, KEL*1/KEL*2,
 FY*A/FY*B</i> and <i>JK*A/JK*B</i>).</font></p>     ^cY#v33n1a09.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010300076002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#44#40#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Statistical analysis</font></p>     
^cY#v33n1a09.htm##
01113000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087800076002001300954#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#45#41#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The genotypic and allelic frequencie
s were obtained by direct counting on Excel spreadsheets (Microsoft&reg; Office 
Excel 2003). A comparison of the genetic and allelic frequencies in blood groups
 from the population of blood and bone marrow donors in this study and the two p
reviously studied populations of blood donors from Campinas, S&atilde;o Paulo, w
as carried out.<sup>(16,17)</sup> The comparison was performed using the Chi-squ
are test or Fisher's exact test, where appropriate, using a 2x2 contingency tabl
e.<sup>(18) </sup>The Arlequin computer program version 3.1 available at: <a hre
f="http://cmpg.unibe.ch/software/arlequin3/" target="_blank">http://cmpg.unibe.c
h/software/arlequin3/</a> was used to see if the distributions of genes and alle
les were in Hardy-Weinberg equilibrium.</font></p>     ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#46#42#article#138#<p>&nbsp;</p>     ^
cY#v33n1a09.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#47#43#article#138#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>     ^cY#v3
3n1a09.htm##
00622000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038700076002001300463#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#48#44#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The present study is the first to re
port the frequency of <i>HR, KEL, FY</i> and <i>JK</i> gene polymorphisms in a p
opulation from the northwestern region of the State of Paran&aacute; (<a href="#
tab1">Table 1</a>). The population was found to be in Hardy-Weinberg equilibrium
 for all the genes analyzed.</font></p>     ^cY#v33n1a09.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#49#45#article#138#<p><a name="tab1"><
/a></p>     ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#50#46#article#138#<p>&nbsp;</p>     ^
cY#v33n1a09.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#51#47#article#138#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a09tab01.jpg"></p>     ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#52#48#article#138#<p>&nbsp;</p>     ^
cY#v33n1a09.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#53#49#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Rh system</font></p>     ^cY#v33
n1a09.htm##
01004000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076900076002001300845#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#54#50#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Of the 400 samples analyzed, 345 (86
.25%) were <i>RHD</i> positive (presence of the <i>RHD</i> gene) and 55 (13.75%)
 <i>RHD</i> negative (absence of the <i>RHD </i>gene). The <i>RHD</i> pseudogene
 (<i>RHD</i></font>&#936;<font size="2" face="Verdana, Arial, Helvetica, sans-se
rif">) was present in only four heterozygous samples (1.0%) and so none of the s
amples presented the <i>RhD</i> negative phenotype. The frequencies for the <i>R
HCE</i> gene were: 17.50% for the <i>RHCE*C/C </i>genotype, 42.75% for <i>RHCE*C
/c</i> and 39.75% for <i>RHCE*c/c</i>. For the <i>RHCE</i> gene the frequencies 
were: 2.25% for <i>RHCE*E/E</i>, 25.75% for R<i>HCE*E/e</i> and 72.0% for <i>RHC
E*e/e.</i></font></p>     ^cY#v33n1a09.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#55#51#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Kell system</font></p>     ^cY#v
33n1a09.htm##
00503000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026800076002001300344#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#56#52#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The <i>KEL*2/KEL*2</i> genotype was 
observed in 379 samples (94.75%), <i>KEL*1/KEL*2 </i>was observed in 20 samples 
(5.0%) and only one had the rare <i>KEL*1/KEL*1</i> genotype (0.25%).</font></p>
     ^cY#v33n1a09.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#57#53#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Kidd system</font></p>     ^cY#v
33n1a09.htm##
00499000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026400076002001300340#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#58#54#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The genotype distribution for this s
ystem was as follows: <i>JK*A/JK*A</i> was observed in 109 (27.25%) samples, <i>
JK*A/JK*B</i> in 192 (48.0%) and <i>JK*B/JK*B</i> in 99 (24.75%).</font></p>    
 ^cY#v33n1a09.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009900076002001300175#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#59#55#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Duffy system</font></p>     ^cY#
v33n1a09.htm##
01325000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109000076002001301166#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#60#56#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The <i>FY*A/FY*A</i> genotype was ob
served in 50 (12.60%) samples, <i>FY*A/FY*B</i> in 192 samples (48.0%) and <i>FY
*B/FY*B</i> in 158 (39.50%) samples. The mutation (-33T&gt;C), which occurs in t
he <i>GATA</i>-box erythroid promoter region and prevents the expression of the 
<i>FY*B</i> allele on the surface of red blood cells, was evaluated. For this po
lymorphism, 10 (2.5%) samples were genotyped as being homozygous (<i>GATA-33C/C<
/i>), 78 (19.5%) as heterozygous (<i>GATA-33T/C</i>) and the vast majority, 312 
samples (78.0%), without this mutation (<i>GATA-33T/T</i>). All of the homozygou
s samples (<i>GATA-33C/C</i>) had the <i>FY*B/FY*B</i> genotype, which correspon
ds to the Fy(a-b-) phenotype. Among the heterozygous samples (<i>GATA-33T/C</i>)
, 35 (44.87%) had the <i>FY*A/FY*B</i> genotype, i.e. they expressed the Fy(a+b-
) phenotype and 43 (55.13%) had <i>FY*B/FY*B</i>, which corresponds to the Fy(a-
b+) phenotype which is characterized by a reduced expression of the Fy<sup>b</su
p> antigen.</font></p>     ^cY#v33n1a09.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020600076002001300282#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#61#57#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Allele frequencies and comparison of
 red blood cell gene frequencies in populations from Paran&aacute; and S&atilde;
o Paulo</font></p>     ^cY#v33n1a09.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020600076002001300282#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#62#58#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Allele frequencies were calculated a
nd the results are shown in <a href="/img/revistas/rbhh/v33n1/a09ab02.jpg">Table
 2</a>.</font></p>     ^cY#v33n1a09.htm##
00601000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036600076002001300442#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#63#59#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The gene frequencies observed in the
 voluntary blood and bone marrow donors evaluated in this study were compared wi
th those found in two populations of voluntary blood donors from the city of Cam
pinas in the State of S&atilde;o Paulo (<a href="#tab3">Table 3</a>).<sup>(16,17
)</sup></font></p>     ^cY#v33n1a09.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#64#60#article#138#<p><a name="tab3"><
/a></p>     ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#65#61#article#138#<p>&nbsp;</p>     ^
cY#v33n1a09.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#66#62#article#138#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a09tab03.jpg"></p>     ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#67#63#article#138#<p>&nbsp;</p>     ^
cY#v33n1a09.htm##
00990000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075500076002001300831#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#68#64#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Several statistical differences were
 observed in red blood cell gene frequencies. The <i>RHCE*C/c, FY*B/FY*B, GATA-3
3 C/C</i> and <i>JK*A/JK*B </i>genotypes were more prevalent in the populations 
from S&atilde;o Paulo, while the <i>RHCE*c/c, FY*A/FY*B, GATA-33 T/T</i> and <i>
JK*B/JK*B</i> genotypes were more common in the population from Paran&aacute;. T
here was a difference in the frequency of the <i>GATA-33 T/C</i> genotype betwee
n the two populations from S&atilde;o Paulo: in one of the populations the frequ
ency was 0.25,<sup>(16)</sup> while in the other it was 0.12.<sup>(17)</sup> In 
the population from Paran&aacute;, the frequency for this genotype was 0.19.</fo
nt></p>     ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#69#65#article#138#<p>&nbsp;</p>     ^
cY#v33n1a09.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#70#66#article#138#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p>     ^cY
#v33n1a09.htm##
00607000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037200076002001300448#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#71#67#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The population of Brazil is one of t
he most heterogeneous in the world, resulting from interbreeding of races from t
hree continents over a period of five centuries: the European colonizers (mainly
 from Portugal and Italy), African slaves and local Amerindian populations.<sup>
(19,20)</sup></font></p>     ^cY#v33n1a09.htm##
00799000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056400076002001300640#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#72#68#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The samples evaluated in the present
 study from the State of Paran&aacute;, in the south of Brazil, represent an int
erracial mixture of European, African and Amerindian genes, as the region is pre
dominantly populated by European immigrants (80.5%), with small but significant 
numbers of Africans (12.5%) and Amerindians (7.0%).<sup>(21) </sup>For this reas
on, in Brazil, skin color, determined by physical evaluation, is a poor predicto
r of genomic African ancestry.<sup>(19)</sup></font></p>     ^cY#v33n1a09.htm##
00730000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049500076002001300571#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#73#69#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In a study carried out on a populati
on from Amazonia in the north of Brazil, the frequency of the <i>FY*A</i> allele
 was 0.365, of <i>FY*B</i> (adding together the frequencies of the <i>FY*B</i> a
nd <i>FY*B-33</i> alleles) was 0.62 and of the <i>FY*X</i> allele the frequency 
was 0.014.<sup>(22)</sup> These allele frequencies are similar to those found in
 the population from Paran&aacute; in the current study.</font></p>     ^cY#v33n
1a09.htm##
01123000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088800076002001300964#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#74#70#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">According to the Brazilian Census In
stitute (Instituto Brasileiro de Geografia Estat&iacute;stica <a href="http://ww
w.ibge.gov.br" target="_blank">http://www.ibge.gov.br</a>), the population of th
e State of S&atilde;o Paulo can also be considered as being of mixed ethnic orig
in, with a predominance of Europeans (70.0%) and Africans (28.0%). When the gene
 frequencies of the samples from Paran&aacute; were compared with those of the t
wo populations from S&atilde;o Paulo, statistically significant differences were
 observed for the <i>RHCE*c/c, FY*A/FY*B, GATA-33 T/T, JK*B/JK*B</i> genotypes, 
which were more common in the population from Paran&aacute;, and for the <i>RHCE
*C/c, FY*B/FY*B, GATA-33 C/C</i>, J<i>K*A/JK*B</i> genotypes, which were more pr
evalent in the populations from S&atilde;o Paulo.</font></p>     ^cY#v33n1a09.ht
m##
00921000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068600076002001300762#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#75#71#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A previous study carried out with po
pulations from the same geographical regions (the northwest of Paran&aacute; Sta
te and the east of S&atilde;o Paulo State) compared the polymorphisms of cytokin
e genes and found no statistical differences between the two populations for the
 genes studied.<sup>(23)</sup> The genetic similarity observed between these two
 populations could be due to a similar pattern of miscegenation. However, the di
fferences observed for some red blood cell genes demonstrates that, although sim
ilar, they may have been subject to a greater influence of one or another ethnic
 group.</font></p>     ^cY#v33n1a09.htm##
01346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704111100076002001301187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#76#72#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Knowledge of the molecular basis of 
blood groups has made the study of red blood cell gene frequencies possible in d
ifferent parts of the world. However, until now, few studies have been carried o
ut on Brazilian populations. Further research must be carried out in all regions
 of the country in order to gain a greater understanding of the genetic variabil
ity and distribution of these systems to discover new alleles and to design new 
studies and strategies to study rare genotypes and phenotypes. This would enhanc
e the search for compatible blood when carrying out transfusions in different ge
ographical regions. These studies should include other blood group systems that 
are relevant to transfusion medicine, such as the MNS, Diego, Dombrock, Colton a
nd Lutheran systems, among others. In the near future, DNA array technology coul
d be widely used for this type of research, as it allows the identification of v
arious polymorphisms within a single platform, as well as the simultaneous analy
sis of large numbers of samples.</font></p>     ^cY#v33n1a09.htm##
00930000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069500076002001300771#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#77#73#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Genotyping techniques used in this s
tudy enabled the evaluation of the genetic frequencies of Rh, Kell, Duffy and Ki
dd polymorphisms in a population from the northwestern region of the State of Pa
ran&aacute;, and the results obtained can be used for anthropological comparison
s, as well as for association studies for different diseases. Furthermore, this 
study enabled the evaluation of the genotyping method for the identification of 
red blood cell genes; this was considered to be a reliable alternative to resolv
e transfusion complications, where conventional immunohematological techniques h
ave limitations.</font></p>     ^cY#v33n1a09.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#78#74#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Acknowledgements</b></font></p>  
   ^cY#v33n1a09.htm##
00641000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040600076002001300482#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#79#75#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The authors would like to thank the 
voluntary donors who participated in this study and everyone that contributed to
 its completion. This research was financially supported by LIG-UEM and by the F
unda&ccedil;&atilde;o Arauc&aacute;ria do Estado do Paran&aacute;. The manuscrip
t was linguistically revised by Peter Grimshaw.</font></p>     ^cY#v33n1a09.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#80#76#article#138#<p>&nbsp;</p>     ^
cY#v33n1a09.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#81#77#article#138#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY
#v33n1a09.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029500078002001300373#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#82#78#article#138#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Daniels G, Castilho
 L, Flegel WA, Fletcher A, Garratty G, Levene C, et al. International Society of
 Blood Transfusion Committee on Terminology for red blood cell surface antigens:
 Macao report. Vox Sang. 2009;96(2):153-6.    ^cY#v33n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#83#79#article#138#</font></p>     ^cY
#v33n1a09.htm##
00545000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029600078002001300374#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#84#80#article#138#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Hellberg A, Chester
 MA, Olsson ML. Two previously proposed P1/P2-differentiating and nine novel pol
ymorphisms at the A4GALT (Pk) locus do not correlate with the presence of the P1
 blood group antigen. BMC Genet. 2005;6:49.    ^cY#v33n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#85#81#article#138#</font></p>     ^cY
#v33n1a09.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028200078002001300360#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#86#82#article#138#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Tilley L, Green C, 
Daniels G. Sequence variation in the 5' untranslated region of the human A4GALT 
gene is associated with, but does not define, the P1 blood group polymorphism. V
ox Sang. 2006;90 (3):198-203.    ^cY#v33n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#87#83#article#138#</font></p>     ^cY
#v33n1a09.htm##
00407000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015800078002001300236#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#88#84#article#138#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Yip SP. Sequence va
riation at the human ABO locus. Ann Hum Genet. 2002;66(Pt1):1-27.    ^cY#v33n1a0
9.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#89#85#article#138#</font></p>     ^cY
#v33n1a09.htm##
00416000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016700078002001300245#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#90#86#article#138#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Daniels G. The mole
cular genetics of blood group polymorphism. Hum Genet. 2009;126(6):729-42.    ^c
Y#v33n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#91#87#article#138#</font></p>     ^cY
#v33n1a09.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019100078002001300269#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#92#88#article#138#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Lee S. Molecular ba
sis of Kell blood group phenotypes. Vox Sang. 1997;73(1):1-11. Erratum in: Vox S
ang 1998;74(1):58.    ^cY#v33n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#93#89#article#138#</font></p>     ^cY
#v33n1a09.htm##
00497000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024800078002001300326#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#94#90#article#138#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Lee S, Zambas ED, M
arsh WL, Redman CM. The human Kell blood group gene maps to chromosome 7q33 and 
its expression is restricted to erythroid cells. Blood. 1993;81(10):2804-9.    ^
cY#v33n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#95#91#article#138#</font></p>     ^cY
#v33n1a09.htm##
00406000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015700078002001300235#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#96#92#article#138#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Pruenster M, Rot A.
 Throwing light on DARC. Biochem Soc Trans. 2006;34(Pt6):1005-8.    ^cY#v33n1a09
.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#97#93#article#138#</font></p>     ^cY
#v33n1a09.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025200078002001300330#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#98#94#article#138#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Miller LH, Mason SJ
, Dvorak JA, McGinniss MH, Rothman IK. Erythrocyte receptors for (Plasmodium kno
wlesi) malaria: Duffy blood group determinants. Science. 1975;189(4202): 561-3. 
   ^cY#v33n1a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#99#95#article#138#</font></p>     ^cY
#v33n1a09.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704023900080002001300319#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#100#96#article#138#10#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. You G, Smith CP,
 Kanai Y, Lee W-S, Stelzner M, Hediger MA. Cloning and characterization of the v
asopressin-regulated urea transporter. Nature. 1993;365(6449):844-7.    ^cY#v33n
1a09.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#101#97#article#138#</font></p>     ^c
Y#v33n1a09.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704030300080002001300383#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#102#98#article#138#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Oliv&egrave;s B,
 Merriman M, Bailly P, Bain S, Barnett A, Todd J, et al. The molecular basis of 
the Kidd blood group polymorphism and its lack of association with type 1 diabet
es susceptibility. Hum Mol Genet. 1997;6(7):1017-20.    ^cY#v33n1a09.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#103#99#article#138#</font></p>     ^c
Y#v33n1a09.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027800081002001300359#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#104#100#article#138#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Lin Y, Pavenski
 K, Saidenberg E, Branch DR. Blood group antigens and normal red blood cell phys
iology: a Canadian blood services research and development symposium. Transfus M
ed Rev. 2009; 23(4):292-309.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#105#101#article#138#</font></p>     ^
cY#v33n1a09.htm##
00573000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032100081002001300402#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#106#102#article#138#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Singleton BK, G
reen CA, Avent ND, Martin PG, Smart E, Daka A, et al. The presence of an RHD pse
udogene containing a 37 base pair duplication phenotype and a nonsense mutation 
in africans with the Rh D-negative blood group. Blood. 2000;95(1):12-8.    ^cY#v
33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#107#103#article#138#</font></p>     ^
cY#v33n1a09.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024700081002001300328#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#108#104#article#138#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Rios M, Cash K,
 Strupp A, Uehlinger J, Reid ME. DNA from urine sediment or buccal cells can be 
used for blood group molecular genotyping. Immunohematology. 1999;15(2):61-5.   
 ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#109#105#article#138#</font></p>     ^
cY#v33n1a09.htm##
00463000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021100081002001300292#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#110#106#article#138#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Reid ME, Rios M
, Yazdanbakhsh K. Applications of molecular biology techniques to transfusion me
dicine. Semin Hematol. 2000;37(2):166-76.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#111#107#article#138#</font></p>     ^
cY#v33n1a09.htm##
00581000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032900081002001300410#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#112#108#article#138#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Ribeiro KR, Gua
rnieri MH, da Costa DC, Costa FF, Pellegrino J Jr, Castilho L. DNA array analysi
s for red blood cell antigens facilitates the transfusion support with antigen-m
atched blood in patients with sickle cell disease. Vox Sang. 2009;97(2):147-52. 
   ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#113#109#article#138#</font></p>     ^
cY#v33n1a09.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022500081002001300306#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#114#110#article#138#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Pellegrino J Jr
, Castilho L, Rios M, De Souza CA. Blood group genotyping in a population of hig
hly diverse ancestry. J Clin Lab Anal. 2001;15(1):8-13.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#115#111#article#138#</font></p>     ^
cY#v33n1a09.htm##
00459000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020700081002001300288#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#116#112#article#138#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Svejgaard A, Je
rsild C, Nielsen S, Bodmer WF. HLA and disease. Statistical genetic consideratio
n. Tissue Antigens. 1974;4(2):95-105.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#117#113#article#138#</font></p>     ^
cY#v33n1a09.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022700081002001300308#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#118#114#article#138#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Parra FC, Amado
 RC, Lambertucci JR, Rocha J, Antunes CM, Pena SDJ. Color and genomic ancestry i
n Brazilians. Proc Natl Acad Sci USA. 2003;100(1):177-82.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#119#115#article#138#</font></p>     ^
cY#v33n1a09.htm##
00463000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021100081002001300292#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#120#116#article#138#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Carvalho-Silva 
DR, Santos FR, Rocha J, Pena SD. The phylogeography of Brazilian Y-chromosome li
neages. Am J Hum Genet. 2001;68(1):281-6.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#121#117#article#138#</font></p>     ^
cY#v33n1a09.htm##
00592000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034000081002001300421#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#122#118#article#138#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Probst CM, Bomp
eixe EP, Pereira NF, de O Dalalio MM, Visentainer JE, Tsuneto LT, et al. HLA pol
ymorphism and evaluation of European, African, and Amerindian contribution to th
e white and mulatto populations from Paran&aacute;, Brazil. Hum Biol. 2000;72(4)
: 597-617.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#123#119#article#138#</font></p>     ^
cY#v33n1a09.htm##
00539000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028700081002001300368#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#124#120#article#138#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Cavasini CE, de
 Mattos LC, Couto AA, Couto VS, Gollino Y, Moretti LJ, et al. Duffy blood group 
gene polymorphisms among malaria vivax patients in four areas of the Brazilian A
mazon region. Malar J. 2007;6:167-74.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#125#121#article#138#</font></p>     ^
cY#v33n1a09.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#126#122#article#138#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Visentainer JE,
 Sell AM, da Silva GC, Cavichioli AD, Franceschi DS, Lieber SR, et al. TNF, IFNG
, IL6, IL10 and TGFB1 gene polymorphisms in South and Southeast Brazil. Int J Im
munogenet. 2008;35(4-5):287-93.    ^cY#v33n1a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#127#123#article#138#</font></p>     ^
cY#v33n1a09.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#128#124#article#138#<p>&nbsp;</p>    
 ^cY#v33n1a09.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#129#125#article#138#<p>&nbsp;</p>    
 ^cY#v33n1a09.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018600078002001300264#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#130#126#article#138#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b
>    ^cY#v33n1a09.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004700078002001300125#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#131#127#article#138#<br>   Jeane Elie
te Laguila Visentainer    ^cY#v33n1a09.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011800078002001300196#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#132#128#article#138#<br>   Universida
de Estadual de Maring&aacute; - Departamento de Ci&ecirc;ncias B&aacute;sicas da
 Sa&uacute;de    ^cY#v33n1a09.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003200078002001300110#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#133#129#article#138#<br>   Av. Colomb
o, 5790    ^cY#v33n1a09.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005300078002001300131#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#134#130#article#138#<br>   87020-900 
 Maring&aacute; ( PR) Brazil    ^cY#v33n1a09.htm##
00295000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005800078002001300136#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#135#131#article#138#<br>   Phone: 55 
44 3011-4864/Fax: 55 44 3011-4931    ^cY#v33n1a09.htm##
00399000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704016200078002001300240#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#136#132#article#138#<br>   <a href="m
ailto:jelvisentainer@uem.br">jelvisentainer@uem.br</a> <a href="mailto:jelvisent
ainer@gmail.com">jelvisentainer@gmail.com</a></font></p>     ^cY#v33n1a09.htm##
00327000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009000078002001300168#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#137#133#article#138#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted: 4/7/2010    ^cY#v33n1a0
9.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#138#134#article#138#<br>   Accepted: 
11/21/2010    ^cY#v33n1a09.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011100078002001300189#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#139#135#article#138#<br>   Conflict-o
f-interest disclosure: The authors declare no competing financial interest</font
></p>     ^cY#v33n1a09.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#140#136#article#138#<p>&nbsp;</p>    
 ^cY#v33n1a09.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#141#137#article#138#<p>&nbsp;</p>    
 ^cY#v33n1a09.htm##
00460000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022300078002001300301#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a09.htm#S#p#142#138#article#138#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" targ
et="_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_bla
nk">www.scielo.br/rbhh</a></font></p>     ^cY#v33n1a09.htm##
00734000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01700112010001800129010001800147010001600165810000600181012012200187030000900309
06500090031806400050032703100030033203200020033501400060033786500090034300200130
0352035001000365801000900375#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.h
tm#S#c#143#1#article#23#1#^rND^sDaniels^nG#^rND^sCastilho^nL#^rND^sFlegel^nWA#^r
ND^sFletcher^nA#^rND^sGarratty^nG#^rND^sLevene^nC#et al#International Society of
 Blood Transfusion Committee on Terminology for red blood cell surface antigens:
 Macao report^len#Vox Sang#20090000#2009#96#2#153-6#20110200#v33n1a09.htm#0042-9
007#Vox sang##
00630000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950100
01700113012016900130030001000299710000200309065000900311064000500320031000200325
020000300327865000900330002001300339#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a09.htm#S#c#144#2#article#23#2#^rND^sHellberg^nA#^rND^sChester^nMA#^rND^sOlss
on^nML#Two previously proposed P1/P2-differentiating and nine novel polymorphism
s at the A4GALT (Pk) locus do not correlate with the presence of the P1 blood gr
oup antigen^len#BMC Genet#2#20050000#2005#6#49#20110200#v33n1a09.htm##
00655000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100015000930100
01700108012015100125030000900276065000900285064000500294031000300299032000200302
014000800304865000900312002001300321035001000334801000900344#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a09.htm#S#c#145#3#article#23#3#^rND^sTilley^nL#^rND^s
Green^nC#^rND^sDaniels^nG#Sequence variation in the 5' untranslated region of th
e human A4GALT gene is associated with, but does not define, the P1 blood group 
polymorphism^len#Vox Sang#20060000#2006#90#3#198-203#20110200#v33n1a09.htm#0042-
9007#Vox sang##
00499000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770120046000910300
01400137065000900151064000500160031000300165061000200168014000500170865000900175
002001300184035001000197801001400207#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a09.htm#S#c#146#4#article#23#4#^rND^sYip^nSP#Sequence variation at the human 
ABO locus^len#Ann Hum Genet#20020000#2002#66#1#1-27#20110200#v33n1a09.htm#0003-4
800#Ann Hum Genet##
00506000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120055000940300
01000149065000900159064000500168031000400173032000200177014000700179865000900186
002001300195035001000208801001000218#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a09.htm#S#c#147#5#article#23#5#^rND^sDaniels^nG#The molecular genetics of blo
od group polymorphism^len#Hum Genet#20090000#2009#126#6#729-42#20110200#v33n1a09
.htm#0340-6717#Hum Genet##
00540000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100013000770120051000900300
00900141065000900150064000500159031000300164032000200167014000500169014003500174
865000900209002001300218035001000231801000900241#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a09.htm#S#c#148#6#article#23#6#^rND^sLee^nS#Molecular basis of Ke
ll blood group phenotypes^len#Vox Sang#19970000#1997#73#1#1-11#Erratum in: Vox S
ang 1998;74(1):58#20110200#v33n1a09.htm#0042-9007#Vox sang##
00637000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100013000770100017000900100
01600107010001700123012011200140030000600252065000900258064000500267031000300272
032000300275014000700278865000900285002001300294035001000307801000600317#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#c#149#7#article#23#7#^rND^sLee^
nS#^rND^sZambas^nED#^rND^sMarsh^nWL#^rND^sRedman^nCM#The human Kell blood group 
gene maps to chromosome 7q33 and its expression is restricted to erythroid cells
^len#Blood#19930000#1993#81#10#2804-9#20110200#v33n1a09.htm#0006-4971#Blood##
00520000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100013000960120
02700109030001800136065000900154064000500163031000300168061000200171014000700173
865000900180002001300189035001000202801001800212#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a09.htm#S#c#150#8#article#23#8#^rND^sPruenster^nM#^rND^sRot^nA#Th
rowing light on DARC^len#Biochem Soc Trans#20060000#2006#34#6#1005-8#20110200#v3
3n1a09.htm#0300-5127#Biochem Soc Trans##
00660000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01700110010002000127010001800147012009200165030000800257065000900265064000500274
03100040027903200050028301400060028886500090029400200130030303500100031680100080
0326#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#c#151#9#article#23#
9#^rND^sMiller^nLH#^rND^sMason^nSJ#^rND^sDvorak^nJA#^rND^sMcGinniss^nMH#^rND^sRo
thman^nIK#Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood g
roup determinants^len#Science#19750000#1975#189#4202#561-3#20110200#v33n1a09.htm
#0036-8075#Science##
00666000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100016000920100
01500108010001500123010001800138010001800156012007900174030000700253065000900260
06400050026903100040027403200050027801400060028386500090028900200130029803500100
0311801000700321#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#c#152#1
0#article#23#10#^rND^sYou^nG#^rND^sSmith^nCP#^rND^sKanai^nY#^rND^sLee^nW-S#^rND^
sStelzner^nM#^rND^sHediger^nMA#Cloning and characterization of the vasopressin-r
egulated urea transporter^len#Nature#19930000#1993#365#6449#844-7#20110200#v33n1
a09.htm#0028-0836#Nature##
00741000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01600113010001400129010001700143010001400160810000600174012012500180030001400305
06500090031906400050032803100020033303200020033501400080033786500090034500200130
0354035001000367801001400377#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.h
tm#S#c#153#11#article#23#11#^rND^sOlivès^nB#^rND^sMerriman^nM#^rND^sBailly^nP#^r
ND^sBain^nS#^rND^sBarnett^nA#^rND^sTodd^nJ#et al#The molecular basis of the Kidd
 blood group polymorphism and its lack of association with type 1 diabetes susce
ptibility^len#Hum Mol Genet#19970000#1997#6#7#1017-20#20110200#v33n1a09.htm#0964
-6906#Hum Mol Genet##
00678000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100018000920100
02000110010001700130012012400147030001700271065000900288064000500297031000300302
032000200305014000800307865000900315002001300324035001000337801001700347#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#c#154#12#article#23#12#^rND^sLi
n^nY#^rND^sPavenski^nK#^rND^sSaidenberg^nE#^rND^sBranch^nDR#Blood group antigens
 and normal red blood cell physiology: a Canadian blood services research and de
velopment symposium^len#Transfus Med Rev#20090000#2009#23#4#292-309#20110200#v33
n1a09.htm#0887-7963#Transfus Med Rev##
00758000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100016000990100
01600115010001700131010001500148010001400163810000600177012015700183030000600340
06500090034606400050035503100030036003200020036301400050036586500090037000200130
0379035001000392801000600402#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.h
tm#S#c#155#13#article#23#13#^rND^sSingleton^nBK#^rND^sGreen^nCA#^rND^sAvent^nND#
^rND^sMartin^nPG#^rND^sSmart^nE#^rND^sDaka^nA#et al#The presence of an RHD pseud
ogene containing a 37 base pair duplication phenotype and a nonsense mutation in
 africans with the Rh D-negative blood group^len#Blood#20000000#2000#95#1#12-8#2
0110200#v33n1a09.htm#0006-4971#Blood##
00629000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100014000930100
01600107010001900123010001500142012009300157030001700250710000200267065000900269
064000500278031000300283032000200286014000500288865000900293002001300302#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#c#156#14#article#23#14#^rND^sRi
os^nM#^rND^sCash^nK#^rND^sStrupp^nA#^rND^sUehlinger^nJ#^rND^sReid^nME#DNA from u
rine sediment or buccal cells can be used for blood group molecular genotyping^l
en#Immunohematology#2#19990000#1999#15#2#61-5#20110200#v33n1a09.htm##
00591000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940100
02200108012007300130030001400203065000900217064000500226031000300231032000200234
014000700236865000900243002001300252035001000265801001400275#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a09.htm#S#c#157#15#article#23#15#^rND^sReid^nME#^rND^
sRios^nM#^rND^sYazdanbakhsh^nK#Applications of molecular biology techniques to t
ransfusion medicine^len#Semin Hematol#20000000#2000#37#2#166-76#20110200#v33n1a0
9.htm#0037-1963#Semin Hematol##
00758000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100020000970100
01900117010001600136010002300152010001800175012015100193030000900344065000900353
06400050036203100030036703200020037001400070037286500090037900200130038803500100
0401801000900411#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#c#158#1
6#article#23#16#^rND^sRibeiro^nKR#^rND^sGuarnieri^nMH#^rND^sda Costa^nDC#^rND^sC
osta^nFF#^rND^sPellegrino^nJ Jr#^rND^sCastilho^nL#DNA array analysis for red blo
od cell antigens facilitates the transfusion support with antigen-matched blood 
in patients with sickle cell disease^len#Vox Sang#20090000#2009#97#2#147-52#2011
0200#v33n1a09.htm#0042-9007#Vox sang##
00625000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100018001020100
01400120010001900134012007000153030001600223065000900239064000500248031000300253
032000200256014000500258865000900263002001300272035001000285801001600295#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#c#159#17#article#23#17#^rND^sPe
llegrino^nJ Jr#^rND^sCastilho^nL#^rND^sRios^nM#^rND^sDe Souza^nCA#Blood group ge
notyping in a population of highly diverse ancestry^len#J Clin Lab Anal#20010000
#2001#15#1#8-13#20110200#v33n1a09.htm#0887-8013#J Clin Lab Anal##
00607000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01700115010001700132012005500149030001600204065000900220064000500229031000200234
032000200236014000700238865000900245002001300254035001000267801001600277#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#c#160#18#article#23#18#^rND^sSv
ejgaard^nA#^rND^sJersild^nC#^rND^sNielsen^nS#^rND^sBodmer^nWF#HLA and disease: S
tatistical genetic consideration^len#Tissue Antigens#19740000#1974#4#2#95-105#20
110200#v33n1a09.htm#0001-2815#Tissue Antigens##
00670000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
02200111010001500133010001800148010001600166012004500182030002300227065000900250
06400050025903100040026403200020026801400070027086500090027700200130028603500100
0299801002300309#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#c#161#1
9#article#23#19#^rND^sParra^nFC#^rND^sAmado^nRC#^rND^sLambertucci^nJR#^rND^sRoch
a^nJ#^rND^sAntunes^nCM#^rND^sPena^nSDJ#Color and genomic ancestry in Brazilians^
len#Proc Natl Acad Sci USA#20030000#2003#100#1#177-82#20110200#v33n1a09.htm#0027
-8424#Proc Natl Acad Sci USA##
00610000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100025000790100017001040100
01500121010001500136012005800151030001500209065000900224064000500233031000300238
032000200241014000600243865000900249002001300258035001000271801001500281#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#c#162#20#article#23#20#^rND^sCa
rvalho-Silva^nDR#^rND^sSantos^nFR#^rND^sRocha^nJ#^rND^sPena^nSD#The phylogeograp
hy of Brazilian Y-chromosome lineages^len#Am J Hum Genet#20010000#2001#68#1#281-
6#20110200#v33n1a09.htm#0002-9297#Am J Hum Genet##
00772000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01800115010002300133010002200156010001800178810000600196012014300202030000900345
06500090035406400050036303100030036803200020037101400080037386500090038100200130
0390035001000403801000900413#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.h
tm#S#c#163#21#article#23#21#^rND^sProbst^nCM#^rND^sBompeixe^nEP#^rND^sPereira^nN
F#^rND^sde O Dalalio^nMM#^rND^sVisentainer^nJE#^rND^sTsuneto^nLT#et al#HLA polym
orphism and evaluation of European, African, and Amerindian contribution to the 
white and mulatto populations from Paraná, Brazil^len#Hum Biol#20000000#2000#72#
4#597-617#20110200#v33n1a09.htm#0018-7143#Hum Biol##
00687000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100020000980100
01600118010001600134010001700150010001800167810000600185012011500191030000800306
71000020031406500090031606400050032503100020033001400070033286500090033900200130
0348#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#c#164#22#article#23
#22#^rND^sCavasini^nCE#^rND^sde Mattos^nLC#^rND^sCouto^nAA#^rND^sCouto^nVS#^rND^
sGollino^nY#^rND^sMoretti^nLJ#et al#Duffy blood group gene polymorphisms among m
alaria vivax patients in four areas of the Brazilian Amazon region^len#Malar J#2
#20070000#2007#6#167-74#20110200#v33n1a09.htm##
00692000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100015001010100
01900116010002100135010002100156010001700177810000600194012008400200030001800284
71000020030206500090030406400050031303100030031803200040032101400070032586500090
0332002001300341#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a09.htm#S#c#165#2
3#article#23#23#^rND^sVisentainer^nJE#^rND^sSell^nAM#^rND^sda Silva^nGC#^rND^sCa
vichioli^nAD#^rND^sFranceschi^nDS#^rND^sLieber^nSR#et al#TNF, IFNG, IL6, IL10 an
d TGFB1 gene polymorphisms in South and Southeast Brazil^len#Int J Immunogenet#2
#20080000#2008#35#4-5#287-93#20110200#v33n1a09.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#o#1#1#article#1
#20110411#115530#v33n1a10.htm#196##
03143000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120066002020100032002680100037003000100039003370100039003760100038004150100
04300453010004000496070005900536070005600595070005800651083167700709085001002386
08500310239608500240242708500300245111700060248107200030248711200090249011100100
2499114000902509113001002518002001302528#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a10.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#10#RBHH340#nd#Rev. B
ras. Hematol. Hemoter.#33#1#20110200#^f26^l30#1516-8484#10.5581/1516-8484.201100
10#Resting blood lactate in individuals with sickle cell disease^len#^rND^1A01 A
02^nJefferson^sPetto#^rND^1A03^nJaqueline Brito de^sJesus#^rND^1A01^nLeila Moniq
ue Reis^sVasques#^rND^1A01^nRenata Leão Silva^sPinheiro#^rND^1A02^nAila Mascaren
has^sOliveira#^rND^1A02^nKelly Aparecida Borges^sSpinola#^rND^1A03^nWellington d
os Santos^sSilva#Universidade do Estado da Bahia^iA01^cSalvador^sBA^pBrazil#Univ
ersidade Social da Bahia^iA02^cSalvador^sBA^pBrazil#Faculdade Adventista da Bahi
a^iA03^cCachoeira^sBA^pBrazil#^len^aBACKGROUND: The most common hereditary hemog
lobin disorder, affecting 20 million individuals worldwide, is sickle cell disea
se. The vascular obstruction resulting from the sickling of cells in this diseas
e can produce local hypoxemia, pain crises and infarction in several tissues, in
cluding the bones, spleen, kidneys and lungs. METHODS: The present study is char
acterized as a case control study, with the aim of identifying the baseline bloo
d lactate concentration in individuals with hemoglobin SS and SC diseases. One-w
ay ANOVA with the Tukey post-test was used to analyze the results and a p-value 
< 0.05 was considered significant. Calculations were made using the INSTAT stati
stical program. The graphs were generated using the ORING program. The study sam
ple was composed of 31 men and women residing in the city of Santo Antônio de Je
sus, Bahia, Brazil. The individuals were divided into two groups: Group GC of 16
 subjects who did not present with any type of structural hemoglobinopathy; and 
Group GE composed of 15 individuals with ages between 2 and 35 years old, who ha
d the SS and SC genotypes. Sample analyses were performed with 3 mL of blood dur
ing fasting. RESULTS: The baseline blood lactate concentration of the SS and SC 
individuals was higher than that of the control group (p<0.001) with means of 4.
86 ± 0.95; 3.30 ± 0.33; 1.31 ± 0.08 IU/L for SS, SC and controls, respectively. 
This corroborates the initial research hypothesis. CONCLUSION: The baseline bloo
d lactate of SS and SC individuals is 3 to 4 times higher than that of healthy s
ubjects, probably due to the fact that these patients have a metabolic deviation
 to the anaerobic pathway.#^ddecs^i1#^tm^len^kSickle cell anemia^i1#^tm^len^kLac
tic acid^i1#^tm^len^kPhysical exercise^i1#other#38#20100415#4/15/2010#20100911#1
1/9/2010#v33n1a10.htm##
03184000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120073002020100032002750100037003070100039003440100039003830100038004220100
04300460010004000503070005900543070005600602070005800658083171100716085001002427
08500310243708500240246808500300249211700060252207200030252811200090253111100100
2540114000902550113001002559002001302569#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a10.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#10#RBHH340#nd#Rev. B
ras. Hematol. Hemoter.#33#1#20110200#^f26^l30#1516-8484#10.5581/1516-8484.201100
10#<b>Resting blood lactate in individuals with sickle cell disease</b>^len#^rND
^1A01 A02^nJefferson^sPetto#^rND^1A03^nJaqueline Brito de^sJesus#^rND^1A01^nLeil
a Monique Reis^sVasques#^rND^1A01^nRenata Leão Silva^sPinheiro#^rND^1A02^nAila M
ascarenhas^sOliveira#^rND^1A02^nKelly Aparecida Borges^sSpinola#^rND^1A03^nWelli
ngton dos Santos^sSilva#Universidade do Estado da Bahia^iA01^cSalvador^sBA^pBraz
il#Universidade Social da Bahia^iA02^cSalvador^sBA^pBrazil#Faculdade Adventista 
da Bahia^iA03^cCachoeira^sBA^pBrazil#^len^a<b>BACKGROUND:</b> The most common he
reditary hemoglobin disorder, affecting 20 million individuals worldwide, is sic
kle cell disease. The vascular obstruction resulting from the sickling of cells 
in this disease can produce local hypoxemia, pain crises and infarction in sever
al tissues, including the bones, spleen, kidneys and lungs. <b>METHODS:</b> The 
present study is characterized as a case control study, with the aim of identify
ing the baseline blood lactate concentration in individuals with hemoglobin SS a
nd SC diseases. One-way ANOVA with the Tukey post-test was used to analyze the r
esults and a p-value &lt; 0.05 was considered significant. Calculations were mad
e using the INSTAT statistical program. The graphs were generated using the ORIN
G program. The study sample was composed of 31 men and women residing in the cit
y of Santo Antônio de Jesus, Bahia, Brazil. The individuals were divided into tw
o groups: Group GC of 16 subjects who did not present with any type of structura
l hemoglobinopathy; and Group GE composed of 15 individuals with ages between 2 
and 35 years old, who had the SS and SC genotypes. Sample analyses were performe
d with 3 mL of blood during fasting. <b>RESULTS:</b> The baseline blood lactate 
concentration of the SS and SC individuals was higher than that of the control g
roup (p&lt;0.001) with means of 4.86 ± 0.95; 3.30 ± 0.33; 1.31 ± 0.08 IU/L for S
S, SC and controls, respectively. This corroborates the initial research hypothe
sis. <b>CONCLUSION:</b> The baseline blood lactate of SS and SC individuals is 3
 to 4 times higher than that of healthy subjects, probably due to the fact that 
these patients have a metabolic deviation to the anaerobic pathway.#^ddecs^i1#^t
m^len^kSickle cell anemia^i1#^tm^len^kLactic acid^i1#^tm^len^kPhysical exercise^
i1#other#38#20100415#4/15/2010#20100911#11/9/2010#v33n1a10.htm##
03274000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103038000400108121000300112049000800115
15800030012303000280012603100030015403200020015706500090015901400090016803500100
01772370027001870120066002140100032002800100037003120100039003490100039003880100
03800427010004300465010004000508070006100548070005800609070006000667083167700727
08500100240408500310241408500240244508500300246911700060249907200030250511200090
2508111001002517114000902527113001002536002001302546008008902559#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#l#4#1#article#1#^mFeb.^a2011#oa#en#br1.
1#1#4.0#ilus#tab#10#RBHH340#nd#Rev. bras. hematol. hemoter#33#1#20110200#^f26^l3
0#1516-8484#10.5581/1516-8484.20110010#Resting blood lactate in individuals with
 sickle cell disease^len#^rND^1A01 A02^nJefferson^sPetto#^rND^1A03^nJaqueline Br
ito de^sJesus#^rND^1A01^nLeila Monique Reis^sVasques#^rND^1A01^nRenata Leão Silv
a^sPinheiro#^rND^1A02^nAila Mascarenhas^sOliveira#^rND^1A02^nKelly Aparecida Bor
ges^sSpinola#^rND^1A03^nWellington dos Santos^sSilva#^iA01^1Universidade do Esta
do da Bahia^cSalvador^sBA^pBrazil#^iA02^1Universidade Social da Bahia^cSalvador^
sBA^pBrazil#^iA03^1Faculdade Adventista da Bahia^cCachoeira^sBA^pBrazil#^len^aBA
CKGROUND: The most common hereditary hemoglobin disorder, affecting 20 million i
ndividuals worldwide, is sickle cell disease. The vascular obstruction resulting
 from the sickling of cells in this disease can produce local hypoxemia, pain cr
ises and infarction in several tissues, including the bones, spleen, kidneys and
 lungs. METHODS: The present study is characterized as a case control study, wit
h the aim of identifying the baseline blood lactate concentration in individuals
 with hemoglobin SS and SC diseases. One-way ANOVA with the Tukey post-test was 
used to analyze the results and a p-value < 0.05 was considered significant. Cal
culations were made using the INSTAT statistical program. The graphs were genera
ted using the ORING program. The study sample was composed of 31 men and women r
esiding in the city of Santo Antônio de Jesus, Bahia, Brazil. The individuals we
re divided into two groups: Group GC of 16 subjects who did not present with any
 type of structural hemoglobinopathy; and Group GE composed of 15 individuals wi
th ages between 2 and 35 years old, who had the SS and SC genotypes. Sample anal
yses were performed with 3 mL of blood during fasting. RESULTS: The baseline blo
od lactate concentration of the SS and SC individuals was higher than that of th
e control group (p<0.001) with means of 4.86 ± 0.95; 3.30 ± 0.33; 1.31 ± 0.08 IU
/L for SS, SC and controls, respectively. This corroborates the initial research
 hypothesis. CONCLUSION: The baseline blood lactate of SS and SC individuals is 
3 to 4 times higher than that of healthy subjects, probably due to the fact that
 these patients have a metabolic deviation to the anaerobic pathway.#^ddecs^i1#^
tm^len^kSickle cell anemia^i1#^tm^len^kLactic acid^i1#^tm^len^kPhysical exercise
^i1#other#38#20100415#4/15/2010#20100911#11/9/2010#v33n1a10.htm#Internet^ihttp:/
/www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100010##
00354000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012100074002001300195#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#5#1#article#154#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLES</b>
</font></p>     ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#6#2#article#154#<p>&nbsp;</p>     ^cY
#v33n1a10.htm##
00402000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704016900074002001300243#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#7#3#article#154#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Resting blood lac
tate in individuals with sickle cell disease</b></font></p>     ^cY#v33n1a10.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#8#4#article#154#<p>&nbsp;</p>     ^cY
#v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#9#5#article#154#<p>&nbsp;</p>     ^cY
#v33n1a10.htm##
00609000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704037500075002001300450#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#10#6#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Jefferson Petto<sup>I,II</sup>; Ja
queline Brito de Jesus<sup>III</sup>; Leila Monique Reis Vasques<sup>I</sup>; Re
nata Le&atilde;o Silva Pinheiro<sup>I</sup>; Aila Mascarenhas Oliveira<sup>II</s
up>; Kelly Aparecida Borges Spinola<sup>II</sup>; Wellington dos Santos Silva<su
p>III</sup></b></font></p>     ^cY#v33n1a10.htm##
00378000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704014400075002001300219#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#11#7#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Universidade do Estado da
 Bahia - UNEB, Salvador (BA), Brazil    ^cY#v33n1a10.htm##
00320000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704008600075002001300161#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#12#8#article#154#<br>   <sup>II</sup>
Universidade Social da Bahia - FSBA, Salvador (BA), Brazil    ^cY#v33n1a10.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704010200075002001300177#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#13#9#article#154#<br>   <sup>III</sup
>Faculdade Adventista da Bahia - FAFIS, Cachoeira (BA), Brazil</font></p>     ^c
Y#v33n1a10.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#14#10#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></fo
nt></p>     ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#15#11#article#154#<p>&nbsp;</p>     ^
cY#v33n1a10.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#16#12#article#154#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v33n1a10.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#17#13#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
33n1a10.htm##
00643000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040800076002001300484#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#18#14#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>BACKGROUND:</b> The most common h
ereditary hemoglobin disorder, affecting 20 million individuals worldwide, is si
ckle cell disease. The vascular obstruction resulting from the sickling of cells
 in this disease can produce local hypoxemia, pain crises and infarction in seve
ral tissues, including the bones, spleen, kidneys and lungs.     ^cY#v33n1a10.ht
m##
01115000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088000076002001300956#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#19#15#article#154#<br>     <b>METHODS
:</b> The present study is characterized as a case control study, with the aim o
f identifying the baseline blood lactate concentration in individuals with hemog
lobin SS and SC diseases. One-way ANOVA with the Tukey post-test was used to ana
lyze the results and a p-value &lt; 0.05 was considered significant. Calculation
s were made using the INSTAT statistical program. The graphs were generated usin
g the ORING program. The study sample was composed of 31 men and women residing 
in the city of Santo Ant&ocirc;nio de Jesus, Bahia, Brazil. The individuals were
 divided into two groups: Group GC of 16 subjects who did not present with any t
ype of structural hemoglobinopathy; and Group GE composed of 15 individuals with
 ages between 2 and 35 years old, who had the SS and SC genotypes. Sample analys
es were performed with 3 mL of blood during fasting.     ^cY#v33n1a10.htm##
00540000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030500076002001300381#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#20#16#article#154#<br>     <b>RESULTS
:</b> The baseline blood lactate concentration of the SS and SC individuals was 
higher than that of the control group (p&lt;0.001) with means of 4.86 ± 0.95; 3.
30 ± 0.33; 1.31 ± 0.08 IU/L for SS, SC and controls, respectively. This corrobor
ates the initial research hypothesis.     ^cY#v33n1a10.htm##
00487000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025200076002001300328#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#21#17#article#154#<br>     <b>CONCLUS
ION:</b> The baseline blood lactate of SS and SC individuals is 3 to 4 times hig
her than that of healthy subjects, probably due to the fact that these patients 
have a metabolic deviation to the anaerobic pathway. </font></p>     ^cY#v33n1a1
0.htm##
00407000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017200076002001300248#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#22#18#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Sickle cell anemia;
 Lactic acid; Physical exercise</font></p> <hr size="1" noshade>     ^cY#v33n1a1
0.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#23#19#article#154#<p>&nbsp;</p>     ^
cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#24#20#article#154#<p>&nbsp;</p>     ^
cY#v33n1a10.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#25#21#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></p>     ^
cY#v33n1a10.htm##
00856000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062100076002001300697#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#26#22#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Hereditary hemoglobin disorders are 
the most common genetic diseases of humankind.<sup>(1)</sup> The most important 
of these is sickle cell disease, a disorder that affects 20 million people world
wide.<sup>(2)</sup> Few populations are exempt and its presence in many regions 
is a concern for public health.<sup>(3,4)</sup> Therefore, considering the heter
ogeneous origin of the Brazilian population, it is not surprising that hereditar
y hemoglobin disorders are common and that their occurrence varies in different 
regions.<sup>(3)</sup></font></p>     ^cY#v33n1a10.htm##
00997000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076200076002001300838#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#27#23#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Sickle cell disease is characterized
 by a point mutation (GAG-GTG), corresponding to the substitution of glutamic ac
id by valine at position 6 of the beta chain of the hemoglobin molecule, giving 
rise to the hemoglobin mutant S (Hb S).<sup>(5-7)</sup> This small alteration ch
anges the entire rheology of the red blood cell; the primary process of this eve
nt is polymerization or jellification of hemoglobin.<sup>(8,9)</sup> The speed a
nd extent of the formation of polymers within red blood cells primarily depend o
n three factors: The degree of deoxygenating, intracellular concentration of hem
oglobin S (Hb S) and presence or absence of Fetal Hemoglobin (Hb F).<sup>(10)</s
up></font></p>     ^cY#v33n1a10.htm##
00976000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074100076002001300817#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#28#24#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This change in the amino acid alters
 the characteristics of the hemoglobin molecule in such a manner that red blood 
cells become sickle-shaped under conditions of low oxygen tension, making them l
ess flexible and unable to move easily. The resultant vascular obstruction produ
ces local hypoxemia, pain crises and infarction in various tissues, including th
e bones, spleen, kidneys and lungs. The premature destruction of sickled cells d
iminishes the level of hemoglobin, causing anemia.<sup>(1)</sup> These factors, 
associated with sickled cell adherence to the endothelium, favor the formation o
f thrombi in the micro and macrocirculation.<sup>(10,11)</sup></font></p>     ^c
Y#v33n1a10.htm##
01162000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704092700076002001301003#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#29#25#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The main signs and symptoms of sickl
e cell disease are: greater susceptibility to infections; osteoarticular manifes
tations, such as aseptic femur head necrosis and hand-foot syndrome, splenomegal
y, hepatomegaly, strokes, priapism, leg ulcers, pain crises, fever, pulmonary co
mplications,<sup>(12,13)</sup> and alterations in heart function. Heart alterati
ons involve cardiomegaly, systolic heart murmur, electrocardiographic alteration
s (alterations of the T wave or ST segment), uni- or bilateral hypertrophy (with
 hypertrophy of the right ventricle appearing later and being less intense) and 
increases in pre-load and reductions in post-load.<sup>(14-17)</sup> Cardiovascu
lar disease is a frequent clinical manifestation in sickle cell disease and cont
ributes to the increases in morbidity and mortality of these individuals.<sup>(1
7)</sup></font></p>     ^cY#v33n1a10.htm##
00661000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042600076002001300502#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#30#26#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The general treatment is based on pr
oviding clinical support and specific care<sup>(2,18)</sup> with the goal of min
imizing and preventing the consequences of chronic anemia, sickling crises and s
usceptibility to infections.<sup>(8)</sup> At present, a curative treatment, by 
hematopoietic stem cell transplant is being studied.<sup>(19)</sup></font></p>  
   ^cY#v33n1a10.htm##
00937000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070200076002001300778#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#31#27#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It is worth pointing out that there 
is no indication for sickle cell anemia individuals to perform intense physical 
exercise, as this increases the demand for oxygen, overloading the red blood cel
ls that may under these circumstances become sickled, and consequently, occlude 
blood vessels, resulting in vaso-occlusive crises.<sup>(20-22)</sup> Therefore, 
a different type of physical exercise program is suggested in order to avoid suc
h crises. It is important to determine at what time the lactate threshold occurs
 in these individuals, as their baseline blood lactate level may be higher than 
in healthy individuals.</font></p>     ^cY#v33n1a10.htm##
00764000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052900076002001300605#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#32#28#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The lactate threshold is defined as 
the point during exercise, at which the serum lactate rapidly begins to accumula
te above the baseline concentration.<sup>(23)</sup> The onset of this accumulati
on indicates an imbalance between the production and removal of blood lactate de
nominated as the anaerobiosis threshold (AT). The standard value, fixed at 4 mmo
l of lactate per liter of blood, is used as a common point of reference.<sup>(23
-27)</sup></font></p>     ^cY#v33n1a10.htm##
00688000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045300076002001300529#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#33#29#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It is believed that exercise leads t
o increases in the oxidation of lactic acid by muscles and more intense exercise
s could result in an increase in the production of lactic acid and prevent it fr
om being removed. Therefore, the increase in the blood lactic acid concentration
 may occur as a result of both its production and the reduction in its removal.<
sup>(25)</sup></font></p>     ^cY#v33n1a10.htm##
00612000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037700076002001300453#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#34#30#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Therefore the aim of the present stu
dy is to measure the baseline blood lactate levels in sickle cell disease indivi
duals with the purpose of seeing whether there is a difference between the SS an
d SC genotypes in respect to lactate and compare this with the level found in he
althy individuals.</font></p>     ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#35#31#article#154#<p>&nbsp;</p>     ^
cY#v33n1a10.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#36#32#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Methods</b></font></p>     ^cY#v3
3n1a10.htm##
00450000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021500076002001300291#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#37#33#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The present study is a case control 
study, in which 31 individuals were divided into two groups, Control (CG) and Ex
perimental (EG).</font></p>     ^cY#v33n1a10.htm##
00762000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052700076002001300603#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#38#34#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The EG consisted of 15 volunteer me
n and women aged between 2 and 35 years old with laboratory diagnosis of sickle 
cell disease, who were regularly attended at the Hematology Clinic in the city o
f Santo Ant&ocirc;nio de Jesus, BA, Brazil. The EG volunteers were further subdi
vided into two sub-groups, six individuals with the SS genotype and a mean age o
f 18 years old and nine individuals with the SC genotype and a mean age of 13 ye
ars old.</font></p>     ^cY#v33n1a10.htm##
00805000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057000076002001300646#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#39#35#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The laboratory diagnoses of sickle c
ell disease and genotypes (SS or SC) were obtained by the association of alkalin
e (cellulose acetate) and acid (agar) electrophoresis techniques complemented by
 the Hb F concentration. Hb F was measured by the alkaline denaturing method bas
ed on its higher resistance compared to other hemoglobins.<sup>(26)</sup> These 
diagnostic techniques are considered the most precise to detect sickle cell dise
ase and the respective genotypes.<sup>(27,28)</sup></font></p>     ^cY#v33n1a10.
htm##
00452000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021700076002001300293#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#40#36#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The CG consisted of 16 male and fema
le volunteers with a mean age of 17 years old but without any type of structural
 hemoglobinopathy.</font></p>     ^cY#v33n1a10.htm##
00718000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048300076002001300559#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#41#37#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although it is known that age has a 
direct influence on the clinical symptoms and manifestations of sickle cell dise
ase,<sup>(9)</sup> no age range was delimited in this study as the volunteers in
 the EG and CG Groups did not presented any hepatic or renal involvement that co
uld have led to inadequate metabolism of blood lactate and consequently that cou
ld have influenced the results of the study.</font></p>     ^cY#v33n1a10.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#42#38#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ethical aspects</font></p>     ^cY#v
33n1a10.htm##
00867000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063200076002001300708#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#43#39#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">After having received guidance about
 their participation in the research, and information about the risks and benefi
ts of the research, the volunteers signed an informed consent form in accordance
 with Resolution CNS 196/1996 related to the Guidelines and Rules Regulating Res
earch Involving Human Beings. In cases of under 18-year-old volunteers, the pare
nts or guardians signed the consent form. This research was registered with and 
approved by the Research Ethics Committee of the Adventist Physiotherapy School 
under CAAE No. 0032.0.070.000-05.</font></p>     ^cY#v33n1a10.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010300076002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#44#40#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Collection procedure</font></p>     
^cY#v33n1a10.htm##
00642000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040700076002001300483#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#45#41#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">After 12h fasting, 3 mL of blood was
 collected from each of the 31 participants to measure the baseline lactate leve
l. To measure blood lactate, the serum was separated from the plasma by centrifu
gation and harvested. Subsequently the serum was separated and the spectrophotom
etric method was used to quantify blood lactate.</font></p>     ^cY#v33n1a10.htm
##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010300076002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#46#42#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Statistical analysis</font></p>     
^cY#v33n1a10.htm##
00793000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055800076002001300634#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#47#43#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Data were evaluated by descriptive a
nalysis for all the variables. The variables are expressed as means ± standard e
rror. One-way ANOVA complemented by the Tukey-Kramer post-test was used to analy
ze the results and identify possible significant differences. The level of signi
ficance adopted was for p-values &lt; 0.05 with a 95% confidence interval. The c
alculations were made using the GraphPad Instat 2.01 statistics program. Graphs 
were generated using the ORING program.</font></p>     ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#48#44#article#154#<p>&nbsp;</p>     ^
cY#v33n1a10.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#49#45#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>     ^cY#v3
3n1a10.htm##
00432000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019700076002001300273#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#50#46#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The hematologic data of the study sa
mple are shown in <a href="/img/revistas/rbhh/v33n1/a10tab01.jpg">Table 1</a>.</
font></p>     ^cY#v33n1a10.htm##
00879000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064400076002001300720#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#51#47#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The data show that the baseline bloo
d lactate concentration for Hb SS and Hb SC individuals was three to four times 
higher than that of the Control Group (p &lt; 0.001), with mean values of 4.86 ±
 0.95; 3.30 ± 0.33; 1.31 ± 0.08 IU/L, respectively. A significant difference (p&
lt;0.05) was observed between the baseline blood lactate of Hb SS individuals co
mpared to Hb SC individuals with the value for Hb SS being higher than that for 
Hb SC, which possibly justifies the more severe clinical conditions seen in thes
e individuals (<a href="#fig1">Figure 1</a>).</font></p>     ^cY#v33n1a10.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#52#48#article#154#<p><a name="fig1"><
/a></p>     ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#53#49#article#154#<p>&nbsp;</p>     ^
cY#v33n1a10.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#54#50#article#154#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a10fig01.jpg"></p>     ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#55#51#article#154#<p>&nbsp;</p>     ^
cY#v33n1a10.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#56#52#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p>     ^cY
#v33n1a10.htm##
00877000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064200076002001300718#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#57#53#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The basal metabolism is essentially 
maintained by two energy pathways - aerobic and anaerobic. Under normal conditio
ns, in a healthy individual the baseline metabolism is maintained by a predomina
nce of the aerobic pathway, in which the energy substrates involved are basicall
y the lipids and carbohydrates. It is known that there is a higher use of lipids
 compared to carbohydrates and that the end result of aerobic energy production 
consists of water (H<sub>2</sub>O), carbon dioxide gas (CO<sub>2</sub>) and aden
osine-triphosphate (ATP).<sup>(23,29)</sup></font></p>     ^cY#v33n1a10.htm##
00918000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068300076002001300759#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#58#54#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Furthermore, under normal conditions
, the proportion of ATP used from the anaerobic pathway increases, as exercising
 becomes more intense. In very intense exercising, that is to say, over 80% of d
irect maximum oxygen consumption (VO<sub>2</sub>max) or above 85% of the maximum
 heart rate is obtained, the anaerobic pathway begins to provide more energy tha
n the aerobic pathway. However, different to the aerobic pathway, the lactic ana
erobic pathway produces ATP and lactic acid as the end products, with the latter
 being transformed into lactate and released into the bloodstream.<sup>(30,31)</
sup></font></p>     ^cY#v33n1a10.htm##
01281000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704104600076002001301122#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#59#55#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In a healthy body, all the lactate p
roduced is buffered in the kidneys, heart muscle and mainly in the liver. In the
 kidneys, lactate binds to bicarbonate and is transformed into sodium lactate, w
hereas in the heart muscle and liver tissue, two molecules of lactate (C<sub>3</
sub>H<sub>6</sub>O<sub>3</sub>) are transformed into glucose (C<sub>6</sub>H<sub
>12</sub>O<sub>6</sub>) and this is re-used by the body.<sup>(32)</sup> When lac
tate production occurs at a higher rate than can be buffered, it accumulates bot
h in the active tissues and in the bloodstream. This sets off metabolic acidosis
 and causes a reduction in the hepatic glucose activity and the capacity of intr
amuscular calcium to bind with troponin. Troponin is a contractile protein; when
 it binds with calcium, myosin can bind to actin, thus stimulating muscle contra
ction. This explains in part why the accumulation of lactate is one of the bioch
emical mechanisms that leads to muscle fatigue.</font></p>     ^cY#v33n1a10.htm#
#
00721000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048600076002001300562#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#60#56#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It is also important to point out th
at lactate production is directly proportional to CO<sub>2</sub> production, and
 consequently to a reduction in the supply of oxygen (O<sub>2</sub>) to the cell
s. As the demand for O<sub>2</sub> is greater than the supply, the oxidative aer
obic mechanism is then supplemented by the anaerobic mechanism;<sup>(33)</sup> a
 metabolic deviation from aerobic to anaerobic.</font></p>     ^cY#v33n1a10.htm#
#
00700000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046500076002001300541#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#61#57#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> From the results shown in <a href="
#fig1">Figure 1</a>, it is observed that at rest, the lactate levels for both Hb
 SS and HB SC volunteers were higher than the control group. This finding may be
 explained in two ways: by the increased lactate production reflecting the devia
tion from aerobic to anaerobic metabolic predominance or by a reduction in the l
actate buffering capacity.</font></p>     ^cY#v33n1a10.htm##
01098000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704086300076002001300939#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#62#58#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Two studies reported that the mean b
aseline lactate levels for sickle cell disease individuals were higher than the 
normal values and above the lactate threshold.<sup>(34,35)</sup> It was found th
at the value found in these patients was 660 - 7760 IU/L, well above the mean of
 the present research, which was 330 IU/L for Hb SC individuals and 486 IU/L for
 Hb SS individuals. However, these two studies analyzed blood lactate of sickle 
cell disease patients with acute or chronic hepatic impairment; some also had ki
dney dysfunction and thus different from the sample of this study, in which only
 patients who did not present these conditions were selected. These results high
light a strong correlation between the accumulation of blood lactate and the hep
atic lactate metabolism.</font></p>     ^cY#v33n1a10.htm##
00901000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066600076002001300742#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#63#59#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This reinforces the idea that, irres
pective of hepatic or renal involvement, sickle cell disease individuals with th
e SS or SC genotype have a baseline metabolic deviation of the aerobic to the an
aerobic pathway, possibly caused by an adaptation to the reduced O<sub>2</sub> b
ioavailability to the cells of the body as a result of the sickling process. Sic
kling causes a reduction in the half life of red blood cells, diminishing their 
absolute number in sickle cell disease patients compared to healthy individuals 
and consequently O<sub>2</sub> transport is reduced.<sup>(27)</sup></font></p>  
   ^cY#v33n1a10.htm##
00878000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064300076002001300719#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#64#60#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Moreover, it is known that elevation
s in the blood lactate level have been considered an indication of an increase i
n anaerobic metabolism of the muscle because of the low levels of O<sub>2</sub> 
in its cells.<sup>(27)</sup> From this finding we may also infer that the aerobi
c functional capacity measured by VO<sub>2</sub>max is diminished in sickle cell
 disease patients, not only because of cardiovascular or pulmonary involvement,<
sup>(6)</sup> but also because of presenting an altered basal metabolism, that i
s to say, permanently in metabolic acidosis.</font></p>     ^cY#v33n1a10.htm##
01327000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109200076002001301168#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#65#61#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Metabolic acidosis is a very frequen
t disorder in patients hospitalized in intensive care units and is associated wi
th elevated mortality,<sup>(36)</sup> although the prognoses of these patients d
epend a great deal more on the severity of the disease underlying the acid-base 
disorder than on the severity of the metabolic acidosis itself.<sup>(37)</sup> I
t is well known that extreme levels of acidemia cause various undesirable effect
s on cell function. Among these effects one may point out weakness and fatigue o
f the respiratory musculature,<sup>(38)</sup> an increase in insulin resistance 
and consequent increase in protein catabolism,<sup>(36)</sup> which may explain 
the sarcopenia observed in sickle cell disease individuals, reduction in cardiov
ascular response at effort and reductions in myocardial contractility,<sup>(6)</
sup> as well as increases in pulmonary vascular resistance. This explains the hi
gh number of sickle cell disease patients that develop pulmonary hypertension.<s
up>(38)</sup></font></p>     ^cY#v33n1a10.htm##
00652000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041700076002001300493#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#66#62#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> Finally, it can be affirmed that th
e more severe the sickling of cells is, the higher the basal lactate level will 
be; this is proven when the mean lactate value of SS subjects is compared with t
hat of SC subjects, as both suffer from vaso-occlusive phenomena, although norma
lly the symptoms are milder in SC subjects.<sup>(28)</sup></font></p>     ^cY#v3
3n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#67#63#article#154#<p>&nbsp;</p>     ^
cY#v33n1a10.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#68#64#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Conclusion</b></font></p>     ^cY
#v33n1a10.htm##
00667000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043200076002001300508#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#69#65#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The resting blood lactate value in i
ndividuals with Hb SS and Hb SC diseases, but without hepatic involvement, is 4 
and 3 times higher, respectively than that of healthy subjects, possibly caused 
by a deviation from the predominantly aerobic to the anaerobic metabolic pathway
 as a result of the sickling process from which these individuals suffer.</font>
</p>     ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#70#66#article#154#<p>&nbsp;</p>     ^
cY#v33n1a10.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#71#67#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY
#v33n1a10.htm##
00403000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015400078002001300232#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#72#68#article#154#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Amoretti R, Brion R
. Cardiologia do Esporte. S&atilde;o Paulo: Ed. Manole; 2001.    ^cY#v33n1a10.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#73#69#article#154#</font></p>     ^cY
#v33n1a10.htm##
00635000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704038600078002001300464#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#74#70#article#154#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Gualandro SF, Silve
ira PA, Fonseca GH. Anemias heredit&aacute;rias. In: Martins MA, Carrilho FJ, Al
ves VA, Castilho AC, Cerri GG,  Wen CL. Cl&iacute;nica M&eacute;dica, volume 3: 
Doen&ccedil;as hematol&oacute;gicas, oncologia, doen&ccedil;as renais e genituri
n&aacute;rias. Barueri (SP): Manole; 2009. p.109-112.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#75#71#article#154#</font></p>     ^cY
#v33n1a10.htm##
00437000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018800078002001300266#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#76#72#article#154#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Beiguelman, B. Gen&
eacute;tica M&eacute;dica. 3a ed. S&atilde;o Paulo: Ed. Universidade de S&atilde
;o Paulo; 1998.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#77#73#article#154#</font></p>     ^cY
#v33n1a10.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026500078002001300343#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#78#74#article#154#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Ramalho AS, Giraldi
 T, Magna LA. Estudo gen&eacute;tico-epidemiol&oacute;gico da hemoglobina S em u
ma popula&ccedil;&atilde;o do Sudeste do Brasil. Rev Bras Hematol Hemoter. 2008;
30(2):89-94.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#79#75#article#154#</font></p>     ^cY
#v33n1a10.htm##
00575000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032600078002001300404#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#80#76#article#154#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Diniz D, Guedes C, 
Barbosa L, Tauil PL, Magalh&atilde;es I. Preval&ecirc;ncia do tra&ccedil;o e da 
anemia falciforme em rec&eacute;m-nascidos do Distrito Federal, Brasil, 2004 a 2
006. Cad. Sa&uacute;de P&uacute;blica, Rio de Janeiro, 2009;25(1):188-94.    ^cY
#v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#81#77#article#154#</font></p>     ^cY
#v33n1a10.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025200078002001300330#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#82#78#article#154#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Martins WA, Mesquit
a ET, Cunha DM, Ferrari AH, Pinheiro LAF, Romeo LJ, et al. Altera&ccedil;&otilde
;es cardiovasculares na anemia falciforme. Arq Bras Cardiol. 1998;70(5):365-70. 
   ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#83#79#article#154#</font></p>     ^cY
#v33n1a10.htm##
00447000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019800078002001300276#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#84#80#article#154#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Zanette, AM. Gravid
ez e contracep&ccedil;&atilde;o na doen&ccedil;a falciforme. Rev Bras Hematol He
moter. 2007;29(3):309-12.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#85#81#article#154#</font></p>     ^cY
#v33n1a10.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024500078002001300323#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#86#82#article#154#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Ag&ecirc;ncia Nacio
nal de Vigil&acirc;ncia Sanit&aacute;ria. Manual de Diagn&oacute;stico e Tratame
nto de Doen&ccedil;as Falciformes. 1a ed. Bras&iacute;lia: ANVISA, 2001.    ^cY#
v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#87#83#article#154#</font></p>     ^cY
#v33n1a10.htm##
00545000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029600078002001300374#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#88#84#article#154#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Zago MA, Pinto AC. 
Fisiopatologia das doen&ccedil;as falciformes: da muta&ccedil;&atilde;o gen&eacu
te;tica &agrave; insufici&ecirc;ncia de m&uacute;ltiplos &oacute;rg&atilde;os. R
ev Bras Hematol Hemoter. 2007;29(3):207-14.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#89#85#article#154#</font></p>     ^cY
#v33n1a10.htm##
00449000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019900079002001300278#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#90#86#article#154#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Hutz MH, Salzano 
FM. Fecundidade em uma amostra brasileira de mulheres com anemia falciforme. Rev
ista da AMB. 1983; 29:66-8.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#91#87#article#154#</font></p>     ^cY
#v33n1a10.htm##
00481000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023100079002001300310#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#92#88#article#154#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 11. Figueiredo MS. F
atores moduladores da gravidade da evolu&ccedil;&atilde;o cl&iacute;nica da anem
ia falciforme. Rev Bras Hematol Hemoter. 2007; 29(3):215-7.    ^cY#v33n1a10.htm#
#
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#93#89#article#154#</font></p>     ^cY
#v33n1a10.htm##
00446000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019600079002001300275#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#94#90#article#154#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Machado RF. Hiper
tens&atilde;o arterial pulmonar associada &agrave; anemia falciforme. J Bras Pne
umol. 2007;33(5):583-91.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#95#91#article#154#</font></p>     ^cY
#v33n1a10.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023200079002001300311#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#96#92#article#154#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Gualandro SF, Gua
landro DM, Fonseca GH. Complica&ccedil;&otilde;es cardiopulmonares da doen&ccedi
l;a falciforme. Rev. Bras Hematol Hemoter. 2007;29(3):291-8.    ^cY#v33n1a10.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#97#93#article#154#</font></p>     ^cY
#v33n1a10.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021500079002001300294#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#98#94#article#154#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Herdy GV, &Aacute
;guas AF, Chedid TC. Altera&ccedil;&otilde;es card&iacute;acas na anemia falcifo
rme. Arq. Bras. Cardiol. 1983;40(5):311-15.    ^cY#v33n1a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#99#95#article#154#</font></p>     ^cY
#v33n1a10.htm##
00561000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704031000080002001300390#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#100#96#article#154#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Martins WA, Mesq
uita ET, Cunha DM, Pinheiro LA, Rom&ecirc;o Filho LJ, Pareto J&uacute;nior RC. E
studo ecodopplercardiogr&aacute;fico em adolescentes e adultos jovens portadores
 de anemia falciforme. Arq Bras Cardiol, 1999;73(6):463-98.    ^cY#v33n1a10.htm#
#
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#101#97#article#154#</font></p>     ^c
Y#v33n1a10.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704020900080002001300289#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#102#98#article#154#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Herdy GV, Pinhei
ro LA, Couto AA, Gabetto M. Miocardiopatia e anemia falciforme em crian&ccedil;a
s. Arq Bras Cardiol. 1987;49(2):87-93.    ^cY#v33n1a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#103#99#article#154#</font></p>     ^c
Y#v33n1a10.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023700081002001300318#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#104#100#article#154#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Souza Jr JL, Ro
drigues AC, Buck PC, Guallandro SF, Mady C. Reserva de fluxo coronariano na anem
ia falciforme. Arq Bras Cardiol. &#91;S.I.&#93;, 2007;88(5):552-88.    ^cY#v33n1
a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#105#101#article#154#</font></p>     ^
cY#v33n1a10.htm##
00442000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019000081002001300271#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#106#102#article#154#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Braga JAP. Medi
das gerais no tratamento das doen&ccedil;as falciformes. Rev Bras Hematol Hemote
r. 2007;29(3):233-8.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#107#103#article#154#</font></p>     ^
cY#v33n1a10.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027100081002001300352#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#108#104#article#154#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Pieroni F, Barr
os GM, Voltarelli JC, Sim&otilde;es BP. Transplante de c&eacute;lulas-tronco hem
atopo&eacute;ticas (TCTH) em doen&ccedil;as falciformes. Rev Bras Hematol Hemote
r. 2007;29(3):327-30.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#109#105#article#154#</font></p>     ^
cY#v33n1a10.htm##
00433000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018100081002001300262#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#110#106#article#154#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Klug PP, Lessin
 LS. Radice-P-Rheological aspects of sickel cell disease. Arch Intern Med. 1974;
133:577-90.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#111#107#article#154#</font></p>     ^
cY#v33n1a10.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024900081002001300330#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#112#108#article#154#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Woods KF. Can s
ickle cell patient live longer with more exercise? Medical College of Georgia. 4
7th Annual Meeting of the American College of Sports Medicine. 1997</font></p>  
   ^cY#v33n1a10.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026400081002001300345#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#113#109#article#154#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Moreira GF, Net
o LM, Fernandes PA, Ficarelli VF. Aspectos fisiol&oacute;gicos da atividade f&ia
cute;sica em portadores da anemia falciforme (monografia) UNIFESP/EPM. S&atilde;
o Paulo, 2002.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#114#110#article#154#</font></p>     ^
cY#v33n1a10.htm##
00438000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018600081002001300267#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#115#111#article#154#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Costill DL, Wil
more JH. Fisiologia do esporte e do exerc&iacute;cio. 2a ed. S&atilde;o Paulo: E
d. Manole, 2001.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#116#112#article#154#</font></p>     ^
cY#v33n1a10.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#117#113#article#154#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Wasserman K, Ha
nsen JE, Sue D, Whipp BJ, Casaburi R. Principles of exercise testing and interpr
etation. 3a ed. Philadelphia: Lippincott Williams and Wilkins; 1999.    ^cY#v33n
1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#118#114#article#154#</font></p>     ^
cY#v33n1a10.htm##
00636000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704038400081002001300465#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#119#115#article#154#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Garcez AR, Visc
onde FJ, Zaitune MA, Mar&atilde;es VR, Moura MA, Verzola RM, et al. Avalia&ccedi
l;&atilde;o do limiar de anaerobiose em homens com fatores de risco para doen&cc
edil;a da art&eacute;ria coron&aacute;ria e com doen&ccedil;a da art&eacute;ria 
coron&aacute;ria. Rev Soc de Cardiol. 2001;11(3):5-17.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#120#116#article#154#</font></p>     ^
cY#v33n1a10.htm##
00669000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704041700081002001300498#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#121#117#article#154#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Mar&atilde;es V
R, Teixeira LC, Catai AM, Milan LA, Rojas FA, Oliveira L, et al. Determina&ccedi
l;&atilde;o e valida&ccedil;&atilde;o do limiar de anaerobiose a partir de m&eac
ute;todos de an&aacute;lise da freq&uuml;&ecirc;ncia card&iacute;aca e de sua va
riabilidade. Rev Soc Cardiol Estado de S&atilde;o Paulo. 2003;(4th) Suplemento A
: 1-16.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#122#118#article#154#</font></p>     ^
cY#v33n1a10.htm##
00522000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027000081002001300351#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#123#119#article#154#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Loggetto SR, Pe
llegrini-Braga JA, Costa-Carvalho BT, Sol&eacute; D. Altera&ccedil;&otilde;es im
unol&oacute;gicas em pacientes com anemia falciforme. Rev Bras Alergia Imunopato
l. 1999;22(3):77-82.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#124#120#article#154#</font></p>     ^
cY#v33n1a10.htm##
00431000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017900081002001300260#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#125#121#article#154#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Mateo RJ, Lapie
za LM. Anemia do atleta: fisiopatologia do ferro. Rev Bras Med Esporte. 2000;6(3
):108-14.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#126#122#article#154#</font></p>     ^
cY#v33n1a10.htm##
00452000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020000081002001300281#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#127#123#article#154#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Naoum PC. Eletr
oforese - T&eacute;cnicas e Diagn&oacute;sticos. S&atilde;o Paulo: 2a ed. Santos
 Livraria &amp; Editora, 1999.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#128#124#article#154#</font></p>     ^
cY#v33n1a10.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#129#125#article#154#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Domingos CR. He
moglobinopatias no Brasil - Variabilidade gen&eacute;tica e metodologia laborato
rial (thesis). S&atilde;o Jos&eacute; do Rio Preto, SP: UNESP; 1993.    ^cY#v33n
1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#130#126#article#154#</font></p>     ^
cY#v33n1a10.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028500081002001300366#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#131#127#article#154#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Galacteros F. N
eonatal detection of sickle cell disease in metropolitan France. Association fra
ncaise pour le depistage et la prevention des handcaps de l&eacute;nfant (AFDPHE
). Arch Pediatr. 1996;3(4):1026-31.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#132#128#article#154#</font></p>     ^
cY#v33n1a10.htm##
00423000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017100081002001300252#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#133#129#article#154#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Powers SK, Howl
ey ET. Fisiologia do exerc&iacute;cio. 3a ed. S&atilde;o Paulo: Ed. Manole; 2000
.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#134#130#article#154#</font></p>     ^
cY#v33n1a10.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020900081002001300290#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#135#131#article#154#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Bacon L, Kern M
. Evaluating a test protocol for predicting maximum lactate steady state. J Spor
ts Med Phys Fitness. 1999; 39(4):300-8.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#136#132#article#154#</font></p>     ^
cY#v33n1a10.htm##
00412000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016000081002001300241#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#137#133#article#154#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Banerjee S, Owe
n C, Chopra S. Sickle cell hepatopathy. Hepatology. 2001;33(5):1021-8.    ^cY#v3
3n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#138#134#article#154#</font></p>     ^
cY#v33n1a10.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020900081002001300290#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#139#135#article#154#35#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Shao SH, Orring
er EP. Sickle cell intrahepatic cholestasis: approach to a difficult problem. Am
 J Gastroenterol. 1995;90(11): 2048-50.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#140#136#article#154#</font></p>     ^
cY#v33n1a10.htm##
00466000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021400081002001300295#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#141#137#article#154#36#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Rocha PN. Uso d
e bicarbonato de s&oacute;dio na acidose metab&oacute;lica do paciente gravement
e enfermo J Bras Nefrol. 2009;31(4):297-306.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#142#138#article#154#</font></p>     ^
cY#v33n1a10.htm##
00785000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704053300081002001300614#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#143#139#article#154#37#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Adrogue HJ, Mad
ias NE. Management of life-threatening acid-base disorders. First of two parts. 
N Engl J Med. 1998;338:26-34. Erratum in: N Engl J Med 1999;340(3):247. Comment 
in: N Engl J Med. 1998 May 28;338(22):1627-8; author reply 1628-9. N Engl J Med.
 1998;338(22):1628-9. N Engl J Med. 1998; 338 (22):1627; author reply 1628-9. N 
Engl J Med. 1998;339 (14): 1005-6. N Engl J Med. 1998;338(22):1626-7; author rep
ly 1628-9. N Engl J Med. 1999;341(25):1938.    ^cY#v33n1a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#144#140#article#154#</font></p>     ^
cY#v33n1a10.htm##
00639000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704038700081002001300468#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#145#141#article#154#38#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Machado RF. A h
ipertens&atilde;o pulmonar na doen&ccedil;a falciforme. PVRI Review &#91;serial 
online&#93; 2009 &#91;cited 2011 Feb 12&#93;;1:85-91. Available from: <a href="h
ttp://www.pvrireview.org/text.asp?2009/1/1/85/44894" target="_blank">http://www.
pvrireview.org/text.asp?2009/1/1/85/44894</a></font></p>     ^cY#v33n1a10.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#146#142#article#154#<p>&nbsp;</p>    
 ^cY#v33n1a10.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#147#143#article#154#<p>&nbsp;</p>    
 ^cY#v33n1a10.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018600078002001300264#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#148#144#article#154#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b
>    ^cY#v33n1a10.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002800078002001300106#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#149#145#article#154#<br> Jefferson Pe
tto    ^cY#v33n1a10.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008900078002001300167#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#150#146#article#154#<br> Rua Para&iac
ute;ba 178, apto 605 Edif&iacute;cio Jardim Vela Branca - Pituba    ^cY#v33n1a10
.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004600078002001300124#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#151#147#article#154#<br> 41830-100 - 
Salvador (BA), Brazil    ^cY#v33n1a10.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010100078002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#152#148#article#154#<br> <a href="mai
lto:jeffersonpetto@yahoo.com.br">jeffersonpetto@yahoo.com.br</a></font></p>     
^cY#v33n1a10.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#153#149#article#154#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted: 4/15/2010    ^cY#v33n1a
10.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003200078002001300110#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#154#150#article#154#<br> Accepted: 11
/9/2010    ^cY#v33n1a10.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010900078002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#155#151#article#154#<br> Conflict-of-
interest disclosure: The authors declare no competing financial interest</font><
/p>     ^cY#v33n1a10.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#156#152#article#154#<p>&nbsp;</p>    
 ^cY#v33n1a10.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#157#153#article#154#<p>&nbsp;</p>    
 ^cY#v33n1a10.htm##
00460000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022300078002001300301#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a10.htm#S#p#158#154#article#154#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" targ
et="_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_bla
nk">www.scielo.br/rbhh</a></font></p>     ^cY#v33n1a10.htm##
00436000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160018000770160015000950180
02700110066001000137062001100147065000900158064000500167865000900172002001300181
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#159#1#article#38#1#^r
ND^sAmoretti^nR#^rND^sBrion^nR#Cardiologia do Esporte^lpt#São Paulo#Ed. Manole#2
0010000#2001#20110200#v33n1a10.htm##
00770000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100019000970100
01800116012002500134016001800159016001900177016001600196016001900212016001600231
01600140024701800960026106600120035706200070036906500090037606400050038501400080
0390865000900398002001300407#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.h
tm#S#c#160#2#article#38#2#^rND^sGualandro^nSF#^rND^sSilveira^nPA#^rND^sFonseca^n
GH#Anemias hereditárias^lpt#^rND^sMartins^nMA#^rND^sCarrilho^nFJ#^rND^sAlves^nVA
#^rND^sCastilho^nAC#^rND^sCerri^nGG#^rND^sWen^nCL#Clínica Médica, volume 3: Doen
ças hematológicas, oncologia, doenças renais e geniturinárias^lpt#Barueri^eSP#Ma
nole#20090000#2009#109-112#20110200#v33n1a10.htm##
00437000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160020000770180020000970630
00200117066001000119062003000129065000900159064000500168865000900173002001300182
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#161#3#article#38#3#^r
ND^sBeiguelman^nB#Genética Médica^lpt#3#São Paulo#Ed. Universidade de São Paulo#
19980000#1998#20110200#v33n1a10.htm##
00582000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100017000950100
01600112012009000128030002500218710000200243065000900245064000500254031000300259
032000200262014000600264865000900270002001300279#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a10.htm#S#c#162#4#article#38#4#^rND^sRamalho^nAS#^rND^sGiraldi^nT
#^rND^sMagna^nLA#Estudo genético-epidemiológico da hemoglobina S em uma populaçã
o do Sudeste do Brasil^lpt#Rev Bras Hematol Hemoter#2#20080000#2008#30#2#89-94#2
0110200#v33n1a10.htm##
00716000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920100
01700108010001600125010001900141012010700160030001900267066001500286065000900301
06400050031003100030031503200020031801400070032086500090032700200130033603500100
0349801001900359#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#163#5
#article#38#5#^rND^sDiniz^nD#^rND^sGuedes^nC#^rND^sBarbosa^nL#^rND^sTauil^nPL#^r
ND^sMagalhães^nI#Prevalência do traço e da anemia falciforme em recém-nascidos d
o Distrito Federal, Brasil, 2004 a 2006^lpt#Cad. Saúde Pública#Rio de Janeiro#20
090000#2009#25#1#188-94#20110200#v33n1a10.htm#0102-311X#Cad. saúde pública##
00685000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100019000950100
01600114010001800130010002000148010001600168810000600184012005300190030001700243
06500090026006400050026903100030027403200020027701400070027986500090028600200130
0295035001000308801001700318#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.h
tm#S#c#164#6#article#38#6#^rND^sMartins^nWA#^rND^sMesquita^nET#^rND^sCunha^nDM#^
rND^sFerrari^nAH#^rND^sPinheiro^nLAF#^rND^sRomeo^nLJ#et al#Alterações cardiovasc
ulares na anemia falciforme^lpt#Arq Bras Cardiol#19980000#1998#70#5#365-70#20110
200#v33n1a10.htm#0066-782X#Arq Bras Cardiol##
00485000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120049000950300
02500144710000200169065000900171064000500180031000300185032000200188014000700190
865000900197002001300206#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S
#c#165#7#article#38#7#^rND^sZanette^nAM#Gravidez e contracepção na doença falcif
orme^lpt#Rev Bras Hematol Hemoter#2#20070000#2007#29#3#309-12#20110200#v33n1a10.
htm##
00476000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170041000770180062001180630
00200180066000900182062000700191065000900198064000500207865000900212002001300221
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#166#8#article#38#8#Ag
ência Nacional de Vigilância Sanitária#Manual de Diagnóstico e Tratamento de Doe
nças Falciformes^lpt#1#Brasília#ANVISA#20010000#2001#20110200#v33n1a10.htm##
00561000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920120
10000108030002500208710000200233065000900235064000500244031000300249032000200252
014000700254865000900261002001300270#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a10.htm#S#c#167#9#article#38#9#^rND^sZago^nMA#^rND^sPinto^nAC#Fisiopatologia 
das doenças falciformes: da mutação genética à insuficiência de múltiplos órgãos
^lpt#Rev Bras Hematol Hemoter#2#20070000#2007#29#3#207-14#20110200#v33n1a10.htm#
#
00515000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940120
07600112030001500188710000200203065000900205064000500214031000300219014000500222
865000900227002001300236#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S
#c#168#10#article#38#10#^rND^sHutz^nMH#^rND^sSalzano^nFM#Fecundidade em uma amos
tra brasileira de mulheres com anemia falciforme^lpt#Revista da AMB#2#19830000#1
983#29#66-8#20110200#v33n1a10.htm##
00518000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790120078001000300
02500178710000200203065000900205064000500214031000300219032000200222014000600224
865000900230002001300239#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S
#c#169#11#article#38#11#^rND^sFigueiredo^nMS#Fatores moduladores da gravidade da
 evolução clínica da anemia falciforme^lpt#Rev Bras Hematol Hemoter#2#20070000#2
007#29#3#215-7#20110200#v33n1a10.htm##
00492000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120064000970300
01500161710000200176065000900178064000500187031000300192032000200195014000700197
865000900204002001300213#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S
#c#170#12#article#38#12#^rND^sMachado^nRF#Hipertensão arterial pulmonar associad
a à anemia falciforme^lpt#J Bras Pneumol#2#20070000#2007#33#5#583-91#20110200#v3
3n1a10.htm##
00557000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100020000990100
01800119012005500137030002600192710000200218065000900220064000500229031000300234
032000200237014000600239865000900245002001300254#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a10.htm#S#c#171#13#article#38#13#^rND^sGualandro^nSF#^rND^sGualan
dro^nDM#^rND^sFonseca^nGH#Complicações cardiopulmonares da doença falciforme^lpt
#Rev. Bras Hematol Hemoter#2#20070000#2007#29#3#291-8#20110200#v33n1a10.htm##
00572000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01700111012004600128030001900174065000900193064000500202031000300207032000200210
014000700212865000900219002001300228035001000241801001900251#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a10.htm#S#c#172#14#article#38#14#^rND^sHerdy^nGV#^rND
^sÁguas^nAF#^rND^sChedid^nTC#Alterações cardíacas na anemia falciforme^lpt#Arq. 
Bras. Cardiol#19830000#1983#40#5#311-15#20110200#v33n1a10.htm#0066-782X#Arq. bra
s. cardiol##
00727000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01600116010001900132010002200151010002400173012010000197030001700297065000900314
06400050032303100030032803200020033101400070033386500090034000200130034903500100
0362801001700372#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#173#1
5#article#38#15#^rND^sMartins^nWA#^rND^sMesquita^nET#^rND^sCunha^nDM#^rND^sPinhe
iro^nLA#^rND^sRomêo Filho^nLJ#^rND^sPareto Júnior^nRC#Estudo ecodopplercardiográ
fico em adolescentes e adultos jovens portadores de anemia falciforme^lpt#Arq Br
as Cardiol#19990000#1999#73#6#463-98#20110200#v33n1a10.htm#0066-782X#Arq Bras Ca
rdiol##
00603000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01600114010001700130012005100147030001700198065000900215064000500224031000300229
032000200232014000600234865000900240002001300249035001000262801001700272#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#174#16#article#38#16#^rND^sHe
rdy^nGV#^rND^sPinheiro^nLA#^rND^sCouto^nAA#^rND^sGabetto^nM#Miocardiopatia e ane
mia falciforme em crianças^lpt#Arq Bras Cardiol#19870000#1987#49#2#87-93#2011020
0#v33n1a10.htm#0066-782X#Arq Bras Cardiol##
00656000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100020000980100
01500118010002100133010001400154012005400168030001700222061000400239065000900243
06400050025203100030025703200020026001400070026286500090026900200130027803500100
0291801001700301#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#175#1
7#article#38#17#^rND^sSouza^nJr JL#^rND^sRodrigues^nAC#^rND^sBuck^nPC#^rND^sGual
landro^nSF#^rND^sMady^nC#Reserva de fluxo coronariano na anemia falciforme^lpt#A
rq Bras Cardiol#S.I#20070000#2007#88#5#552-88#20110200#v33n1a10.htm#0066-782X#Ar
q Bras Cardiol##
00493000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120057000960300
02500153710000200178065000900180064000500189031000300194032000200197014000600199
865000900205002001300214#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S
#c#176#18#article#38#18#^rND^sBraga^nJAP#Medidas gerais no tratamento das doença
s falciformes^lpt#Rev Bras Hematol Hemoter#2#20070000#2007#29#3#233-8#20110200#v
33n1a10.htm##
00607000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
02100113010001700134012007900151030002500230710000200255065000900257064000500266
031000300271032000200274014000700276865000900283002001300292#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a10.htm#S#c#177#19#article#38#19#^rND^sPieroni^nF#^rN
D^sBarros^nGM#^rND^sVoltarelli^nJC#^rND^sSimões^nBP#Transplante de células-tronc
o hematopoéticas (TCTH) em doenças falciformes^lpt#Rev Bras Hematol Hemoter#2#20
070000#2007#29#3#327-30#20110200#v33n1a10.htm##
00534000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940120
05600111030001600167065000900183064000500192031000400197014000700201865000900208
002001300217035001000230801001600240#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a10.htm#S#c#178#20#article#38#20#^rND^sKlug^nPP#^rND^sLessin^nLS#Radice-P-Rhe
ological aspects of sickel cell disease^len#Arch Intern Med#19740000#1974#133#57
7-90#20110200#v33n1a10.htm#0003-9926#Arch Intern Med##
00522000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790180060000950620
02700155053006800182055001200250054000800262865000900270002001300279#v33n1#V:\Sc
iELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#179#21#article#38#21#^rND^sWoods^
nKF#Can sickle cell patient live longer with more exercise?^len#Medical College 
of Georgia#Annual Meeting of the American College of Sports Medicine^n47^i1^i1#1
9970000^i1#1997^i1#20110200#v33n1a10.htm##
00558000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160018000790160015000970160
02000112016002000132018008100152050001300233046001000246045000900256044000500265
865000900270002001300279#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S
#c#180#22#article#38#22#^rND^sMoreira^nGF#^rND^sNeto^nLM#^rND^sFernandes^nPA#^rN
D^sFicarelli^nVF#Aspectos fisiológicos da atividade física em portadores da anem
ia falciforme^lpt#UNIFESP^dEPM#São Paulo#20020000#2002#20110200#v33n1a10.htm##
00469000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160018000790160018000970180
04100115063000200156066001000158062001100168065000900179064000500188865000900193
002001300202#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#181#23#ar
ticle#38#23#^rND^sCostill^nDL#^rND^sWilmore^nJH#Fisiologia do esporte e do exerc
ício^lpt#2#São Paulo#Ed. Manole#20010000#2001#20110200#v33n1a10.htm##
00589000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160019000790160017000980160
01300115016001600128016001800144018005400162063000200216066001300218062003200231
065000900263064000500272865000900277002001300286#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a10.htm#S#c#182#24#article#38#24#^rND^sWasserman^nK#^rND^sHansen^
nJE#^rND^sSue^nD#^rND^sWhipp^nBJ#^rND^sCasaburi^nR#Principles of exercise testin
g and interpretation^len#3#Philadelphia#Lippincott Williams and Wilkins#19990000
#1999#20110200#v33n1a10.htm##
00732000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01800115010001700133010001600150010001800166810000600184012013700190030001900327
71000020034606500090034806400050035703100030036203200020036501400050036786500090
0372002001300381#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#183#2
5#article#38#25#^rND^sGarcez^nAR#^rND^sVisconde^nFJ#^rND^sZaitune^nMA#^rND^sMarã
es^nVR#^rND^sMoura^nMA#^rND^sVerzola^nRM#et al#Avaliação do limiar de anaerobios
e em homens com fatores de risco para doença da artéria coronária e com doença d
a artéria coronária^lpt#Rev Soc de Cardiol#2#20010000#2001#11#3#5-17#20110200#v3
3n1a10.htm##
00739000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01600115010001600131010001600147010001800163810000600181012013100187030003600318
71000020035406500090035606400050036503200160037001400050038686500090039100200130
0400#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#184#26#article#38
#26#^rND^sMarães^nVR#^rND^sTeixeira^nLC#^rND^sCatai^nAM#^rND^sMilan^nLA#^rND^sRo
jas^nFA#^rND^sOliveira^nL#et al#Determinação e validação do limiar de anaerobios
e a partir de métodos de análise da freqüência cardíaca e de sua variabilidade^l
pt#Rev Soc Cardiol Estado de São Paulo#2#20030000#2003#4^sSuplemento A#1-16#2011
0200#v33n1a10.htm##
00606000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100027000980100
02500125010001400150012006300164030002800227710000200255065000900257064000500266
031000300271032000200274014000600276865000900282002001300291#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a10.htm#S#c#185#27#article#38#27#^rND^sLoggetto^nSR#^
rND^sPellegrini-Braga^nJA#^rND^sCosta-Carvalho^nBT#^rND^sSolé^nD#Alterações imun
ológicas em pacientes com anemia falciforme^lpt#Rev Bras Alergia Imunopatol#2#19
990000#1999#22#3#77-82#20110200#v33n1a10.htm##
00569000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950120
04600113030002100159065000900180064000500189031000200194032000200196014000700198
865000900205002001300214035001000227801004200237#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a10.htm#S#c#186#28#article#38#28#^rND^sMateo^nRJ#^rND^sLapieza^nL
M#Anemia do atleta: fisiopatologia do ferro^lpt#Rev Bras Med Esporte#20000000#20
00#6#3#108-14#20110200#v33n1a10.htm#1517-8692#Revista Brasileira de Medicina do 
Esporte##
00453000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790180042000950660
01000137063000200147062002600149065000900175064000500184865000900189002001300198
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#187#29#article#38#29#
^rND^sNaoum^nPC#Eletroforese: Técnicas e Diagnósticos^lpt#São Paulo#2#Santos Liv
raria & Editora#19990000#1999#20110200#v33n1a10.htm##
00479000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160019000790180083000980660
02600181062000600207065000900213064000500222865000900227002001300236#v33n1#V:\Sc
iELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#188#30#article#38#30#^rND^sDoming
os^nCR#Hemoglobinopatias no Brasil: Variabilidade genética e metodologia laborat
orial^lpt#São José do Rio Preto^eSP#UNESP#19930000#1993#20110200#v33n1a10.htm##
00621000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790120160000990300
01300259065000900272064000500281031000200286032000200288014000800290865000900298
002001300307035001000320801001300330#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a10.htm#S#c#189#31#article#38#31#^rND^sGalacteros^nF#Neonatal detection of si
ckle cell disease in metropolitan France: Association francaise pour le depistag
e et la prevention des handcaps de lénfant (AFDPHE)^len#Arch Pediatr#19960000#19
96#3#4#1026-31#20110200#v33n1a10.htm#0096-6630#Arch Pediatr##
00454000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160017000790160017000960180
02800113063000200141066001000143062001100153065000900164064000500173865000900178
002001300187#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a10.htm#S#c#190#32#ar
ticle#38#32#^rND^sPowers^nSK#^rND^sHowley^nET#Fisiologia do exercício^lpt#3#São 
Paulo#Ed. Manole#20000000#2000#20110200#v33n1a10.htm##
00582000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940120
07500108030002600183065000900209064000500218031000300223032000200226014000600228
865000900234002001300243035001000256801002600266#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a10.htm#S#c#191#33#article#38#33#^rND^sBacon^nL#^rND^sKern^nM#Eva
luating a test protocol for predicting maximum lactate steady state^len#J Sports
 Med Phys Fitness#19990000#1999#39#4#300-8#20110200#v33n1a10.htm#0022-4707#J Spo
rts Med Phys Fitness##
00537000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100014000970100
01600111012002800127030001100155065000900166064000500175031000300180032000200183
014000700185865000900192002001300201035001000214801001100224#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a10.htm#S#c#192#34#article#38#34#^rND^sBanerjee^nS#^r
ND^sOwen^nC#^rND^sChopra^nS#Sickle cell hepatopathy^len#Hepatology#20010000#2001
#33#5#1021-8#20110200#v33n1a10.htm#0161-0538#HEPATOLOGY##
00575000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100019000940120
07400113030001900187065000900206064000500215031000300220032000300223014000800226
865000900234002001300243035001000256801001900266#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a10.htm#S#c#193#35#article#38#35#^rND^sShao^nSH#^rND^sOrringer^nE
P#Sickle cell intrahepatic cholestasis: approach to a difficult problem^len#Am J
 Gastroenterol#19950000#1995#90#11#2048-50#20110200#v33n1a10.htm#0002-9270#Am J 
Gastroenterol##
00545000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120085000950300
01400180065000900194064000500203031000300208032000200211014000800213865000900221
002001300230035001000243801001400253#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a10.htm#S#c#194#36#article#38#36#^rND^sRocha^nPN#Uso de bicarbonato de sódio 
na acidose metabólica do paciente gravemente enfermo^lpt#J Bras Nefrol#20090000#
2009#31#4#297-306#20110200#v33n1a10.htm#0101-2800#J Bras Nefrol##
00895000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970120
07500114030001300189065000900202064000500211031000400216014000600220061033400226
865000900560002001300569035001000582801001300592#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a10.htm#S#c#195#37#article#38#37#^rND^sAdrogue^nHJ#^rND^sMadias^n
NE#Management of life-threatening acid-base disorders: First of two parts^len#N 
Engl J Med#19980000#1998#338#26-34#Erratum in: N Engl J Med 1999;340(3):247. Com
ment in: N Engl J Med. 1998 May 28;338(22):1627-8; author reply 1628-9. N Engl J
 Med. 1998;338(22):1628-9. N Engl J Med. 1998; 338 (22):1627; author reply 1628-
9. N Engl J Med. 1998;339 (14): 1005-6. N Engl J Med. 1998;338(22):1626-7; autho
r reply 1628-9. N Engl J Med. 1999;341(25):1938.#20110200#v33n1a10.htm#0028-4793
#N Engl J Med##
00593000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120048000970300
01200145710000200157061001400159065000900173064000500182110000900187109001200196
031000200208014000600210037005300216865000900269002001300278#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a10.htm#S#c#196#38#article#38#38#^rND^sMachado^nRF#A 
hipertensão pulmonar na doença falciforme^lpt#PVRI Review#2#serial online#200900
00#2009#20110212#2011 Feb 12#1#85-91#http://www.pvrireview.org/text.asp?2009/1/1
/85/44894#20110200#v33n1a10.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#o#1#1#article#1
#20110411#115531#v33n1a11.htm#148##
02782000000000517000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120064002020100025002660100041002910700050003320831727003820850010021090850
02202119085002802141085003402169117000602203072000302209112000902212111001002221
114000902231113001102240002001302251#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a11.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#11#RBHH340#nd#Rev. Bras.
 Hematol. Hemoter.#33#1#20110200#^f31^l34#1516-8484#10.5581/1516-8484.20110011#C
ost of the treatment of myelodisplastic syndrome in Brazil^len#^rND^1A01^nOtávio
^sClark#^rND^1A01^nEnéas José de Matos^sFaleiros#Evidências Consultoria^iA01^cCa
mpinas^sSP^pBrazil#^len^aINTRODUCTION: Myelodysplastic syndrome is an incurable 
and rare hematological disease that affects the production of blood cells. One a
im of treatment is to maintain the blood-cell count to near-normal levels. This 
is mainly achieved with hematopoietic- growth factors and transfusions. Our obje
ctive was to determine the cost of supportive treatment/care for patients with l
ow and intermediate I risk myelodysplastic syndrome in respect to private health
care plans in Brazil. METHOD: We adapted the National Comprehensive Cancer Netwo
rk treatment guidelines for intermediate risk myelodysplastic syndrome patients 
to the Brazilian reality, adopting a decision tree to explore treatment combinat
ions. Then, we calculated the costs for each branch of the tree, according to na
tional prices. We also estimated total costs for a cohort of 100 patients, distr
ibuted across treatment combinations according to the expected epidemiology. We 
assumed a horizon of one year of treatment. RESULTS: The mean cost of treatment 
for low and intermediate I risk myelodysplastic syndrome is US$ 42,758/patient/y
ear. This cost can vary from US$ 24,282 to US$ 121,952, according to patient cha
racteristics and the treatment used. Overall, patients that require immunotherap
y with antithymocyte globulins are associated with the highest cost. Those that 
achieve disease stability solely with the use of erythropoietin were associated 
with the lowest cost. CONCLUSION: In Brazil, treatment of low and intermediate I
 risk myelodysplastic syndrome is associated with a mean cost of the order of US
$ 42,700/patient/year. New types of therapy have the potential to change this sc
enario if they can diminish the requirements for supportive care.#^ddecs^i1#^tm^
len^kNeoplasms^i1#^tm^len^kCost of illness^i1#^tm^len^kHematologic neoplasms^i1#
other#15#20100920#9/20/2010#20101123#11/23/2010#v33n1a11.htm##
02817000000000517000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120071002020100025002730100041002980700050003390831755003890850010021440850
02202154085002802176085003402204117000602238072000302244112000902247111001002256
114000902266113001102275002001302286#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a11.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#11#RBHH340#nd#Rev. Bras.
 Hematol. Hemoter.#33#1#20110200#^f31^l34#1516-8484#10.5581/1516-8484.20110011#<
b>Cost of the treatment of myelodisplastic syndrome in Brazil</b>^len#^rND^1A01^
nOtávio^sClark#^rND^1A01^nEnéas José de Matos^sFaleiros#Evidências Consultoria^i
A01^cCampinas^sSP^pBrazil#^len^a<b>INTRODUCTION:</b> Myelodysplastic syndrome is
 an incurable and rare hematological disease that affects the production of bloo
d cells. One aim of treatment is to maintain the blood-cell count to near-normal
 levels. This is mainly achieved with hematopoietic- growth factors and transfus
ions. Our objective was to determine the cost of supportive treatment/care for p
atients with low and intermediate I risk myelodysplastic syndrome in respect to 
private healthcare plans in Brazil. <b>METHOD:</b> We adapted the National Compr
ehensive Cancer Network treatment guidelines for intermediate risk myelodysplast
ic syndrome patients to the Brazilian reality, adopting a decision tree to explo
re treatment combinations. Then, we calculated the costs for each branch of the 
tree, according to national prices. We also estimated total costs for a cohort o
f 100 patients, distributed across treatment combinations according to the expec
ted epidemiology. We assumed a horizon of one year of treatment. <b>RESULTS:</b>
 The mean cost of treatment for low and intermediate I risk myelodysplastic synd
rome is US$ 42,758/patient/year. This cost can vary from US$ 24,282 to US$ 121,9
52, according to patient characteristics and the treatment used. Overall, patien
ts that require immunotherapy with antithymocyte globulins are associated with t
he highest cost. Those that achieve disease stability solely with the use of ery
thropoietin were associated with the lowest cost. <b>CONCLUSION:</b> In Brazil, 
treatment of low and intermediate I risk myelodysplastic syndrome is associated 
with a mean cost of the order of US$ 42,700/patient/year. New types of therapy h
ave the potential to change this scenario if they can diminish the requirements 
for supportive care.#^ddecs^i1#^tm^len^kNeoplasms^i1#^tm^len^kCost of illness^i1
#^tm^len^kHematologic neoplasms^i1#other#15#20100920#9/20/2010#20101123#11/23/20
10#v33n1a11.htm##
02909000000000541000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103038000400108121000300112049000800115
15800030012303000280012603100030015403200020015706500090015901400090016803500100
01772370027001870120064002140100025002780100041003030700052003440831727003960850
01002123085002202133085002802155085003402183117000602217072000302223112000902226
111001002235114000902245113001102254002001302265008008902278#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a11.htm#S#l#4#1#article#1#^mFeb.^a2011#oa#en#br1.1#1#
4.0#ilus#tab#11#RBHH340#nd#Rev. bras. hematol. hemoter#33#1#20110200#^f31^l34#15
16-8484#10.5581/1516-8484.20110011#Cost of the treatment of myelodisplastic synd
rome in Brazil^len#^rND^1A01^nOtávio^sClark#^rND^1A01^nEnéas José de Matos^sFale
iros#^iA01^1Evidências Consultoria^cCampinas^sSP^pBrazil#^len^aINTRODUCTION: Mye
lodysplastic syndrome is an incurable and rare hematological disease that affect
s the production of blood cells. One aim of treatment is to maintain the blood-c
ell count to near-normal levels. This is mainly achieved with hematopoietic- gro
wth factors and transfusions. Our objective was to determine the cost of support
ive treatment/care for patients with low and intermediate I risk myelodysplastic
 syndrome in respect to private healthcare plans in Brazil. METHOD: We adapted t
he National Comprehensive Cancer Network treatment guidelines for intermediate r
isk myelodysplastic syndrome patients to the Brazilian reality, adopting a decis
ion tree to explore treatment combinations. Then, we calculated the costs for ea
ch branch of the tree, according to national prices. We also estimated total cos
ts for a cohort of 100 patients, distributed across treatment combinations accor
ding to the expected epidemiology. We assumed a horizon of one year of treatment
. RESULTS: The mean cost of treatment for low and intermediate I risk myelodyspl
astic syndrome is US$ 42,758/patient/year. This cost can vary from US$ 24,282 to
 US$ 121,952, according to patient characteristics and the treatment used. Overa
ll, patients that require immunotherapy with antithymocyte globulins are associa
ted with the highest cost. Those that achieve disease stability solely with the 
use of erythropoietin were associated with the lowest cost. CONCLUSION: In Brazi
l, treatment of low and intermediate I risk myelodysplastic syndrome is associat
ed with a mean cost of the order of US$ 42,700/patient/year. New types of therap
y have the potential to change this scenario if they can diminish the requiremen
ts for supportive care.#^ddecs^i1#^tm^len^kNeoplasms^i1#^tm^len^kCost of illness
^i1#^tm^len^kHematologic neoplasms^i1#other#15#20100920#9/20/2010#20101123#11/23
/2010#v33n1a11.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&
pid=S1516-84842011000100011##
00354000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012100074002001300195#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#5#1#article#129#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLES</b>
</font></p>     ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#6#2#article#129#<p>&nbsp;</p>     ^cY
#v33n1a11.htm##
00400000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704016700074002001300241#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#7#3#article#129#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Cost of the treat
ment of myelodisplastic syndrome in Brazil</b></font></p>     ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#8#4#article#129#<p>&nbsp;</p>     ^cY
#v33n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#9#5#article#129#<p>&nbsp;</p>     ^cY
#v33n1a11.htm##
00387000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015300075002001300228#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#10#6#article#129#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Ot&aacute;vio Clark; En&eacute;as 
Jos&eacute; de Matos Faleiros</b></font></p>     ^cY#v33n1a11.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704013400075002001300209#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#11#7#article#129#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Evid&ecirc;ncias Consultoria, Campina
s (SP), Brazil</font></p>     ^cY#v33n1a11.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#12#8#article#129#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></fon
t></p>     ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#13#9#article#129#<p>&nbsp;</p>     ^c
Y#v33n1a11.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#14#10#article#129#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v33n1a11.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#15#11#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
33n1a11.htm##
00790000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055500076002001300631#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#16#12#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION:</b> Myelodysplastic
 syndrome is an incurable and rare hematological disease that affects the produc
tion of blood cells. One aim of treatment is to maintain the blood-cell count to
 near-normal levels. This is mainly achieved with hematopoietic- growth factors 
and transfusions. Our objective was to determine the cost of supportive treatmen
t/care for patients with low and intermediate I risk myelodysplastic syndrome in
 respect to private healthcare plans in Brazil.     ^cY#v33n1a11.htm##
00759000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052400076002001300600#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#17#13#article#129#<br>   <b>METHOD:</
b> We adapted the National Comprehensive Cancer Network treatment guidelines for
 intermediate risk myelodysplastic syndrome patients to the Brazilian reality, a
dopting a decision tree to explore treatment combinations. Then, we calculated t
he costs for each branch of the tree, according to national prices. We also esti
mated total costs for a cohort of 100 patients, distributed across treatment com
binations according to the expected epidemiology. We assumed a horizon of one ye
ar of treatment.     ^cY#v33n1a11.htm##
00715000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048000076002001300556#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#18#14#article#129#<br>   <b>RESULTS:<
/b> The mean cost of treatment for low and intermediate I risk myelodysplastic s
yndrome is US$ 42,758/patient/year. This cost can vary from US$ 24,282 to US$ 12
1,952, according to patient characteristics and the treatment used. Overall, pat
ients that require immunotherapy with antithymocyte globulins are associated wit
h the highest cost. Those that achieve disease stability solely with the use of 
erythropoietin were associated with the lowest cost.     ^cY#v33n1a11.htm##
00551000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031600076002001300392#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#19#15#article#129#<br> <b>CONCLUSION:
</b> In Brazil, treatment of low and intermediate I risk myelodysplastic syndrom
e is associated with a mean cost of the order of US$ 42,700/patient/year. New ty
pes of therapy have the potential to change this scenario if they can diminish t
he requirements for supportive care. </font></p>     ^cY#v33n1a11.htm##
00406000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017100076002001300247#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#20#16#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Neoplasms; Cost of 
illness; Hematologic neoplasms</font></p> <hr size="1" noshade>     ^cY#v33n1a11
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#21#17#article#129#<p>&nbsp;</p>     ^
cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#22#18#article#129#<p>&nbsp;</p>     ^
cY#v33n1a11.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#23#19#article#129#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></p>     ^
cY#v33n1a11.htm##
00814000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057900076002001300655#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#24#20#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Myelodysplastic syndrome (MDS) is a 
designation for clonal hematopoietic diseases that present as a common character
istic blood cytopenias, cellular dysplasia and a predisposition to develop leuke
mia (usually acute myelogenous leukemia) in the course of the disease. The clini
cal presentation and the prognosis are very variable.<sup>(1,2)</sup> The morbid
ity of the MDS is related to two of the clinical characteristics: cytopenia and 
the development of acute myelogenous leukemia.<sup>(3)</sup></font></p>     ^cY#
v33n1a11.htm##
00611000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037600076002001300452#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#25#21#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">MDS has many different prognostic in
dexes but one of the most used is the "International Prognostic Scoring System (
IPSS)" which classifies the patient according to three factors: percentage of bl
ast cells in bone marrow, cytogenetic findings and peripheral red blood cell cou
nt.<sup>(4)</sup></font></p>     ^cY#v33n1a11.htm##
00584000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034900076002001300425#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#26#22#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">According to these results, patients
 are classified as low risk, intermediate I (Int I), intermediate II (Int II) or
 high risk. Patients classified as Int II or high risk have a bad prognosis, wit
h a median survival of between four and twelve months.<sup>(5,6)</sup></font></p
>     ^cY#v33n1a11.htm##
00521000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028600076002001300362#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#27#23#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The real prevalence of MDS in Brazil
 in unknown, but in the USA it is approximately 35 cases for every one million o
f people, that is, approximately one in every 12,000 individuals has MDS.<sup>(1
)</sup></font></p>     ^cY#v33n1a11.htm##
00794000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055900076002001300635#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#28#24#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Until recently, no specific treatmen
t existed for MDS, and the therapeutic effort was focused to hematologic complic
ations, such as anemia, neutropenia and thrombocytopenia. These treatments are o
f high cost and require intensive use of medical resources.<sup>(3,7,8)</sup> Th
e aim of treatment is to improve the red blood cell indices of these patients in
 order to improve the length or the quality of life of patients and to delay tra
nsformation to leukemia.<sup>(5,6)</sup></font></p>     ^cY#v33n1a11.htm##
00559000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032400076002001300400#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#29#25#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In studies made in Europe and in USA
, one year of supportive treatment for MDS costs between US$ 63,000 and US$ 87,0
00.<sup>(3,7,9)</sup> Only with transfusions, the cost is between US$ 4,000 and 
US$ 13,000 for each patient.<sup>(8,10)</sup></font></p>     ^cY#v33n1a11.htm##
00471000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023600076002001300312#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#30#26#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Our aim was to estimate the costs of
 supportive treatment of MDS in patients classified as low or Int I risk for the
 Brazilian private healthcare system.</font></p>     ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#31#27#article#129#<p>&nbsp;</p>     ^
cY#v33n1a11.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#32#28#article#129#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Methods</b></font></p>     ^cY#v3
3n1a11.htm##
00660000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042500076002001300501#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#33#29#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We adapted the National Comprehensiv
e Cancer Network (NCCN) guidelines for the treatment of low and int I risk MDS,<
sup>(3)</sup> for the Brazilian reality. Then we calculated the direct costs of 
treatment with a horizon of one year. The choice to use an American guideline wa
s due to the lack of publications and studies performed in Brazil.</font></p>   
  ^cY#v33n1a11.htm##
00580000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034500076002001300421#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#34#30#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We developed a decision tree for a h
ypothetic cohort of 100 patients (<a href="/img/revistas/rbhh/v33n1/a11fig01.jpg
">Figure 1</a>). The probability of success of failure for each treatment strate
gy has been described previously by Greenberg et al.<sup>(3)</sup></font></p>   
  ^cY#v33n1a11.htm##
00763000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052800076002001300604#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#35#31#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The treatment regimens recommended b
y the NCCN guidelines include the use of hematopoietic stimulating factors &#91;
erythropoietin (EPO) and neutrophil colony stimulating factors (CSF)&#93;, chemo
therapy (chemo) with cytarabin and idarubicin, use of anti-thymocyte globulin (A
TGAM), cyclosporin and blood cell transfusions (Tx) (red blood cells and platele
ts) and the use of iron chelators (Chel), due to transfusion iron overload.<sup>
(5)</sup></font></p>     ^cY#v33n1a11.htm##
00724000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048900076002001300565#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#36#32#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">According to the NCCN and the Greenb
erg study,<sup>(3,5)</sup> patients are initially classified according to the pr
esence of anemia (83%) or thrombocytopenia/neutropenia (7%). A third group of pa
tients (10%) has a mutation in the 5q gene (Del-5q). This last group was exclude
d in this analysis due to the fact that their first therapeutic option is lenali
domide, which has not been licensed in Brazil yet.</font></p>     ^cY#v33n1a11.h
tm##
00469000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023400076002001300310#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#37#33#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The modeling of the decision tree wa
s performed according to the following distribution (<a href="/img/revistas/rbhh
/v33n1/a11fig01.jpg">Figure 1</a>):</font></p>     ^cY#v33n1a11.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011100076002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#38#34#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Anemia patients (92%)</b></font><
/p>     ^cY#v33n1a11.htm##
00388000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015300076002001300229#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#39#35#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i> - EPO arm (72%) those with blood
 erythropoietin &lt; 500 mU/ML</i></font></p>     ^cY#v33n1a11.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#40#36#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> - 30% responsive to EPO</font></p> 
    ^cY#v33n1a11.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#41#37#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> - in 20% CSF is added to EPO</font>
</p>     ^cY#v33n1a11.htm##
00373000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013800076002001300214#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#42#38#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> - 25% are not responsive and also r
eceive chemotherapy</font></p>     ^cY#v33n1a11.htm##
00403000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016800076002001300244#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#43#39#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> - The remaining are treated with tr
ansfusions and require iron chelators (Tx + Chel)</font></p>     ^cY#v33n1a11.ht
m##
00419000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018400076002001300260#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#44#40#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i> - EPO + SCF (13%) those with blo
od erythropoietin &lt; 500 mU/ML and presence of sideroblasts</i></font></p>    
 ^cY#v33n1a11.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#45#41#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> - Initial treatment with EPO + CSF<
/font></p>     ^cY#v33n1a11.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#46#42#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> -  35% achieve a response</font></p
>     ^cY#v33n1a11.htm##
00363000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012800076002001300204#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#47#43#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> -  25% do not respond, chemotherapy
 is added</font></p>     ^cY#v33n1a11.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#48#44#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> - The others receive Tx + Chel</fon
t></p>     ^cY#v33n1a11.htm##
00404000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016900076002001300245#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#49#45#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i> - Immunotherapy arm (IT) (15%): 
those with blood erythropoietin &gt; 500 mU/ML</i></font></p>     ^cY#v33n1a11.h
tm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#50#46#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> - 25% achieve a response with ATGAM
 + Cyclosporin</font></p>     ^cY#v33n1a11.htm##
00388000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015300076002001300229#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#51#47#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> - If resistant, 25% respond to chem
otherapy and 75% receive Tx + Chel</font></p>     ^cY#v33n1a11.htm##
00373000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013800076002001300214#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#52#48#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Patients with thrombocytopenia/ n
eutropenia (8%)</b></font></p>     ^cY#v33n1a11.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#53#49#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i> - Chemotherapy</i></font></p>   
  ^cY#v33n1a11.htm##
00374000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013900076002001300215#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#54#50#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> - 25% achieve a response and contin
ue with chemotherapy</font></p>     ^cY#v33n1a11.htm##
00377000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014200076002001300218#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#55#51#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> - 75% are not responsive to chemoth
erapy and receive ATGAM</font></p>     ^cY#v33n1a11.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011600076002001300192#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#56#52#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> -50% continue with the treatment</f
ont></p>     ^cY#v33n1a11.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009900076002001300175#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#57#53#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> - 50% Tx + Chel</font></p>     ^cY#
v33n1a11.htm##
00478000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024300076002001300319#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#58#54#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">According to the model, patients who
 are resistant to all treatments all end up receiving chronic transfusions of re
d blood cells, platelets and iron chelation.</font></p>     ^cY#v33n1a11.htm##
00517000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028200076002001300358#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#59#55#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Following this sequence of treatment
, there are 13 possible pathways that a patient can follow on the decision tree 
(numbered 1 to 13 on <a href="/img/revistas/rbhh/v33n1/a11fig01.jpg">Figure 1</a
>).</font></p>     ^cY#v33n1a11.htm##
00598000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036300076002001300439#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#60#56#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We adopted an assumption that all pa
tients stay on treatment for one year and thus did not take into account early d
eaths or abandonment of treatment. We only considered changes in treatment due t
o therapeutic failure. No costs with hospitalizations or side effects were inclu
ded.</font></p>     ^cY#v33n1a11.htm##
00718000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048300076002001300559#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#61#57#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">For the costs, we considered purchas
e costs of medicines for outpatients care. The source of costs was the Brazilian
 official price list<sup>(11)</sup> and for medical procedures we used the offic
ial price list of the Associa&ccedil;&atilde;o M&eacute;dica Brasileira.<sup>(12
)</sup> ATGAM is only available from other countries and so, we considered the i
mported price (<a href="#tab1">Table 1</a>).</font></p>     ^cY#v33n1a11.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#62#58#article#129#<p><a name="tab1"><
/a></p>     ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#63#59#article#129#<p>&nbsp;</p>     ^
cY#v33n1a11.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#64#60#article#129#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a11tab01.jpg"></p>     ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#65#61#article#129#<p>&nbsp;</p>     ^
cY#v33n1a11.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#66#62#article#129#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>     ^cY#v3
3n1a11.htm##
00611000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037600076002001300452#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#67#63#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The costs of treatment for the whole
 cohort were US$ 4,275,800 /year or US$ 42,758 /patient/year. This cost varies g
reatly between the 13 different treatment pathways that are possible in our mode
l (<a href="/img/revistas/rbhh/v33n1/a11fig01.jpg">Figure 1</a> and <a href="#ta
b2">Table 2</a>).</font></p>     ^cY#v33n1a11.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#68#64#article#129#<p><a name="tab2"><
/a></p>     ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#69#65#article#129#<p>&nbsp;</p>     ^
cY#v33n1a11.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#70#66#article#129#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a11tab02.jpg"></p>     ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#71#67#article#129#<p>&nbsp;</p>     ^
cY#v33n1a11.htm##
00567000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033200076002001300408#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#72#68#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Pathway 1 (patients that started tre
atment with EPO and are responsive) has the lowest cost/patient/year (US$ 24,282
), and pathway 13 (patients with thrombocytopenia, that do not respond to chemot
herapy or to IT) is the most expensive (US$ 121,952).</font></p>     ^cY#v33n1a1
1.htm##
00519000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028400076002001300360#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#73#69#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Patients that started treatment with
 EPO (US$ 37,244) or IT (US$ 38,461) have a lower final mean cost when compared 
to those that initially received chemotherapy (US$ 60,288) or EPO + CSF (US$ 43,
876).</font></p>     ^cY#v33n1a11.htm##
00569000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033400076002001300410#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#74#70#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The response to initial treatment is
 usually a factor associated to a lower cost: Pathways 1, 5 and 11 (the first pa
thway of each treatment arm) are the cheapest. The exception is the pathway of i
mmunotherapy (pathway 8) due to the high cost of ATGAM.</font></p>     ^cY#v33n1
a11.htm##
00494000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025900076002001300335#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#75#71#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Among the therapeutic needs, transfu
sions and the use of iron chelators were alone responsible for more than half of
 the total costs: US$ 2,450,000 or 57.5% of the total costs.</font></p>     ^cY#
v33n1a11.htm##
00685000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045000076002001300526#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#76#72#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">If we accept that the incidence of M
DS in Brazil is similar to that of the USA,<sup>(1)</sup> we can expect around 1
500 MDS cases in the private healthcare system. From these, 70% (1050) will be f
rom the low and Int I risk categories. And thus, according to the estimate of th
is model, we can expect around US$ 45,000,000 to be spent in MDS supportive care
 each year.</font></p>     ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#77#73#article#129#<p>&nbsp;</p>     ^
cY#v33n1a11.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#78#74#article#129#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p>     ^cY
#v33n1a11.htm##
00656000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042100076002001300497#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#79#75#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">These results show that the costs li
nked to the supportive care of MDS in the private healthcare system in Brazil ar
e high, but lower than in other countries. If we compare the mean cost (US$ 42,7
58) of a patient from our model to the lowest cost described for USA (US$ 63,000
), in Brazil a patient costs around 35% less.<sup>(8,10)</sup></font></p>     ^c
Y#v33n1a11.htm##
01033000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079800076002001300874#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#80#76#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In this analysis, patients were cate
gorized according to the initial symptoms and followed for one year. As we did n
ot take into account losses to treatment including deaths, our results may be an
 overestimate, as some patients die or stop treatment in the course of this peri
od. Also, the costs may have been overestimated due to the intensive use of tran
sfusions and chelators in the model, as recommended by the NCCN guidelines; this
 intensive use may not reflect the reality in Brazil.<sup>(13)</sup> On the othe
r hand, we did not take into account hospitalizations, progression to leukemia a
nd indirect costs that increase the price, and hence, in these cases, our number
s are an underestimation.<sup>(3)</sup></font></p>     ^cY#v33n1a11.htm##
00529000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029400076002001300370#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#81#77#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The two major sources of costs are E
PO support and the need of iron chelators. These two medications are used due to
 the profound anemia that MDS patients develop during the course of the disease.
<sup>(14)</sup></font></p>     ^cY#v33n1a11.htm##
00865000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063000076002001300706#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#82#78#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Recently, new drugs have been develo
ped specifically for MDS and have reached the market. The most important effect 
of decitabine and azacitidine is an improvement in red blood cell indexes with a
 consequent reduction in the needs for transfusions and chelators.<sup>(13,15)</
sup> Therefore, there is a possibility that these new medications may have a str
ong influence on the cost of treatment. In the future another pharmacoeconomic a
nalysis should be performed to take the effectiveness and the costs of decitabin
e and azacitidine into account.</font></p>     ^cY#v33n1a11.htm##
00653000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041800076002001300494#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#83#79#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The estimate of the total costs asso
ciated to the supportive treatment of MDS in the private healthcare system in Br
azil is very high   US$ 45 million for patients with low and Int I risk. This ca
lls attention to this disease that, although rare, has an important clinical and
 financial impact on the system as well as on the patients.</font></p>     ^cY#v
33n1a11.htm##
00688000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045300076002001300529#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#84#80#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In face of these data, it is importa
nt that some measures are taken to guarantee early access of patients to treatme
nt, as patients that are responsive to therapy have a better prognosis and a low
er cost than those that do not respond. For instance, patients that are responsi
ve to EPO (Pathway 1) have a lower cost than those that did not respond (Pathway
s 2, 3 and 4).</font></p>     ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#85#81#article#129#<p>&nbsp;</p>     ^
cY#v33n1a11.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#86#82#article#129#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Conclusion</b></font></p>     ^cY
#v33n1a11.htm##
00491000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025600076002001300332#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#87#83#article#129#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The mean cost for the treatment of M
DS in the Brazilian private healthcare system is US$ 42,758 /patient/year. This 
value varies greatly depending on the interventions used.</font></p>     ^cY#v33
n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#88#84#article#129#<p>&nbsp;</p>     ^
cY#v33n1a11.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#89#85#article#129#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY
#v33n1a11.htm##
00429000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018000078002001300258#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#90#86#article#129#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Sekeres MA. The epi
demiology of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2):
287-94.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#91#87#article#129#</font></p>     ^cY
#v33n1a11.htm##
00430000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018100078002001300259#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#92#88#article#129#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Steensma DP. Novel 
therapies for myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2)
:423-41.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#93#89#article#129#</font></p>     ^cY
#v33n1a11.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027900078002001300357#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#94#90#article#129#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Greenberg PL, Cosle
r LE, Ferro SA, Lyman GH. The costs of drugs used to treat myelodysplastic syndr
omes following National Comprehensive Cancer Network Guidelines. J Natl Compr Ca
nc Netw. 2008;6(9):942-53.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#95#91#article#129#</font></p>     ^cY
#v33n1a11.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022100078002001300299#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#96#92#article#129#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Cazzola M, Malcovat
i L. Prognostic classification and risk assessment in myelodysplastic syndromes.
 Hematol Oncol Clin North Am. 2010;24(2):459-68.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#97#93#article#129#</font></p>     ^cY
#v33n1a11.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028400078002001300362#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#98#94#article#129#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Greenberg P. Clinic
al Practice Guidelines in Oncology: Myelodysplatic Syndromes. National Comprehen
sive Cancer Network. 2009. Available at: <a href="http://www.nccn.org" target="_
blank">http://www.nccn.org</a>.    ^cY#v33n1a11.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#99#95#article#129#</font></p>     ^cY
#v33n1a11.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704022100079002001300300#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#100#96#article#129#6#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Komrokji RS, Zhang
 L, Bennett JM. Myelodysplastic syndromes classification and risk stratification
. Hematol Oncol Clin North Am. 2010;24(2):443-57.    ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#101#97#article#129#</font></p>     ^c
Y#v33n1a11.htm##
00608000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704035800079002001300437#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#102#98#article#129#7#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Casadevall N, Duri
eux P, Dubois S, Hemery F, Lepage E, Quarre MC, et al. Health, economic, and qua
lity-of-life effects of erythropoietin and granulocyte colony-stimulating factor
 for the treatment of myelodysplastic syndromes: a randomized, controlled trial.
 Blood. 2004;104(2):321-7.    ^cY#v33n1a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#103#99#article#129#</font></p>     ^c
Y#v33n1a11.htm##
00536000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704028500080002001300365#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#104#100#article#129#8#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Gupta P, LeRoy SC
, Luikart SD, Bateman A, Morrison VA. Long-term blood product transfusion suppor
t for patients with myelodysplastic syndromes (MDS): cost analysis and complicat
ions. Leuk Res. 1999;23(10):953-9.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#105#101#article#129#</font></p>     ^
cY#v33n1a11.htm##
00559000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704030800080002001300388#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#106#102#article#129#9#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Goss TF, Szende A
, Schaefer C, Totten PJ, Knight R, Jadersten M, et al. Cost effectiveness of len
alidomide in the treatment of transfusion-dependent myelodysplastic syndromes in
 the United States. Cancer Control. 2006;13(Suppl):17-25.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#107#103#article#129#</font></p>     ^
cY#v33n1a11.htm##
00538000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028600081002001300367#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#108#104#article#129#10#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Gattermann N, H
ofmann WK, Meessen A, Schmitz S, Tsamaloukas A, Vollmer T, et al. Myelodysplasti
c syndromes: aspects of current medical care and economic considerations in Germ
any. Onkologie. 2008;31(8-9):477-84.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#109#105#article#129#</font></p>     ^
cY#v33n1a11.htm##
00402000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015000081002001300231#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#110#106#article#129#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Revista Simpro:
 Simpro Publica&ccedil;&otilde;es e teleprocessamento; 2009.    ^cY#v33n1a11.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#111#107#article#129#</font></p>     ^
cY#v33n1a11.htm##
00597000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034500081002001300426#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#112#108#article#129#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Classifica&cced
il;&atilde;o Brasileira Hierarquizada de Procedimentos M&eacute;dicos &#91;datab
ase on the Internet&#93;. AMB. 2008 &#91;cited 12-jul-2010&#93;. Available from:
 <a href="http://www.amb.org.br/cbhpm.php" target="_blank">http://www.amb.org.br
/cbhpm.php</a>.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#113#109#article#129#</font></p>     ^
cY#v33n1a11.htm##
00417000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016500081002001300246#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#114#110#article#129#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Muller A, Flore
k M. 5-Azacytidine/Azacitidine. Recent results Cancer Res. 2010;184:159-70.    ^
cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#115#111#article#129#</font></p>     ^
cY#v33n1a11.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018900081002001300270#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#116#112#article#129#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. List AF. Iron o
verload in myelodysplastic syndromes: diagnosis and management. Cancer Control. 
2010;17(Suppl):2-8.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#117#113#article#129#</font></p>     ^
cY#v33n1a11.htm##
00427000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017500081002001300256#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#118#114#article#129#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Daskalakis M, B
lagitko-Dorfs N, Hackanson B. Decitabine. Recent Results Cancer Res. 2010;184:13
1-57.    ^cY#v33n1a11.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#119#115#article#129#</font></p>     ^
cY#v33n1a11.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#120#116#article#129#<p>&nbsp;</p>    
 ^cY#v33n1a11.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#121#117#article#129#<p>&nbsp;</p>    
 ^cY#v33n1a11.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018600078002001300264#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#122#118#article#129#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b
>    ^cY#v33n1a11.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#123#119#article#129#<br>   Ot&aacute;
vio Clark    ^cY#v33n1a11.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004300078002001300121#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#124#120#article#129#<br>   Rua Tranqu
illo Prosperi, 143    ^cY#v33n1a11.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004700078002001300125#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#125#121#article#129#<br>   13084-778 
 Campinas (SP), Brazil    ^cY#v33n1a11.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003900078002001300117#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#126#122#article#129#<br> Phone:  55 1
9 3287 8310       ^cY#v33n1a11.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009300078002001300171#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#127#123#article#129#<br> <a href="mai
lto:clark@evidencias.com.br">clark@evidencias.com.br</a></font></p>     ^cY#v33n
1a11.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#128#124#article#129#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted: 9/20/2010    ^cY#v33n1a
11.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#129#125#article#129#<br>   Accepted: 
 11/23/2010    ^cY#v33n1a11.htm##
00409000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704017200078002001300250#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#130#126#article#129#<br>   Conflicts 
of interest: Both authors, Ot&aacute;vio Clark and En&eacute;as Faleiros, work f
or Evid&ecirc;ncias Consultoria , Campinas (SP), Brazil</font></p>     ^cY#v33n1
a11.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#131#127#article#129#<p>&nbsp;</p>    
 ^cY#v33n1a11.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#132#128#article#129#<p>&nbsp;</p>    
 ^cY#v33n1a11.htm##
00460000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022300078002001300301#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a11.htm#S#p#133#129#article#129#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" targ
et="_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_bla
nk">www.scielo.br/rbhh</a></font></p>     ^cY#v33n1a11.htm##
00537000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120050000950300
02800145065000900173064000500182031000300187032000200190014000700192865000900199
002001300208035001000221801002800231#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a11.htm#S#c#134#1#article#15#1#^rND^sSekeres^nMA#The epidemiology of myelodys
plastic syndromes^len#Hematol Oncol Clin North Am#20100000#2010#24#2#287-94#2011
0200#v33n1a11.htm#0889-8588#Hematol Oncol Clin North Am##
00538000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770120050000960300
02800146065000900174064000500183031000300188032000200191014000700193865000900200
002001300209035001000222801002800232#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a11.htm#S#c#135#2#article#15#2#^rND^sSteensma^nDP#Novel therapies for myelody
splastic syndromes^len#Hematol Oncol Clin North Am#20100000#2010#24#2#423-41#201
10200#v33n1a11.htm#0889-8588#Hematol Oncol Clin North Am##
00642000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100017000970100
01600114010001600130012012200146030002300268710000200291065000900293064000500302
031000200307032000200309014000700311865000900318002001300327#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a11.htm#S#c#136#3#article#15#3#^rND^sGreenberg^nPL#^r
ND^sCosler^nLE#^rND^sFerro^nSA#^rND^sLyman^nGH#The costs of drugs used to treat 
myelodysplastic syndromes following National Comprehensive Cancer Network Guidel
ines^len#J Natl Compr Canc Netw#2#20080000#2008#6#9#942-53#20110200#v33n1a11.htm
##
00596000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940120
07900113030002800192065000900220064000500229031000300234032000200237014000700239
865000900246002001300255035001000268801002800278#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a11.htm#S#c#137#4#article#15#4#^rND^sCazzola^nM#^rND^sMalcovati^n
L#Prognostic classification and risk assessment in myelodysplastic syndromes^len
#Hematol Oncol Clin North Am#20100000#2010#24#2#459-68#20110200#v33n1a11.htm#088
9-8588#Hematol Oncol Clin North Am##
00491000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160019000770180071000960620
03800167065000900205064000500214037002000219865000900239002001300248#v33n1#V:\Sc
iELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#c#138#5#article#15#5#^rND^sGreenber
g^nP#Clinical Practice Guidelines in Oncology: Myelodysplatic Syndromes^len#Nati
onal Comprehensive Cancer Network#20090000#2009#http://www.nccn.org#20110200#v33
n1a11.htm##
00614000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100015000960100
01800111012006900129030002800198065000900226064000500235031000300240032000200243
014000700245865000900252002001300261035001000274801002800284#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a11.htm#S#c#139#6#article#15#6#^rND^sKomrokji^nRS#^rN
D^sZhang^nL#^rND^sBennett^nJM#Myelodysplastic syndromes classification and risk 
stratification^len#Hematol Oncol Clin North Am#20100000#2010#24#2#443-57#2011020
0#v33n1a11.htm#0889-8588#Hematol Oncol Clin North Am##
00794000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100017000970100
01600114010001600130010001600146010001700162810000600179012018900185030000600374
06500090038006400050038903100040039403200020039801400060040086500090040600200130
0415035001000428801000600438#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.h
tm#S#c#140#7#article#15#7#^rND^sCasadevall^nN#^rND^sDurieux^nP#^rND^sDubois^nS#^
rND^sHemery^nF#^rND^sLepage^nE#^rND^sQuarre^nMC#et al#Health, economic, and qual
ity-of-life effects of erythropoietin and granulocyte colony-stimulating factor 
for the treatment of myelodysplastic syndromes: a randomized, controlled trial^l
en#Blood#20040000#2004#104#2#321-7#20110200#v33n1a11.htm#0006-4971#Blood##
00695000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920100
01800108010001700126010001900143012013100162030000900293065000900302064000500311
03100030031603200030031901400060032286500090032800200130033703500100035080100090
0360#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#c#141#8#article#15#
8#^rND^sGupta^nP#^rND^sLeRoy^nSC#^rND^sLuikart^nSD#^rND^sBateman^nA#^rND^sMorris
on^nVA#Long-term blood product transfusion support for patients with myelodyspla
stic syndromes (MDS): cost analysis and complications^len#Leuk Res#19990000#1999
#23#10#953-9#20110200#v33n1a11.htm#0145-2126#Leuk Res##
00755000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920100
01800108010001700126010001600143010001900159810000600178012012800184030001500312
06500090032706400050033603100030034103200080034401400060035286500090035800200130
0367035001000380801001500390#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.h
tm#S#c#142#9#article#15#9#^rND^sGoss^nTF#^rND^sSzende^nA#^rND^sSchaefer^nC#^rND^
sTotten^nPJ#^rND^sKnight^nR#^rND^sJadersten^nM#et al#Cost effectiveness of lenal
idomide in the treatment of transfusion-dependent myelodysplastic syndromes in t
he United States^len#Cancer Control#20060000#2006#13#^sSuppl#17-25#20110200#v33n
1a11.htm#1073-2748#CANCER CONTROL##
00727000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
01700117010001700134010002100151010001700172810000600189012010200195030001000297
06500090030706400050031603100030032103200040032401400070032886500090033500200130
0344035001000357801001000367#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.h
tm#S#c#143#10#article#15#10#^rND^sGattermann^nN#^rND^sHofmann^nWK#^rND^sMeessen^
nA#^rND^sSchmitz^nS#^rND^sTsamaloukas^nA#^rND^sVollmer^nT#et al#Myelodysplastic 
syndromes: aspects of current medical care and economic considerations in German
y^len#Onkologie#20080000#2008#31#8-9#477-84#20110200#v33n1a11.htm#0378-584X#Onko
logie##
00389000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760300015000797100002000940620
03900096065000900135064000500144865000900149002001300158#v33n1#V:\SciELO\serial\
rbhh\v33n1\markup\v33n1a11.htm#S#c#144#11#article#15#11#Revista Simpro#2#Simpro 
Publicações e teleprocessamento#20090000#2009#20110200#v33n1a11.htm##
00519000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760180068000790610025001470620
00400172065000900176064000500185110000900190109001200199037003200211865000900243
002001300252#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a11.htm#S#c#145#12#ar
ticle#15#12#Classificação Brasileira Hierarquizada de Procedimentos Médicos^lpt#
database on the Internet#AMB#20080000#2008#20100712#12-jul-2010#http://www.amb.o
rg.br/cbhpm.php#20110200#v33n1a11.htm##
00528000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950120
03000111030002600141065000900167064000500176031000400181014000700185865000900192
002001300201035001000214801002600224#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a11.htm#S#c#146#13#article#15#13#^rND^sMuller^nA#^rND^sFlorek^nM#5-Azacytidin
e/Azacitidine^len#Recent results Cancer Res#20100000#2010#184#159-70#20110200#v3
3n1a11.htm#0080-0015#Recent results cancer res##
00536000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790120073000940300
01500167065000900182064000500191031000300196032000800199014000400207865000900211
002001300220035001000233801001500243#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a11.htm#S#c#147#14#article#15#14#^rND^sList^nAF#Iron overload in myelodysplas
tic syndromes: diagnosis and management^len#Cancer Control#20100000#2010#17#^sSu
ppl#2-8#20110200#v33n1a11.htm#1073-2748#CANCER CONTROL##
00556000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100024000990100
01900123012001500142030002600157065000900183064000500192031000400197014000700201
865000900208002001300217035001000230801002600240#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a11.htm#S#c#148#15#article#15#15#^rND^sDaskalakis^nM#^rND^sBlagit
ko-Dorfs^nN#^rND^sHackanson^nB#Decitabine^len#Recent Results Cancer Res#20100000
#2010#184#131-57#20110200#v33n1a11.htm#0080-0015#Recent results cancer res##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#o#1#1#article#1
#20110411#115533#v33n1a12.htm#129##
02776000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030002900109
03100030013803200020014106500090014301400090015203500100016123700270017101200970
01980100045002950100049003400100031003890100026004200100026004460100037004720700
05300509070007700562083128600639085001001925085003001935085002701965085004801992
08500220204008500260206208500260208811700060211407200030212011200090212311100090
2132114000902141113001102150002001302161#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a12.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#12#RBHH340#nd#Rev. Bras.
 Hematol. Hemoter.#33#1#20110200#^f35^l37#1516-8484#10.5581/1516-8484.20110012#F
requency of paroxysmal nocturnal hemoglobinuria in patients attended in Belém, P
ará, Brazil^len#^rND^1A01 A02^nLacy Cardoso de^sBrito Junior#^rND^1A01^nMaria do
 Socorro de Oliveira^sCardoso#^rND^1A01^nEuzamar Gaby^sRocha#^rND^1A01^nHerika^s
Anijar#^rND^1A01^nMariana^sCunha#^rND^1A02^nJoão Carlos Pina^sSaraiva#Universida
de Federal do Pará^iA01^cBelém^sPA^pBrazil#Fundação Centro de Hematologia e Hemo
terapia do Pará^iA02^cBelém^sPA^pBrazil#^len^aBACKGROUND: Paroxysmal nocturnal h
emoglobinuria is a hematological disease with complex physiopathology. It is gen
etically characterized by a somatic mutation in the PIG-A gene (phosphatidylinos
itol glycan anchor biosynthesis, class A), in which the best known antigens are 
DAF (decay accelerating factor or CD55) and MIRL (membrane inhibitor of reactive
 lysis or CD59). OBJECTIVE: To determine the frequency of paroxysmal nocturnal h
emoglobinuria in patients attended at the HEMOPA foundation from November 2008 t
o July 2009. METHOD: Thirty patients, with ages ranging from two to 79 years old
 and suspected of having paroxysmal nocturnal hemoglobinuria were examined. All 
patients were immunophenotyped by flow cytometry for the CD5, CD59, CD16 and CD4
5 antigens. RESULTS: Paroxysmal nocturnal hemoglobinuria was identified in nine 
of the thirty patients investigated. Another 3 cases had inconclusive results wi
th CD59-negative labeling only for neutrophils. The highest frequency of paroxys
mal nocturnal hemoglobinuria patients (7/9) and inconclusive cases (2/3) were be
tween 19 years old and 48 years old, with a median of 28 years. CONCLUSION: Thes
e results show the importance of flow cytometry to identify cases in which patie
nts are deficient in only one antigen (CD59).#^ddecs^i1#^tm^len^kImmunophenotypi
ng^i1#^tm^len^kFlow cytometry^i1#^tm^len^kParoxysmal nocturnal hemoglobinuria^i1
#^tm^len^kDiagnosis^i1#^tm^len^kAntigen, CD55^i1#^tm^len^kAntigen, CD59^i1#other
#17#20100502#5/2/2010#20101121#11/21/2010#v33n1a12.htm##
02818000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030002900109
03100030013803200020014106500090014301400090015203500100016123700270017101201040
01980100045003020100049003470100031003960100026004270100026004530100037004790700
05300516070007700569083132100646085001001967085003001977085002702007085004802034
08500220208208500260210408500260213011700060215607200030216211200090216511100090
2174114000902183113001102192002001302203#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a12.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#12#RBHH340#nd#Rev. Bras.
 Hematol. Hemoter.#33#1#20110200#^f35^l37#1516-8484#10.5581/1516-8484.20110012#<
b>Frequency of paroxysmal nocturnal hemoglobinuria in patients attended in Belém
, Pará, Brazil</b>^len#^rND^1A01 A02^nLacy Cardoso de^sBrito Junior#^rND^1A01^nM
aria do Socorro de Oliveira^sCardoso#^rND^1A01^nEuzamar Gaby^sRocha#^rND^1A01^nH
erika^sAnijar#^rND^1A01^nMariana^sCunha#^rND^1A02^nJoão Carlos Pina^sSaraiva#Uni
versidade Federal do Pará^iA01^cBelém^sPA^pBrazil#Fundação Centro de Hematologia
 e Hemoterapia do Pará^iA02^cBelém^sPA^pBrazil#^len^a<b>BACKGROUND:</b> Paroxysm
al nocturnal hemoglobinuria is a hematological disease with complex physiopathol
ogy. It is genetically characterized by a somatic mutation in the PIG-A gene (ph
osphatidylinositol glycan anchor biosynthesis, class A), in which the best known
 antigens are DAF (decay accelerating factor or CD55) and MIRL (membrane inhibit
or of reactive lysis or CD59). <b>OBJECTIVE:</b> To determine the frequency of p
aroxysmal nocturnal hemoglobinuria in patients attended at the HEMOPA foundation
 from November 2008 to July 2009. <b>METHOD:</b> Thirty patients, with ages rang
ing from two to 79 years old and suspected of having paroxysmal nocturnal hemogl
obinuria were examined. All patients were immunophenotyped by flow cytometry for
 the CD5, CD59, CD16 and CD45 antigens. <b>RESULTS:</b> Paroxysmal nocturnal hem
oglobinuria was identified in nine of the thirty patients investigated. Another 
3 cases had inconclusive results with CD59-negative labeling only for neutrophil
s. The highest frequency of paroxysmal nocturnal hemoglobinuria patients (7/9) a
nd inconclusive cases (2/3) were between 19 years old and 48 years old, with a m
edian of 28 years. <b>CONCLUSION:</b> These results show the importance of flow 
cytometry to identify cases in which patients are deficient in only one antigen 
(CD59).#^ddecs^i1#^tm^len^kImmunophenotyping^i1#^tm^len^kFlow cytometry^i1#^tm^l
en^kParoxysmal nocturnal hemoglobinuria^i1#^tm^len^kDiagnosis^i1#^tm^len^kAntige
n, CD55^i1#^tm^len^kAntigen, CD59^i1#other#17#20100502#5/2/2010#20101121#11/21/2
010#v33n1a12.htm##
02905000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103121000300108049000800111158000300119
03000280012203100030015003200020015306500090015501400090016403500100017323700270
01830120097002100100045003070100049003520100031004010100026004320100026004580100
03700484070005500521070007900576083128600655085001001941085003001951085002701981
08500480200808500220205608500260207808500260210411700060213007200030213611200090
2139111000902148114000902157113001102166002001302177008008902190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#l#4#1#article#1#^mFeb.^a2011#oa#en#br1.
1#1#4.0#ilus#12#RBHH340#nd#Rev. bras. hematol. hemoter#33#1#20110200#^f35^l37#15
16-8484#10.5581/1516-8484.20110012#Frequency of paroxysmal nocturnal hemoglobinu
ria in patients attended in Belém, Pará, Brazil^len#^rND^1A01 A02^nLacy Cardoso 
de^sBrito Junior#^rND^1A01^nMaria do Socorro de Oliveira^sCardoso#^rND^1A01^nEuz
amar Gaby^sRocha#^rND^1A01^nHerika^sAnijar#^rND^1A01^nMariana^sCunha#^rND^1A02^n
João Carlos Pina^sSaraiva#^iA01^1Universidade Federal do Pará^cBelém^sPA^pBrazil
#^iA02^1Fundação Centro de Hematologia e Hemoterapia do Pará^cBelém^sPA^pBrazil#
^len^aBACKGROUND: Paroxysmal nocturnal hemoglobinuria is a hematological disease
 with complex physiopathology. It is genetically characterized by a somatic muta
tion in the PIG-A gene (phosphatidylinositol glycan anchor biosynthesis, class A
), in which the best known antigens are DAF (decay accelerating factor or CD55) 
and MIRL (membrane inhibitor of reactive lysis or CD59). OBJECTIVE: To determine
 the frequency of paroxysmal nocturnal hemoglobinuria in patients attended at th
e HEMOPA foundation from November 2008 to July 2009. METHOD: Thirty patients, wi
th ages ranging from two to 79 years old and suspected of having paroxysmal noct
urnal hemoglobinuria were examined. All patients were immunophenotyped by flow c
ytometry for the CD5, CD59, CD16 and CD45 antigens. RESULTS: Paroxysmal nocturna
l hemoglobinuria was identified in nine of the thirty patients investigated. Ano
ther 3 cases had inconclusive results with CD59-negative labeling only for neutr
ophils. The highest frequency of paroxysmal nocturnal hemoglobinuria patients (7
/9) and inconclusive cases (2/3) were between 19 years old and 48 years old, wit
h a median of 28 years. CONCLUSION: These results show the importance of flow cy
tometry to identify cases in which patients are deficient in only one antigen (C
D59).#^ddecs^i1#^tm^len^kImmunophenotyping^i1#^tm^len^kFlow cytometry^i1#^tm^len
^kParoxysmal nocturnal hemoglobinuria^i1#^tm^len^kDiagnosis^i1#^tm^len^kAntigen,
 CD55^i1#^tm^len^kAntigen, CD59^i1#other#17#20100502#5/2/2010#20101121#11/21/201
0#v33n1a12.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=
S1516-84842011000100012##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#5#1#article#108#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLE</b><
/font></p>     ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#6#2#article#108#<p>&nbsp;</p>     ^cY
#v33n1a12.htm##
00447000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704021400074002001300288#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#7#3#article#108#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Frequency of paro
xysmal nocturnal hemoglobinuria in patients attended in Bel&eacute;m, Par&aacute
;, Brazil</b></font></p>     ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#8#4#article#108#<p>&nbsp;</p>     ^cY
#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#9#5#article#108#<p>&nbsp;</p>     ^cY
#v33n1a12.htm##
00549000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704031500075002001300390#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#10#6#article#108#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Lacy Cardoso de Brito Junior<sup>I
,II</sup>; Maria do Socorro de Oliveira Cardoso<sup>I</sup>; Euzamar Gaby Rocha<
sup>I</sup>; Herika Anijar<sup>I</sup>; Mariana Cunha<sup>I</sup>; Jo&atilde;o C
arlos Pina Saraiva<sup>II</sup></b></font></p>     ^cY#v33n1a12.htm##
00386000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015200075002001300227#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#11#7#article#108#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Universidade Federal do P
ar&aacute; - UFPA, Bel&eacute;m (PA), Brazil    ^cY#v33n1a12.htm##
00383000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704014900075002001300224#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#12#8#article#108#<br>   <sup>II</sup>
Funda&ccedil;&atilde;o Centro de Hematologia e Hemoterapia do Par&aacute; - HEMO
PA, Bel&eacute;m (PA), Brazil</font></p>     ^cY#v33n1a12.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#13#9#article#108#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></fon
t></p>     ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#14#10#article#108#<p>&nbsp;</p>     ^
cY#v33n1a12.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#15#11#article#108#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v33n1a12.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#16#12#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
33n1a12.htm##
00683000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044800076002001300524#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#17#13#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>BACKGROUND:</b> Paroxysmal noctur
nal hemoglobinuria is a hematological disease with complex physiopathology. It i
s genetically characterized by a somatic mutation in the PIG-A gene (phosphatidy
linositol glycan anchor biosynthesis, class A), in which the best known antigens
 are DAF (decay accelerating factor or CD55) and MIRL (membrane inhibitor of rea
ctive lysis or CD59).    ^cY#v33n1a12.htm##
00414000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017900076002001300255#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#18#14#article#108#<br>     <b>OBJECTI
VE:</b> To determine the frequency of paroxysmal nocturnal hemoglobinuria in pat
ients attended at the HEMOPA foundation from November 2008 to July 2009.    ^cY#
v33n1a12.htm##
00497000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026200076002001300338#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#19#15#article#108#<br>     <b>METHOD:
</b> Thirty patients, with ages ranging from two to 79 years old and suspected o
f having paroxysmal nocturnal hemoglobinuria were examined. All patients were im
munophenotyped by flow cytometry for the CD5, CD59, CD16 and CD45 antigens.    ^
cY#v33n1a12.htm##
00628000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039300076002001300469#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#20#16#article#108#<br>   <b>RESULTS:<
/b> Paroxysmal nocturnal hemoglobinuria was identified in nine of the thirty pat
ients investigated. Another 3 cases had inconclusive results with CD59-negative 
labeling only for neutrophils. The highest frequency of paroxysmal nocturnal hem
oglobinuria patients (7/9) and inconclusive cases (2/3) were between 19 years ol
d and 48 years old, with a median of 28 years.    ^cY#v33n1a12.htm##
00412000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017700076002001300253#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#21#17#article#108#<br>     <b>CONCLUS
ION:</b> These results show the importance of flow cytometry to identify cases i
n which patients are deficient in only one antigen (CD59).</font></p>     ^cY#v3
3n1a12.htm##
00468000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023300076002001300309#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#22#18#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Immunophenotyping; 
Flow cytometry; Paroxysmal nocturnal hemoglobinuria; Diagnosis; Antigen, CD55; A
ntigen, CD59</font></p> <hr size="1" noshade>     ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#23#19#article#108#<p>&nbsp;</p>     ^
cY#v33n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#24#20#article#108#<p>&nbsp;</p>     ^
cY#v33n1a12.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#25#21#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></p>     ^
cY#v33n1a12.htm##
00668000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043300076002001300509#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#26#22#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Paroxysmal nocturnal hemoglobinuria 
(PNH), first described in 1882, is a hematological disorder of complex physiopat
hology which leads to multiple clinical disorders and complications. Its exact i
ncidence is unknown but it equally affects both genders and occurs at any age, b
ut mainly in young adults with a mean age of 35 years old.<sup>(1,2)</sup></font
></p>     ^cY#v33n1a12.htm##
00966000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073100076002001300807#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#27#23#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">PNH is a clonal, acquired and rare d
isease, which is characterized genetically by a somatic mutation in the PIG-A ge
ne (phosphatidylinositol glycan anchor biosynthesis, class A), located on the sh
ort arm of chromosome X (Xp22.1). The molecular alterations of this gene are het
erogeneous with more than 180 mutations having been described in patients with P
NH; the majority of these result from small insertions or deletions of one or tw
o nucleotides, which cause alterations and block gene transcription and where th
e production of the gene product is null. Point mutations can also occur produci
ng a partially functional molecule.<sup>(3- 6)</sup></font></p>     ^cY#v33n1a12
.htm##
01174000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093900076002001301015#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#28#24#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This defect results in a deficiency 
in the biosynthesis of glycosylphosphatidylinositol (GPI) which is responsible f
or the anchorage and fixation of the regulatory antigens of the complement syste
m (CS), CD55 antigen or decay accelerating factor (DAF) and CD59 antigen or memb
rane inhibitor of reactive lysis (MIRL), on the outer surface of erythrocyte, le
ukocyte and platelet membranes. This makes these cells vulnerable to lysis media
ted by complement which results in hemolytic anemia, a certain degree of bone ma
rrow insufficiency and the release of large amounts of free hemoglobin into the 
plasma, which can lead to an increase in the consumption of nitric oxide and cli
nical manifestations that include fatigue, abdominal pain, esophageal spasms, er
ectile dysfunction and various degrees of thrombosis (classic or subclinical PNH
).<sup>(1,7,8)</sup></font></p>     ^cY#v33n1a12.htm##
00530000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029500076002001300371#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#29#25#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In some special situations, PNH can 
be associated with other specific disorders of the bone marrow such as aplastic 
anemia, myelodysplastic syndrome or other myelopathies including myelofibrosis.<
sup>(9-12)</sup></font></p>     ^cY#v33n1a12.htm##
00633000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039800076002001300474#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#30#26#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Estimated survival for untreated pat
ients with classic or subclinical PNH is approximately 8 years with the main cau
ses of death being thrombotic complications and progressive pancytopenia. Rarely
, spontaneous remission occurs (10% to 15% of cases) or transformation to acute 
myeloid leukemia.<sup>(3,9,13,14)</sup></font></p>     ^cY#v33n1a12.htm##
00999000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076400076002001300840#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#31#27#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The diagnosis of PNH is based on cli
nical findings and laboratory tests that detect GPI-binding to red cell membrane
 proteins or that demonstrate the presence of red blood cells that are exception
ally sensitive to hemolysis by the complement system. These tests include the ac
idified serum test (Ham's test), determination of the CD55 and CD59 antigens usi
ng gel column technology or immunophenotyping by flow cytometry. The last test i
s the most sensitive, specific and precise in the diagnosis of PNH, because it i
dentifies this defect in red blood cells, granulocytes and platelets and shows t
he stage of the disease based on the quantification of PNH cells.<sup>(5,11,12)<
/sup></font></p>     ^cY#v33n1a12.htm##
00692000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045700076002001300533#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#32#28#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Anti-CD55 and anti-CD59, the most co
mmonly tested monoclonal antibodies in the diagnosis of PNH by immunophenotyping
 using flow cytometry, are sufficient for a definitive diagnosis. However, a def
iciency of GPI can also be detected by testing these monoclonal antibodies along
 with anti-CD58, anti-CD14, anti-CD24, anti-CD48, and anti-CD16, among others.<s
up>(7,10,15)</sup></font></p>     ^cY#v33n1a12.htm##
00502000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026700076002001300343#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#33#29#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Thus, the objective of this study wa
s to implement a diagnostic service for PNH using flow cytometry and to define t
he frequency of this disease among patients suspected of having PNH.</font></p> 
    ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#34#30#article#108#<p>&nbsp;</p>     ^
cY#v33n1a12.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#35#31#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Methods</b></font></p>     ^cY#v3
3n1a12.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009100076002001300167#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#36#32#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Patients</font></p>     ^cY#v33n1a12
.htm##
00692000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045700076002001300533#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#37#33#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In the period from November 2008 to 
July 2009, a study was carried out of 30 patients with ages between 2 and 79 yea
rs, suspected of having PNH. These patients were attended at the HEMOPA Foundati
on and referred by the attending physician to the flow cytometry laboratory of t
he HEMOPA Foundation for immunophenotying by flow cytometry of anti-CD55 and ant
i-CD59 antibodies.</font></p>     ^cY#v33n1a12.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#38#34#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Biological samples</font></p>     ^c
Y#v33n1a12.htm##
00519000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028400076002001300360#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#39#35#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In this descriptive, cross-sectional
 study, peripheral blood samples from the patients were collected in hemolysis t
ubes with 0.5 mL EDTA. The patients underwent further diagnostic evaluations for
 PNH.</font></p>     ^cY#v33n1a12.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#40#36#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Immunophenotyping</font></p>     ^cY
#v33n1a12.htm##
01652000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704141700076002001301493#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#41#37#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Each Falcon tube was first labeled f
or either red blood cells or neutrophils of suspected (patient) and control (nor
mal) blood samples. In the analysis of red blood cells and neutrophils, 50 &#181
;L and 100 &#181;L of peripheral blood was added to tubes, respectively. An addi
tional volume of 95 &#181;L PBS diluted 10 times was added to each tube. Five mi
croliters of the CD55, CD59, CD16 and CD45 antibodies (labeled with FITC, PE and
 Pe-Cy5 fluorochromes) were added to each tube, and the tubes were vortexed and 
incubated for 30 minutes in the dark. For neutrophil analysis, 100 &#181;L of th
e first Lysis Solution (DAKO) were added, and the tubes were vortexed and incuba
ted for ten minutes in the dark. Next, 1 mL of the second Lysis Solution (DAKO) 
was added, and the tubes were vortexed and incubated for twenty minutes in the d
ark. At the end of the incubation period, tubes both for the analysis of red blo
od cells and for neutrophils were centrifuged at 700 rpm for five minutes and th
e supernatants were discarded. Three mL and 1 mL of PBS diluted ten times were a
dded to the tubes for red cell and neutrophils analysis, respectively and the tu
bes were vortexed. Subsequently, 10,000 cells were separated and analyzed for th
ree colors in a FACS Calibur flow cytometer, with Cell Quest Pro (Becton Dickins
on, San Jose, CA).</font></p>     ^cY#v33n1a12.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010300076002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#42#38#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Statistical analysis</font></p>     
^cY#v33n1a12.htm##
00493000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025800076002001300334#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#43#39#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Descriptive and nonparametric method
s were employed to statistically analyze the incidence of PNH in the patients wi
th a p-value <u>&lt;</u> 0.05 being considered significant.</font></p>     ^cY#v
33n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#44#40#article#108#<p>&nbsp;</p>     ^
cY#v33n1a12.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#45#41#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>     ^cY#v3
3n1a12.htm##
00653000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041800076002001300494#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#46#42#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Of the total of 30 patients studied,
 nine had positive diagnoses for PNH and 18 had negative results. In three cases
, it was not possible to arrive at a conclusive diagnosis, as on staining for CD
59 in neutrophils, the patients showed cells that were partially negative, but s
howed normal staining for CD55 and CD59 in red blood cells.</font></p>     ^cY#v
33n1a12.htm##
00677000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044200076002001300518#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#47#43#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The majority of the patients with PN
H (7/9) or with inconclusive diagnosis (2/3) were between 19 years and 48 years 
old with a median age of 28 years. The highest number of positive cases (3/9) oc
curred in the 21 to 30 age range. There was no significant difference for PNH po
sitive cases between genders with four positive cases in males and five in femal
es.</font></p>     ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#48#44#article#108#<p>&nbsp;</p>     ^
cY#v33n1a12.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#49#45#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p>     ^cY
#v33n1a12.htm##
00583000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034800076002001300424#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#50#46#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">One of the main causes of complicati
ons in PNH, is the delay in establishing a correct diagnosis and discarding myel
odysplastic syndromes in view of the many similarities in the clinical signs and
 laboratory results of patients with these diseases.<sup>(9-11)</sup></font></p>
     ^cY#v33n1a12.htm##
00481000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024600076002001300322#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#51#47#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As tests for PNH do not exist yet in
 several state capitals of North Brazil, it is necessary to refer patients with 
PNH to other centers that provide this service.</font></p>     ^cY#v33n1a12.htm#
#
00489000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025400076002001300330#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#52#48#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It became possible to precisely iden
tify PNH patients only recently in Par&aacute;, after the implantation of immuno
phenotyping by flow cytometry at the HEMOPA Foundation.</font></p>     ^cY#v33n1
a12.htm##
00633000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039800076002001300474#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#53#49#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This study shows that despite the sm
all sample size, 1) there was no statistical difference in respect to gender and
 2) the majority of cases showing positivity for PNH were between 19 and 48 year
s old, with a median age of 28 years. These findings are similar to those report
ed in the literature.<sup>(11,12)</sup></font></p>     ^cY#v33n1a12.htm##
00534000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029900076002001300375#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#54#50#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Bessler et al.<sup>(1)</sup> reporte
d that the diagnosis of PNH is more often made in young adults with a median age
 of 35 years, but that PNH also occurs in the elderly and children and affects b
oth genders equally.</font></p>     ^cY#v33n1a12.htm##
01232000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099700076002001301073#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#55#51#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Despite of not having been one of th
e objectives of this work, it is important to comment that some hypotheses could
 explain the occurrence of the three inconclusive cases: the presence of small c
lonal populations of PNH cells masked by normal cells from transfusions within t
he three months prior to the tests;<sup>(5,7,11-13,16,17)</sup> small population
s of granulocytes without glycosylphosphatidylinositol-anchored proteins in pati
ents with aplastic anemia or myelodysplastic syndrome but without evidence of he
molysis or other presentations of PNH, with the exception of altered hematopoiet
ic production, and cross reactions with auto-antibodies for other autoimmune dis
eases such as systemic lupus erythematosus,<sup>(3,9,10,12)</sup> as was observe
d in one of the inconclusive cases presented in this study and only diagnosed co
rrectly as negative for PNH after the suspension of treatment with prednisone.</
font></p>     ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#56#52#article#108#<p>&nbsp;</p>     ^
cY#v33n1a12.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#57#53#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Conclusion</b></font></p>     ^cY
#v33n1a12.htm##
00501000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026600076002001300342#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#58#54#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Thus, our results confirm the import
ance of the use of flow cytometry and its relevance for the identification of PN
H in which the patient is deficient in at least one antigen (CD59).</font></p>  
   ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#59#55#article#108#<p>&nbsp;</p>     ^
cY#v33n1a12.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#60#56#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Acknowledgments</b></font></p>   
  ^cY#v33n1a12.htm##
00533000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029800076002001300374#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#61#57#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We are truly grateful to all at the 
Cellular and Molecular Biology management of the HEMOPA Foundation for their tec
hnical support while carrying out this work, as without it this study would not 
have been possible.</font></p>     ^cY#v33n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#62#58#article#108#<p>&nbsp;</p>     ^
cY#v33n1a12.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#63#59#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY
#v33n1a12.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023100078002001300309#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#64#60#article#108#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Bessler M, Hiken J.
 The pathophysiology of disease in patients with paroxysmal nocturnal hemoglobin
uria. Hematology Am Soc Hematol Educ Program. 2008:104-10.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#65#61#article#108#</font></p>     ^cY
#v33n1a12.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020900078002001300287#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#66#62#article#108#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Hu R, Mukhina GL, P
iantadosi S, Barber JP, Jones RJ, Brodsky RA. PIG-A mutations in normal hematopo
iesis. Blood. 2005;105(10): 3848-54.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#67#63#article#108#</font></p>     ^cY
#v33n1a12.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030000078002001300378#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#68#64#article#108#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Alegretti AP, et al
. O papel das prote&iacute;nas reguladoras do complemento CD55/CD59 em c&eacute;
lulas de sangue perif&eacute;rico de pacientes com l&uacute;pus eritematoso sist
&ecirc;mico. Rev Bras Reumatol. 2009;49:276-87.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#69#65#article#108#</font></p>     ^cY
#v33n1a12.htm##
00468000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021900078002001300297#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#70#66#article#108#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Araten DJ, Luzzatto
 L. The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal h
emoglobinuria (PNH). Blood. 2006;108(2):734-6.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#71#67#article#108#</font></p>     ^cY
#v33n1a12.htm##
00576000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032700078002001300405#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#72#68#article#108#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5.  Borowitz MJ, Craig
 FE, Digiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, et al. Guidelines fo
r the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and relate
d disorders by flow cytometry. Cytometry B Clin Cytom. 2010; 78(4):211-30.    ^c
Y#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#73#69#article#108#</font></p>     ^cY
#v33n1a12.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020100078002001300279#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#74#70#article#108#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Brodsky RA. Paroxys
mal nocturnal hemoglobinuria: stem cells and clonality. Hematology Am Soc Hemato
l Educ Program. 2008: 111-5.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#75#71#article#108#</font></p>     ^cY
#v33n1a12.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019200078002001300270#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#76#72#article#108#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Brodsky RA. Advance
s in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev
. 2008;22(2):65-74.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#77#73#article#108#</font></p>     ^cY
#v33n1a12.htm##
00527000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027800078002001300356#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#78#74#article#108#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Franco De Carvalho 
R, Arruda VR, Saad ST, Costa FF. Detection of somatic mutations of the PIG-A gen
e in Brazilian patients with paroxysmal nocturnal hemoglobinuria. Braz J Med Bio
l Res. 2001; 34(6):763-6.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#79#75#article#108#</font></p>     ^cY
#v33n1a12.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022800078002001300306#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#80#76#article#108#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Magalh&atilde;es SM
, Lorand-Metze I. S&iacute;ndromes mielodispl&aacute;sicas - Protocolo de exclus
&atilde;o. Rev Bras Hematol Hemoter. 2004;26(4): 263-7.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#81#77#article#108#</font></p>     ^cY
#v33n1a12.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025800079002001300337#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#82#78#article#108#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Young NS. Paroxys
mal nocturnal hemoglobinuria and myelodysplastic sydromes: clonal expansion of P
IG-A-mutant hematopoietic cells in bone marrow failure. Haematologica. 2009;94(1
):3-7.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#83#79#article#108#</font></p>     ^cY
#v33n1a12.htm##
00527000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027700079002001300356#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#84#80#article#108#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Wang H, Chuhjo T,
 Yasue S, Omine M, Nakao S. Clinical significance of a minor population of parox
ysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood
. 2002;100(12): 3897-902.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#85#81#article#108#</font></p>     ^cY
#v33n1a12.htm##
00667000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704041700079002001300496#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#86#82#article#108#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Wang SA, Pozdnyak
ova O, Jorgensen JL, Medeiros LJ, Stachurski D, Anderson M, et al. Detection of 
paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic synd
romes and related bone marrow diseases, with emphasis on diagnostic pitfalls and
 caveats. Haematologica. 2009;94(1):29-37. Comment in: Haematologica. 2009;94(1)
:3-7.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#87#83#article#108#</font></p>     ^cY
#v33n1a12.htm##
00543000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029300079002001300372#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#88#84#article#108#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Hillmen P, Hall C
, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemo
lysis and transfusion requirements in patients with paroxysmal nocturnal hemoglo
binuria. N Engl J Med. 2004;350(6):552-9.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#89#85#article#108#</font></p>     ^cY
#v33n1a12.htm##
00610000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704036000079002001300439#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#90#86#article#108#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Modesto TM, Neves
 MAB, Brito AE, Ara&uacute;jo RCP, Santos NFG, Valgueiro MC, et al. Import&acirc
;ncia e vantagem da citometria de fluxo frente aos testes de triagem no diagn&oa
cute;stico da hemoglobin&uacute;ria parox&iacute;stica noturna. Rev Bras Hematol
 Hemoter. 2006; 28(4):275-9.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#91#87#article#108#</font></p>     ^cY
#v33n1a12.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023900079002001300318#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#92#88#article#108#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Parker C, Omine M
, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of
 paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699-709.    ^cY#v33n1
a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#93#89#article#108#</font></p>     ^cY
#v33n1a12.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026300079002001300342#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#94#90#article#108#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16.  Canalejo K, Gala
ssi N, Riera N, Bengio R, Aixala M. Evolucion del clon de la hemoglobinuria paro
xistica nocturna en la crisis hemolitica de una anemia aplasica. Medicina. 2001;
5(1):581-4.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#95#91#article#108#</font></p>     ^cY
#v33n1a12.htm##
00446000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019600079002001300275#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#96#92#article#108#17#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Dingli D, Luzzatt
o L, Pacheco JM. Neutral evolution in paroxysmal nocturnal hemoglobinuria. PNAS.
 2008;105(47):18496-500.    ^cY#v33n1a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#97#93#article#108#</font></p>     ^cY
#v33n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#98#94#article#108#<p>&nbsp;</p>     ^
cY#v33n1a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#99#95#article#108#<p>&nbsp;</p>     ^
cY#v33n1a12.htm##
00422000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704018600077002001300263#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#100#96#article#108#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><im
g src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b>
    ^cY#v33n1a12.htm##
00277000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704004100077002001300118#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#101#97#article#108#<br> Lacy Cardoso 
de Brito Junior    ^cY#v33n1a12.htm##
00316000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704008000077002001300157#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#102#98#article#108#<br> Funda&ccedil;
&atilde;o HEMOPA -  N&uacute;cleo de Ensino e Pesquisa    ^cY#v33n1a12.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704006300077002001300140#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#103#99#article#108#<br> Trav. Padre E
ut&iacute;quio, 2109 - Batista Campos    ^cY#v33n1a12.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005000078002001300128#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#104#100#article#108#<br> 66033-000 - 
Bel&eacute;m (PA), Brazil    ^cY#v33n1a12.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006100078002001300139#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#105#101#article#108#<br> Phone: 55  9
1 32429100 ext. 361 55 (91) 32426905    ^cY#v33n1a12.htm##
00380000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704014300078002001300221#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#106#102#article#108#<br> <a href="mai
lto:lcdbrito@ufpa.br">lcdbrito@ufpa.br</a> or <a href="mailto:lcdbrito@bol.com.b
r">lcdbrito@bol.com.br</a></font></p>     ^cY#v33n1a12.htm##
00327000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009000078002001300168#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#107#103#article#108#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted: 5/2/2010    ^cY#v33n1a1
2.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003300078002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#108#104#article#108#<br> Accepted: 11
/21/2010    ^cY#v33n1a12.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010900078002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#109#105#article#108#<br> Conflict-of-
interest disclosure: The authors declare no competing financial interest</font><
/p>     ^cY#v33n1a12.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#110#106#article#108#<p>&nbsp;</p>    
 ^cY#v33n1a12.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#111#107#article#108#<p>&nbsp;</p>    
 ^cY#v33n1a12.htm##
00460000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022300078002001300301#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a12.htm#S#p#112#108#article#108#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" targ
et="_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_bla
nk">www.scielo.br/rbhh</a></font></p>     ^cY#v33n1a12.htm##
00535000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100015000940120
08800109030003900197710000200236065000900238064000500247014000700252865000900259
002001300268#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#c#113#1#art
icle#17#1#^rND^sBessler^nM#^rND^sHiken^nJ#The pathophysiology of disease in pati
ents with paroxysmal nocturnal hemoglobinuria^len#Hematology Am Soc Hematol Educ
 Program#2#20080000#2008#104-10#20110200#v33n1a12.htm##
00633000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100012000770100018000890100
02000107010001700127010001600144010001800160012004400178030000600222065000900228
06400050023703100040024203200030024601400080024986500090025700200130026603500100
0279801000600289#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#c#114#2
#article#17#2#^rND^sHu^nR#^rND^sMukhina^nGL#^rND^sPiantadosi^nS#^rND^sBarber^nJP
#^rND^sJones^nRJ#^rND^sBrodsky^nRA#PIG-A mutations in normal hematopoiesis^len#B
lood#20050000#2005#105#10#3848-54#20110200#v33n1a12.htm#0006-4971#Blood##
00575000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000778100006000970120
14000103030001800243710000200261065000900263064000500272031000300277014000700280
865000900287002001300296#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S
#c#115#3#article#17#3#^rND^sAlegretti^nAP#et al#O papel das proteínas reguladora
s do complemento CD55/CD59 em células de sangue periférico de pacientes com lúpu
s eritematoso sistêmico^lpt#Rev Bras Reumatol#2#20090000#2009#49#276-87#20110200
#v33n1a12.htm##
00572000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940120
10000112030000600212065000900218064000500227031000400232032000200236014000600238
865000900244002001300253035001000266801000600276#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a12.htm#S#c#116#4#article#17#4#^rND^sAraten^nDJ#^rND^sLuzzatto^nL
#The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemo
globinuria (PNH)^len#Blood#20060000#2006#108#2#734-6#20110200#v33n1a12.htm#0006-
4971#Blood##
00735000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100016000960100
02100112010002200133010001500155010002100170810000600191012012700197030002300324
71000020034706500090034906400050035803100030036303200020036601400070036886500090
0375002001300384#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#c#117#5
#article#17#5#^rND^sBorowitz^nMJ#^rND^sCraig^nFE#^rND^sDigiuseppe^nJA#^rND^sIlli
ngworth^nAJ#^rND^sRosse^nW#^rND^sSutherland^nDR#et al#Guidelines for the diagnos
is and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders b
y flow cytometry^len#Cytometry B Clin Cytom#2#20100000#2010#78#4#211-30#20110200
#v33n1a12.htm##
00486000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120066000950300
03900161710000200200065000900202064000500211014000600216865000900222002001300231
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#c#118#6#article#17#6#^r
ND^sBrodsky^nRA#Paroxysmal nocturnal hemoglobinuria: stem cells and clonality^le
n#Hematology Am Soc Hematol Educ Program#2#20080000#2008#111-5#20110200#v33n1a12
.htm##
00531000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120081000950300
01000176065000900186064000500195031000300200032000200203014000600205865000900211
002001300220035001000233801001000243#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a12.htm#S#c#119#7#article#17#7#^rND^sBrodsky^nRA#Advances in the diagnosis an
d therapy of paroxysmal nocturnal hemoglobinuria^len#Blood Rev#20080000#2008#22#
2#65-74#20110200#v33n1a12.htm#0268-960X#Blood Rev##
00680000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100028000770100017001050100
01500122010001600137012011600153030002000269065000900289064000500298031000300303
032000200306014000600308865000900314002001300323035001000336801002000346#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#c#120#8#article#17#8#^rND^sFran
co De Carvalho^nR#^rND^sArruda^nVR#^rND^sSaad^nST#^rND^sCosta^nFF#Detection of s
omatic mutations of the PIG-A gene in Brazilian patients with paroxysmal nocturn
al hemoglobinuria^len#Braz J Med Biol Res#20010000#2001#34#6#763-6#20110200#v33n
1a12.htm#0100-879X#Braz J Med Biol Res##
00525000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100022000970120
05400119030002500173710000200198065000900200064000500209031000300214032000200217
014000600219865000900225002001300234#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a12.htm#S#c#121#9#article#17#9#^rND^sMagalhães^nSM#^rND^sLorand-Metze^nI#Sínd
romes mielodisplásicas: Protocolo de exclusão^lpt#Rev Bras Hematol Hemoter#2#200
40000#2004#26#4#263-7#20110200#v33n1a12.htm##
00602000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120146000950300
01400241065000900255064000500264031000300269032000200272014000400274865000900278
002001300287035001000300801001400310#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a12.htm#S#c#122#10#article#17#10#^rND^sYoung^nNS#Paroxysmal nocturnal hemoglo
binuria and myelodysplastic sydromes: clonal expansion of PIG-A-mutant hematopoi
etic cells in bone marrow failure^len#Haematologica#20090000#2009#94#1#3-7#20110
200#v33n1a12.htm#0390-6078#Haematologica##
00684000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01500109010001500124010001500139012013000154030000600284065000900290064000500299
03100040030403200030030801400090031186500090032000200130032903500100034280100060
0352#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#c#123#11#article#17
#11#^rND^sWang^nH#^rND^sChuhjo^nT#^rND^sYasue^nS#^rND^sOmine^nM#^rND^sNakao^nS#C
linical significance of a minor population of paroxysmal nocturnal hemoglobinuri
a-type cells in bone marrow failure syndrome^len#Blood#20020000#2002#100#12#3897
-902#20110200#v33n1a12.htm#0006-4971#Blood##
00874000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100021000940100
02000115010001900135010002000154010001800174810000600192012018600198030001400384
06500090039806400050040703100030041203200020041501400060041706100430042386500090
0466002001300475035001000488801001400498#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a12.htm#S#c#124#12#article#17#12#^rND^sWang^nSA#^rND^sPozdnyakova^nO#^rND
^sJorgensen^nJL#^rND^sMedeiros^nLJ#^rND^sStachurski^nD#^rND^sAnderson^nM#et al#D
etection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodys
plastic syndromes and related bone marrow diseases, with emphasis on diagnostic 
pitfalls and caveats^len#Haematologica#20090000#2009#94#1#29-37#Comment in: Haem
atologica. 2009;94(1):3-7.#20110200#v33n1a12.htm#0390-6078#Haematologica##
00737000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100014000960100
01600110010001700126010001800143010001600161810000600177012012000183030001300303
06500090031606400050032503100040033003200020033401400060033686500090034200200130
0351035001000364801001300374#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.h
tm#S#c#125#13#article#17#13#^rND^sHillmen^nP#^rND^sHall^nC#^rND^sMarsh^nJC#^rND^
sElebute^nM#^rND^sBombara^nMP#^rND^sPetro^nBE#et al#Effect of eculizumab on hemo
lysis and transfusion requirements in patients with paroxysmal nocturnal hemoglo
binuria^len#N Engl J Med#20040000#2004#350#6#552-9#20110200#v33n1a12.htm#0028-47
93#N Engl J Med##
00736000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01600114010001800130010001800148010002000166810000600186012013200192030002500324
71000020034906500090035106400050036003100030036503200020036801400060037086500090
0376002001300385#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#c#126#1
4#article#17#14#^rND^sModesto^nTM#^rND^sNeves^nMAB#^rND^sBrito^nAE#^rND^sAraújo^
nRCP#^rND^sSantos^nNFG#^rND^sValgueiro^nMC#et al#Importância e vantagem da citom
etria de fluxo frente aos testes de triagem no diagnóstico da hemoglobinúria par
oxística noturna^lpt#Rev Bras Hematol Hemoter#2#20060000#2006#28#4#275-9#2011020
0#v33n1a12.htm##
00676000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01800110010001900128010001700147010001400164810000600178012006800184030000600252
06500090025806400050026703100040027203200030027601400090027986500090028800200130
0297035001000310801000600320#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.h
tm#S#c#127#15#article#17#15#^rND^sParker^nC#^rND^sOmine^nM#^rND^sRichards^nS#^rN
D^sNishimura^nJ#^rND^sBessler^nM#^rND^sWare^nR#et al#Diagnosis and management of
 paroxysmal nocturnal hemoglobinuria^len#Blood#20050000#2005#106#12#3699-709#201
10200#v33n1a12.htm#0006-4971#Blood##
00673000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01500114010001600129010001600145012011200161030000900273065000900282064000500291
03100020029603200020029801400060030086500090030600200130031503500100032880100090
0338#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a12.htm#S#c#128#16#article#17
#16#^rND^sCanalejo^nK#^rND^sGalassi^nN#^rND^sRiera^nN#^rND^sBengio^nR#^rND^sAixa
la^nM#Evolucion del clon de la hemoglobinuria paroxistica nocturna en la crisis 
hemolitica de una anemia aplasica^les#Medicina#20010000#2001#5#1#581-4#20110200#
v33n1a12.htm#0025-7680#MEDICINA##
00542000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01800113012006100131030000500192710000200197065000900199064000500208031000400213
032000300217014001000220865000900230002001300239#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a12.htm#S#c#129#17#article#17#17#^rND^sDingli^nD#^rND^sLuzzatto^n
L#^rND^sPacheco^nJM#Neutral evolution in paroxysmal nocturnal hemoglobinuria^len
#PNAS#2#20080000#2008#105#47#18496-500#20110200#v33n1a12.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#o#1#1#article#1
#20110411#115535#v33n1a13.htm#147##
02811000000000565000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120127002020100049003290100041003780100049004190100033004680100032005010700
05400533083147900587085001002066085003802076085002902114085002302143085001902166
11700060218507200030219111200090219411100090220311400090221211300110222100200130
2232#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#h#2#1#article#1#oa#
en#br1.1#1#4.0#ILUS#TAB#13#RBHH340#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200
#^f38^l42#1516-8484#10.5581/1516-8484.20110013#Epidemiology of hepatitis B virus
 infection in first-time blood donors in the southwestern region of Goiás, centr
al Brazil^len#^rND^1A01^nGiulena Rosa Leite Cardoso dos^sAnjos#^rND^1A01^nRegina
 Maria Bringel^sMartins#^rND^1A01^nMegmar Aparecida dos Santos^sCarneiro#^rND^1A
01^nSandra Maria^sBrunini#^rND^1A01^nSheila Araujo^sTeles#Universidade Federal d
e Goiás^iA01^cJataí^sGO^pBrazil#^len^aINTRODUCTION: Little is known about the ep
idemiology of hepatitis B virus (HBV) infection in populations from inner cities
, especially in Central Brazil. Thus the objective of this study was to estimate
 the prevalence of HBV infection, and to analyze the factors associated with HBV
 infection, in a population of first-time blood donors in the southwestern regio
n of Goiás, Central Brazil. METHODS: A total of 984 individuals were interviewed
 and gave blood samples to detect serological markers of HBV (HBsAg, anti-HBs, a
nd anti-HBc) by enzyme linked immunosorbent assays. RESULTS: An overall prevalen
ce of 6.9% was found for HBV, with constituent prevalence rates of 3.6% and 11.6
%, in subjects classified as fit and unfit to donate blood according the epidemi
ological screening, respectively. Only three individuals were positive for anti-
HBs alone, suggesting previous vaccination against HBV. The variables of prior b
lood transfusion (OR = 2.3), tattoo/piercing (OR = 2.1), illicit drug use (OR = 
2.3), sex with a partner with hepatitis (OR = 14.7), and history of sexually tra
nsmitted diseases (OR = 2.9) were independently associated with HBV-positivity. 
These data suggested a low endemicity of hepatitis B in the studied population. 
CONCLUSION: The findings of low hepatitis B immunization coverage and the associ
ation of hepatitis B with risky behavior highlight that there is a need to inten
sify hepatitis B prevention programs in the southwest region of Goiás.#^ddecs^i1
#^tm^len^kHepatitis B^i1^sepidemiology#^tm^len^kHepatits B virus^i1#^tm^len^kPre
valence^i1#^tm^len^kBrazil^i1#other#24#20100208#2/8/2010#20101021#10/21/2010#v33
n1a13.htm##
02846000000000565000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120134002020100049003360100041003850100049004260100033004750100032005080700
05400540083150700594085001002101085003802111085002902149085002302178085001902201
11700060222007200030222611200090222911100090223811400090224711300110225600200130
2267#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#f#3#1#article#1#oa#
en#br1.1#1#4.0#ILUS#TAB#13#RBHH340#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200
#^f38^l42#1516-8484#10.5581/1516-8484.20110013#<b>Epidemiology of hepatitis B vi
rus infection in first-time blood donors in the southwestern region of Goiás, ce
ntral Brazil</b>^len#^rND^1A01^nGiulena Rosa Leite Cardoso dos^sAnjos#^rND^1A01^
nRegina Maria Bringel^sMartins#^rND^1A01^nMegmar Aparecida dos Santos^sCarneiro#
^rND^1A01^nSandra Maria^sBrunini#^rND^1A01^nSheila Araujo^sTeles#Universidade Fe
deral de Goiás^iA01^cJataí^sGO^pBrazil#^len^a<b>INTRODUCTION:</b> Little is know
n about the epidemiology of hepatitis B virus (HBV) infection in populations fro
m inner cities, especially in Central Brazil. Thus the objective of this study w
as to estimate the prevalence of HBV infection, and to analyze the factors assoc
iated with HBV infection, in a population of first-time blood donors in the sout
hwestern region of Goiás, Central Brazil. <b>METHODS:</b> A total of 984 individ
uals were interviewed and gave blood samples to detect serological markers of HB
V (HBsAg, anti-HBs, and anti-HBc) by enzyme linked immunosorbent assays. <b>RESU
LTS:</b> An overall prevalence of 6.9% was found for HBV, with constituent preva
lence rates of 3.6% and 11.6%, in subjects classified as fit and unfit to donate
 blood according the epidemiological screening, respectively. Only three individ
uals were positive for anti-HBs alone, suggesting previous vaccination against H
BV. The variables of prior blood transfusion (OR = 2.3), tattoo/piercing (OR = 2
.1), illicit drug use (OR = 2.3), sex with a partner with hepatitis (OR = 14.7),
 and history of sexually transmitted diseases (OR = 2.9) were independently asso
ciated with HBV-positivity. These data suggested a low endemicity of hepatitis B
 in the studied population. <b>CONCLUSION:</b> The findings of low hepatitis B i
mmunization coverage and the association of hepatitis B with risky behavior high
light that there is a need to intensify hepatitis B prevention programs in the s
outhwest region of Goiás.#^ddecs^i1#^tm^len^kHepatitis B^i1^sepidemiology#^tm^le
n^kHepatits B virus^i1#^tm^len^kPrevalence^i1#^tm^len^kBrazil^i1#other#24#201002
08#2/8/2010#20101021#10/21/2010#v33n1a13.htm##
02959000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103038000400108121000300112049000800115
15800030012303000280012603100030015403200020015706500090015901400090016803500100
01772370027001870120127002140100049003410100041003900100049004310100033004800100
03200513070005600545083150000601085001002101085003802111085002902149085002302178
08500190220111700060222007200030222611200090222911100090223811400090224711300110
2256002001302267008008902280#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.h
tm#S#l#4#1#article#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#13#RBHH340#nd#Rev. 
bras. hematol. hemoter#33#1#20110200#^f38^l42#1516-8484#10.5581/1516-8484.201100
13#Epidemiology of hepatitis B virus infection in first-time blood donors in the
 southwestern region of Goiás, central Brazil^len#^rND^1A01^nGiulena Rosa Leite 
Cardoso dos^sAnjos#^rND^1A01^nRegina Maria Bringel^sMartins#^rND^1A01^nMegmar Ap
arecida dos Santos^sCarneiro#^rND^1A01^nSandra Maria^sBrunini#^rND^1A01^nSheila 
Araujo^sTeles#^iA01^1Universidade Federal de Goiás^cJataí^sGO^pBrazil#^len^aINTR
ODUCTION: Little is known about the epidemiology of hepatitis B virus (HBV) infe
ction in populations from inner cities, especially in Central Brazil. Thus the o
bjective of this study was to estimate the prevalence of HBV infection, and to a
nalyze the factors associated with HBV infection, in a population of first-time 
blood donors in the southwestern region of Goiás, Central Brazil. METHODS: A tot
al of 984 individuals were interviewed and gave blood samples to detect serologi
cal markers of HBV (HBsAg, anti-HBs, and anti-HBc) by enzyme linked immunosorben
t assays. RESULTS: An overall prevalence of 6.9 percent was found for HBV, with 
constituent prevalence rates of 3.6 percent and 11.6 percent, in subjects classi
fied as fit and unfit to donate blood according the epidemiological screening, r
espectively. Only three individuals were positive for anti-HBs alone, suggesting
 previous vaccination against HBV. The variables of prior blood transfusion (OR 
= 2.3), tattoo/piercing (OR = 2.1), illicit drug use (OR = 2.3), sex with a part
ner with hepatitis (OR = 14.7), and history of sexually transmitted diseases (OR
 = 2.9) were independently associated with HBV-positivity. These data suggested 
a low endemicity of hepatitis B in the studied population. CONCLUSION: The findi
ngs of low hepatitis B immunization coverage and the association of hepatitis B 
with risky behavior highlight that there is a need to intensify hepatitis B prev
ention programs in the southwest region of Goiás.#^ddecs^i1#^tm^len^kHepatitis B
^i1^sepidemiology#^tm^len^kHepatits B virus^i1#^tm^len^kPrevalence^i1#^tm^len^kB
razil^i1#other#24#20100208#2/8/2010#20101021#10/21/2010#v33n1a13.htm#Internet^ih
ttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100013##
00354000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012100074002001300195#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#5#1#article#119#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLES</b>
</font></p>     ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#6#2#article#119#<p>&nbsp;</p>     ^cY
#v33n1a13.htm##
00470000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704023700074002001300311#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#7#3#article#119#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Epidemiology of h
epatitis B virus infection in first-time blood donors in the southwestern region
 of Goi&aacute;s, central Brazil</b></font></p>     ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#8#4#article#119#<p>&nbsp;</p>     ^cY
#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#9#5#article#119#<p>&nbsp;</p>     ^cY
#v33n1a13.htm##
00535000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704030100075002001300376#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#10#6#article#119#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Giulena Rosa Leite Cardoso dos Anj
os<sup>I</sup>; Regina Maria Bringel Martins<sup>II</sup>; Megmar Aparecida dos 
Santos Carneiro<sup>II</sup>; Sandra Maria Brunini<sup>II</sup>; Sheila Araujo T
eles<sup>II</sup></b></font></p>     ^cY#v33n1a13.htm##
00406000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017200075002001300247#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#11#7#article#119#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Universidade Federal de G
oi&aacute;s - UFG Campus Jata&iacute;, Jata&iacute; (GO), Brazil    ^cY#v33n1a13
.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011000075002001300185#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#12#8#article#119#<br>   <sup>II</sup>
Universidade Federal de Goi&aacute;s - UFG, Goi&acirc;nia (GO), Brazil</font></p
>     ^cY#v33n1a13.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#13#9#article#119#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></fon
t></p>     ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#14#10#article#119#<p>&nbsp;</p>     ^
cY#v33n1a13.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#15#11#article#119#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v33n1a13.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#16#12#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
33n1a13.htm##
00710000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047500076002001300551#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#17#13#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>INTRODUCTION:</b> Little is known
 about the epidemiology of hepatitis B virus (HBV) infection in populations from
 inner cities, especially in Central Brazil. Thus the objective of this study wa
s to estimate the prevalence of HBV infection, and to analyze the factors associ
ated with HBV infection, in a population of first-time blood donors in the south
western region of Goi&aacute;s, Central Brazil.     ^cY#v33n1a13.htm##
00443000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020800076002001300284#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#18#14#article#119#<br>     <b>METHODS
:</b> A total of 984 individuals were interviewed and gave blood samples to dete
ct serological markers of HBV (HBsAg, anti-HBs, and anti-HBc) by enzyme linked i
mmunosorbent assays.     ^cY#v33n1a13.htm##
00927000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069200076002001300768#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#19#15#article#119#<br>     <b>RESULTS
:</b> An overall prevalence of 6.9% was found for HBV, with constituent prevalen
ce rates of 3.6% and 11.6%, in subjects classified as fit and unfit to donate bl
ood according the epidemiological screening, respectively. Only three individual
s were positive for anti-HBs alone, suggesting previous vaccination against HBV.
 The variables of prior blood transfusion (OR = 2.3), tattoo/piercing (OR = 2.1)
, illicit drug use (OR = 2.3), sex with a partner with hepatitis (OR = 14.7), an
d history of sexually transmitted diseases (OR = 2.9) were independently associa
ted with HBV-positivity. These data suggested a low endemicity of hepatitis B in
 the studied population.     ^cY#v33n1a13.htm##
00506000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027100076002001300347#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#20#16#article#119#<br>   <b>CONCLUSIO
N:</b> The findings of low hepatitis B immunization coverage and the association
 of hepatitis B with risky behavior highlight that there is a need to intensify 
hepatitis B prevention programs in the southwest region of Goi&aacute;s.</font><
/p>     ^cY#v33n1a13.htm##
00435000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020000076002001300276#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#21#17#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Hepatitis B /epidem
iology; Hepatits B virus; Prevalence; <em>&nbsp;</em>Brazil</font></p> <hr size=
"1" noshade>     ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#22#18#article#119#<p>&nbsp;</p>     ^
cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#23#19#article#119#<p>&nbsp;</p>     ^
cY#v33n1a13.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#24#20#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></p>     ^
cY#v33n1a13.htm##
01165000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093000076002001301006#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#25#21#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Hepatitis B virus (HBV) infection is
 a serious public health concern. Currently, there are approximately 350 million
 HBV carriers at risk of developing terminal hepatic diseases, such as cirrhosis
 and hepatocellular carcinoma.<sup>(1)</sup> The Brazilian Ministry of Health ha
s estimated that 15% of the Brazilian population has been exposed to HBV and tha
t 1% suffer from chronic diseases caused by this virus.<sup>(2)</sup> HBV can be
 transmitted through contaminated blood or other bodily fluids, via percutaneous
 or mucosal exposure.<sup>(3)</sup> As such, children born from women infected w
ith hepatitis B,<sup>(4,5)</sup> individuals who have received multiple blood tr
ansfusions,<sup>(6)</sup> drug users,<sup>(7,8)</sup> and individuals with multi
ple sexual partners<sup>(9)</sup> are considered to be high risk groups for HBV 
infection. </font></p>     ^cY#v33n1a13.htm##
00973000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073800076002001300814#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#26#22#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The transmission pattern of hepatiti
s B varies across the world. In regions with a high prevalence of carriers &#91;
i.e., &gt; 8% of population as carriers of the hepatitis B surface antigen (HBsA
g)&#93;, infection patterns are vertical and horizontal/intrafamilial. In contra
st, in regions with a low prevalence of carriers (&lt; 2% carriers), adolescents
 and adults are mainly afflicted, as lifestyle plays the principle role in viral
 transmission. Regions that have intermediate endemicity (2-8% HBsAg carriers) s
how all forms of viral transmission.<sup>(3)</sup> Brazil is considered to be a 
region of low to intermediate endemicity.<sup>(10,11)</sup></font></p>     ^cY#v
33n1a13.htm##
01137000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090200076002001300978#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#27#23#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Brazilian state of Goi&aacute;s 
covers an area of 340,086 km<sup>2</sup> and has a population of 6 million inhab
itants. It is the most populous state in the Midwest region of Brazil.<sup>(12)<
/sup> Its large size and geographic location has favored the influx of culturall
y and ethnically diverse migrants from other Brazilian states as well as from ot
her countries. This diverse immigration contributes to the variable epidemiologi
cal patterns that exist within the state. With regards to HBV infection, the maj
ority of studies have been conducted within the metropolitan region of Goi&acirc
;nia. Little information is available from rural areas of the state, though ther
e are limited data that have been obtained from patients undergoing hemodialysis
<sup>(13)</sup> and from quilombolo settlements.<sup>(14)</sup></font></p>     ^
cY#v33n1a13.htm##
00508000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027300076002001300349#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#28#24#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The purpose of this study was to est
imate the prevalence of, and factors associated with, HBV infection in a populat
ion of prospective blood donors in the southwestern region of Goi&aacute;s</font
></p>     ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#29#25#article#119#<p>&nbsp;</p>     ^
cY#v33n1a13.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#30#26#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Methods</b></font></p>     ^cY#v3
3n1a13.htm##
00932000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069700076002001300773#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#31#27#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This is an observational, cross-sect
ional, study performed on prospective blood donors from HEMOJATA&Iacute;, the on
ly blood collection point for the Jata&iacute; city (81,972 residents) and nine 
other cities in the southwestern region of Goi&aacute;s (Apor&eacute;, 3,554 inh
abitants; Caiap&ocirc;nia, 15,747 inhabitants; Chapad&atilde;o do C&eacute;u, 5,
289 inhabitants; Doverl&acirc;ndia, 8,344 inhabitants; Mineiros, 45,189 inhabita
nts; Perol&acirc;ndia, 2,748 inhabitants; Portel&acirc;ndia, 3,310 inhabitants; 
Santa Rita do Araguaia, 5,873 inhabitants; Serran&oacute;polis, 7,333 inhabitant
s).<sup>(12)</sup></font></p>     ^cY#v33n1a13.htm##
00937000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070200076002001300778#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#32#28#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A total of 984 individuals participa
ted in this study. To calculate the needed sample size, an HBV prevalence of 10.
7% was assumed,<sup>(11)</sup> with a standard deviation of 3%, a design effect 
of 2.0, and 80% statistical power; the significance level was set at 95%. Data w
ere collected between August 1<sup>st</sup> of 2008 and January 31<sup>st</sup> 
of 2009. All individuals who voluntarily came to HEMOJATA&Iacute; for their firs
t blood donation within the aforementioned period were included in the study. In
dividuals who were recruited to donate through businesses or the military were e
xcluded from the study.</font></p>     ^cY#v33n1a13.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#33#29#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Data collection</font></p>     ^cY#v
33n1a13.htm##
01036000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080100076002001300877#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#34#30#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Participants were first informed abo
ut the project and asked to sign an informed consent form prior to being intervi
ewed. The interview was conducted using a standardized questionnaire designed to
 collect information on the participants' risk factors for hepatitis B and their
 sociodemographic data. The questionnaire included questions on the participants
 surgical, medical, and blood transfusion history. It also collected information
 on the presence of tattoos and piercings, the use of illegal drugs, unprotected
 sexual contact, prostitution (sex in exchange for money or gifts), history of s
exually transmitted disease (STD), HIV tests, incarceration, and current or prev
ious contact with an HBV infected partner.</font></p>     ^cY#v33n1a13.htm##
01321000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704108600076002001301162#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#35#31#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Following administration of the ques
tionnaire, a 10-mL peripheral venous blood sample was drawn from each participan
t. The blood samples were stored in test tubes and identified with a number corr
esponding to the participant's questionnaire. Blood serum was separated from the
 samples and stored at -20ºC until tested. Blood samples from prospective blood 
donors considered suitable for clinical screening were sent to the Blood Center 
Laboratory of Goi&acirc;nia (HE-MOG) for serological testing. Blood samples from
 candidates considered unfit to donate blood were sent to and tested at the muni
cipal reference laboratory Euzevir de Carvalho, at the Dr. Serafim de Carvalho M
unicipal Health Center in Jata&iacute;, Goi&aacute;s. At both laboratories, enzy
me immunoassays (Bio-Rad Laboratories, Inc.) were utilized to test the blood sam
ples for the following serological markers of HBV: HBsAg, total anti-HBc, and an
ti-HBs. The assays were performed in accordance with the manufacturer's specific
ations.</font></p>     ^cY#v33n1a13.htm##
00498000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026300076002001300339#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#36#32#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This study was approved by the Human
 and Animal Ethics Committee at the Hospital das Cl&iacute;nicas at the Federal 
University of Goias (UFG) and assigned protocol number 076/2008.</font></p>     
^cY#v33n1a13.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#37#33#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Data analysis</font></p>     ^cY#v33
n1a13.htm##
00757000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052200076002001300598#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#38#34#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Infection rates were calculated with
 a confidence interval of 95%. Univariate analysis was performed for association
 of seropositivity to HBV (HBsAg or anti-HBc) with the variables studied. The va
riables showing statistical significance (p-value &lt; 0.05) were included in a 
logistic regression model. Correlations were verified using chi-square and Fishe
r's exact tests where a p-value &lt; 0.05 was considered statistically significa
nt.</font></p>     ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#39#35#article#119#<p>&nbsp;</p>     ^
cY#v33n1a13.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#40#36#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>     ^cY#v3
3n1a13.htm##
00588000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035300076002001300429#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#41#37#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The majority of prospective blood do
nors were male (55.6%), 40 years of age or younger (71.5%), had attained an aver
age education level (77.2%), and had a monthly family income of more than R$ 100
0 (73.6%). These characteristics are typical among blood donors in Brazil.</font
></p>     ^cY#v33n1a13.htm##
01138000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090300076002001300979#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#42#38#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Of the 984 total prospective donors,
 68 (6.9%) tested positive for the anti-HBc marker. This marker was associated w
ith the presence of HBsAg in only 3/984 (0.3%) subjects and was associated with 
anti-HBs in 41/984 (4.2%) subjects. Also, in 24/984 (2.4%) subjects only the ant
i-HBc marker was detected. The three individuals who tested positive for anti-HB
s had likely received a previous vaccination against hepatitis B (<a href="#tab1
">Table 1</a>). Overall, positive HBV results varied in accordance with the clin
ical and epidemiological screening classifications. There was a 3.6% prevalence 
of HBV infection among subjects considered to be suitable blood donors based on 
their blood donor screening results, and an 11.6% prevalence of HBV-positive sub
jects among those classified as unsuitable donors (p &lt; 0.01).</font></p>     
^cY#v33n1a13.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#43#39#article#119#<p><a name="tab1"><
/a></p>     ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#44#40#article#119#<p>&nbsp;</p>     ^
cY#v33n1a13.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#45#41#article#119#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a13tab01.jpg"></p>     ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#46#42#article#119#<p>&nbsp;</p>     ^
cY#v33n1a13.htm##
01358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112300076002001301199#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#47#43#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Univariate analysis revealed that bl
ood transfusion history, the presence of a piercing or tattoo, use of illegal dr
ugs, unprotected sexual contact, sexual contact with a hepatitis carrier, histor
y of prostitution, history of STD infection, and incarceration were associated w
ith HBV infection (p-value &lt; 0.01) (<a href="#tab2">Table 2</a>). These varia
bles, as well as clinical screening, gender, and age, were subjected to multivar
iate analysis. Following the multivariate analysis, a blood transfusion history 
(adjusted OR = 2.3; CI 95% 1.1-4.9), the presence of a piercing and/or tattoo (a
djusted OR = 2.1; CI 95% 1.2-3.7), the use of illegal drugs (adjusted OR 2.3; CI
 95%: 1.0-5.1), sexual contact with a hepatitis carrier (adjusted OR = 14.7; CI 
95%: 2.7-80.7), and a history of STD (adjusted OR = 2.9; CI 95%: 1.4-5.9) remain
ed independently associated to HBV infection. Furthermore, a history of prostitu
tion was found to be marginally associated with HBV infection (adjusted OR = 2.1
; CI 0.9-5.0) (<a href="#tab3">Table 3</a>).</font></p>     ^cY#v33n1a13.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#48#44#article#119#<p><a name="tab2"><
/a></p>     ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#49#45#article#119#<p>&nbsp;</p>     ^
cY#v33n1a13.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#50#46#article#119#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a13tab02.jpg"></p>     ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#51#47#article#119#<p>&nbsp;</p>     ^
cY#v33n1a13.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#52#48#article#119#<p><a name="tab3"><
/a></p>     ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#53#49#article#119#<p>&nbsp;</p>     ^
cY#v33n1a13.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#54#50#article#119#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a13tab03.jpg"></p>     ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#55#51#article#119#<p>&nbsp;</p>     ^
cY#v33n1a13.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#56#52#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p>     ^cY
#v33n1a13.htm##
01161000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704092600076002001301002#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#57#53#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The process of ascertaining blood tr
ansfusion safety starts during the recruitment of prospective donors through cli
nical and epidemiological screening.<sup>(15)</sup> Thus, individuals who report
 a history of having received blood transfusions and/or of having behavioral ris
k factors for hepatitis B infection (i.e., having a tattoo and/or body piercing,
 using illegal drugs, having unprotected sex) are screened as unfit to donate bl
ood. In the current study, screening indicated that 41% of the subjects were cla
ssified as unfit donors. HBV infection was 3.2 times more prevalent in this unfi
t group than in subjects designated by the screening as being fit to donate (11.
6% vs. 3.6%; p &lt; 0.001). This difference confirms the importance of this scre
ening strategy to ensure the safety of blood products for use in transfusion the
rapies.</font></p>     ^cY#v33n1a13.htm##
01122000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088700076002001300963#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#58#54#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It is noteworthy that the prevalence
 rate of current or previous HBV infection positivity in this study (6.9%) was h
igher than the prevalence rates found in blood donors from Manaus (4.8%, p &lt; 
0.05), S&atilde;o Paulo (4.3%, p &lt; 0.01), and Salvador (4.0%, p &lt; 0.01),<s
up>(16)</sup> as well as those in blood donors from Rio de Janeiro (2.05%, p &lt
; 0.01)<sup>(17)</sup> and Santa Catarina (5.3%, p &lt; 0.05).<sup>(18)</sup> On
 the other hand, the prevalence observed in this study was lower than that previ
ously found in blood donors in the greater Midwest region of Brazil,<sup>(11)</s
up> but similar to those reported recently in a population-based study conducted
 in the capital cities of the Midwest region (Goi&acirc;nia, Campo Grande, and C
uiab&aacute;; 5.3%, p &gt; 0.05).<sup>(10)</sup></font></p>     ^cY#v33n1a13.htm
##
01040000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080500076002001300881#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#59#55#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A weak association between HBV expos
ure markers and a history of blood transfusions was observed. However, it should
 be noted that the majority of the marker-positive subjects reported having unde
rgone blood transfusions more than a decade prior to the study. As such, it is p
ossible that these individuals received blood transfusions prior to the institut
ionalization of serological screening for HBsAg (1989) or anti-HBc (1993).<sup>(
19,20)</sup> In fact, countries that have introduced these screening measures ex
perienced a drastic reduction in cases of post-transfusion hepatitis B infection
; nevertheless, HBV transmission remains the most common cause of viral infectio
n acquired through transfusion.<sup>(21)</sup></font></p>     ^cY#v33n1a13.htm##
01538000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704130300076002001301379#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#60#56#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In areas of low endemicity for hepat
itis B, infection typically occurs in adolescence and adulthood, when lifestyle 
is a determining factor in viral transmission.<sup>(3)</sup> In fact, the three 
individuals that tested positive for HBsAg were between the ages of 20 and 24. E
ven so, typical risk factors for hepatitis B infection that are associated with 
life style choices, such as having tattoos or body piercings,<sup>(22,23)</sup> 
use of illegal drugs,<sup>(7)</sup> and a history of STDs,<sup>(9)</sup> were in
dependently correlated with HBV positivity in the present study. Furthermore, of
 the seven individuals who reported having HBV-positive sexual partners, four sh
owed markers of HBV infection. One result that deserves particular attention is 
the extremely low frequency of subjects vaccinated against hepatitis B. Only thr
ee individuals demonstrated serological evidence of vaccination, although most o
f the people in the group were younger than 20 years of age, and therefore eligi
ble for free hepatitis B vaccination in Brazil. Indeed, since 2004, hepatitis B 
vaccination has been mandatory for admission of students to state schools as wel
l as to private elementary and secondary schools.<sup>(24)</sup></font></p>     
^cY#v33n1a13.htm##
01142000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090700076002001300983#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#61#57#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Hepatitis B infection rates among bl
ood donors are usually underestimated in relation to the general public; thus su
ch extrapolations must be regarded with some caution. In this study, all prospec
tive blood donors were included, regardless of their clinical and epidemiologica
l screening results. Using this strategy, a low prevalence of hepatitis B infect
ion would be estimated in a population of prospective blood donors from the sout
hwestern region of Goi&aacute;s. The present data confirm previous studies that 
have ranked Midwest Brazil as a region of low endemicity for hepatitis B.<sup>(1
0,11)</sup> Nonetheless, the low vaccination rates and the presence of risky beh
aviors found in these results highlight a need for improved health awareness and
 hepatitis B prevention programs in the urban areas of Goi&aacute;s.</font></p> 
    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#62#58#article#119#<p>&nbsp;</p>     ^
cY#v33n1a13.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#63#59#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY
#v33n1a13.htm##
00400000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015100078002001300229#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#64#60#article#119#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Liaw YF, Chu CM. He
patitis B virus infection. Lancet. 2009; 373(9663):582-92.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#65#61#article#119#</font></p>     ^cY
#v33n1a13.htm##
00448000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019900078002001300277#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#66#62#article#119#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Brasil. Minist&eacu
te;rio da Sa&uacute;de. Hepatites Virais: o Brasil est&aacute; atento.  3a ed. B
ras&iacute;lia. 2008:60 p.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#67#63#article#119#</font></p>     ^cY
#v33n1a13.htm##
00420000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017100078002001300249#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#68#64#article#119#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Alter MJ. Epidemiol
ogy of hepatitis B in Europe and worldwide. J Hepatol. 2003;39 Suppl 1:S64-69.  
  ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#69#65#article#119#</font></p>     ^cY
#v33n1a13.htm##
00436000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018700078002001300265#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#70#66#article#119#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Ranger-Rogez S, Den
is F. Hepatitis B mother-to-child transmission. Expert Rev Anti Infect Ther. 200
4;2(1):133-45.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#71#67#article#119#</font></p>     ^cY
#v33n1a13.htm##
00561000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031200078002001300390#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#72#68#article#119#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Wiseman E, Fraser M
A, Holden S, Glass A, Kidson BL, Heron LG, et al. Perinatal transmission of hepa
titis B virus: an Australian experience. Med J Aust. 2009;190 (9):489-92. Commen
t in: Med J Aust. 2009 Sep 21;191(6):357; author reply 357.    ^cY#v33n1a13.htm#
#
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#73#69#article#119#</font></p>     ^cY
#v33n1a13.htm##
00605000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704035600078002001300434#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#74#70#article#119#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Tavares RS, Barbosa
 AP, Teles SA, Carneiro MA, Lopes CL, Silva SA, et al. Infec&ccedil;&atilde;o pe
lo v&iacute;rus da hepatite B em hemof&iacute;licos em Goi&aacute;s: soropreval&
ecirc;ncia, fatores de risco associados e resposta vacinal. Rev Bras Hematol Hem
oter. 2004;26(3):183-8.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#75#71#article#119#</font></p>     ^cY
#v33n1a13.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027500078002001300353#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#76#72#article#119#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Ferreira RC, Rodrig
ues FP, Teles SA, Lopes CL, Motta-Castro AR, Novais AC, et al. Prevalence of hep
atitis B virus and risk factors in Brazilian non-injecting drug users. J Med Vir
ol. 2009; 81(4):602-9.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#77#73#article#119#</font></p>     ^cY
#v33n1a13.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029500078002001300373#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#78#74#article#119#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Kuo I, Sherman SG, 
Thomas DL, Strathdee SA. Hepatitis B virus infection and vaccination among young
 injection and non-injection drug users: missed opportunities to prevent infecti
on. Drug Alcohol Depend. 2004;73(1):69-78.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#79#75#article#119#</font></p>     ^cY
#v33n1a13.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028100078002001300359#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#80#76#article#119#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Matos MA, Martins R
M, da Silva Franca DD, Pessoni GC, Ferreira RC, Matos MA, et al. Epidemiology of
 hepatitis B virus infection in truck drivers in Brazil, South America. Sex Tran
sm Infect. 2008;84(5):386-9.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#81#77#article#119#</font></p>     ^cY
#v33n1a13.htm##
00726000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704047600079002001300555#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#82#78#article#119#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Pereira  LM, Mart
elli CM, Merchan-Hamann E, Montarroyos UR, Braga MC, de Lima ML,  Cardoso MR, Tu
rchi MD, Costa MA, de Alencar LC, Moreira RC, Figueiredo GM,  Ximenes RA; Hepati
tis Study Group. Population-based multicentric survey of  hepatitis B infection 
and risk factor differences among three regions in  Brazil. Am J Trop Med Hyg. 2
009;81(2):240-7. Comment in: Am J Trop Med Hyg.  2010;82(1):165.    ^cY#v33n1a13
.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#83#79#article#119#</font></p>     ^cY
#v33n1a13.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027600079002001300355#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#84#80#article#119#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Martelli CM, Turc
hi M, Souto FJ, Saez-Alquezar A, Andrade AL, Zicker F. Anti-HBc testing for bloo
d donations in areas with intermediate hepatitis B endemicity. Rev Panam Salud P
ublica. 1999;6(1):69-73.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#85#81#article#119#</font></p>     ^cY
#v33n1a13.htm##
00630000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704038000079002001300459#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#86#82#article#119#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. IBGE. Cidades@[Ho
me page on the  Internet]. Bras&iacute;lia:  Instituto Brasileiro de Geografia e
 Estat&iacute;stica; 2007. &#91;citado 2010 Jun 27&#93;. Disponível em: <a href=
"http://www.ibge.gov.br/cidadesat/topwindow.htm" target="_blank">http://www.ibge
.gov.br/cidadesat/topwindow.htm</a>?</font></p>     ^cY#v33n1a13.htm##
00559000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030900079002001300388#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#87#83#article#119#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Ferreira RC, Tele
s SA, Dias MA, Tavares VR, Silva SA, Gomes SA, et al. Hepatitis B virus infectio
n profile in hemodialysis patients in Central Brazil: prevalence, risk factors, 
and genotypes. Mem Inst Oswaldo Cruz. 2006;101(6):689-92.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#88#84#article#119#</font></p>     ^cY
#v33n1a13.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029400079002001300373#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#89#85#article#119#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Matos MA, Reis NR
, Kozlowski AG, Teles SA, Motta-Castro AR, Mello FC, et al. Epidemiological stud
y of hepatitis A, B and C in the largest Afro-Brazilian isolated community. Tran
s R Soc Trop Med Hyg. 2009;103(9):899-905.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#90#86#article#119#</font></p>     ^cY
#v33n1a13.htm##
00519000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026900079002001300348#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#91#87#article#119#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Carrazzone CFV, d
e Brito AM, Gomes YM. Import&acirc;ncia da avalia&ccedil;&atilde;o sorol&oacute;
gica p&oacute;s-transfusional em receptores de sangue. Rev Bras Hematol Hemoter.
 2004;26(2):93-8.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#92#88#article#119#</font></p>     ^cY
#v33n1a13.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028500079002001300364#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#93#89#article#119#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Nascimento MC, Ma
yaud P, Sabino EC, Torres KL, Franceschi S. Prevalence of hepatitis B and C sero
logical markers among first-time blood donors in Brazil: a multi-center serosurv
ey. J Med Virol. 2008;80(1):53-7.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#94#90#article#119#</font></p>     ^cY
#v33n1a13.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028700079002001300366#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#95#91#article#119#17#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Andrade AF, Olive
ira-Silva M, Silva SG, Motta IJ, Bonvicino CR. Seroprevalence of hepatitis B and
 C virus markers among blood donors in Rio de Janeiro, Brazil, 1998-2005. Mem In
st Oswaldo Cruz. 2006;101(6):673-6.    ^cY#v33n1a13.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#96#92#article#119#</font></p>     ^cY
#v33n1a13.htm##
00481000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023100079002001300310#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#97#93#article#119#18#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Rosini N, Mousse 
D, Spada C, Treitinger A. Seroprevalence of HbsAg, Anti-HBc and anti-HCV in Sout
hern Brazil, 1999-2001. Braz J Infect Dis. 2003;7(4):262-7.    ^cY#v33n1a13.htm#
#
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#98#94#article#119#</font></p>     ^cY
#v33n1a13.htm##
00842000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704059200079002001300671#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#99#95#article#119#19#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Brasil.  Minist&e
acute;rio da Sa&uacute;de. Portaria n. 721, de 9 de agosto de 1989. Aprova norma
s  t&eacute;cnicas para a coleta, processamento e transfus&atilde;o de sangue, c
omponentes e  derivados; e d&aacute; outras provid&ecirc;ncias &#91;Internet&#93
;. Bras&iacute;lia: Ag&ecirc;ncia de Vigil&acirc;ncia  Sanit&aacute;ria; 1989. &
#91;citado 2000 Jun 21&#93;. Dispon&iacute;vel em: <a href="http://www.anvisa.go
v.br/legis/portarias/721_89.pdf">http://www.anvisa.gov.br/legis/portarias/721_89
.pdf</a></font></p>     ^cY#v33n1a13.htm##
00899000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704064800080002001300728#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#100#96#article#119#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Brasil. Minist&e
acute;rio da Sa&uacute;de. Portaria n. 1326, de 19 de  novembro de 1993. Aprova 
altera&ccedil;&otilde;es na Portaria n. 721/GM, de 9 de agosto de  1989, que apr
ova normas t&eacute;cnicas para a coleta, processamento e transfus&atilde;o de  
sangue, componentes e derivados; e d&aacute; outras provid&ecirc;ncias &#91;Inte
rnet&#93;. Bras&iacute;lia:  Ag&ecirc;ncia de Vigil&acirc;ncia Sanit&aacute;ria;
 1993. &#91;citado 2000 Jun 21&#93;. Dispon&iacute;vel em: <a href="http://www.a
nvisa">http://www.anvisa</a>.  gov.br/legis/portarias/1376-93.pdf</font></p>    
 ^cY#v33n1a13.htm##
00432000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704018100080002001300261#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#101#97#article#119#21#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Candotti D, Alla
in JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol. 2009;51(4
):798-809.    ^cY#v33n1a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#102#98#article#119#</font></p>     ^c
Y#v33n1a13.htm##
00569000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704031800080002001300398#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#103#99#article#119#22#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Nishioka S, Gyor
kos T, Joseph L, Collet JP, Mclean JD. Tattooing and transfusion-transmitted dis
eases: the role of the type, number and desing of the tattoos, and the condition
s in which they were performed. Epidem Infect. 2002;128 (1): 63-71.    ^cY#v33n1
a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#104#100#article#119#</font></p>     ^
cY#v33n1a13.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025000081002001300331#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#105#101#article#119#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Oliveira MD, Ma
tos MA, Martins RM, Teles SA. Tattooing and body piercing as lifestyle indicator
 of risk behaviors in Brazilian adolescents. Eur J Epidemiol. 2006;21(7):559-60.
    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#106#102#article#119#</font></p>     ^
cY#v33n1a13.htm##
00744000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704049200081002001300573#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#107#103#article#119#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24.Brasil. Ministér
io da Saúde. Portaria nº 597/GM de 8 de abril de 2004. Institui em todo territór
io nacional os calendários de vacinação &#91;Internet&#93;. Brasília: Departamen
to de Vigilância Epidemiológica; 2004. &#91;citado 2008 Abr 29&#93;. Disponível 
em: <a href="http://portal.saude.gov.br/portal/arquivos/pdf/portaria_597.pdf" ta
rget="_blank">http://portal.saude.gov.br/portal/arquivos/pdf/portaria_597.pdf</a
>.    ^cY#v33n1a13.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#108#104#article#119#</font></p>     ^
cY#v33n1a13.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#109#105#article#119#<p>&nbsp;</p>    
 ^cY#v33n1a13.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#110#106#article#119#<p>&nbsp;</p>    
 ^cY#v33n1a13.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018600078002001300264#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#111#107#article#119#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b
>    ^cY#v33n1a13.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#112#108#article#119#<br>   Sheila Ara
ujo Teles    ^cY#v33n1a13.htm##
00286000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004900078002001300127#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#113#109#article#119#<br> Universidade
 Federal de Goi&aacute;s    ^cY#v33n1a13.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#114#110#article#119#<br>Rua 227 quadr
a 68, S/N,    ^cY#v33n1a13.htm##
00281000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004400078002001300122#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#115#111#article#119#<br>Setor Leste U
niversit&aacute;rio    ^cY#v33n1a13.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005000078002001300128#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#116#112#article#119#<br>74605-080 - G
oi&acirc;nia (GO), Brazil    ^cY#v33n1a13.htm##
00318000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008100078002001300159#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#117#113#article#119#<br> <a href="mai
lto:sheila@fen.ufg.br">sheila@fen.ufg.br</a></font></p>     ^cY#v33n1a13.htm##
00327000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009000078002001300168#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#118#114#article#119#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted: 2/8/2010    ^cY#v33n1a1
3.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003300078002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#119#115#article#119#<br> Accepted: 10
/21/2010    ^cY#v33n1a13.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010900078002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#120#116#article#119#<br> Conflict-of-
interest disclosure: The authors declare no competing financial interest</font><
/p>     ^cY#v33n1a13.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#121#117#article#119#<p>&nbsp;</p>    
 ^cY#v33n1a13.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#122#118#article#119#<p>&nbsp;</p>    
 ^cY#v33n1a13.htm##
00460000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022300078002001300301#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a13.htm#S#p#123#119#article#119#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" targ
et="_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_bla
nk">www.scielo.br/rbhh</a></font></p>     ^cY#v33n1a13.htm##
00504000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100014000920120
03200106030000700138065000900145064000500154031000400159032000500163014000700168
865000900175002001300184035001000197801000700207#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a13.htm#S#c#124#1#article#24#1#^rND^sLiaw^nYF#^rND^sChu^nCM#Hepat
itis B virus infection^len#Lancet#20090000#2009#373#9663#582-92#20110200#v33n1a1
3.htm#0099-5355#Lancet##
00451000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170007000770170020000840180
04300104063000200147066000900149065000900158064000500167020000300172865000900175
002001300184#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#c#125#2#art
icle#24#2#Brasil#Ministério da Saúde#Hepatites Virais: o Brasil está atento^lpt#
3#Brasília#20080000#2008#60#20110200#v33n1a13.htm##
00507000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120056000930300
01000149065000900159064000500168031000300173032000400176014000700180865000900187
002001300196035001000209801001000219#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a13.htm#S#c#126#3#article#24#3#^rND^sAlter^nMJ#Epidemiology of hepatitis B in
 Europe and worldwide^len#J Hepatol#20030000#2003#39#^s1#S64-69#20110200#v33n1a1
3.htm#0168-8278#J Hepatol##
00514000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100022000770100015000990120
04500114030002800159710000200187065000900189064000500198031000200203032000200205
014000700207865000900214002001300223#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a13.htm#S#c#127#4#article#24#4#^rND^sRanger-Rogez^nS#^rND^sDenis^nF#Hepatitis
 B mother-to-child transmission^len#Expert Rev Anti Infect Ther#2#20040000#2004#
2#1#133-45#20110200#v33n1a13.htm##
00686000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01600111010001500127010001700142010001600159810000600175012007400181030001100255
06500090026606400050027503100040028003200020028401400070028686500090029300200130
0302035001000315801001100325#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.h
tm#S#c#128#5#article#24#5#^rND^sWiseman^nE#^rND^sFraser^nMA#^rND^sHolden^nS#^rND
^sGlass^nA#^rND^sKidson^nBL#^rND^sHeron^nLG#et al#Perinatal transmission of hepa
titis B virus: an Australian experience^len#Med J Aust#20090000#2009#190#9#489-9
2#20110200#v33n1a13.htm#0025-729X#Med J Aust##
00725000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950100
01600113010001900129010001600148010001600164810000600180012012700186030002500313
71000020033806500090034006400050034903100030035403200020035701400060035986500090
0365002001300374#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#c#129#6
#article#24#6#^rND^sTavares^nRS#^rND^sBarbosa^nAP#^rND^sTeles^nSA#^rND^sCarneiro
^nMA#^rND^sLopes^nCL#^rND^sSilva^nSA#et al#Infecção pelo vírus da hepatite B em 
hemofílicos em Goiás: soroprevalência, fatores de risco associados e resposta va
cinal^lpt#Rev Bras Hematol Hemoter#2#20040000#2004#26#3#183-8#20110200#v33n1a13.
htm##
00716000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100020000960100
01600116010001600132010002300148010001700171810000600188012009100194030001200285
06500090029706400050030603100030031103200020031401400060031686500090032200200130
0331035001000344801001200354#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.h
tm#S#c#130#7#article#24#7#^rND^sFerreira^nRC#^rND^sRodrigues^nFP#^rND^sTeles^nSA
#^rND^sLopes^nCL#^rND^sMotta-Castro^nAR#^rND^sNovais^nAC#et al#Prevalence of hep
atitis B virus and risk factors in Brazilian non-injecting drug users^len#J Med 
Virol#20090000#2009#81#4#602-9#20110200#v33n1a13.htm#0146-6615#J Med Virol##
00698000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100013000770100018000900100
01700108010002000125012014200145030002000287065000900307064000500316031000300321
032000200324014000600326865000900332002001300341035001000354801002000364#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#c#131#8#article#24#8#^rND^sKuo^
nI#^rND^sSherman^nSG#^rND^sThomas^nDL#^rND^sStrathdee^nSA#Hepatitis B virus infe
ction and vaccination among young injection and non-injection drug users: missed
 opportunities to prevent infection^len#Drug Alcohol Depend#20040000#2004#73#1#6
9-78#20110200#v33n1a13.htm#0376-8716#Drug Alcohol Depend##
00729000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930100
02600111010001800137010001900155010001600174810000600190012009000196030001800286
06500090030406400050031303100030031803200020032101400060032386500090032900200130
0338035001000351801001800361#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.h
tm#S#c#132#9#article#24#9#^rND^sMatos^nMA#^rND^sMartins^nRM#^rND^sda Silva Franc
a^nDD#^rND^sPessoni^nGC#^rND^sFerreira^nRC#^rND^sMatos^nMA#et al#Epidemiology of
 hepatitis B virus infection in truck drivers in Brazil, South America^len#Sex T
ransm Infect#20080000#2008#84#5#386-9#20110200#v33n1a13.htm#1368-4973#Sex Transm
 Infect##
01056000000000445000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
02400116010002200140010001600162010001800178010001800196010001700214010001600231
01000210024701000180026801000210028601000180030701100220032501201240034703000180
04710650009004890640005004980310003005030320002005060140006005080610046005148650
00900560002001300569035001000582801001800592#v33n1#V:\SciELO\serial\rbhh\v33n1\m
arkup\v33n1a13.htm#S#c#133#10#article#24#10#^rND^sPereira^nLM#^rND^sMartelli^nCM
#^rND^sMerchan-Hamann^nE#^rND^sMontarroyos^nUR#^rND^sBraga^nMC#^rND^sde Lima^nML
#^rND^sCardoso^nMR#^rND^sTurchi^nMD#^rND^sCosta^nMA#^rND^sde Alencar^nLC#^rND^sM
oreira^nRC#^rND^sFigueiredo^nGM#^rND^sXimenes^nRA#Hepatitis Study Group#Populati
on-based multicentric survey of hepatitis B infection and risk factor difference
s among three regions in Brazil^len#Am J Trop Med Hyg#20090000#2009#81#2#240-7#C
omment in: Am J Trop Med Hyg. 2010;82(1):165#20110200#v33n1a13.htm#0002-9637#Am 
J Trop Med Hyg##
00720000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01600114010002300130010001800153010001600171012009100187030002400278065000900302
06400050031103100020031603200020031801400060032086500090032600200130033503500100
0348801002400358#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#c#134#1
1#article#24#11#^rND^sMartelli^nCM#^rND^sTurchi^nM#^rND^sSouto^nFJ#^rND^sSaez-Al
quezar^nA#^rND^sAndrade^nAL#^rND^sZicker^nF#Anti-HBc testing for blood donations
 in areas with intermediate hepatitis B endemicity^len#Rev Panam Salud Publica#1
9990000#1999#6#1#69-73#20110200#v33n1a13.htm#1020-4989#Rev Panam Salud Publica##
00562000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170005000790180013000840610
02600097066000900123062004800132065000900180064000500189110000900194109001200203
037004700215865000900262002001300271#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a13.htm#S#c#135#12#article#24#12#IBGE#Cidades@^lpt#Home page on the Internet#
Brasília#Instituto Brasileiro de Geografia e Estatística#20070000#2007#20100627#
2010 Jun 27#http://www.ibge.gov.br/cidadesat/topwindow.htm#20110200#v33n1a13.htm
##
00762000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01500114010001800129010001600147010001600163810000600179012012400185030002200309
06500090033106400050034003100040034503200020034901400070035186500090035800200130
0367035001000380801002200390#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.h
tm#S#c#136#13#article#24#13#^rND^sFerreira^nRC#^rND^sTeles^nSA#^rND^sDias^nMA#^r
ND^sTavares^nVR#^rND^sSilva^nSA#^rND^sGomes^nSA#et al#Hepatitis B virus infectio
n profile in hemodialysis patients in Central Brazil: prevalence, risk factors, 
and genotypes^len#Mem Inst Oswaldo Cruz#20060000#2006#101#6#689-92#20110200#v33n
1a13.htm#0074-0276#Mem Inst Oswaldo Cruz##
00750000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
02000110010001600130010002300146010001600169810000600185012009900191030002500290
06500090031506400050032403100040032903200020033301400080033586500090034300200130
0352035001000365801002500375#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.h
tm#S#c#137#14#article#24#14#^rND^sMatos^nMA#^rND^sReis^nNR#^rND^sKozlowski^nAG#^
rND^sTeles^nSA#^rND^sMotta-Castro^nAR#^rND^sMello^nFC#et al#Epidemiological stud
y of hepatitis A, B and C in the largest Afro-Brazilian isolated community^len#T
rans R Soc Trop Med Hyg#20090000#2009#103#9#899-905#20110200#v33n1a13.htm#0035-9
203#Trans R Soc Trop Med Hyg##
00581000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100019001010100
01600120012008200136030002500218710000200243065000900245064000500254031000300259
032000200262014000500264865000900269002001300278#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a13.htm#S#c#138#15#article#24#15#^rND^sCarrazzone^nCFV#^rND^sde B
rito^nAM#^rND^sGomes^nYM#Importância da avaliação sorológica pós-transfusional e
m receptores de sangue^lpt#Rev Bras Hematol Hemoter#2#20040000#2004#26#2#93-8#20
110200#v33n1a13.htm##
00699000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100016001000100
01700116010001700133010002000150012012300170030001200293065000900305064000500314
03100030031903200020032201400050032486500090032900200130033803500100035180100120
0361#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#c#139#16#article#24
#16#^rND^sNascimento^nMC#^rND^sMayaud^nP#^rND^sSabino^nEC#^rND^sTorres^nKL#^rND^
sFranceschi^nS#Prevalence of hepatitis B and C serological markers among first-t
ime blood donors in Brazil: a multi-center serosurvey^len#J Med Virol#20080000#2
008#80#1#53-7#20110200#v33n1a13.htm#0146-6615#J Med Virol##
00711000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100024000970100
01600121010001600137010002000153012011000173030002200283065000900305064000500314
03100040031903200020032301400060032586500090033100200130034003500100035380100220
0363#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#c#140#17#article#24
#17#^rND^sAndrade^nAF#^rND^sOliveira-Silva^nM#^rND^sSilva^nSG#^rND^sMotta^nIJ#^r
ND^sBonvicino^nCR#Seroprevalence of hepatitis B and C virus markers among blood 
donors in Rio de Janeiro, Brazil, 1998-2005^len#Mem Inst Oswaldo Cruz#20060000#2
006#101#6#673-6#20110200#v33n1a13.htm#0074-0276#Mem Inst Oswaldo Cruz##
00595000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01500111010002000126012008100146030001800227710000200245065000900247064000500256
031000200261032000200263014000600265865000900271002001300280#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a13.htm#S#c#141#18#article#24#18#^rND^sRosini^nN#^rND
^sMousse^nD#^rND^sSpada^nC#^rND^sTreitinger^nA#Seroprevalence of HbsAg, Anti-HBc
 and anti-HCV in Southern Brazil, 1999-2001^len#Braz J Infect Dis#2#20030000#200
3#7#4#262-7#20110200#v33n1a13.htm##
00715000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170028000790180171001070610
00900278066000900287062003200296065000900328064000500337110000900342109001200351
037005200363865000900415002001300424#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a13.htm#S#c#142#19#article#24#19#Brasil^dMinistério da Saúde#Portaria n. 721,
 de 9 de agosto de 1989: Aprova normas técnicas para a coleta, processamento e t
ransfusão de sangue, componentes e derivados; e dá outras providências^lpt#Inter
net#Brasília#Agência de Vigilância Sanitária#19890000#1989#20000621#2000 Jun 21#
http://www.anvisa.gov.br/legis/portarias/721_89.pdf#20110200#v33n1a13.htm##
00789000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170028000790180244001070610
00900351066000900360062003200369065000900401064000500410110000900415109001200424
037005300436865000900489002001300498#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a13.htm#S#c#143#20#article#24#20#Brasil^dMinistério da Saúde#Portaria n. 1326
, de 19 de novembro de 1993: Aprova alterações na Portaria n. 721/GM, de 9 de ag
osto de 1989, que aprova normas técnicas para a coleta, processamento e transfus
ão de sangue, componentes e derivados; e dá outras providências^lpt#Internet#Bra
sília#Agência de Vigilância Sanitária#19930000#1993#20000621#2000 Jun 21#http://
www.anvisa.gov.br/legis/portarias/1376-93.pdf#20110200#v33n1a13.htm##
00539000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970120
05600114030001000170065000900180064000500189031000300194032000200197014000800199
865000900207002001300216035001000229801001000239#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a13.htm#S#c#144#21#article#24#21#^rND^sCandotti^nD#^rND^sAllain^n
JP#Transfusion-transmitted hepatitis B virus infection^len#J Hepatol#20090000#20
09#51#4#798-809#20110200#v33n1a13.htm#0168-8278#J Hepatol##
00698000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01600114010001700130010001700147012015600164030001400320710000200334065000900336
064000500345031000400350032000200354014000600356865000900362002001300371#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#c#145#22#article#24#22#^rND^sNi
shioka^nS#^rND^sGyorkos^nT#^rND^sJoseph^nL#^rND^sCollet^nJP#^rND^sMclean^nJD#Tat
tooing and transfusion-transmitted diseases: the role of the type, number and de
sing of the tattoos, and the conditions in which they were performed^len#Epidem 
Infect#2#20020000#2002#128#1#63-71#20110200#v33n1a13.htm##
00650000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01800114010001600132012009800148030001600246065000900262064000500271031000300276
032000200279014000700281865000900288002001300297035001000310801001600320#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a13.htm#S#c#146#23#article#24#23#^rND^sOl
iveira^nMD#^rND^sMatos^nMA#^rND^sMartins^nRM#^rND^sTeles^nSA#Tattooing and body 
piercing as lifestyle indicator of risk behaviors in Brazilian adolescents^len#E
ur J Epidemiol#20060000#2006#21#7#559-60#20110200#v33n1a13.htm#0392-2990#Eur J E
pidemiol##
00677000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170028000790180111001070610
00900218066000900227062004200236065000900278064000500287110000900292109001200301
037006400313865000900377002001300386#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a13.htm#S#c#147#24#article#24#24#Brasil^dMinistério da Saúde#Portaria nº 597/
GM de 8 de abril de 2004: Institui em todo território nacional os calendários de
 vacinação^lpt#Internet#Brasília#Departamento de Vigilância Epidemiológica#20040
000#2004#20080429#2008 Abr 29#http://portal.saude.gov.br/portal/arquivos/pdf/por
taria_597.pdf#20110200#v33n1a13.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#o#1#1#article#1
#20110411#115540#v33n1a14.htm#194##
05034000000000949000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120103002020100042003050100036003470100048003830100043004310100037004740100
03900511010003000550010003300580010003600613010004800649010003600697010003600733
01000350076901000270080401000330083101000290086401000250089301000430091801000380
09610100025009990100037010240700097010610700074011580700077012320700123013090700
05301432070009401485070012901579070006201708070010301770070005501873070012901928
07000590205707000770211608315410219308500100373408500600374408500430380408500410
38470850031038880850041039190850018039600850023039780850022040011170006040230720
00304029112000904032111001004041114000904051113001104060002001304071#v33n1#V:\Sc
iELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#I
LUS#TAB#14#RBHH050#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f43^l48#1516-8
484#10.5581/1516-8484.20110014#Brazilian Guidelines for transcranial doppler in 
children and adolescents with sickle cell disease^len#^rND^1A01^nClarisse Lopes 
de Castro^sLobo#^rND^1A02^nRodolfo Delfini^sCançado#^rND^1A01^nAna Claudia Celes
tino Bezerra^sLeite#^rND^1A02^nAna Claudia Mendonça dos^sAnjos#^rND^1A03^nAna Cr
istina Silva^sPinto#^rND^1A04^nAndre Palma da Cunha^sMatta#^rND^1A05^nCélia Mari
a^sSilva#^rND^1A06^nGisele Sampaio^sSilva#^rND^1A07^nJoão Ricardo^sFriedrisch#^r
ND^1A08^nJosefina Aparecida Pellegrini^sBraga#^rND^1A09^nMarcos Christiano^sLang
e#^rND^1A08^nMaria Stella^sFigueiredo#^rND^1A01^nMarília Álvares^sRugani#^rND^1A
10^nOrlando^sVeloso#^rND^1A01^nPatrícia Gomes^sMoura#^rND^1A11^nPaulo Ivo^sCorte
z#^rND^1A12^nRobert^sAdams#^rND^1A13^nSandra Fátima Menosi^sGualandro#^rND^1A01^
nShirley Lopes de^sCastilho#^rND^1A01^nUrsula^sThomé#^rND^1A09^nViviane Flumigna
n^sZetola#Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti^iA01^c
Rio de Janeiro^sRJ^pBrazil#Faculdade de Ciências Médicas da Santa Casa de São Pa
ulo^iA02^sSP^pBrazil#Fundação de Hematologia e Hemoterapia de Pernambuco^iA03^cR
ecife^sPE^pBrazil#Universidade de São Paulo^iA04^1Faculdade de Medicina de Ribei
rão Preto^2Hospital das Clínicas^cRibeirão Preto^sSP^pBrazil#Fundação Hemocentro
^iA05^cRibeirão Preto^sSP^pBrazil#Fundação Centro de Hematologia e Hemoterapia d
e Minas Gerais^iA06^cBelo Horizonte^sMG^pBrazil#UFRGS^iA07^1Hospital de Clínicas
 de Porto Alegre^2Serviço de Hematologia e Transplante de Medula Óssea^cPorto Al
egre^sRS^pBrazil#Universidade Federal de São Paulo^iA08^cSão Paulo^sSP^pBrazil#U
niversidade Federal do Paraná^iA09^1Hospital de Clínicas^2Serviço de Neurologia^
cCuritiba^sPR^pBrazil#Ecodopler Laboratório^iA10^cRio de Janeiro^sRJ^pBrazil#Uni
versidade Federal do Rio de Janeiro^iA11^1Instituto de Puericultura e Pediatria 
Martagão Gesteira^cRio de Janeiro^sRJ^pBrazil#Medical University of South Caroli
na^iA12^cCharleston^pUSA#Universidade de São Paulo^iA13^1Faculdade de Medicina^c
São Paulo^sSP^pBrazil#^len^aBACKGROUND: Sickle cell disease is the most common m
onogenic hereditary disease in Brazil. Although strokes are one of the main caus
es of morbidity and mortality in these patients, the use of transcranial Doppler
 to identify children at risk is not universally used. OBJECTIVE: To develop Bra
zilian guidelines for the use of transcranial Doppler in sickle cell disease chi
ldren and adolescents, so that related health policies can be expanded, and thus
 contribute to reduce morbidity and mortality. METHODS: The guidelines were form
ulated in a consensus meeting of experts in transcranial Doppler and sickle cell
 disease. The issues discussed were previously formulated and scientific article
s in databases (MEDLINE, SciELO and Cochrane) were carefully analyzed. The conse
nsus for each question was obtained by a vote of experts on the specific theme. 
RESULTS: Recommendations were made, including indications for the use of transcr
anial Doppler according to the sickle cell disease genotype and patients age; th
e necessary conditions to perform the exam and its periodicity depending on exam
 results; the criteria for the indication of blood transfusions and iron chelati
on therapy; the indication of hydroxyurea; and the therapeutic approach in cases
 of conditional transcranial Doppler. CONCLUSION: The Brazilian guidelines on th
e use of transcranial doppler in sickle cell disease patients may reduce the ris
k of strokes, and thus reduce the morbidity and mortality and improve the qualit
y of life of sickle cell disease patients.#^ddecs^i1#^tm^len^kUltrasonography, d
oppler, transcranial^i1^smethods#^tm^len^kAnemia, sickle cell^i1^sdiagnosis#^tm^
len^kAnemia, sickle cell^i1^stherapy#^tm^len^kHemoglobin^i1^ssickle#^tm^len^kStr
oke^i1^sprevention & control#^tm^len^kChild^i1#^tm^len^kAdolescent^i1#^tm^len^kG
uideline^i1#other#32#20100920#9/20/2010#20101123#11/23/2010#v33n1a14.htm##
05076000000000949000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120110002020100042003120100036003540100048003900100043004380100037004810100
03900518010003000557010003300587010003600620010004800656010003600704010003600740
01000350077601000270081101000330083801000290087101000250090001000430092501000380
09680100025010060100037010310700097010680700074011650700077012390700123013160700
05301439070009401492070012901586070006201715070010301777070005501880070012901935
07000590206407000770212308315760220008500100377608500600378608500430384608500410
38890850031039300850041039610850018040020850023040200850022040431170006040650720
00304071112000904074111001004083114000904093113001104102002001304113#v33n1#V:\Sc
iELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#I
LUS#TAB#14#RBHH050#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f43^l48#1516-8
484#10.5581/1516-8484.20110014#<b>Brazilian Guidelines for transcranial doppler 
in children and adolescents with sickle cell disease</b>^len#^rND^1A01^nClarisse
 Lopes de Castro^sLobo#^rND^1A02^nRodolfo Delfini^sCançado#^rND^1A01^nAna Claudi
a Celestino Bezerra^sLeite#^rND^1A02^nAna Claudia Mendonça dos^sAnjos#^rND^1A03^
nAna Cristina Silva^sPinto#^rND^1A04^nAndre Palma da Cunha^sMatta#^rND^1A05^nCél
ia Maria^sSilva#^rND^1A06^nGisele Sampaio^sSilva#^rND^1A07^nJoão Ricardo^sFriedr
isch#^rND^1A08^nJosefina Aparecida Pellegrini^sBraga#^rND^1A09^nMarcos Christian
o^sLange#^rND^1A08^nMaria Stella^sFigueiredo#^rND^1A01^nMarília Álvares^sRugani#
^rND^1A10^nOrlando^sVeloso#^rND^1A01^nPatrícia Gomes^sMoura#^rND^1A11^nPaulo Ivo
^sCortez#^rND^1A12^nRobert^sAdams#^rND^1A13^nSandra Fátima Menosi^sGualandro#^rN
D^1A01^nShirley Lopes de^sCastilho#^rND^1A01^nUrsula^sThomé#^rND^1A09^nViviane F
lumignan^sZetola#Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti
^iA01^cRio de Janeiro^sRJ^pBrazil#Faculdade de Ciências Médicas da Santa Casa de
 São Paulo^iA02^sSP^pBrazil#Fundação de Hematologia e Hemoterapia de Pernambuco^
iA03^cRecife^sPE^pBrazil#Universidade de São Paulo^iA04^1Faculdade de Medicina d
e Ribeirão Preto^2Hospital das Clínicas^cRibeirão Preto^sSP^pBrazil#Fundação Hem
ocentro^iA05^cRibeirão Preto^sSP^pBrazil#Fundação Centro de Hematologia e Hemote
rapia de Minas Gerais^iA06^cBelo Horizonte^sMG^pBrazil#UFRGS^iA07^1Hospital de C
línicas de Porto Alegre^2Serviço de Hematologia e Transplante de Medula Óssea^cP
orto Alegre^sRS^pBrazil#Universidade Federal de São Paulo^iA08^cSão Paulo^sSP^pB
razil#Universidade Federal do Paraná^iA09^1Hospital de Clínicas^2Serviço de Neur
ologia^cCuritiba^sPR^pBrazil#Ecodopler Laboratório^iA10^cRio de Janeiro^sRJ^pBra
zil#Universidade Federal do Rio de Janeiro^iA11^1Instituto de Puericultura e Ped
iatria Martagão Gesteira^cRio de Janeiro^sRJ^pBrazil#Medical University of South
 Carolina^iA12^cCharleston^pUSA#Universidade de São Paulo^iA13^1Faculdade de Med
icina^cSão Paulo^sSP^pBrazil#^len^a<b>BACKGROUND:</b> Sickle cell disease is the
 most common monogenic hereditary disease in Brazil. Although strokes are one of
 the main causes of morbidity and mortality in these patients, the use of transc
ranial Doppler to identify children at risk is not universally used. <b>OBJECTIV
E:</b> To develop Brazilian guidelines for the use of transcranial Doppler in si
ckle cell disease children and adolescents, so that related health policies can 
be expanded, and thus contribute to reduce morbidity and mortality. <b>METHODS:<
/b> The guidelines were formulated in a consensus meeting of experts in transcra
nial Doppler and sickle cell disease. The issues discussed were previously formu
lated and scientific articles in databases (MEDLINE, SciELO and Cochrane) were c
arefully analyzed. The consensus for each question was obtained by a vote of exp
erts on the specific theme. <b>RESULTS:</b> Recommendations were made, including
 indications for the use of transcranial Doppler according to the sickle cell di
sease genotype and patients age; the necessary conditions to perform the exam an
d its periodicity depending on exam results; the criteria for the indication of 
blood transfusions and iron chelation therapy; the indication of hydroxyurea; an
d the therapeutic approach in cases of conditional transcranial Doppler. <b>CONC
LUSION:</b> The Brazilian guidelines on the use of transcranial doppler in sickl
e cell disease patients may reduce the risk of strokes, and thus reduce the morb
idity and mortality and improve the quality of life of sickle cell disease patie
nts.#^ddecs^i1#^tm^len^kUltrasonography, doppler, transcranial^i1^smethods#^tm^l
en^kAnemia, sickle cell^i1^sdiagnosis#^tm^len^kAnemia, sickle cell^i1^stherapy#^
tm^len^kHemoglobin^i1^ssickle#^tm^len^kStroke^i1^sprevention & control#^tm^len^k
Child^i1#^tm^len^kAdolescent^i1#^tm^len^kGuideline^i1#other#32#20100920#9/20/201
0#20101123#11/23/2010#v33n1a14.htm##
05185000000000973000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103038000400108121000300112049000800115
15800030012303000280012603100030015403200020015706500090015901400090016803500100
01772370027001870120103002140100042003170100036003590100048003950100043004430100
03700486010003900523010003000562010003300592010003600625010004800661010003600709
01000360074501000350078101000270081601000330084301000290087601000250090501000430
09300100038009730100025010110100037010360700099010730700076011720700079012480700
12501327070005501452070009601507070013101603070006401734070010501798070005701903
07001310196007000610209107000790215208315410223108500100377208500600378208500430
38420850041038850850031039260850041039570850018039980850023040160850022040391170
00604061072000304067112000904070111001004079114000904089113001104098002001304109
008008904122#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#l#4#1#artic
le#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#14#RBHH050#nd#Rev. bras. hematol. h
emoter#33#1#20110200#^f43^l48#1516-8484#10.5581/1516-8484.20110014#Brazilian Gui
delines for transcranial doppler in children and adolescents with sickle cell di
sease^len#^rND^1A01^nClarisse Lopes de Castro^sLobo#^rND^1A02^nRodolfo Delfini^s
Cançado#^rND^1A01^nAna Claudia Celestino Bezerra^sLeite#^rND^1A02^nAna Claudia M
endonça dos^sAnjos#^rND^1A03^nAna Cristina Silva^sPinto#^rND^1A04^nAndre Palma d
a Cunha^sMatta#^rND^1A05^nCélia Maria^sSilva#^rND^1A06^nGisele Sampaio^sSilva#^r
ND^1A07^nJoão Ricardo^sFriedrisch#^rND^1A08^nJosefina Aparecida Pellegrini^sBrag
a#^rND^1A09^nMarcos Christiano^sLange#^rND^1A08^nMaria Stella^sFigueiredo#^rND^1
A01^nMarília Álvares^sRugani#^rND^1A10^nOrlando^sVeloso#^rND^1A01^nPatrícia Gome
s^sMoura#^rND^1A11^nPaulo Ivo^sCortez#^rND^1A12^nRobert^sAdams#^rND^1A13^nSandra
 Fátima Menosi^sGualandro#^rND^1A01^nShirley Lopes de^sCastilho#^rND^1A01^nUrsul
a^sThomé#^rND^1A09^nViviane Flumignan^sZetola#^iA01^1Instituto Estadual de Hemat
ologia Arthur de Siqueira Cavalcanti^cRio de Janeiro^sRJ^pBrazil#^iA02^1Faculdad
e de Ciências Médicas da Santa Casa de São Paulo^sSP^pBrazil#^iA03^1Fundação de 
Hematologia e Hemoterapia de Pernambuco^cRecife^sPE^pBrazil#^iA04^1Universidade 
de São Paulo^2Faculdade de Medicina de Ribeirão Preto^3Hospital das Clínicas^cRi
beirão Preto^sSP^pBrazil#^iA05^1Fundação Hemocentro^cRibeirão Preto^sSP^pBrazil#
^iA06^1Fundação Centro de Hematologia e Hemoterapia de Minas Gerais^cBelo Horizo
nte^sMG^pBrazil#^iA07^1UFRGS^2Hospital de Clínicas de Porto Alegre^3Serviço de H
ematologia e Transplante de Medula Óssea^cPorto Alegre^sRS^pBrazil#^iA08^1Univer
sidade Federal de São Paulo^cSão Paulo^sSP^pBrazil#^iA09^1Universidade Federal d
o Paraná^2Hospital de Clínicas^3Serviço de Neurologia^cCuritiba^sPR^pBrazil#^iA1
0^1Ecodopler Laboratório^cRio de Janeiro^sRJ^pBrazil#^iA11^1Universidade Federal
 do Rio de Janeiro^2Instituto de Puericultura e Pediatria Martagão Gesteira^cRio
 de Janeiro^sRJ^pBrazil#^iA12^1Medical University of South Carolina^cCharleston^
pUSA#^iA13^1Universidade de São Paulo^2Faculdade de Medicina^cSão Paulo^sSP^pBra
zil#^len^aBACKGROUND: Sickle cell disease is the most common monogenic hereditar
y disease in Brazil. Although strokes are one of the main causes of morbidity an
d mortality in these patients, the use of transcranial Doppler to identify child
ren at risk is not universally used. OBJECTIVE: To develop Brazilian guidelines 
for the use of transcranial Doppler in sickle cell disease children and adolesce
nts, so that related health policies can be expanded, and thus contribute to red
uce morbidity and mortality. METHODS: The guidelines were formulated in a consen
sus meeting of experts in transcranial Doppler and sickle cell disease. The issu
es discussed were previously formulated and scientific articles in databases (ME
DLINE, SciELO and Cochrane) were carefully analyzed. The consensus for each ques
tion was obtained by a vote of experts on the specific theme. RESULTS: Recommend
ations were made, including indications for the use of transcranial Doppler acco
rding to the sickle cell disease genotype and patients age; the necessary condit
ions to perform the exam and its periodicity depending on exam results; the crit
eria for the indication of blood transfusions and iron chelation therapy; the in
dication of hydroxyurea; and the therapeutic approach in cases of conditional tr
anscranial Doppler. CONCLUSION: The Brazilian guidelines on the use of transcran
ial doppler in sickle cell disease patients may reduce the risk of strokes, and 
thus reduce the morbidity and mortality and improve the quality of life of sickl
e cell disease patients.#^ddecs^i1#^tm^len^kUltrasonography, doppler, transcrani
al^i1^smethods#^tm^len^kAnemia, sickle cell^i1^sdiagnosis#^tm^len^kAnemia, sickl
e cell^i1^stherapy#^tm^len^kHemoglobin^i1^ssickle#^tm^len^kStroke^i1^sprevention
 & control#^tm^len^kChild^i1#^tm^len^kAdolescent^i1#^tm^len^kGuideline^i1#other#
32#20100920#9/20/2010#20101123#11/23/2010#v33n1a14.htm#Internet^ihttp://www.scie
lo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100014##
00352000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704011900074002001300193#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#5#1#article#158#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>SPECIAL ARTICLE</b></
font></p>     ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#6#2#article#158#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00439000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704020600074002001300280#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#7#3#article#158#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Brazilian Guideli
nes for transcranial doppler in children and adolescents with sickle cell diseas
e</b></font></p>     ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#8#4#article#158#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#9#5#article#158#<p>&nbsp;</p>     ^cY
#v33n1a14.htm##
01182000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704094800075002001301023#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#10#6#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Clarisse Lopes de Castro Lobo<sup>I</
sup>; Rodolfo Delfini Can&ccedil;ado<sup>II</sup>; Ana Claudia Celestino Bezerra
 Leite<sup>I</sup>; Ana Claudia Mendon&ccedil;a dos Anjos<sup>II</sup>; Ana Cris
tina Silva Pinto<sup>III</sup>; Andre Palma da Cunha Matta<sup>IV</sup>; C&eacut
e;lia Maria Silva<sup>V</sup>; Gisele Sampaio Silva<sup>VI</sup>; Jo&atilde;o Ri
cardo Friedrisch<sup>VII</sup>; Josefina Aparecida Pellegrini Braga<sup>VIII</su
p>; Marcos Christiano Lange<sup>IX</sup>; Maria Stella Figueiredo<sup>VIII</sup>
; Mar&iacute;lia &Aacute;lvares Rugani<sup>I</sup>; Orlando Veloso<sup>X</sup>; 
Patr&iacute;cia Gomes Moura<sup>I</sup>; Paulo Ivo Cortez<sup>XI</sup>; Robert A
dams<sup>XII</sup>; Sandra F&aacute;tima Menosi Gualandro<sup>XIII</sup> ; Shirl
ey Lopes de Castilho<sup>I</sup>; Ursula Thom&eacute;<sup>I</sup>; Viviane Flumi
gnan Zetola<sup>IX</sup></b></font></p>     ^cY#v33n1a14.htm##
00419000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704018500075002001300260#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#11#7#article#158#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Instituto Estadual de Hem
atologia Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro (RJ), Brazil   
 ^cY#v33n1a14.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011700075002001300192#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#12#8#article#158#<br>   <sup>II</sup>
Faculdade de Ci&ecirc;ncias M&eacute;dicas da Santa Casa de S&atilde;o Paulo (SP
), Brazil    ^cY#v33n1a14.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012400075002001300199#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#13#9#article#158#<br>   <sup>III</sup
>Funda&ccedil;&atilde;o de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Rec
ife (PE), Brazil    ^cY#v33n1a14.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018200076002001300258#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#14#10#article#158#<br>   <sup>IV</sup
>Hospital das Cl&iacute;nicas, Faculdade de Medicina de Ribeir&atilde;o Preto da
 Universidade de S&atilde;o Paulo -USP,  Ribeir&atilde;o Preto (SP), Brazil    ^
cY#v33n1a14.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#15#11#article#158#<br>   <sup>V</sup>
Funda&ccedil;&atilde;o Hemocentro - Ribeir&atilde;o Preto(SP), Brazil    ^cY#v33
n1a14.htm##
00379000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014400076002001300220#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#16#12#article#158#<br>   <sup>VI</sup
>Funda&ccedil;&atilde;o Centro de Hematologia e Hemoterapia de Minas Gerais  - H
EMOMINAS, Belo Horizonte (MG), Brazil    ^cY#v33n1a14.htm##
00411000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017600076002001300252#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#17#13#article#158#<br>   <sup>VII</su
p>Servi&ccedil;o de Hematologia e Transplante de Medula &Oacute;ssea, Hospital d
e Cl&iacute;nicas de Porto Alegre da UFRGS, Porto Alegre (RS), Brazil    ^cY#v33
n1a14.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#18#14#article#158#<br>   <sup>VIII</s
up>Universidade Federal de S&atilde;o Paulo - >UNIFESP, S&atilde;o Paulo (SP), B
razil    ^cY#v33n1a14.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015600076002001300232#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#19#15#article#158#<br>   <sup>IX</sup
>Servi&ccedil;o de Neurologia do Hospital de Cl&iacute;nicas, Universidade Feder
al do Paran&aacute; - UFPR, Curitiba (PR), Brazil    ^cY#v33n1a14.htm##
00320000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008500076002001300161#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#20#16#article#158#<br>   <sup>X</sup>
Ecodopler Laborat&oacute;rio - Rio de Janeiro (RJ), Brazil    ^cY#v33n1a14.htm##
00416000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018100076002001300257#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#21#17#article#158#<br>   <sup>XI</sup
>Instituto de Puericultura e Pediatria Martag&atilde;o Gesteira - IPPMG - Univer
sidade Federal do Rio de Janeiro &ndash; UFRJ, Rio de Janeiro (RJ), Brazil    ^c
Y#v33n1a14.htm##
00323000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008800076002001300164#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#22#18#article#158#<br>   <sup>XII</su
p>Medical University of South Carolina MUSC - Charleston, USA    ^cY#v33n1a14.ht
m##
00375000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014000076002001300216#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#23#19#article#158#<br>   <sup>XIII</s
up>Faculdade de Medicina, Universidade de S&atilde;o Paulo &ndash; USP, S&atilde
;o Paulo (SP), Brazil</font></p>     ^cY#v33n1a14.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#24#20#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></fo
nt></p>     ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#25#21#article#158#<p>&nbsp;</p>     ^
cY#v33n1a14.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#26#22#article#158#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v33n1a14.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#27#23#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
33n1a14.htm##
00579000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034400076002001300420#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#28#24#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>BACKGROUND:</b> Sickle cell disea
se is the most common monogenic hereditary disease in Brazil. Although strokes a
re one of the main causes of morbidity and mortality in these patients, the use 
of transcranial Doppler to identify children at risk is not universally used.   
 ^cY#v33n1a14.htm##
00490000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025500076002001300331#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#29#25#article#158#<br>     <b>OBJECTI
VE:</b> To develop Brazilian guidelines for the use of transcranial Doppler in s
ickle cell disease children and adolescents, so that related health policies can
 be expanded, and thus contribute to reduce morbidity and mortality.    ^cY#v33n
1a14.htm##
00611000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037600076002001300452#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#30#26#article#158#<br>     <b>METHODS
:</b> The guidelines were formulated in a consensus meeting of experts in transc
ranial Doppler and sickle cell disease. The issues discussed were previously for
mulated and scientific articles in databases (MEDLINE, SciELO and Cochrane) were
 carefully analyzed. The consensus for each question was obtained by a vote of e
xperts on the specific theme.    ^cY#v33n1a14.htm##
00696000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046100076002001300537#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#31#27#article#158#<br>     <b>RESULTS
:</b> Recommendations were made, including indications for the use of transcrani
al Doppler according to the sickle cell disease genotype and patients age; the n
ecessary conditions to perform the exam and its periodicity depending on exam re
sults; the criteria for the indication of blood transfusions and iron chelation 
therapy; the indication of hydroxyurea; and the therapeutic approach in cases of
 conditional transcranial Doppler.    ^cY#v33n1a14.htm##
00515000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028000076002001300356#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#32#28#article#158#<br>     <b>CONCLUS
ION:</b> The Brazilian guidelines on the use of transcranial doppler in sickle c
ell disease patients may reduce the risk of strokes, and thus reduce the morbidi
ty and mortality and improve the quality of life of sickle cell disease patients
.</font></p>     ^cY#v33n1a14.htm##
00546000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031100076002001300387#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#33#29#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Ultrasonography, do
ppler, transcranial/methods; Anemia, sickle cell/diagnosis; Anemia, sickle cell/
therapy; Hemoglobin, sickle; Stroke/prevention &amp; control; Child; Adolescent;
 Guideline</font></p> <hr size="1" noshade>     ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#34#30#article#158#<p>&nbsp;</p>     ^
cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#35#31#article#158#<p>&nbsp;</p>     ^
cY#v33n1a14.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#36#32#article#158#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></p>     ^
cY#v33n1a14.htm##
01033000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079800076002001300874#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#37#33#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Sickle cell disease (SCD) is the mos
t common monogenic hereditary disease in Brazil occurring predominantly among Af
rican descents.<sup>(1)</sup> (A) The term SCD includes sickle cell anemia (SCA)
 the form of the disease that occurs in homozygotes of hemoglobin S (Hb SS), as 
well as pathological conditions caused by combinations of the hemoglobin S gene 
with other hereditary hemoglobin disorders such as sickle cell SC disease, Hb S/
&#223;+ thalassemia and Hb S/&#223;0 thalassemia. Complications of SCD, such as 
renal failure, vaso-occlusive crisis, acute chest syndrome and strokes result in
 a reduction of 25 to 30 years of life expectancy of SCD patients compared to th
e general population.<sup>(2)</sup> (B)</font></p>     ^cY#v33n1a14.htm##
00927000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069200076002001300768#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#38#34#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Recently, several aspects have contr
ibuted significantly to the reduction in mortality in SCD patients. These includ
e the control of infections through immunization and the prophylactic use of ant
ibiotics during early life; watchfulness and appropriate guidance for parents or
 caregivers to recognize early signs of splenic sequestration; the diagnosis and
 treatment of acute chest syndrome; and the identification of children at risk f
or developing strokes using transcranial doppler (TCD), combined with early use 
of packed red blood cell (RBC) transfusions when test results are abnormal.<sup>
(1)</sup> (D)</font></p>     ^cY#v33n1a14.htm##
01125000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704089000076002001300966#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#39#35#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">HEMORIO, with the support of the Min
istry of Health in Brazil, the Associa&ccedil;&atilde;o Brasileira de Hematologi
a e Hemoterapia, and the Pro-HEMORIO Foundation, decided to develop the Brazilia
n guidelines on the use of transcranial doppler in sickle cell disease patients 
with the intention of expanding health policies for SCD and to contribute in red
ucing morbidity and mortality resulting from this pathology. This work was devel
oped in line with the National Newborn Screening Program which guarantees univer
sal access of newborns to screening for hemoglobinopathies, and Government decre
e 1391, which establishes guidelines for the National Policy of Comprehensive Ca
re for People with Sickle Cell Disease and other Hemoglobinopathies in the Brazi
lian national healthcare service.<sup>(1)</sup> (D)</font></p>     ^cY#v33n1a14.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#40#36#article#158#<p>&nbsp;</p>     ^
cY#v33n1a14.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#41#37#article#158#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Methods</b></font></p>     ^cY#v3
3n1a14.htm##
01092000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085700076002001300933#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#42#38#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A committee of specialists was forme
d and the guidelines were formulated in two parallel consensus meetings. At a co
nsensus meeting of experts on TCD, nine regional facilitators, reference physici
ans in their regions on this theme, discussed the technical issues of the proced
ure. Four national facilitators, physicians who are recognized as experts in the
se sub-themes, presented the issues and the supporting scientific evidence. Reco
rds of the debate and a final summary of the findings for each question were ent
rusted to two other specialists in TCD. The consensus meeting was attended by ex
perts in SCD, 26 regional facilitators who discussed technical matters involving
 the indication of TCD and the treatment to be adopted depending on the differen
t findings of TCD.</font></p>     ^cY#v33n1a14.htm##
01505000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704127000076002001301346#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#43#39#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The issues discussed at both consens
us meetings were previously formulated by the national facilitators and two coor
dinators of the event, all nationally renowned physicians. Before the meeting, t
he national facilitators and coordinators were also responsible for the identifi
cation of regional facilitators assigned to each theme as well as the selection 
and distribution of publications to all participants. The scientific papers were
 identified from the MEDLINE, SciELO and Cochrane databases and papers were clas
sified according to the degree of recommendation and level of evidence. The foll
owing designations were adopted: (A) highly consistent experimental or observati
onal studies; (B) less consistent experimental or observational studies; (C) cas
e reports (uncontrolled studies); (D) opinions without critical assessment based
 on consensus, physiologic studies or animal models. The consensus for each ques
tion was obtained by voting and proposals were accepted even if there was a maxi
mum of three opposing votes. Abstentions were not considered opposing votes. All
 participants had the right to vote, except for five participants of organizatio
ns that represent SCD carriers.</font></p>     ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#44#40#article#158#<p>&nbsp;</p>     ^
cY#v33n1a14.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#45#41#article#158#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>     ^cY#v3
3n1a14.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#46#42#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Genotype of hemoglobinopathies</font
></p>     ^cY#v33n1a14.htm##
00526000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029100076002001300367#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#47#43#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Recommendation: TCD should be used f
or primary prevention of strokes in SCD patients, regardless of the genotype of 
the disease, but with priority to those with the Hb SS and Hb S/&#223;0talassemi
a genotypes.</font></p>     ^cY#v33n1a14.htm##
01262000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102700076002001301103#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#48#44#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although the incidence of strokes is
 higher in patients with the Hb SS genotype, it should be noted that strokes als
o occur in patients with other genotypes. According to a publication of the Coop
erative Study of Sickle Cell Disease Group, the incidence of strokes (number of 
 acute events/100 patients/year) is 0.61 for patients with Hb SS, 0.17 for Hb SC
, 0.11 for Hb S/&#223;+ thalassemia and 0.10 for Hb S/&#223;0 thalassemia. It is
 estimated that 11%, 15% and 24% of SCA patients and 2%, 4% and 10% of Hb SC pat
ients develop symptomatic strokes up to the ages of 20, 30 and 45 years old, res
pectively. The acute event may occur spontaneously or after any acute complicati
on such as, for example, infections. Additionally, the study showed that the est
imated prevalence of strokes adjusted for age was 4.01% in patients with Hb SS; 
2.43% in Hb S/&#223;0 thalassemia, 1.29% for Hb S/&#223;+ thalassemia and 0.84% 
for Hb SC.<sup>(3)</sup> (B)</font></p>     ^cY#v33n1a14.htm##
00754000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051900076002001300595#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#49#45#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Given these data, it was deemed appr
opriate to recommend TCD as a method of primary prevention for all SCD patients 
regardless of genotype. The long-term monitoring of the population might allow f
or eventual determination of various intervals between examinations according to
 the genotype of the disease, as well as a reassessment of the necessity of scre
ening for genotypes with lower risk, such as Hb SC and Hb S/&#223;+ thalassemia.
</font></p>     ^cY#v33n1a14.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#50#46#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Age of patients</font></p>     ^cY#v
33n1a14.htm##
00440000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020500076002001300281#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#51#47#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Recommendation: TCD should be used f
or primary prevention of strokes in SCD patients aged between two and 16 years o
f age.</font></p>     ^cY#v33n1a14.htm##
01013000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077800076002001300854#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#52#48#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In the publication of the Cooperativ
e Study of Sickle Cell Disease Group, the overall incidence of the first stroke 
among SCD patients was 0.08 acute events/100 patients/year in under two-year old
s; 0.75 in patients between two and five years old, 0.55 between six and nine ye
ars old, 0.30 between 10 and 19 years old, and 0.45 between 20 and 29 years old.
<sup>(3)</sup> (B) Although over 16-year-old SCD patients may be at increased ri
sk of strokes, the association between flow velocity measured by TCD and the ris
k of strokes was first demonstrated in the cohort of SCD patients from the Medic
al College of Georgia, which involved children between three and 18 years old.<s
up>(4,5)</sup> (B) </font></p>     ^cY#v33n1a14.htm##
01262000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102700076002001301103#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#53#49#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Subsequently the study, Stroke Preve
ntion Trial in Sickle Cell Anemia (STOP), which included patients with SCA aged 
between two and 16 years, confirmed the predictive value of TCD for strokes in t
his patient population<sup>(6)</sup> (A) and demonstrated that blood transfusion
s significantly reduced the risk of strokes among children in this age range wit
h abnormal TCD.<sup>(7,8)</sup> (A) Moreover, these studies established their ow
n parameters for the definition of abnormal TCD in this cohort of patients.<sup>
(6,7)</sup> (A) Given the fact that the cerebral blood flow (CBF) and the estima
ted speed of this flow (CBFV) measured by TCD, are increased in anemic condition
s due to decreased oxygen transport capacity of the blood, it was shown that the
 parameters of TCD related to stenosis in adults could not be applied to SCD chi
ldren, because of the age and the anemia itself.<sup>(9)</sup> (B) <sup>(10,11)<
/sup> (C)<sup>(12)</sup> (D)</font></p>     ^cY#v33n1a14.htm##
00730000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049500076002001300571#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#54#50#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Thus, considering the relatively low
 risk of strokes in under 2-year-old children with SCD; the absence of validated
 parameters of abnormal TCD in SCD patients of &lt; 2 years old and &gt; 18 year
s old; and lack of evidence to support transfusion therapy in SCA patients with 
ages &gt; 16 years, the consensus recommendation is to perform TCD for primary p
revention in patients aged between two and 16 years old.</font></p>     ^cY#v33n
1a14.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011600076002001300192#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#55#51#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Frequency of transcranial doppler</f
ont></p>     ^cY#v33n1a14.htm##
00767000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053200076002001300608#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#56#52#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Recommendation: Conventional TCD is 
the method of choice and should be repeated frequency according to the criteria 
listed in <a href="/img/revistas/rbhh/v33n1/a14tab01.jpg">table 1</a>. The exami
nation must be conducted and interpreted in accordance with the parameters set b
y the STOP study.<sup>(4,5)</sup> (B) The examination should be performed with t
he patient awake, afebrile and at least four weeks after acute events and blood 
transfusions.</font></p>     ^cY#v33n1a14.htm##
00987000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075200076002001300828#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#57#53#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although the parameters in the STOP 
study were arbitrarily defined, the risk categories proved to be excellent for t
he stratification of risk of strokes and the decision to start transfusion thera
py.<sup>(13)</sup> (C) Thus we recommend the adoption of the STOP study protocol
 for the indication of TCD as a primary stroke prevention method in SCD patients
. TCD may vary due to individual physiological factors (such as sleep, for examp
le) and pathological factors (such as fever, for example) that increase the CBFV
,<sup>(12)</sup> (D)<sup>(13)</sup> (C)<sup>(14)</sup> (B) which is the reason t
hat it is recommended to defer examinations for four weeks in such cases.</font>
</p>     ^cY#v33n1a14.htm##
01407000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704117200076002001301248#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#58#54#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">TCD based on the methodology adopted
 in the STOP study included insonation of 15 arterial segments of the Circle of 
Willis: the M1 segment of the middle cerebral artery (MCA) and to check its enti
re length at 2-mm intervals to the bifurcation; the bifurcation of the internal 
carotid artery (ICA); the distal or terminal ICA, anterior cerebral artery, post
erior cerebral artery, in both transtemporal windows; and the basilar artery (to
p or its bifurcation) through the transforaminal window. The predictive risk fac
tor for strokes according to the STOP study was determined by the mean maximum s
peed of the CBF in segments of MCA, and at the bifurcation and distal ICA bilate
rally. Wave spectral information was not used in the STOP study and the submandi
bular and transorbital windows were not evaluated.<sup>(4,5)</sup> (B) <sup>(7)<
/sup> (A) It should be noted that very low speeds (&lt; 70 cm/s) may be indicati
ve of severe stenosis, <sup>(13)</sup> (C) which is the reason that it is recomm
ended to repeat the examination after one month, or to examine the image by medi
cal criteria.</font></p>     ^cY#v33n1a14.htm##
00639000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040400076002001300480#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#59#55#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In addition, the meeting considered 
that it is essential to use educational interventions to target parents and care
givers as well as children, about the importance of conducting systematic TCD ex
aminations as well as the need for different therapeutic interventions for those
 at high risk for strokes.<sup>(15)</sup> (B)</font></p>     ^cY#v33n1a14.htm##
00354000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011900076002001300195#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#60#56#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Conventional TCD versus TCD imaging 
</font></p>     ^cY#v33n1a14.htm##
00555000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032000076002001300396#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#61#57#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As mentioned previously, conventiona
l TCD is the method of choice for primary stroke prevention in SCD patients and 
the test should be performed and interpreted in accordance with the parameters s
et by the STOP study.<sup>(4,5)</sup> (B)</font></p>     ^cY#v33n1a14.htm##
00853000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061800076002001300694#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#62#58#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">TCD imaging techniques were not inve
stigated in the STOP study. However, a few scientific papers have been published
 using TCD imaging that tried to evaluate and establish possible correlations be
tween the findings using this method and data obtained with conventional TCD. <s
up>(16,17)</sup>(A)<sup>(18-20)</sup>(B)<sup>(21,22)</sup>(C)<sup>(23)</sup>(D) 
It was observed that the velocities obtained by TCD imaging ranged from values s
imilar to conventional TCD to values 20% lower and this variation depended on th
e insonation angle.</font></p>     ^cY#v33n1a14.htm##
01109000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087400076002001300950#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#63#59#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Thus, the meeting considered that th
ere is not enough scientific evidence to make any recommendation of cutoff value
s for TCD imaging. Services and Institutions that only have TCD imaging must tak
e into account differences in speeds that are reported in the literature.<sup>(4
,5,18-20)</sup> (B) <sup>(16,17)</sup> (A) <sup>(21,22)</sup> (C)<sup>(23)</sup>
 (D) Some clinical studies provide regression equations to convert the speed of 
blood flow from TCD imaging to corresponding conventional TCD velocities and thu
s compatible with those used in the STOP study. However, it must be remembered t
hat such regression equations may not apply to all TCD imaging devices. It is re
commended that the method employed (conventional TCD or TCD imaging) should be c
ited in the report of test results.</font></p>     ^cY#v33n1a14.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011700076002001300193#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#64#60#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">RBC transfusion and iron chelation</
font></p>     ^cY#v33n1a14.htm##
01093000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085800076002001300934#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#65#61#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Recommendation: RBC transfusion regi
mens of three to six weeks using exchange transfusion or partial exsanguinous tr
ansfusion is indicated for patients who present at least two consecutive TCD exa
minations with average CBFV&gt; 200 cm/s (<a href="/img/revistas/rbhh/v33n1/a14t
ab01.jpg">Table 1</a>). Phenotyping should be made for Kell, Kidd, Duffy and MNS
s and when possible for the Lewis, P and Lutheran blood group systems. Always us
e samples leucocyted depleted RBC and phenotyped RBCs, in principle, for the ABO
, Rh and Kell systems. It is recommended that the storage time of RBCs to be tra
nsfused does not exceed seven days and are negative for Hb S. The patient should
 be maintained with a maximum Hb level of up to 10 g/dL and pre-transfusion Hb l
evel less than 50%.</font></p>     ^cY#v33n1a14.htm##
00867000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063200076002001300708#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#66#62#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Iron chelation therapy is indicated 
for patients submitted to a simple transfusion regimen who have received more th
an twenty units of packed red blood cells and who have serum ferritin concentrat
ions greater than 1000 ng/mL (at least two measurements under normal conditions)
 or grade III or IV hepatic siderosis by liver biopsy or liver iron concentratio
ns equal to 4 mg/gram dry matter or above by magnetic resonance imaging (MRI). T
he therapeutic alternatives include orally administered deferasirox and subcutan
eously administered deferoxamine.</font></p>     ^cY#v33n1a14.htm##
02033000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704179800076002001301874#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#67#63#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In the STOP study, 130 of the 1934 p
articipants were 2- to 16-year-old children who had changed TCD (mean CBFV &gt; 
200 cm/s in one or both of the middle cerebral arteries or the distal segment of
 the internal carotid artery in two exams at an interval of at least two weeks).
 These children were randomized into two groups: observation (with occasional tr
ansfusions) and a regular transfusion regimen aiming at maintaining Hb S below 3
0%. After 20 months of follow up, there was one case of a stroke in the 63 child
ren in the transfusion group versus 11 cases of strokes in 67 children in the ob
servation group. These results indicate a 92% reduction in relative risk for the
 occurrence of strokes (reduction in the risk of strokes from 10% per year to &l
t; 1% per year). <sup>(7)</sup> (A) The follow-up of patients undergoing chronic
 transfusion regimens for primary prevention of strokes in the STOP study also s
howed significant reductions in the levels of free hemoglobin compared to contro
ls not subjected to transfusion or only to occasional transfusions. Furthermore,
 other markers of hemolysis such as lactate dehydrogenase and alanine aminotrans
ferase levels were reduced. It is believed that the increase in circulating hemo
globin and the reduction in hemolysis with consequent reductions in free hemoglo
bin plasma levels increase bioavailability of nitric oxide and its effects by re
ducing or preventing endothelial dysfunction, which would help to explain the ro
le of transfusions in preventing strokes.<sup>(24)</sup> (A) Therefore, it is re
commended to start packed red blood cell transfusions according to the TCD resul
ts as described in <a href="/img/revistas/rbhh/v33n1/a14tab01.jpg">Table 1</a>.<
/font></p>     ^cY#v33n1a14.htm##
00835000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060000076002001300676#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#68#64#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">However, regular blood transfusion r
egimens can lead to an accumulation of iron in the body, as physiological mechan
isms to excrete excessive iron are restricted. SCD Patients appear to suffer tis
sue damage similar to other populations of chronically transfused patients, incl
uding iron deposits in the liver, heart and endocrine organs. The therapeutic al
ternatives for iron chelation therapy in SCD patients undergoing blood transfusi
ons include deferoxamine and deferasirox. <sup>(25)</sup> (A) <sup>(26)</sup> (B
)</font></p>     ^cY#v33n1a14.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#69#65#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Indication of hydroxyurea</font></p>
     ^cY#v33n1a14.htm##
00805000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057000076002001300646#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#70#66#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Recommendation: Although the exchang
e transfusion regimen is the method of choice for primary prevention of strokes 
in SCD patients who are indicated for this procedure, treatment with hydroxyurea
 (HU) may be indicated in cases in which Hb S levels can not be maintained &lt; 
50%, in cases of patients who do not comply to the red blood cell transfusion re
gimen, in cases of alloimmunization, in situations that phenotyped blood is unav
ailable and in children without intravenous access.</font></p>     ^cY#v33n1a14.
htm##
00779000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054400076002001300620#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#71#67#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">HU is an antimetabolite that blocks 
the synthesis of deoxyribonucleic acid by inhibiting ribonucleotide reductase. T
he efficacy of this agent in the treatment of SCD appears to be related to incre
ased levels of hemoglobin F (which reduces the formation of hemoglobin S), cytor
eduction of neutrophils, increased water content inside the RBCs, and increased 
capacity for deformation and improvement of microvascular flow of sickle erythro
cytes.<sup>(27)</sup> (D)</font></p>     ^cY#v33n1a14.htm##
00817000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058200076002001300658#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#72#68#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Since the classic Multicenter Study 
of Hydroxyurea (MSH) study published in 1995 by Charach et al.,<sup>(28)</sup> (
A) and the data obtained by Steinberg et al.<sup>(29)</sup> (A) over more than n
ine years of follow-up of patients using HU, such as the reduction in the number
 and intensity of pain crises, decreased hospitalization and reduction in mortal
ity, HU has been recommended in an ever increasing number of cases, not only for
 adults but for children from two years of age or even earlier.</font></p>     ^
cY#v33n1a14.htm##
00545000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031000076002001300386#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#73#69#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">These are cheap, easy-to-use oral me
dications with few serious adverse effects. However, one of the key issues is th
e use of the maximum tolerated dose, which can reach 35 mg/kg/day in order to ob
tain the best possible outcome.</font></p>     ^cY#v33n1a14.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020600076002001300282#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#74#70#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">One important issue regarding the us
e of HU is whether such treatment can prevent the occurrence and recurrence of s
trokes.</font></p>     ^cY#v33n1a14.htm##
01186000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704095100076002001301027#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#75#71#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In a prospective study, 35 children 
who had suffered strokes discontinued their red blood cell transfusion regimens 
and started drug therapy with HU associated with serial phlebotomy to reduce iro
n overload. The study showed a reduction in the rate of recurrent strokes from 5
.7 events/100 patient-years to 3.6 events/100 patient-years as well as reduction
 in iron overload evaluated by serum ferritin levels and liver biopsy. The autho
rs concluded that HU partially prevents the occurrence of strokes and that seria
l phlebotomy is capable of preventing transfusional iron overload.<sup>(30)</sup
> (B) In a Belgian study on the use of HU in SCD children at high risk of stroke
s as detected by TCD, the CBFV decreased significantly in 11 of 34 children with
 abnormal TCDs, and only one developed a primary stroke over a follow-up of 96 p
atient-years.<sup>(19)</sup> (B)</font></p>     ^cY#v33n1a14.htm##
00520000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028500076002001300361#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#76#72#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Due to this data there was a consens
us in the meeting that HU therapy is an alternative to the blood transfusion reg
imen particularly in situations where patients do not comply with transfusion th
erapy.</font></p>     ^cY#v33n1a14.htm##
00374000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013900076002001300215#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#77#73#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Therapeutic approach to conditional 
transcranial doppler</font></p>     ^cY#v33n1a14.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019100076002001300267#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#78#74#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Recommendation: There is no scientif
ic evidence to recommend the use of HU in patients with conditional TCD.</font><
/p>     ^cY#v33n1a14.htm##
01310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704107500076002001301151#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#79#75#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The evaluation of the effects of HU 
on CBFV measured by TCD in SCA children showed that medication use at the maximu
m tolerated dose resulted in a significant decrease of the velocities. After a y
ear of full-dose treatment, the following results were obtained from 15 children
 with conditional values of velocities; the velocity decreased in 14; the veloci
ties dropped below 200 cm/s in five of six children with abnormal initial values
 at TCD and whose parents had refused treatment by transfusions.<sup>(31)</sup> 
(B) In a cohort of 24 SCD patients, treatment with HU has shown to result in ave
rage reductions in CBFV of 13.0 cm/s at TCD imaging. Patients with untreated SCD
 constituted the control group adjusted for age, in which the CBFV showed an inc
rease of 4.72 cm/s (significant difference, p &lt;0.001). Of the five patients w
ith velocities &gt; 170 cm/s who were treated with HU, four progressed to normal
 values, resulting in an average reduction of 34.75 cm/s.<sup>(32)</sup> (C)</fo
nt></p>     ^cY#v33n1a14.htm##
00594000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035900076002001300435#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#80#76#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Considering the relative paucity of 
data relating to the administration of HU in patients with conditional TCD, the 
panel chose not to make any recommendation to use the agent in this situation, a
lthough it was acknowledged that in practice, this approach might be beneficial.
</font></p>     ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#81#77#article#158#<p>&nbsp;</p>     ^
cY#v33n1a14.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#82#78#article#158#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Conclusion</b></font></p>     ^cY
#v33n1a14.htm##
01007000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077200076002001300848#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#83#79#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Early diagnosis and treatment have p
roven to increase survival and improve quality of life of SCD patients. However,
 achieving these goals is directly related to the organization of a SCD patient 
care network in all Brazilian states, through the formation of specialized refer
ence centers capable of providing global, multidisciplinary and multi-profession
al services. Thus, the development of public policies and other actions that con
sider the socioeconomic and cultural issues and care related to SCD, as well as 
the commitment of competent health agencies, healthcare professionals and organi
zations that represent patients are key factors and determinants to improve SCD 
patient care.</font></p>     ^cY#v33n1a14.htm##
00907000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067200076002001300748#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#84#80#article#158#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Brazilian Guidelines on the use 
of transcranial Doppler in Sickle Cell Disease Children and Adolescents is an in
itiative of leading experts in the areas of diagnosis and treatment of SCD, with
 the participation of those responsible for public health agencies, national med
ical societies, and institutions that representative SCD patients. The adoption 
of these guidelines may result in a reduction in the risk of strokes in this pat
ient population as demonstrated by scientific evidence, thereby helping to reduc
e morbidity and mortality and to improve quality of life of SCD patients.</font>
</p>     ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#85#81#article#158#<p>&nbsp;</p>     ^
cY#v33n1a14.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#86#82#article#158#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY
#v33n1a14.htm##
00426000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017700078002001300255#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#87#83#article#158#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Can&ccedil;ado RD, 
Jesus JA. Sickle cell disease in Brazil. Rev Bras Hematol Hemoter. 2007;29(3):20
3-6.    ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#88#84#article#158#</font></p>     ^cY
#v33n1a14.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031600078002001300394#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#89#85#article#158#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Platt OS, Brambilla
 DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cel
l disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;
330(23):1639-44. Comment in: N Engl J Med. 1994;331(15):1022-3.    ^cY#v33n1a14.
htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#90#86#article#158#</font></p>     ^cY
#v33n1a14.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025200078002001300330#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#91#87#article#158#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Ohene-Frempong K, W
einer SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular acci
dents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288-94. 
   ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#92#88#article#158#</font></p>     ^cY
#v33n1a14.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026500078002001300343#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#93#89#article#158#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Adams RJ, McKie VC,
 Carl EM, Nichols FT, Perry R, Brock K, et al. Long-term stroke risk in children
 with sickle cell disease screened with transcranial Doppler Ann Neurol. 1997;42
(5):699-704.    ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#94#90#article#158#</font></p>     ^cY
#v33n1a14.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029700078002001300375#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#95#91#article#158#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Adams R, McKie V, N
ichols F, Carl E, Zhang DL, McKie K, et al. The use of transcranial ultrasonogra
phy to predict stroke in sickle cell disease. N Engl J Med. 1992;326(9):605-10. 
Comment in: N Engl J Med. 1992;326(9):637-9.    ^cY#v33n1a14.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#96#92#article#158#</font></p>     ^cY
#v33n1a14.htm##
00656000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704040700078002001300485#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#97#93#article#158#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Adams RJ, Brambilla
 DJ, Granger S, Gallagher D, Vichinsky E, Abboud MR, Pegelow CH, Woods G, Rohde 
EM, Nichols FT, Jones A, Luden JP, Bowman L, Hagner S, Morales KH, Roach ES; STO
P Study. Stroke and conversion to high risk in children screened with transcrani
al Doppler ultrasound during the STOP study. Blood. 2004 ;103(10):3689-94.    ^c
Y#v33n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#98#94#article#158# </font></p>     ^c
Y#v33n1a14.htm##
00609000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704036000078002001300438#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#99#95#article#158#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Adams RJ, McKie VC,
 Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by 
transfusions in children with sickle cell anemia and abnormal results on transcr
anial Doppler ultrasonography. N Engl J Med.1998;339(1):5-11.Comment in: N Engl 
J Med. 1998;339(20):1477-8.    ^cY#v33n1a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#100#96#article#158#</font></p>     ^c
Y#v33n1a14.htm##
00547000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704029700079002001300376#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#101#97#article#158#8#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Lee MT, Piomelli S
, Granger S, Miller ST, Harkness S, Brambilla DJ, Adams RJ; STOP Study Investiga
tors. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up a
nd final results. Blood. 2006 ;108(3):847-52.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#102#98#article#158# </font></p>     ^
cY#v33n1a14.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704024200079002001300321#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#103#99#article#158#9#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Brass LM, Pavlakis
 SG, DeVivo D, Piomelli S, Mohr JP. Transcranial Doppler measurements of the mid
dle cerebral artery. Effect of hematocrit. Stroke. 1988;19(12):1466-9.    ^cY#v3
3n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#104#100#article#158#</font></p>     ^
cY#v33n1a14.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025000081002001300331#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#105#101#article#158#10#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Sampaio Silva G
, Vicari P, Figueiredo MS, Filho AC, Valadi N, Massaro AR. Transcranial Doppler 
in adult patients with sickle cell disease. Cerebrovasc Dis. 2006;21(1-2):38-41.
    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#106#102#article#158#</font></p>     ^
cY#v33n1a14.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024600081002001300327#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#107#103#article#158#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Valadi N, Silva
 GS, Bowman LS, Ramsingh D, Vicari P, Filho AC, et al. Transcranial Doppler ultr
asonography in adults with sickle cell disease. Neurology. 2006;67(4):572-4.    
^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#108#104#article#158#</font></p>     ^
cY#v33n1a14.htm##
00401000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704014900081002001300230#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#109#105#article#158#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Adams RJ. Big s
trokes in small persons. Arch Neurol. 2007; 64(11):1567-74.    ^cY#v33n1a14.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#110#106#article#158#</font></p>     ^
cY#v33n1a14.htm##
00497000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024500081002001300326#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#111#107#article#158#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Adams C, Hwang 
PA, Gilday DL, Armstrong DC, Becker LE, Hoffman HJ. Comparison of SPECT, EEG, CT
, MRI, and pathology in partial epilepsy. Pediatr Neurol. 1992;8(2):97-103.    ^
cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#112#108#article#158#</font></p>     ^
cY#v33n1a14.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031400081002001300395#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#113#109#article#158#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Silva GS, Vicar
i P, Figueiredo MS, Carrete H Jr, Idagawa MH, Massaro AR. Brain magnetic resonan
ce imaging abnormalities in adult patients with sickle cell disease: correlation
 with transcranial Doppler findings. Stroke. 2009;40(7):2408-12.    ^cY#v33n1a14
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#114#110#article#158#</font></p>     ^
cY#v33n1a14.htm##
00550000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029800081002001300379#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#115#111#article#158#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Katz ML, Smith-
Whitley K, Ruzek SB, Ohene-Frempong K. Knowledge of stroke risk, signs of stroke
, and the need for stroke education among children with sickle cell disease and 
their caregivers. Ethn Health. 2002;7(2):115-23.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#116#112#article#158#</font></p>     ^
cY#v33n1a14.htm##
00722000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704047000081002001300551#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#117#113#article#158#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. NHS Sickle Cell
 &amp; Thalassaemia Screening Programme. TD Standards Writing Group of the Sickl
e Cell and Thalassaemia Screening Programme. Transcranial Doppler Scanning for C
hildren with Sickle Cell Disease. Standards and Guidance. NHS; March 2009. &#91;
cited 2010 Oct 12&#93;.  Available from: <a href="http://www.sct.screening.nhs.u
k" target="_blank">www.sct.screening.nhs.uk</a> </font></p>     ^cY#v33n1a14.htm
##
00520000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026800081002001300349#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#118#114#article#158#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Jones A, Grange
r S, Brambilla D, Gallagher D, Vichinsky E, Woods G, et al. Can peak systolic ve
locities be used for prediction of stroke in sickle cell anemia? Pediatr Radiol.
 2005;35(1):66-72.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#119#115#article#158#</font></p>     ^
cY#v33n1a14.htm##
00610000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035800081002001300439#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#120#116#article#158#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Jones AM, Seibe
rt JJ, Nichols FT, Kinder DL, Cox K, Luden J, et al. Comparison of transcranial 
color Doppler imaging (TCDI) and transcranial Doppler (TCD) in children with sic
kle-cell anemia. Pediatr Radiol. 2001;31(7):461-9. Comment in: Pediatr Radiol. 2
002;32(9):690-1 reply 692-3.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#121#117#article#158#</font></p>     ^
cY#v33n1a14.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027200081002001300353#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#122#118#article#158#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Kratovil T, Bul
as D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP. Hydroxyurea therapy 
lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer
. 2006; 47(7):894-900.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#123#119#article#158#</font></p>     ^
cY#v33n1a14.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027600081002001300357#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#124#120#article#158#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Neish AS, Blews
 DE, Simms CA, Merritt RK, Spinks AJ. Screening for stroke in sickle cell anemia
: comparison of transcranial Doppler imaging and non-imaging US techniques. Radi
ology. 2002;222(3):709-14.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#125#121#article#158#</font></p>     ^
cY#v33n1a14.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028900081002001300370#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#126#122#article#158#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Bulas DI, Jones
 A, Seibert JJ, Driscoll C, ODonnell R, Adams RJ. Transcranial Doppler (TCD) scr
eening for stroke prevention in sickle cell anemia: pitfalls in technique variat
ion. Pediatr Radiol. 2000;30(11):733-8.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#127#123#article#158#</font></p>     ^
cY#v33n1a14.htm##
00605000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035300081002001300434#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#128#124#article#158#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Krejza J, Rudzi
nski W, Pawlak MA, Tomaszewski M, Ichord R, Kwiatkowski J, et al. Angle-correcte
d imaging transcranial doppler sonography versus imaging and nonimaging transcra
nial doppler sonography in children with sickle cell disease. AJNR Am J Neurorad
iol. 2007;28(8):1613-8.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#129#125#article#158#</font></p>     ^
cY#v33n1a14.htm##
00429000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017700081002001300258#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#130#126#article#158#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Adams RJ. TCD i
n sickle cell disease: an important and useful test. Pediatr Radiol. 2005;35(3):
229-34.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#131#127#article#158#</font></p>     ^
cY#v33n1a14.htm##
00512000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026000081002001300341#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#132#128#article#158#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Lezcano NE, Odo
 N, Kutlar A, Brambilla D, Adams RJ. Regular transfusion lowers plasma free hemo
globin in children with sickle-cell disease at risk for stroke. Stroke. 2006;37(
6):1424-6.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#133#129#article#158#</font></p>     ^
cY#v33n1a14.htm##
00764000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704051200081002001300593#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#134#130#article#158#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Vichinsky E, On
yekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, 
Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Hollan
d J, Marks P, Fung E, Fischer R, Mueller BU, Coates T; Deferasirox in Sickle Cel
l Investigators. A randomised comparison of deferasirox versus deferoxamine for 
the treatment of transfusional iron overload in sickle cell disease. Br J Haemat
ol. 2007;136(3):501-8.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#135#131#article#158#</font></p>     ^
cY#v33n1a14.htm##
00745000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704049300081002001300574#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#136#132#article#158#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Cappellini MD, 
Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S,
 Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domok
os G, Roubert B, Kattamis A; EPIC Study Investigators. Tailoring iron chelation 
by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 
1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557-
66.    ^cY#v33n1a14.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#137#133#article#158# </font></p>     
^cY#v33n1a14.htm##
00474000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022200081002001300303#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#138#134#article#158#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Aliyu ZY, Tumbl
in AR, Kato GJ. Current therapy of sickle cell disease. Haematologica. 2006;91(1
):7-10. Comment on: Haematologica. 2006;91(1):125-8.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#139#135#article#158#</font></p>     ^
cY#v33n1a14.htm##
00792000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704054000081002001300621#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#140#136#article#158#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Charache S, Ter
rin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea o
n the frequency of painful crises in sickle cell anemia. Investigators of the Mu
lticenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332 (20
): 1317-22. Comment in: N Engl J Med. 1995;333(15):1008; author reply 1009. N En
gl J Med. 1996;334(5):333-4. N Engl J Med. 1996;334(5):333. N Engl J Med. 1995 ;
332(20):1372-4. N Engl J Med. 1995;333(15):1008-9.    ^cY#v33n1a14.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#141#137#article#158# </font></p>     
^cY#v33n1a14.htm##
00774000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704052200081002001300603#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#142#138#article#158#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Steinberg MH, B
arton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea
 on mortality and morbidity in adult sickle cell anemia: risks and benefits up t
o 9 years of treatment. JAMA. 2003;289(13):1645-51. Comment in: JAMA. 2003; 289(
13):1692-4. JAMA. 2003;290(6):752; author reply 754. JAMA. 2003;290(6):752-3; au
thor reply 754. JAMA. 2003; 290 (6):753; author reply 754. JAMA. 2003;290(6):753
-4; author reply 754</font></p>     ^cY#v33n1a14.htm##
00652000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704040000081002001300481#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#143#139#article#158#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Ware RE, Zimmer
man SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, et al. Prevention of secon
dary stroke and resolution of transfusional iron overload in children with sickl
e cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145(3):346-52. C
omment in: J Pediatr. 2004;145(3):287-8. J Pediatr. 2005;147(4):560-1.    ^cY#v3
3n1a14.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#144#140#article#158# </font></p>     
^cY#v33n1a14.htm##
00569000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031700081002001300398#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#145#141#article#158#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Zimmerman SA, S
chultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcrani
al Doppler flow velocities in children with sickle cell anemia. Blood. 2007;110 
(3):1043-7. Comment in: Blood. 2008;111(2):963-4; author reply 964.    ^cY#v33n1
a14.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#146#142#article#158# </font></p>     
^cY#v33n1a14.htm##
00550000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029800081002001300379#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#147#143#article#158#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Gulbis B, Haber
man D, Dufour D, Christophe C, Vermylen C, Kagambega F, et al. Hydroxyurea for s
ickle cell disease in children and for prevention of cerebrovascular events: the
 Belgian experience. Blood. 2005;105(7):2685-90.    ^cY#v33n1a14.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#148#144#article#158#</font></p>     ^
cY#v33n1a14.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#149#145#article#158#<p>&nbsp;</p>    
 ^cY#v33n1a14.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#150#146#article#158#<p>&nbsp;</p>    
 ^cY#v33n1a14.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018600078002001300264#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#151#147#article#158#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b
>    ^cY#v33n1a14.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002800078002001300106#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#152#148#article#158#<br>   Clarisse L
obo    ^cY#v33n1a14.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008500078002001300163#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#153#149#article#158#<br> Instituto Es
tadual de Hematologia Arthur de Siqueira Cavalcanti, HEMORIO    ^cY#v33n1a14.htm
##
00279000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004200078002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#154#150#article#158#<br> Rua Frei Can
eca, 08 -  Centro    ^cY#v33n1a14.htm##
00291000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005400078002001300132#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#155#151#article#158#<br> 20211-030  -
 Rio de Janeiro ( RJ), Brazil    ^cY#v33n1a14.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010100078002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#156#152#article#158#<br> <a href="mai
lto:diretoria@hemorio.rj.gov.br">diretoria@hemorio.rj.gov.br</a></font></p>     
^cY#v33n1a14.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#157#153#article#158#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted: 9/20/2010    ^cY#v33n1a
14.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003300078002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#158#154#article#158#<br> Accepted: 11
/23/2010    ^cY#v33n1a14.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011200078002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#159#155#article#158#<br> Conflict-of-
interest disclosure:  The authors declare no competing financial disclosure</fon
t></p>     ^cY#v33n1a14.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#160#156#article#158#<p>&nbsp;</p>    
 ^cY#v33n1a14.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#161#157#article#158#<p>&nbsp;</p>    
 ^cY#v33n1a14.htm##
00461000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022400078002001300302#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a14.htm#S#p#162#158#article#158#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" targ
et="_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_bla
nk">www.scielo.br/rbhh</a> </font></p>     ^cY#v33n1a14.htm##
00497000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950120
03400111030002500145710000200170065000900172064000500181031000300186032000200189
014000600191865000900197002001300206#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a14.htm#S#c#163#1#article#32#1#^rND^sCançado^nRD#^rND^sJesus^nJA#Sickle cell 
disease in Brazil^len#Rev Bras Hematol Hemoter#2#20070000#2007#29#3#203-6#201102
00#v33n1a14.htm##
00770000000000361000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100020000930100
01600113010001700129010001600146010002000162810000600182012008700188030001300275
06500090028806400050029703100040030203200030030601400080030906100460031786500090
0363002001300372035001000385801001300395#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a14.htm#S#c#164#2#article#32#2#^rND^sPlatt^nOS#^rND^sBrambilla^nDJ#^rND^s
Rosse^nWF#^rND^sMilner^nPF#^rND^sCastro^nO#^rND^sSteinberg^nMH#et al#Mortality i
n sickle cell disease: Life expectancy and risk factors for early death^len#N En
gl J Med#19940000#1994#330#23#1639-44#Comment in: N Engl J Med. 1994;331(15):102
2-3#20110200#v33n1a14.htm#0028-4793#N Engl J Med##
00688000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100024000770100017001010100
01800118010001700136010001600153010001600169810000600185012007700191030000600268
06500090027406400050028303100030028803200020029101400070029386500090030000200130
0309035001000322801000600332#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.h
tm#S#c#165#3#article#32#3#^rND^sOhene-Frempong^nK#^rND^sWeiner^nSJ#^rND^sSleeper
^nLA#^rND^sMiller^nST#^rND^sEmbury^nS#^rND^sMoohr^nJW#et al#Cerebrovascular acci
dents in sickle cell disease: rates and risk factors^len#Blood#19980000#1998#91#
1#288-94#20110200#v33n1a14.htm#0006-4971#Blood##
00676000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01500109010001800124010001500142010001500157810000600172012009000178030001900268
71000020028706500090028906400050029803100030030303200020030601400080030886500090
0316002001300325#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#166#4
#article#32#4#^rND^sAdams^nRJ#^rND^sMcKie^nVC#^rND^sCarl^nEM#^rND^sNichols^nFT#^
rND^sPerry^nR#^rND^sBrock^nK#et al#Long-term stroke risk in children with sickle
 cell disease screened with transcranial^len#Doppler Ann Neurol#2#19970000#1997#
42#5#699-704#20110200#v33n1a14.htm##
00751000000000361000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100015000920100
01700107010001400124010001600138010001500154810000600169012008500175030001300260
06500090027306400050028203100040028703200020029101400070029306100440030086500090
0344002001300353035001000366801001300376#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a14.htm#S#c#167#5#article#32#5#^rND^sAdams^nR#^rND^sMcKie^nV#^rND^sNichol
s^nF#^rND^sCarl^nE#^rND^sZhang^nDL#^rND^sMcKie^nK#et al#The use of transcranial 
ultrasonography to predict stroke in sickle cell disease^len#N Engl J Med#199200
00#1992#326#9#605-10#Comment in: N Engl J Med. 1992;326(9):637-9#20110200#v33n1a
14.htm#0028-4793#N Engl J Med##
01022000000000469000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100020000930100
01700113010001900130010001900149010001700168010001800185010001500203010001600218
01000180023401000150025201000160026701000160028301000160029901000180031501000160
03330110011003490120119003600300006004790650009004850640005004940310004004990320
00300503014000800506865000900514002001300523035001000536801000600546#v33n1#V:\Sc
iELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#168#6#article#32#6#^rND^sAdams^nR
J#^rND^sBrambilla^nDJ#^rND^sGranger^nS#^rND^sGallagher^nD#^rND^sVichinsky^nE#^rN
D^sAbboud^nMR#^rND^sPegelow^nCH#^rND^sWoods^nG#^rND^sRohde^nEM#^rND^sNichols^nFT
#^rND^sJones^nA#^rND^sLuden^nJP#^rND^sBowman^nL#^rND^sHagner^nS#^rND^sMorales^nK
H#^rND^sRoach^nES#STOP Study#Stroke and conversion to high risk in children scre
ened with transcranial Doppler ultrasound during the STOP study^len#Blood#200400
00#2004#103#10#3689-94#20110200#v33n1a14.htm#0006-4971#Blood##
00817000000000361000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01300109010001500122010001900137010001700156810000600173012014600179030001300325
06500090033806400050034703100040035203200020035601400050035806100470036386500090
0410002001300419035001000432801001300442#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a14.htm#S#c#169#7#article#32#7#^rND^sAdams^nRJ#^rND^sMcKie^nVC#^rND^sHsu^
nL#^rND^sFiles^nB#^rND^sVichinsky^nE#^rND^sPegelow^nC#et al#Prevention of a firs
t stroke by transfusions in children with sickle cell anemia and abnormal result
s on transcranial Doppler ultrasonography^len#N Engl J Med#19980000#1998#339#1#5
-11#Comment in: N Engl J Med. 1998;339(20):1477-8.#20110200#v33n1a14.htm#0028-47
93#N Engl J Med##
00750000000000361000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100018000910100
01700109010001700126010001800143010002000161010001600181011002500197012009500222
03000060031706500090032306400050033203100040033703200020034101400070034386500090
0350002001300359035001000372801000600382#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a14.htm#S#c#170#8#article#32#8#^rND^sLee^nMT#^rND^sPiomelli^nS#^rND^sGran
ger^nS#^rND^sMiller^nST#^rND^sHarkness^nS#^rND^sBrambilla^nDJ#^rND^sAdams^nRJ#ST
OP Study Investigators#Stroke Prevention Trial in Sickle Cell Anemia (STOP): ext
ended follow-up and final results^len#Blood#20060000#2006#108#3#847-52#20110200#
v33n1a14.htm#0006-4971#Blood##
00650000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100019000930100
01600112010001800128010001500146012009000161030000700251065000900258064000500267
03100030027203200030027501400070027886500090028500200130029403500100030780100070
0317#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#171#9#article#32#
9#^rND^sBrass^nLM#^rND^sPavlakis^nSG#^rND^sDeVivo^nD#^rND^sPiomelli^nS#^rND^sMoh
r^nJP#Transcranial Doppler measurements of the middle cerebral artery: Effect of
 hematocrit^len#Stroke#19880000#1988#19#12#1466-9#20110200#v33n1a14.htm#0039-249
9#Stroke##
00686000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100016001020100
02100118010001600139010001600155010001800171012006800189030001600257065000900273
06400050028203100030028703200040029001400060029486500090030000200130030903500100
0322801001600332#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#172#1
0#article#32#10#^rND^sSampaio Silva^nG#^rND^sVicari^nP#^rND^sFigueiredo^nMS#^rND
^sFilho^nAC#^rND^sValadi^nN#^rND^sMassaro^nAR#Transcranial Doppler in adult pati
ents with sickle cell disease^len#Cerebrovasc Dis#20060000#2006#21#1-2#38-41#201
10200#v33n1a14.htm#0146-6917#Cerebrovasc Dis##
00687000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01700111010001800128010001600146010001600162810000600178012007600184030001000260
06500090027006400050027903100030028403200020028701400060028986500090029500200130
0304035001000317801001000327#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.h
tm#S#c#173#11#article#32#11#^rND^sValadi^nN#^rND^sSilva^nGS#^rND^sBowman^nLS#^rN
D^sRamsingh^nD#^rND^sVicari^nP#^rND^sFilho^nAC#et al#Transcranial Doppler ultras
onography in adults with sickle cell disease^len#Neurology#20060000#2006#67#4#57
2-4#20110200#v33n1a14.htm#0028-3878#Neurology##
00490000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120033000950300
01200128065000900140064000500149031000300154032000300157014000800160865000900168
002001300177035001000190801001200200#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a14.htm#S#c#174#12#article#32#12#^rND^sAdams^nRJ#Big strokes in small persons
^len#Arch Neurol#20070000#2007#64#11#1567-74#20110200#v33n1a14.htm#0003-9942#Arc
h Neurol##
00680000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01700110010002000127010001700147010001800164012007300182030001500255065000900270
06400050027903100020028403200020028601400070028886500090029500200130030403500100
0317801001500327#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#175#1
3#article#32#13#^rND^sAdams^nC#^rND^sHwang^nPA#^rND^sGilday^nDL#^rND^sArmstrong^
nDC#^rND^sBecker^nLE#^rND^sHoffman^nHJ#Comparison of SPECT, EEG, CT, MRI, and pa
thology in partial epilepsy^len#Pediatr Neurol#19920000#1992#8#2#97-103#20110200
#v33n1a14.htm#0887-8994#Pediatr Neurol##
00741000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
02100111010002000132010001800152010001800170012014200188030000700330065000900337
06400050034603100030035103200020035401400080035686500090036400200130037303500100
0386801000700396#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#176#1
4#article#32#14#^rND^sSilva^nGS#^rND^sVicari^nP#^rND^sFigueiredo^nMS#^rND^sCarre
te^nH Jr#^rND^sIdagawa^nMH#^rND^sMassaro^nAR#Brain magnetic resonance imaging ab
normalities in adult patients with sickle cell disease: correlation with transcr
anial Doppler findings^len#Stroke#20090000#2009#40#7#2408-12#20110200#v33n1a14.h
tm#0039-2499#Stroke##
00694000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100023000940100
01600117010002400133012014200157030001200299065000900311064000500320031000200325
032000200327014000700329865000900336002001300345035001000358801001200368#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#177#15#article#32#15#^rND^sKa
tz^nML#^rND^sSmith-Whitley^nK#^rND^sRuzek^nSB#^rND^sOhene-Frempong^nK#Knowledge 
of stroke risk, signs of stroke, and the need for stroke education among childre
n with sickle cell disease and their caregivers^len#Ethn Health#20020000#2002#7#
2#115-23#20110200#v33n1a14.htm#1355-7858#Ethn Health##
00656000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170135000790180096002140620
00400310065000900314064001100323110000900334109001200343037002500355865000900380
002001300389#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#178#16#ar
ticle#32#16#NHS Sickle Cell & Thalassaemia Screening Programme^dTD Standards Wri
ting Group of the Sickle Cell and Thalassaemia Screening Programme#Transcranial 
Doppler Scanning for Children with Sickle Cell Disease: Standards and Guidance^l
en#NHS#20090300#March 2009#20101012#2010 Oct 12#www.sct.screening.nhs.uk#2011020
0#v33n1a14.htm##
00715000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01900111010001900130010001900149010001500168810000600183012008900189030001500278
06500090029306400050030203100030030703200020031001400060031286500090031800200130
0327035001000340801001500350#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.h
tm#S#c#179#17#article#32#17#^rND^sJones^nA#^rND^sGranger^nS#^rND^sBrambilla^nD#^
rND^sGallagher^nD#^rND^sVichinsky^nE#^rND^sWoods^nG#et al#Can peak systolic velo
cities be used for prediction of stroke in sickle cell anemia?^len#Pediatr Radio
l#20050000#2005#35#1#66-72#20110200#v33n1a14.htm#0301-0449#Pediatr Radiol##
00815000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01800113010001700131010001300148010001500161810000600176012012700182030001500309
06500090032406400050033303100030033803200020034101400060034306100570034986500090
0406002001300415035001000428801001500438#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a14.htm#S#c#180#18#article#32#18#^rND^sJones^nAM#^rND^sSeibert^nJJ#^rND^s
Nichols^nFT#^rND^sKinder^nDL#^rND^sCox^nK#^rND^sLuden^nJ#et al#Comparison of tra
nscranial color Doppler imaging (TCDI) and transcranial Doppler (TCD) in childre
n with sickle-cell anemia^len#Pediatr Radiol#20010000#2001#31#7#461-9#Comment in
: Pediatr Radiol. 2002;32(9):690-1 reply 692-3#20110200#v33n1a14.htm#0301-0449#P
ediatr Radiol##
00671000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01900112010002300131010001800154010001800172012008300190030002100273710000200294
06500090029606400050030503100030031003200020031301400080031586500090032300200130
0332#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#181#19#article#32
#19#^rND^sKratovil^nT#^rND^sBulas^nD#^rND^sDriscoll^nMC#^rND^sSpeller-Brown^nB#^
rND^sMcCarter^nR#^rND^sMinniti^nCP#Hydroxyurea therapy lowers TCD velocities in 
children with sickle cell disease^len#Pediatr Blood Cancer#2#20060000#2006#47#7#
894-900#20110200#v33n1a14.htm##
00688000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01600111010001800127010001700145012012100162030001000283065000900293064000500302
03100040030703200020031101400070031386500090032000200130032903500100034280100100
0352#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#182#20#article#32
#20#^rND^sNeish^nAS#^rND^sBlews^nDE#^rND^sSimms^nCA#^rND^sMerritt^nRK#^rND^sSpin
ks^nAJ#Screening for stroke in sickle cell anemia: comparison of transcranial Do
ppler imaging and non-imaging US techniques^len#Radiology#20020000#2002#222#3#70
9-14#20110200#v33n1a14.htm#0033-8419#Radiology##
00724000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01800110010001800128010001800146010001600164012011800180030001500298065000900313
06400050032203100030032703200030033001400060033386500090033900200130034803500100
0361801001500371#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#183#2
1#article#32#21#^rND^sBulas^nDI#^rND^sJones^nA#^rND^sSeibert^nJJ#^rND^sDriscoll^
nC#^rND^sODonnell^nR#^rND^sAdams^nRJ#Transcranial Doppler (TCD) screening for st
roke prevention in sickle cell anemia: pitfalls in technique variation^len#Pedia
tr Radiol#20000000#2000#30#11#733-8#20110200#v33n1a14.htm#0301-0449#Pediatr Radi
ol##
00806000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01700114010002100131010001600152010002100168810000600189012015900195030002200354
06500090037606400050038503100030039003200020039301400070039586500090040200200130
0411035001000424801002200434#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.h
tm#S#c#184#22#article#32#22#^rND^sKrejza^nJ#^rND^sRudzinski^nW#^rND^sPawlak^nMA#
^rND^sTomaszewski^nM#^rND^sIchord^nR#^rND^sKwiatkowski^nJ#et al#Angle-corrected 
imaging transcranial doppler sonography versus imaging and nonimaging transcrani
al doppler sonography in children with sickle cell disease^len#AJNR Am J Neurora
diol#20070000#2007#28#8#1613-8#20110200#v33n1a14.htm#0195-6108#AJNR Am J Neurora
diol##
00522000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120061000950300
01500156065000900171064000500180031000300185032000200188014000700190865000900197
002001300206035001000219801001500229#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a14.htm#S#c#185#23#article#32#23#^rND^sAdams^nRJ#TCD in sickle cell disease: 
an important and useful test^len#Pediatr Radiol#20050000#2005#35#3#229-34#201102
00#v33n1a14.htm#0301-0449#Pediatr Radiol##
00669000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100013000970100
01600110010001900126010001600145012011000161030000700271065000900278064000500287
03100030029203200020029501400070029786500090030400200130031303500100032680100070
0336#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#186#24#article#32
#24#^rND^sLezcano^nNE#^rND^sOdo^nN#^rND^sKutlar^nA#^rND^sBrambilla^nD#^rND^sAdam
s^nRJ#Regular transfusion lowers plasma free hemoglobin in children with sickle-
cell disease at risk for stroke^len#Stroke#20060000#2006#37#6#1424-6#20110200#v3
3n1a14.htm#0039-2499#Stroke##
01227000000000529000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
01600117010001800133010001600151010001400167010001500181010001700196010001500213
01000160022801000190024401000160026301000160027901000260029501000170032101000170
03380100015003550100014003700100017003840100018004010100016004190110041004350120
13500476030001400611065000900625064000500634031000400639032000200643014000600645
865000900651002001300660035001000673801001400683#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a14.htm#S#c#187#25#article#32#25#^rND^sVichinsky^nE#^rND^sOnyekwe
re^nO#^rND^sPorter^nJ#^rND^sSwerdlow^nP#^rND^sEckman^nJ#^rND^sLane^nP#^rND^sFile
s^nB#^rND^sHassell^nK#^rND^sKelly^nP#^rND^sWilson^nF#^rND^sBernaudin^nF#^rND^sFo
rni^nGL#^rND^sOkpala^nI#^rND^sRessayre-Djaffer^nC#^rND^sAlberti^nD#^rND^sHolland
^nJ#^rND^sMarks^nP#^rND^sFung^nE#^rND^sFischer^nR#^rND^sMueller^nBU#^rND^sCoates
^nT#Deferasirox in Sickle Cell Investigators#A randomised comparison of deferasi
rox versus deferoxamine for the treatment of transfusional iron overload in sick
le cell disease^len#Br J Haematol#20070000#2007#136#3#501-8#20110200#v33n1a14.ht
m#0007-1048#Br J Haematol##
01172000000000505000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100016001000100
02100116010001300137010001800150010001600168010002000184010001900204010001400223
01000150023701000140025201000140026601000150028001000160029501000200031101000140
03310100017003450100017003620100018003790110025003970120158004220300014005800650
00900594064000500603031000300608032000200611014000700613865000900620002001300629
035001000642801001400652#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S
#c#188#26#article#32#26#^rND^sCappellini^nMD#^rND^sPorter^nJ#^rND^sEl-Beshlawy^n
A#^rND^sLi^nCK#^rND^sSeymour^nJF#^rND^sElalfy^nM#^rND^sGattermann^nN#^rND^sGirau
dier^nS#^rND^sLee^nJW#^rND^sChan^nLL#^rND^sLin^nKH#^rND^sRose^nC#^rND^sTaher^nA#
^rND^sThein^nSL#^rND^sViprakasit^nV#^rND^sHabr^nD#^rND^sDomokos^nG#^rND^sRoubert
^nB#^rND^sKattamis^nA#EPIC Study Investigators#Tailoring iron chelation by iron 
intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 pat
ients with transfusion-dependent anemias^len#Haematologica#20100000#2010#95#4#55
7-66#20110200#v33n1a14.htm#0390-6078#Haematologica##
00613000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01500113012004300128030001400171065000900185064000500194031000300199032000200202
014000500204061004400209865000900253002001300262035001000275801001400285#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#189#27#article#32#27#^rND^sAl
iyu^nZY#^rND^sTumblin^nAR#^rND^sKato^nGJ#Current therapy of sickle cell disease^
len#Haematologica#20060000#2006#91#1#7-10#Comment on: Haematologica. 2006;91(1):
125-8#20110200#v33n1a14.htm#0390-6078#Haematologica##
00993000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01600114010001600130010001700146010001700163810000600180012016000186030001300346
06500090035906400050036803100040037303200030037701400080038006101980038886500090
0586002001300595035001000608801001300618#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a14.htm#S#c#190#28#article#32#28#^rND^sCharache^nS#^rND^sTerrin^nML#^rND^
sMoore^nRD#^rND^sDover^nGJ#^rND^sBarton^nFB#^rND^sEckert^nSV#et al#Effect of hyd
roxyurea on the frequency of painful crises in sickle cell anemia: Investigators
 of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia^len#N Engl J Med#
19950000#1995#332#20#1317-22#Comment in: N Engl J Med. 1995;333(15):1008; author
 reply 1009. N Engl J Med. 1996;334(5):333-4. N Engl J Med. 1996;334(5):333. N E
ngl J Med. 1995 ;332(20):1372-4. N Engl J Med. 1995;333(15):1008-9#20110200#v33n
1a14.htm#0028-4793#N Engl J Med##
00958000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100016000990100
01600115010001800131010001700149010001600166810000600182012012800188030000500316
06500090032106400050033003100040033503200030033901400080034206102090035086500090
0559002001300568035001000581801000500591#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a14.htm#S#c#191#29#article#32#29#^rND^sSteinberg^nMH#^rND^sBarton^nF#^rND
^sCastro^nO#^rND^sPegelow^nCH#^rND^sBallas^nSK#^rND^sKutlar^nA#et al#Effect of h
ydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and ben
efits up to 9 years of treatment^len#JAMA#20030000#2003#289#13#1645-51#Comment i
n: JAMA. 2003; 289(13):1692-4. JAMA. 2003;290(6):752; author reply 754. JAMA. 20
03;290(6):752-3; author reply 754. JAMA. 2003; 290 (6):753; author reply 754. JA
MA. 2003;290(6):753-4; author reply 754#20110200#v33n1a14.htm#0098-7484#JAMA##
00852000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100020000940100
02000114010001800134010001600152010001600168810000600184012015000190030001000340
06500090035006400050035903100040036403200020036801400070037006100710037786500090
0448002001300457035001000470801001000480#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a14.htm#S#c#192#30#article#32#30#^rND^sWare^nRE#^rND^sZimmerman^nSA#^rND^
sSylvestre^nPB#^rND^sMortier^nNA#^rND^sDavis^nJS#^rND^sTreem^nWR#et al#Preventio
n of secondary stroke and resolution of transfusional iron overload in children 
with sickle cell anemia using hydroxyurea and phlebotomy^len#J Pediatr#20040000#
2004#145#3#346-52#Comment in: J Pediatr. 2004;145(3):287-8. J Pediatr. 2005;147(
4):560-1#20110200#v33n1a14.htm#0022-3476#J Pediatr##
00735000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
01700117010001800134010001500152012010400167030000600271065000900277064000500286
03100040029103200020029501400070029706100550030486500090035900200130036803500100
0381801000600391#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.htm#S#c#193#3
1#article#32#31#^rND^sZimmerman^nSA#^rND^sSchultz^nWH#^rND^sBurgett^nS#^rND^sMor
tier^nNA#^rND^sWare^nRE#Hydroxyurea therapy lowers transcranial Doppler flow vel
ocities in children with sickle cell anemia^len#Blood#20070000#2007#110#3#1043-7
#Comment in: Blood. 2008;111(2):963-4; author reply 964#20110200#v33n1a14.htm#00
06-4971#Blood##
00735000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01600113010002000129010001800149010001900167810000600186012012100192030000600313
06500090031906400050032803100040033303200020033701400080033986500090034700200130
0356035001000369801000600379#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a14.h
tm#S#c#194#32#article#32#32#^rND^sGulbis^nB#^rND^sHaberman^nD#^rND^sDufour^nD#^r
ND^sChristophe^nC#^rND^sVermylen^nC#^rND^sKagambega^nF#et al#Hydroxyurea for sic
kle cell disease in children and for prevention of cerebrovascular events: the B
elgian experience^len#Blood#20050000#2005#105#7#2685-90#20110200#v33n1a14.htm#00
06-4971#Blood##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#o#1#1#article#1
#20110411#115542#v33n1a15.htm#139##
02997000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120099002020100037003010100045003380100034003830100033004170100028004500100
04100478070005400519070005100573083160100624085001002225085003102235085003102266
08500310229708500190232811700060234707200030235311200090235611100100236511400090
2375113001002384002001302394#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.h
tm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#15#RBHH350#nd#Rev. Bras. Hematol
. Hemoter.#33#1#20110200#^f49^l54#1516-8484#10.5581/1516-8484.20110015#Prevalenc
e of sickle cell disease and sickle cell trait in national neonatal screening st
udies^len#^rND^1A01^nLuciana Garcia^sLervolino#^rND^1A01 A02^nPaulo Eduardo Alme
ida^sBaldin#^rND^1A01^nSilvia Miguéis^sPicado#^rND^1A01^nKarina Barreto^sCalil#^
rND^1A01^nAna Amélia^sViel#^rND^1A01^nLuiz Alexandre Freixo^sCampos#Centro Unive
rsitário Lusíada^iA01^cSantos^sSP^pBrazil#Hospital Guilherme Álvaro^iA02^cSantos
^sSP^pBrazil#^len^aSickle cell anemia is the best known hereditary blood disorde
r; there are serious complications associated with the condition. Diagnosis and 
early intervention reduce morbidity and mortality. These benefits have resulted 
in the widespread use of newborn screening education programs. In Brazil, the Na
tional Neonatal Screening Program established by decree 822/01 included sickle c
ell disease in the list of diseases tested in the so called "heel prick test". S
ince then, national studies of the results of this program have been periodicall
y published. To review the literature in order to assess the prevalence of sickl
e cell trait and sickle cell anemia from data of national neonatal screening stu
dies on hemoglobin S (Hb S). A bibliographic review was carried out using the ke
y words: sickle cell anemia & hemoglobinopathies & neonatal screening & Brazil i
n the Bireme and SciELO databases. Original Brazilian studies presenting data on
 prevalence of the sickle cell trait (Hb AS) and sickle cell anemia (Hb SS) base
d on neonatal screening for Hb S were analysed. Twelve original national studies
 were identified with prevalences varying from 1.1% to 9.8% for the sickle cell 
trait and from 0.8 to 60 per 100,000 live births for sickle cell disease in diff
erent Brazilian regions. Conclusion: Neonatal screening for Hb S is a very usefu
l method to assess the prevalence of sickle cell trait (Hb AS) and sickle cell a
nemia (Hb SS) in Brazil. There is a heterogeneous distribution of this disease w
ith the highest prevalence in the northeastern region and the lowest prevalence 
in the south.#^ddecs^i1#^tm^len^kSickle cell anemia^i1#^tm^len^kHemoglobinopathi
es^i1#^tm^len^kNeonatal screening^i1#^tm^len^kBrazil^i1#other#17#20090829#8/29/2
009#20110120#1/20/2011#v33n1a15.htm##
03004000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120106002020100037003080100045003450100034003900100033004240100028004570100
04100485070005400526070005100580083160100631085001002232085003102242085003102273
08500310230408500190233511700060235407200030236011200090236311100100237211400090
2382113001002391002001302401#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.h
tm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#15#RBHH350#nd#Rev. Bras. Hematol
. Hemoter.#33#1#20110200#^f49^l54#1516-8484#10.5581/1516-8484.20110015#<b>Preval
ence of sickle cell disease and sickle cell trait in national neonatal screening
 studies</b>^len#^rND^1A01^nLuciana Garcia^sLervolino#^rND^1A01 A02^nPaulo Eduar
do Almeida^sBaldin#^rND^1A01^nSilvia Miguéis^sPicado#^rND^1A01^nKarina Barreto^s
Calil#^rND^1A01^nAna Amélia^sViel#^rND^1A01^nLuiz Alexandre Freixo^sCampos#Centr
o Universitário Lusíada^iA01^cSantos^sSP^pBrazil#Hospital Guilherme Álvaro^iA02^
cSantos^sSP^pBrazil#^len^aSickle cell anemia is the best known hereditary blood 
disorder; there are serious complications associated with the condition. Diagnos
is and early intervention reduce morbidity and mortality. These benefits have re
sulted in the widespread use of newborn screening education programs. In Brazil,
 the National Neonatal Screening Program established by decree 822/01 included s
ickle cell disease in the list of diseases tested in the so called "heel prick t
est". Since then, national studies of the results of this program have been peri
odically published. To review the literature in order to assess the prevalence o
f sickle cell trait and sickle cell anemia from data of national neonatal screen
ing studies on hemoglobin S (Hb S). A bibliographic review was carried out using
 the key words: sickle cell anemia & hemoglobinopathies & neonatal screening & B
razil in the Bireme and SciELO databases. Original Brazilian studies presenting 
data on prevalence of the sickle cell trait (Hb AS) and sickle cell anemia (Hb S
S) based on neonatal screening for Hb S were analysed. Twelve original national 
studies were identified with prevalences varying from 1.1% to 9.8% for the sickl
e cell trait and from 0.8 to 60 per 100,000 live births for sickle cell disease 
in different Brazilian regions. Conclusion: Neonatal screening for Hb S is a ver
y useful method to assess the prevalence of sickle cell trait (Hb AS) and sickle
 cell anemia (Hb SS) in Brazil. There is a heterogeneous distribution of this di
sease with the highest prevalence in the northeastern region and the lowest prev
alence in the south.#^ddecs^i1#^tm^len^kSickle cell anemia^i1#^tm^len^kHemoglobi
nopathies^i1#^tm^len^kNeonatal screening^i1#^tm^len^kBrazil^i1#other#17#20090829
#8/29/2009#20110120#1/20/2011#v33n1a15.htm##
03140000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103038000400108121000300112049000800115
15800030012303000280012603100030015403200020015706500090015901400090016803500100
01772370027001870120099002140100037003130100045003500100034003950100033004290100
02800462010004100490070005600531070005300587083161500640085001002255085003102265
08500310229608500310232708500190235811700060237707200030238311200090238611100100
2395114000902405113001002414002001302424008008902437#v33n1#V:\SciELO\serial\rbhh
\v33n1\markup\v33n1a15.htm#S#l#4#1#article#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#ilus
#tab#15#RBHH350#nd#Rev. bras. hematol. hemoter#33#1#20110200#^f49^l54#1516-8484#
10.5581/1516-8484.20110015#Prevalence of sickle cell disease and sickle cell tra
it in national neonatal screening studies^len#^rND^1A01^nLuciana Garcia^sLervoli
no#^rND^1A01 A02^nPaulo Eduardo Almeida^sBaldin#^rND^1A01^nSilvia Miguéis^sPicad
o#^rND^1A01^nKarina Barreto^sCalil#^rND^1A01^nAna Amélia^sViel#^rND^1A01^nLuiz A
lexandre Freixo^sCampos#^iA01^1Centro Universitário Lusíada^cSantos^sSP^pBrazil#
^iA02^1Hospital Guilherme Álvaro^cSantos^sSP^pBrazil#^len^aSickle cell anemia is
 the best known hereditary blood disorder; there are serious complications assoc
iated with the condition. Diagnosis and early intervention reduce morbidity and 
mortality. These benefits have resulted in the widespread use of newborn screeni
ng education programs. In Brazil, the National Neonatal Screening Program establ
ished by decree 822/01 included sickle cell disease in the list of diseases test
ed in the so called "heel prick test". Since then, national studies of the resul
ts of this program have been periodically published. To review the literature in
 order to assess the prevalence of sickle cell trait and sickle cell anemia from
 data of national neonatal screening studies on hemoglobin S (Hb S). A bibliogra
phic review was carried out using the key words: sickle cell anemia & hemoglobin
opathies & neonatal screening & Brazil in the Bireme and SciELO databases. Origi
nal Brazilian studies presenting data on prevalence of the sickle cell trait (Hb
 AS) and sickle cell anemia (Hb SS) based on neonatal screening for Hb S were an
alysed. Twelve original national studies were identified with prevalences varyin
g from 1.1 percent to 9.8 percent for the sickle cell trait and from 0.8 to 60 p
er 100,000 live births for sickle cell disease in different Brazilian regions. C
onclusion: Neonatal screening for Hb S is a very useful method to assess the pre
valence of sickle cell trait (Hb AS) and sickle cell anemia (Hb SS) in Brazil. T
here is a heterogeneous distribution of this disease with the highest prevalence
 in the northeastern region and the lowest prevalence in the south.#^ddecs^i1#^t
m^len^kSickle cell anemia^i1#^tm^len^kHemoglobinopathies^i1#^tm^len^kNeonatal sc
reening^i1#^tm^len^kBrazil^i1#other#17#20090829#8/29/2009#20110120#1/20/2011#v33
n1a15.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516
-84842011000100015##
00352000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704011900074002001300193#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#5#1#article#118#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>REVIEW ARTICLES</b></
font></p>     ^cY#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#6#2#article#118#<p>&nbsp;</p>     ^cY
#v33n1a15.htm##
00435000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704020200074002001300276#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#7#3#article#118#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Prevalence of sic
kle cell disease and sickle cell trait in national neonatal screening studies</b
></font></p>     ^cY#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#8#4#article#118#<p>&nbsp;</p>     ^cY
#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#9#5#article#118#<p>&nbsp;</p>     ^cY
#v33n1a15.htm##
00559000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704032500075002001300400#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#10#6#article#118#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Luciana Garcia Lervolino<sup>I</su
p>; Paulo Eduardo Almeida Baldin<sup>I,II</sup>; Silvia Migu&eacute;is Picado<su
p>I</sup>; Karina Barreto Calil<sup>I</sup>; Ana Am&eacute;lia Viel<sup>I</sup>;
 Luiz Alexandre Freixo Campos<sup>I</sup></b></font></p>     ^cY#v33n1a15.htm##
00388000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015400075002001300229#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#11#7#article#118#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Centro Universit&aacute;r
io Lus&iacute;ada  UNILUS, Santos (SP), Brazil    ^cY#v33n1a15.htm##
00325000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704009100075002001300166#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#12#8#article#118#<br> <sup>II</sup>Ho
spital Guilherme &Aacute;lvaro, Santos (SP), Brazil</font></p>     ^cY#v33n1a15.
htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#13#9#article#118#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></fon
t></p>     ^cY#v33n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#14#10#article#118#<p>&nbsp;</p>     ^
cY#v33n1a15.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#15#11#article#118#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v33n1a15.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#16#12#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
33n1a15.htm##
01925000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704169000076002001301766#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#17#13#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Sickle cell anemia is the best known
 hereditary blood disorder; there are serious complications associated with the 
condition. Diagnosis and early intervention reduce morbidity and mortality. Thes
e benefits have resulted in the widespread use of newborn screening education pr
ograms. In Brazil, the National Neonatal Screening Program established by decree
 822/01 included sickle cell disease in the list of diseases tested in the so ca
lled "heel prick test". Since then, national studies of the results of this prog
ram have been periodically published. To review the literature in order to asses
s the prevalence of sickle cell trait and sickle cell anemia from data of nation
al neonatal screening studies on hemoglobin S (Hb S). A bibliographic review was
 carried out using the key words: sickle cell anemia &amp; hemoglobinopathies &a
mp; neonatal screening &amp; Brazil in the Bireme and SciELO databases. Original
 Brazilian studies presenting data on prevalence of the sickle cell trait (Hb AS
) and sickle cell anemia (Hb SS) based on neonatal screening for Hb S were analy
sed. Twelve original national studies were identified with prevalences varying f
rom 1.1% to 9.8% for the sickle cell trait and from 0.8 to 60 per 100,000 live b
irths for sickle cell disease in different Brazilian regions. Conclusion: Neonat
al screening for Hb S is a very useful method to assess the prevalence of sickle
 cell trait (Hb AS) and sickle cell anemia (Hb SS) in Brazil. There is a heterog
eneous distribution of this disease with the highest prevalence in the northeast
ern region and the lowest prevalence in the south. </font></p>     ^cY#v33n1a15.
htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018800076002001300264#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#18#14#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Sickle cell anemia;
 Hemoglobinopathies; Neonatal screening; Brazil</font></p> <hr size="1" noshade>
     ^cY#v33n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#19#15#article#118#<p>&nbsp;</p>     ^
cY#v33n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#20#16#article#118#<p>&nbsp;</p>     ^
cY#v33n1a15.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#21#17#article#118#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></p>     ^
cY#v33n1a15.htm##
00611000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037600076002001300452#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#22#18#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Sickle cell anemia is the best known
 hereditary hematological disorder in human beings. Estimates suggest that 250,0
00 children are born annually with sickle cell anemia worldwide and thus it is a
mong the most important epidemiological genetic diseases in Brazil and the world
.<sup>(1,2)</sup></font></p>     ^cY#v33n1a15.htm##
00830000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059500076002001300671#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#23#19#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Originally from Africa and brought t
o the Americas by the forced immigration of slaves, it is more frequent where th
e proportion of African descendents is greater (the northeastern region and the 
States of S&atilde;o Paulo, Rio de Janeiro and Minas Gerais). In these regions, 
we observe new cases of sickle cell disease in every 1000 births and sickle cell
 trait carriers in every 27 births. It is estimated that approximately 2500 chil
dren are born every year with sickle cell disease in Brazil.<sup>(3,4)</sup></fo
nt></p>     ^cY#v33n1a15.htm##
00613000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037800076002001300454#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#24#20#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The non-white population in Brazil w
as estimated at 44.66% by the 2000 Population Census and from 1% to 6% of them h
ave the Hb S gene, thus favoring the continuation of sickle cell anemia in what 
is suggested by Brazilian scientific literature as a serious public health probl
em.<sup>(3,4)</sup></font></p>     ^cY#v33n1a15.htm##
00931000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069600076002001300772#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#25#21#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The disease occurs due to a mutation
 of the beta globin gene of hemoglobin, causing a substitution of the glutamic a
mino acid for valine at position 6 of the beta chain, thereby producing an abnor
mal hemoglobin, called hemoglobin S (Hb S), instead of normal hemoglobin, hemogl
obin A (Hb A).<sup>(1,2) </sup>With modified physicochemical characteristics, th
e molecules of hemoglobin S suffer polymerization and precipitation, leading to 
a change in form, a deformity of red blood cells which become sickle-shaped. In 
this case, the viscosity of the blood increases due to the formation of tactoids
.<sup>(2,5)</sup></font></p>     ^cY#v33n1a15.htm##
00590000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035500076002001300431#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#26#22#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The inheritance of sickle cell anemi
a occurs via an autosomal recessive gene with both parents, in general, asymptom
atic carriers of a single affected gene (heterozygous), transmitting the defecti
ve gene to their child, who therefore is homozygous (Hb SS).<sup>(1,4)</sup></fo
nt></p>     ^cY#v33n1a15.htm##
00450000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021500076002001300291#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#27#23#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Clinical manifestations are observed
 only in homozygous individuals for Hb S (Hb SS), resulting in sickle cell anemi
a.<sup>(5)</sup></font></p>     ^cY#v33n1a15.htm##
00833000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059800076002001300674#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#28#24#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">During fetal and early postnatal lif
e, the lack of expression of the Hb SS phenotype is explained by the production 
of fetal hemoglobin (Hb F) which is sufficient to limit, by dilution, the effect
s of sickling. As the red cells that emerge from the bone marrow carry increasin
g amounts of Hb S and smaller amounts of Hb F, the results of sickling gradually
 appear. Therefore, newborns begin to manifest the disease from the sixth month 
of life, when the amount of Hb F begins to approach adult levels.<sup>(3)</sup><
/font></p>     ^cY#v33n1a15.htm##
01043000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080800076002001300884#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#29#25#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The clinical manifestations of sickl
e cell disease are the result of two characteristic processes: severe anemia and
 vaso-occlusion. Anemia results from a shorter half-life of the red blood cells 
containing primarily Hb S. While normal red blood cells circulate for about 120 
days, those containing Hb S only last for 10 to 20 days, leading patients to pre
sent moderate to severe anemia. The second process, which is physiopathologicall
y more complicated, is vaso-occlusion. The intravascular effect from the spatial
 change of hemoglobin leads to the formation of helical bundles that greatly alt
er the membrane's permeability to ions, and the red cell/blood vessel and the re
d cell aggregation/red cell ratios.<sup>(4)</sup></font></p>     ^cY#v33n1a15.ht
m##
00650000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041500076002001300491#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#30#26#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The effects of the phenomena of vaso
-occlusion vary in intensity but include tissue ischemia, painful episodes, acut
e osteo-articular or abdominal crises and chronic organic injuries such as funct
ional asplenia, cerebral-vascular disease and kidney, heart and lung failure; pa
tients require frequent hospitalization.<sup>(2,4)</sup></font></p>     ^cY#v33n
1a15.htm##
00722000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048700076002001300563#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#31#27#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although the sickle cell trait (Hb A
S) is usually asymptomatic, there are reports of sudden death and medical compli
cations such as hematuria, hyposthenuria, pulmonary embolism and splenic infarct
ion, especially when carriers are exposed to extreme conditions of low oxygen te
nsion, such as in strenuous physical exertion, depressurization of a flight cabi
n, and high altitude environments.<sup>(6)</sup></font></p>     ^cY#v33n1a15.htm
##
01120000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088500076002001300961#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#32#28#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In children, infections caused by en
capsulated bacteria and intra-splenic vaso-occlusion (splenic sequestration) are
 the main causes of mortality. These begin after the first two to three months o
f life and affect 20-25% of children in the first 5 years of age.<sup>(2,4,7) </
sup>Children who have overcome this initial barrier, face the effects of chronic
 vaso-occlusion. Over the years, these small strokes are the determining factor 
for the impairment of organs, leading to pulmonary, liver or brain infarction, k
idney failure and retardation in growth and sexual maturation, with progressive 
impairment of multiple organs. These phenomena significantly reduce the quality 
of life of individuals, increase need for medical care, and diminish the capacit
y to work and life expectancy.<sup>(2,4)</sup></font></p>     ^cY#v33n1a15.htm##
00891000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065600076002001300732#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#33#29#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The benefits of early diagnosis and 
intervention in the monitoring of sickle cell disease have led to widespread use
 of education programs to detect these conditions. Through neonatal screening pr
ograms, it is possible to reduce morbidity and mortality in the first five years
 of life. Furthermore, the prophylactic use of penicillin, the administration of
 pneumococcal vaccine and intensive care significantly increase the survival and
 quality of life of patients with sickle cell disease, reducing and extenuating 
the consequences of clinical complications.<sup>(5)</sup></font></p>     ^cY#v33
n1a15.htm##
00869000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063400076002001300710#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#34#30#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In 1986, one of the first Brazilian 
studies was published demonstrating the importance of detecting hemoglobin disea
ses early through a study that analyzed blood samples from the umbilical cord by
 means of electrophoresis in starch agar gel. The study tested 2281 samples, 78 
of which had abnormal hemoglobins with preponderance among children from black m
others. In addition, it was shown that hemoglobin S represented 80.8% of abnorma
l samples, thereby proving the importance of neonatal screening for the detectio
n of this alteration.<sup>(8)</sup></font></p>     ^cY#v33n1a15.htm##
00962000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072700076002001300803#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#35#31#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In Brazil, the Newborn Screening Pro
gram began in 1976 with the pioneering project coordinated by Professor Benjamin
 Schmidt with the Association of Parents and Friends of the Disabled of S&atilde
;o Paulo (APAESP), to screen for phenylketonuria (PKU). Screening for congenital
 hypothyroidism and PKU (Guthrie test) only became mandatory in the State of S&a
tilde;o Paulo for children born in government and maternity hospitals in 1983 (S
tate Law 3.914 of November 14, 1983); in 1990 this requirement was extended to c
hildren born nationwide, in both government and private healthcare systems (Fede
ral Law Nº 8069 of July 13, 1990).<sup>(9)</sup></font></p>     ^cY#v33n1a15.htm
##
00755000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052000076002001300596#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#36#32#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In 2001, the Ministry of Health incl
uded testing for hemoglobinopathies in the National Neonatal Screening Program (
PNTN) through Decree Nº 822/01. Thus all children who are submitted to the Guthr
ie test in Brazilian states after completing implantation phases II and III  of 
the Neonatal Screening program are also screened for hemoglobinopathies, in part
icular sickle cell anemia, in order to provide an early diagnosis.<sup>(10)</sup
></font></p>     ^cY#v33n1a15.htm##
00922000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068700076002001300763#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#37#33#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There are three phases of implementa
tion: phase I includes Brazilian states that only perform neonatal screening for
 PKU and congenital hypothyroidism, phase II consists of states that perform scr
eening for PKU, congenital hypothyroidism and hemoglobinopathies and phase III i
ncludes states that perform the phase II tests plus screening to identify childr
en with cystic fibrosis. The phase in which each state is classified is determin
ed by the structure and capacity of the state's healthcare system, the percentag
e of newborns screened and the regional characteristics of the population.<sup>(
2)</sup></font></p>     ^cY#v33n1a15.htm##
01048000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081300076002001300889#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#38#34#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Data released from the National Neon
atal Screening Program, reported that 284 patients were identified with phenylke
tonuria, 2270 patients with congenital hypothyroidism, 2554 with hemoglobinopath
ies and 68 patients with cystic fibrosis from 2001 to 2005. Hence, hemoglobinopa
thies are the commonest genetic disorders in Brazilian newborns compared to othe
r diseases diagnosed by the National Neonatal Screening Program. However, the av
ailable epidemiological data on sickle cell anemia probably do not show the true
 prevalence of the disease in the country because of the small number of states 
in phase II and III (ten states) and the low coverage (on average 58%) according
 to reports from the Ministry of Health.<sup>(2)</sup></font></p>     ^cY#v33n1a
15.htm##
00689000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045400076002001300530#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#39#35#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Given these data, we suppose that as
 more states reach Phase II of neonatal screening, information on the prevalence
 of the sickle cell trait and disease in Brazil will be more consistent. Therefo
re, the aim of this study was to review the literature on the prevalence of sick
le cell trait and sickle cell disease based on national studies of neonatal scre
ening for Hb S.</font></p>     ^cY#v33n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#40#36#article#118#<p>&nbsp;</p>     ^
cY#v33n1a15.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#41#37#article#118#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Methods</b></font></p>     ^cY#v3
3n1a15.htm##
00415000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018000076002001300256#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#42#38#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A bibliographic review was conducted
 using studies obtained from the SciELO and BIREME databases.</font></p>     ^cY
#v33n1a15.htm##
00688000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045300076002001300529#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#43#39#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The keywords 'Sickle Cell Anemia', '
Newborn Screening' and 'Brazil' were used for an integrated search of all indice
s and sources of the BIREME database. Twenty papers were identified, of which on
ly eight were selected. Additionally, a search was made using the keywords 'Neon
atal' and 'Hemoglobinopathies' in BIREME, which found 113 publications but only 
ten were used.</font></p>     ^cY#v33n1a15.htm##
00451000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021600076002001300292#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#44#40#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In SciELO, the keywords 'Neonatal Sc
reening' and 'Hemoglobinopathies' were used; this identified 26 papers of which 
12 were selected.</font></p>     ^cY#v33n1a15.htm##
00515000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028000076002001300356#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#45#41#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Inclusion criteria were original Bra
zilian papers that reported on the prevalence of sickle cell trait (Hb AS) and a
nemia (Hb SS) from neonatal screening regardless of the sample size and coverage
.</font></p>     ^cY#v33n1a15.htm##
00829000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059400076002001300670#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#46#42#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Despite having the same methods as t
he studies included, two studies were excluded: the first because it was a pilot
 project that was subsequently published in full and included in this study and 
the second because the statistics on a table were inaccurate. To evaluate the co
verage of studies, the publication sample size was compared with the number of l
ive births in the region in the study period using data from the Live Birth Info
rmation System (SINASC) of the Brazilian Ministry of Health.<sup>(11)</sup></fon
t></p>     ^cY#v33n1a15.htm##
00773000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053800076002001300614#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#47#43#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The studies were classified as being
 of high, medium or low relevance according to the following criteria: studies w
ith sample sizes larger than 100,000 or coverage more than 60% of live births (h
igher than the national average of 58%) were considered highly relevant, studies
 with sample sizes lower than 100,000 but greater than 10,000 were considered me
dium relevance, and studies with sample sizes smaller than 10,000 were considere
d of low relevance.</font></p>     ^cY#v33n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#48#44#article#118#<p>&nbsp;</p>     ^
cY#v33n1a15.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#49#45#article#118#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>     ^cY#v3
3n1a15.htm##
00509000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027400076002001300350#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#50#46#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The results are shown in <a href="/i
mg/revistas/rbhh/v33n1/a15tab01.jpg">Tables 1</a> and <a href="/img/revistas/rbh
h/v33n1/a15tab02.jpg">2</a>, in alphabetical order of the regions analyzed.</fon
t></p>     ^cY#v33n1a15.htm##
00653000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041800076002001300494#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#51#47#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The data from all studies are summar
ized in <a href="/img/revistas/rbhh/v33n1/a15tab01.jpg">Table 1</a>. <a href="/i
mg/revistas/rbhh/v33n1/a15tab02.jpg">Table 2</a> shows the estimated values of t
he range of neonatal screening obtained in each study according to the total liv
e births for the period and the region according to SINASC.</font></p>     ^cY#v
33n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#52#48#article#118#<p>&nbsp;</p>     ^
cY#v33n1a15.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#53#49#article#118#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p>     ^cY
#v33n1a15.htm##
00607000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037200076002001300448#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#54#50#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A precise calculation of the number 
of children born with sickle cell anemia (Hb SS) in a period of time is crucial 
for the organization of the healthcare system, especially if there are significa
nt differences between regions in the country which consequently require differe
nt resources.</font></p>     ^cY#v33n1a15.htm##
00545000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031000076002001300386#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#55#51#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Therefore, a review of published stu
dies that report the prevalence in Brazil may provide important information in s
cientific terms even if it is a study of secondary data from various authors wit
h non-uniform sampling designs.</font></p>     ^cY#v33n1a15.htm##
00694000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045900076002001300535#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#56#52#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The solution found by the authors to
 mitigate this problem was to seek the total number of live births in the Live B
irths Information System (SINASC) of the Ministry of Health for the region and f
or the period of the studies presented. This allowed us to calculate the coverag
e and classify the studies according to relevance, enabling better mapping of th
e situation to date.</font></p>     ^cY#v33n1a15.htm##
01520000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704128500076002001301361#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#57#53#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The studies conducted in the State o
f S&atilde;o Paulo produced results that varied according to their relevance. Th
e study of Campinas was of high relevance with the sample size being higher than
 100,000. With the involvement of 78 institutions in 36 cities, including 4 hosp
itals in the city of S&atilde;o Paulo, it was impossible to calculate the percen
tage coverage because the study did not delimit with precision the region studie
d. The study reported the prevalence of Hb AS in 1.98% of newborns and Hb SS in 
0.01%.<sup>(12)</sup> The study of Ribeir&atilde;o Preto reported Hb AS in 2.6% 
and Hb SS in 0.015% with high relevance, because the coverage was on average 94.
5% of live births (figure indicated in the study).<sup>(9)</sup> In the west of 
S&atilde;o Paulo State there was a prevalence of 2.35% of Hb AS and 0.004% of Hb
 SS with medium relevance because the study was conducted in 168 cities of the s
tate of S&atilde;o Paulo, the equivalent of 35% of all cities, with the sample s
ize between 10,000 and 100,000. It was impossible to calculate coverage in the s
tudy because the statistics of some micro regions surveyed (Presidente Venceslau
) are not available in SINASC. <sup>(13)</sup></font></p>     ^cY#v33n1a15.htm##
00828000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059300076002001300669#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#58#54#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The results for S&atilde;o Jos&eacut
e; do Rio Preto were flawed as the study was conducted in just one hospital and 
no cases of Hb SS were discovered probably due to a relatively low sample size. 
From the average figures of live births from 1997 and 1998 obtained in SINASC th
e coverage in S&atilde;o Jos&eacute; do Rio Preto was calculated at 17.70% thus 
the study is considered of low relevance. As for the State of Sao Paulo, the est
imated prevalence was 0.0655% of live births in the period.<sup>(14)</sup></font
></p>     ^cY#v33n1a15.htm##
00814000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057900076002001300655#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#59#55#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In the study carried out in Rio de J
aneiro, prevalences of 3.96% and 0.06% were obtained for Hb AS and Hb SS, respec
tively. The paper presented medium relevance because the sample size was signifi
cant (between 100,000 and 10,000) and the estimate, using SINASC data, for cover
age was approximately 40% of live births during the period. Taking into account 
that the study was conducted over 15 months and SINASC provides annual figures, 
the real value is perhaps less than estimated.<sup>(4)</sup></font></p>     ^cY#
v33n1a15.htm##
00543000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030800076002001300384#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#60#56#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In the Federal District, Hb AS was 3
.23% and Hb SS was 0.09%. The study was considered of high relevance, as the sam
ple size was greater than 100,000 and the coverage was 85.07% of live births dur
ing the period.<sup>(2)</sup></font></p>     ^cY#v33n1a15.htm##
00603000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036800076002001300444#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#61#57#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The results of Rio Grande do Sul sho
wed prevalences of 1.14% for Hb AS and 0.0009% for Hb SS, with high relevance du
e to the sample size and coverage. From the SINASC data, there was an average of
 151,074 live births in 2003 and 2004 and so the coverage was about 77.65%.<sup>
(5)</sup></font></p>     ^cY#v33n1a15.htm##
00801000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056600076002001300642#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#62#58#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The study from the State of Paran&aa
cute; reported prevalences of 1.52% for Hb AS and 0.002% for Hb SS. The relevanc
e was considered high because the coverage was 100% of the live births registere
d in "SRTN FEPE" (Newborn Screening Reference Service of the Ecumenical Foundati
on for Protection of the Handicapped) of Paran&aacute; State. This figure was co
nfirmed by SINASC data, which show that the study size was greater than the numb
er of live births in the period.<sup>(10)</sup></font></p>     ^cY#v33n1a15.htm#
#
00595000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036000076002001300436#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#63#59#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The values for the State of Mato Gro
sso do Sul were 1.64% and 0.01% for Hb AS and Hb SS, respectively, with high rel
evance because the average coverage was 88.62% except for 2000 with coverage of 
28.38% (an overall average of 78.6% of live births in the period).<sup>(15)</sup
></font></p>     ^cY#v33n1a15.htm##
00818000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058300076002001300659#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#64#60#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In Fortaleza, Cear&aacute;, a preval
ence of 3.8% was reported for Hb AS and 0.2% for Hb SS with low relevance becaus
e despite of the precise technique for identifying changes in hemoglobin, the st
udy has a small sample size and was performed in only one maternity hospital.<su
p>(3)</sup> According to SINASC, there were 40,532 live births in 2001 and 2002 
in Fortaleza which gives a coverage of only 0.95% for this study. On considering
 the state of Cear&aacute;, the coverage is approximately 0.26%.</font></p>     
^cY#v33n1a15.htm##
00682000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044700076002001300523#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#65#61#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In the study conducted in Natal, Rio
 Grande do Norte, the reported prevalence was 1.5% for Hb AS and 0.05% for Hb SS
. The relevance was low, because although the study was carried out in three pub
lic hospitals, the sample size is small and the calculation of the coverage was 
14.03% of all newborns in Natal and 3.61% of those in Rio Grande do Norte.<sup>(
6)</sup></font></p>     ^cY#v33n1a15.htm##
00592000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035700076002001300433#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#66#62#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In Salvador, Bahia, the values were 
9.8% and 0.2% for Hb AS and Hb SS, respectively, with low relevance; screening w
as performed in only one hospital and so the sample size was small and the study
 period of five months was too short to calculate the coverage.<sup>(16)</sup></
font></p>     ^cY#v33n1a15.htm##
00512000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027700076002001300353#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#67#63#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="/img/revistas/rbhh/v33n1/ht
ml/a15fig01.htm">Figure 1</a> shows the distribution and prevalence of sickle ce
ll anemia and sickle cell trait according to the figures found in the studies.</
font></p>     ^cY#v33n1a15.htm##
00871000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063600076002001300712#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#68#64#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Note that the Hb S gene is heterogen
eously distributed in the Northeast with higher prevalences in the states of Bah
ia, Rio de Janeiro, Cear&aacute; and the Federal District. According to the Mini
stry of Health, sickle cell trait is present in approximately 5.3% of the popula
tion in Bahia, the state with the highest percentage, data that supports the num
bers presented in our study. In addition, the Ministry of Health reported a valu
e of 4% for sickle cell trait in the State of Rio de Janeiro, similar to the 3.9
% found in our review.<sup>(17)</sup></font></p>     ^cY#v33n1a15.htm##
00694000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045900076002001300535#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#69#65#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Like Bahia, Cear&aacute; has a high 
prevalence of blacks compared to other Brazilian states, such as Paran&aacute; a
nd Rio Grande do Sul, with 3.8% of Hb AS, compared to 1.52% and 1.14%, respectiv
ely. This fact can be justified historically by the period of colonization of Br
azil, where there was a great migration of black Africans to the northeast of Br
azil due to slavery.</font></p>     ^cY#v33n1a15.htm##
00734000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049900076002001300575#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#70#66#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The values of Hb AS found in S&atild
e;o Paulo, the Federal District and Rio de Janeiro (2.35%, 3.23% and 3.96%, resp
ectively), are not as low to those of southern regions, possibly due to the grea
t migration that took place from the northeast to these states. An example is th
e Federal District; the most likely explanation is the large migration that occu
rred during the construction of the city of Bras&iacute;lia.</font></p>     ^cY#
v33n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#71#67#article#118#<p>&nbsp;</p>     ^
cY#v33n1a15.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#72#68#article#118#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Conclusion</b></font></p>     ^cY
#v33n1a15.htm##
00581000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034600076002001300422#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#73#69#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The national data, despite the varia
bility of coverage of screening for Hb S (Phase II), shows the heterogeneity of 
the prevalence of sickle cell trait and sickle cell disease in different regions
 of Brazil. This information is crucial for Public health policies.</font></p>  
   ^cY#v33n1a15.htm##
00861000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062600076002001300702#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#74#70#article#118#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It is observed that studies from the
 Northeast have the lowest coverage compared to the total live births, despite o
f this being the region that has the highest numbers of individuals with sickle 
cell anemia in Brazil. In contrast, the South has the best screening coverage an
d the lowest values for sickle cell trait and sickle cell disease. This fact sho
ws not only the difference in access to health care in both regions, but the nee
d for an extension of screening to the Northeast. There were no studies from the
 northern region of Brazil.</font></p>     ^cY#v33n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#75#71#article#118#<p>&nbsp;</p>     ^
cY#v33n1a15.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#76#72#article#118#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY
#v33n1a15.htm##
00596000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704034700078002001300425#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#77#73#article#118#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Silva WS, Lastra A,
 Oliveira SF, Guimar&atilde;es NK, Grisolia CK. Avalia&ccedil;&atilde;o da cober
tura do programa de triagem neonatal de hemoglobinopatias em popula&ccedil;&otil
de;es do Rec&ocirc;ncavo Baiano, Brasil. Cad Sa&uacute;de P&uacute;blica. 2006;2
2(12):2561-66.    ^cY#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#78#74#article#118#</font></p>     ^cY
#v33n1a15.htm##
00559000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031000078002001300388#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#79#75#article#118#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Diniz D, Guedes C, 
Barbosa L, Tauil PL, Magalh&atilde;es I. Preval&ecirc;ncia do tra&ccedil;o e da 
anemia falciforme em rec&eacute;m-nascidos do Distrito Federal, Brasil, 2004 a 2
006. Cad Sa&uacute;de P&uacute;blica. 2009;25(1): 188-94.    ^cY#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#80#76#article#118#</font></p>     ^cY
#v33n1a15.htm##
00589000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704034000078002001300418#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#81#77#article#118#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Pinheiro LS, Gon&cc
edil;alves RP, Tom&eacute; CA, Alc&acirc;ntara AE, Marques AR, Silva MM. Preval&
ecirc;ncia de hemoglobina S em rec&eacute;m-nascidos de Fortaleza: import&acirc;
ncia da investiga&ccedil;&atilde;o neonatal. Rev Bras Ginecol Obstet. 2006;28(2)
:122-5.    ^cY#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#82#78#article#118#</font></p>     ^cY
#v33n1a15.htm##
00496000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024700078002001300325#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#83#79#article#118#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Lobo CL, Bueno LM, 
Moura P, Ogeda LL, Castilho S, Carvalho SM. Triagem neonatal para hemoglobinopat
ias no Rio de Janeiro, Brasil. Pan Am J Public Health. 2003;13(2/3):154-9.    ^c
Y#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#84#80#article#118#</font></p>     ^cY
#v33n1a15.htm##
00560000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031100078002001300389#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#85#81#article#118#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Sommer CK, Goldbeck
 AS, Wagner SC, Castro SM. Triagem neonatal para hemoglobinopatias: experi&ecirc
;ncia de um ano na rede de sa&uacute;de p&uacute;blica do Rio Grande do Sul, Bra
sil. Cad Sa&uacute;de P&uacute;blica. 2006; 22(8):1709-14.    ^cY#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#86#82#article#118#</font></p>     ^cY
#v33n1a15.htm##
00548000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029900078002001300377#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#87#83#article#118#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Ara&uacute;jo MC, S
erafim ES, Castro Jr WA, Medeiros TM. Preval&ecirc;ncia de hemoglobinas anormais
 em rec&eacute;m-nascidos da cidade de Natal, Rio Grande do Norte, Brasil. Cad S
a&uacute;de P&uacute;blica. 2004; 20(1):123-8.    ^cY#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#88#84#article#118#</font></p>     ^cY
#v33n1a15.htm##
00500000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025100078002001300329#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#89#85#article#118#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Ferraz MH, Murao M.
 Diagn&oacute;stico laboratorial da doen&ccedil;a falciforme em neonatos e ap&oa
cute;s o sexto m&ecirc;s de vida. Rev Bras Hematol Hemoter. 2007;29(3):218-22.  
  ^cY#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#90#86#article#118#</font></p>     ^cY
#v33n1a15.htm##
00593000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704034400078002001300422#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#91#87#article#118#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Ruiz MA, Guerra CC,
 Naoum PC. Detec&ccedil;&atilde;o de hemoglobinas anormais em sangue de cord&ati
lde;o de rec&eacute;m-nascidos na cidade de Santos, S&atilde;o Paulo, atrav&eacu
te;s da eletroforese em gel de Agar de amido. Bol Soc Bras Hematol Hemot. 1986;8
(137):8-13.    ^cY#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#92#88#article#118#</font></p>     ^cY
#v33n1a15.htm##
00583000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704033400078002001300412#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#93#89#article#118#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Magalh&atilde;es PK
, Turcato MF, Angulo IL, Maciel LM. Programa de Triagem Neonatal do Hospital das
 Cl&iacute;nicas da Faculdade de Medicina de Ribeir&atilde;o Preto, Universidade
 de S&atilde;o Paulo, Brasil. Cad Sa&uacute;de P&uacute;blica. 2009;25(2):445-54
.    ^cY#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#94#90#article#118#</font></p>     ^cY
#v33n1a15.htm##
00563000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704031300079002001300392#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#95#91#article#118#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Watanabe AM, Pian
ovski MA, Zanis Neto J, Lichtvan LC, Maia EA, Domingos MT, et al. Preval&ecirc;n
cia da hemoglobina S no Estado do Paran&aacute;, Brasil, obtida pela triagem neo
natal. Cad. Sa&uacute;de P&uacute;blica. 2008;24(5):993-1000.    ^cY#v33n1a15.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#96#92#article#118#</font></p>     ^cY
#v33n1a15.htm##
00692000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704044200079002001300521#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#97#93#article#118#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Banco de dados do
 Sistema &Uacute;nico de Sa&uacute;de. Sistema de Informa&ccedil;&otilde;es sobr
e Nascidos Vivos - SINASC.&#91;Internet&#93; 2009 &#91;cited 2009 May 26&#93;. A
vaiable from: URL: <a href="http://tabnet.datasus.gov.br/tabdata/sinasc/dados/no
v_indice.htm" target="_blank">http://tabnet.datasus.gov.br/tabdata/sinasc/dados/
nov_indice.htm</a></font></p>     ^cY#v33n1a15.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026300079002001300342#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#98#94#article#118#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Brandelise S, Pin
heiro V, Gabetta CS, Hambleton I, Serjeant B, Serjeant G. Newborn screening for 
sickle cell disease in Brazil: the Campinas experience. Clin Lab Haematol. 2004;
26(1):15-9.    ^cY#v33n1a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#99#95#article#118#</font></p>     ^cY
#v33n1a15.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704026200080002001300342#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#100#96#article#118#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Pultrini T, Pedr
o KP, Ferreira RR. Triagem neonatal para hemoglobinopatias em munic&iacute;pios 
da regi&atilde;o Oeste de S&atilde;o Paulo. Arq Ci&ecirc;nc Sa&uacute;de. 2004;1
1(1):20-24.    ^cY#v33n1a15.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#101#97#article#118#</font></p>     ^c
Y#v33n1a15.htm##
00606000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704035500080002001300435#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#102#98#article#118#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Ducatti RP, Teix
eira AEA, Gal&atilde;o HA, Domingos CRB, Conte ACF. Investiga&ccedil;&atilde;o d
e hemoglobinopatias em sangue de cord&atilde;o umbilical de rec&eacute;m-nascido
s do Hospital de Base de S&atilde;o Jos&eacute; do Rio Preto. Rev Bras Hematol H
emoter. 2001;23(1):23-9.    ^cY#v33n1a15.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#103#99#article#118#</font></p>     ^c
Y#v33n1a15.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024100081002001300322#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#104#100#article#118#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Holsbach DR, Iv
o ML, Honer MR, Rigo L, Botelho CA. Ocorr&ecirc;ncia de hemoglobina S no estado 
de Mato Grosso do Sul, Brasil. J Bras Patol Med Lab. 2008;44(4):277-82.    ^cY#v
33n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#105#101#article#118#</font></p>     ^
cY#v33n1a15.htm##
00538000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028600081002001300367#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#106#102#article#118#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Adorno EV, Cout
o FD, Moura Neto JP, Menezes JF, R&ecirc;go M, Reis MG, et al. Hemoglobinopatias
 em rec&eacute;m-nascidos de Salvador, Bahia, Nordeste do Brasil. Cad Sa&uacute;
de P&uacute;blica. 2005;21(1):292-8.    ^cY#v33n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#107#103#article#118#</font></p>     ^
cY#v33n1a15.htm##
00437000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018500081002001300266#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#108#104#article#118#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Can&ccedil;ado 
RD, Jesus JA. A doen&ccedil;a falciforme no Brasil. Rev Bras Hematol Hemoter. 20
07;29(3):204-6.    ^cY#v33n1a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#109#105#article#118#</font></p>     ^
cY#v33n1a15.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#110#106#article#118#<p>&nbsp;</p>    
 ^cY#v33n1a15.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#111#107#article#118#<p>&nbsp;</p>    
 ^cY#v33n1a15.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018600078002001300264#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#112#108#article#118#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b
>    ^cY#v33n1a15.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#113#109#article#118#<br> Luciana Garc
ia  Iervolino    ^cY#v33n1a15.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007400078002001300152#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#114#110#article#118#<br> Av. Bartolom
eu de Gusm&atilde;o, 16/apto 22  Boqueir&atilde;o    ^cY#v33n1a15.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004300078002001300121#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#115#111#article#118#<br> 11045-400  S
antos (SP), Brazil    ^cY#v33n1a15.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009500078002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#116#112#article#118#<br> <a href="mai
lto:luiervolino@yahoo.com.br">luiervolino@yahoo.com.br</a></font></p>     ^cY#v3
3n1a15.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#117#113#article#118#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted: 8/29/2009    ^cY#v33n1a
15.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003200078002001300110#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#118#114#article#118#<br> Accepted: 1/
20/2011    ^cY#v33n1a15.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010900078002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#119#115#article#118#<br> Conflict-of-
interest disclosure: The authors declare no competing financial interest</font><
/p>     ^cY#v33n1a15.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#120#116#article#118#<p>&nbsp;</p>    
 ^cY#v33n1a15.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#121#117#article#118#<p>&nbsp;</p>    
 ^cY#v33n1a15.htm##
00461000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022400078002001300302#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a15.htm#S#p#122#118#article#118#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" targ
et="_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_bla
nk">www.scielo.br/rbhh</a> </font></p>     ^cY#v33n1a15.htm##
00673000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01900109010002000128010001900148012012200167030001800289710000200307065000900309
064000500318031000300323032000300326014000800329865000900337002001300346#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#c#123#1#article#17#1#^rND^sSilv
a^nWS#^rND^sLastra^nA#^rND^sOliveira^nSF#^rND^sGuimarães^nNK#^rND^sGrisolia^nCK#
Avaliação da cobertura do programa de triagem neonatal de hemoglobinopatias em p
opulações do Recôncavo Baiano, Brasil^lpt#Cad Saúde Pública#2#20060000#2006#22#1
2#2561-66#20110200#v33n1a15.htm##
00649000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920100
01700108010001600125010001900141012010700160030001800267710000200285065000900287
064000500296031000300301032000200304014000700306865000900313002001300322#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#c#124#2#article#17#2#^rND^sDini
z^nD#^rND^sGuedes^nC#^rND^sBarbosa^nL#^rND^sTauil^nPL#^rND^sMagalhães^nI#Prevalê
ncia do traço e da anemia falciforme em recém-nascidos do Distrito Federal, Bras
il, 2004 a 2006^lpt#Cad Saúde Pública#2#20090000#2009#25#1#188-94#20110200#v33n1
a15.htm##
00730000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100020000960100
01500116010002000131010001800151010001600169012010200185030002400287065000900311
06400050032003100030032503200020032801400060033086500090033600200130034503500100
0358801002400368#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#c#125#3
#article#17#3#^rND^sPinheiro^nLS#^rND^sGonçalves^nRP#^rND^sTomé^nCA#^rND^sAlcânt
ara^nAE#^rND^sMarques^nAR#^rND^sSilva^nMM#Prevalência de hemoglobina S em recém-
nascidos de Fortaleza: importância da investigação neonatal^lpt#Rev Bras Ginecol
 Obstet#20060000#2006#28#2#122-5#20110200#v33n1a15.htm#0100-7253#Rev Bras Gineco
l Obstet##
00646000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920100
01500108010001600123010001800139010001900157012007000176030002300246710000200269
06500090027106400050028003100030028503200040028801400060029286500090029800200130
0307#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#c#126#4#article#17#
4#^rND^sLobo^nCL#^rND^sBueno^nLM#^rND^sMoura^nP#^rND^sOgeda^nLL#^rND^sCastilho^n
S#^rND^sCarvalho^nSM#Triagem neonatal para hemoglobinopatias no Rio de Janeiro, 
Brasil^lpt#Pan Am J Public Health#2#20030000#2003#13#2/3#154-9#20110200#v33n1a15
.htm##
00639000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940100
01700113010001700130012012100147030001800268710000200286065000900288064000500297
031000300302032000200305014000800307865000900315002001300324#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a15.htm#S#c#127#5#article#17#5#^rND^sSommer^nCK#^rND^
sGoldbeck^nAS#^rND^sWagner^nSC#^rND^sCastro^nSM#Triagem neonatal para hemoglobin
opatias: experiência de um ano na rede de saúde pública do Rio Grande do Sul, Br
asil^lpt#Cad Saúde Pública#2#20060000#2006#22#8#1709-14#20110200#v33n1a15.htm##
00627000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
02000112010001900132012010700151030001800258710000200276065000900278064000500287
031000300292032000200295014000600297865000900303002001300312#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a15.htm#S#c#128#6#article#17#6#^rND^sAraújo^nMC#^rND^
sSerafim^nES#^rND^sCastro Jr^nWA#^rND^sMedeiros^nTM#Prevalência de hemoglobinas 
anormais em recém-nascidos da cidade de Natal, Rio Grande do Norte, Brasil^lpt#C
ad Saúde Pública#2#20040000#2004#20#1#123-8#20110200#v33n1a15.htm##
00551000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100015000940120
08900109030002500198710000200223065000900225064000500234031000300239032000200242
014000700244865000900251002001300260#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a15.htm#S#c#129#7#article#17#7#^rND^sFerraz^nMH#^rND^sMurao^nM#Diagnóstico la
boratorial da doença falciforme em neonatos e após o sexto mês de vida^lpt#Rev B
ras Hematol Hemoter#2#20070000#2007#29#3#218-22#20110200#v33n1a15.htm##
00647000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100017000920100
01600109012015600125030002700281710000200308065000900310064000500319031000200324
032000400326014000500330865000900335002001300344#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a15.htm#S#c#130#8#article#17#8#^rND^sRuiz^nMA#^rND^sGuerra^nCC#^r
ND^sNaoum^nPC#Detecção de hemoglobinas anormais em sangue de cordão de recém-nas
cidos na cidade de Santos, São Paulo, através da eletroforese em gel de Agar de 
amido^lpt#Bol Soc Bras Hematol Hemot#2#19860000#1986#8#137#8-13#20110200#v33n1a1
5.htm##
00655000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100018000970100
01700115010001700132012013600149030001800285710000200303065000900305064000500314
031000300319032000200322014000700324865000900331002001300340#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a15.htm#S#c#131#9#article#17#9#^rND^sMagalhães^nPK#^r
ND^sTurcato^nMF#^rND^sAngulo^nIL#^rND^sMaciel^nLM#Programa de Triagem Neonatal d
o Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade
 de São Paulo, Brasil^lpt#Cad Saúde Pública#2#20090000#2009#25#2#445-54#20110200
#v33n1a15.htm##
00736000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100020000980100
02000118010001900138010001500157010001900172810000600191012009100197030001900288
06500090030706400050031603100030032103200020032401400090032686500090033500200130
0344035001000357801001900367#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.h
tm#S#c#132#10#article#17#10#^rND^sWatanabe^nAM#^rND^sPianovski^nMA#^rND^sZanis N
eto^nJ#^rND^sLichtvan^nLC#^rND^sMaia^nEA#^rND^sDomingos^nMT#et al#Prevalência da
 hemoglobina S no Estado do Paraná, Brasil, obtida pela triagem neonatal^lpt#Cad
. Saúde Pública#20080000#2008#24#5#993-1000#20110200#v33n1a15.htm#0102-311X#Cad.
 saúde pública##
00572000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170041000790180048001200620
00700168061000900175065000900184064000500193110000900198109001200207037006500219
865000900284002001300293#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S
#c#133#11#article#17#11#Banco de dados do Sistema Único de Saúde#Sistema de Info
rmações sobre Nascidos Vivos^lpt#SINASC#Internet#20090000#2009#20090526#2009 May
 26#http://tabnet.datasus.gov.br/tabdata/sinasc/dados/nov_indice.htm#20110200#v3
3n1a15.htm##
00701000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
01800117010001900135010001800154010001800172012008100190030001800271065000900289
06400050029803100030030303200020030601400050030886500090031300200130032203500100
0335801001800345#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#c#134#1
2#article#17#12#^rND^sBrandelise^nS#^rND^sPinheiro^nV#^rND^sGabetta^nCS#^rND^sHa
mbleton^nI#^rND^sSerjeant^nB#^rND^sSerjeant^nG#Newborn screening for sickle cell
 disease in Brazil: the Campinas experience^len#Clin Lab Haematol#20040000#2004#
26#1#15-9#20110200#v33n1a15.htm#0141-9854#Clin Lab Haematol##
00574000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01900113012008700132030001600219710000200235065000900237064000500246031000300251
032000200254014000600256865000900262002001300271#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a15.htm#S#c#135#13#article#17#13#^rND^sPultrini^nT#^rND^sPedro^nK
P#^rND^sFerreira^nRR#Triagem neonatal para hemoglobinopatias em municípios da re
gião Oeste de São Paulo^lpt#Arq Ciênc Saúde#2#20040000#2004#11#1#20-24#20110200#
v33n1a15.htm##
00688000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100020000970100
01600117010002000133010001700153012013100170030002500301710000200326065000900328
064000500337031000300342032000200345014000500347865000900352002001300361#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#c#136#14#article#17#14#^rND^sDu
catti^nRP#^rND^sTeixeira^nAEA#^rND^sGalão^nHA#^rND^sDomingos^nCRB#^rND^sConte^nA
CF#Investigação de hemoglobinopatias em sangue de cordão umbilical de recém-nasc
idos do Hospital de Base de São José do Rio Preto^lpt#Rev Bras Hematol Hemoter#2
#20010000#2001#23#1#23-9#20110200#v33n1a15.htm##
00617000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100014000980100
01600112010001400128010001800142012007200160030002100232710000200253065000900255
064000500264031000300269032000200272014000700274865000900281002001300290#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#c#137#15#article#17#15#^rND^sHo
lsbach^nDR#^rND^sIvo^nML#^rND^sHoner^nMR#^rND^sRigo^nL#^rND^sBotelho^nCA#Ocorrên
cia de hemoglobina S no estado de Mato Grosso do Sul, Brasil^lpt#J Bras Patol Me
d Lab#2#20080000#2008#44#4#277-82#20110200#v33n1a15.htm##
00670000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
02100112010001800133010001400151010001500165810000600180012007900186030001800265
71000020028306500090028506400050029403100030029903200020030201400060030486500090
0310002001300319#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a15.htm#S#c#138#1
6#article#17#16#^rND^sAdorno^nEV#^rND^sCouto^nFD#^rND^sMoura Neto^nJP#^rND^sMene
zes^nJF#^rND^sRêgo^nM#^rND^sReis^nMG#et al#Hemoglobinopatias em recém-nascidos d
e Salvador, Bahia, Nordeste do Brasil^lpt#Cad Saúde Pública#2#20050000#2005#21#1
#292-8#20110200#v33n1a15.htm##
00499000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970120
03400113030002500147710000200172065000900174064000500183031000300188032000200191
014000600193865000900199002001300208#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a15.htm#S#c#139#17#article#17#17#^rND^sCançado^nRD#^rND^sJesus^nJA#A doença f
alciforme no Brasil^lpt#Rev Bras Hematol Hemoter#2#20070000#2007#29#3#204-6#2011
0200#v33n1a15.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#o#1#1#article#1
#20110411#115556#v33n1a16.htm#477##
02220000000000553000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120074002020100040002760100040003160700052003560831016004080850010014240850
03701434085002001471085002901491085002301520085003201543085003101575117000601606
072000401612112000901616111001001625114000901635113000901644002001301653#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#h#2#1#article#1#oa#en#br1.1#1#4
.0#ILUS#TAB#16#RBHH350#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f55^l64#15
16-8484#10.5581/1516-8484.20110016#Duffy blood group system and the malaria adap
tation process in humans^len#^rND^1A01^nGledson Barbosa de^sCarvalho#^rND^1A01^n
Glauber Barbosa de^sCarvalho#Universidade de Pernambuco^iA01^cRecife^sPE^pBrazil
#^len^aMalaria is an acute infectious disease caused by the protozoa of the genu
s Plasmodium. The antigens of the Duffy Blood Group System, in addition to incom
patibilities in transfusions and hemolytic disease of the newborn, are of great 
interest in medicine due to their association with the invasion of red blood cel
ls by the parasite Plasmodium vivax. For invasions to occur an interaction betwe
en the parasites and antigens of the Duffy Blood Group System is necessary. In C
aucasians six antigens are produced by the Duffy locus (Fya, Fyb, F3, F4, F5 and
 F6). It has been observed that Fy(a-b-) individuals are resistant to Plasmodium
 knowlesi and P. vivax infection, because the invasion requires at least one of 
these antigens. The P. vivax Duffy Binding Protein (PvDBP) is functionally impor
tant in the invasion process of these parasites in Duffy / DARC positive humans.
 The proteins or fractions may be considered, therefore, an important and potent
ial inoculum to be used in immunization against malaria.#^ddecs^i1#^tm^len^kDuff
y Blood Group System^i1#^tm^len^kMalaria^i1#^tm^len^kPlasmodium vivax^i1#^tm^len
^kChemokines^i1#^tm^len^kAntigens, protozoan^i1#^tm^len^kProtozoan proteins^i1#o
ther#120#20101201#1/12/2010#20110402#2/4/2011#v33n1a16.htm##
02227000000000553000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120081002020100040002830100040003230700052003630831016004150850010014310850
03701441085002001478085002901498085002301527085003201550085003101582117000601613
072000401619112000901623111001001632114000901642113000901651002001301660#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#f#3#1#article#1#oa#en#br1.1#1#4
.0#ILUS#TAB#16#RBHH350#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f55^l64#15
16-8484#10.5581/1516-8484.20110016#<b>Duffy blood group system and the malaria a
daptation process in humans</b>^len#^rND^1A01^nGledson Barbosa de^sCarvalho#^rND
^1A01^nGlauber Barbosa de^sCarvalho#Universidade de Pernambuco^iA01^cRecife^sPE^
pBrazil#^len^aMalaria is an acute infectious disease caused by the protozoa of t
he genus Plasmodium. The antigens of the Duffy Blood Group System, in addition t
o incompatibilities in transfusions and hemolytic disease of the newborn, are of
 great interest in medicine due to their association with the invasion of red bl
ood cells by the parasite Plasmodium vivax. For invasions to occur an interactio
n between the parasites and antigens of the Duffy Blood Group System is necessar
y. In Caucasians six antigens are produced by the Duffy locus (Fya, Fyb, F3, F4,
 F5 and F6). It has been observed that Fy(a-b-) individuals are resistant to Pla
smodium knowlesi and P. vivax infection, because the invasion requires at least 
one of these antigens. The P. vivax Duffy Binding Protein (PvDBP) is functionall
y important in the invasion process of these parasites in Duffy / DARC positive 
humans. The proteins or fractions may be considered, therefore, an important and
 potential inoculum to be used in immunization against malaria.#^ddecs^i1#^tm^le
n^kDuffy Blood Group System^i1#^tm^len^kMalaria^i1#^tm^len^kPlasmodium vivax^i1#
^tm^len^kChemokines^i1#^tm^len^kAntigens, protozoan^i1#^tm^len^kProtozoan protei
ns^i1#other#120#20101201#1/12/2010#20110402#2/4/2011#v33n1a16.htm##
02347000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103038000400108121000300112049000800115
15800030012303000280012603100030015403200020015706500090015901400090016803500100
01772370027001870120074002140100040002880100040003280700054003680831016004220850
01001438085003701448085002001485085002901505085002301534085003201557085003101589
11700060162007200040162611200090163011100100163911400090164911300090165800200130
1667008008901680#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#l#4#1#a
rticle#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#16#RBHH350#nd#Rev. bras. hemato
l. hemoter#33#1#20110200#^f55^l64#1516-8484#10.5581/1516-8484.20110016#Duffy blo
od group system and the malaria adaptation process in humans^len#^rND^1A01^nGled
son Barbosa de^sCarvalho#^rND^1A01^nGlauber Barbosa de^sCarvalho#^iA01^1Universi
dade de Pernambuco^cRecife^sPE^pBrazil#^len^aMalaria is an acute infectious dise
ase caused by the protozoa of the genus Plasmodium. The antigens of the Duffy Bl
ood Group System, in addition to incompatibilities in transfusions and hemolytic
 disease of the newborn, are of great interest in medicine due to their associat
ion with the invasion of red blood cells by the parasite Plasmodium vivax. For i
nvasions to occur an interaction between the parasites and antigens of the Duffy
 Blood Group System is necessary. In Caucasians six antigens are produced by the
 Duffy locus (Fya, Fyb, F3, F4, F5 and F6). It has been observed that Fy(a-b-) i
ndividuals are resistant to Plasmodium knowlesi and P. vivax infection, because 
the invasion requires at least one of these antigens. The P. vivax Duffy Binding
 Protein (PvDBP) is functionally important in the invasion process of these para
sites in Duffy / DARC positive humans. The proteins or fractions may be consider
ed, therefore, an important and potential inoculum to be used in immunization ag
ainst malaria.#^ddecs^i1#^tm^len^kDuffy Blood Group System^i1#^tm^len^kMalaria^i
1#^tm^len^kPlasmodium vivax^i1#^tm^len^kChemokines^i1#^tm^len^kAntigens, protozo
an^i1#^tm^len^kProtozoan proteins^i1#other#120#20101201#1/12/2010#20110402#2/4/2
011#v33n1a16.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pi
d=S1516-84842011000100016##
00351000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704011800074002001300192#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#5#1#article#353#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>REVIEW ARTICLE</b></f
ont></p>     ^cY#v33n1a16.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#6#2#article#353#<p>&nbsp;</p>     ^cY
#v33n1a16.htm##
00410000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704017700074002001300251#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#7#3#article#353#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Duffy blood group
 system and the malaria adaptation process in humans</b></font></p>     ^cY#v33n
1a16.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#8#4#article#353#<p>&nbsp;</p>     ^cY
#v33n1a16.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#9#5#article#353#<p>&nbsp;</p>     ^cY
#v33n1a16.htm##
00380000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704014600075002001300221#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#10#6#article#353#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Gledson Barbosa de Carvalho; Glaub
er Barbosa de Carvalho</b></font></p>     ^cY#v33n1a16.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704013600075002001300211#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#11#7#article#353#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Universidade de Pernambuco (UPE), Rec
ife (PE), Brazil</font></p>     ^cY#v33n1a16.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#12#8#article#353#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></fon
t></p>     ^cY#v33n1a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#13#9#article#353#<p>&nbsp;</p>     ^c
Y#v33n1a16.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#14#10#article#353#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v33n1a16.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#15#11#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
33n1a16.htm##
01327000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109200076002001301168#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#16#12#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Malaria is an acute infectious disea
se caused by the protozoa of the genus Plasmodium. The antigens of the Duffy Blo
od Group System, in addition to incompatibilities in transfusions and hemolytic 
disease of the newborn, are of great interest in medicine due to their associati
on with the invasion of red blood cells by the parasite Plasmodium vivax. For in
vasions to occur an interaction between the parasites and antigens of the Duffy 
Blood Group System is necessary. In Caucasians six antigens are produced by the 
Duffy locus (Fya, Fyb, F3, F4, F5 and F6). It has been observed that Fy(a-b-) in
dividuals are resistant to Plasmodium knowlesi and P. vivax infection, because t
he invasion requires at least one of these antigens. The P. vivax Duffy Binding 
Protein (PvDBP) is functionally important in the invasion process of these paras
ites in Duffy / DARC positive humans. The proteins or fractions may be considere
d, therefore, an important and potential inoculum to be used in immunization aga
inst malaria.</font></p>     ^cY#v33n1a16.htm##
00461000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022600076002001300302#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#17#13#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Duffy Blood Group S
ystem; Malaria; Plasmodium vivax; Chemokines; Antigens, protozoan; Protozoan pro
teins</font></p> <hr size="1" noshade>     ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#18#14#article#353#<p>&nbsp;</p>     ^
cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#19#15#article#353#<p>&nbsp;</p>     ^
cY#v33n1a16.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#20#16#article#353#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></p>     ^
cY#v33n1a16.htm##
00696000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046100076002001300537#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#21#17#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Malaria is an acute infectious disea
se caused by protozoa of the genus <i>Plasmodium</i>. The etiologic agents in Br
azil are the species <i>Plasmodium vivax, Plasmodium falciparum</i> and <i>Plasm
odium malariae</i>. The disease is transmitted through the bite of female <i>Ano
pheles mosquitoes</i>, even though in certain situations other mechanisms are po
ssible. <sup>(1)</sup></font></p>     ^cY#v33n1a16.htm##
00726000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049100076002001300567#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#22#18#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The antigens of the Duffy Blood Grou
p System, in addition to involvement in transfusion incompatibility and hemolyti
c disease of the newborn, are of great interest in medicine because of their ass
ociation with the invasion of red blood cells (RBCs) by the parasite <i>P. vivax
</i>. Additionally they are receptors for the chemokine family involved in the r
egulation of inflammatory processes.<sup>(2-5)</sup></font></p>     ^cY#v33n1a16
.htm##
00746000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051100076002001300587#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#23#19#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The finding that Fy(a-b-) erythrocyt
es are resistant to infection by <i>Plasmodium knowlesi</i> and <i>P. vivax</i> 
validated the proposition that the absence of these antigens represents an examp
le of natural selection especially in areas where <i>P. vivax</i> is widespread.
 This resistance appears to have significantly influenced the distribution of Du
ffy system phenotypes in areas where malaria is endemic.<sup>(5-7)</sup></font><
/p>     ^cY#v33n1a16.htm##
00594000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035900076002001300435#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#24#20#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This article discusses the prospect 
of a vaccine against malaria and also makes a brief review of the parasite and i
ts interaction with Fy<sup>a</sup> and Fy<sup>b</sup> antigens as resistance and
 susceptibility factors to malaria, particularly that caused by <i>P. vivax.</i>
</font></p>     ^cY#v33n1a16.htm##
00511000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027600076002001300352#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#25#21#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The terminology used in this article
, to refer to antigens and antibodies to the Duffy Blood Group System was recomm
ended by the International Society of Blood Transfusion (ISBT).<sup>(8)</sup></f
ont></p>     ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#26#22#article#353#<p>&nbsp;</p>     ^
cY#v33n1a16.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#27#23#article#353#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Malaria</b></font></p>     ^cY#v3
3n1a16.htm##
00325000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009000076002001300166#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#28#24#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">General</font></p>     ^cY#v33n1a16.
htm##
00948000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071300076002001300789#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#29#25#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Malaria, also known as paludism, pal
ustre fever and ague is one of the most important parasitic diseases among popul
ations of tropical and subtropical countries of the world. The etiologic agent, 
<i>Plasmodium sp</i>., was first identified in 1880 by Charles Alphonse Laveran.
 Malaria is caused by infestation of different species of protozoa of the genus 
<i>Plasmodium: P. vivax</i>, is responsible for the benign tertian disease, <i>P
. falciparum</i>, the malignant tertian disease, <i>P. malariae</i>, the benign 
quartan disease, and <i>P. ovale</i>, also causes benign tertian disease, but on
ly exists in Africa.<sup>(9)</sup></font></p>     ^cY#v33n1a16.htm##
00660000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042500076002001300501#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#30#26#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Malaria caused by <i>P. falciparum</
i> is more severe because it causes microvascular impairment, which makes it pat
hophysiologically different from the malaria caused by <i>P. vivax</i> that unde
r certain conditions may have less severe clinical symptoms, as the immune respo
nse is more of the inflammatory and hemolytic type.<sup>(10)</sup></font></p>   
  ^cY#v33n1a16.htm##
00586000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035100076002001300427#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#31#27#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The most characteristic clinical sig
ns and symptoms of malaria are fever, chills, sweating and anemia, as well as ge
neral symptoms such as headaches, myalgia, malaise and weakness and in severe ca
ses, visceral involvement (splenomegaly and hepatomegaly).<sup>(9)</sup></font><
/p>     ^cY#v33n1a16.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009500076002001300171#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#32#28#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Epidemiology</font></p>     ^cY#v33n
1a16.htm##
00737000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050200076002001300578#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#33#29#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The overall socioeconomic impact of 
Malaria is extensive, as this disease is still a major public health problem in 
tropical and subtropical areas of the world.<sup>(1)</sup> <i>P. vivax</i> accou
nts for less than half of all malaria cases in Latin America, Oceania and Asia<s
up>(11)</sup> and it is calculated that from 70 to 80 million clinical cases cau
sed by <i>P. vivax</i> occur annually worldwide.<sup>(12)</sup></font></p>     ^
cY#v33n1a16.htm##
01543000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704130800076002001301384#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#34#30#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In Brazil, there has been a decrease
 in the annual parasite incidence in the states of the Brazilian Amazon region f
rom 32 per 1,000 inhabitants in 1999 to 13 per 1,000 inhabitants in 2008. Mortal
ity was also reduced from 3 deaths per 10,000 cases in 1999 to 1.5 in 10,000 cas
es in 2008, and the proportion of hospital admissions dropped from 3.3% in 1999 
to 1.3% in 2008. In this same period, there was a considerable change in the tra
nsmission dynamics of malaria with concentrations of cases in specific municipal
ities. The number of municipalities at high risk, i.e. an incidence of 50 cases 
or more per 1,000 inhabitants, was reduced from 160 to 67 municipalities. Over 8
0% of reported cases outside the Amazon were imported from other states in endem
ic regions, from Africa or from Paraguay. Sporadic autochthonic cases occurred i
n restricted focal areas. It is important to mention the municipals located on t
he shores of the lake of the Itaipu hydroelectric plant, areas covered by Atlant
ic Forest in the states of Esp&iacute;rito Santo, Minas Gerais, Rio de Janeiro, 
S&atilde;o Paulo and Bahia, the central-west states of Goi&aacute;s and Mato Gro
sso do Sul and the northeastern state of Piau&iacute;.<sup>(13)</sup></font></p>
     ^cY#v33n1a16.htm##
00554000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031900076002001300395#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#35#31#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Children are the most affected with 
between one or two million childhood deaths each year. Often, infant mortality a
nd morbidity are related to delay in establishing the correct diagnosis because 
of few clinical features.<sup>(14)</sup></font></p>     ^cY#v33n1a16.htm##
00775000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054000076002001300616#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#36#32#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In school children and adolescents, 
the clinical symptoms resemble those seen in adults, whereas in infants and pres
chool children, the clinical characteristics of the disease are often atypical a
nd the triad of fever, chills and headache may not be presented. Ventura et al. 
evaluated the clinical presentation of malaria in 100 children and adolescents a
nd found that the combination of these three symptoms occurred in only 13.6% of 
cases.<sup>(15)</sup></font></p>     ^cY#v33n1a16.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009500076002001300171#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#37#33#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Transmission</font></p>     ^cY#v33n
1a16.htm##
01436000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704120100076002001301277#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#38#34#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Transmission occurs through the bite
 of female <i>Anopheles mosquitoes</i> that feed on human blood that is infected
 with gametocytes. This promotes the fertilization process producing zygotes tha
t become invasive and grow and divide thus producing thousands of invasive sporo
zoites. These migrate through the body and invade the salivary glands of female 
mosquitoes. Females, when they feed again, inoculate sporozoites in the blood of
 man, which rapidly migrate into hepatocytes and transform into trophozoites in 
the liver where they mature and divide to form thousands of merozoites. The live
r cells rupture releasing merozoites into the circulation, thereby initiating th
e blood cycle. In this phase, symptoms do not appear in the host. In the blood c
ycle, the merozoites develop into trophozoites forming schizonts. These, when ri
pe, lead to the rupture of RBCs releasing merozoites that can re-infect other RB
Cs. This stage of the cycle is associated with clinical symptoms. After a period
 of asexual replication, some merozoites differentiate into gametocytes and beco
me infective to mosquitoes.<sup>(16)</sup></font></p>     ^cY#v33n1a16.htm##
00647000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041200076002001300488#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#39#35#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The transmission dynamics is variabl
e among human groups belonging to different epidemiological strata, because of t
he interaction of risk factors, including biological, ecological, economic, soci
ocultural and public health. The combination of these factors establishes differ
ent transmission rates for the disease.<sup>(1)</sup></font></p>     ^cY#v33n1a1
6.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009300076002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#40#36#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Diagnosis </font></p>     ^cY#v33n1a
16.htm##
00910000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067500076002001300751#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#41#37#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Routine laboratory diagnosis uses li
ght microscopy of thick blood smears, with the identification of parasites in pe
ripheral blood. Improvement of microscopy and the introduction of biological sta
ins that identify the species, developmental stage, viability and quantification
 of parasites, have made this test simple, rapid and satisfactory in terms of it
s sensitivity and specificity.<sup>(17)</sup> However, the low sensitivity of th
e technique to diagnose patients with low parasitemia (common in asymptomatic ca
rriers of malaria) and mixed infections is under discussion.<sup>(18)</sup> </fo
nt></p>     ^cY#v33n1a16.htm##
00978000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074300076002001300819#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#42#38#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Since 1990, several studies have men
tioned the application of polymerase chain reaction (PCR) in the molecular diagn
osis of malaria for epidemiological surveys, in screening of infected donors in 
blood banks, in the identification of asymptomatic carriers of malaria and in th
e monitoring therapeutic response.<sup>(19)</sup> Despite several experiments sh
owing that PCR is more sensitive than microscopy and its use by some authors as 
the gold standard in diagnosis, the employment of this technique under current c
onditions requires more evidence, especially due to its high cost and the sophis
ticated infrastructure needed for implementation.<sup>(20)</sup></font></p>     
^cY#v33n1a16.htm##
01148000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091300076002001300989#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#43#39#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">New rapid methods that detect antige
nic components of <i>Plasmodium</i>, including immunochromatographic assays, are
 being developed. Performed on nitrocellulose strips containing monoclonal antib
odies against specific antigens of the parasite, the sensitivity of the test is 
above 95% and comparable to thick smears with parasitemia of more than 100 paras
ites/&#181;L. Although the tests available today specifically differentiate <i>P
. falciparum</i> and other species, they are not able to diagnose mixed malaria.
 Because of their convenience and simplicity, they are useful for screening and 
even diagnostic confirmation, especially in situations where the processing of a
 thick blood smears is complicated, such as in remote areas with difficult acces
s to healthcare services and in regions with low incidence.<sup>(13)</sup></font
></p>     ^cY#v33n1a16.htm##
00327000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009200076002001300168#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#44#40#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Treatment</font></p>     ^cY#v33n1a1
6.htm##
00671000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043600076002001300512#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#45#41#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Treatment is by a combination of chl
oroquine (blood schizonticide) and primaquine, the drug of choice to eliminate h
ypnozoites. Because of its oxidizing character, primaquine can induce severe hem
olytic anemia, even at the conventional dose of 0.25 mg/kg/day, but only in pati
ents with glucose-6-phosphate dehydrogenase deficiency (G6PD).<sup>(21)</sup></f
ont></p>     ^cY#v33n1a16.htm##
00627000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039200076002001300468#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#46#42#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The regimen using primaquine adopted
 by the National Health Foundation for the rapid treatment of malaria due to <i>
P. vivax</i> infection was over fourteen days. Although effective, this extended
 regimen can explain the high number of cases of noncompliance and thus the appe
arance of relapse.<sup>(22)</sup></font></p>     ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#47#43#article#353#<p>&nbsp;</p>     ^
cY#v33n1a16.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011600076002001300192#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#48#44#article#353#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Duffy blood group antigens</b></f
ont></p>     ^cY#v33n1a16.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#49#45#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Brief history</font></p>     ^cY#v33
n1a16.htm##
01070000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083500076002001300911#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#50#46#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In 1950 Cutbush, Mollison and Parkin
<sup>(23)</sup> discovered anti-Fy<sup>a</sup>, by detecting an agglutinin in th
e serum of a multitransfused hemophiliac patient that was not recognized as a bl
ood group antigen. This antibody was named anti-Fy<sup>a</sup>, after the patien
t in question, Mr. Duffy; the antibody reacted with 64.9% of 205 blood samples f
rom unrelated English individuals. The following year, Ikin et al.<sup>(24)</sup
> described the anti-Fy<sup>b</sup> antibody that defined the antithetical pair 
to Fy<sup>a</sup>. In 1955, Sanger, Race, and Jack<sup>(25)</sup> observed that 
the Fy(a-b-) phenotype was rare in Caucasians but was the most common in African
-Americans and probably represented a product of a silent allele, <i>FY.</i></fo
nt></p>     ^cY#v33n1a16.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009500076002001300171#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#51#47#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Biochemistry</font></p>     ^cY#v33n
1a16.htm##
00870000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063500076002001300711#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#52#48#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Duffy blood group antigen was id
entified on the surface of RBCs eliminating toxic excesses of circulating chemok
ines, called DARC.<sup>(26)</sup> The determinant is a glycoprotein that travers
es the membrane seven times and includes an extracellular epitope, N-terminal do
main that mediates RBC invasion by merozoites of <i>P. vivax.</i><sup>(27)</sup>
 The <i>FY</i> gene has two exons (<i>FY</i><sup>A</sup> and <i>FY</i><sup>B</su
p>) that are encoded by the codominant <i>FYA</i> and <i>FYB</i> alleles, locate
d on chromosome 1.<sup>(28,29)</sup></font></p>     ^cY#v33n1a16.htm##
00688000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045300076002001300529#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#53#49#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>FYA</i> and <i>FYB</i> alleles di
ffer by a single base substitution at nucleotide 125. Such an amino acid substit
ution in the amino-terminal domain of the protein is sufficient to define the tw
o antithetical antigens. This variation leads to the identification of the Fy(a+
b-), Fy(a-b+), Fy(a-b-) and Fy(a+b+) phenotypes (<a href="#tab1">Table 1</a>).<s
up>(30)</sup> </font></p>     ^cY#v33n1a16.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#54#50#article#353#<p><a name="tab1"><
/a></p>     ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#55#51#article#353#<p>&nbsp;</p>     ^
cY#v33n1a16.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#56#52#article#353#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a16tab01.jpg"></p>     ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#57#53#article#353#<p>&nbsp;</p>     ^
cY#v33n1a16.htm##
00925000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069000076002001300766#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#58#54#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>FYA</i> and <i>FYB</i> alleles di
ffer by a mutation in an important transcription complementary <i>DNA</i> (cDNA)
 that encodes glycine (<i>FYA</i>) or aspartic acid (<i>FYB</i>) at position 42 
of the most important proteins encoded by exon 2. The molecular mechanism that g
ives rise to the null Duffy phenotype &#91;Fy (a-b-)&#93; has been classically a
ssociated with a mutation in the Graphic Alignment Tool for Comparative Sequence
 Analysis (GATA)-box of the DARC silent promoter gene encoding the Duffy antigen
 system in RBCs of these individuals, resulting in the <i>FYB</i> allele.<sup>(3
1-33)</sup></font></p>     ^cY#v33n1a16.htm##
01542000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704130700076002001301383#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#59#55#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It was demonstrated that Caucasian a
nd African descent blood donors in southeastern Brazil were serologically Fy(b-)
 with the majority of African descents presenting <i>FYB</i> with the GATA box s
ingle nucleotide polymorphism (SNP), while the majority of Fy(b-) type Caucasian
s presented <i>FYB</i> and 265 thymine/298 adenine SNPs.<sup>(34)</sup> Fy(a-b-)
 RBCs are common in black African ethnic groups but rare in many other populatio
ns.<sup>(35)</sup> In blacks it was shown to be due to a mutation at position -3
3 (T&gt;C) in the promoter region of the <i>FYB</i> gene, the GATA-box.<sup>(31,
36)</sup> This change leads to a disruption in erythroid transcription factor GA
TA-1, resulting in an absence of the Fy<sup>b</sup> antigen expression only in R
BCs without changing the expression of this protein in other tissues. As a resul
t, these individuals may develop anti-Fy<sup>a</sup>, but not anti-Fy<sup>b</sup
> antibodies.<sup>(37)</sup> Most individuals of West African and 68% of African
-Americans do not express Fy<sup>a</sup> or Fy<sup>b</sup> in their RBCs, which 
results in resistance to infection by <i>P. vivax</i> because RBCs with the Fy(a
-b-) phenotype cannot be invaded by this parasite.<sup>(25,31)</sup></font></p> 
    ^cY#v33n1a16.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009500076002001300171#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#60#56#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Epidemiology</font></p>     ^cY#v33n
1a16.htm##
00841000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060600076002001300682#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#61#57#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The phenotype frequencies found in s
tudies of blood donors in S&atilde;o Paulo for antigens of the Duffy blood group
 system were: the Fy(a+b-) phenotype in 19.8% of Caucasians and in 14.0% of Blac
ks; the Fy(a+b+) phenotype in 41.4% of Caucasians and in 1.6% of Blacks; the Fy(
a-b+) phenotype in 37.8% of Caucasians and in 17.5% of Blacks and the Fy(a-b-) p
henotype in 1.1% of Caucasians and in 66.9% Blacks (this phenotype is considered
 to be a marker for Black individuals).  (<a href="#fig1">Figure 1</a>).<sup>(38
)</sup></font></p>     ^cY#v33n1a16.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#62#58#article#353#<p><a name="fig1"><
/a></p>     ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#63#59#article#353#<p>&nbsp;</p>     ^
cY#v33n1a16.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#64#60#article#353#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a16fig01.jpg"></p>     ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#65#61#article#353#<p>&nbsp;</p>     ^
cY#v33n1a16.htm##
00652000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041700076002001300493#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#66#62#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Fy<sup>a</sup> antigen is common
 among the Chinese, Japanese and Melanesians, but uncommon among Black Africans.
<sup>(39,40)</sup> However, the Fy<sup>b</sup> antigen is more frequent in the C
aucasian population than in Asians and Blacks and the Fy(a-b-) phenotype is extr
emely rare outside the black population.<sup>(41,42)</sup></font></p>     ^cY#v3
3n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#67#63#article#353#<p>&nbsp;</p>     ^
cY#v33n1a16.htm##
00388000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015300076002001300229#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#68#64#article#353#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Relationship between Plasmodium v
ivax and Duffy system antigens</b></font></p>     ^cY#v33n1a16.htm##
00325000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009000076002001300166#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#69#65#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">History</font></p>     ^cY#v33n1a16.
htm##
00969000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073400076002001300810#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#70#66#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The discussion about the role of the
 RBC antigens of the Duffy system began in 1975 when Miller et al.<sup>(41)</sup
> suggested that the Fy<sup>a</sup> or Fy<sup>b</sup> antigenic determinants cou
ld be receptors for <i>P. knowlesi</i> and that resistance to the invasion of th
is merozoite in Blacks was due to the Fy(a-b-) phenotype. The strength of Fy(a-b
-) against invasion by <i>P. knowlesi</i> merozoites was demonstrated <i>in vitr
o</i> and Barnwell et al.<sup>(43)</sup> confirmed this with <i>P. vivax</i> sug
gesting that there was a natural selection of individuals with the <i>FY</i> gen
e who do not produce Fy<sup>a</sup> and Fy<sup>b</sup>.</font></p>     ^cY#v33n1
a16.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009500076002001300171#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#71#67#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Epidemiology</font></p>     ^cY#v33n
1a16.htm##
01236000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704100100076002001301077#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#72#68#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>P. falciparum</i> uses a series o
f receptors on the surface of human RBCs to invade them, while <i>P. vivax</i> a
nd <i>P. knowlesi</i> depend on an interaction with the Fy<sup>a</sup> or Fy<sup
>b</sup> antigens of the Duffy Blood Group System.<sup>(5,41,44,45)</sup> In Afr
ica, where the Fy(a-b-) phenotype has achieved stability in different ethnic gro
ups, the transmission of <i>P. vivax</i> is uncommon.<sup>(46,47)</sup> In the P
apua New Guinea population, carriers of the Fy(a-b+) or Fy(a+b-) express half th
e level of Duffy antigens on red blood cells compared to wild type homozygotes a
nd exhibit reduced susceptibility to blood stage infection by <i>P. vivax</i>.<s
up>(33,48)</sup> These observations suggest that total or partial restriction to
 access Duffy antigen reduces the ability of the parasite to invade new red bloo
d cells and thus this might inhibit parasitemia by <i>P. vivax.</i><sup>(49)</su
p></font></p>     ^cY#v33n1a16.htm##
01044000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080900076002001300885#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#73#69#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>P. vivax</i> Duffy binding protei
n (PvDBP) is functionally important in the invasion process of parasites in huma
n Duffy/DARC positive RBCs, and it has recently been demonstrated that regions w
here malaria transmission rates are low or medium, such as in inhabitants of the
 Brazilian Amazon, this protein is naturally immunogenic.<sup>(50)</sup> In thes
e populations, the proportion of DBP Immunoglobulin G (IgG) increased with expos
ure to malaria, reaching a peak in individuals with prolonged exposure such as i
n residents of endemic areas (&gt; 15 years). This observation was later confirm
ed in the Rondonia population, an malaria endemic area where IgG1 and IgG3 DBP-s
pecific antibodies were identified.<sup>(51)</sup></font></p>     ^cY#v33n1a16.h
tm##
01258000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102300076002001301099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#74#70#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The populations of various ethnic re
gions of Thailand and Indonesia were studied, and there was a high incidence of 
the <i>FYA</i> allele (&gt; 0.9) and the presence of a new phenotype, Fy(a+<sup>
weak</sup> b-), while these data were similar to those found in previous phenoty
pic studies conducted in Southeast Asia and Australasia. It is striking that Fy(
a+<sup>weak</sup> b-) individuals had <i>FYA/FYA</i> genotypes while Fy(a-b-) in
dividuals had <i>FYA/FYA</i> or <i>FYA/FYB</i> genotypes as seen by Polymerase C
hain Reaction-Restriction Fragment Lenght Polymorphism (PCR-RFLP) using BanI and
 the Sty enzymes; the genetic mechanisms that cause this phenotype have not been
 determined. The implications of the presence of these phenotypes are still unkn
own but it has been suggested that in malaria endemic regions, there are defense
 mechanisms against <i>P. vivax</i> infection distinct from those in African des
cendents.<sup>(40)</sup></font></p>     ^cY#v33n1a16.htm##
00903000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066800076002001300744#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#75#71#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Field observations in West Africa an
d Ethiopia have established strong correlations between the absence or low endem
icity for <i>P. vivax</i> and the high prevalence of negative <i>FYA</i> and <i>
FYB</i> alleles.<sup>(47,52)</sup> In these populations in which there is an Afr
ican gene influence, four main phenotypes, Fy(a+b-), Fy(a-b+), Fy(a+b+) and Fy(a
-b-), have been identified.<sup>(53)</sup> Thus, the Duffy blood group system is
 considered one of the most interesting chromosomal loci to assess the impact of
 natural selection in different geographic regions.<sup>(54,55)</sup></font></p>
     ^cY#v33n1a16.htm##
00826000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059100076002001300667#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#76#72#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The Brazilian population has a great
 diversity in its ethnic composition as a result of the hybridization of numerou
s indigenous populations and immigrants from Europe, Africa and Asia. Immigratio
n was not uniform across the country.<sup>(56,57)</sup> The differential distrib
ution of Duffy antigenic determinants among ethnic groups is a characteristic fe
ature of this blood group system. So this has been used as a marker for ethnic c
omposition, as well as an indicator of population trends.<sup>(58)</sup></font><
/p>     ^cY#v33n1a16.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#77#73#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Mechanism of action</font></p>     ^
cY#v33n1a16.htm##
01029000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079400076002001300870#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#78#74#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In regards to merozoite invasion of 
RBCs, Aikawa et al.<sup>(59)</sup> and Miller et al.<sup>(60)</sup> observed by 
electron microscopy that the apical portion of the merozoite makes the first con
tact with the RBC creating a small depression in the membrane. This area begins 
to thicken and binds with the membrane of the merozoite which then enters the re
d blood cell by invagination. After the <i>Plasmodium</i> enters, this access cl
oses. This binding is crucial for parasite invasion. The presence of one member 
of a large family of proteins bound to RBCs, referred to as Duffy Binding Protei
n (DBP), is required to mediate with the DARC as this antigen was identified as 
a chemokine receptor.<sup>(2)</sup></font></p>     ^cY#v33n1a16.htm##
01158000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704092300076002001300999#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#79#75#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This critical binding occurs in the 
cysteine-rich domain between the amino acids at positions 291 and 460 of region 
II.<sup>(61)</sup> According to several observations, region II of the DBP (DBPI
I) can be a critical target for protective immunity of the host. Firstly, certai
n DBPII are highly polymorphic and appear to be maintained by immune selection<s
up>.(62-64)</sup> Secondly, antibodies against DBPII found in populations of end
emic areas for <i>P. vivax</i> inhibit binding of COS-7 cells expressing the DBP
II ligand to DARC-positive RBCs.<sup>(65,66)</sup> Thirdly, the high antibody le
vels against region II of <i>P. knowlesi</i> a protein, a molecule that is 70% h
omologous to <i>P. vivax</i> DBP, also mediates infections of human DARC-depende
nt RBCs and may inhibit invasion of human RBCs by <i>P. knowlesi</i>.<sup>(67)</
sup></font></p>     ^cY#v33n1a16.htm##
00828000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059300076002001300669#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#80#76#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>P. vivax</i> DBP is a 140-kDa pro
tein that belongs to a family homologous to Duffy DBL-EBP, located inside organe
lles of merozoites of <i>Plasmodium</i>.<sup>(68)</sup> The similarity between D
BL-EBPs is most prominent in two conserved cysteine-rich domains in regions II a
nd VI. The binding functional domains of DBL-EBP lie in region II, which for <i>
P. vivax</i> is DBP 330-amino acid and the critical residues of map linking a ce
ntral region of 170- amino acid including cysteines 5-8.<sup>(61,69)</sup></font
></p>     ^cY#v33n1a16.htm##
00634000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039900076002001300475#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#81#77#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The gene encoding the <i>P. vivax</i
> DBPII is highly polymorphic and this diversity varies geographically from regi
on to region.<sup>(70,71)</sup> This polymorphism is consistent with a high pres
sure on DBP selection and suggests that an allelic variation functions as an imm
une evasion mechanism.<sup>(72,73)</sup></font></p>     ^cY#v33n1a16.htm##
00606000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037100076002001300447#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#82#78#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">DBP is likely to be exposed during t
he invasion, therefore, it can become accessible to antibodies. Currently, data 
on humoral immune response to DBP in the human population is limited, and studie
s have been mainly restricted to areas where malaria is highly endemic.<sup>(65,
74,75)</sup></font></p>     ^cY#v33n1a16.htm##
00990000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075500076002001300831#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#83#79#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Research on cytokines and their rece
ptors converged in the investigation of the antigens of the Duffy Blood Group Sy
stem, showing an important physiological role for the alleles of this glycoprote
in.<sup>(76)</sup> Horuk et al. showed in a study of multispecific chemokine rec
eptors in human RBCs, that interleukin (IL)-8 minimally binds to Fy(a-b-) RBCs, 
that monoclonal antibodies against Duffy antigens block the binding of IL-8 to p
ositive Duffy RBC antigens and that IL-8 also prevented the binding and invasion
 of RBCs by <i>P. knowlesi</i>. This led to several lines of evidence suggesting
 that Duffy blood group antigens are receptors for chemokines.<sup>(2)</sup></fo
nt></p>     ^cY#v33n1a16.htm##
00564000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032900076002001300405#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#84#80#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It was also observed that if a mutat
ion occurred in the DARC promoter region of the gene in erythroid precursor cell
s, this would prevent its expression in RBCs and complete resistance to infectio
n by <i>P. vivax</i> would occur.<sup>(5,31)</sup></font></p>     ^cY#v33n1a16.h
tm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#85#81#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Immune response</font></p>     ^cY#v
33n1a16.htm##
01262000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102700076002001301103#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#86#82#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It is believed that merozoite invasi
ons seize organelle protein until contact of merozoites with the target RBC pres
umably as a mechanism to reduce the exposure of DBP to immune inhibition.<sup>(7
7)</sup> At present, the data available on the humoral immune response to DBP in
 human populations show that anti-DBP antibodies increase with exposure to <i>P.
 vivax</i> and that immune response, which includes antibody activity, blocks ad
hesion of DBPII to its receptor on RBCs.<sup>(50,65,74,78)</sup> The same antibo
dies that block DBPII-DARC also interact inhibiting RBC invasion by <i>P. vivax<
/i><sup>(49)</sup> which is the concept that proves that the <i>P. vivax</i> Duf
fy Binding Protein antibody (anti-PvDBP) can inhibit invasion of merozoites. It 
is notable, that children living in endemic areas of <i>P. vivax</i> develop inh
ibitory anti-DBP antibodies that seem to confer protection against the blood inf
ection stage.<sup>(79)</sup></font></p>     ^cY#v33n1a16.htm##
01271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704103600076002001301112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#87#83#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Over 90% of sub-Saharan Africans do 
not express DARC, and as a result, <i>P. vivax</i> has limited distribution in t
his region of Africa. Therefore, the BPD protein represents one of the most prom
ising antigens among the candidates to be used in the production of vaccines aga
inst malaria, but little is known about the immune response against this molecul
e. However, host immune responses to <i>P. vivax</i> DBP appear to play a key ro
le in acquired immunity to P. vivax, due to their essential role in the invasion
 of RBCs by merozoites. This acquired immunity is probably partly due to the pro
duction of anti-BPD antibodies that block it binding to receptors in red blood c
ells. In support of this model, an increase in the proportion of bonds and antib
odies that recognize recombinant Duffy Binding Protein (rDBP) was observed as th
e age advanced, concomitant with a reduction in prevalence and intensity of <i>P
. vivax</i> infection.<sup>(80)</sup></font></p>     ^cY#v33n1a16.htm##
00840000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060500076002001300681#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#88#84#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">To better define potentially protect
ive epitopes in the critical link of DBPII, at least four dominant linear epitop
es were identified, two of which correspond to the aforementioned T cell epitope
s.<sup>(80)</sup> The accumulation of these antibodies against linear epitopes i
s closely correlated with the correct recognition of folded rDBPII antibodies.<s
up>(66)</sup> This suggests that antibodies directed to some of these linear epi
topes also recognize native DBP expressed on the surface of merozoites.<sup>(75)
</sup></font></p>     ^cY#v33n1a16.htm##
00468000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023300076002001300309#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#89#85#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">With current knowledge, the innate r
esistance to malaria infections in humans has been attributed to the polymorphis
ms of blood groups.<sup>(81)</sup></font></p>     ^cY#v33n1a16.htm##
00325000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009000076002001300166#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#90#86#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Vaccine</font></p>     ^cY#v33n1a16.
htm##
00694000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045900076002001300535#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#91#87#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The attempt to control malaria throu
gh the use of a vaccine has been encouraged for years and today it is a controve
rsial and widely discussed topic. The development of a vaccine is of great impor
tance for infection control, since resistance to drugs used in therapy is increa
sing around the world as is the emergence of the vector's resistance to insectic
ides.<sup>(82)</sup></font></p>     ^cY#v33n1a16.htm##
00686000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045100076002001300527#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#92#88#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Several antigens of asexual blood fo
rms of <i>P. vivax</i> are considered potential components to include in a vacci
ne for species-specific malaria.<sup>(83)</sup> Among these, the three best char
acterized from the immune viewpoint are the merozoite surface protein 1 (MSP-1),
<sup>(84)</sup> DBP <sup>(66,85)</sup> and apical membrane antigen 1 (AMA-1).<su
p>(86)</sup></font></p>     ^cY#v33n1a16.htm##
00841000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060600076002001300682#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#93#89#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">MSP-1 is the best characterized prot
ein in the blood stage of <i>Plasmodium.</i> This antigen is an integral membran
e protein that appears to be linked to the merozoite surface through Glycosylpho
sphatidylinositol anchors (GPI) and is synthesized as a high molecular weight pr
ecursor (180 to 230 kDa) during the schizogony stage. After being processed, the
 MSP-1 protein generates smaller fragments of 19 kDa and 42 kDa which remain on 
the surface of the parasite; these are essential for merozoite invasion.<sup>(87
)</sup></font></p>     ^cY#v33n1a16.htm##
00924000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068900076002001300765#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#94#90#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Several studies have shown that the 
<i>P. vivax</i> MSP-1 protein (PvMSP-1) is highly immunogenic in different regio
ns of the world including Korea,<sup>(88)</sup> Sri Lanka,<sup>(89)</sup> Colomb
ia<sup>(90)</sup> and Brazil.<sup>(91-94)</sup> Additionally, studies in BALB/c<
sup>(90,93)</sup> and nonhuman primate  immunization<sup>(90,95,96)</sup> perfor
med with PvMSP-1 showed the presence of high levels of IgG antibodies and anti-P
vMSP-1. In addition, nonhuman primates immunized with this protein showed a part
ial protective immunity when tested with blood forms of the parasite.<sup>(90,95
,96)</sup></font></p>     ^cY#v33n1a16.htm##
00539000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030400076002001300380#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#95#91#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Recently, PvMSP-1 has been tested in
 preclinical and clinical studies, however, additional studies are needed to ide
ntify the main fragment of this protein that is capable of inducing a protective
 response.<sup>(97)</sup></font></p>     ^cY#v33n1a16.htm##
00947000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071200076002001300788#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#96#92#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Despite the PvMSP-1 antigen being co
nsidered an important candidate for the inoculation of the vaccine against the a
sexual blood stage of the parasite,<sup>(84,96,98,99)</sup> other studies have d
emonstrated that this protein shows polymorphisms which certainly could compromi
se its potential for this purpose.<sup>(89,100,101)</sup> Other proteins, also a
ssociated with the merozoite surface such as MSP-3, MSP-4, MSP-5 and MSP-9, have
 been identified and characterized as potentially useful for vaccines<sup>(102-1
05)</sup> while some of these have already been produced for studies as recombin
ant proteins.<sup>(106,107)</sup></font></p>     ^cY#v33n1a16.htm##
01457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704122200076002001301298#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#97#93#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">DBP represents one of the most promi
sing vaccine candidate antigens against <i>P. vivax</i> infection.<sup>(78)</sup
> This is probably exposed on the surface of merozoites during invasion of RBCs,
 which allows its binding to the receptor and, importantly from the standpoint o
f a vaccine, makes it accessible to antibodies in the serum. Although having gre
at importance as a candidate protein, there are some limitations that have hinde
red its study such as its low abundance in the parasite, low immunogenicity, as 
well as the limitations for the <i>in vitro</i> cultivation of <i>P. vivax.</i><
sup>(74,75,108,109)</sup> With the spread of drug resistance and with cases of <
i>P. vivax</i> infection increasing, more emphasis has been placed on developing
 a vaccine against the malaria caused by <i>P. vivax</i>.<sup>(46)</sup> Residen
ts of a specific endemic area develop acquired immunity to <i>P. vivax</i> over 
several years. The gradual acquisition of immunity probably occurs because of th
e many antigenically different strains of the parasite and/or weakly immunogenic
 epitopes recognized by the host immune system.<sup>(110)</sup></font></p>     ^
cY#v33n1a16.htm##
00716000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048100076002001300557#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#98#94#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although this molecule represents a 
good candidate to be used in vaccine production, polymorphisms may be a serious 
difficulty, and therefore probably conserved regions within the protein should b
e used or multiple allelic forms of the antigen should be incorporated. Understa
nding the nature and origin of this polymorphism in Plasmodium antigens is cruci
al for vaccine development.<sup>(72)</sup></font></p>     ^cY#v33n1a16.htm##
01018000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704078300076002001300859#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#99#95#article#353#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">One of the goals to be achieved will
 be to determine how the genetic diversity of parasites is related to vaccine im
munity, and thus the DBP antigen of <i>P. vivax</i> is a leading candidate. To a
ttain this goal, it is important to assess levels of genetic diversity of DBP wi
thin and between populations in different geographic regions and assess how this
 genetic diversity is generated and maintained. Many factors can contribute to t
he genetic diversity of the population with malaria, especially mutations, intra
genic recombination (determined by the multiplicity of infection and transmissio
n intensity), natural selection, gene flow between different regions and populat
ion size.<sup>(72)</sup></font></p>     ^cY#v33n1a16.htm##
00879000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704064300077002001300720#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#100#96#article#353#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">The AMA-1 protein is a member of a 
family of molecules expressed in micronemes of <i>Plasmodium merozoites</i>. Thi
s protein is 83 kDa in <i>P. falciparum</i> and 66 kDa in the other species and 
plays an important role in the invasion of RBCs in the asexual blood stage. In a
ddition, the AMA-1 protein is also expressed in sporozoites, and seems to be inv
olved in the invasion of hepatocytes.<sup>(111)</sup> However, despite the impor
tance of this protein as a vaccine candidate antigen, few studies have been cond
ucted on its immune response. <sup>(97)</sup></font></p>     ^cY#v33n1a16.htm##
00856000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704062000077002001300697#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#101#97#article#353#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">In experimental models using nonhum
an primates, the AMA-1 protein showed high immunogenicity.<sup>(86)</sup> Subseq
uently, immuno-epidemiological studies conducted in Korea<sup>(112)</sup> and Sr
i Lanka<sup>(89)</sup> showed that individuals with positive stool examinations 
for <i>P. vivax</i> developed antibodies against AMA-1. Similarly, in Brazil, th
e AMA-1 protein was highly immunogenic in individuals from endemic areas during 
natural infections and antibody levels increased depending on exposure to malari
a.<sup>(113,114)</sup></font></p>     ^cY#v33n1a16.htm##
00936000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704070000077002001300777#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#102#98#article#353#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Many studies have shown that the ge
netic diversity of AMA-1 is variable between different regions of the world. In 
highly endemic areas such as Papua New Guinea,<sup>(115)</sup> a high polymorphi
sm diversity was observed among different isolates of the region, however in low
 endemic regions such as Korea,<sup>(116)</sup> there was a low polymorphism div
ersity. In Brazil, the MSP-1 protein has been shown to be highly immunogenic in 
natural infections of individuals originating from six different endemic malaria
 regions<sup>(113,114)</sup> with limited polymorphism diversity<sup>(113)</sup>
 as observed in Korea.</font></p>     ^cY#v33n1a16.htm##
01257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704102100077002001301098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#103#99#article#353#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">In the last decade, research to pro
duce a vaccine received much investment.<sup>(117)</sup> RTS,S, the most advance
d vaccine in development, will cost $500 million in its next phase.<sup>(118)</s
up> In August 2006, the organization Malaria Vaccine Technology Roadmap stipulat
ed that its goal was to develop a vaccine by 2015, which offered 50% protection 
against the severe form of infection for at least one year. Today, however, only
 one may achieve this goal, the RTS,S (project of the Glaxo Smith Kline pharmace
utical industry in conjunction with the Research Institute Walter Reed Army).<su
p>(117)</sup> The challenge of an effective vaccine against malaria is to develo
p immunity against the etiologic agent, as the infection occurs again and again 
and evolves to a chronic infection. Moreover, existing knowledge about the compl
ex host-parasite interaction is still a major limitation in the development of r
esearch.<sup>(82)</sup></font></p>     ^cY#v33n1a16.htm##
01480000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704124300078002001301321#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#104#100#article#353#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">New perspectives for malaria vacci
nation arise with the use of monoclonal antibodies (AcM). AcM are attractive too
ls to assist in the identification of epitopes and mechanisms. These antibodies 
show specificity to antigens in the asexual blood stage of the parasite and also
 showed <i>in vitro</i> and <i>in vivo</i> neutralizing capacity. Most specific 
AcM result from hybridoma technology in mice, which makes their use restrictive 
both for <i>in vitro</i> investigations and for studies employing mice infected 
with common rodents species of <i>Plasmodium.</i> To meet this deficiency, a rec
ent alternative is the development of recombinant human antibodies employing the
 use of genomic libraries, thus avoiding the need for hybridomas or vaccines. Th
is technology enables the creation of monoclonal IgG antibodies specific to huma
n <i>Plasmodium</i> and recent work has demonstrated the effectiveness of this m
ethodology in <i>in vitro</i> and <i>in vivo</i> models. This new approach also 
offers advantages, allowing "molecular adjustments" to the specific antigens and
 functional characteristics of antibodies produced in this way.<sup>(82,119,120)
</sup></font></p>     ^cY#v33n1a16.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#105#101#article#353#<p>&nbsp;</p>    
 ^cY#v33n1a16.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010000078002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#106#102#article#353#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>Conclusion</b></font></p>     ^
cY#v33n1a16.htm##
02000000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704176300078002001301841#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#107#103#article#353#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">There have been significant advanc
es in recent years in studies on the relationship between human infestation by p
athogens of malaria antigens and the Duffy blood group system. However much rema
ins to be discovered and better understood as, for example, the mechanisms that 
allow interaction between <i>Plasmodium</i> and the Fy<sup>a</sup> and Fy<sup>b<
/sup> antigens. The intense polymorphism and different alleles of the immuno-dom
inant region that produce potential candidate antigens for use as inocula for th
e vaccine, emphasize the need to better understand the relationship between gene
tic and humoral immunity. Studies show that PvDBP is equally or more promising t
han other protein candidates for vaccine antigens; it is naturally immunogenic i
n different populations of the Brazilian Amazon, the antibody response is propor
tional to the length of individual exposure to the parasite in areas of malaria 
transmission. A major challenge to vaccine development is the specific technical
 difficulties to cultivate <i>in vitro</i> in a continuous and efficient process
, although today, with a new perspective in using monoclonal antibodies, the lim
itation is not to be able to extrapolate the results to <i>in vitro</i> to <i>in
 vivo</i> models. We believe that with the development of new molecular and immu
nological technology, the challenges can be overcome in a relatively short time 
thus allowing the production of human vaccine against malaria, in order thus to 
prevent an endemic disease that affects millions of people in various regions of
 the world. We emphasize that an additional difficulty in Brazil is the limited 
resources available for research in this area.</font></p>     ^cY#v33n1a16.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#108#104#article#353#<p>&nbsp;</p>    
 ^cY#v33n1a16.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010000078002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#109#105#article#353#<p><font size="3"
 face="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^
cY#v33n1a16.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704028000080002001300360#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#110#106#article#353#1#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Machado RL, D'Alm
eica Couto AA, Cavasini CE, Calvosa VS. &#91;Malaria outside the Brazilian Amazo
nian region: the situation in Santa Catarina state&#93;. Rev Soc Bras Med Trop. 
2003;36(5):581-6. Portuguese.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#111#107#article#353#</font></p>     ^
cY#v33n1a16.htm##
00521000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704027000080002001300350#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#112#108#article#353#2#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Horuk R, Chitnis 
CE, Darbonne WC, Colby TJ, Rybicki A, Hadley TJ, et al. A receptor for the malar
ial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science. 1993
;261(5125): 1182-4.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#113#109#article#353#</font></p>     ^
cY#v33n1a16.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704024100080002001300321#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#114#110#article#353#3#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Szabo MC, Soo KS,
 Zlotnik A, Schall TJ. Chemokine class differences in binding to the Duffy antig
en-erythrocyte chemokine receptor. J Biol Chem. 1995;270(43):25348-51.    ^cY#v3
3n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#115#111#article#353# </font></p>     
^cY#v33n1a16.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704019000080002001300270#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#116#112#article#353#4#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Klein HG, Anstee 
DJ. Mollison's blood transfusion in clinical medicine. 11<sup>th</sup> ed. Oxfor
d: Blackwell; 2005.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#117#113#article#353#</font></p>     ^
cY#v33n1a16.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704024200080002001300322#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#118#114#article#353#5#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Miller LH, Mason 
SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks.
 The Duffy-blood-group genotype, FyFy. N Engl J Med. 1976;295(6):302-4.    ^cY#v
33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#119#115#article#353#</font></p>     ^
cY#v33n1a16.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704023800080002001300318#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#120#116#article#353#6#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Mourant AE, Kopec
 AC, Domanewska-Sobczak K. The distribution of human blood groups and other poly
morphisms. London: Oxford University Press; 1976. p.140</font></p>     ^cY#v33n1
a16.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704026400080002001300344#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#121#117#article#353#7#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Wertheimer SP, Ba
rnwell JW. Plasmodium vivax interaction with the human Duffy blood group glycopr
otein: identification of a parasite receptor-like protein. Exp Parasitol. 1989;6
9(4): 340-50.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#122#118#article#353# </font></p>     
^cY#v33n1a16.htm##
00759000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704050800080002001300588#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#123#119#article#353#8#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Daniels GL, Fletc
her A, Garratty G, Henry S, J&#248;rgensen J, Judd WJ, Levene C, Lomas-Francis C
, Moulds JJ, Moulds JM, Moulds M, Overbeeke M, Reid ME, Rouger P, Scott M, Sisto
nen P, Smart E, Tani Y, Wendel S, Zelinski T; International Society of Blood Tra
nsfusion. Blood group terminology 2004: from the International Society of Blood 
Transfusion committee on terminology for red cell surface antigens. Vox Sang. 20
04;87 (4):304-16.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#124#120#article#353# </font></p>     
^cY#v33n1a16.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704030000080002001300380#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#125#121#article#353#9#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Matsumoto WK, Vic
ente MG, Silva MA, de Castro LL. &#91;Epidemiological trends for malaria in the 
Upper Paraguay River Basin, Mato Grosso Grosso do Sul, Brazil 1990-1996&#93;. Ca
d Saude Publica. 1998;14(4): 797-802. Portuguese.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#126#122#article#353#</font></p>     ^
cY#v33n1a16.htm##
00421000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016900081002001300250#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#127#123#article#353#10#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Hickmann MS. Ca
se based pediatrics for medical students and residents. Malaria. 2003;30:254-6. 
   ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#128#124#article#353#</font></p>     ^
cY#v33n1a16.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021300081002001300294#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#129#125#article#353#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Mendis K, Sina 
BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am
 J Trop Med Hyg. 2001;64(1-2 Suppl):97-106.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#130#126#article#353# </font></p>     
^cY#v33n1a16.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024100081002001300322#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#131#127#article#353#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Adams JH, Sim B
K, Dolan SA, Fang X, Kaslow DC, Miller LH. A family of erythrocyte binding prote
ins of malaria parasites. Proc Natl Acad Sci U S A. 1992;89(15):7085-9.    ^cY#v
33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#132#128#article#353#</font></p>     ^
cY#v33n1a16.htm##
00728000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704047600081002001300557#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#133#129#article#353#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Brasil. Minist&
eacute;rio da Sa&uacute;de. Aspectos epidemiol&oacute;gicos &#91;Internet&#93;. 
Bras&iacute;lia. &#91;citado 201 maio 16&#93;.  Dispon&iacute;vel em: <a href="h
ttp://portal.saude.gov.br/portal/saude/profissional/visualizar_texto.cfm?idtxt=3
1086&amp;janela=2" target="_blank">http://portal.saude.gov.br/portal/saude/profi
ssional/visualizar_texto.cfm?idtxt=31086&janela=2</a> </font></p>     ^cY#v33n1a
16.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031600081002001300397#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#134#130#article#353#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. do Amaral CN, d
e Albuquerque YD, das Neves Pinto AY, de Souza JM. &#91;Importance of clinical a
nd laboratory profiles for the differential diagnosis of malaria and acute viral
 hepatitis&#93;. J Pediatr (Rio J). 2003;79(5):429-34. Portuguese.    ^cY#v33n1a
16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#135#131#article#353#</font></p>     ^
cY#v33n1a16.htm##
00562000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031000081002001300391#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#136#132#article#353#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Ventura AM, Pin
to AY, Silva RS, Calvosa VS, Silva Filho MG, Souza JM. &#91;Plasmodium vivax mal
aria in children and adolescents- epidemiological, clinical and laboratory featu
res&#93;. J Pediatr (Rio J.). 1999;75(3):187-94. Portuguese.    ^cY#v33n1a16.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#137#133#article#353#</font></p>     ^
cY#v33n1a16.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020500081002001300286#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#138#134#article#353#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Ferreira AW, &A
acute;vila SL. Diagn&oacute;stico laboratorial. 2a ed. S&atilde;o Paulo: Guanaba
ra Koogan; 2001. Cap. 25, p.263-73.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#139#135#article#353#</font></p>     ^
cY#v33n1a16.htm##
00699000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704044700081002001300528#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#140#136#article#353#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Brasil. Minist&
eacute;rio da Sa&uacute;de. Manual de diagn&oacute;stico laboratorial da Mal&aac
ute;ria. 2a ed. Bras&iacute;lia; 2009. &#91;citado 2010 Jan 11&#93;. Dispon&iacu
te;vel em: <a href="http://bvsms.saude.gov.br/bvs/publicacoes/malaria_diag_manua
l_final.pdf" target="_blank">http://bvsms.saude.gov.br/bvs/publicacoes/malaria_d
iag_manual_final.pdf</a> </font></p>     ^cY#v33n1a16.htm##
00591000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033900081002001300420#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#141#137#article#353#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Lorenzetti A, F
ornazari PA, Bonini-Domingos AC, de Souza Rodrigues Penhalbel R,  Fugikaha E, Bo
nini-Domingos CR,  et al. Mixed Plasmodium falciparum infections and its clinica
l implications in four areas of the Brazilian Amazon region. Acta Trop. 2008;107
(1):8-12.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#142#138#article#353# </font></p>     
^cY#v33n1a16.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024200081002001300323#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#143#139#article#353#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Cavasini MT, Ri
beiro WL, Kawamoto F, Ferreira MU. How prevalent is Plasmodium malariae in Rondo
nia, western Brazilian Amazon? Rev Soc Bras Med Trop. 2000;33(5):489-92.    ^cY#
v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#144#140#article#353#</font></p>     ^
cY#v33n1a16.htm##
00553000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030100081002001300382#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#145#141#article#353#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Costa MR, Vieir
a PP, Ferreira CO, Lacerda MV, Alecrim WD, Alecrim, MG. D. &#91;Molecular diagno
sing of malaria in a tertiary care center in the Brazilian Amazon region&#93;. R
ev Soc Bras Med Trop. 2008;41(4):381-5. Portuguese.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#146#142#article#353# </font></p>     
^cY#v33n1a16.htm##
00632000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704038000081002001300461#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#147#143#article#353#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Silva MC, Santo
s EB, Costa EG, Filho MG, Guerreiro JF, P&oacute;voa, MM. &#91;Clinical and labo
ratorial alterations in plasmodium vivax malaria patients and glucose-6-phosphat
e dehydrogenase deficiency treated with primaquine at 0.50 mg/kg/day&#93;. A  Re
v Soc Bras Med Trop. 2004;37(3):215-7. Portuguese.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#148#144#article#353# </font></p>     
^cY#v33n1a16.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025600081002001300337#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#149#145#article#353#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Abdon NP, Pinto
 AY, Silva RS, de Souza JM. &#91;Assessment of the response to reduced treatment
 schemes for vivax malaria&#93;. Rev Soc Bras Med Trop. 2001;34(4): 343-8. Portu
guese.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#150#146#article#353#</font></p>     ^
cY#v33n1a16.htm##
00411000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015900081002001300240#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#151#147#article#353#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Cutbush M, Moll
ison PL, Parkin DM. A new human blood group. Nature. 1950;165:188-89.    ^cY#v33
n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#152#148#article#353#</font></p>     ^
cY#v33n1a16.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020800081002001300289#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#153#149#article#353#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Ikin EW, Mouran
t AE, Pettenkofer HJ, Blumenthal G. Discovery of the excepted haemagglutinin ant
i-Fyb. Nature. 1951;168(4288): 1077-8.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#154#150#article#353#</font></p>     ^
cY#v33n1a16.htm##
00455000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020300081002001300284#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#155#151#article#353#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Sanger R, Race 
RR, Jack J. The Duffy blood groups of New York Negroes: the phenotype Fy (a-b-).
 Br J Haematol. 1955;1(4): 370-4.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#156#152#article#353#</font></p>     ^
cY#v33n1a16.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025000081002001300331#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#157#153#article#353#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Darbonne WC, Ri
ce GC, Mohler MA, Apple T, Hebert CA, Valente AJ, et al. Red blood cells are a s
ink for interleukin 8, a leukocyte chemotaxin. J Clin Invest. 1991;88(4):1362-9.
    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#158#154#article#353# </font></p>     
^cY#v33n1a16.htm##
00598000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034600081002001300427#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#159#155#article#353#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Chaudhuri A, Po
lyakova J, Zbrzezna V, Williams K, Gulati S, Pogo AO. Cloning of glycoprotein D 
cDNA, which encodes the major subunit of the Duffy blood group system and the re
ceptor for the Plasmodium vivax malaria parasite. Proc Natl Acad Sci U S A. 1993
;90(22):10793-7.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#160#156#article#353#</font></p>     ^
cY#v33n1a16.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024000081002001300321#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#161#157#article#353#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Donahue RP, Bia
s WB, Renwick JH, McKusick VA. Probable assignment of the Duffy blood group locu
s to chromosome 1 in man. Proc Natl Acad Sci U S A. 1968;61(3):949-55.    ^cY#v3
3n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#162#158#article#353#</font></p>     ^
cY#v33n1a16.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021900081002001300300#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#163#159#article#353#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Collins A, Keat
s BJ, Dracopoli N, Shields DC, Morton NE. Integration of gene maps: chromosome 1
. Proc Natl Acad Sci U S A. 1992;89(10):4598-602.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#164#160#article#353#</font></p>     ^
cY#v33n1a16.htm##
00563000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031100081002001300392#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#165#161#article#353#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Parasol N, Reid
 M, Rios M, Castilho L, Harari I, Kosower NS. A novel mutation in the coding seq
uence of the FY*B allele of the Duffy chemokine receptor gene is associated with
 an altered erythrocyte phenotype. Blood. 1998;92(7):2237-43.    ^cY#v33n1a16.ht
m##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#166#162#article#353# </font></p>     
^cY#v33n1a16.htm##
00527000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027500081002001300356#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#167#163#article#353#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Tournamille C, 
Colin Y, Cartron JP, Le Van Kim C. Disruption of a GATA motif in the Duffy gene 
promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat 
Genet. 1995; 10(2):224-8.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#168#164#article#353#</font></p>     ^
cY#v33n1a16.htm##
00635000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704038300081002001300464#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#169#165#article#353#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Mallinson G, So
o KS, Schall TJ, Pisacka M, Anstee DJ. Mutations in the erythrocyte chemokine re
ceptor (Duffy) gene: the molecular basis of the Fya/Fyb antigens and identificat
ion of a deletion in the Duffy gene of an apparently healthy individual with the
 Fy(a-b-) phenotype. Br J Haematol. 1995;90(4):823-9.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#170#166#article#353#</font></p>     ^
cY#v33n1a16.htm##
00534000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028200081002001300363#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#171#167#article#353#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Zimmerman PA, W
oolley I, Masinde GL, Miller SM, McNamara DT, Hazlett F, et al. Emergence of FY*
A(null) in a Plasmodium vivax-endemic region of Papua New Guinea. Proc Natl Acad
 Sci U S A. 1999;96(24):13973-7.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#172#168#article#353#</font></p>     ^
cY#v33n1a16.htm##
00449000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019700081002001300278#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#173#169#article#353#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Castilho L, Rio
s M, Pellegrino J, Saad ST, Costa FF, Reid ME. A novel FY allele in Brazilians. 
Vox Sang. 2004;87(3):190-5.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#174#170#article#353#</font></p>     ^
cY#v33n1a16.htm##
00431000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017900081002001300260#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#175#171#article#353#35#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Race RR, Sanger
 R. Blood groups in man. 6th ed. Oxford: Blackwell Scientific Publications; 1975
. p. 864.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#176#172#article#353#</font></p>     ^
cY#v33n1a16.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030200081002001300383#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#177#173#article#353#36#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Iwamoto S, Li J
, Sugimoto N, Okuda H, Kajii E. Characterization of the Duffy gene promoter: evi
dence for tissue-specific abolishment of expression in Fy(a-b-) of black individ
uals. Biochem Biophys Res Commun. 1996;222(3):852-9.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#178#174#article#353#</font></p>     ^
cY#v33n1a16.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020800081002001300289#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#179#175#article#353#37#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Le Pennec PY, R
ouger P, Klein MT, Robert N, Salmon C. Study of anti-Fya in five black Fy(a-b-) 
patients. Vox Sang. 1987;52 (3):246-9.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#180#176#article#353#</font></p>     ^
cY#v33n1a16.htm##
00543000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029100081002001300372#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#181#177#article#353#38#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Novaretti MC, D
orlhiac-Llacer PE, Chamone DA. Estudo de grupos sangu&iacute;neos em doadores de
 sangue caucas&oacute;ides e negr&oacute;ides na cidade de S&atilde;o Paulo. Rev
 Bras Hematol Hemoter. 2000;22 (1):23-32.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#182#178#article#353#</font></p>     ^
cY#v33n1a16.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026300081002001300344#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#183#179#article#353#39#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Shimizu Y, Kimu
ra M, Settheetham-Ishida W, Duangchang P, Ishida T. Serotyping of Duffy blood gr
oup in several Thai ethnic groups. Southeast Asian J Trop Med Public Health. 199
7;28(1):32-5.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#184#180#article#353#</font></p>     ^
cY#v33n1a16.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026800081002001300349#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#185#181#article#353#40#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Shimizu Y, Ao H
, Soemantri A, Tiwawech D, Settheetham-Ishida W, Kayame OW, et al. Sero- and mol
ecular typing of Duffy blood group in Southeast Asians and Oceanians. Hum Biol. 
2000;72 (3):511-8.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#186#182#article#353#</font></p>     ^
cY#v33n1a16.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025100081002001300332#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#187#183#article#353#41#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">41. Miller LH, Maso
n SJ, Dvorak JA, McGinniss MH, Rothman IK. Erythrocyte receptors for (Plasmodium
 knowlesi) malaria: Duffy blood group determinants. Science 1975;189(4202):561-3
.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#188#184#article#353# </font></p>     
^cY#v33n1a16.htm##
00433000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018100081002001300262#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#189#185#article#353#42#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">42. Moulds JM, Haye
s S, Wells TD. DNA analysis of Duffy genes in American blacks. Vox Sang. 1998;74
(4):248-52.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#190#186#article#353#</font></p>     ^
cY#v33n1a16.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024600081002001300327#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#191#187#article#353#43#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">43. Barnwell JW, Ni
chols ME, Rubinstein. In vitro evaluation of the role of the Duffy blood group i
n erythrocyte invasion by Plasmodium vivax. J Exp Med. 1989;169(5):1795-802.    
^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#192#188#article#353# </font></p>     
^cY#v33n1a16.htm##
00574000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032200081002001300403#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#193#189#article#353#44#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">44. Rayner JC, Varg
as-Serrato E, Huber CS, Galinski MR, Barnwell JW. A Plasmodium falciparum homolo
gue of Plasmodium vivax reticulocyte binding protein (PvRBP1) defines a trypsin-
resistant erythrocyte invasion pathway. J Exp Med. 2001;194(11):1571-81.    ^cY#
v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#194#190#article#353# </font></p>     
^cY#v33n1a16.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020500081002001300286#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#195#191#article#353#45#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">45. Dvorak JA, Mill
er LH, Whitehouse WC, Shiroishi T. Invasion of erythrocytes by malaria merozoite
s. Science. 1975;187(4178): 748-50.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#196#192#article#353# </font></p>     
^cY#v33n1a16.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021300081002001300294#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#197#193#article#353#46#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">46. Mendis K, Sina 
BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am
 J Trop Med Hyg. 2001;64(1-2 Suppl):97-106.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#198#194#article#353# </font></p>     
^cY#v33n1a16.htm##
00476000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022400081002001300305#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#199#195#article#353#47#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">47. Welch SG, McGre
gor IA, Williams K. The Duffy blood group and malaria prevalence in Gambian West
 Africans. Trans R Soc Trop Med Hyg. 1977;71(4):295-6.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#200#196#article#353# </font></p>     
^cY#v33n1a16.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026200081002001300343#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#201#197#article#353#48#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">48. Kasehagen LJ, M
ueller I, Kiniboro B, Bockarie MJ, Reeder JC, Kazura JW, et al. Reduced Plasmodi
um vivax erythrocyte infection in PNG Duffy-negative heterozygotes. PLoS One 200
7;2(3):e336.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#202#198#article#353# </font></p>     
^cY#v33n1a16.htm##
00594000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034200081002001300423#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#203#199#article#353#49#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">49. Grimberg BT, Ud
omsangpetch R, Xainli J, McHenry A, Panichakul T, Sattabongkot J, et al. Plasmod
ium vivax invasion of human erythrocytes inhibited by antibodies directed agains
t the Duffy binding protein. PLoS Med 2007;4(12):337. Comment in: PLoS Med. 2007
;4(12):e350.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#204#200#article#353#</font></p>     ^
cY#v33n1a16.htm##
00556000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030400081002001300385#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#205#201#article#353#50#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">50. Ceravolo IP, Br
u&ntilde;a-Romero O, Braga EM, Fontes CJ, Brito CF, Souza JM, et al. Anti-Plasmo
dium vivax duffy binding protein antibodies measure exposure to malaria in the B
razilian Amazon. Am J Trop Med Hyg. 2005;72(6):675-81.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#206#202#article#353#</font></p>     ^
cY#v33n1a16.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030600081002001300387#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#207#203#article#353#51#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">51. Tran TM, Olivei
ra-Ferreira J, Moreno A, Santos F, Yazdani SS, Chitnis CE, et al. Comparison of 
IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian 
Amazon population. Am J Trop Med Hyg. 2005;73(2):244-55.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#208#204#article#353# </font></p>     
^cY#v33n1a16.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018800081002001300269#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#209#205#article#353#52#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">52. Mathews HM, Arm
strong JC. Duffy blood types and vivax malaria in Ethiopia. Am J Trop Med Hyg. 1
981;30(2):299-303.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#210#206#article#353# </font></p>     
^cY#v33n1a16.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018900081002001300270#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#211#207#article#353#53#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">53. Beiguelman B. S
istemas sangu&iacute;neos eritrocit&aacute;rios. Ribeir&atilde;o Preto: (SP): Fu
npec; 2003. p. 234.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#212#208#article#353#</font></p>     ^
cY#v33n1a16.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#213#209#article#353#54#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">54. Hamblin MT, Di 
Rienzo A. Detection of the signature of natural selection in humans: evidence fr
om the Duffy blood group locus. Am J Hum Genet. 2000;66(5):1669-79. Erratum in: 
Am J Hum Genet. 2002;70(1):284.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#214#210#article#353#</font></p>     ^
cY#v33n1a16.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021800081002001300299#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#215#211#article#353#55#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">55. Hamblin MT, Tho
mpson EE, Di Rienzo A. Complex signatures of natural selection at the Duffy bloo
d group locus Am J Hum Genet. 2002;70(2):369-83.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#216#212#article#353#</font></p>     ^
cY#v33n1a16.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024900081002001300330#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#217#213#article#353#56#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">56. Azevedo ES, Sil
va KM, da Silva MC, Lima AM, Fortuna CM, Santos MG. Genetic and anthropological 
studies in the island of Itaparica, Bahia, Brazil. Hum Hered. 1981;31(6):353-7. 
   ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#218#214#article#353#</font></p>     ^
cY#v33n1a16.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020200081002001300283#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#219#215#article#353#57#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">57. Zago MA, Costa 
FF, Tone LG, Bottura C. Hereditary hemoglobin disorders in a Brazilian populatio
n. Hum Hered. 1983;33(2): 125-9.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#220#216#article#353#</font></p>     ^
cY#v33n1a16.htm##
00536000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028400081002001300365#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#221#217#article#353#58#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">58. Cavasini CE, de
 Mattos LC, Couto AA, Couto VS, Gollino Y, Moretti LJ, et al. Duffy blood group 
gene polymorphisms among malaria vivax patients in four areas of the Brazilian A
mazon region. Malar J. 2007;6:167.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#222#218#article#353#</font></p>     ^
cY#v33n1a16.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024100081002001300322#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#223#219#article#353#59#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">59. Aikawa M, Mille
r LH, Johnson J, Rabbege J. Erythrocyte entry by malarial parasites. A moving ju
nction between erythrocyte and parasite. J Cell Biol. 1978;77(1):72-82.    ^cY#v
33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#224#220#article#353#</font></p>     ^
cY#v33n1a16.htm##
00519000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026700081002001300348#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#225#221#article#353#60#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">60. Miller LH, Aika
wa M, Johnson JG, Shiroishi T. Interaction between cytochalasin B-treated malari
al parasites and erythrocytes. Attachment and junction formation. J Exp Med. 197
9;149(1): 172-84.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#226#222#article#353# </font></p>     
^cY#v33n1a16.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028800081002001300369#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#227#223#article#353#61#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">61. Ranjan A, Chitn
is CE. Mapping regions containing binding residues within functional domains of 
Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins. Proc Natl
 Acad Sci U S A. 1999;96(24):14067-72.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#228#224#article#353#</font></p>     ^
cY#v33n1a16.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027600081002001300357#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#229#225#article#353#62#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">62. Tsuboi T, Kappe
 SH, al-Yaman F, Prickett MD, Alpers M, Adams JH. Natural variation within the p
rincipal adhesion domain of the Plasmodium vivax Duffy binding protein. Infect I
mmun. 1994; 62(12):5581-6.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#230#226#article#353#</font></p>     ^
cY#v33n1a16.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030200081002001300383#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#231#227#article#353#63#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">63. Xainli J, Adams
 JH, King CL. The erythrocyte binding motif of plasmodium vivax duffy binding pr
otein is highly polymorphic and functionally conserved in isolates from Papua Ne
w Guinea. Mol Biochem Parasitol. 2000;111(2):253-60.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#232#228#article#353# </font></p>     
^cY#v33n1a16.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027100081002001300352#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#233#229#article#353#64#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">64. Cole-Tobian JL,
 Cortes A, Baisor M, Kastens W, Xainli J, Bockarie M, et al. Age-acquired immuni
ty to a Plasmodium vivax invasion ligand, the duffy binding protein. J Infect Di
s. 2002;186(4):531-9.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#234#230#article#353#</font></p>     ^
cY#v33n1a16.htm##
00521000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026900081002001300350#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#235#231#article#353#65#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">65. Michon P, Frase
r T, Adams JH. Naturally acquired and vaccine-elicited antibodies block erythroc
yte cytoadherence of the Plasmodium vivax Duffy binding protein. Infect Immun. 2
000; 68(6):3164-71.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#236#232#article#353#</font></p>     ^
cY#v33n1a16.htm##
00601000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034900081002001300430#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#237#233#article#353#66#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">66. Singh S, Pandey
 K, Chattopadhayay R, Yazdani SS, Lynn A, Bharadwaj A, et al. Biochemical, bioph
ysical, and functional characterization of bacterially expressed and refolded re
ceptor binding domain of Plasmodium vivax duffy-binding protein. J Biol Chem. 20
01;276(20):17111-6.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#238#234#article#353#</font></p>     ^
cY#v33n1a16.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027300081002001300354#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#239#235#article#353#67#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">67. Singh AP, Puri 
SK, Chitnis CE. Antibodies raised against receptor-binding domain of Plasmodium 
knowlesi Duffy binding protein inhibit erythrocyte invasion. Mol Biochem Parasit
ol. 2002;121 (1):21-31.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#240#236#article#353# </font></p>     
^cY#v33n1a16.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#241#237#article#353#68#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">68. Adams JH, Hudso
n DE, Torii M, Ward GE, Wellems TE, Aikawa M, et al. The Duffy receptor family o
f Plasmodium knowlesi is located within the micronemes of invasive malaria meroz
oites. Cell. 1990;63(1):141-53.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#242#238#article#353#</font></p>     ^
cY#v33n1a16.htm##
00539000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028700081002001300368#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#243#239#article#353#69#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">69. VanBuskirk KM, 
Sevova E, Adams JH. Conserved residues in the Plasmodium vivax Duffy-binding pro
tein ligand domain are critical for erythrocyte receptor recognition. Proc Natl 
Acad Sci U S A. 2004;101(44):15754-9.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#244#240#article#353#</font></p>     ^
cY#v33n1a16.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031300081002001300394#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#245#241#article#353#70#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">70. VanBuskirk KM, 
Cole-Tobian JL, Baisor M, Sevova ES, Bockarie M, King CL, et al. Antigenic drift
 in the ligand domain of Plasmodium vivax Duffy binding protein confers resistan
ce to inhibitory antibodies. J Infect Dis. 2004;190(9):1556-62.    ^cY#v33n1a16.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#246#242#article#353#</font></p>     ^
cY#v33n1a16.htm##
00587000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033500081002001300416#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#247#243#article#353#71#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">71. Sousa TN, Cerav
olo IP, Fernandes Fontes CJ, Couto A, Carvalho LH, Brito CF. The pattern of majo
r polymorphisms in the Duffy binding protein ligand domain among Plasmodium viva
x isolates from the Brazilian Amazon area. Mol Biochem Parasitol. 2006; 146(2):2
51-4.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#248#244#article#353#</font></p>     ^
cY#v33n1a16.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022100081002001300302#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#249#245#article#353#72#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">72. Cole-Tobian J, 
King CL. Diversity and natural selection in Plasmodium vivax Duffy binding prote
in gene. Mol Biochem Parasitol. 2003;127(2):121-32.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#250#246#article#353#</font></p>     ^
cY#v33n1a16.htm##
00483000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023100081002001300312#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#251#247#article#353#73#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">73. Martinez P, Sua
rez CF, Cardenas PP, Patarroyo MA. Plasmodium vivax Duffy binding protein: a mod
ular evolutionary proposal. Parasitology. 2004;128(4):353-66.    ^cY#v33n1a16.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#252#248#article#353#</font></p>     ^
cY#v33n1a16.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027800081002001300359#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#253#249#article#353#74#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">74. Fraser T, Micho
n P, Barnwell JW, Noe AR, Al-Yaman F, Kaslow DC, et al. Expression and serologic
 activity of a soluble recombinant Plasmodium vivax Duffy binding protein. Infec
t Immun. 1997; 65(7):2772-7.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#254#250#article#353#</font></p>     ^
cY#v33n1a16.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026400081002001300345#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#255#251#article#353#75#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">75. Xainli J, Cole-
Tobian JL, Baisor M, Kastens W, Bockarie M, Yazdani SS, et al. Epitope-specific 
humoral immunity to Plasmodium vivax Duffy binding protein. Infect Immun. 2003;7
1(5): 2508-15.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#256#252#article#353#</font></p>     ^
cY#v33n1a16.htm##
00488000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023600081002001300317#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#257#253#article#353#76#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">76. Jens E, Pagliar
ini T, Novaretti MC. Sistema de grupo sangu&iacute;neo Duffy: biologia e pr&aacu
te;tica transfusional. Rev Bras Hematol Hemoter. 2005;27(2):110-9.    ^cY#v33n1a
16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#258#254#article#353#</font></p>     ^
cY#v33n1a16.htm##
00529000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027700081002001300358#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#259#255#article#353#77#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">77. McHenry AM, Ada
ms JH. The crystal structure of P. knowlesi DBP-alpha DBL domain and its implica
tions for immune evasion. Trends Biochem Sci. 2006;31(9):487-91.  Comment on: Na
ture. 2006;439(7077):741-4.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#260#256#article#353#</font></p>     ^
cY#v33n1a16.htm##
00580000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032800081002001300409#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#261#257#article#353#78#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">78. Ceravolo IP, So
uza-Silva FA, Fontes CJ, Braga EM, Madureira AP, Krettli AU, et al. Inhibitory p
roperties of the antibody response to Plasmodium vivax Duffy binding protein in 
an area with unstable malaria transmission. Scand J Immunol. 2008;67(3):270-8.  
  ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#262#258#article#353#</font></p>     ^
cY#v33n1a16.htm##
00592000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034000081002001300421#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#263#259#article#353#79#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">79. King CL, Michon
 P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, et al. Naturally acquired D
uffy-binding protein-specific binding inhibitory antibodies confer protection fr
om blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A. 2008;105 (2
4):8363-8.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#264#260#article#353#</font></p>     ^
cY#v33n1a16.htm##
00512000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026000081002001300341#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#265#261#article#353#80#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">80. Xainli J, Baiso
r M, Kastens W, Bockarie M, Adams JH, King CL. Age-dependent cellular immune res
ponses to Plasmodium vivax Duffy binding protein in humans. J Immunol. 2002;169(
6):3200-7.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#266#262#article#353#</font></p>     ^
cY#v33n1a16.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022800081002001300309#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#267#263#article#353#81#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">81. Miller LH. Impa
ct of malaria on genetic polymorphism and genetic diseases in Africans and Afric
an Americans. Proc Natl Acad Sci U S A. 1994;91(7):2415-9.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#268#264#article#353#</font></p>     ^
cY#v33n1a16.htm##
00749000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704049700081002001300578#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#269#265#article#353#82#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">82. Frason AP, Barl
ette AG, Dalpizolo C, Sauter IP, Macedo AJ, Tasca T. Estrat&eacute;gias e desafi
os no combate &agrave; mal&aacute;ria. Rev Liberato (Novo Hamburgo) &#91;Interne
t&#93;. 2009 &#91;citado 2010 Nov 21&#93;;10(14):201-8. Dispon&iacute;vel em: <a
 href="http://www.liberato.com.br/upload/arquivos/0106110920064219.pdf" target="
_blank">http://www.liberato.com.br/upload/arquivos/0106110920064219.pdf</a></fon
t></p>     ^cY#v33n1a16.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018800081002001300269#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#270#266#article#353#83#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">83. Ar&eacute;valo-
Herrera M, Herrera S. Plasmodium vivax malaria vaccine development. Mol Immunol.
 2001;38(6):443-5.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#271#267#article#353#</font></p>     ^
cY#v33n1a16.htm##
00598000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034600081002001300427#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#272#268#article#353#84#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">84. Dutta S, Ware L
A, Barbosa A, Ockenhouse CF, Lanar DE. Purification, characterization, and immun
ogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen
, merozoite surface protein 1, expressed in Escherichia coli. Infect Immun. 2001
;69(9):5.464-70.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#273#269#article#353#</font></p>     ^
cY#v33n1a16.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029000081002001300371#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#274#270#article#353#85#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">85. Dutta S, Daughe
rty JR, Ware LA, Lanar DE, Ockenhouse CF. Expression, purification and character
ization of a functional region of the Plasmodium vivax Duffy binding protein. Mo
l Biochem Parasitol. 2000;109(2):179-84.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#275#271#article#353#</font></p>     ^
cY#v33n1a16.htm##
00625000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704037300081002001300454#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#276#272#article#353#86#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">86. Kocken CH, Dubb
eld MA, Van Der Wel A, Pronk JT, Waters AP, Langermans JA, et al. High-level exp
ression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris
: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adju
vant SBAS2. Infect Immun. 1999;67 (1):43-9.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#277#273#article#353#</font></p>     ^
cY#v33n1a16.htm##
00548000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029600081002001300377#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#278#274#article#353#87#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">87. Gibson HL, Tuck
er JE, Kaslow DC, Krettli AU, Collins WE, Kiefer MC, et al. Structure and expres
sion of the gene for Pv200, a major blood-stage surface antigen of Plasmodium vi
vax. Mol Biochem Parasitol. 1992;50(2):325-33.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#279#275#article#353#</font></p>     ^
cY#v33n1a16.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029900081002001300380#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#280#276#article#353#88#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">88. Park JW, Moon S
H, Yeom JS, Lim KJ, Sohn MJ, Jung WC, et al. Naturally acquired antibody respons
es to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax i
n Korea. Clin Diagn Lab Immunol. 2001;8(1):14-20.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#281#277#article#353#</font></p>     ^
cY#v33n1a16.htm##
00703000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704045100081002001300532#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#282#278#article#353#89#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">89. Wickramarachchi
 T, Illeperuma RJ, Perera L, Bandara S, Holm I, Longacre S, et al. Comparison of
 naturally acquired antibody responses against the C-terminal processing product
s of Plasmodium vivax Merozoite Surface Protein-1 under low transmission and uns
table malaria conditions in Sri Lanka. Int J Parasitol. 2007;37(2):199-208. Erra
tum in: Int J Parasitol. 2007; 37(5):579.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#283#279#article#353#</font></p>     ^
cY#v33n1a16.htm##
00600000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034800081002001300429#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#284#280#article#353#90#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">90. Valderrama-Agui
rre A, Quintero G, G&oacute;mez A, Castellanos A, P&eacute;rez Y, M&eacute;ndez 
F, et al. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vi
vax MSP1 PV200l:: a potential malaria vaccine subunit. Am J Trop Med Hyg. 2005; 
73(5 Suppl):16-24.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#285#281#article#353#</font></p>     ^
cY#v33n1a16.htm##
00564000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031200081002001300393#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#286#282#article#353#91#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">91. Soares IS, Levi
tus G, Souza JM, Del Portillo HA, Rodrigues MM. Acquired immune responses to the
 N-and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in ind
ividuals exposed to malaria. Infect Immun. 1997;65(5):1606-14.    ^cY#v33n1a16.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#287#283#article#353#</font></p>     ^
cY#v33n1a16.htm##
00567000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031500081002001300396#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#288#284#article#353#92#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">92. Soares IS, Barn
well JW, Ferreira MU, Gomes Da Cunha M, Laurino JP, Castilho BA, et al. A Plasmo
dium vivax vaccine candidate displays limited allele polymorphism, which does no
t restrict recognition by antibodies. Mol Med. 1999;5 (7):459-70.    ^cY#v33n1a1
6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#289#285#article#353#</font></p>     ^
cY#v33n1a16.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027100081002001300352#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#290#286#article#353#93#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">93. de Oliveira CI,
 Wunderlich G, Levitus G, Soares IS, Rodrigues MM, Tsuji M, et al. Antigenic pro
perties of the merozoite surface protein 1 gene of Plasmodium vivax. Vaccine. 19
99;17(23-24):2959-68.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#291#287#article#353#</font></p>     ^
cY#v33n1a16.htm##
00587000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033500081002001300416#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#292#288#article#353#94#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">94. Rodrigues MHC, 
Cunha MG, Machado RLD, Ferreira Jr OC, Rodrigues MM, Soares IS. Serological dete
ction of Plasmodium vivax malaria using recombinant proteins corresponding to th
e 19-kDa C-terminal region of the merozoite surface protein-1. Malar J. 2003;2(1
):39.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#293#289#article#353#</font></p>     ^
cY#v33n1a16.htm##
00619000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036700081002001300448#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#294#290#article#353#95#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">95. Yang C, Collins
 WE, Sullivan JS, Kaslow DC, Xiao L, Lal AA. Partial protection against Plasmodi
um vivax blood-stage infection in Saimiri monkeys by immunization with a recombi
nant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuv
ant. Infect Immun. 1999; 67(1):342-9.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#295#291#article#353#</font></p>     ^
cY#v33n1a16.htm##
00592000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034000081002001300421#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#296#292#article#353#96#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">96. Sierra AY, Barr
ero CA, Rodriguez R, Silva Y, Moncada C, Vanegas M, Patarroyo MA. Splenectomised
 and spleen intact Aotus monkeys' immune response to Plasmodium vivax MSP-1 prot
ein fragments and their high activity binding peptides. Vaccine. 2003; 21(27-30-
):4133-44.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#297#293#article#353#</font></p>     ^
cY#v33n1a16.htm##
00899000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704064700081002001300728#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#298#294#article#353#97#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">97. Cer&aacute;volo
 IP. Caracteriza&ccedil;&atilde;o imunol&oacute;gica e molecular da Duffy Bindin
g Protein do Plasmodium vivax em &aacute;reas de transmiss&atilde;o de mal&aacut
e;ria da tegi&atilde;o amaz&ocirc;nica e extra-amaz&ocirc;nica brasileira. &#91;
tese na Internet&#93;. Belo Horizonte: Funda&ccedil;&atilde;o Oswaldo Cruz; 2007
. &#91;citado 2010 Jul 27&#93;. Dispon&iacute;vel em: <a href="http://netra.cpqr
r.fiocruz.br/download/Tese_Isabela_Penna_Ceravolo.pdf" target="_blank">http://ne
tra.cpqrr.fiocruz.br/download/Tese_Isabela_Penna_Ceravolo.pdf</a></font></p>    
 ^cY#v33n1a16.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019800081002001300279#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#299#295#article#353#98#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">98. Holder AA. The 
precursor to major merozoite surface antigens: structure and role in immunity. P
rog. Allergy. 1988;41:72-97.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#300#296#article#353#</font></p>     ^
cY#v33n1a16.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031300081002001300394#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#301#297#article#353#99#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">99. Collins WE, Kas
low DC, Sullivan JS, Morris CL, Galland GG, Yang C, et al. Testing the efficacy 
of a recombinant merozoite surface protein (MSP-1(19)) of Plasmodium vivax in Sa
imiri boliviensis monkeys. Am J Trop Med Hyg. 1999;60(3):350-6.    ^cY#v33n1a16.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#302#298#article#353#</font></p>     ^
cY#v33n1a16.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704022000082002001300302#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#303#299#article#353#100#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">100. Joshi H. Mark
ers for population genetic analysis of human plasmodia species, P. falciparum an
d P. vivax. J Vector Borne Dis. 2003;40(3-4):78-83.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#304#300#article#353#</font></p>     ^
cY#v33n1a16.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704023600082002001300318#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#305#301#article#353#101#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">101. Zakeri S, Bar
jesteh H, Djadid ND. Merozoite surface protein-3alpha is a reliable marker for p
opulation genetic analysis of Plasmodium vivax. Malar J. 2006;5:53.    ^cY#v33n1
a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#306#302#article#353#</font></p>     ^
cY#v33n1a16.htm##
00559000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704030600082002001300388#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#307#303#article#353#102#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">102. Galinski MR, 
Corredor-Medina C, Povoa M, Crosby J, Ingravallo P, Barnwell JW. Plasmodium viva
x merozoite surface protein-3 contains coiled-coil motifs in an alanine-rich cen
tral domain. Mol Biochem Parasitol. 1999;101(1-2):131-47.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#308#304#article#353#</font></p>     ^
cY#v33n1a16.htm##
00560000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704030700082002001300389#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#309#305#article#353#103#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">103. Galinski MR, 
Xu M, Barnwell1 JW. Plasmodium vivax reticulocyte binding protein-2 (PvRBP-2) sh
ares structural features with PvRBP-1 and the Plasmodium yoelii 235 kDa rhoptry 
protein family. Mol Biochem Parasitol. 2000;108(2):257-62.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#310#306#article#353#</font></p>     ^
cY#v33n1a16.htm##
00581000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704032800082002001300410#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#311#307#article#353#104#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">104. Black CG, Bar
nwell JW, Huber CS, Galinski MR, Coppel RL. The Plasmodium vivax homologues of m
erozoite surface proteins 4 and 5 from Plasmodium falciparum are expressed at di
fferent locations in the merozoite. Mol Biochem Parasitol. 2002; 120(2):215-24. 
   ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#312#308#article#353#</font></p>     ^
cY#v33n1a16.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704027100082002001300353#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#313#309#article#353#105#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">105. Malkin EM, Du
rbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, et al. Phase 1 vaccine trial
 of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccin
e. 2005;23(24):3131-8.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#314#310#article#353#</font></p>     ^
cY#v33n1a16.htm##
00562000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704030900082002001300391#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#315#311#article#353#106#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">106.  Galinski MR,
 Xu M,  Barnwell1 JW. Plasmodium vivax reticulocyte binding protein-2 (PvRBP-2) 
shares structural features with PvRBP-1 and the Plasmodium yoelii 235 kDa rhoptr
y protein family. Mol Biochem Parasitol. 2000;108(2):257-62.    ^cY#v33n1a16.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#316#312#article#353#</font></p>     ^
cY#v33n1a16.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704028900082002001300371#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#317#313#article#353#107#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">107. Oliveira-Ferr
eira J, Vargas-Serrato E, Barnwell JW, Moreno A, Galinski MR. Immunogenicity of 
Plasmodium vivax merozoite surface protein-9 recombinant proteins expressed in E
. coli. Vaccine. 2004;22(15-16):2023-30.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#318#314#article#353#</font></p>     ^
cY#v33n1a16.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704027100082002001300353#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#319#315#article#353#108#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">108. Michon PA, Ar
evalo-Herrera M, Fraser T, Herrera S, Adams JH. Serologic responses to recombina
nt Plasmodium vivax Duffy binding protein in a Colombian village. Am J Trop Med 
Hyg. 1998;59(4):597-9.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#320#316#article#353#</font></p>     ^
cY#v33n1a16.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704031500082002001300397#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#321#317#article#353#109#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">109. Suh IB, Choi 
HK, Lee SW, Woo SK, Kang HY, Won YD, et al. Reactivity of sera from cases of Pla
smodium vivax malaria towards three recombinant antigens based on the surface pr
oteins of the parasite. Ann Trop Med Parasitol. 2003;97 (5):481-7.    ^cY#v33n1a
16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#322#318#article#353#</font></p>     ^
cY#v33n1a16.htm##
00483000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704023000082002001300312#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#323#319#article#353#110#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">110. Polley SD, Co
nway DJ. Strong diversifying selection on domains of the Plasmodium falciparum a
pical membrane antigen 1 gene. Genetics. 2001;158(4):1505-12.    ^cY#v33n1a16.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#324#320#article#353#</font></p>     ^
cY#v33n1a16.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704028900082002001300371#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#325#321#article#353#111#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">111. Silvie O, Fra
netich JF, Charrin S, Mueller MS, Siau A, Bodescot M, et al. A role for apical m
embrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporoz
oites. J Biol Chem. 2004;279(10):9490-6.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#326#322#article#353#</font></p>     ^
cY#v33n1a16.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704028800082002001300370#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#327#323#article#353#112#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">112. Kim S, Ahn HJ
, Kim TS, Nam HW. ELISA detection of vivax malaria with recombinant multiple sta
ge-specific antigens and its application to survey of residents in endemic areas
. Korean J Parasitol. 2003;41(4):203-7.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#328#324#article#353#</font></p>     ^
cY#v33n1a16.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704031200082002001300394#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#329#325#article#353#113#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">113. Rodrigues MH,
 Rodrigues KM, Oliveira TR, C&ocirc;modo AN, Rodrigues MM, Kocken CH, et al. Ant
ibody response of naturally infected individuals to recombinant Plasmodium vivax
 apical membrane antigen-1. Int J Parasitol. 2005;35(2):185-92.    ^cY#v33n1a16.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#330#326#article#353#</font></p>     ^
cY#v33n1a16.htm##
00556000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704030300082002001300385#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#331#327#article#353#114#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">114. Morais CG, So
ares IS, Carvalho LH, Fontes CJ, Krettli AU, Braga EM. Antibodies to Plasmodium 
vivax apical membrane antigen 1: persistence and correlation with malaria transm
ission intensity. Am J Trop Med Hyg. 2006;75(4):582-7.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#332#328#article#353#</font></p>     ^
cY#v33n1a16.htm##
00576000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704032300082002001300405#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#333#329#article#353#115#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">115. Figtree M, Pa
say CJ, Slade R, Cheng Q, Cloonan N, Walker J, et al. Plasmodium vivax synonymou
s substitution frequencies, evolution and population structure deduced from dive
rsity in AMA 1 and MSP 1 genes. Mol Biochem Parasitol. 2000;108(1): 53-66.    ^c
Y#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#334#330#article#353#</font></p>     ^
cY#v33n1a16.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704026300082002001300345#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#335#331#article#353#116#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">116. Han ET, Park 
JH, Shin EH, Choi MH, Oh MD, Chai JY. Apical membrane antigen-1 (AMA-1) gene seq
uences of re-emerging Plasmodium vivax in South Korea. Korean J Parasitol. 2002;
 40(3):157-62.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#336#332#article#353#</font></p>     ^
cY#v33n1a16.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704019800082002001300280#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#337#333#article#353#117#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">117. Greenwood BM.
 Control to elimination: implications for malaria research. Trends Parasitol.  2
008;24(10):449-54</font></p>     ^cY#v33n1a16.htm##
00434000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704018100082002001300263#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#338#334#article#353#118#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">118. Maher B. The 
end of the beginning. Nature. 2008;451(7182):1042-6. Comment in: Nature. 2008;45
2(7189):810.    ^cY#v33n1a16.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#339#335#article#353#</font></p>     ^
cY#v33n1a16.htm##
00602000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704034900082002001300431#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#340#336#article#353#119#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">119. McIntosh RS, 
Shi J, Jennings RM, Chappel JC, de Koning-Ward TF, Smith T, Green J, van Egmond 
M, Leusen JH, Lazarou M, van de Winkel J, Jones TS, Crabb BS, Holder AA, Pleass 
RJ. The importance of human FcgammaRI in mediating protectionto malaria. PLoS Pa
thog. 2007;3(5):e72.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#341#337#article#353# </font></p>     
^cY#v33n1a16.htm##
00445000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000400078704019200082002001300274#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#342#338#article#353#120#<
p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">120. Hviid L, Barf
od L. Malaria vaccines: immunity, models and monoclonal antibodies. Trends Paras
itol. 2008;24(9):392-5.    ^cY#v33n1a16.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#343#339#article#353# </font></p>     
^cY#v33n1a16.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#344#340#article#353#<p>&nbsp;</p>    
 ^cY#v33n1a16.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#345#341#article#353#<p>&nbsp;</p>    
 ^cY#v33n1a16.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018600078002001300264#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#346#342#article#353#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b
>    ^cY#v33n1a16.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004200078002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#347#343#article#353#<br>   Gledson Ba
rbosa de Carvalho    ^cY#v33n1a16.htm##
00317000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008000078002001300158#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#348#344#article#353#<br>   Rua An&iac
ute;bal Falc&atilde;o 93, apto 602 Bairro Gra&ccedil;as    ^cY#v33n1a16.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004600078002001300124#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#349#345#article#353#<br>   52011-150 
- Recife (PE), Brazil    ^cY#v33n1a16.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003700078002001300115#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#350#346#article#353#<br>   Phone: 55 
81 3221-7896    ^cY#v33n1a16.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#351#347#article#353#<br>   <a href="m
ailto:gledsonbc@hotmail.com">gledsonbc@hotmail.com</a></font></p>     ^cY#v33n1a
16.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#352#348#article#353#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted: 1/12/2010    ^cY#v33n1a
16.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#353#349#article#353#<br>   Accepted: 
 2/4/2011    ^cY#v33n1a16.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011300078002001300191#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#354#350#article#353#<br>   Conflict-o
f-interest disclosure: The authors declare no competing financial disclosure</fo
nt></p>     ^cY#v33n1a16.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#355#351#article#353#<p>&nbsp;</p>    
 ^cY#v33n1a16.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#356#352#article#353#<p>&nbsp;</p>    
 ^cY#v33n1a16.htm##
00461000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022400078002001300302#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#p#357#353#article#353#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" targ
et="_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_bla
nk">www.scielo.br/rbhh</a> </font></p>     ^cY#v33n1a16.htm##
00687000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080004000721180002000760100018000780100026000960100
01900122010001800141012009000159030002200249065000900271064000500280031000300285
03200020028801400060029006100110029686500090030700200130031603500100032980100220
0339#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#358#1#article#120
#1#^rND^sMachado^nRL#^rND^sD'Almeica Couto^nAA#^rND^sCavasini^nCE#^rND^sCalvosa^
nVS#Malaria outside the Brazilian Amazonian region: the situation in Santa Catar
ina state^len#Rev Soc Bras Med Trop#20030000#2003#36#5#581-6#Portuguese#20110200
#v33n1a16.htm#0037-8682#Rev Soc Bras Med Trop##
00708000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080004000721180002000760100015000780100018000930100
01900111010001600130010001700146010001700163810000600180012009400186030000800280
06500090028806400050029703100040030203200050030601400070031186500090031800200130
0327035001000340801000800350#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#359#2#article#120#2#^rND^sHoruk^nR#^rND^sChitnis^nCE#^rND^sDarbonne^nWC#^
rND^sColby^nTJ#^rND^sRybicki^nA#^rND^sHadley^nTJ#et al#A receptor for the malari
al parasite Plasmodium vivax: the erythrocyte chemokine receptor^len#Science#199
30000#1993#261#5125#1182-4#20110200#v33n1a16.htm#0036-8075#Science##
00637000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080004000721180002000760100016000780100014000940100
01700108010001700125012009500142030001200237065000900249064000500258031000400263
032000300267014000900270865000900279002001300288035001000301801001200311#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#360#3#article#120#3#^rND^sSza
bo^nMC#^rND^sSoo^nKS#^rND^sZlotnik^nA#^rND^sSchall^nTJ#Chemokine class differenc
es in binding to the Duffy antigen-erythrocyte chemokine receptor^len#J Biol Che
m#19950000#1995#270#43#25348-51#20110200#v33n1a16.htm#0021-9258#J Biol Chem##
00475000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080004000721180002000760160016000780160017000940180
05400111063000300165066000700168062001000175065000900185064000500194865000900199
002001300208#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#361#4#art
icle#120#4#^rND^sKlein^nHG#^rND^sAnstee^nDJ#Mollison's blood transfusion in clin
ical medicine^len#11#Oxford#Blackwell#20050000#2005#20110200#v33n1a16.htm##
00639000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080004000721180002000760100017000780100016000950100
01600111010002000127012009400147030001300241065000900254064000500263031000400268
032000200272014000600274865000900280002001300289035001000302801001300312#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#362#5#article#120#5#^rND^sMil
ler^nLH#^rND^sMason^nSJ#^rND^sClyde^nDF#^rND^sMcGinniss^nMH#The resistance facto
r to Plasmodium vivax in blacks: The Duffy-blood-group genotype, FyFy^len#N Engl
 J Med#19760000#1976#295#6#302-4#20110200#v33n1a16.htm#0028-4793#N Engl J Med##
00544000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080004000721180002000760160018000780160016000960160
02800112018006700140066000700207062002400214065000900238064000500247020000400252
865000900256002001300265#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S
#c#363#6#article#120#6#^rND^sMourant^nAE#^rND^sKopec^nAC#^rND^sDomanewska-Sobcza
k^nK#The distribution of human blood groups and other polymorphisms^len#London#O
xford University Press#19760000#1976#140#20110200#v33n1a16.htm##
00625000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080004000721180002000760100021000780100019000990120
13100118030001400249065000900263064000500272031000300277032000200280014000700282
865000900289002001300298035001000311801001400321#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a16.htm#S#c#364#7#article#120#7#^rND^sWertheimer^nSP#^rND^sBarnwe
ll^nJW#Plasmodium vivax interaction with the human Duffy blood group glycoprotei
n: identification of a parasite receptor-like protein^len#Exp Parasitol#19890000
#1989#69#4#340-50#20110200#v33n1a16.htm#0014-4894#Exp Parasitol##
01194000000000517000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080004000721180002000760100018000780100018000960100
01800114010001500132010001900147010001500166010001600181010002300197010001700220
01000170023701000160025401000190027001000150028901000160030401000150032001000180
03350100015003530100014003680100016003820100018003980110043004160120141004590300
00900600065000900609064000500618031000300623032000200626014000700628865000900635
002001300644035001000657801000900667#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a16.htm#S#c#365#8#article#120#8#^rND^sDaniels^nGL#^rND^sFletcher^nA#^rND^sGar
ratty^nG#^rND^sHenry^nS#^rND^sJørgensen^nJ#^rND^sJudd^nWJ#^rND^sLevene^nC#^rND^s
Lomas-Francis^nC#^rND^sMoulds^nJJ#^rND^sMoulds^nJM#^rND^sMoulds^nM#^rND^sOverbee
ke^nM#^rND^sReid^nME#^rND^sRouger^nP#^rND^sScott^nM#^rND^sSistonen^nP#^rND^sSmar
t^nE#^rND^sTani^nY#^rND^sWendel^nS#^rND^sZelinski^nT#International Society of Bl
ood Transfusion#Blood group terminology 2004: from the International Society of 
Blood Transfusion committee on terminology for red cell surface antigens^len#Vox
 Sang#20040000#2004#87#4#304-16#20110200#v33n1a16.htm#0042-9007#Vox sang##
00702000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080004000721180002000760100020000780100018000980100
01600116010002000132012011800152030001800270065000900288064000500297031000300302
03200020030501400080030706100110031586500090032600200130033503500100034880100180
0358#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#366#9#article#120
#9#^rND^sMatsumoto^nWK#^rND^sVicente^nMG#^rND^sSilva^nMA#^rND^sde Castro^nLL#Epi
demiological trends for malaria in the Upper Paraguay River Basin, Mato Grosso G
rosso do Sul, Brazil 1990-1996^len#Cad Saude Publica#19980000#1998#14#4#797-802#
Portuguese#20110200#v33n1a16.htm#0102-311X#Cad Saude Publica##
00469000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100019000800120061000990300
00800160710000200168065000900170064000500179031000300184014000600187865000900193
002001300202#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#367#10#ar
ticle#120#10#^rND^sHickmann^nMS#Case based pediatrics for medical students and r
esidents^len#Malaria#2#20030000#2003#30#254-6#20110200#v33n1a16.htm##
00612000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100015000960100
02000111010001600131012005300147030001800200065000900218064000500227031000300232
032000600235014000700241865000900248002001300257035001000270801001800280#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#368#11#article#120#11#^rND^sM
endis^nK#^rND^sSina^nBJ#^rND^sMarchesini^nP#^rND^sCarter^nR#The neglected burden
 of Plasmodium vivax malaria^len#Am J Trop Med Hyg#20010000#2001#64#^s1-2#97-106
#20110200#v33n1a16.htm#0002-9637#Am J Trop Med Hyg##
00687000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100014000960100
01600110010001400126010001700140010001700157012006600174030002500240065000900265
06400050027403100030027903200030028201400070028586500090029200200130030103500100
0314801002500324#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#369#1
2#article#120#12#^rND^sAdams^nJH#^rND^sSim^nBK#^rND^sDolan^nSA#^rND^sFang^nX#^rN
D^sKaslow^nDC#^rND^sMiller^nLH#A family of erythrocyte binding proteins of malar
ia parasites^len#Proc Natl Acad Sci U S A#19920000#1992#89#15#7085-9#20110200#v3
3n1a16.htm#0027-8424#Proc Natl Acad Sci U S A##
00491000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770170028000800180029001080610
00900137066000900146037009600155865000900251002001300260#v33n1#V:\SciELO\serial\
rbhh\v33n1\markup\v33n1a16.htm#S#c#370#13#article#120#13#Brasil^dMinistério da S
aúde#Aspectos epidemiológicos^lpt#Internet#Brasília#http://portal.saude.gov.br/p
ortal/saude/profissional/visualizar_texto.cfm?idtxt=31086& janela=2#20110200#v33
n1a16.htm##
00722000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100020000800100025001000100
02600125010001900151012011900170030001000289066000600299065000900305064000500314
03100030031903200020032201400070032406100110033186500090034200200130035103500100
0364801001000374#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#371#1
4#article#120#14#^rND^sdo Amaral^nCN#^rND^sde Albuquerque^nYD#^rND^sdas Neves Pi
nto^nAY#^rND^sde Souza^nJM#Importance of clinical and laboratory profiles for th
e differential diagnosis of malaria and acute viral hepatitis^len#J Pediatr#Rio 
J#20030000#2003#79#5#429-34#Portuguese#20110200#v33n1a16.htm#0022-3476#J Pediatr
##
00751000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100018000800100016000980100
01600114010001800130010002200148010001600170012010800186030001000294066000600304
06500090031006400050031903100030032403200020032701400070032906100110033686500090
0347002001300356035001000369801001000379#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a16.htm#S#c#372#15#article#120#15#^rND^sVentura^nAM#^rND^sPinto^nAY#^rND^
sSilva^nRS#^rND^sCalvosa^nVS#^rND^sSilva Filho^nMG#^rND^sSouza^nJM#Plasmodium vi
vax malaria in children and adolescents- epidemiological, clinical and laborator
y features^len#J Pediatr#Rio J#19990000#1999#75#3#187-94#Portuguese#20110200#v33
n1a16.htm#0022-3476#J Pediatr##
00502000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770160019000800160016000990180
02900115063000200144066001000146062001700156065000900173064000500182061000800187
014000700195865000900202002001300211#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a16.htm#S#c#373#16#article#120#16#^rND^sFerreira^nAW#^rND^sÁvila^nSL#Diagnóst
ico laboratorial^lpt#2#São Paulo#Guanabara Koogan#20010000#2001#Cap. 25#263-73#2
0110200#v33n1a16.htm##
00564000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770170028000800180050001080630
00200158066000900160065000900169064000500178110000900183109001200192037007200204
865000900276002001300285#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S
#c#374#17#article#120#17#Brasil^dMinistério da Saúde#Manual de diagnóstico labor
atorial da Malária^lpt#2#Brasília#20090000#2009#20100111#2010 Jan 11#http://bvsm
s.saude.gov.br/bvs/publicacoes/malaria_diag_manual_final.pdf#20110200#v33n1a16.h
tm##
00779000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100020000800100020001000100
02600120010003800146010001800184010002600202810000600228012011800234030001000352
06500090036206400050037103100040037603200020038001400050038286500090038700200130
0396035001000409801001000419#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#375#18#article#120#18#^rND^sLorenzetti^nA#^rND^sFornazari^nPA#^rND^sBonin
i-Domingos^nAC#^rND^sde Souza Rodrigues Penhalbel^nR#^rND^sFugikaha^nE#^rND^sBon
ini-Domingos^nCR#et al#Mixed Plasmodium falciparum infections and its clinical i
mplications in four areas of the Brazilian Amazon region^len#Acta Trop#20080000#
2008#107#1#8-12#20110200#v33n1a16.htm#0001-706X#Acta Trop##
00650000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100019000800100018000990100
01800117010001900135012008000154030002200234065000900256064000500265031000300270
032000200273014000700275865000900282002001300291035001000304801002200314#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#376#19#article#120#19#^rND^sC
avasini^nMT#^rND^sRibeiro^nWL#^rND^sKawamoto^nF#^rND^sFerreira^nMU#How prevalent
 is Plasmodium malariae in Rondonia, western Brazilian Amazon?^len#Rev Soc Bras 
Med Trop#20000000#2000#33#5#489-92#20110200#v33n1a16.htm#0037-8682#Rev Soc Bras 
Med Trop##
00744000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100017000960100
01900113010001800132010001800150010002100168012009300189030002200282065000900304
06400050031303100030031803200020032101400060032306100110032986500090034000200130
0349035001000362801002200372#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#377#20#article#120#20#^rND^sCosta^nMR#^rND^sVieira^nPP#^rND^sFerreira^nCO
#^rND^sLacerda^nMV#^rND^sAlecrim^nWD#^rND^sAlecrim^nMG. D#Molecular diagnosing o
f malaria in a tertiary care center in the Brazilian Amazon region^len#Rev Soc B
ras Med Trop#20080000#2008#41#4#381-5#Portuguese#20110200#v33n1a16.htm#0037-8682
#Rev Soc Bras Med Trop##
00813000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100017000960100
01600113010001600129010002000145010001600165012017000181030002200351065000900373
06400050038203100030038703200020039001400060039206100110039886500090040900200130
0418035001000431801002200441#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#378#21#article#120#21#^rND^sSilva^nMC#^rND^sSantos^nEB#^rND^sCosta^nEG#^r
ND^sFilho^nMG#^rND^sGuerreiro^nJF#^rND^sPóvoa^nMM#Clinical and laboratorial alte
rations in plasmodium vivax malaria patients and glucose-6-phosphate dehydrogena
se deficiency treated with primaquine at 0.50 mg/kg/day^len#Rev Soc Bras Med Tro
p#20040000#2004#37#3#215-7#Portuguese#20110200#v33n1a16.htm#0037-8682#Rev Soc Br
as Med Trop##
00663000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100016000960100
01600112010001900128012007800147030002200225065000900247064000500256031000300261
03200020026401400060026606100110027286500090028300200130029203500100030580100220
0315#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#379#22#article#12
0#22#^rND^sAbdon^nNP#^rND^sPinto^nAY#^rND^sSilva^nRS#^rND^sde Souza^nJM#Assessme
nt of the response to reduced treatment schemes for vivax malaria^len#Rev Soc Br
as Med Trop#20010000#2001#34#4#343-8#Portuguese#20110200#v33n1a16.htm#0037-8682#
Rev Soc Bras Med Trop##
00522000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100019000970100
01700116012002800133030000700161065000900168064000500177031000400182014000700186
865000900193002001300202035001000215801000700225#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a16.htm#S#c#380#23#article#120#23#^rND^sCutbush^nM#^rND^sMollison
^nPL#^rND^sParkin^nDM#A new human blood group^len#Nature#19500000#1950#165#188-8
9#20110200#v33n1a16.htm#0028-0836#Nature##
00599000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100015000800100018000950100
02200113010002000135012005400155030000700209065000900216064000500225031000400230
032000500234014000700239865000900246002001300255035001000268801000700278#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#381#24#article#120#24#^rND^sI
kin^nEW#^rND^sMourant^nAE#^rND^sPettenkofer^nHJ#^rND^sBlumenthal^nG#Discovery of
 the excepted haemagglutinin anti-Fyb^len#Nature#19510000#1951#168#4288#1077-8#2
0110200#v33n1a16.htm#0028-0836#Nature##
00583000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100015000960100
01400111012007200125030001400197065000900211064000500220031000200225032000200227
014000600229865000900235002001300244035001000257801001400267#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#382#25#article#120#25#^rND^sSanger^nR#^rN
D^sRace^nRR#^rND^sJack^nJ#The Duffy blood groups of New York Negroes: the phenot
ype Fy (a-b-)^len#Br J Haematol#19550000#1955#1#4#370-4#20110200#v33n1a16.htm#00
07-1048#Br J Haematol##
00696000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100019000800100015000990100
01700114010001500131010001700146010001800163810000600181012007300187030001400260
06500090027406400050028303100030028803200020029101400070029386500090030000200130
0309035001000322801001400332#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#383#26#article#120#26#^rND^sDarbonne^nWC#^rND^sRice^nGC#^rND^sMohler^nMA#
^rND^sApple^nT#^rND^sHebert^nCA#^rND^sValente^nAJ#et al#Red blood cells are a si
nk for interleukin 8, a leukocyte chemotaxin^len#J Clin Invest#19910000#1991#88#
4#1362-9#20110200#v33n1a16.htm#0021-9738#J Clin Invest##
00792000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100019000800100019000990100
01800118010001800136010001600154010001500170012015900185030002500344065000900369
06400050037803100030038303200030038601400080038986500090039700200130040603500100
0419801002500429#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#384#2
7#article#120#27#^rND^sChaudhuri^nA#^rND^sPolyakova^nJ#^rND^sZbrzezna^nV#^rND^sW
illiams^nK#^rND^sGulati^nS#^rND^sPogo^nAO#Cloning of glycoprotein D cDNA, which 
encodes the major subunit of the Duffy blood group system and the receptor for t
he Plasmodium vivax malaria parasite^len#Proc Natl Acad Sci U S A#19930000#1993#
90#22#10793-7#20110200#v33n1a16.htm#0027-8424#Proc Natl Acad Sci U S A##
00650000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100018000800100015000980100
01800113010001900131012007800150030002500228065000900253064000500262031000300267
032000200270014000700272865000900279002001300288035001000301801002500311#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#385#28#article#120#28#^rND^sD
onahue^nRP#^rND^sBias^nWB#^rND^sRenwick^nJH#^rND^sMcKusick^nVA#Probable assignme
nt of the Duffy blood group locus to chromosome 1 in man^len#Proc Natl Acad Sci 
U S A#19680000#1968#61#3#949-55#20110200#v33n1a16.htm#0027-8424#Proc Natl Acad S
ci U S A##
00647000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100016000970100
01900113010001800132010001700150012004300167030002500210065000900235064000500244
03100030024903200030025201400090025586500090026400200130027303500100028680100250
0296#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#386#29#article#12
0#29#^rND^sCollins^nA#^rND^sKeats^nBJ#^rND^sDracopoli^nN#^rND^sShields^nDC#^rND^
sMorton^nNE#Integration of gene maps: chromosome 1^len#Proc Natl Acad Sci U S A#
19920000#1992#89#10#4598-602#20110200#v33n1a16.htm#0027-8424#Proc Natl Acad Sci 
U S A##
00738000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100014000970100
01400111010001800125010001600143010001800159012015200177030000600329065000900335
06400050034403100030034903200020035201400080035486500090036200200130037103500100
0384801000600394#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#387#3
0#article#120#30#^rND^sParasol^nN#^rND^sReid^nM#^rND^sRios^nM#^rND^sCastilho^nL#
^rND^sHarari^nI#^rND^sKosower^nNS#A novel mutation in the coding sequence of the
 FY*B allele of the Duffy chemokine receptor gene is associated with an altered 
erythrocyte phenotype^len#Blood#19980000#1998#92#7#2237-43#20110200#v33n1a16.htm
#0006-4971#Blood##
00669000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100021000800100015001010100
01800116010002000134012012400154030001000278065000900288064000500297031000300302
032000200305014000600307865000900313002001300322035001000335801001000345#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#388#31#article#120#31#^rND^sT
ournamille^nC#^rND^sColin^nY#^rND^sCartron^nJP#^rND^sLe Van Kim^nC#Disruption of
 a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in 
Duffy-negative individuals^len#Nat Genet#19950000#1995#10#2#224-8#20110200#v33n1
a16.htm#1061-4036#Nat Genet##
00800000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100019000800100014000990100
01700113010001700130010001700147012022500164030001400389065000900403064000500412
03100030041703200020042001400060042286500090042800200130043703500100045080100140
0460#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#389#32#article#12
0#32#^rND^sMallinson^nG#^rND^sSoo^nKS#^rND^sSchall^nTJ#^rND^sPisacka^nM#^rND^sAn
stee^nDJ#Mutations in the erythrocyte chemokine receptor (Duffy) gene: the molec
ular basis of the Fya/Fyb antigens and identification of a deletion in the Duffy
 gene of an apparently healthy individual with the Fy(a-b-) phenotype^len#Br J H
aematol#19950000#1995#90#4#823-9#20110200#v33n1a16.htm#0007-1048#Br J Haematol##
00739000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100020000800100017001000100
01800117010001700135010001900152010001700171810000600188012008500194030002500279
06500090030406400050031303100030031803200030032101400080032486500090033200200130
0341035001000354801002500364#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#390#33#article#120#33#^rND^sZimmerman^nPA#^rND^sWoolley^nI#^rND^sMasinde^
nGL#^rND^sMiller^nSM#^rND^sMcNamara^nDT#^rND^sHazlett^nF#et al#Emergence of FY*A
(null) in a Plasmodium vivax-endemic region of Papua New Guinea^len#Proc Natl Ac
ad Sci U S A#19990000#1999#96#24#13973-7#20110200#v33n1a16.htm#0027-8424#Proc Na
tl Acad Sci U S A##
00627000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100018000800100014000980100
02000112010001500132010001600147010001500163012003600178030000900214065000900223
06400050023203100030023703200020024001400060024286500090024800200130025703500100
0270801000900280#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#391#3
4#article#120#34#^rND^sCastilho^nL#^rND^sRios^nM#^rND^sPellegrino^nJ#^rND^sSaad^
nST#^rND^sCosta^nFF#^rND^sReid^nME#A novel FY allele in Brazilians^len#Vox Sang#
20040000#2004#87#3#190-5#20110200#v33n1a16.htm#0042-9007#Vox sang##
00484000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770160015000800160016000950180
02400111063000200135066000700137062003400144065000900178064000500187020000400192
865000900196002001300205#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S
#c#392#35#article#120#35#^rND^sRace^nRR#^rND^sSanger^nR#Blood groups in man^len#
6#Oxford#Blackwell Scientific Publications#19750000#1975#864#20110200#v33n1a16.h
tm##
00732000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100012000970100
01800109010001500127010001500142012013700157030002700294065000900321064000500330
03100040033503200020033901400060034186500090034700200130035603500100036980100270
0379#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#393#36#article#12
0#36#^rND^sIwamoto^nS#^rND^sLi^nJ#^rND^sSugimoto^nN#^rND^sOkuda^nH#^rND^sKajii^n
E#Characterization of the Duffy gene promoter: evidence for tissue-specific abol
ishment of expression in Fy(a-b-) of black individuals^len#Biochem Biophys Res C
ommun#19960000#1996#222#3#852-9#20110200#v33n1a16.htm#0006-291X#Biochem Biophys 
Res Commun##
00619000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100020000800100016001000100
01600116010001600132010001600148012005400164030000900218065000900227064000500236
03100030024103200020024401400060024686500090025200200130026103500100027480100090
0284#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#394#37#article#12
0#37#^rND^sLe Pennec^nPY#^rND^sRouger^nP#^rND^sKlein^nMT#^rND^sRobert^nN#^rND^sS
almon^nC#Study of anti-Fya in five black Fy(a-b-) patients^len#Vox Sang#19870000
#1987#52#3#246-9#20110200#v33n1a16.htm#0042-9007#Vox sang##
00609000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100020000800100026001000100
01800126012010100144030002500245710000200270065000900272064000500281031000300286
032000200289014000600291865000900297002001300306#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a16.htm#S#c#395#38#article#120#38#^rND^sNovaretti^nMC#^rND^sDorlh
iac-Llacer^nPE#^rND^sChamone^nDA#Estudo de grupos sanguíneos em doadores de sang
ue caucasóides e negróides na cidade de São Paulo^lpt#Rev Bras Hematol Hemoter#2
#20000000#2000#22#1#23-32#20110200#v33n1a16.htm##
00707000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100016000970100
02800113010002000141010001600161012006600177030004100243065000900284064000500293
03100030029803200020030101400050030386500090030800200130031703500100033080100410
0340#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#396#39#article#12
0#39#^rND^sShimizu^nY#^rND^sKimura^nM#^rND^sSettheetham-Ishida^nW#^rND^sDuangcha
ng^nP#^rND^sIshida^nT#Serotyping of Duffy blood group in several Thai ethnic gro
ups^len#Southeast Asian J Trop Med Public Health#19970000#1997#28#1#32-5#2011020
0#v33n1a16.htm#0038-3619#Southeast Asian J Trop Med Public Health##
00708000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100012000970100
01900109010001800128010002800146010001700174810000600191012008600197030000900283
06500090029206400050030103100030030603200020030901400060031186500090031700200130
0326035001000339801000900349#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#397#40#article#120#40#^rND^sShimizu^nY#^rND^sAo^nH#^rND^sSoemantri^nA#^rN
D^sTiwawech^nD#^rND^sSettheetham-Ishida^nW#^rND^sKayame^nOW#et al#Sero- and mole
cular typing of Duffy blood group in Southeast Asians and Oceanians^len#Hum Biol
#20000000#2000#72#3#511-8#20110200#v33n1a16.htm#0018-7143#Hum Biol##
00663000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100016000970100
01700113010002000130010001800150012009200168030000800260065000900268064000500277
03100040028203200050028601400060029186500090029700200130030603500100031980100080
0329#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#398#41#article#12
0#41#^rND^sMiller^nLH#^rND^sMason^nSJ#^rND^sDvorak^nJA#^rND^sMcGinniss^nMH#^rND^
sRothman^nIK#Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy bloo
d group determinants^len#Science#19750000#1975#189#4202#561-3#20110200#v33n1a16.
htm#0036-8075#Science##
00557000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100015000970100
01600112012005100128030000900179065000900188064000500197031000300202032000200205
014000700207865000900214002001300223035001000236801000900246#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#399#42#article#120#42#^rND^sMoulds^nJM#^r
ND^sHayes^nS#^rND^sWells^nTD#DNA analysis of Duffy genes in American blacks^len#
Vox Sang#19980000#1998#74#4#248-52#20110200#v33n1a16.htm#0042-9007#Vox sang##
00622000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100019000800100018000990100
01700117012010500134030001000239065000900249064000500258031000400263032000200267
014000900269865000900278002001300287035001000300801001000310#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#400#43#article#120#43#^rND^sBarnwell^nJW#
^rND^sNichols^nME#^rND^sRubinstein#In vitro evaluation of the role of the Duffy 
blood group in erythrocyte invasion by Plasmodium vivax^len#J Exp Med#19890000#1
989#169#5#1795-802#20110200#v33n1a16.htm#0022-1007#J Exp Med##
00735000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100024000970100
01600121010001900137010001900156012015300175030001000328065000900338064000500347
03100040035203200030035601400080035986500090036700200130037603500100038980100100
0399#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#401#44#article#12
0#44#^rND^sRayner^nJC#^rND^sVargas-Serrato^nE#^rND^sHuber^nCS#^rND^sGalinski^nMR
#^rND^sBarnwell^nJW#A Plasmodium falciparum homologue of Plasmodium vivax reticu
locyte binding protein (PvRBP1) defines a trypsin-resistant erythrocyte invasion
 pathway^len#J Exp Med#20010000#2001#194#11#1571-81#20110200#v33n1a16.htm#0022-1
007#J Exp Med##
00597000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100017000970100
02100114010001900135012005100154030000800205065000900213064000500222031000400227
032000500231014000700236865000900243002001300252035001000265801000800275#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#402#45#article#120#45#^rND^sD
vorak^nJA#^rND^sMiller^nLH#^rND^sWhitehouse^nWC#^rND^sShiroishi^nT#Invasion of e
rythrocytes by malaria merozoites^len#Science#19750000#1975#187#4178#748-50#2011
0200#v33n1a16.htm#0036-8075#Science##
00612000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100015000960100
02000111010001600131012005300147030001800200065000900218064000500227031000300232
032000600235014000700241865000900248002001300257035001000270801001800280#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#403#46#article#120#46#^rND^sM
endis^nK#^rND^sSina^nBJ#^rND^sMarchesini^nP#^rND^sCarter^nR#The neglected burden
 of Plasmodium vivax malaria^len#Am J Trop Med Hyg#20010000#2001#64#^s1-2#97-106
#20110200#v33n1a16.htm#0002-9637#Am J Trop Med Hyg##
00616000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100019000960100
01800115012007400133030002500207065000900232064000500241031000300246032000200249
014000600251865000900257002001300266035001000279801002500289#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#404#47#article#120#47#^rND^sWelch^nSG#^rN
D^sMcGregor^nIA#^rND^sWilliams^nK#The Duffy blood group and malaria prevalence i
n Gambian West Africans^len#Trans R Soc Trop Med Hyg#19770000#1977#71#4#295-6#20
110200#v33n1a16.htm#0035-9203#Trans R Soc Trop Med Hyg##
00674000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100020000800100017001000100
01800117010001900135010001700154010001700171810000600188012008700194030000900281
71000020029006500090029206400050030103100020030603200020030802000040031086500090
0314002001300323#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#405#4
8#article#120#48#^rND^sKasehagen^nLJ#^rND^sMueller^nI#^rND^sKiniboro^nB#^rND^sBo
ckarie^nMJ#^rND^sReeder^nJC#^rND^sKazura^nJW#et al#Reduced Plasmodium vivax eryt
hrocyte infection in PNG Duffy-negative heterozygotes^len#PLoS One#2#20070000#20
07#2#3#336#20110200#v33n1a16.htm##
00766000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100019000800100023000990100
01600122010001700138010002000155010002200175810000600197012011900203030000900322
71000020033106500090033306400050034203100020034703200030034902000040035206100380
0356865000900394002001300403#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#406#49#article#120#49#^rND^sGrimberg^nBT#^rND^sUdomsangpetch^nR#^rND^sXai
nli^nJ#^rND^sMcHenry^nA#^rND^sPanichakul^nT#^rND^sSattabongkot^nJ#et al#Plasmodi
um vivax invasion of human erythrocytes inhibited by antibodies directed against
 the Duffy binding protein^len#PLoS Med#2#20070000#2007#4#12#337#Comment in: PLo
S Med. 2007;4(12):e350#20110200#v33n1a16.htm##
00747000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100019000800100022000990100
01600121010001700137010001600154010001600170810000600186012011100192030001800303
06500090032106400050033003100030033503200020033801400070034086500090034700200130
0356035001000369801001800379#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#407#50#article#120#50#^rND^sCeravolo^nIP#^rND^sBruña-Romero^nO#^rND^sBrag
a^nEM#^rND^sFontes^nCJ#^rND^sBrito^nCF#^rND^sSouza^nJM#et al#Anti-Plasmodium viv
ax duffy binding protein antibodies measure exposure to malaria in the Brazilian
 Amazon^len#Am J Trop Med Hyg#20050000#2005#72#6#675-81#20110200#v33n1a16.htm#00
02-9637#Am J Trop Med Hyg##
00756000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100015000800100027000950100
01600122010001600138010001800154010001800172810000600190012011600196030001800312
06500090033006400050033903100030034403200020034701400070034986500090035600200130
0365035001000378801001800388#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#408#51#article#120#51#^rND^sTran^nTM#^rND^sOliveira-Ferreira^nJ#^rND^sMor
eno^nA#^rND^sSantos^nF#^rND^sYazdani^nSS#^rND^sChitnis^nCE#et al#Comparison of I
gG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian A
mazon population^len#Am J Trop Med Hyg#20050000#2005#73#2#244-55#20110200#v33n1a
16.htm#0002-9637#Am J Trop Med Hyg##
00555000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100018000800100020000980120
05200118030001800170065000900188064000500197031000300202032000200205014000800207
865000900215002001300224035001000237801001800247#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a16.htm#S#c#409#52#article#120#52#^rND^sMathews^nHM#^rND^sArmstro
ng^nJC#Duffy blood types and vivax malaria in Ethiopia^len#Am J Trop Med Hyg#198
10000#1981#30#2#299-303#20110200#v33n1a16.htm#0002-9637#Am J Trop Med Hyg##
00447000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770160020000800180039001000660
01900139062000700158065000900165064000500174020000400179865000900183002001300192
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#410#53#article#120#53
#^rND^sBeiguelman^nB#Sistemas sanguíneos eritrocitários^lpt#Ribeirão Preto^eSP#F
unpec#20030000#2003#234#20110200#v33n1a16.htm##
00656000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100018000800100019000980120
10500117030001500222065000900237064000500246031000300251032000200254014000800256
061004300264865000900307002001300316035001000329801001500339#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#411#54#article#120#54#^rND^sHamblin^nMT#^
rND^sDi Rienzo^nA#Detection of the signature of natural selection in humans: evi
dence from the Duffy blood group locus^len#Am J Hum Genet#20000000#2000#66#5#166
9-79#Erratum in: Am J Hum Genet. 2002;70(1):284#20110200#v33n1a16.htm#0002-9297#
Am J Hum Genet##
00601000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100018000800100019000980100
01900117012007500136030001500211065000900226064000500235031000300240032000200243
014000700245865000900252002001300261035001000274801001500284#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#412#55#article#120#55#^rND^sHamblin^nMT#^
rND^sThompson^nEE#^rND^sDi Rienzo^nA#Complex signatures of natural selection at 
the Duffy blood group locus^len#Am J Hum Genet#20020000#2002#70#2#369-83#2011020
0#v33n1a16.htm#0002-9297#Am J Hum Genet##
00680000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100018000800100016000980100
01900114010001500133010001800148010001700166012008200183030001000265065000900275
06400050028403100030028903200020029201400060029486500090030000200130030903500100
0322801001000332#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#413#5
6#article#120#56#^rND^sAzevedo^nES#^rND^sSilva^nKM#^rND^sda Silva^nMC#^rND^sLima
^nAM#^rND^sFortuna^nCM#^rND^sSantos^nMG#Genetic and anthropological studies in t
he island of Itaparica, Bahia, Brazil^len#Hum Hered#19810000#1981#31#6#353-7#201
10200#v33n1a16.htm#0001-5652#Hum Hered##
00596000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100015000800100016000950100
01500111010001700126012006200143030001000205065000900215064000500224031000300229
032000200232014000600234865000900240002001300249035001000262801001000272#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#414#57#article#120#57#^rND^sZ
ago^nMA#^rND^sCosta^nFF#^rND^sTone^nLG#^rND^sBottura^nC#Hereditary hemoglobin di
sorders in a Brazilian population^len#Hum Hered#19830000#1983#33#2#125-9#2011020
0#v33n1a16.htm#0001-5652#Hum Hered##
00685000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100019000800100020000990100
01600119010001600135010001700151010001800168810000600186012011500192030000800307
71000020031506500090031706400050032603100020033102000040033386500090033700200130
0346#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#415#58#article#12
0#58#^rND^sCavasini^nCE#^rND^sde Mattos^nLC#^rND^sCouto^nAA#^rND^sCouto^nVS#^rND
^sGollino^nY#^rND^sMoretti^nLJ#et al#Duffy blood group gene polymorphisms among 
malaria vivax patients in four areas of the Brazilian Amazon region^len#Malar J#
2#20070000#2007#6#167#20110200#v33n1a16.htm##
00638000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100017000960100
01700113010001700130012009600147030001200243065000900255064000500264031000300269
032000200272014000600274865000900280002001300289035001000302801001200312#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#416#59#article#120#59#^rND^sA
ikawa^nM#^rND^sMiller^nLH#^rND^sJohnson^nJ#^rND^sRabbege^nJ#Erythrocyte entry by
 malarial parasites: A moving junction between erythrocyte and parasite^len#J Ce
ll Biol#19780000#1978#77#1#72-82#20110200#v33n1a16.htm#0021-9525#J Cell Biol##
00661000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100016000970100
01800113010001900131012011800150030001000268065000900278064000500287031000400292
032000200296014000700298865000900305002001300314035001000327801001000337#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#417#60#article#120#60#^rND^sM
iller^nLH#^rND^sAikawa^nM#^rND^sJohnson^nJG#^rND^sShiroishi^nT#Interaction betwe
en cytochalasin B-treated malarial parasites and erythrocytes: Attachment and ju
nction formation^len#J Exp Med#19790000#1979#149#1#172-84#20110200#v33n1a16.htm#
0022-1007#J Exp Med##
00662000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100018000960120
14700114030002500261065000900286064000500295031000300300032000300303014000900306
865000900315002001300324035001000337801002500347#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a16.htm#S#c#418#61#article#120#61#^rND^sRanjan^nA#^rND^sChitnis^n
CE#Mapping regions containing binding residues within functional domains of Plas
modium vivax and Plasmodium knowlesi erythrocyte-binding proteins^len#Proc Natl 
Acad Sci U S A#19990000#1999#96#24#14067-72#20110200#v33n1a16.htm#0027-8424#Proc
 Natl Acad Sci U S A##
00709000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100016000960100
01800112010001900130010001600149010001600165012010500181030001300286065000900299
06400050030803100030031303200030031601400070031986500090032600200130033503500100
0348801001300358#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#419#6
2#article#120#62#^rND^sTsuboi^nT#^rND^sKappe^nSH#^rND^sal-Yaman^nF#^rND^sPricket
t^nMD#^rND^sAlpers^nM#^rND^sAdams^nJH#Natural variation within the principal adh
esion domain of the Plasmodium vivax Duffy binding protein^len#Infect Immun#1994
0000#1994#62#12#5581-6#20110200#v33n1a16.htm#0019-9567#Infect Immun##
00691000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100016000960100
01500112012015900127030002200286065000900308064000500317031000400322032000200326
014000700328865000900335002001300344035001000357801002200367#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#420#63#article#120#63#^rND^sXainli^nJ#^rN
D^sAdams^nJH#^rND^sKing^nCL#The erythrocyte binding motif of plasmodium vivax du
ffy binding protein is highly polymorphic and functionally conserved in isolates
 from Papua New Guinea^len#Mol Biochem Parasitol#20000000#2000#111#2#253-60#2011
0200#v33n1a16.htm#0166-6851#Mol Biochem Parasitol##
00716000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100022000800100016001020100
01600118010001700134010001600151010001800167810000600185012009100191030001300282
06500090029506400050030403100040030903200020031301400060031586500090032100200130
0330035001000343801001300353#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#421#64#article#120#64#^rND^sCole-Tobian^nJL#^rND^sCortes^nA#^rND^sBaisor^
nM#^rND^sKastens^nW#^rND^sXainli^nJ#^rND^sBockarie^nM#et al#Age-acquired immunit
y to a Plasmodium vivax invasion ligand, the duffy binding protein^len#J Infect 
Dis#20020000#2002#186#4#531-9#20110200#v33n1a16.htm#0022-1899#J Infect Dis##
00648000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100016000960100
01600112012013300128030001300261065000900274064000500283031000300288032000200291
014000800293865000900301002001300310035001000323801001300333#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#422#65#article#120#65#^rND^sMichon^nP#^rN
D^sFraser^nT#^rND^sAdams^nJH#Naturally acquired and vaccine-elicited antibodies 
block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein^le
n#Infect Immun#20000000#2000#68#6#3164-71#20110200#v33n1a16.htm#0019-9567#Infect
 Immun##
00793000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100015000800100016000950100
02400111010001800135010001400153010001900167810000600186012016600192030001200358
06500090037006400050037903100040038403200030038801400080039186500090039900200130
0408035001000421801001200431#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#423#66#article#120#66#^rND^sSingh^nS#^rND^sPandey^nK#^rND^sChattopadhayay
^nR#^rND^sYazdani^nSS#^rND^sLynn^nA#^rND^sBharadwaj^nA#et al#Biochemical, biophy
sical, and functional characterization of bacterially expressed and refolded rec
eptor binding domain of Plasmodium vivax duffy-binding protein^len#J Biol Chem#2
0010000#2001#276#20#17111-6#20110200#v33n1a16.htm#0021-9258#J Biol Chem##
00661000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100015000960100
01800111012012800129030002200257065000900279064000500288031000400293032000200297
014000600299865000900305002001300314035001000327801002200337#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#424#67#article#120#67#^rND^sSingh^nAP#^rN
D^sPuri^nSK#^rND^sChitnis^nCE#Antibodies raised against receptor-binding domain 
of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion^len#Mo
l Biochem Parasitol#20020000#2002#121#1#21-31#20110200#v33n1a16.htm#0166-6851#Mo
l Biochem Parasitol##
00718000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100017000960100
01500113010001500128010001800143010001600161810000600177012011700183030000500300
06500090030506400050031403100030031903200020032201400070032486500090033100200130
0340035001000353801000500363#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#425#68#article#120#68#^rND^sAdams^nJH#^rND^sHudson^nDE#^rND^sTorii^nM#^rN
D^sWard^nGE#^rND^sWellems^nTE#^rND^sAikawa^nM#et al#The Duffy receptor family of
 Plasmodium knowlesi is located within the micronemes of invasive malaria merozo
ites^len#Cell#19900000#1990#63#1#141-53#20110200#v33n1a16.htm#0092-8674#Cell##
00679000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100021000800100016001010100
01600117012013300133030002500266065000900291064000500300031000400305032000300309
014000800312865000900320002001300329035001000342801002500352#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#426#69#article#120#69#^rND^sVanBuskirk^nK
M#^rND^sSevova^nE#^rND^sAdams^nJH#Conserved residues in the Plasmodium vivax Duf
fy-binding protein ligand domain are critical for erythrocyte receptor recogniti
on^len#Proc Natl Acad Sci U S A#20040000#2004#101#44#15754-9#20110200#v33n1a16.h
tm#0027-8424#Proc Natl Acad Sci U S A##
00758000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100021000800100022001010100
01600123010001700139010001800156010001500174810000600189012012700195030001300322
06500090033506400050034403100040034903200020035301400080035586500090036300200130
0372035001000385801001300395#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#427#70#article#120#70#^rND^sVanBuskirk^nKM#^rND^sCole-Tobian^nJL#^rND^sBa
isor^nM#^rND^sSevova^nES#^rND^sBockarie^nM#^rND^sKing^nCL#et al#Antigenic drift 
in the ligand domain of Plasmodium vivax Duffy binding protein confers resistanc
e to inhibitory antibodies^len#J Infect Dis#20040000#2004#190#9#1556-62#20110200
#v33n1a16.htm#0022-1899#J Infect Dis##
00777000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100019000960100
02700115010001500142010001900157010001600176012014500192030002200337065000900359
06400050036803100040037303200020037701400060037986500090038500200130039403500100
0407801002200417#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#428#7
1#article#120#71#^rND^sSousa^nTN#^rND^sCeravolo^nIP#^rND^sFernandes Fontes^nCJ#^
rND^sCouto^nA#^rND^sCarvalho^nLH#^rND^sBrito^nCF#The pattern of major polymorphi
sms in the Duffy binding protein ligand domain among Plasmodium vivax isolates f
rom the Brazilian Amazon area^len#Mol Biochem Parasitol#20060000#2006#146#2#251-
4#20110200#v33n1a16.htm#0166-6851#Mol Biochem Parasitol##
00592000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100021000800100015001010120
08300116030002200199065000900221064000500230031000400235032000200239014000700241
865000900248002001300257035001000270801002200280#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a16.htm#S#c#429#72#article#120#72#^rND^sCole-Tobian^nJ#^rND^sKing
^nCL#Diversity and natural selection in Plasmodium vivax Duffy binding protein g
ene^len#Mol Biochem Parasitol#20030000#2003#127#2#121-32#20110200#v33n1a16.htm#0
166-6851#Mol Biochem Parasitol##
00629000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100018000800100017000980100
01900115010002000134012007600154030001300230065000900243064000500252031000400257
032000200261014000700263865000900270002001300279035001000292801001300302#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#430#73#article#120#73#^rND^sM
artinez^nP#^rND^sSuarez^nCF#^rND^sCardenas^nPP#^rND^sPatarroyo^nMA#Plasmodium vi
vax Duffy binding protein: a modular evolutionary proposal^len#Parasitology#2004
0000#2004#128#4#353-66#20110200#v33n1a16.htm#0031-1820#Parasitology##
00722000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100016000960100
01900112010001400131010001800145010001700163810000600180012010200186030001300288
06500090030106400050031003100030031503200020031801400070032086500090032700200130
0336035001000349801001300359#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#431#74#article#120#74#^rND^sFraser^nT#^rND^sMichon^nP#^rND^sBarnwell^nJW#
^rND^sNoe^nAR#^rND^sAl-Yaman^nF#^rND^sKaslow^nDC#et al#Expression and serologic 
activity of a soluble recombinant Plasmodium vivax Duffy binding protein^len#Inf
ect Immun#19970000#1997#65#7#2772-7#20110200#v33n1a16.htm#0019-9567#Infect Immun
##
00708000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100022000960100
01600118010001700134010001800151010001800169810000600187012008000193030001300273
06500090028606400050029503100030030003200020030301400080030586500090031300200130
0322035001000335801001300345#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#432#75#article#120#75#^rND^sXainli^nJ#^rND^sCole-Tobian^nJL#^rND^sBaisor^
nM#^rND^sKastens^nW#^rND^sBockarie^nM#^rND^sYazdani^nSS#et al#Epitope-specific h
umoral immunity to Plasmodium vivax Duffy binding protein^len#Infect Immun#20030
000#2003#71#5#2508-15#20110200#v33n1a16.htm#0019-9567#Infect Immun##
00569000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100014000800100020000940100
02000114012007100134030002500205710000200230065000900232064000500241031000300246
032000200249014000600251865000900257002001300266#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a16.htm#S#c#433#76#article#120#76#^rND^sJens^nE#^rND^sPagliarini^
nT#^rND^sNovaretti^nMC#Sistema de grupo sanguíneo Duffy: biologia e prática tran
sfusional^lpt#Rev Bras Hematol Hemoter#2#20050000#2005#27#2#110-9#20110200#v33n1
a16.htm##
00655000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100018000800100016000980120
10200114030001900216065000900235064000500244031000300249032000200252014000700254
061004100261865000900302002001300311035001000324801001900334#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#434#77#article#120#77#^rND^sMcHenry^nAM#^
rND^sAdams^nJH#The crystal structure of P. knowlesi DBP-alpha DBL domain and its
 implications for immune evasion^len#Trends Biochem Sci#20060000#2006#31#9#487-9
1#Comment on: Nature. 2006;439(7077):741-4#20110200#v33n1a16.htm#0167-7640#Trend
s Biochem Sci##
00776000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100019000800100022000990100
01700121010001600138010002000154010001800174810000600192012013900198030001600337
06500090035306400050036203100030036703200020037001400060037286500090037800200130
0387035001000400801001600410#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#435#78#article#120#78#^rND^sCeravolo^nIP#^rND^sSouza-Silva^nFA#^rND^sFont
es^nCJ#^rND^sBraga^nEM#^rND^sMadureira^nAP#^rND^sKrettli^nAU#et al#Inhibitory pr
operties of the antibody response to Plasmodium vivax Duffy binding protein in a
n area with unstable malaria transmission^len#Scand J Immunol#20080000#2008#67#3
#270-8#20110200#v33n1a16.htm#0300-9475#Scand J Immunol##
00796000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100015000800100016000950100
01700111010001800128010001800146010002000164810000600184012014600190030002500336
06500090036106400050037003100040037503200030037901400070038286500090038900200130
0398035001000411801002500421#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#436#79#article#120#79#^rND^sKing^nCL#^rND^sMichon^nP#^rND^sShakri^nAR#^rN
D^sMarcotty^nA#^rND^sStanisic^nD#^rND^sZimmerman^nPA#et al#Naturally acquired Du
ffy-binding protein-specific binding inhibitory antibodies confer protection fro
m blood-stage Plasmodium vivax infection^len#Proc Natl Acad Sci U S A#20080000#2
008#105#24#8363-8#20110200#v33n1a16.htm#0027-8424#Proc Natl Acad Sci U S A##
00691000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100016000800100016000960100
01700112010001800129010001600147010001500163012009600178030001000274065000900284
06400050029303100040029803200020030201400070030486500090031100200130032003500100
0333801001000343#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#437#8
0#article#120#80#^rND^sXainli^nJ#^rND^sBaisor^nM#^rND^sKastens^nW#^rND^sBockarie
^nM#^rND^sAdams^nJH#^rND^sKing^nCL#Age-dependent cellular immune responses to Pl
asmodium vivax Duffy binding protein in humans^len#J Immunol#20020000#2002#169#6
#3200-7#20110200#v33n1a16.htm#0022-1767#J Immunol##
00584000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800120101000970300
02500198065000900223064000500232031000300237032000200240014000700242865000900249
002001300258035001000271801002500281#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a16.htm#S#c#438#81#article#120#81#^rND^sMiller^nLH#Impact of malaria on genet
ic polymorphism and genetic diseases in Africans and African Americans^len#Proc 
Natl Acad Sci U S A#19940000#1994#91#7#2415-9#20110200#v33n1a16.htm#0027-8424#Pr
oc Natl Acad Sci U S A##
00789000000000385000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100019000970100
01900116010001700135010001700152010001500169012004800184030001300232710000200245
06600140024706100090026106500090027006400050027911000090028410900120029303100030
0305032000300308014000600311037006400317865000900381002001300390#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#439#82#article#120#82#^rND^sFrason^nA
P#^rND^sBarlette^nAG#^rND^sDalpizolo^nC#^rND^sSauter^nIP#^rND^sMacedo^nAJ#^rND^s
Tasca^nT#Estratégias e desafios no combate à malária^lpt#Rev Liberato#2#Novo Ham
burgo#Internet#20090000#2009#20101121#2010 Nov 21#10#14#201-8#http://www.liberat
o.com.br/upload/arquivos/0106110920064219.pdf#20110200#v33n1a16.htm##
00542000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100025000800100017001050120
04900122030001200171065000900183064000500192031000300197032000200200014000600202
865000900208002001300217035001000230801001200240#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a16.htm#S#c#440#83#article#120#83#^rND^sArévalo-Herrera^nM#^rND^s
Herrera^nS#Plasmodium vivax malaria vaccine development^len#Mol Immunol#20010000
#2001#38#6#443-5#20110200#v33n1a16.htm#0161-5890#Mol Immunol##
00762000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100015000800100015000950100
01700110010002100127010001600148012018600164030001300350065000900363064000500372
03100030037703200020038001400090038286500090039100200130040003500100041380100130
0423#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#441#84#article#12
0#84#^rND^sDutta^nS#^rND^sWare^nLA#^rND^sBarbosa^nA#^rND^sOckenhouse^nCF#^rND^sL
anar^nDE#Purification, characterization, and immunogenicity of a disulfide cross
-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1,
 expressed in Escherichia coli^len#Infect Immun#20010000#2001#69#9#5.464-70#2011
0200#v33n1a16.htm#0019-9567#Infect Immun##
00715000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100015000800100020000950100
01500115010001600130010002100146012011900167030002200286065000900308064000500317
03100040032203200020032601400070032886500090033500200130034403500100035780100220
0367#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#442#85#article#12
0#85#^rND^sDutta^nS#^rND^sDaugherty^nJR#^rND^sWare^nLA#^rND^sLanar^nDE#^rND^sOck
enhouse^nCF#Expression, purification and characterization of a functional region
 of the Plasmodium vivax Duffy binding protein^len#Mol Biochem Parasitol#2000000
0#2000#109#2#179-84#20110200#v33n1a16.htm#0166-6851#Mol Biochem Parasitol##
00817000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100018000970100
02100115010001600136010001700152010002100169810000600190012018900196030001300385
06500090039806400050040703100030041203200020041501400050041786500090042200200130
0431035001000444801001300454#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#443#86#article#120#86#^rND^sKocken^nCH#^rND^sDubbeld^nMA#^rND^sVan Der We
l^nA#^rND^sPronk^nJT#^rND^sWaters^nAP#^rND^sLangermans^nJA#et al#High-level expr
ession of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris:
 strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuv
ant SBAS2^len#Infect Immun#19990000#1999#67#1#43-9#20110200#v33n1a16.htm#0019-95
67#Infect Immun##
00750000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100017000970100
01700114010001800131010001800149010001700167810000600184012010800190030002200298
06500090032006400050032903100030033403200020033701400070033986500090034600200130
0355035001000368801002200378#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#444#87#article#120#87#^rND^sGibson^nHL#^rND^sTucker^nJE#^rND^sKaslow^nDC#
^rND^sKrettli^nAU#^rND^sCollins^nWE#^rND^sKiefer^nMC#et al#Structure and express
ion of the gene for Pv200, a major blood-stage surface antigen of Plasmodium viv
ax^len#Mol Biochem Parasitol#19920000#1992#50#2#325-33#20110200#v33n1a16.htm#016
6-6851#Mol Biochem Parasitol##
00754000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100015000800100015000950100
01500110010001400125010001500139010001500154810000600169012012700175030002300302
06500090032506400050033403100020033903200020034101400060034386500090034900200130
0358035001000371801002300381#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#445#88#article#120#88#^rND^sPark^nJW#^rND^sMoon^nSH#^rND^sYeom^nJS#^rND^s
Lim^nKJ#^rND^sSohn^nMJ#^rND^sJung^nWC#et al#Naturally acquired antibody response
s to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in
 Korea^len#Clin Diagn Lab Immunol#20010000#2001#8#1#14-20#20110200#v33n1a16.htm#
1071-412X#Clin Diagn Lab Immunol##
00910000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100025000800100021001050100
01600126010001700142010001400159010001800173810000600191012021500197030001600412
06500090042806400050043703100030044203200020044501400080044706100450045586500090
0500002001300509035001000522801001600532#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a16.htm#S#c#446#89#article#120#89#^rND^sWickramarachchi^nT#^rND^sIlleperu
ma^nRJ#^rND^sPerera^nL#^rND^sBandara^nS#^rND^sHolm^nI#^rND^sLongacre^nS#et al#Co
mparison of naturally acquired antibody responses against the C-terminal process
ing products of Plasmodium vivax Merozoite Surface Protein-1 under low transmiss
ion and unstable malaria conditions in Sri Lanka^len#Int J Parasitol#20070000#20
07#37#2#199-208#Erratum in: Int J Parasitol. 2007; 37(5):579#20110200#v33n1a16.h
tm#0020-7519#Int J Parasitol##
00771000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100028000800100018001080100
01500126010002100141010001500162010001600177810000600193012012700199030001800326
06500090034406400050035303100030035803200040036101400060036586500090037100200130
0380035001000393801001800403#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#447#90#article#120#90#^rND^sValderrama-Aguirre^nA#^rND^sQuintero^nG#^rND^
sGómez^nA#^rND^sCastellanos^nA#^rND^sPérez^nY#^rND^sMéndez^nF#et al#Antigenicity
, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a pot
ential malaria vaccine subunit^len#Am J Trop Med Hyg#20050000#2005#73#^s5#16-24#
20110200#v33n1a16.htm#0002-9637#Am J Trop Med Hyg##
00728000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100017000970100
01600114010002300130010002000153012014400173030001300317065000900330064000500339
03100030034403200020034701400080034986500090035700200130036603500100037980100130
0389#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#448#91#article#12
0#91#^rND^sSoares^nIS#^rND^sLevitus^nG#^rND^sSouza^nJM#^rND^sDel Portillo^nHA#^r
ND^sRodrigues^nMM#Acquired immune responses to the N-and C-terminal regions of P
lasmodium vivax merozoite surface protein 1 in individuals exposed to malaria^le
n#Infect Immun#19970000#1997#65#5#1606-14#20110200#v33n1a16.htm#0019-9567#Infect
 Immun##
00754000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100019000970100
01900116010002400135010001800159010001900177810000600196012012900202030000800331
06500090033906400050034803100020035303200020035501400070035786500090036400200130
0373035001000386801000800396#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#449#92#article#120#92#^rND^sSoares^nIS#^rND^sBarnwell^nJW#^rND^sFerreira^
nMU#^rND^sGomes Da Cunha^nM#^rND^sLaurino^nJP#^rND^sCastilho^nBA#et al#A Plasmod
ium vivax vaccine candidate displays limited allele polymorphism, which does not
 restrict recognition by antibodies^len#Mol Med#19990000#1999#5#7#459-70#2011020
0#v33n1a16.htm#1076-1551#Mol Med##
00711000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100022000800100020001020100
01700122010001700139010002000156010001500176810000600191012008500197030000800282
06500090029006400050029903100030030403200060030701400080031386500090032100200130
0330035001000343801000800353#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#450#93#article#120#93#^rND^sde Oliveira^nCI#^rND^sWunderlich^nG#^rND^sLev
itus^nG#^rND^sSoares^nIS#^rND^sRodrigues^nMM#^rND^sTsuji^nM#et al#Antigenic prop
erties of the merozoite surface protein 1 gene of Plasmodium vivax^len#Vaccine#1
9990000#1999#17#23-24#2959-68#20110200#v33n1a16.htm#0264-410X#Vaccine##
00736000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100021000800100016001010100
01900117010002200136010002000158010001700178012016200195030000800357710000200365
06500090036706400050037603100020038103200020038302000030038586500090038800200130
0397#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#451#94#article#12
0#94#^rND^sRodrigues^nMHC#^rND^sCunha^nMG#^rND^sMachado^nRLD#^rND^sFerreira Jr^n
OC#^rND^sRodrigues^nMM#^rND^sSoares^nIS#Serological detection of Plasmodium viva
x malaria using recombinant proteins corresponding to the 19-kDa C-terminal regi
on of the merozoite surface protein-1^len#Malar J#2#20030000#2003#2#1#39#2011020
0#v33n1a16.htm##
00800000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100014000800100018000940100
01900112010001700131010001400148010001400162012020300176030001300379065000900392
06400050040103100030040603200020040901400060041186500090041700200130042603500100
0439801001300449#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#452#9
5#article#120#95#^rND^sYang^nC#^rND^sCollins^nWE#^rND^sSullivan^nJS#^rND^sKaslow
^nDC#^rND^sXiao^nL#^rND^sLal^nAA#Partial protection against Plasmodium vivax blo
od-stage infection in Saimiri monkeys by immunization with a recombinant C-termi
nal fragment of merozoite surface protein 1 in block copolymer adjuvant^len#Infe
ct Immun#19990000#1999#67#1#342-9#20110200#v33n1a16.htm#0019-9567#Infect Immun##
00785000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800100018000970100
01900115010001500134010001700149010001700166010002000183012015300203030000800356
06500090036406400050037303100030037803200060038101400080038786500090039500200130
0404035001000417801000800427#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#453#96#article#120#96#^rND^sSierra^nAY#^rND^sBarrero^nCA#^rND^sRodriguez^
nR#^rND^sSilva^nY#^rND^sMoncada^nC#^rND^sVanegas^nM#^rND^sPatarroyo^nMA#Splenect
omised and spleen intact Aotus monkeys' immune response to Plasmodium vivax MSP-
1 protein fragments and their high activity binding peptides^len#Vaccine#2003000
0#2003#21#27-30#4133-44#20110200#v33n1a16.htm#0264-410X#Vaccine##
00702000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770160019000800180172000990460
01500271050002200286045000900308044000500317110000900322109001200331037007100343
865000900414002001300423#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S
#c#454#97#article#120#97#^rND^sCerávolo^nIP#Caracterização imunológica e molecul
ar da Duffy Binding Protein do Plasmodium vivax em áreas de transmissão de malár
ia da tegião amazônica e extra-amazônica brasileira^lpt#Belo Horizonte#Fundação 
Oswaldo Cruz#20070000#2007#20100727#2010 Jul 27#http://netra.cpqrr.fiocruz.br/do
wnload/Tese_Isabela_Penna_Ceravolo.pdf#20110200#v33n1a16.htm##
00498000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100017000800120086000970300
01400183710000200197065000900199064000500208031000300213014000600216865000900222
002001300231#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#455#98#ar
ticle#120#98#^rND^sHolder^nAA#The precursor to major merozoite surface antigens:
 structure and role in immunity^len#Prog. Allergy#2#19880000#1988#41#72-97#20110
200#v33n1a16.htm##
00763000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080004000731180003000770100018000800100017000980100
01900115010001700134010001800151010001400169810000600183012013100189030001800320
06500090033806400050034703100030035203200020035501400060035786500090036300200130
0372035001000385801001800395#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#456#99#article#120#99#^rND^sCollins^nWE#^rND^sKaslow^nDC#^rND^sSullivan^n
JS#^rND^sMorris^nCL#^rND^sGalland^nGG#^rND^sYang^nC#et al#Testing the efficacy o
f a recombinant merozoite surface protein (MSP-1(19)) of Plasmodium vivax in Sai
miri boliviensis monkeys^len#Am J Trop Med Hyg#19990000#1999#60#3#350-6#20110200
#v33n1a16.htm#0002-9637#Am J Trop Med Hyg##
00532000000000265000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100015000820120099000970300
01900196710000200215065000900217064000500226031000300231032000400234014000600238
865000900244002001300253#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S
#c#457#100#article#120#100#^rND^sJoshi^nH#Markers for population genetic analysi
s of human plasmodia species, P. falciparum and P. vivax^len#J Vector Borne Dis#
2#20030000#2003#40#3-4#78-83#20110200#v33n1a16.htm##
00573000000000277000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100016000820100019000980100
01700117012011000134030000800244710000200252065000900254064000500263031000200268
020000300270865000900273002001300282#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a16.htm#S#c#458#101#article#120#101#^rND^sZakeri^nS#^rND^sBarjesteh^nH#^rND^s
Djadid^nND#Merozoite surface protein-3alpha is a reliable marker for population 
genetic analysis of Plasmodium vivax^len#Malar J#2#20060000#2006#5#53#20110200#v
33n1a16.htm##
00750000000000337000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100019000820100025001010100
01500126010001600141010002000157010001900177012011100196030002200307065000900329
06400050033803100040034303200040034701400070035186500090035800200130036703500100
0380801002200390#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#459#1
02#article#120#102#^rND^sGalinski^nMR#^rND^sCorredor-Medina^nC#^rND^sPovoa^nM#^r
ND^sCrosby^nJ#^rND^sIngravallo^nP#^rND^sBarnwell^nJW#Plasmodium vivax merozoite 
surface protein-3 contains coiled-coil motifs in an alanine-rich central domain^
len#Mol Biochem Parasitol#19990000#1999#101#1-2#131-47#20110200#v33n1a16.htm#016
6-6851#Mol Biochem Parasitol##
00697000000000301000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100019000820100012001010100
02000113012015900133030002200292065000900314064000500323031000400328032000200332
014000700334865000900341002001300350035001000363801002200373#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#460#103#article#120#103#^rND^sGalinski^nM
R#^rND^sXu^nM#^rND^sBarnwell1^nJW#Plasmodium vivax reticulocyte binding protein-
2 (PvRBP-2) shares structural features with PvRBP-1 and the Plasmodium yoelii 23
5 kDa rhoptry protein family^len#Mol Biochem Parasitol#20000000#2000#108#2#257-6
2#20110200#v33n1a16.htm#0166-6851#Mol Biochem Parasitol##
00753000000000325000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100016000820100019000980100
01600117010001900133010001700152012015500169030002200324065000900346064000500355
03100040036003200020036401400070036686500090037300200130038203500100039580100220
0405#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#461#104#article#1
20#104#^rND^sBlack^nCG#^rND^sBarnwell^nJW#^rND^sHuber^nCS#^rND^sGalinski^nMR#^rN
D^sCoppel^nRL#The Plasmodium vivax homologues of merozoite surface proteins 4 an
d 5 from Plasmodium falciparum are expressed at different locations in the meroz
oite^len#Mol Biochem Parasitol#20020000#2002#120#2#215-24#20110200#v33n1a16.htm#
0166-6851#Mol Biochem Parasitol##
00712000000000349000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100017000820100017000990100
01800116010002200134010001200156010001500168810000600183012009800189030000800287
06500090029506400050030403100030030903200030031201400070031586500090032200200130
0331035001000344801000800354#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#462#105#article#120#105#^rND^sMalkin^nEM#^rND^sDurbin^nAP#^rND^sDiemert^n
DJ#^rND^sSattabongkot^nJ#^rND^sWu^nY#^rND^sMiura^nK#et al#Phase 1 vaccine trial 
of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria^len#Vacc
ine#20050000#2005#23#24#3131-8#20110200#v33n1a16.htm#0264-410X#Vaccine##
00697000000000301000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100019000820100012001010100
02000113012015900133030002200292065000900314064000500323031000400328032000200332
014000700334865000900341002001300350035001000363801002200373#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a16.htm#S#c#463#106#article#120#106#^rND^sGalinski^nM
R#^rND^sXu^nM#^rND^sBarnwell1^nJW#Plasmodium vivax reticulocyte binding protein-
2 (PvRBP-2) shares structural features with PvRBP-1 and the Plasmodium yoelii 23
5 kDa rhoptry protein family^len#Mol Biochem Parasitol#20000000#2000#108#2#257-6
2#20110200#v33n1a16.htm#0166-6851#Mol Biochem Parasitol##
00701000000000325000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100027000820100024001090100
01900133010001600152010001900168012010900187030000800296065000900304064000500313
03100030031803200060032101400080032786500090033500200130034403500100035780100080
0367#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#464#107#article#1
20#107#^rND^sOliveira-Ferreira^nJ#^rND^sVargas-Serrato^nE#^rND^sBarnwell^nJW#^rN
D^sMoreno^nA#^rND^sGalinski^nMR#Immunogenicity of Plasmodium vivax merozoite sur
face protein-9 recombinant proteins expressed in E. coli^len#Vaccine#20040000#20
04#22#15-16#2023-30#20110200#v33n1a16.htm#0264-410X#Vaccine##
00693000000000325000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100017000820100025000990100
01600124010001700140010001600157012010100173030001800274065000900292064000500301
03100030030603200020030901400060031186500090031700200130032603500100033980100180
0349#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#465#108#article#1
20#108#^rND^sMichon^nPA#^rND^sArevalo-Herrera^nM#^rND^sFraser^nT#^rND^sHerrera^n
S#^rND^sAdams^nJH#Serologic responses to recombinant Plasmodium vivax Duffy bind
ing protein in a Colombian village^len#Am J Trop Med Hyg#19980000#1998#59#4#597-
9#20110200#v33n1a16.htm#0002-9637#Am J Trop Med Hyg##
00770000000000349000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100014000820100015000960100
01400111010001400125010001500139010001400154810000600168012014300174030002300317
06500090034006400050034903100030035403200020035701400060035986500090036500200130
0374035001000387801002300397#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#466#109#article#120#109#^rND^sSuh^nIB#^rND^sChoi^nHK#^rND^sLee^nSW#^rND^s
Woo^nSK#^rND^sKang^nHY#^rND^sWon^nYD#et al#Reactivity of sera from cases of Plas
modium vivax malaria towards three recombinant antigens based on the surface pro
teins of the parasite^len#Ann Trop Med Parasitol#20030000#2003#97#5#481-7#201102
00#v33n1a16.htm#0003-4983#Ann Trop Med Parasitol##
00589000000000289000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100017000820100017000990120
10500116030000900221065000900230064000500239031000400244032000200248014000800250
865000900258002001300267035001000280801000900290#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a16.htm#S#c#467#110#article#120#110#^rND^sPolley^nSD#^rND^sConway
^nDJ#Strong diversifying selection on domains of the Plasmodium falciparum apica
l membrane antigen 1 gene^len#Genetics#20010000#2001#158#4#1505-12#20110200#v33n
1a16.htm#0016-6731#Genetics##
00734000000000349000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100016000820100020000980100
01700118010001800135010001400153010001800167810000600185012010900191030001200300
06500090031206400050032103100040032603200030033001400070033386500090034000200130
0349035001000362801001200372#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#468#111#article#120#111#^rND^sSilvie^nO#^rND^sFranetich^nJF#^rND^sCharrin
^nS#^rND^sMueller^nMS#^rND^sSiau^nA#^rND^sBodescot^nM#et al#A role for apical me
mbrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozo
ites^len#J Biol Chem#20040000#2004#279#10#9490-6#20110200#v33n1a16.htm#0021-9258
#J Biol Chem##
00693000000000313000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100013000820100014000950100
01400109010001400123012014700137030001900284065000900303064000500312031000300317
032000200320014000600322865000900328002001300337035001000350801001900360#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#469#112#article#120#112#^rND^
sKim^nS#^rND^sAhn^nHJ#^rND^sKim^nTS#^rND^sNam^nHW#ELISA detection of vivax malar
ia with recombinant multiple stage-specific antigens and its application to surv
ey of residents in endemic areas^len#Korean J Parasitol#20030000#2003#41#4#203-7
#20110200#v33n1a16.htm#0023-4001#Korean J Parasitol##
00755000000000349000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100020000820100020001020100
01900122010001700141010002000158010001700178810000600195012011400201030001600315
06500090033106400050034003100030034503200020034801400070035086500090035700200130
0366035001000379801001600389#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#470#113#article#120#113#^rND^sRodrigues^nMH#^rND^sRodrigues^nKM#^rND^sOli
veira^nTR#^rND^sCômodo^nAN#^rND^sRodrigues^nMM#^rND^sKocken^nCH#et al#Antibody r
esponse of naturally infected individuals to recombinant Plasmodium vivax apical
 membrane antigen-1^len#Int J Parasitol#20050000#2005#35#2#185-92#20110200#v33n1
a16.htm#0020-7519#Int J Parasitol##
00743000000000337000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100017000820100017000990100
01900116010001700135010001800152010001600170012012600186030001800312065000900330
06400050033903100030034403200020034701400060034986500090035500200130036403500100
0377801001800387#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#471#1
14#article#120#114#^rND^sMorais^nCG#^rND^sSoares^nIS#^rND^sCarvalho^nLH#^rND^sFo
ntes^nCJ#^rND^sKrettli^nAU#^rND^sBraga^nEM#Antibodies to Plasmodium vivax apical
 membrane antigen 1: persistence and correlation with malaria transmission inten
sity^len#Am J Trop Med Hyg#20060000#2006#75#4#582-7#20110200#v33n1a16.htm#0002-9
637#Am J Trop Med Hyg##
00777000000000349000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100017000820100016000990100
01500115010001500130010001700145010001600162810000600178012014100184030002200325
06500090034706400050035603100040036103200020036501400060036786500090037300200130
0382035001000395801002200405#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.h
tm#S#c#472#115#article#120#115#^rND^sFigtree^nM#^rND^sPasay^nCJ#^rND^sSlade^nR#^
rND^sCheng^nQ#^rND^sCloonan^nN#^rND^sWalker^nJ#et al#Plasmodium vivax synonymous
 substitution frequencies, evolution and population structure deduced from diver
sity in AMA 1 and MSP 1 genes^len#Mol Biochem Parasitol#20000000#2000#108#1#53-6
6#20110200#v33n1a16.htm#0166-6851#Mol Biochem Parasitol##
00703000000000337000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100014000820100015000960100
01500111010001500126010001300141010001500154012010000169030001900269065000900288
06400050029703100030030203200020030501400070030786500090031400200130032303500100
0336801001900346#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S#c#473#1
16#article#120#116#^rND^sHan^nET#^rND^sPark^nJH#^rND^sShin^nEH#^rND^sChoi^nMH#^r
ND^sOh^nMD#^rND^sChai^nJY#Apical membrane antigen-1 (AMA-1) gene sequences of re
-emerging Plasmodium vivax in South Korea^len#Korean J Parasitol#20020000#2002#4
0#3#157-62#20110200#v33n1a16.htm#0023-4001#Korean J Parasitol##
00498000000000265000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100020000820120062001020300
01700164710000200181065000900183064000500192031000300197032000300200014000700203
865000900210002001300219#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a16.htm#S
#c#474#117#article#120#117#^rND^sGreenwood^nBM#Control to elimination: implicati
ons for malaria research^len#Trends Parasitol#2#20080000#2008#24#10#449-54#20110
200#v33n1a16.htm##
00531000000000289000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100015000820120029000970300
00700126065000900133064000500142031000400147032000500151014000700156061003900163
865000900202002001300211035001000224801000700234#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a16.htm#S#c#475#118#article#120#118#^rND^sMaher^nB#The end of the
 beginning^len#Nature#20080000#2008#451#7182#1042-6#Comment in: Nature. 2008;452
(7189):810#20110200#v33n1a16.htm#0028-0836#Nature##
00912000000000433000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100019000820100013001010100
01900114010001800133010002500151010001500176010001500191010002000206010001700226
01000170024301000230026001000160028301000160029901000170031501000170033201200720
03490300012004217100002004330650009004350640005004440310002004490320002004510200
00300453865000900456002001300465#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a
16.htm#S#c#476#119#article#120#119#^rND^sMcIntosh^nRS#^rND^sShi^nJ#^rND^sJenning
s^nRM#^rND^sChappel^nJC#^rND^sde Koning-Ward^nTF#^rND^sSmith^nT#^rND^sGreen^nJ#^
rND^svan Egmond^nM#^rND^sLeusen^nJH#^rND^sLazarou^nM#^rND^svan de Winkel^nJ#^rND
^sJones^nTS#^rND^sCrabb^nBS#^rND^sHolder^nAA#^rND^sPleass^nRJ#The importance of 
human FcgammaRI in mediating protectionto malaria^len#PLoS Pathog#2#20070000#200
7#3#5#72#20110200#v33n1a16.htm##
00522000000000277000450000400060000070200480000670500020005470600020005670000040
00587010004000627090008000667080004000741180004000780100015000820100016000970120
06500113030001700178710000200195065000900197064000500206031000300211032000200214
014000600216865000900222002001300231#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a16.htm#S#c#477#120#article#120#120#^rND^sHviid^nL#^rND^sBarfod^nL#Malaria va
ccines: immunity, models and monoclonal antibodies^len#Trends Parasitol#2#200800
00#2008#24#9#392-5#20110200#v33n1a16.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#o#1#1#article#1
#20110411#115604#v33n1a17.htm#253##
02375000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120194002020100033003960100043004290100042004720100037005140700100005510700
08100651070006100732083055400793085001001347085007501357085002801432085003801460
08500460149808500410154408500590158508500230164408500220166711700060168907200030
1695112000901698111001001707114000901717113001001726002001301736#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#h#2#1#article#1#ra#en#br1.1#1#4.0#ILUS#
TAB#17#RBHH350#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f65^l72#1516-8484#
10.5581/1516-8484.20110017#Importance of monitoring and early switch to second g
eneration tyrosine kinase inhibitors for the prognosis of patients with chronic 
myeloid leukemia with imatinib resistance or intolerance^len#^rND^1A01^nBelinda 
Pinto^sSimões#^rND^1A02^nJosé Wilson Ramos^sBraga Junior#^rND^1A02^nMaria Aparec
ida do Carmo^sRego#^rND^1A03^nCármino Antônio de^sSouza#Universidade de São Paul
o^iA01^1Faculdade de Medicina de Ribeirão Preto^cRibeirão Preto^sSP^pBrazil#Bris
tol-Myers Squibb^iA02^1Departamento de Oncologia^cRio de Janeiro^sRJ^pBrazil#Uni
versidade Estadual de Campinas^iA03^cCampinas^sSP^pBrazil#^len^aImatinib mesylat
e was the first BCR-ABL-target agent approved for the treatment of chronic myelo
id leukemia. Although most patients respond well to imatinib therapy, the litera
ture shows that one third develops resistance or intolerance. The timing of seco
nd-line treatment after failure of initial treatment may have a significant impa
ct on long-term outcome. Thus, appropriate monitoring to identify resistance and
/or intolerance is crucial to early intervention with second generation tyrosine
 kinase inhibitors and attainment of better results#^ddecs^i1#^tm^len^kLeukemia,
 myelogenous, chronic, BCR-ABL positive^i1^sdrug therapy#^tm^len^kDrug resistanc
e^i1#^tm^len^kDrug monitoring, neoplasm^i1#^tm^len^kReceptor Protein-Tyrosine Ki
nases^i1#^tm^len^kPyrimidines^i1^stherapeutic use#^tm^len^kAntineoplastic agents
^i1^sadministration & dosage#^tm^len^kMonitoring^i1#^tm^len^kPrognosis^i1#other#
51#20100427#4/27/2010#20100924#9/24/2010#v33n1a17.htm##
02382000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000290011303100030014203200020014506500090014701400090015603500100016523700270
01750120201002020100033004030100043004360100042004790100037005210700100005580700
08100658070006100739083055400800085001001354085007501364085002801439085003801467
08500460150508500410155108500590159208500230165108500220167411700060169607200030
1702112000901705111001001714114000901724113001001733002001301743#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#f#3#1#article#1#ra#en#br1.1#1#4.0#ILUS#
TAB#17#RBHH350#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f65^l72#1516-8484#
10.5581/1516-8484.20110017#<b>Importance of monitoring and early switch to secon
d generation tyrosine kinase inhibitors for the prognosis of patients with chron
ic myeloid leukemia with imatinib resistance or intolerance</b>^len#^rND^1A01^nB
elinda Pinto^sSimões#^rND^1A02^nJosé Wilson Ramos^sBraga Junior#^rND^1A02^nMaria
 Aparecida do Carmo^sRego#^rND^1A03^nCármino Antônio de^sSouza#Universidade de S
ão Paulo^iA01^1Faculdade de Medicina de Ribeirão Preto^cRibeirão Preto^sSP^pBraz
il#Bristol-Myers Squibb^iA02^1Departamento de Oncologia^cRio de Janeiro^sRJ^pBra
zil#Universidade Estadual de Campinas^iA03^cCampinas^sSP^pBrazil#^len^aImatinib 
mesylate was the first BCR-ABL-target agent approved for the treatment of chroni
c myeloid leukemia. Although most patients respond well to imatinib therapy, the
 literature shows that one third develops resistance or intolerance. The timing 
of second-line treatment after failure of initial treatment may have a significa
nt impact on long-term outcome. Thus, appropriate monitoring to identify resista
nce and/or intolerance is crucial to early intervention with second generation t
yrosine kinase inhibitors and attainment of better results#^ddecs^i1#^tm^len^kLe
ukemia, myelogenous, chronic, BCR-ABL positive^i1^sdrug therapy#^tm^len^kDrug re
sistance^i1#^tm^len^kDrug monitoring, neoplasm^i1#^tm^len^kReceptor Protein-Tyro
sine Kinases^i1#^tm^len^kPyrimidines^i1^stherapeutic use#^tm^len^kAntineoplastic
 agents^i1^sadministration & dosage#^tm^len^kMonitoring^i1#^tm^len^kPrognosis^i1
#other#51#20100427#4/27/2010#20100924#9/24/2010#v33n1a17.htm##
02506000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103038000400108121000300112049000800115
15800030012303000280012603100030015403200020015706500090015901400090016803500100
01772370027001870120194002140100033004080100043004410100042004840100037005260700
10200563070008300665070006300748083055400811085001001365085007501375085002801450
08500380147808500460151608500410156208500590160308500230166208500220168511700060
17070720003017131120009017161110010017251140009017351130010017440020013017540080
08901767#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#l#4#1#article#1
#^mFeb.^a2011#ra#en#br1.1#1#4.0#ilus#tab#17#RBHH350#nd#Rev. bras. hematol. hemot
er#33#1#20110200#^f65^l72#1516-8484#10.5581/1516-8484.20110017#Importance of mon
itoring and early switch to second generation tyrosine kinase inhibitors for the
 prognosis of patients with chronic myeloid leukemia with imatinib resistance or
 intolerance^len#^rND^1A01^nBelinda Pinto^sSimões#^rND^1A02^nJosé Wilson Ramos^s
Braga Junior#^rND^1A02^nMaria Aparecida do Carmo^sRego#^rND^1A03^nCármino Antôni
o de^sSouza#^iA01^1Universidade de São Paulo^2Faculdade de Medicina de Ribeirão 
Preto^cRibeirão Preto^sSP^pBrazil#^iA02^1Bristol-Myers Squibb^2Departamento de O
ncologia^cRio de Janeiro^sRJ^pBrazil#^iA03^1Universidade Estadual de Campinas^cC
ampinas^sSP^pBrazil#^len^aImatinib mesylate was the first BCR-ABL-target agent a
pproved for the treatment of chronic myeloid leukemia. Although most patients re
spond well to imatinib therapy, the literature shows that one third develops res
istance or intolerance. The timing of second-line treatment after failure of ini
tial treatment may have a significant impact on long-term outcome. Thus, appropr
iate monitoring to identify resistance and/or intolerance is crucial to early in
tervention with second generation tyrosine kinase inhibitors and attainment of b
etter results#^ddecs^i1#^tm^len^kLeukemia, myelogenous, chronic, BCR-ABL positiv
e^i1^sdrug therapy#^tm^len^kDrug resistance^i1#^tm^len^kDrug monitoring, neoplas
m^i1#^tm^len^kReceptor Protein-Tyrosine Kinases^i1#^tm^len^kPyrimidines^i1^sther
apeutic use#^tm^len^kAntineoplastic agents^i1^sadministration & dosage#^tm^len^k
Monitoring^i1#^tm^len^kPrognosis^i1#other#51#20100427#4/27/2010#20100924#9/24/20
10#v33n1a17.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid
=S1516-84842011000100017##
00352000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704011900074002001300193#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#5#1#article#198#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>REVIEW ARTICLES</b></
font></p>     ^cY#v33n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#6#2#article#198#<p>&nbsp;</p>     ^cY
#v33n1a17.htm##
00530000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704029700074002001300371#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#7#3#article#198#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Importance of mon
itoring and early switch to second generation tyrosine kinase inhibitors for the
 prognosis of patients with chronic myeloid leukemia with imatinib resistance or
 intolerance</b></font></p>     ^cY#v33n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#8#4#article#198#<p>&nbsp;</p>     ^cY
#v33n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#9#5#article#198#<p>&nbsp;</p>     ^cY
#v33n1a17.htm##
00499000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704026500075002001300340#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#10#6#article#198#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Belinda Pinto Sim&otilde;es<sup>I<
/sup>; Jos&eacute; Wilson Ramos Braga Junior<sup>II</sup>; Maria Aparecida do Ca
rmo Rego<sup>II</sup>; Cármino Antônio de Souza<sup>III</sup></b></font></p>    
 ^cY#v33n1a17.htm##
00438000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020400075002001300279#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#11#7#article#198#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Faculdade de Medicina de 
Ribeir&atilde;o Preto, Universidade de S&atilde;o Paulo  USP, Ribeir&atilde;o Pr
eto (SP), Brazil    ^cY#v33n1a17.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#12#8#article#198#<br>   <sup>II</sup>
Departamento de Oncologia, Bristol-Myers Squibb, Rio de Janeiro (RJ), Brazil    
^cY#v33n1a17.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#13#9#article#198#<br>   <sup>III</sup
>Universidade Estadual de Campinas  Unicamp, Campinas (SP), Brazil</font></p>   
  ^cY#v33n1a17.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#14#10#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></fo
nt></p>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#15#11#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#16#12#article#198#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v33n1a17.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#17#13#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
33n1a17.htm##
00866000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063100076002001300707#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#18#14#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Imatinib mesylate was the first BCR-
ABL-target agent approved for the treatment of chronic myeloid leukemia. Althoug
h most patients respond well to imatinib therapy, the literature shows that one 
third develops resistance or intolerance. The timing of second-line treatment af
ter failure of initial treatment may have a significant impact on long-term outc
ome. Thus, appropriate monitoring to identify resistance and/or intolerance is c
rucial to early intervention with second generation tyrosine kinase inhibitors a
nd attainment of better results.</font></p>     ^cY#v33n1a17.htm##
00602000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036700076002001300443#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#19#15#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Leukemia, myelogeno
us, chronic, BCR-ABL positive/drug therapy; Drug resistance; Drug monitoring, ne
oplasm; Receptor Protein-Tyrosine Kinases; Pyrimidines/therapeutic use;  Antineo
plastic agents/administration &amp; dosage;  Monitoring; Prognosis</font></p> <h
r size="1" noshade>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#20#16#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#21#17#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#22#18#article#198#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></p>     ^
cY#v33n1a17.htm##
00842000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060700076002001300683#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#23#19#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Chronic Myeloid Leukemia (CML) is a 
clonal hematological disease associated with a reciprocal chromosomal translocat
ion between chromosomes 9 and 22, resulting in the Philadelphia (Ph) chromosome.
<sup>(1)</sup> This gene fusion codes for a chimeric protein, BCR-ABL, which is 
associated with the uncontrolled activity of ABL tyrosine kinase (TK). <sup>(1)<
/sup> The Ph chromosome is detected in 95% of patients with CML.<sup>(2)</sup> T
he estimated incidence of CML is 1 to 2 cases per 100,000 people per year.<sup>(
3)</sup></font></p>     ^cY#v33n1a17.htm##
01093000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085800076002001300934#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#24#20#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The International Randomized Study o
f Interferon <i>versus</i> STI-571 (IRIS) study established the superiority of i
matinib, an ABL kinase inhibitor, over the interferon-alpha and cytarabine combi
nation in terms of hematologic response (HR), cytogenetic response (CyR) and mol
ecular response (MolR).<sup>(4,5)</sup> Since then, imatinib is the first-line t
reatment of choice for CML. The intent-to-treat analysis of the IRIS study showe
d an accumulated incidence of complete cytogenetic response (CCyR) of 82.7%, eve
nt-free survival (EFS) of 81.3% and overall survival (OS) of 83.2% over 60 month
s.<sup>(6)</sup> Patients who reached a CyR and a MolR during treatment showed a
 longer EFS and protection against progression to the advanced phases of the dis
ease.<sup>(7)</sup></font></p>     ^cY#v33n1a17.htm##
01183000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704094800076002001301024#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#25#21#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">After seven years of follow-up of th
e IRIS study, 40% of patients were found to have discontinued the treatment, and
 adverse events accounted for 5% of the cases, lack of efficacy for 15%, undergo
ing bone marrow transplant for 3%, death for 2% and the remaining 15% withdrew f
or other reasons (protocol violation, consented withdrawal or non-renewal, lost 
to follow-up).<sup>(8)</sup> A similar result was observed during follow-up of p
atients with CML on imatinib outside a clinical trial, by the Hammersmith Hospit
al (De Lavallade) group. After five years of follow-up, the EFS was 62.7%, imati
nib was then suspended for nearly 40% of the patients. The definition of event f
or this study was death for any cause, loss of hematologic response or major cyt
ogenetic response, white blood cell increase, absence of major cytogenetic respo
nse and imatinib intolerance.</font></p>     ^cY#v33n1a17.htm##
01288000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704105300076002001301129#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#26#22#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Imatinib resistance is generally due
 to the appearance of clones expressing mutated forms of BCR-ABL, in which the a
mino acid replacements in the ABL kinase domain prevent imatinib binding but sus
tain kinase activity.<sup>(9-11)</sup> In the IRIS study, the accumulated mutati
on rate over five years was 8.6% (95% CI: 4.5% to 15.8%).<sup>(6)</sup> Recent s
tudies suggest that these mutations occur in 40% of patients with imatinib failu
re.<sup>(9,10,12) </sup>Soverini et al.<sup>(13)</sup> evaluated the frequency o
f mutations in 297 patients with hematologic or cytogenetic resistance to imatin
ib. Mutations were observed in 127 (43%) patients; 27% during the chronic phase,
 52% during the accelerated phase, 75% during myeloid blast crisis, and 83% duri
ng lymphoid blast crisis/Ph-positive ALL. Jabbour et al. evaluated the frequency
 of mutations in 171 patients after imatinib treatment failure with 66 mutations
 being identified in 62 (36%) patients.<sup>(14)</sup></font></p>     ^cY#v33n1a
17.htm##
00884000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064900076002001300725#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#27#23#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Mascarenhas et al. correlated the pr
esence of mutations with OS in 93 imatinib resistant patients. A mutation was de
tected in 25% of patients. The OS over 30 months was 87% for patients without mu
tations and 56% for the mutation group (RR = 68; p &lt; 0.0001). Due to the asso
ciation of some mutations and imatinib resistance, it is clear that approximatel
y 30-40% of patients will eventually need a more effective treatment. Early dete
ction of the presence of mutated clones may help the therapeutic decision and th
e choice of alternative treatments.<sup>(15)</sup></font></p>     ^cY#v33n1a17.h
tm##
00901000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066600076002001300742#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#28#24#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Dasatinib is an ABL kinase activity 
inhibitor which is different from imatinib as it binds  to both to the active an
d inactive conformation in the ABL domain, in addition to inhibiting other kinas
es, such as the Src family (Src, Lck, Yes, Fyn), ckit, EphA2 and PDGPR-&#223;, p
roviding lasting responses in patients with and without BCR-ABL mutations.<sup>(
16)</sup> Dasatinib was evaluated in clinical trials (Phase I, II and III) in ad
ults with Ph-positive leukemias after imatinib failure or intolerance and showed
 effectiveness in the chronic, accelerated and blast phases of CML.</font></p>  
   ^cY#v33n1a17.htm##
00439000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020400076002001300280#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#29#25#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Dasatinib has been approved by the F
DA since 2006 for CML treatment during the three phases and also for Ph-positive
 ALL.</font></p>     ^cY#v33n1a17.htm##
00625000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039000076002001300466#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#30#26#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Nilotinib is a BCR-ABL kinase, c-KIT
, platelet-derived growth factor receptor (PDGFR) and ephrin receptor inhibitor.
<sup>(17)</sup> It proved to be 43 to 60 times more potent than imatinib in cell
 lines. Similar to imatinib and dasatinib, nilotinib showed no activity against 
T315L mutations.<sup>(18)</sup></font></p>     ^cY#v33n1a17.htm##
00601000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036600076002001300442#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#31#27#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As imatinib, nilotinib only binds to
 the BCR-ABL inactive conformation and does not inhibit Src kinases.<sup>(18)</s
up> Nilotinib has been approved by the FDA in the treatment of patients with chr
onic or accelerated phase CML, who are imatinib intolerant or resistant.<sup>(17
)</sup></font></p>     ^cY#v33n1a17.htm##
00704000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046900076002001300545#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#32#28#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Unlike dasatinib, bosutinib does not
 inhibit PDGFR and c-kit.<sup>(19)</sup> It may bind both to inactive and interm
ediate BCR-ABL conformations, but it does not show activity against T315L mutati
ons.<sup>(19)</sup> In Phase II studies it has also demonstrated activity in pat
ients with accelerated and blast phase CML, previously treated with imatinib and
 other TKIs.<sup>(20,21)</sup></font></p>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#33#29#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#34#30#article#198#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Monitoring CML treatment</b></fon
t></p>     ^cY#v33n1a17.htm##
00778000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054300076002001300619#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#35#31#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Since imatinib was introduced, it is
 clear that the appropriate monitoring of the treatment response is an essential
 and relevant part of the therapeutic strategy.<sup>(22)</sup> The objectives of
 monitoring minimal residual disease in CML include: to demonstrate the efficacy
 of the initial treatment, to detect treatment relapse or resistance and to iden
tify the mechanisms of treatment failure to help in the choice of alternative tr
eatments.<sup>(23)</sup></font></p>     ^cY#v33n1a17.htm##
00724000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048900076002001300565#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#36#32#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The initial evaluation before the st
art of the treatment must include the calculation of the prognosis rates using t
he  Sokal<sup>(24,25)</sup> or Hasford Score<sup>(26)</sup> methods and demonstr
ated in <a href="#tab1">Tables 1</a> and <a href="#tab2">2</a>. Despite having b
een described in the pre-imatinib era, they maintain an important prognostic rol
e, even with the use of imatinib.<sup>(4,25)</sup></font></p>     ^cY#v33n1a17.h
tm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#37#33#article#198#<p><a name="tab1"><
/a></p>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#38#34#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#39#35#article#198#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a17tab01.jpg"></p>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#40#36#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#41#37#article#198#<p><a name="tab2"><
/a></p>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#42#38#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#43#39#article#198#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a17tab02.jpg"></p>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#44#40#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
01392000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704115700076002001301233#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#45#41#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">After treatment starts, for the eval
uation of imatinib response it is required that complete blood counts with diffe
rential, cytogenetic and molecular examinations be performed to evaluate the BCR
-ABL transcript level. Monitoring of the percentage of Ph-positive cells is the 
best validated system to evaluate the response to interferon-alpha and TKIs, as 
cytogenetic response is the best survival marker.<sup>(4) </sup>Thus, cytogeneti
c response remains the gold standard to evaluate CML response.<sup>(23)</sup> No
twithstanding, most sites perform the evaluation through molecular analysis to m
onitor treatment response in addition to cytogenetic evaluation.<sup>(27-29) </s
up>Reaching a major molecular response (MMolR) after 12 months of imatinib treat
ment has been associated with a longer progression-free survival (PFS).<sup>(5,7
)</sup> In general, the use of molecular studies to detect mutations has been re
commended only if there is evidence of hematologic, cytogenetic relapse or resis
tance and a 2- to 5-fold increase in BCR-ABL transcript levels.<sup>(23)</sup></
font></p>     ^cY#v33n1a17.htm##
00601000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036600076002001300442#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#46#42#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The European LeukemiaNet (ELN) updat
ed the recommendations published in 2006 in order to optimize and standardize CM
L management.<sup>(30)</sup> The response definitions according to the ELN are p
resented in <a href="/img/revistas/rbhh/v33n1/a17tab03.jpg">Table 3</a>.<sup>(30
)</sup></font></p>     ^cY#v33n1a17.htm##
00678000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044300076002001300519#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#47#43#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The ELN recommendations for imatinib
 response monitoring are presented in <a href="/img/revistas/rbhh/v33n1/a17tab04
.jpg">Table 4</a>.<sup>(30)</sup> Based on HR, CyR, and MolR and time to respons
e, imatinib overall response can be defined as: optimal, suboptimal and absence 
of response as shown in <a href="/img/revistas/rbhh/v33n1/a17tab05.jpg">Table 5<
/a>.</font></p>     ^cY#v33n1a17.htm##
00785000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055000076002001300626#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#48#44#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The recommendations further include 
some alert situations. Optimal response means that switching medication will not
 increase survival, which is anticipated at 100% after six to seven years of tre
atment.<sup>(30)</sup> Suboptimal response means the patient will still receive 
further benefit from the continued treatment, but the chances of optimal respons
e are reduced. Treatment failure suggests switching the approach, as the chances
 of favorable outcomes are low.</font></p>     ^cY#v33n1a17.htm##
01019000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704078400076002001300860#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#49#45#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Regarding previous recommendations,<
sup>(29)</sup> a new definition for optimal response has been introduced. In cas
e some type of cytogenetic response does not occur at three months (introducing,
 therefore, bone marrow puncture at this point, differing from 2006 recommendati
ons), we consider it a suboptimal response. In case there is no complete hematol
ogic response at three months, we refer to it as failure, as well as in case no 
cytogenetic response is achieved at six months. Clonal progression during treatm
ent was defined as treatment failure. The deletion of the long arm of chromosome
 9, considered in previous works as an alert signal, is no longer considered a c
ause for special concern.</font></p>     ^cY#v33n1a17.htm##
00584000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034900076002001300425#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#50#46#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There is evidence in the literature 
claiming that early introduction of treatment with a second generation TKI, such
 as dasatinib, improves CML prognosis, making adequate monitoring of patients us
ing first-line medication, such as imatinib, imperative.<sup>(31</sup></font></p
>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#51#47#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013100076002001300207#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#52#48#article#198#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Importance of early response in p
rognosis</b></font></p>     ^cY#v33n1a17.htm##
00682000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044700076002001300523#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#53#49#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Imatinib response is the most import
ant prognostic factor to achieve prolonged survival in CML.<sup>(7,32) </sup>The
 response grade achieved during treatment is also an important prognostic factor
. <sup>(32) </sup>The 5-year follow-up of the IRIS study showed longer PFS for p
atients who achieved a CCyR compared to the ones who achieved only a PCyR.<sup>(
7)</sup></font></p>     ^cY#v33n1a17.htm##
00912000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067700076002001300753#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#54#50#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Sixty-nine percent of patients with 
early chronic phase CML are known to achieve a CCyR after 12 months of imatinib 
treatment.<sup>(4) </sup>With continued treatment, only a fraction (13%) may sti
ll achieve this response.<sup>(7)</sup> It is controversial whether achieving an
 early or delayed complete cytogenetic response is directly related to disease p
rogression. Some recent analyses suggest that the risk of disease progression am
ong patients who achieve a CCyR during the first 12 months of imatinib treatment
 is similar to that of those who achieve this response later.<sup>(7,33)</sup></
font></p>     ^cY#v33n1a17.htm##
01809000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704157400076002001301650#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#55#51#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">However, other studies suggest early
 responses predict a better prognosis.<sup>(4,34) </sup>In a retrospective analy
sis, Quint&aacute;s-Cardama et al.<sup>(32)</sup> evaluated 258 patients with ch
ronic phase CML regarding the probability of achieving a CCyR, a major molecular
 response (MMolR) and progression at three, six, and 12 months after imatinib wa
s started. The initial dose of imatinib was 800 mg/day in 208 patients and 400 m
g/day in 50 patients. The probability of achieving a CCyR or MMolR decreased sig
nificantly over time for patients who did not achieve a CCyR at three months, si
x months and 12 months, while the progression risk increased at each assessment 
period. Thus, a patient who did not achieve a CCyR at six months still had a 57%
 probability of achieving this response and a 34% probability of having an event
 (defined as evolution to more advanced phases, loss of response and death). For
 patients who did not achieve a CCyR up to 12 months, the probability of still a
chieving this response eventually dropped to 42%, and the risk of events increas
ed to 38%. The authors suggest that failure to achieve a CCyR within the first 1
2 months of imatinib treatment is associated with higher disease progression rat
es. The same result was seen when the molecular response was used as response pa
rameter. Thus, the authors claim that the evaluation already at three months may
 guide the rational use of therapeutic strategies able to provide higher rates o
f CyR and MolR.</font></p>     ^cY#v33n1a17.htm##
00759000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052400076002001300600#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#56#52#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Marin et al. evaluated 224 patients 
with chronic phase CML treated with imatinib regarding response and prognosis in
 order to validate the 2006 ELN recommendations.<sup>(35)</sup> For the few pati
ents who did not achieve a CHR after three months of treatment, the probability 
of achieving a CCyR was zero (p=0.0003); OS over five years was 60% (p=0.003) an
d PFS was 56% (p=0.002), thus significantly lower than those who had achieved a 
CCyR.</font></p>     ^cY#v33n1a17.htm##
01215000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704098000076002001301056#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#57#53#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The introduction of cytogenetic anal
ysis at three months is based on the data that patients who remain without a cyt
ogenetic response at three months have a lower probability of achieving a CCyR w
ith continued treatment.<sup>(6,29)</sup> Other retrospective analyses have show
n that patients who did not achieve any cytogenetic response at six months (Ph+ 
&gt;95%) have a low probability of achieving a CCyR (25%) or a CMolR, (12%) and 
are, therefore, considered treatment failure.<sup>(6,36)</sup> In addition, pati
ents who achieved a CCyR at six months present higher PFS and EFS than those wit
h a delayed response.<sup>(37,38)</sup> The advantage of achieving a complete cy
togenetic remission at 12 months was also evidenced in terms of OS and PFS,<sup>
(6,7)</sup> as well as at 18 months (CCyR <i>versus</i> PCyR, 99% <i>versus</i> 
87% and 98% <i>versus</i> 76%, respectively).<sup>(6,7)</sup></font></p>     ^cY
#v33n1a17.htm##
00609000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037400076002001300450#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#58#54#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">These results suggest the early iden
tification of high risk patients is fundamental for a better therapeutic plannin
g, such as switching to second generation TKIs. The data are clearer when cytoge
netic response is considered, differently from the data where molecular response
 is considered.</font></p>     ^cY#v33n1a17.htm##
00895000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066000076002001300736#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#59#55#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Cortes et al.  evaluated 280 patient
s who achieved a CCyR on imatinib, including 117 after interferon-alpha failure 
and 163 treatment-na&iuml;ve patients. Patients who did not achieve a MMolR with
in 12 months of treatment had a higher chance of losing CyR than those who achie
ved it (37% <i>versus</i> 5%; p=0.0001). Patients who achieved a decrease of <u>
&lt;</u>1-log after three months of treatment had a lower probability of achievi
ng a MMolR at 24 months compared to those who had a decrease higher than 1-log o
r 2-log (84% and 95%, respectively. P=0.0002).<sup>(34)</sup></font></p>     ^cY
#v33n1a17.htm##
01246000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101100076002001301087#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#60#56#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Iacobucci et al. conducted a retrosp
ective trial of 284 patients with late chronic phase CML treated with imatinib 4
00 mg daily after interferon-alpha failure. The pattern and time to imatinib res
ponse were evaluated, comparing CyR and MolR, PFS and OS in patients who achieve
d a CCyR within one year of treatment (early responders) and in patients with a 
CCyR detected after 12 months (late responders). After three to four years of fo
llow-up, patients who had a delayed CyR presented a MolR rate that was similar t
o that of those who had had an early CyR. No difference was seen in the measure 
of residual disease through quantitative PCR at 36 months and at 48 months among
 the groups. Estimated PFS at 4 years was 88% for early responders and 100% for 
late responders, while the estimated OS was 92% and 100%, respectively. The auth
ors suggest that at least 12 months are required to assess imatinib response.<su
p>(33)</sup></font></p>     ^cY#v33n1a17.htm##
00675000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044000076002001300516#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#61#57#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A study with 120 patients with chron
ic phase CML after interferon-alpha failure assessed whether early MolR (at one 
and two months) measured by real time PCR could predict or not the CyR at six mo
nths.<sup>(39)</sup> The authors concluded that a BCR-ABL/ABL ratio &lt; 20% aft
er two months of imatinib treatment was correlated to CyR at 6 months (p=0.0008)
.</font></p>     ^cY#v33n1a17.htm##
00839000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060400076002001300680#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#62#58#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">From the studies referenced, we obse
rved that the exact value of MolR is more difficult to evaluate.<sup>(30) </sup>
The first analysis of the IRIS study showed that achieving a CMolR at 12 months 
of treatment predicted a higher PFS.<sup>(5)</sup> However, this difference beca
me borderline in the subsequent analysis (100% <i>versus</i> 98%; p=0.11).<sup>(
7) </sup>Patients who did not achieve a MolR during treatment are at a higher ri
sk of losing CyR and developing resistance to imatinib and other TKIs.<sup>(40)<
/sup></font></p>     ^cY#v33n1a17.htm##
00533000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029800076002001300374#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#63#59#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Thus, the prognostic value of MMolR 
is still controversial, although there is a consensus that not achieving a MMolR
 and the increase in BCR-ABL transcript levels require more careful monitoring.<
sup>(6,29,37)</sup></font></p>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#64#60#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00363000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012800076002001300204#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#65#61#article#198#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>When to start a second generation
 TKI?</b></font></p>     ^cY#v33n1a17.htm##
00786000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055100076002001300627#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#66#62#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Quint&aacute;s-Cardama et al.<sup>(3
1) </sup>evaluated 293 patients with chronic phase CML and imatinib resistance a
s to whether early intervention (in cytogenetic recurrence) with dasatinib was s
uperior to delayed intervention (in hematologic recurrence). Out of 293 eligible
 patients, 151 patients had loss of major cytogenetic response (MCyR) (Group 1),
 33 patients had loss of MCyR and CHR (Group 2) and 109 patients had loss of CHR
 without loss of MCyR (Group 3).</font></p>     ^cY#v33n1a17.htm##
01341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704110600076002001301182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#67#63#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The results from dasatinib treatment
 may be observed on <a href="#tab6">Table 6</a>. Among the patients with loss of
 MCyR during imatinib treatment (Group 1, early intervention), 72% achieved CCyR
 with dasatinib, compared to 42% of those who had lost both responses, MCyR and 
CHR (Group 2, delayed intervention) and 26% of those who lost CHR without loss o
f previous MCyR (Group 3). The MMolR rate was higher (60%) in Group 1 compared t
o Groups 2 (29%) and 3 (26%). EFS at 24 months was also higher in the group give
n early intervention (89% in Group 1 <i>versus</i> 29% in Group 2 <i>versus</i> 
64% in Group 3). The transformation-free survival (TFS) for accelerated and blas
t phases at 24 months was 98% in Group 1 and 93% in Group 2, while the OS was 98
% and 93%, respectively. In Group 3, TFS at 24 months was 79% and OS was 86%. Th
e authors suggest regular monitoring of response during imatinib treatment is es
sential to identify recurrence through loss of MCyR without the occurrence of lo
ss of hematologic response.</font></p>     ^cY#v33n1a17.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#68#64#article#198#<p><a name="tab6"><
/a></p>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#69#65#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#70#66#article#198#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a17tab06.jpg"></p>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#71#67#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00708000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047300076002001300549#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#72#68#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Another important factor when decidi
ng whether to start a second generation TKI relates to mutations. The appearance
 of a mutation with an imatinib resistance profile is considered by the 2009 ELN
 definitions as failure and requires switching medications. Different mutations 
may confer distinct levels of resistance, depending on the location and their ef
fect on the kinase.<sup>(23)</sup></font></p>     ^cY#v33n1a17.htm##
01178000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704094300076002001301019#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#73#69#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Some imatinib resistance mechanisms 
may be overcome by dose escalation.<sup>(41,42)</sup> A retrospective analysis w
as carried out for IRIS study patients who underwent imatinib dose escalation fr
om 400 mg to 600 mg or 800 mg in the event of treatment failure or suboptimal re
sponse (ELN criteria) or according to the IRIS study criteria.<sup>(43)</sup> Th
ese criteria included: failure to achieve CHR at three months, failure to achiev
e at least a minor CyR at 12 months and loss of major CyR at any time point. Out
 of 533 patients initially randomized to receive imatinib in the IRIS study, 106
 (19%) patients had their dose escalated to 600 mg or 800 mg daily. In this stud
y, 67% to 86% of patients achieved or recovered a HR, and 38% to 42% a CyR withi
n up to 12 months after dose escalation, depending on the failure or suboptimal 
response criterion used.</font></p>     ^cY#v33n1a17.htm##
00495000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026000076002001300336#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#74#70#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The PFS for the accelerated or blast
 phase within three years was 89% and the OS was 84%. Other studies, however, su
ggest the escalation benefit is transient.<sup>(44, 45)</sup></font></p>     ^cY
#v33n1a17.htm##
00587000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035200076002001300428#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#75#71#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Some mutations are known to make the
 disease completely resistant to imatinib, for example, the T315l mutation. Thus
, in case other mutations are acquired, switching to a second generation TKI suc
h as dasatinib or nilotinib may yield superior results.<sup>(46-48)</sup></font>
</p>     ^cY#v33n1a17.htm##
01428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704119300076002001301269#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#76#72#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">START-R was a Phase II randomized tr
ial comparing dasatinib to high doses of imatinib with imatinib failure at a con
ventional dose.<sup>(48)</sup> Imatinib resistant patients with chronic phase CM
L at daily doses of 400 mg or 600 mg were randomized to receive dasatinib (140 m
g daily) or imatinib at a higher dose (800 mg). This trial enrolled 150 patients
 with a 2:1 randomization (101 received dasatinib and 49 received imatinib). The
 primary endpoint analyzed was the MCyR rate over 12 months and the secondary en
dpoints were the MCyR and CHR rates at any period before cross-over, duration of
 the MCyR and CHR and time to MCyR and CHR before cross-over. The endpoints were
 also evaluated after cross-over. The response rates are illustrated in <a href=
"/img/revistas/rbhh/v33n1/a17tab03.jpg">Table 3</a>. The mean time to treatment 
failure was longer for dasatinib, with an 84% decrease in relative risk (HR=0.16
; 95% CI=0.1 to 0.26; p&lt;0.001). Progression-free survival was also favorable 
towards dasatinib, with an 86% decrease in relative risk (HR=0.14; 95% CI=0.05 t
o 0.4; p&lt;0.001).<sup>(49)</sup></font></p>     ^cY#v33n1a17.htm##
00599000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036400076002001300440#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#77#73#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Kantarjian et al. published a phase 
II study with a                2-year follow-up, demonstrating that dasatinib su
stained higher responses (<a href="#tab7">Table 7</a>) compared to high doses of
 imatinib, in addition to longer progression-free survival (p=0.0012).<sup>(50)<
/sup></font></p>     ^cY#v33n1a17.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#78#74#article#198#<p><a name="tab7"><
/a></p>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#79#75#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#80#76#article#198#<p align="center"><
img src="/img/revistas/rbhh/v33n1/a17tab07.jpg"></p>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#81#77#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00789000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055400076002001300630#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#82#78#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Thus, an investigation of mutations 
in patients during progression is fundamental when planning the best therapeutic
 strategy. The presence of the T315l mutation confers resistance both to imatini
b and to second generation TKIs, such as dasatinib and nilotinib.<sup>(51)</sup>
 Although there is no head-to-head comparison of the efficacy of second generati
on agents, the identification of specific mutations could help towards the choic
e of best option.<sup>(30,51)</sup></font></p>     ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#83#79#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#84#80#article#198#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Conclusions</b></font></p>     ^c
Y#v33n1a17.htm##
00887000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065200076002001300728#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#85#81#article#198#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"> The introduction of TKIs had an imp
ortant impact on the prognosis of patients with CML over the last years. The ris
ing increase of effective therapeutic options justifies the need for adequate mo
nitoring, for the choice of the best second-line treatment option and its introd
uction at the most adequate time point. In the same manner that CML treatment ha
s been rapidly evolving, the concepts related to monitoring, including the avail
able techniques and the interpretation of their results, in addition to the best
 use of all this information, also evolve constantly.</font></p>     ^cY#v33n1a1
7.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#86#82#article#198#<p>&nbsp;</p>     ^
cY#v33n1a17.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#87#83#article#198#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY
#v33n1a17.htm##
00442000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019300078002001300271#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#88#84#article#198#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Sawyers CL. Chronic
 myeloid leukemia. N Engl J Med. 1999; 340(17):1330-40. Comment in: N Engl J Med
. 1999;341 (10):765.    ^cY#v33n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#89#85#article#198#</font></p>     ^cY
#v33n1a17.htm##
00497000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024800078002001300326#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#90#86#article#198#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Khoury HJ, Guilhot 
F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome
-positive leukemias: practical considerations. Cancer. 2009;115(7):1381-94.    ^
cY#v33n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#91#87#article#198#</font></p>     ^cY
#v33n1a17.htm##
00509000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026000078002001300338#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#92#88#article#198#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Redaelli A, Bell C,
 Casagrande J, Stephens J, Botteman M, Laskin B, et al. Clinical and epidemiolog
ic burden of chronic myelogenous leukemia. Expert Rev Anticancer Ther. 2004;4(1)
:85-96.    ^cY#v33n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#93#89#article#198#</font></p>     ^cY
#v33n1a17.htm##
00917000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704066800078002001300746#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#94#90#article#198#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. O'Brien SG, Guilhot
 F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, 
Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, 
Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef
 G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators. Imatinib compared wi
th interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic 
myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. Comment in: Curr Hematol 
Rep. 2004;3(1):37-8. N Engl J Med. 2003; 348(11): 1048-50. Clin Lab Haematol. 20
05;27(6):416-7.    ^cY#v33n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#95#91#article#198#</font></p>     ^cY
#v33n1a17.htm##
00750000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704050100078002001300579#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#96#92#article#198#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Hughes TP, Kaeda J,
 Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomis
sen IC, Goldman JM, Radich JP; International Randomised Study of Interferon vers
us STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib
 or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
 N Engl J Med. 2003; 349(15):1423-32. Comment in: N Engl J Med. 2003;349 (15): 1
399-401.    ^cY#v33n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#97#93#article#198#</font></p>     ^cY
#v33n1a17.htm##
00666000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704041700078002001300495#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#98#94#article#198#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. de Lavallade H, App
erley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly 
diagnosed patients with chronic myeloid leukemia: incidence of sustained respons
es in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358-63. Comment
 in: J Clin Oncol. 2008;26(20):3308-9. Comment in: J Clin Oncol. 2008;26(20):330
8-9.    ^cY#v33n1a17.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#99#95#article#198#</font></p>     ^cY
#v33n1a17.htm##
00896000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704064600079002001300725#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#100#96#article#198#7#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Druker BJ, Guilhot
 F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT,
 Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Roussel
ot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shephe
rd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccar
ani M, So C, Letvak L, Larson RA; IRIS Investigators. Five-year follow-up of pat
ients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23
):2408-17. Comment in: N Engl J Med. 2007;356(17):1780; author reply 1780.    ^c
Y#v33n1a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#101#97#article#198#</font></p>     ^c
Y#v33n1a17.htm##
00873000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704062300079002001300702#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#102#98#article#198#8#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Deininger M, edito
r. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow u
p: sustained survival and low risk for progression or events in patients with ne
wly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with im
atinib. Presented in:  51º ASH Annual Meeting and Exposition. New Orleans, La; 2
009 dec 5-8. &#91;abstract 1126&#93;. Available from: <a href="http://ash.confex
.com/ash/2009/webprogram/Paper23968.html" target="_blank">http://ash.confex.com/
ash/2009/webprogram/Paper23968.html</a></font></p>     ^cY#v33n1a17.htm##
00643000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704039300079002001300472#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#103#99#article#198#9#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Branford S, Rudzki
 Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations
 in patients with CML treated with imatinib is virtually always accompanied by c
linical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are
 associated with a poor prognosis. Blood. 2003;102(1):276-83.    ^cY#v33n1a17.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#104#100#article#198#</font></p>     ^
cY#v33n1a17.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023000081002001300311#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#105#101#article#198#10#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Hochhaus A, La 
Ros&eacute;e P. Imatinib therapy in chronic myelogenous leukemia: strategies to 
avoid and overcome resistance. Leukemia. 2004;18(8):1321-31.    ^cY#v33n1a17.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#106#102#article#198#</font></p>     ^
cY#v33n1a17.htm##
00690000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704043800081002001300519#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#107#103#article#198#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Branford S, Rud
zki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point muta
tions clustered within the adenosine triphosphate-binding region of BCR/ABL in p
atients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemi
a who develop imatinib (STI571) resistance. Blood. 2002;99(9): 3472-5. Comment i
n: Blood. 2002 ;100(3):1105.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#108#104#article#198#</font></p>     ^
cY#v33n1a17.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023400081002001300315#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#109#105#article#198#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Kantarjian HM, 
Giles F, Quint&aacute;s-Cardama A, Cortes J. Important therapeutic targets in ch
ronic myelogenous leukemia. Clin Cancer Res. 2007;13(4):1089-97.    ^cY#v33n1a17
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#110#106#article#198#</font></p>     ^
cY#v33n1a17.htm##
00827000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704057500081002001300656#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#111#107#article#198#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Soverini S, Col
arossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abr
uzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciol
o C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G; GIMEMA Working Party o
n Chronic Myeloid Leukemia. Contribution of ABL kinase domain mutations to imati
nib resistance in different subsets of Philadelphia-positive patients: by the GI
MEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006; 12(24):73
74-9.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#112#108#article#198#</font></p>     ^
cY#v33n1a17.htm##
00560000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030800081002001300389#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#113#109#article#198#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Jabbour E, Kant
arjian H, Jones D, Talpaz M, Bekele N, O'Brien S, et al. Frequency and clinical 
significance of BCR-ABL mutations in patients with chronic myeloid leukemia trea
ted with imatinib mesylate. Leukemia. 2006;20(10):1767-73.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#114#110#article#198#</font></p>     ^
cY#v33n1a17.htm##
00643000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704039100081002001300472#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#115#111#article#198#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Mascarenhas CC,
 Cunha AF, Miranda EC, Zulli R, Silveira RA, Costa FF, et al. New mutations dete
cted by denaturing high performance liquid chromatography during screening of ex
on 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with ty
rosine kinase inhibitors. Leuk Lymphoma. 2009;50 (7):1148-54.    ^cY#v33n1a17.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#116#112#article#198#</font></p>     ^
cY#v33n1a17.htm##
00640000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704038800081002001300469#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#117#113#article#198#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. M&uuml;ller MC,
 Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, et al. Dasatinib treatment o
f chronic-phase chronic myeloid leukemia: analysis of responses according to pre
existing BCR-ABL mutations. Blood. 2009;114(24):4944-53. Comment in: Blood. 2009
; 114(24):4914-5. Comment in: Blood. 2009; 114(24):4914-5.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#118#114#article#198#</font></p>     ^
cY#v33n1a17.htm##
00478000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022600081002001300307#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#119#115#article#198#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. McFarland KL, W
etzstein GA. Chronic myeloid leukemia therapy: focus on second-generation tyrosi
ne kinase inhibitors. Cancer Control. 2009;16(2):132-40.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#120#116#article#198#</font></p>     ^
cY#v33n1a17.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031300081002001300394#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#121#117#article#198#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Martinelli G, I
acobucci I, Soverini S, Palandri F, Castagnetti F, Rosti G, et al. Nilotinib: a 
novel encouraging therapeutic option for chronic myeloid leukemia patients with 
imatinib resistance or intolerance. Biologics. 2007;1(2):121-7.    ^cY#v33n1a17.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#122#118#article#198#</font></p>     ^
cY#v33n1a17.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031400081002001300395#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#123#119#article#198#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Puttini M, Colu
ccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, et al. In vitro and
 in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resist
ant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66(23):11314-22.    ^cY#v33n1a17
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#124#120#article#198#</font></p>     ^
cY#v33n1a17.htm##
00850000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704059800081002001300679#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#125#121#article#198#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Gambacorti-Pass
erini C, editor. Activity and tolerance of bosutinib in patients with AP and BPC
ML and Ph+ ALL &#91;Internet&#93;. Poster presented in: ASCO Annual Meeting 2008
. Alexandria: American Society of Clinical Oncology.  &#91;cited 2010 Jan 20&#93
;. Available from: <a href="http://www.asco.org/ascov2/Meetings/Abstracts?&amp;v
mview=abst_detail_view&amp;confID=55&amp;abstractID=35805" target="_blank">http:
//www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abst
ractID=35805</a></font></p>     ^cY#v33n1a17.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021300081002001300294#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#126#122#article#198#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Melo JV, Chuah 
C. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. Hematolog
y Am Soc Hematol Educ Program. 2008:427-35.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#127#123#article#198#</font></p>     ^
cY#v33n1a17.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023400081002001300315#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#128#124#article#198#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Baccarani M, Pa
ne F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica.
 2008;93(2):161-9. Comment in: Haematologica. 2008;93(2):186-92.    ^cY#v33n1a17
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#129#125#article#198#</font></p>     ^
cY#v33n1a17.htm##
00590000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033800081002001300419#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#130#126#article#198#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Kantarjian H, S
chiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myel
oid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical 
advice on the use and interpretation of monitoring methods. Blood. 2008;111(4): 
1774-80.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#131#127#article#198#</font></p>     ^
cY#v33n1a17.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024200081002001300323#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#132#128#article#198#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Sokal JE, Cox E
B, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination
 in "good-risk" chronic granulocytic leukemia. Blood. 1984;63(4):789-99.    ^cY#
v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#133#129#article#198#</font></p>     ^
cY#v33n1a17.htm##
00840000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704058800081002001300669#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#134#130#article#198#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Baccarani M, Ro
sti G, Castagnetti F, Palandri F, Gugliotta G, Ferrara F, et al.  SOKAL Score an
d response to imatinib in early chronic phase CML: the GIMEMA  CML Working Party
 Experience on 559 patients. Haematologica &#91;Internet&#93;. 2009 &#91;cited 2
010 Jan 20&#93;(suppl2):255 abs. Available from: <a href="http://online.haematol
ogica.org/EHA14/browserecord.php?-action=browse&amp;-recid=3732" target="_blank"
>http://online.haematologica.org/EHA14/browserecord.php?-action=browse&-recid=37
32</a></font></p>     ^cY#v33n1a17.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030600081002001300387#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#135#131#article#198#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Thomas MJ, Irvi
ng JA, Lennard AL, Proctor SJ, Taylor PR; On behalf of the Northern Region Haema
tology Group. Validation of the Hasford score in a demographic study in chronic 
granulocytic leukaemia. J Clin Pathol. 2001;54(6):491-3.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#136#132#article#198#</font></p>     ^
cY#v33n1a17.htm##
00607000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035500081002001300436#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#137#133#article#198#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Branford S, Rud
zki Z, Harper A, Grigg A, Taylor K, Durrant S, et al. Imatinib produces signific
antly superior molecular responses compared to interferon alpha plus cytarabine 
in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leuk
emia. 2003;17(12):2401-9.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#138#134#article#198#</font></p>     ^
cY#v33n1a17.htm##
00719000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704046700081002001300548#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#139#135#article#198#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Hughes T, Deini
nger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patient
s responding to treatment with tyrosine kinase inhibitors: review and recommenda
tions for harmonizing current methodology for detecting BCR-ABL transcripts and 
kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37. Co
mment in: Blood. 2007;109 (5): 2263; author reply 2263-4.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#140#136#article#198#</font></p>     ^
cY#v33n1a17.htm##
00745000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704049300081002001300574#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#141#137#article#198#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Baccarani M, Sa
glio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F
, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian
 H, Larson R, Niederwieser D, Silver R, Hehlmann R; European LeukemiaNet. Evolvi
ng concepts in the management of chronic myeloid leukemia: recommendations from 
an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6): 1809-
20.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#142#138#article#198#</font></p>     ^
cY#v33n1a17.htm##
00783000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704053100081002001300612#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#143#139#article#198#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Baccarani M, Co
rtes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, 
Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R,
 Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R; European LeukemiaNet. 
Chronic myeloid leukemia: an update of concepts and management recommendations o
f European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-51. Comment in: J Clin On
col. 2010;28(18):e310; author reply e311.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#144#140#article#198#</font></p>     ^
cY#v33n1a17.htm##
00570000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031800081002001300399#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#145#141#article#198#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Quint&aacute;s-
Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, et al. Dasatinib
 early intervention after cytogenetic or hematologic resistance to imatinib in p
atients with chronic myeloid leukemia. Cancer. 2009;115(13):2912-21.    ^cY#v33n
1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#146#142#article#198#</font></p>     ^
cY#v33n1a17.htm##
00672000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704042000081002001300501#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#147#143#article#198#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Quint&aacute;s-
Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, et al. Delayed 
achievement of cytogenetic and molecular response is associated with increased r
isk of progression among patients with chronic myeloid leukemia in early chronic
 phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113(25
):6315-21.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#148#144#article#198#</font></p>     ^
cY#v33n1a17.htm##
00673000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704042100081002001300502#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#149#145#article#198#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Iacobucci I, Ro
sti G, Amabile M, Poerio A, Soverini S, Cilloni D, et al. Comparison between pat
ients with Philadelphia-positive chronic phase chronic myeloid leukemia who obta
ined a complete cytogenetic response within 1 year of imatinib therapy and those
 who achieved such a response after 12 months of treatment. J Clin Oncol. 2006;2
4(3):454-9.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#150#146#article#198#</font></p>     ^
cY#v33n1a17.htm##
00543000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029100081002001300372#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#151#147#article#198#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Cortes J, Talpa
z M, O'Brien S, Jones D, Luthra R, Shan J, et al. Molecular responses in patient
s with chronic myelogenous leukemia in chronic phase treated with imatinib mesyl
ate. Clin Cancer Res. 2005;11(9):3425-32.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#152#148#article#198#</font></p>     ^
cY#v33n1a17.htm##
00615000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036300081002001300444#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#153#149#article#198#35#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Marin D, Milojk
ovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, et al. European Leuk
emiaNet criteria for failure or suboptimal response reliably identify patients w
ith CML in early chronic phase treated with imatinib whose eventual outcome is p
oor. Blood. 2008;112(12):4437-44.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#154#150#article#198#</font></p>     ^
cY#v33n1a17.htm##
00613000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036100081002001300442#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#155#151#article#198#36#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Alvarado Y, Kan
tarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, et al. Significance of su
boptimal response to imatinib, as defined by the European LeukemiaNet, in the lo
ng-term outcome of patients with early chronic myeloid leukemia in chronic phase
. Cancer. 2009;115(16):3709-18.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#156#152#article#198#</font></p>     ^
cY#v33n1a17.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029400081002001300375#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#157#153#article#198#37#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Kantarjian H, O
'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, et al. Cytogenetic and mol
ecular responses and outcome in chronic myelogenous leukemia: need for new respo
nse definitions? Cancer. 2008;112(4):837-45.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#158#154#article#198#</font></p>     ^
cY#v33n1a17.htm##
00683000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704043100081002001300512#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#159#155#article#198#38#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Hochhaus A, O'B
rien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, M&uuml;ller MC,
 Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA; IRIS Investigat
ors. Six-year follow-up of patients receiving imatinib for thefirst-line treatme
nt of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-61.  Erratum in: Leuke
mia. 2010;24(5):1102.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#160#156#article#198#</font></p>     ^
cY#v33n1a17.htm##
00595000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034300081002001300424#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#161#157#article#198#39#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Merx K, M&uuml;
ller MC, Kreil S, Lahaye T, Paschka P, Schoch C, et al. Early reduction of BCR-A
BL mRNA transcript levels predicts cytogenetic response in chronic phase CML pat
ients treated with imatinib after failure of interferon alpha. Leukemia. 2002; 1
6(9):1579-83.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#162#158#article#198#</font></p>     ^
cY#v33n1a17.htm##
00590000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033800081002001300419#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#163#159#article#198#40#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Branford S, Rud
zki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, et al. Real-time quantitative
 PCR analysis can be used as a primary screen to identify patients with CML trea
ted with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104 (9):
2926-32.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#164#160#article#198#</font></p>     ^
cY#v33n1a17.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027300081002001300354#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#165#161#article#198#41#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">41. Shah NP, Tran C
, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a no
vel ABL kinase inhibitor. Science. 2004;305(5682):399-401. Comment in: Science. 
2004;305 (5692):319-21.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#166#162#article#198#</font></p>     ^
cY#v33n1a17.htm##
00564000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031200081002001300393#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#167#163#article#198#42#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">42. Gorre ME, Moham
med M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-5
71 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 200
1;293 (5531):876-80. Comment on: Science. 2001;293(5538):2163.    ^cY#v33n1a17.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#168#164#article#198#</font></p>     ^
cY#v33n1a17.htm##
00701000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704044900081002001300530#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#169#165#article#198#43#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">43. Kantarjian HM, 
Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker
 BJ; International Randomized Study of Interferon and STI571 (IRIS) Investigator
s. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemi
a in chronic phase. Cancer. 2009;115(3):551-60. Erratum in: Cancer. 2010;116(15)
:3750. Santini, Valeria &#91;added&#93;    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#170#166#article#198#</font></p>     ^
cY#v33n1a17.htm##
00618000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036600081002001300447#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#171#167#article#198#44#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">44. Zonder JA, Pemb
erton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imati
nib mesylate in patients with chronic or accelerated phase chronic myelogenous l
eukemia with inadequate hematologic or cytogenetic response to initial treatment
. Clin Cancer Res. 2003;9(6):2092-7.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#172#168#article#198#</font></p>     ^
cY#v33n1a17.htm##
00586000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033400081002001300415#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#173#169#article#198#45#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">45. Marin D, Goldma
n JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imati
nib dose in CML patients who do not achieve complete cytogenetic remissions on c
onventional doses. Blood. 2003;102(7):2702-3; Comment on: Blood. 2003; 101(2):47
3-5.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#174#170#article#198#</font></p>     ^
cY#v33n1a17.htm##
00613000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036100081002001300442#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#175#171#article#198#46#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">46. Hochhaus A, Kan
tarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib ind
uces notable hematologic and cytogenetic responses in chronic-phase chronic myel
oid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303-9. Errat
um in: Blood. 2007;110(5):1438.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#176#172#article#198#</font></p>     ^
cY#v33n1a17.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030600081002001300387#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#177#173#article#198#47#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">47. Hughes T, Sagli
o G, Branford S, Soverini S, Kim DW, M&uuml;ller MC, et al. Impact of baseline B
CR-ABL mutations on response to nilotinib in patients with chronic myeloid leuke
mia in chronic phase. J Clin Oncol. 2009;27(25):4204-10.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#178#174#article#198#</font></p>     ^
cY#v33n1a17.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021300081002001300294#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#179#175#article#198#48#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">48. Breccia M, Alim
ena G. Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myel
oid leukemia. Leuk Res. 2010; 34(2):129-34.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#180#176#article#198#</font></p>     ^
cY#v33n1a17.htm##
00581000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032900081002001300410#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#181#177#article#198#49#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">49. Kantarjian H, P
asquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib 
or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure o
f first-line imatinib: a randomized phase 2 trial. Blood. 2007;109(12):5143-50. 
   ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#182#178#article#198#</font></p>     ^
cY#v33n1a17.htm##
00643000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704039100081002001300472#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#183#179#article#198#50#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">50. Kantarjian H, P
asquini R, L&eacute;vy V, Jootar S, Holowiecki J, Hamerschlak N, et al. Dasatini
b or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to 
imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a rando
mized phase 2 study (START-R). Cancer. 2009;115(18): 4136-47.    ^cY#v33n1a17.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#184#180#article#198#</font></p>     ^
cY#v33n1a17.htm##
00615000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036300081002001300444#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#185#181#article#198#51#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">51. Jabbour E, Hoch
haus A, Cortes J, La Ros&eacute;e P, Kantarjian HM. Choosing the best treatment 
strategy for chronic myeloid leukemia patients resistant to imatinib: weighing t
he efficacy and safety of individual drugs with BCR-ABL mutations and patient hi
story. Leukemia. 2010;24(1):6-12.    ^cY#v33n1a17.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#186#182#article#198#</font></p>     ^
cY#v33n1a17.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#187#183#article#198#<p>&nbsp;</p>    
 ^cY#v33n1a17.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#188#184#article#198#<p>&nbsp;</p>    
 ^cY#v33n1a17.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018600078002001300264#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#189#185#article#198#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b
>    ^cY#v33n1a17.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004600078002001300124#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#190#186#article#198#<br>   C&aacute;r
mino Antonio de Souza    ^cY#v33n1a17.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010700078002001300185#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#191#187#article#198#<br>   Centro de 
Hematologia e Hemoterapia de Campinas, Universidade Estadual de Campinas   Unica
mp    ^cY#v33n1a17.htm##
00357000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012000078002001300198#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#192#188#article#198#<br>   Rua Carlos
 Chagas,  450 Cidade Universit&aacute;ria "Prof. Zeferino Vaz" Distrito de Bar&a
tilde;o Geraldo    ^cY#v33n1a17.htm##
00285000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004800078002001300126#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#193#189#article#198#<br>   13083- 878
  Campinas (SP), Brazil    ^cY#v33n1a17.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003700078002001300115#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#194#190#article#198#<br>   Phone: 55 
19-3521 8740    ^cY#v33n1a17.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008500078002001300163#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#195#191#article#198#<br>   <a href="m
ailto:carmino@unicamp.br">carmino@unicamp.br</a></font></p>     ^cY#v33n1a17.htm
##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#196#192#article#198#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted: 4/27/2010    ^cY#v33n1a
17.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#197#193#article#198#<br>   Accepted: 
9/24/2010    ^cY#v33n1a17.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011000078002001300188#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#198#194#article#198#<br>   Conflict-o
f-interest disclosure:  JWRBS and MACR are employees of Bristol-Meyers Squibb, B
razil    ^cY#v33n1a17.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009200078002001300170#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#199#195#article#198#<br>   This artic
le was written with the support of Bristol-Myers Squibb</font></p>     ^cY#v33n1
a17.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#200#196#article#198#<p>&nbsp;</p>    
 ^cY#v33n1a17.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#201#197#article#198#<p>&nbsp;</p>    
 ^cY#v33n1a17.htm##
00460000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022300078002001300301#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a17.htm#S#p#202#198#article#198#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" targ
et="_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_bla
nk">www.scielo.br/rbhh</a></font></p>     ^cY#v33n1a17.htm##
00545000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120029000950300
01300124065000900137064000500146031000400151032000300155014000800158061004400166
865000900210002001300219035001000232801001300242#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a17.htm#S#c#203#1#article#51#1#^rND^sSawyers^nCL#Chronic myeloid 
leukemia^len#N Engl J Med#19990000#1999#340#17#1330-40#Comment in: N Engl J Med.
 1999;341 (10):765#20110200#v33n1a17.htm#0028-4793#N Engl J Med##
00656000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01700111010001400128010001700142012009700159030000700256065000900263064000500272
03100040027703200020028101400080028386500090029100200130030003500100031380100070
0323#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#204#2#article#51#
2#^rND^sKhoury^nHJ#^rND^sGuilhot^nF#^rND^sHughes^nTP#^rND^sKim^nDW#^rND^sCortes^
nJE#Dasatinib treatment for Philadelphia chromosome-positive leukemias: practica
l considerations^len#Cancer#20090000#2009#115#7#1381-94#20110200#v33n1a17.htm#00
08-543X#Cancer##
00670000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100014000950100
02000109010001800129010001800147010001600165810000600181012007000187030002700257
71000020028406500090028606400050029503100020030003200020030201400060030486500090
0310002001300319#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#205#3
#article#51#3#^rND^sRedaelli^nA#^rND^sBell^nC#^rND^sCasagrande^nJ#^rND^sStephens
^nJ#^rND^sBotteman^nM#^rND^sLaskin^nB#et al#Clinical and epidemiologic burden of
 chronic myelogenous leukemia^len#Expert Rev Anticancer Ther#2#20040000#2004#4#1
#85-96#20110200#v33n1a17.htm##
01464000000000589000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100017000950100
01700112010001800129010001900147010001900166010002200185010001700207010001800224
01000160024201000170025801000180027501000190029301000180031201000160033001000180
03460100019003640100018003830100018004010100020004190100016004390100017004550100
01700472010002000489010001700509011001900526012012100545030001300666065000900679
06400050068803100040069303200030069701400090070006101200070986500090082900200130
0838035001000851801001300861#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#206#4#article#51#4#^rND^sO'Brien^nSG#^rND^sGuilhot^nF#^rND^sLarson^nRA#^r
ND^sGathmann^nI#^rND^sBaccarani^nM#^rND^sCervantes^nF#^rND^sCornelissen^nJJ#^rND
^sFischer^nT#^rND^sHochhaus^nA#^rND^sHughes^nT#^rND^sLechner^nK#^rND^sNielsen^nJ
L#^rND^sRousselot^nP#^rND^sReiffers^nJ#^rND^sSaglio^nG#^rND^sShepherd^nJ#^rND^sS
imonsson^nB#^rND^sGratwohl^nA#^rND^sGoldman^nJM#^rND^sKantarjian^nH#^rND^sTaylor
^nK#^rND^sVerhoef^nG#^rND^sBolton^nAE#^rND^sCapdeville^nR#^rND^sDruker^nBJ#IRIS 
Investigators#Imatinib compared with interferon and low-dose cytarabine for newl
y diagnosed chronic-phase chronic myeloid leukemia^len#N Engl J Med#20030000#200
3#348#11#994-1004#Comment in: Curr Hematol Rep. 2004;3(1):37-8. N Engl J Med. 20
03; 348(11): 1048-50. Clin Lab Haematol. 2005;27(6):416-7#20110200#v33n1a17.htm#
0028-4793#N Engl J Med##
01033000000000409000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100015000940100
01800109010001600127010001800143010001800161010001800179010001700197010002400214
01000180023801000170025601202130027303000130048606500090049906400050050803100040
05130320003005170140008005200610050005288650009005780020013005870350010006008010
01300610#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#207#5#article
#51#5#^rND^sHughes^nTP#^rND^sKaeda^nJ#^rND^sBranford^nS#^rND^sRudzki^nZ#^rND^sHo
chhaus^nA#^rND^sHensley^nML#^rND^sGathmann^nI#^rND^sBolton^nAE#^rND^svan Hoomiss
en^nIC#^rND^sGoldman^nJM#^rND^sRadich^nJP#International Randomised Study of Inte
rferon versus STI571 (IRIS) Study Group: Frequency of major molecular responses 
to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloi
d leukemia^len#N Engl J Med#20030000#2003#349#15#1423-32#Comment in: N Engl J Me
d. 2003;349 (15): 1399-401#20110200#v33n1a17.htm#0028-4793#N Engl J Med##
00871000000000361000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100022000770100019000990100
02000118010002000138010001500158010001300173810000600186012014000192030001300332
06500090034506400050035403100030035903100030036201400080036506100910037386500090
0464002001300473035001000486801001300496#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a17.htm#S#c#208#6#article#51#6#^rND^sde Lavallade^nH#^rND^sApperley^nJF#^
rND^sKhorashad^nJS#^rND^sMilojkovic^nD#^rND^sReid^nAG#^rND^sBua^nM#et al#Imatini
b for newly diagnosed patients with chronic myeloid leukemia: incidence of susta
ined responses in an intention-to-treat analysis^len#J Clin Oncol#20080000#2008#
26#20#3358-63#Comment in: J Clin Oncol. 2008;26(20):3308-9. Comment in: J Clin O
ncol. 2008;26(20):3308-9#20110200#v33n1a17.htm#0732-183X#J Clin Oncol##
01568000000000673000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01800111010001800129010002000147010002000167010002000187010001700207010001800224
01000160024201000190025801000180027701000170029501000200031201000190033201000180
03510100022003690100016003910100014004070100017004210100017004380100018004550100
01600473010001800489010001800507010001700525010001900542010001600561010001900577
01000120059601000160060801000170062401100190064101200840066003000130074406500090
07570640005007660310004007710320003007750140008007780610063007868650009008490020
01300858035001000871801001300881#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a
17.htm#S#c#209#7#article#51#7#^rND^sDruker^nBJ#^rND^sGuilhot^nF#^rND^sO'Brien^nS
G#^rND^sGathmann^nI#^rND^sKantarjian^nH#^rND^sGattermann^nN#^rND^sDeininger^nMW#
^rND^sSilver^nRT#^rND^sGoldman^nJM#^rND^sStone^nRM#^rND^sCervantes^nF#^rND^sHoch
haus^nA#^rND^sPowell^nBL#^rND^sGabrilove^nJL#^rND^sRousselot^nP#^rND^sReiffers^n
J#^rND^sCornelissen^nJJ#^rND^sHughes^nT#^rND^sAgis^nH#^rND^sFischer^nT#^rND^sVer
hoef^nG#^rND^sShepherd^nJ#^rND^sSaglio^nG#^rND^sGratwohl^nA#^rND^sNielsen^nJL#^r
ND^sRadich^nJP#^rND^sSimonsson^nB#^rND^sTaylor^nK#^rND^sBaccarani^nM#^rND^sSo^nC
#^rND^sLetvak^nL#^rND^sLarson^nRA#IRIS Investigators#Five-year follow-up of pati
ents receiving imatinib for chronic myeloid leukemia^len#N Engl J Med#20060000#2
006#355#23#2408-17#Comment in: N Engl J Med. 2007;356(17):1780; author reply 178
0#20110200#v33n1a17.htm#0028-4793#N Engl J Med##
00790000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770120248000960530
04400344056002200388055001200410054001600422018001800438037005800456865000900514
002001300523#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#210#8#art
icle#51#8#^rED^sDeininger^nM#International Randomized Study of Interferon Vs STI
571 (IRIS) 8-year follow up: sustained survival and low risk for progression or 
events in patients with newly diagnosed chronic myeloid leukemia in chronic phas
e (CML-CP) treated with imatinib^len#ASH Annual Meeting and Exposition^n51^i1^i1
#New Orleans^i1^eLa^i1#20091208^i1#2009 dec 5-8^i1#abstract 1126^len#http://ash.
confex.com/ash/2009/webprogram/Paper23968.html#20110200#v33n1a17.htm##
00829000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
01500111010001900126010001500145010001400160810000600174012022800180030000600408
06500090041406400050042303100040042803200020043201400070043486500090044100200130
0450035001000463801000600473#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#211#9#article#51#9#^rND^sBranford^nS#^rND^sRudzki^nZ#^rND^sWalsh^nS#^rND^
sParkinson^nI#^rND^sGrigg^nA#^rND^sSzer^nJ#et al#Detection of BCR-ABL mutations 
in patients with CML treated with imatinib is virtually always accompanied by cl
inical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are 
associated with a poor prognosis^len#Blood#20030000#2003#102#1#276-83#20110200#v
33n1a17.htm#0006-4971#Blood##
00580000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970120
09800115030000900213065000900222064000500231031000300236032000200239014000800241
865000900249002001300258035001000271801000900281#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a17.htm#S#c#212#10#article#51#10#^rND^sHochhaus^nA#^rND^sLa Rosée
^nP#Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and ov
ercome resistance^len#Leukemia#20040000#2004#18#8#1321-31#20110200#v33n1a17.htm#
0887-6924#Leukemia##
00885000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01500113010001500128010001600143010001600159810000600175012023500181030000600416
06500090042206400050043103100030043603200020043901400070044106100370044886500090
0485002001300494035001000507801000600517#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a17.htm#S#c#213#11#article#51#11#^rND^sBranford^nS#^rND^sRudzki^nZ#^rND^s
Walsh^nS#^rND^sGrigg^nA#^rND^sArthur^nC#^rND^sTaylor^nK#et al#High frequency of 
point mutations clustered within the adenosine triphosphate-binding region of BC
R/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblast
ic leukemia who develop imatinib (STI571) resistance^len#Blood#20020000#2002#99#
9#3472-5#Comment in: Blood. 2002 ;100(3):1105#20110200#v33n1a17.htm#0006-4971#Bl
ood##
00627000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100015001000100
02500115010001600140012006600156030001600222065000900238064000500247031000300252
032000200255014000800257865000900265002001300274035001000287801001600297#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#214#12#article#51#12#^rND^sKa
ntarjian^nHM#^rND^sGiles^nF#^rND^sQuintás-Cardama^nA#^rND^sCortes^nJ#Important t
herapeutic targets in chronic myelogenous leukemia^len#Clin Cancer Res#20070000#
2007#13#4#1089-97#20110200#v33n1a17.htm#1078-0432#Clin Cancer Res##
01273000000000517000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01500116010001500131010002100146010001600167010001900183010001700202010001900219
01000170023801000180025501000170027301000190029001000200030901000200032901000140
03490100014003630100016003770100019003930100020004120110049004320120183004810300
01600664065000900680064000500689031000300694032000300697014000700700865000900707
002001300716035001000729801001600739#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v3
3n1a17.htm#S#c#215#13#article#51#13#^rND^sSoverini^nS#^rND^sColarossi^nS#^rND^sG
nani^nA#^rND^sRosti^nG#^rND^sCastagnetti^nF#^rND^sPoerio^nA#^rND^sIacobucci^nI#^
rND^sAmabile^nM#^rND^sAbruzzese^nE#^rND^sOrlandi^nE#^rND^sRadaelli^nF#^rND^sCicc
one^nF#^rND^sTiribelli^nM#^rND^sdi Lorenzo^nR#^rND^sCaracciolo^nC#^rND^sIzzo^nB#
^rND^sPane^nF#^rND^sSaglio^nG#^rND^sBaccarani^nM#^rND^sMartinelli^nG#GIMEMA Work
ing Party on Chronic Myeloid Leukemia#Contribution of ABL kinase domain mutation
s to imatinib resistance in different subsets of Philadelphia-positive patients:
 by the GIMEMA Working Party on Chronic Myeloid Leukemia^len#Clin Cancer Res#200
60000#2006#12#24#7374-9#20110200#v33n1a17.htm#1078-0432#Clin Cancer Res##
00748000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100020000960100
01500116010001600131010001600147010001700163810000600180012013400186030000900320
06500090032906400050033803100030034303200030034601400080034986500090035700200130
0366035001000379801000900389#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#216#14#article#51#14#^rND^sJabbour^nE#^rND^sKantarjian^nH#^rND^sJones^nD#
^rND^sTalpaz^nM#^rND^sBekele^nN#^rND^sO'Brien^nS#et al#Frequency and clinical si
gnificance of BCR-ABL mutations in patients with chronic myeloid leukemia treate
d with imatinib mesylate^len#Leukemia#20060000#2006#20#10#1767-73#20110200#v33n1
a17.htm#0887-6924#Leukemia##
00835000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100016001010100
01800117010001500135010001900150010001600169810000600185012020700191030001400398
06500090041206400050042103100030042603200020042901400080043186500090043900200130
0448035001000461801001400471#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#217#15#article#51#15#^rND^sMascarenhas^nCC#^rND^sCunha^nAF#^rND^sMiranda^
nEC#^rND^sZulli^nR#^rND^sSilveira^nRA#^rND^sCosta^nFF#et al#New mutations detect
ed by denaturing high performance liquid chromatography during screening of exon
 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyro
sine kinase inhibitors^len#Leuk Lymphoma#20090000#2009#50#7#1148-54#20110200#v33
n1a17.htm#1042-8194#Leuk Lymphoma##
00831000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01400113010001700127010001500144010001800159810000600177012013200183030000600315
06500090032106400050033003100040033503200030033901400080034206100810035086500090
0431002001300440035001000453801000600463#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a17.htm#S#c#218#16#article#51#16#^rND^sMüller^nMC#^rND^sCortes^nJE#^rND^s
Kim^nDW#^rND^sDruker^nBJ#^rND^sErben^nP#^rND^sPasquini^nR#et al#Dasatinib treatm
ent of chronic-phase chronic myeloid leukemia: analysis of responses according t
o preexisting BCR-ABL mutations^len#Blood#20090000#2009#114#24#4944-53#Comment i
n: Blood. 2009; 114(24):4914-5. Comment in: Blood. 2009; 114(24):4914-5#20110200
#v33n1a17.htm#0006-4971#Blood##
00589000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100020000990120
09200119030001500211065000900226064000500235031000300240032000200243014000700245
865000900252002001300261035001000274801001500284#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a17.htm#S#c#219#17#article#51#17#^rND^sMcFarland^nKL#^rND^sWetzst
ein^nGA#Chronic myeloid leukemia therapy: focus on second-generation tyrosine ki
nase inhibitors^len#Cancer Control#20090000#2009#16#2#132-40#20110200#v33n1a17.h
tm#1073-2748#CANCER CONTROL##
00724000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100019000990100
01800118010001800136010002100154010001500175810000600190012013200196030001000328
71000020033806500090034006400050034903100020035403200020035601400060035886500090
0364002001300373#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#220#1
8#article#51#18#^rND^sMartinelli^nG#^rND^sIacobucci^nI#^rND^sSoverini^nS#^rND^sP
alandri^nF#^rND^sCastagnetti^nF#^rND^sRosti^nG#et al#Nilotinib: a novel encourag
ing therapeutic option for chronic myeloid leukemia patients with imatinib resis
tance or intolerance^len#Biologics#2#20070000#2007#1#2#121-7#20110200#v33n1a17.h
tm##
00756000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01900115010001600134010001800150010002300168810000600191012012600197030001100323
06500090033406400050034303100030034803200030035101400090035486500090036300200130
0372035001000385801001100395#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#221#19#article#51#19#^rND^sPuttini^nM#^rND^sColuccia^nAM#^rND^sBoschelli^
nF#^rND^sCleris^nL#^rND^sMarchesi^nE#^rND^sDonella-Deana^nA#et al#In vitro and i
n vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistan
t Bcr-Abl+ neoplastic cells^len#Cancer Res#20060000#2006#66#23#11314-22#20110200
#v33n1a17.htm#0008-5472#Cancer res##
00749000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100030000790120093001090180
02100202053002300223055001200246054000800258066001100266062003800277110000900315
109001200324037010100336865000900437002001300446#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a17.htm#S#c#222#20#article#51#20#^rED^sGambacorti-Passerini^nC#Ac
tivity and tolerance of bosutinib in patients with AP and BPCML and Ph+ ALL [Int
ernet]^len#Poster presented^len#ASCO Annual Meeting^i1#20080000^i1#2008^i1#Alexa
ndria#American Society of Clinical Oncology#20100120#2010 Jan 20#http://www.asco
.org/ascov2/Meetings/Abstracts?& vmview=abst_detail_view& confID=55& abstractID=
35805#20110200#v33n1a17.htm##
00518000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940120
07100109030003900180710000200219065000900221064000500230014000700235865000900242
002001300251#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#223#21#ar
ticle#51#21#^rND^sMelo^nJV#^rND^sChuah^nC#Novel agents in CML therapy: tyrosine 
kinase inhibitors and beyond^len#Hematology Am Soc Hematol Educ Program#2#200800
00#2008#427-35#20110200#v33n1a17.htm##
00625000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100014000980100
01600112012005300128030001400181065000900195064000500204031000300209032000200212
014000600214061004500220865000900265002001300274035001000287801001400297#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#224#22#article#51#22#^rND^sBa
ccarani^nM#^rND^sPane^nF#^rND^sSaglio^nG#Monitoring treatment of chronic myeloid
 leukemia^len#Haematologica#20080000#2008#93#2#161-9#Comment in: Haematologica. 
2008;93(2):186-92#20110200#v33n1a17.htm#0390-6078#Haematologica##
00727000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
01500117010001600132012019300148030000600341065000900347064000500356031000400361
032000200365014000800367865000900375002001300384035001000397801000600407#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#225#23#article#51#23#^rND^sKa
ntarjian^nH#^rND^sSchiffer^nC#^rND^sJones^nD#^rND^sCortes^nJ#Monitoring the resp
onse and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosin
e kinase inhibitors: practical advice on the use and interpretation of monitorin
g methods^len#Blood#20080000#2008#111#4#1774-80#20110200#v33n1a17.htm#0006-4971#
Blood##
00679000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950100
01900109010001400128010001600142010002000158810000600178012007500184030000600259
06500090026506400050027403100030027903200020028201400070028486500090029100200130
0300035001000313801000600323#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#226#24#article#51#24#^rND^sSokal^nJE#^rND^sCox^nEB#^rND^sBaccarani^nM#^rN
D^sTura^nS#^rND^sGomez^nGA#^rND^sRobertson^nJE#et al#Prognostic discrimination i
n "good-risk" chronic granulocytic leukemia^len#Blood#19840000#1984#63#4#789-99#
20110200#v33n1a17.htm#0006-4971#Blood##
00883000000000373000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100015000980100
02100113010001800134010001900152010001700171810000600188012012500194030001400319
06500090033306400050034211000090034710900120035603200040036806100080037203700830
0380865000900463002001300472035001000485801001400495#v33n1#V:\SciELO\serial\rbhh
\v33n1\markup\v33n1a17.htm#S#c#227#25#article#51#25#^rND^sBaccarani^nM#^rND^sRos
ti^nG#^rND^sCastagnetti^nF#^rND^sPalandri^nF#^rND^sGugliotta^nG#^rND^sFerrara^nF
#et al#SOKAL Score and response to imatinib in early chronic phase CML: the GIME
MA CML Working Party Experience on 559 patients^len#Haematologica#20090000#2009#
20100120#2010 Jan 20#^s2#255 abs#http://online.haematologica.org/EHA14/browserec
ord.php?-action=browse& -recid=3732#20110200#v33n1a17.htm#0390-6078#Haematologic
a##
00722000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01800113010001800131010001700149012014500166030001400311065000900325064000500334
03100030033903200020034201400060034486500090035000200130035903500100037280100140
0382#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#228#26#article#51
#26#^rND^sThomas^nMJ#^rND^sIrving^nJA#^rND^sLennard^nAL#^rND^sProctor^nSJ#^rND^s
Taylor^nPR#On behalf of the Northern Region Haematology Group: Validation of the
 Hasford score in a demographic study in chronic granulocytic leukaemia^len#J Cl
in Pathol#20010000#2001#54#6#491-3#20110200#v33n1a17.htm#0021-9746#J Clin Pathol
##
00795000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01600113010001500129010001600144010001700160810000600177012018500183030000900368
06500090037706400050038603100030039103200030039401400070039786500090040400200130
0413035001000426801000900436#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#229#27#article#51#27#^rND^sBranford^nS#^rND^sRudzki^nZ#^rND^sHarper^nA#^r
ND^sGrigg^nA#^rND^sTaylor^nK#^rND^sDurrant^nS#et al#Imatinib produces significan
tly superior molecular responses compared to interferon alpha plus cytarabine in
 patients with newly diagnosed chronic myeloid leukemia in chronic phase^len#Leu
kemia#20030000#2003#17#12#2401-9#20110200#v33n1a17.htm#0887-6924#Leukemia##
00915000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01800114010001800132010001600150010001500166810000600181012023700187030000600424
06500090043006400050043903100040044403200020044801400060045006100590045686500090
0515002001300524035001000537801000600547#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a17.htm#S#c#230#28#article#51#28#^rND^sHughes^nT#^rND^sDeininger^nM#^rND^
sHochhaus^nA#^rND^sBranford^nS#^rND^sRadich^nJ#^rND^sKaeda^nJ#et al#Monitoring C
ML patients responding to treatment with tyrosine kinase inhibitors: review and 
recommendations for harmonizing current methodology for detecting BCR-ABL transc
ripts and kinase domain mutations and for expressing results^len#Blood#20060000#
2006#108#1#28-37#Comment in: Blood. 2007;109 (5): 2263; author reply 2263-4#2011
0200#v33n1a17.htm#0006-4971#Blood##
01163000000000505000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01700114010001800131010001900149010001900168010001800187010001900205010001600224
01000190024001000180025901000170027701000180029401000160031201000200032801000160
03480100022003640100016003860100018004020110021004200120144004410300006005850650
00900591064000500600031000400605032000200609014000800611865000900619002001300628
035001000641801000600651#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S
#c#231#29#article#51#29#^rND^sBaccarani^nM#^rND^sSaglio^nG#^rND^sGoldman^nJ#^rND
^sHochhaus^nA#^rND^sSimonsson^nB#^rND^sAppelbaum^nF#^rND^sApperley^nJ#^rND^sCerv
antes^nF#^rND^sCortes^nJ#^rND^sDeininger^nM#^rND^sGratwohl^nA#^rND^sGuilhot^nF#^
rND^sHorowitz^nM#^rND^sHughes^nT#^rND^sKantarjian^nH#^rND^sLarson^nR#^rND^sNiede
rwieser^nD#^rND^sSilver^nR#^rND^sHehlmann^nR#European LeukemiaNet#Evolving conce
pts in the management of chronic myeloid leukemia: recommendations from an exper
t panel on behalf of the European LeukemiaNet^len#Blood#20060000#2006#108#6#1809
-20#20110200#v33n1a17.htm#0006-4971#Blood##
01238000000000529000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01400114010002200128010001600150010001800166010001900184010001900203010001800222
01000170024001000180025701000180027501000160029301000200030901000160032901000160
03450100019003610100017003800100017003970100018004140110021004320120107004530300
01300560065000900573064000500582031000300587032000300590014000800593061006200601
865000900663002001300672035001000685801001300695#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a17.htm#S#c#232#30#article#51#30#^rND^sBaccarani^nM#^rND^sCortes^
nJ#^rND^sPane^nF#^rND^sNiederwieser^nD#^rND^sSaglio^nG#^rND^sApperley^nJ#^rND^sC
ervantes^nF#^rND^sDeininger^nM#^rND^sGratwohl^nA#^rND^sGuilhot^nF#^rND^sHochhaus
^nA#^rND^sHorowitz^nM#^rND^sHughes^nT#^rND^sKantarjian^nH#^rND^sLarson^nR#^rND^s
Radich^nJ#^rND^sSimonsson^nB#^rND^sSilver^nRT#^rND^sGoldman^nJ#^rND^sHehlmann^nR
#European LeukemiaNet#Chronic myeloid leukemia: an update of concepts and manage
ment recommendations of European LeukemiaNet^len#J Clin Oncol#20090000#2009#27#3
5#6041-51#Comment in: J Clin Oncol. 2010;28(18):e310; author reply e311#20110200
#v33n1a17.htm#0732-183X#J Clin Oncol##
00749000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100025000790100017001040100
01700121010001700138010001900155010001300174810000600187012013100193030000700324
06500090033106400050034003100040034503200030034901400080035286500090036000200130
0369035001000382801000700392#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#233#31#article#51#31#^rND^sQuintás-Cardama^nA#^rND^sCortes^nJE#^rND^sO'Br
ien^nS#^rND^sRavandi^nF#^rND^sBorthakur^nG#^rND^sLiu^nD#et al#Dasatinib early in
tervention after cytogenetic or hematologic resistance to imatinib in patients w
ith chronic myeloid leukemia^len#Cancer#20090000#2009#115#13#2912-21#20110200#v3
3n1a17.htm#0008-543X#Cancer##
00850000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100025000790100020001040100
01500124010001400139010001900153010001600172810000600188012023300194030000600427
06500090043306400050044203100040044703200030045101400080045486500090046200200130
0471035001000484801000600494#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#234#32#article#51#32#^rND^sQuintás-Cardama^nA#^rND^sKantarjian^nH#^rND^sJ
ones^nD#^rND^sShan^nJ#^rND^sBorthakur^nG#^rND^sThomas^nD#et al#Delayed achieveme
nt of cytogenetic and molecular response is associated with increased risk of pr
ogression among patients with chronic myeloid leukemia in early chronic phase re
ceiving high-dose or standard-dose imatinib therapy^len#Blood#20090000#2009#113#
25#6315-21#20110200#v33n1a17.htm#0006-4971#Blood##
00865000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100015000980100
01700113010001600130010001800146010001700164810000600181012024500187030001300432
06500090044506400050045403100030045903200020046201400060046486500090047000200130
0479035001000492801001300502#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#235#33#article#51#33#^rND^sIacobucci^nI#^rND^sRosti^nG#^rND^sAmabile^nM#^
rND^sPoerio^nA#^rND^sSoverini^nS#^rND^sCilloni^nD#et al#Comparison between patie
nts with Philadelphia-positive chronic phase chronic myeloid leukemia who obtain
ed a complete cytogenetic response within 1 year of imatinib therapy and those w
ho achieved such a response after 12 months of treatment^len#J Clin Oncol#200600
00#2006#24#3#454-9#20110200#v33n1a17.htm#0732-183X#J Clin Oncol##
00738000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01700111010001500128010001600143010001400159810000600173012011800179030001600297
06500090031306400050032203100030032703200020033001400080033286500090034000200130
0349035001000362801001600372#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#236#34#article#51#34#^rND^sCortes^nJ#^rND^sTalpaz^nM#^rND^sO'Brien^nS#^rN
D^sJones^nD#^rND^sLuthra^nR#^rND^sShan^nJ#et al#Molecular responses in patients 
with chronic myelogenous leukemia in chronic phase treated with imatinib mesylat
e^len#Clin Cancer Res#20050000#2005#11#9#3425-32#20110200#v33n1a17.htm#1078-0432
#Clin Cancer Res##
00800000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100020000940100
01900114010002000133010002200153010001500175810000600190012018100196030000600377
06500090038306400050039203100040039703200030040101400080040486500090041200200130
0421035001000434801000600444#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#237#35#article#51#35#^rND^sMarin^nD#^rND^sMilojkovic^nD#^rND^sOlavarria^n
E#^rND^sKhorashad^nJS#^rND^sde Lavallade^nH#^rND^sReid^nAG#et al#European Leukem
iaNet criteria for failure or suboptimal response reliably identify patients wit
h CML in early chronic phase treated with imatinib whose eventual outcome is poo
r^len#Blood#20080000#2008#112#12#4437-44#20110200#v33n1a17.htm#0006-4971#Blood##
00799000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100020000970100
01700117010001600134010001900150010001600169810000600185012018300191030000700374
06500090038106400050039003100040039503200030039901400080040286500090041000200130
0419035001000432801000700442#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#238#36#article#51#36#^rND^sAlvarado^nY#^rND^sKantarjian^nH#^rND^sO'Brien^
nS#^rND^sFaderl^nS#^rND^sBorthakur^nG#^rND^sBurger^nJ#et al#Significance of subo
ptimal response to imatinib, as defined by the European LeukemiaNet, in the long
-term outcome of patients with early chronic myeloid leukemia in chronic phase^l
en#Cancer#20090000#2009#115#16#3709-18#20110200#v33n1a17.htm#0008-543X#Cancer##
00733000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
01400116010001500130010002300145010001600168810000600184012012000190030000700310
06500090031706400050032603100040033103200020033501400070033786500090034400200130
0353035001000366801000700376#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#239#37#article#51#37#^rND^sKantarjian^nH#^rND^sO'Brien^nS#^rND^sShan^nJ#^
rND^sHuang^nX#^rND^sGarcia-Manero^nG#^rND^sFaderl^nS#et al#Cytogenetic and molec
ular responses and outcome in chronic myelogenous leukemia: need for new respons
e definitions?^len#Cancer#20080000#2008#112#4#837-45#20110200#v33n1a17.htm#0008-
543X#Cancer##
01020000000000457000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01700115010001700132010001800149010001600167010001800183010001700201010001700218
01000170023501000140025201000180026601000170028401000170030101100190031801201100
03370300009004470650009004560640005004650310003004700320002004730140008004750610
03800483865000900521002001300530035001000543801000900553#v33n1#V:\SciELO\serial\
rbhh\v33n1\markup\v33n1a17.htm#S#c#240#38#article#51#38#^rND^sHochhaus^nA#^rND^s
O'Brien^nSG#^rND^sGuilhot^nF#^rND^sDruker^nBJ#^rND^sBranford^nS#^rND^sForoni^nL#
^rND^sGoldman^nJM#^rND^sMüller^nMC#^rND^sRadich^nJP#^rND^sRudoltz^nM#^rND^sMone^
nM#^rND^sGathmann^nI#^rND^sHughes^nTP#^rND^sLarson^nRA#IRIS Investigators#Six-ye
ar follow-up of patients receiving imatinib for thefirst-line treatment of chron
ic myeloid leukemia^len#Leukemia#20090000#2009#23#6#1054-61#Erratum in: Leukemia
. 2010;24(5):1102#20110200#v33n1a17.htm#0887-6924#Leukemia##
00777000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100017000930100
01500110010001600125010001700141010001600158810000600174012017000180030000900350
06500090035906400050036803100030037303200020037601400080037886500090038600200130
0395035001000408801000900418#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#241#39#article#51#39#^rND^sMerx^nK#^rND^sMüller^nMC#^rND^sKreil^nS#^rND^s
Lahaye^nT#^rND^sPaschka^nP#^rND^sSchoch^nC#et al#Early reduction of BCR-ABL mRNA
 transcript levels predicts cytogenetic response in chronic phase CML patients t
reated with imatinib after failure of interferon alpha^len#Leukemia#20020000#200
2#16#9#1579-83#20110200#v33n1a17.htm#0887-6924#Leukemia##
00774000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01900113010001500132010001600147010001800163810000600181012016500187030000600352
06500090035806400050036703100040037203200020037601400080037886500090038600200130
0395035001000408801000600418#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#242#40#article#51#40#^rND^sBranford^nS#^rND^sRudzki^nZ#^rND^sParkinson^nI
#^rND^sGrigg^nA#^rND^sTaylor^nK#^rND^sSeymour^nJF#et al#Real-time quantitative P
CR analysis can be used as a primary screen to identify patients with CML treate
d with imatinib who have BCR-ABL kinase domain mutations^len#Blood#20040000#2004
#104#9#2926-32#20110200#v33n1a17.htm#0006-4971#Blood##
00712000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940100
01400108010001400122010001600136010001800152012006900170030000800239065000900247
06400050025603100040026103200050026501400080027006100440027886500090032200200130
0331035001000344801000800354#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#243#41#article#51#41#^rND^sShah^nNP#^rND^sTran^nC#^rND^sLee^nFY#^rND^sChe
n^nP#^rND^sNorris^nD#^rND^sSawyers^nCL#Overriding imatinib resistance with a nov
el ABL kinase inhibitor^len#Science#20040000#2004#305#5682#399-401#Comment in: S
cience. 2004;305 (5692):319-21#20110200#v33n1a17.htm#0036-8075#Science##
00762000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01700113010001300130010001800143010001400161810000600175012009900181030000800280
06500090028806400050029703100040030203200050030601400070031106100420031886500090
0360002001300369035001000382801000800392#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a17.htm#S#c#244#42#article#51#42#^rND^sGorre^nME#^rND^sMohammed^nM#^rND^s
Ellwood^nK#^rND^sHsu^nN#^rND^sPaquette^nR#^rND^sRao^nPN#et al#Clinical resistanc
e to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification^len
#Science#20010000#2001#293#5531#876-80#Comment on: Science. 2001;293(5538):2163.
#20110200#v33n1a17.htm#0036-8075#Science##
00945000000000397000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100017001000100
01700117010001800134010001400152010001700166010001700183010001600200010001700216
01100770023301201000031003000070041006500090041706400050042603100040043103200020
0435014000700437061006400444865000900508002001300517035001000530801000700540#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#245#43#article#51#43#^rND
^sKantarjian^nHM#^rND^sLarson^nRA#^rND^sGuilhot^nF#^rND^sO'Brien^nSG#^rND^sMone^
nM#^rND^sRudoltz^nM#^rND^sKrahnke^nT#^rND^sCortes^nJ#^rND^sDruker^nBJ#Internatio
nal Randomized Study of Interferon and STI571 (IRIS) Investigators#Efficacy of i
matinib dose escalation in patients with chronic myeloid leukemia in chronic pha
se^len#Cancer#20090000#2009#115#3#551-60#Erratum in: Cancer. 2010;116(15):3750. 
Santini, Valeria [added]#20110200#v33n1a17.htm#0008-543X#Cancer##
00784000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01600115010001800131010001900149012020100168030001600369065000900385064000500394
03100020039903200020040101400070040386500090041000200130041903500100043280100160
0442#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#246#44#article#51
#44#^rND^sZonder^nJA#^rND^sPemberton^nP#^rND^sBrandt^nH#^rND^sMohamed^nAN#^rND^s
Schiffer^nCA#The effect of dose increase of imatinib mesylate in patients with c
hronic or accelerated phase chronic myelogenous leukemia with inadequate hematol
ogic or cytogenetic response to initial treatment^len#Clin Cancer Res#20030000#2
003#9#6#2092-7#20110200#v33n1a17.htm#1078-0432#Clin Cancer Res##
00735000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
01900112010001900131012015000150030000600300065000900306064000500315031000400320
03200020032401400070032606100380033386500090037100200130038003500100039380100060
0403#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#247#45#article#51
#45#^rND^sMarin^nD#^rND^sGoldman^nJM#^rND^sOlavarria^nE#^rND^sApperley^nJF#Trans
ient benefit only from increasing the imatinib dose in CML patients who do not a
chieve complete cytogenetic remissions on conventional doses^len#Blood#20030000#
2003#102#7#2702-3#Comment on: Blood. 2003; 101(2):473-5#20110200#v33n1a17.htm#00
06-4971#Blood##
00809000000000361000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100021000970100
01900118010001700137010001900154010001700173810000600190012014400196030000600340
06500090034606400050035503100040036003200020036401400070036606100360037386500090
0409002001300418035001000431801000600441#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a17.htm#S#c#248#46#article#51#46#^rND^sHochhaus^nA#^rND^sKantarjian^nHM#^
rND^sBaccarani^nM#^rND^sLipton^nJH#^rND^sApperley^nJF#^rND^sDruker^nBJ#et al#Das
atinib induces notable hematologic and cytogenetic responses in chronic-phase ch
ronic myeloid leukemia after failure of imatinib therapy^len#Blood#20070000#2007
#109#6#2303-9#Erratum in: Blood. 2007;110(5):1438#20110200#v33n1a17.htm#0006-497
1#Blood##
00745000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01800111010001800129010001400147010001700161810000600178012012500184030001300309
06500090032206400050033103100030033603200030033901400080034286500090035000200130
0359035001000372801001300382#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#249#47#article#51#47#^rND^sHughes^nT#^rND^sSaglio^nG#^rND^sBranford^nS#^r
ND^sSoverini^nS#^rND^sKim^nDW#^rND^sMüller^nMC#et al#Impact of baseline BCR-ABL 
mutations on response to nilotinib in patients with chronic myeloid leukemia in 
chronic phase^len#J Clin Oncol#20090000#2009#27#25#4204-10#20110200#v33n1a17.htm
#0732-183X#J Clin Oncol##
00569000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960120
09000113030000900203065000900212064000500221031000300226032000200229014000700231
865000900238002001300247035001000260801000900270#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a17.htm#S#c#250#48#article#51#48#^rND^sBreccia^nM#^rND^sAlimena^n
G#Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid l
eukemia^len#Leuk Res#20100000#2010#34#2#129-34#20110200#v33n1a17.htm#0145-2126#L
euk Res##
00766000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
02100117010001900138010002000157010001600177810000600193012014400199030000600343
06500090034906400050035803100040036303200030036701400080037086500090037800200130
0387035001000400801000600410#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#251#49#article#51#49#^rND^sKantarjian^nH#^rND^sPasquini^nR#^rND^sHamersch
lak^nN#^rND^sRousselot^nP#^rND^sHolowiecki^nJ#^rND^sJootar^nS#et al#Dasatinib or
 high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of 
first-line imatinib: a randomized phase 2 trial^len#Blood#20070000#2007#109#12#5
143-50#20110200#v33n1a17.htm#0006-4971#Blood##
00821000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
01400117010001600131010002000147010002100167810000600188012020200194030000700396
06500090040306400050041203100040041703200030042101400080042486500090043200200130
0441035001000454801000700464#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.h
tm#S#c#252#50#article#51#50#^rND^sKantarjian^nH#^rND^sPasquini^nR#^rND^sLévy^nV#
^rND^sJootar^nS#^rND^sHolowiecki^nJ#^rND^sHamerschlak^nN#et al#Dasatinib or high
-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib 
at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized pha
se 2 study (START-R)^len#Cancer#20090000#2009#115#18#4136-47#20110200#v33n1a17.h
tm#0008-543X#Cancer##
00767000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01600114010001800130010002100148012019800169030000900367065000900376064000500385
03100030039003200020039301400050039586500090040000200130040903500100042280100090
0432#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a17.htm#S#c#253#51#article#51
#51#^rND^sJabbour^nE#^rND^sHochhaus^nA#^rND^sCortes^nJ#^rND^sLa Rosée^nP#^rND^sK
antarjian^nHM#Choosing the best treatment strategy for chronic myeloid leukemia 
patients resistant to imatinib: weighing the efficacy and safety of individual d
rugs with BCR-ABL mutations and patient history^len#Leukemia#20100000#2010#24#1#
6-12#20110200#v33n1a17.htm#0887-6924#Leukemia##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#o#1#1#article#1
#20110411#115605#v33n1a18.htm#101##
02004000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030002900109
03100030013803200020014106500090014301400090015203500100016123700270017101200800
01980100038002780100034003160700087003500830674004370850010011110850028011210850
03301149085004101182085003701223085002601260085001801286085001701304085001801321
08500250133911700060136407200030137011200090137311100110138211400090139311300110
1402002001301413#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#h#2#1#a
rticle#1#cr#en#br1.1#1#4.0#ILUS#18#RBHH140#nd#Rev. Bras. Hematol. Hemoter.#33#1#
20110200#^f73^l76#1516-8484#10.5581/1516-8484.20110018#Simultaneous lymph node i
nvolvement by Castleman disease and Kaposi sarcoma^len#^rND^1A01^nLuciana Werner
sbach^sPinto#^rND^1A01^nEstevão Portela^sNunes#Fiocruz^iA01^1Instituto de Pesqui
sa Clínica Evandro Chagas^cRio de Janeiro^sRJ^pBrazil#^len^aBoth multicentric Ca
stleman disease and Kaposi sarcoma are more frequently observed in HIV infected 
patients. The coexistence of these Human herpesvirus 8 related lesions, in the s
ame tissue, has been observed, but literature reports are scant. On the other ha
nd, the expression of HHV-8-LANA-1 is easily demonstrable by immunohistochemistr
y. This has been shown to be a powerful tool for the diagnosis of these entities
. The aim of this report is to communicate our experience with a case of multice
ntric Castleman disease occurring in the setting of HIV infection, which demonst
rated microscopic Kaposi sarcoma in the same lymph node during the pathological 
work-up#^ddecs^i1#^tm^len^kSarcoma, Kaposi^i1#^tm^len^kHerpesvirus 8, human^i1#^
tm^len^kGiant lymph node hyperplasia^i1#^tm^len^kHerpesviridae infections^i1#^tm
^len^kVirus latency^i1#^tm^len^kHuman^i1#^tm^len^kMale^i1#^tm^len^kAdult^i1#^tm^
len^kCase reports^i1#other#10#20101013#10/13/2010#20101224#12/24/2010#v33n1a18.h
tm##
02011000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030002900109
03100030013803200020014106500090014301400090015203500100016123700270017101200870
01980100038002850100034003230700087003570830674004440850010011180850028011280850
03301156085004101189085003701230085002601267085001801293085001701311085001801328
08500250134611700060137107200030137711200090138011100110138911400090140011300110
1409002001301420#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#f#3#1#a
rticle#1#cr#en#br1.1#1#4.0#ILUS#18#RBHH140#nd#Rev. Bras. Hematol. Hemoter.#33#1#
20110200#^f73^l76#1516-8484#10.5581/1516-8484.20110018#<b>Simultaneous lymph nod
e involvement by Castleman disease and Kaposi sarcoma</b>^len#^rND^1A01^nLuciana
 Wernersbach^sPinto#^rND^1A01^nEstevão Portela^sNunes#Fiocruz^iA01^1Instituto de
 Pesquisa Clínica Evandro Chagas^cRio de Janeiro^sRJ^pBrazil#^len^aBoth multicen
tric Castleman disease and Kaposi sarcoma are more frequently observed in HIV in
fected patients. The coexistence of these Human herpesvirus 8 related lesions, i
n the same tissue, has been observed, but literature reports are scant. On the o
ther hand, the expression of HHV-8-LANA-1 is easily demonstrable by immunohistoc
hemistry. This has been shown to be a powerful tool for the diagnosis of these e
ntities. The aim of this report is to communicate our experience with a case of 
multicentric Castleman disease occurring in the setting of HIV infection, which 
demonstrated microscopic Kaposi sarcoma in the same lymph node during the pathol
ogical work-up#^ddecs^i1#^tm^len^kSarcoma, Kaposi^i1#^tm^len^kHerpesvirus 8, hum
an^i1#^tm^len^kGiant lymph node hyperplasia^i1#^tm^len^kHerpesviridae infections
^i1#^tm^len^kVirus latency^i1#^tm^len^kHuman^i1#^tm^len^kMale^i1#^tm^len^kAdult^
i1#^tm^len^kCase reports^i1#other#10#20101013#10/13/2010#20101224#12/24/2010#v33
n1a18.htm##
02131000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103121000300108049000800111158000300119
03000280012203100030015003200020015306500090015501400090016403500100017323700270
01830120080002100100038002900100034003280700089003620830674004510850010011250850
02801135085003301163085004101196085003701237085002601274085001801300085001701318
08500180133508500250135311700060137807200030138411200090138711100110139611400090
1407113001101416002001301427008008901440#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a18.htm#S#l#4#1#article#1#^mFeb.^a2011#cr#en#br1.1#1#4.0#ilus#18#RBHH140#
nd#Rev. bras. hematol. hemoter#33#1#20110200#^f73^l76#1516-8484#10.5581/1516-848
4.20110018#Simultaneous lymph node involvement by Castleman disease and Kaposi s
arcoma^len#^rND^1A01^nLuciana Wernersbach^sPinto#^rND^1A01^nEstevão Portela^sNun
es#^iA01^1Fiocruz^2Instituto de Pesquisa Clínica Evandro Chagas^cRio de Janeiro^
sRJ^pBrazil#^len^aBoth multicentric Castleman disease and Kaposi sarcoma are mor
e frequently observed in HIV infected patients. The coexistence of these Human h
erpesvirus 8 related lesions, in the same tissue, has been observed, but literat
ure reports are scant. On the other hand, the expression of HHV-8-LANA-1 is easi
ly demonstrable by immunohistochemistry. This has been shown to be a powerful to
ol for the diagnosis of these entities. The aim of this report is to communicate
 our experience with a case of multicentric Castleman disease occurring in the s
etting of HIV infection, which demonstrated microscopic Kaposi sarcoma in the sa
me lymph node during the pathological work-up#^ddecs^i1#^tm^len^kSarcoma, Kaposi
^i1#^tm^len^kHerpesvirus 8, human^i1#^tm^len^kGiant lymph node hyperplasia^i1#^t
m^len^kHerpesviridae infections^i1#^tm^len^kVirus latency^i1#^tm^len^kHuman^i1#^
tm^len^kMale^i1#^tm^len^kAdult^i1#^tm^len^kCase reports^i1#other#10#20101013#10/
13/2010#20101224#12/24/2010#v33n1a18.htm#Internet^ihttp://www.scielo.br/scielo.p
hp?script=sci_arttext&pid=S1516-84842011000100018##
00347000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704011500073002001300188#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#5#1#article#87#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>CASE REPORT</b></font>
</p>     ^cY#v33n1a18.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#6#2#article#87#<p>&nbsp;</p>     ^cY#
v33n1a18.htm##
00415000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704018300073002001300256#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#7#3#article#87#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Simultaneous lymph
 node involvement by Castleman disease and Kaposi sarcoma</b></font></p>     ^cY
#v33n1a18.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#8#4#article#87#<p>&nbsp;</p>     ^cY#
v33n1a18.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#9#5#article#87#<p>&nbsp;</p>     ^cY#
v33n1a18.htm##
00378000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704014500074002001300219#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#10#6#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Luciana Wernersbach Pinto; Estev&at
ilde;o Portela Nunes</b></font></p>     ^cY#v33n1a18.htm##
00411000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704017800074002001300252#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#11#7#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Instituto de Pesquisa Cl&iacute;nica E
vandro Chagas (IPE), Fiocruz  Rio de Janeiro (RJ), Brazil</font></p>     ^cY#v33
n1a18.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704011500074002001300189#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#12#8#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></font
></p>     ^cY#v33n1a18.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704002200074002001300096#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#13#9#article#87#<p>&nbsp;</p>     ^cY
#v33n1a18.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004400075002001300119#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#14#10#article#87#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v33n1a18.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009800075002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#15#11#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v3
3n1a18.htm##
00985000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704075100075002001300826#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#16#12#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Both multicentric Castleman disease a
nd Kaposi sarcoma are more frequently observed in HIV infected patients. The coe
xistence of these Human herpesvirus 8 related lesions, in the same tissue, has b
een observed, but literature reports are scant. On the other hand, the expressio
n of HHV-8-LANA-1 is easily demonstrable by immunohistochemistry. This has been 
shown to be a powerful tool for the diagnosis of these entities. The aim of this
 report is to communicate our experience with a case of multicentric Castleman d
isease occurring in the setting of HIV infection, which demonstrated microscopic
 Kaposi sarcoma in the same lymph node during the pathological work-up.</font></
p>     ^cY#v33n1a18.htm##
00499000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704026500075002001300340#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#17#13#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Sarcoma, Kaposi; Her
pesvirus 8, human;  Giant lymph node hyperplasia; Herpesviridae infections; Viru
s latency; Human; Male; Adult; Case reports</font></p> <hr size="1" noshade>    
 ^cY#v33n1a18.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#18#14#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#19#15#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010200075002001300177#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#20#16#article#87#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></p>     ^c
Y#v33n1a18.htm##
00922000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704068800075002001300763#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#21#17#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Castleman disease (CD) is a rare lymp
hoproliferative disease, initially observed in patients with localized disease, 
who are asymptomatic or mildly symptomatic, and were cured with surgical resecti
on. Subsequent observations, based on studies of case series and histopathologic
 reviews, broadened the knowledge about the disease, which is traditionally grou
ped into the following histologic forms: hyaline-vascular variant, plasma cell v
ariant, and those with mixed characteristics. It can present as localized lympha
denopathy (localized form) or as disseminated disease (multicentric form).<sup>(
1)</sup></font></p>     ^cY#v33n1a18.htm##
00893000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704065900075002001300734#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#22#18#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The symptoms associated with morpholo
gic aspects, suggest the participation of a virus in the pathogenesis of the dis
ease. The observation that approximately 13% of patients with multicentric Castl
eman Disease (MCD) develop Kaposi sarcoma (KS), led to an interest in investigat
ing the presence of human herpesvirus 8 (HHV-8) in the lymphoid tissues of patie
nts with MCD.<sup>(2)</sup> Currently it is known that HHV-8 is present in 100% 
of the cases of MCD in patients infected with the human immunodeficiency virus (
HIV) and in 40% to 50% of HIV-negative cases.<sup>(3)</sup></font></p>     ^cY#v
33n1a18.htm##
00966000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704073200075002001300807#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#23#19#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Although the pathogenesis of CD is st
ill not fully understood, the first step in the development of the disease is th
e production of interleukin-6 (IL-6) - a cytokine with lymphoproliferative prope
rties - by B cells in the mantle zone of lymph nodes. The production of IL-6 is 
stimulated by HHV-8 infection and it is believed that some as yet unidentified e
ndogenous or exogenous factor must be involved in the cases not associated with 
the v&iacute;rus.<sup>(4)</sup> In addition to the increase in IL-6, it has been
 observed that  vascular endothelial growth factor (VEGF) levels are increased i
n the lymph nodes of patients with CD.<sup>(1)</sup></font></p>     ^cY#v33n1a18
.htm##
01279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704104500075002001301120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#24#20#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">MCD has a poor prognosis and a clinic
al course that is rapidly fatal. It occurs more frequently in HIV-infected patie
nts that present constitutional symptoms, generalized lymphadenopathy, hepatospl
enomegaly, polyclonal hypergammaglobulinemia, anemia, and elevated serum levels 
of IL-6.<sup>(5)</sup> The histopathologic examination of the lymph nodes shows 
lymphoid follicles largely devoid of germinal centers, some degree of hyalinizat
ion and expansion of the mantle zones, where one observes variable quantities of
 plasmablasts with large and vesicular nuclei, with prominent nucleoli, expressi
ng the latency-associated nuclear antigen 1 (LANA-1) of HHV-8. The interfollicul
ar areas appear expanded and infiltrated by mature plasma cells. The plasmablast
s can coalesce and form microlymphomas or even HHV-8 positive plasmablastic lymp
homa, an entity recently included in the WHO classification for tumors of hemato
poietic and lymphoid tissues.<sup>(3,6)</sup></font></p>     ^cY#v33n1a18.htm##
01184000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704095000075002001301025#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#25#21#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">KS, similar to MCD, is observed with 
increased frequency in HIV-positive patients, with the microscopic involvement o
f lymph nodes and spleen by KS common in patients with acquired immunodeficiency
 syndrome (AIDS).<sup>(7)</sup> The coexistence of these two diseases related to
 HHV-8 in the same tissue has been observed, however there are few reports in th
e literature and only one recent well-documented case series evaluating the pres
ence of the two lesions in the same tissue specimen.<sup>(5,8)</sup> On the othe
r hand, the expression of HHV-8-LANA-1 is easily demonstrated by immunohistochem
istry. The objective of this case report is to share our experience with one cas
e of MCD in an HIV-positive patient, which demonstrated the coexistence of micro
scopic KS in the same lymph node specimen, during the immunohistochemical analys
is for the detection of HHV-8.</font></p>     ^cY#v33n1a18.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#26#22#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010100075002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#27#23#article#87#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Case report</b></font></p>     ^cY
#v33n1a18.htm##
01351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704111700075002001301192#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#28#24#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"> The patient is a 40-year-old male wh
o reports daily fever (39º-40ºC), enlarged lymph nodes, a 6 kg weight loss in th
e past three months, and productive cough for two weeks. Antibiotic therapy was 
initiated, without improvement. Serologic testing during this period was positiv
e for HIV-1. At the time of hospitalization he presented with exertional dyspnea
, cough, fever, cervical and axillary lymphadenomegaly, and hepatosplenomegaly. 
Laboratory tests revealed anemia and thrombocytopenia. Blood and sputum cultures
 were negative for mycobacterium. Chest tomography revealed a ground glass infil
trate at the left base and enlarged mediastinal and axillary lymph nodes. Direct
 examination of sputum did not reveal acid-fast resistant bacilli. Nevertheless,
 treatment with antituberculous and antifungal regimens was started. The patient
, however, developed shortness of breath and worsening thrombocytopenia and rena
l function, and died ten days after admission. During the hospitalization a cerv
ical lymph node biopsy was performed.</font></p>     ^cY#v33n1a18.htm##
00636000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704040200075002001300477#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#29#25#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The lymph node submitted to histopath
ologic examination underwent routine processing and immunohistochemical studies,
 using antibodies to assess the expression of the following antigens: CD20 (1:80
0, DAKO), CD3 (1:400, DAKO), CD138 (1:200, Cell Marque), Bcl-2 (1:200, Novocastr
a) and HHV-8 (LANA-1) (1:200, Novocastra).</font></p>     ^cY#v33n1a18.htm##
00853000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704061900075002001300694#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#30#26#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Microscopic evaluation of the lymph n
ode revealed atrophic or fibrotic lymphoid follicles with increased vascularizat
ion, surrounded by expanded mantle zones, with a concentric appearance, interspe
rsed with scattered plasmablasts. The interfollicular areas also were expanded -
 containing a large quantity of mature plasma cells - and highly vascularized (<
a href="#fig1a">Figures 1A</a> and <a href="#fig1b">1B</a>). Focal areas of caps
ular thickening in the routine H &amp; E stain were also observed (<a href="#fig
2a">Figure 2A</a>).</font></p>     ^cY#v33n1a18.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003600075002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#31#27#article#87#<p><a name="fig1a"><
/a></p>     ^cY#v33n1a18.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#32#28#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007600075002001300151#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#33#29#article#87#<p align="center"><i
mg src="/img/revistas/rbhh/v33n1/a18fig01a.jpg">    ^cY#v33n1a18.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704008500075002001300160#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#34#30#article#87#<br>   <a name="fig1
b"></a><img src="/img/revistas/rbhh/v33n1/a18fig01b.jpg">    ^cY#v33n1a18.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704008800075002001300163#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#35#31#article#87#<br> <a name="fig1c"
></a><img src="/img/revistas/rbhh/v33n1/a18fig01c.jpg"></p>     ^cY#v33n1a18.htm
##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#36#32#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003600075002001300111#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#37#33#article#87#<p><a name="fig2a"><
/a></p>     ^cY#v33n1a18.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#38#34#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007600075002001300151#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#39#35#article#87#<p align="center"><i
mg src="/img/revistas/rbhh/v33n1/a18fig02a.jpg">    ^cY#v33n1a18.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704008800075002001300163#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#40#36#article#87#<br> <a name="fig2b"
></a><img src="/img/revistas/rbhh/v33n1/a18fig02b.jpg"></p>     ^cY#v33n1a18.htm
##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#41#37#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00678000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704044400075002001300519#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#42#38#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The immunohistochemical study with HH
V-8-LANA-1 revealed plasmablasts with nuclear positivity within the mantle zones
, as well as the positivity in scattered endothelial cells in the lymphoid folli
cles (<a href="#fig1c">Figure 1C</a>). This pattern of expression associated wit
h histological features led to the diagnosis of HHV-8-associated CD (plasmablast
ic).</font></p>     ^cY#v33n1a18.htm##
00589000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704035500075002001300430#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#43#39#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The microscopic involvement of the ly
mph node by KS was demonstrated by nuclear positivity for the HHV-8-LANA-1 antig
en in spindle cells and in endothelial cells lining poorly formed vascular chann
els in the regions of capsular thickening (<a href="#fig2b">Figure 2B</a>).</fon
t></p>     ^cY#v33n1a18.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#44#40#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010000075002001300175#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#45#41#article#87#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p>     ^cY#
v33n1a18.htm##
00683000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704044900075002001300524#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#46#42#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Although the frequency of CD as a cau
se of lymphadenopathy in the HIV-infected population is not known, it is not rar
e. CD in these patients has been described as a new variant, the HHV-8-associate
d CD (plasmablastic). It can occur with any CD4 T lymphocyte count and it appear
s that antiretroviral therapy has no effect on the course of the disease.<sup>(1
,6)</sup></font></p>     ^cY#v33n1a18.htm##
01282000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704104800075002001301123#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#47#43#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The cells infected by HHV-8 in MCD re
lated to HIV have been localized and characterized by studies using immunohistoc
hemistry. There is a consensus that they are B cells with plasmablastic morpholo
gy or plasma cell differentiation, localized in the mantle zone of lymphoid foll
icles and interfollicular areas. Brousset et al., <sup>(9)</sup> in a study that
 used double staining to evaluate the expression of LANA-1 and v-IL-6 in cases o
f MCD and KS, observed that in MCD cases, about one-third of the lymphoid cells 
were positive for both of the markers, indicating the expression of genes of the
 lytic phase and of the latency in the plasmablasts. These authors further showe
d that in some of the lymph nodes in MCD there was expression of LANA-1 in spind
le cells (some clearly endothelial cells and others resembling fibroblasts), as 
well as in lymphoid cells. In one of the cases studied, spindle cells were abund
ant, with areas that recalled KS. <sup>(9)</sup></font></p>     ^cY#v33n1a18.htm
##
00753000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704051900075002001300594#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#48#44#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Abe et al.<sup>(8)</sup> reported a c
ase of KS and MCD in a single lymph node from a HIV-positive patient, in which t
hey demonstrated, using immunohistochemistry, the differential expression of the
 viral proteins in the two lesions. In MCD, proteins of the lytic phase and of t
he latency of HHV-8 are observed in the cells of the mantle zone, while in KS ne
oplastic cells are positive for LANA-1, with rare expression of lytic proteins.<
/font></p>     ^cY#v33n1a18.htm##
01437000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704120300075002001301278#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#49#45#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Naresh et al.<sup>(5)</sup> recently 
investigated the coexistence of these two entities related to HHV-8 (KS and MCD)
 in 24 lymph nodes and five spleens from patients with MCD associated with HIV. 
Among the lymph node specimens, 63% had microscopic involvement by KS involving 
the capsule, trabeculae, or hilum. This group was compared with 20 lymph nodes o
f HIV-positive patients without evidence of lymphoproliferative disorders. In th
is second group, 25% of the lymph nodes had microscopic involvement by KS, a per
centage significantly lower than in the group with MCD. The hypothesis of the au
thors was that the association of the two diseases is due to lytic infection of 
the B lymphoid cells by HHV-8, exposing susceptible cells in the vulnerable site
s of the lymph node to very high levels of HHV-8, which results in the formation
 of KS "tumorlets". This study also called attention to the fact that the micros
copic foci of KS spindle cells in the capsule, trabeculae and hilum of lymph nod
es are subtle and can be easily missed in routine histological evaluation or eve
n after immunohistochemistry.<sup>(5)</sup></font></p>     ^cY#v33n1a18.htm##
00754000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704052000075002001300595#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#50#46#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">In the study of the present case, the
 microscopic focus of KS was not detected with routine H &amp; E staining, and i
nitially we only diagnosed Castleman Disease.  With the availability of the anti
-HHV-8-LANA-1 antibody for routine use, it was possible to demonstrate the prese
nce of HHV-8 positive plasmablasts and to detect the slight proliferation of spi
ndle cells and immunopositive vascular channels close to the lymph node capsule.
</font></p>     ^cY#v33n1a18.htm##
00904000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704067000075002001300745#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#51#47#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">In patients with MCD and HIV infectio
n, in addition to antiretroviral therapy, systemic therapy should be instituted.
 This can be done with chemotherapy, immunomodulatory agents or monoclonal antib
odies against the receptor for IL-6 or anti-CD20 (rituximab). Rituximab has show
n promise in inducing a durable remission, but it has been observed that some pa
tients experience adverse effects such as the reactivation of Kaposi sarcoma.<su
p>(10)</sup> This finding emphasizes the importance of the detection by the path
ologist of microscopic foci of KS in lymph nodes of patients with MCD.</font></p
>     ^cY#v33n1a18.htm##
00691000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704045700075002001300532#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#52#48#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Given the findings of this case study
 and the data from the case series of Naresh et al.,<sup>(5)</sup> we suggest th
at the assessment by immunohistochemistry for HHV-8 (LANA-1) should always be co
nsidered in lymph nodes of HIV-positive patients with CD or those with ill-defin
ed areas of capsular/trabecular thickening and vascular proliferation on microsc
opic examination.</font></p>     ^cY#v33n1a18.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#53#49#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010400075002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#54#50#article#87#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Agradecimentos</b></font></p>     
^cY#v33n1a18.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704013600075002001300211#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#55#51#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The authors thank Leigh Passman for e
diting the text.</font></p>     ^cY#v33n1a18.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#56#52#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010000075002001300175#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#57#53#article#87#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY#
v33n1a18.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704023200077002001300309#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#58#54#article#87#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Casper C. The aetiol
ogy and management of Castleman disease at 50 years: translating pathophysiology
 to patient care. Br J Haematol. 2005;129(1):3-17. Review.    ^cY#v33n1a18.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#59#55#article#87#</font></p>     ^cY#
v33n1a18.htm##
00564000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704031600077002001300393#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#60#56#article#87#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2.  Soulier J, Grollet 
L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposis sarcoma-a
ssociated herpesvirus-like DNA sequences in multicentric Castleman's disease. Bl
ood. 1995;86(4): 1276-80. Comment in: Blood. 1996;87(1):414-6.    ^cY#v33n1a18.h
tm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#61#57#article#87#</font></p>     ^cY#
v33n1a18.htm##
00487000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704023900077002001300316#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#62#58#article#87#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Du MQ, Bacon CM, Isa
acson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphopr
oliferative disorders. J Clin Pathol. 2007;60(12):1350-7. Review.    ^cY#v33n1a1
8.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#63#59#article#87#</font></p>     ^cY#
v33n1a18.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704032000077002001300397#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#64#60#article#87#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Aoki Y, Jaffe ES, Ch
ang Y, Jones K, Teruya-Feldstein J, Moore PS, Tosato G. Angiogenesis and hematop
oiesis induced by Kaposis sarcoma-associated herpesvirus-encoded interleukin-6. 
Blood. 1999;93(12):4034-43.Comment in: Blood. 1999;93 (12):4031-3.    ^cY#v33n1a
18.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#65#61#article#87#</font></p>     ^cY#
v33n1a18.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704026500077002001300342#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#66#62#article#87#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Naresh KN, Rice AJ, 
Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positi
ve individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008;32 (
7):1006-12.    ^cY#v33n1a18.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#67#63#article#87#</font></p>     ^cY#
v33n1a18.htm##
00474000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704022600077002001300303#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#68#64#article#87#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Cronin DM, Warnke RA
. Castleman disease: an update on classification and the spectrum of associated 
lesions. Adv Anat Pathol. 2009;16(4):236-46. Review.    ^cY#v33n1a18.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#69#65#article#87#</font></p>     ^cY#
v33n1a18.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704028400077002001300361#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#70#66#article#87#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Moskowitz LB, Hensle
y GT, Gould EW, Weiss SD. Frequency and anatomic distribution of lymphadenopathi
c Kaposis sarcoma in the acquired immunodeficiency syndrome: an autopsy series. 
Hum Pathol. 1985;16(5):447-56.    ^cY#v33n1a18.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#71#67#article#87#</font></p>     ^cY#
v33n1a18.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704030600077002001300383#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#72#68#article#87#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Abe Y, Matsubara D, 
Gatanaga H, Oka S, Kimura S, Sasao Y, et al. Distinct expression of Kaposis sarc
oma-associated herpesvirus-encoded proteins in Kaposis sarcoma and multicentric 
Castleman's disease. Pathol Int. 2006;56(10):617-24.    ^cY#v33n1a18.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#73#69#article#87#</font></p>     ^cY#
v33n1a18.htm##
00607000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704035900077002001300436#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#74#70#article#87#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Brousset P, Cesarman
 E, Meggetto F, Lamant L, Delsol G. Colocalization of the viral interleukin-6 wi
th latent nuclear antigen-1 of human herpesvirus-8 in endothelial spindle cells 
of Kaposis sarcoma and lymphoid cells of multicentric Castleman's disease. Hum P
athol. 2001;32(1):95-100.    ^cY#v33n1a18.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#75#71#article#87#</font></p>     ^cY#
v33n1a18.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704020200078002001300280#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#76#72#article#87#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Casper C. New appr
oaches to the treatment of human herpesvirus 8-associated disease. Rev Med Virol
. 2008;18 (5): 321-9. Review.    ^cY#v33n1a18.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#77#73#article#87#</font></p>     ^cY#
v33n1a18.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#78#74#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#79#75#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00420000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704018600075002001300261#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#80#76#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img 
src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b>  
  ^cY#v33n1a18.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003800075002001300113#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#81#77#article#87#<br> Luciana Werners
bach Pinto    ^cY#v33n1a18.htm##
00308000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007400075002001300149#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#82#78#article#87#<br> Instituto de Pe
squisa Cl&iacute;nica Evandro Chagas - Fiocruz    ^cY#v33n1a18.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004200075002001300117#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#83#79#article#87#<br> Av Brasil , 436
5 - Manguinhos    ^cY#v33n1a18.htm##
00286000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704005200075002001300127#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#84#80#article#87#<br> 21340-360 - Rio
 de Janeiro (RJ), Brazil    ^cY#v33n1a18.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011700075002001300192#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#85#81#article#87#<br> <a href="mailto
:luciana.wernersbach@ipec.fiocruz.br">luciana.wernersbach@ipec.fiocruz.br</a></f
ont></p>     ^cY#v33n1a18.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009200075002001300167#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#86#82#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Submitted: 10/13/2010    ^cY#v33n1a18
.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003300075002001300108#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#87#83#article#87#<br> Accepted: 12/24
/2010    ^cY#v33n1a18.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010900075002001300184#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#88#84#article#87#<br> Conflict-of-int
erest disclosure: The authors declare no competing financial interest</font></p>
     ^cY#v33n1a18.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#89#85#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#90#86#article#87#<p>&nbsp;</p>     ^c
Y#v33n1a18.htm##
00457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704022300075002001300298#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a18.htm#S#p#91#87#article#87#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" target=
"_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_blank"
>www.scielo.br/rbhh</a></font></p>     ^cY#v33n1a18.htm##
00585000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100016000760120111000920300
01400203065000900217064000500226031000400231032000200235014000500237061000700242
865000900249002001300258035001000271801001400281#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a18.htm#S#c#92#1#article#10#1#^rND^sCasper^nC#The aetiology and m
anagement of Castleman disease at 50 years: translating pathophysiology to patie
nt care^len#Br J Haematol#20050000#2005#129#1#3-17#Review#20110200#v33n1a18.htm#
0007-1048#Br J Haematol##
00760000000000361000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100017000760100017000930100
02200110010001600132010002200148010001700170810000600187012009800193030000600291
06500090029706400050030603100030031103200020031401400080031606100360032486500090
0360002001300369035001000382801000600392#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a18.htm#S#c#93#2#article#10#2#^rND^sSoulier^nJ#^rND^sGrollet^nL#^rND^sOks
enhendler^nE#^rND^sCacoub^nP#^rND^sCazals-Hatem^nD#^rND^sBabinet^nP#et al#Kaposi
s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's 
disease^len#Blood#19950000#1995#86#4#1276-80#Comment in: Blood. 1996;87(1):414-6
#20110200#v33n1a18.htm#0006-4971#Blood##
00628000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100013000760100016000890100
01900105012009600124030001400220065000900234064000500243031000300248032000300251
014000700254061000700261865000900268002001300277035001000290801001400300#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#c#94#3#article#10#3#^rND^sDu^nM
Q#^rND^sBacon^nCM#^rND^sIsaacson^nPG#Kaposi sarcoma-associated herpesvirus/human
 herpesvirus 8 and lymphoproliferative disorders^len#J Clin Pathol#20070000#2007
#60#12#1350-7#Review#20110200#v33n1a18.htm#0021-9746#J Clin Pathol##
00774000000000361000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100014000760100016000900100
01500106010001500121010002600136010001600162010001600178012010700194030000600301
06500090030706400050031603100030032103200030032401400080032706100390033586500090
0374002001300383035001000396801000600406#v33n1#V:\SciELO\serial\rbhh\v33n1\marku
p\v33n1a18.htm#S#c#95#4#article#10#4#^rND^sAoki^nY#^rND^sJaffe^nES#^rND^sChang^n
Y#^rND^sJones^nK#^rND^sTeruya-Feldstein^nJ#^rND^sMoore^nPS#^rND^sTosato^nG#Angio
genesis and hematopoiesis induced by Kaposis sarcoma-associated herpesvirus-enco
ded interleukin-6^len#Blood#19990000#1999#93#12#4034-43#Comment in: Blood. 1999;
93 (12):4031-3#20110200#v33n1a18.htm#0006-4971#Blood##
00645000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100017000760100015000930100
01500108012012700123030001700250065000900267064000500276031000300281032000200284
014000800286865000900294002001300303035001000316801001700326#v33n1#V:\SciELO\ser
ial\rbhh\v33n1\markup\v33n1a18.htm#S#c#96#5#article#10#5#^rND^sNaresh^nKN#^rND^s
Rice^nAJ#^rND^sBower^nM#Lymph nodes involved by multicentric Castleman disease a
mong HIV-positive individuals are often involved by Kaposi sarcoma^len#Am J Surg
 Pathol#20080000#2008#32#7#1006-12#20110200#v33n1a18.htm#0147-5185#Am J Surg Pat
hol##
00563000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100017000760100017000930120
09000110030001600200710000200216065000900218064000500227031000300232032000200235
014000700237061000700244865000900251002001300260#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a18.htm#S#c#97#6#article#10#6#^rND^sCronin^nDM#^rND^sWarnke^nRA#C
astleman disease: an update on classification and the spectrum of associated les
ions^len#Adv Anat Pathol#2#20090000#2009#16#4#236-46#Review#20110200#v33n1a18.ht
m##
00677000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100020000760100018000960100
01600114010001600130012013700146030001100283065000900294064000500303031000300308
032000200311014000700313865000900320002001300329035001000342801001100352#v33n1#V
:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#c#98#7#article#10#7#^rND^sMosko
witz^nLB#^rND^sHensley^nGT#^rND^sGould^nEW#^rND^sWeiss^nSD#Frequency and anatomi
c distribution of lymphadenopathic Kaposis sarcoma in the acquired immunodeficie
ncy syndrome: an autopsy series^len#Hum Pathol#19850000#1985#16#5#447-56#2011020
0#v33n1a18.htm#0046-8177#Hum Pathol##
00746000000000349000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100013000760100019000890100
01800108010001300126010001600139010001500155810000600170012013900176030001100315
06500090032606400050033503100030034003200030034301400070034686500090035300200130
0362035001000375801001100385#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.h
tm#S#c#99#8#article#10#8#^rND^sAbe^nY#^rND^sMatsubara^nD#^rND^sGatanaga^nH#^rND^
sOka^nS#^rND^sKimura^nS#^rND^sSasao^nY#et al#Distinct expression of Kaposis sarc
oma-associated herpesvirus-encoded proteins in Kaposis sarcoma and multicentric 
Castleman's disease^len#Pathol Int#20060000#2006#56#10#617-24#20110200#v33n1a18.
htm#1320-5463#Pathol Int##
00771000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950100
01800113010001600131010001600147012020200163030001100365065000900376064000500385
03100030039003200020039301400070039586500090040200200130041103500100042480100110
0434#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a18.htm#S#c#100#9#article#10#
9#^rND^sBrousset^nP#^rND^sCesarman^nE#^rND^sMeggetto^nF#^rND^sLamant^nL#^rND^sDe
lsol^nG#Colocalization of the viral interleukin-6 with latent nuclear antigen-1 
of human herpesvirus-8 in endothelial spindle cells of Kaposis sarcoma and lymph
oid cells of multicentric Castleman's disease^len#Hum Pathol#20010000#2001#32#1#
95-100#20110200#v33n1a18.htm#0046-8177#Hum Pathol##
00555000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120078000950300
01400173065000900187064000500196031000300201032000200204014000600206061000700212
865000900219002001300228035001000241801001400251#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a18.htm#S#c#101#10#article#10#10#^rND^sCasper^nC#New approaches t
o the treatment of human herpesvirus 8-associated disease^len#Rev Med Virol#2008
0000#2008#18#5#321-9#Review#20110200#v33n1a18.htm#1052-9276#Rev Med Virol##
00272000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00400098#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a19.htm#S#o#1#1#text#1#20
110411#115606#v33n1a19.htm#324##
00597000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030002900106
03100030013503200020013806500090014001400090014903500100015812300020016823700270
0170012003700197002001300234#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a19.h
tm#S#h#2#1#text#1#cr#en#br1.1#1#4.0#ILUS#19#RBHH360#nd#Rev. Bras. Hematol. Hemot
er.#33#1#20110200#^f77^l81#1516-8484#1#10.5581/1516-8484.20110019#The transfusio
n medicine we want^len#v33n1a19.htm##
00604000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030002900106
03100030013503200020013806500090014001400090014903500100015812300020016823700270
0170012004400197002001300241#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a19.h
tm#S#f#3#1#text#1#cr#en#br1.1#1#4.0#ILUS#19#RBHH360#nd#Rev. Bras. Hematol. Hemot
er.#33#1#20110200#^f77^l81#1516-8484#1#10.5581/1516-8484.20110019#<b>The transfu
sion medicine we want</b>^len#v33n1a19.htm##
00722000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000800108158000300116
03000280011903100030014703200020015006500090015201400090016103500100017012300020
0180237002700182012003700209002001300246008008900259#v33n1#V:\SciELO\serial\rbhh
\v33n1\markup\v33n1a19.htm#S#l#4#1#text#1#^mFeb.^a2011#cr#en#br1.1#1#4.0#ilus#19
#RBHH360#nd#Rev. bras. hematol. hemoter#33#1#20110200#^f77^l81#1516-8484#1#10.55
81/1516-8484.20110019#The transfusion medicine we want^len#v33n1a19.htm#Internet
^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100019
##
00339000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000400067704010900071002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#5#1#text#320#<p align="right"><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>FORUM</b></font></p>    
 ^cY#v33n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000400067704002200071002001300093#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#6#2#text#320#<p>&nbsp;</p>     ^cY#v3
3n1a19.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000400067704014000071002001300211#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#7#3#text#320#<p><font size="4" face="
Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>The transfusion medi
cine we want</b></font></p>     ^cY#v33n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000400067704002200071002001300093#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#8#4#text#320#<p>&nbsp;</p>     ^cY#v3
3n1a19.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000400067704002200071002001300093#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#9#5#text#320#<p>&nbsp;</p>     ^cY#v3
3n1a19.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000400068704011500072002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#10#6#text#320#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></font><
/p>     ^cY#v33n1a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000400068704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#11#7#text#320#<p>&nbsp;</p>     ^cY#v
33n1a19.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000400068704004400072002001300116#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#12#8#text#320#<p>&nbsp;</p> <hr size=
"1" noshade>     ^cY#v33n1a19.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000400068704009800072002001300170#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#13#9#text#320#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v33n1
a19.htm##
00733000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704050100073002001300574#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#14#10#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">The Associa&ccedil;&atilde;o Brasileira
 de Hematologia e Hemoterapia (ABHH), through its Board of Directors, hosted a n
ational symposium called "Forum: The Transfusion Medicine we want", to discuss p
roposed policies and techniques related to the area. This meeting was held in S&
atilde;o Paulo on August 19 and 20, 2010, with the participation of experts, aut
horities and representatives of organized groups of patients and users.    ^cY#v
33n1a19.htm##
00444000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704021200073002001300285#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#15#11#text#320#<br> The discussions w
ere organized around three specific issues selected from over 100 suggestions se
nt to the ABHH through public consultation on the web: 1. Strategies; 2. Financi
ng; 3. Blood products.    ^cY#v33n1a19.htm##
00373000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704014100073002001300214#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#16#12#text#320#<br> A plenary session
, held at the end of the meeting, adopted recommendations that are relevant to t
he different discussion topics.    ^cY#v33n1a19.htm##
00361000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704012900073002001300202#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#17#13#text#320#<br> This document con
tains actions proposed by the ABHH to meet the demands discussed.</font></p> <hr
 size="1" noshade>     ^cY#v33n1a19.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#18#14#text#320#<p>&nbsp;</p>     ^cY#
v33n1a19.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704002200073002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#19#15#text#320#<p>&nbsp;</p>     ^cY#
v33n1a19.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704010600073002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#20#16#text#320#<p><font size="3" face
="Verdana, Arial, Helvetica, sans-serif"><b>Forum proposals </b></font></p>     
^cY#v33n1a19.htm##
00384000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704015200073002001300225#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#21#17#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Compilation of the proposals to draft t
he final document of the ABHH.</font></p>     ^cY#v33n1a19.htm##
00325000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704009300073002001300166#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#22#18#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Strategies</font></p>     ^cY#v33n1a19.
htm##
00393000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704016100073002001300234#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#23#19#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">1. That the ABHH should have seats on s
tate and national technical committees.</font></p>     ^cY#v33n1a19.htm##
00512000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704028000073002001300353#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#24#20#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">2. That patient care outside the govern
ment healthcare plan in both public and private settings should be paid for acco
rding to the Brazilian Hierarchy Classification of Medical Procedures (CBHPM).</
font></p>     ^cY#v33n1a19.htm##
00552000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704032000073002001300393#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#25#21#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">3. The structuring of educational progr
ams in blood centers, the ABHH and in governmental agencies (funding for courses
, scholarships, etc.) should be stimulated with the aim of qualifying profession
als who work with transfusion therapy.</font></p>     ^cY#v33n1a19.htm##
00575000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704034300073002001300416#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#26#22#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">4. That a minimum curriculum for transf
usion medicine should be proposed for Medicine Schools and for other healthcare 
courses at undergraduate and postgraduate levels. The transfusion committee shou
ld be consulted as a source in transfusion therapy education.</font></p>     ^cY
#v33n1a19.htm##
00463000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704023100073002001300304#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#27#23#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">5. The residency in Hematology and tran
sfusion medicine should be for a minimum of three years with one year devoted so
lely to transfusion medicine.</font></p>     ^cY#v33n1a19.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704020900073002001300282#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#28#24#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">6. The title of specialist in hematolog
y / transfusion medicine should be valorized (salary, valorize the professional,
 etc.).</font></p>     ^cY#v33n1a19.htm##
00532000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704030000073002001300373#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#29#25#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">7. The remuneration of transfusion proc
edures that are developed in transfusion agencies should be reviewed to guarante
e improvements in transfusion procedures and in the pay of doctors active in tra
nsfusion services.</font></p>     ^cY#v33n1a19.htm##
00464000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704023200073002001300305#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#30#26#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">8. A quality certification program for 
transfusion services accredited by the American Association of Blood Banks -  AA
BB/ABHH should be implemented.</font></p>     ^cY#v33n1a19.htm##
00376000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704014400073002001300217#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#31#27#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">9. "Standards" of ABHH similar to the A
ABB should be created.</font></p>     ^cY#v33n1a19.htm##
00442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704021000073002001300283#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#32#28#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">10. There should be stimulation to offe
r internships to all professionals working in transfusion medicine (public and p
rivate).</font></p>     ^cY#v33n1a19.htm##
00504000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704027200073002001300345#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#33#29#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">11. That the coordinator of the Hematol
ogy and Transfusion Medicine Technical Committee at Regional and National Medici
ne Councils (CRM) should be indicated (with a substitute) by the ABHH.</font></p
>     ^cY#v33n1a19.htm##
00542000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704031000073002001300383#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#34#30#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">12. That the ABHH should sponsor discus
sions with ANVISA and the General Coordination of Blood and Blood Products (CGSH
) in order to stimulate the creation of a technical support structure for transf
usion medicine in Hemorrede.</font></p>     ^cY#v33n1a19.htm##
00372000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704014000073002001300213#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#35#31#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">13. Specific forums should be organized
 on health safety.</font></p>     ^cY#v33n1a19.htm##
00629000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704039700073002001300470#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#36#32#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">14. The ABHH should suggest, through it
s scientific committee, issues of relevance to the country that should be public
ized in newsletters, instigating discussions aimed at the inclusion of procedure
s to improve transfusion safety (NAT - nucleic acid testing, Microbiological stu
dy of platelet concentrates, etc.).</font></p>     ^cY#v33n1a19.htm##
00456000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704022400073002001300297#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#37#33#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">15. The ABHH must act together with the
 Ministry of Health for the transfusion committee to work in the contracting of 
the hospital services.</font></p>     ^cY#v33n1a19.htm##
00450000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704021800073002001300291#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#38#34#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">16. Transfusion committee members shoul
d be professionalized similar to members of the Control of Hospital Infection Co
mmittees (CCIH).</font></p>     ^cY#v33n1a19.htm##
00605000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704037300073002001300446#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#39#35#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">17. The ABHH should assess the qualific
ations of those responsible for transfusion services and when considered unquali
fied, they should be trained by the ABHH together with Health Surveillance Insti
tutions (VISAs), so that the minimum standard is achieved for them to perform th
eir duties.</font></p>     ^cY#v33n1a19.htm##
00418000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704018600073002001300259#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#40#36#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">18. The ABHH should sponsor a forum spe
cifically to discuss possible business models for blood centers.</font></p>     
^cY#v33n1a19.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704009200073002001300165#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#41#37#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Financing</font></p>     ^cY#v33n1a19.h
tm##
00497000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704026500073002001300338#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#42#38#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">1. It was proposed that the ABHH should
 participate with the CGSH in negotiations with the Ministry of Health on increa
ses in funding and financing for transfusion medicine services.</font></p>     ^
cY#v33n1a19.htm##
00553000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704032100073002001300394#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#43#39#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">2. The ABHH with the National Supplemen
tary Health Agency (ANS) should discuss with the Confederation of Unimeds and eq
uivalent organizations to clarify procedures that should be performed, and there
fore paid for, to transfusion services.</font></p>     ^cY#v33n1a19.htm##
00526000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704029400073002001300367#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#44#40#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">3. A working group should be set up by 
the ABHH to propose replacing the 1737/04 and 1469/06 federal rulings with new g
uidelines to pay for blood products provided to the private sector based on the 
CBHPM table.</font></p>     ^cY#v33n1a19.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704019100073002001300264#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#45#41#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">4. New procedures should be permanently
 included in the government healthcare and private sector pricelists.</font></p>
     ^cY#v33n1a19.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704020900073002001300282#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#46#42#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">5.  A permanent technical commission sh
ould be created in the ABHH to meet demands on remuneration, updating pricelists
, etc..</font></p>     ^cY#v33n1a19.htm##
00394000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704016200073002001300235#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#47#43#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">6. Nucleic acid testing to screen blood
 donors should be mandatory immediately.</font></p>     ^cY#v33n1a19.htm##
00453000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704022100073002001300294#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#48#44#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">7. Care provided by transfusion service
s should be complete, including everything that is part of the specialty as list
ed in the contract.</font></p>     ^cY#v33n1a19.htm##
00444000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704021200073002001300285#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#49#45#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">8. The ABHH should have greater partici
pation in evaluations and alterations of the values and procedures on the CBHPM 
pricelist.</font></p>     ^cY#v33n1a19.htm##
00462000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704023000073002001300303#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#50#46#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">9. The ABHH should recommend adoption o
f the CBHPM pricelist and reductions in price of more than 20% should be conside
red demeaning and unethical.</font></p>     ^cY#v33n1a19.htm##
00738000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704050600073002001300579#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#51#47#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">10. The ABHH should manifest in respect
 to medical and non-medical societies that are involved in transfusion medicine 
procedures without scientific evidence, except for clinical research after it ha
s been duly approved by Research Ethics Committees. The ABHH should regulate the
 implementation of scientifically-proven proceedings by requiring the active par
ticipation of a hematologist specialist in transfusion medicine.</font></p>     
^cY#v33n1a19.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704015900073002001300232#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#52#48#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">11. Cell Therapy should be incorporatio
n as a transfusion therapy procedure.</font></p>     ^cY#v33n1a19.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704009700073002001300170#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#53#49#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Blood products</font></p>     ^cY#v33n1
a19.htm##
00502000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704027000073002001300343#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#54#50#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">1. The rational use of plasma was propo
sed, suggesting that common plasma should be used by the Butantan Institute (imm
unoglobulin and albumin) and fresh frozen plasma by Hemobr&aacute;s.</font></p> 
    ^cY#v33n1a19.htm##
00454000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704022200073002001300295#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#55#51#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">2. The ABHH and the Brazilian Federatio
n of Hemophilia (FBH) should request a description of the technological processe
s used by producers.</font></p>     ^cY#v33n1a19.htm##
00401000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704016900073002001300242#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#56#52#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">3. It was proposed that factories shoul
d present economic-financial viability studies.</font></p>     ^cY#v33n1a19.htm#
#
00433000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704020100073002001300274#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#57#53#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">4. It was proposed that the investment 
in research and development of recombinant drug production should be increased.<
/font></p>     ^cY#v33n1a19.htm##
00555000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704032300073002001300396#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#58#54#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">5. It was suggested that the ABHH shoul
d formally demonstrate their concern about the possibility that biological medic
ines are considered bio-similar or biogenerics in favor of the requirement of cl
inical trials to be registered in ANVISA.</font></p>     ^cY#v33n1a19.htm##
00491000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704025900073002001300332#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#59#55#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">6. It was suggested that the ABHH shoul
d formally demonstrate regarding the purchase of medicines by the Ministry of He
alth, so that high quality products are always purchased.</font></p>     ^cY#v33
n1a19.htm##
00465000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704023300073002001300306#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#60#56#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">7. It was proposed that immunoglobulin 
should be produced as a liquid, ready to use, without sugar or sodium and prefer
ably at a concentration of 10%.</font></p>     ^cY#v33n1a19.htm##
00440000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704020800073002001300281#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#61#57#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">8. It was proposed that blood transfusi
on therapy should again be the priority, including in respect to government reso
urces.</font></p>     ^cY#v33n1a19.htm##
00573000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704034100073002001300414#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#62#58#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">9. It was proposed that all procedures 
related to hematology and transfusion medicine, including cell therapy and bone 
marrow transplantation, should, in future, be coordinated by one team in the Min
istry of Health as with the coordination of blood services.</font></p>     ^cY#v
33n1a19.htm##
00468000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704023600073002001300309#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#63#59#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">10. It was proposed that cell therapy s
hould be incorporated within the scope of the ABHH and even include 'cell therap
y' in the name of the association.</font></p>     ^cY#v33n1a19.htm##
00440000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704020800073002001300281#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#64#60#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">11. It was recommended that access to b
one marrow transplant should be guaranteed for patients with primary immunodefic
iency </font></p>     ^cY#v33n1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704010700073002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#65#61#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Actions proposed by ABHH</font></p>    
 ^cY#v33n1a19.htm##
00582000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704035000073002001300423#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#66#62#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">1. ABHH will send a document to the Min
istry of Health and State Health Departments, stating that the ABHH represents t
he specialty in Hematology and Transfusion Medicine in the country and, as such,
 requests representation on Medical Specialties Advisory Committees.</font></p> 
    ^cY#v33n1a19.htm##
00567000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704033500073002001300408#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#67#63#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">2. The ABHH will defend the use of the 
CBHPM pricelist as the only reference for remuneration of hematology and transfu
sion medicine services carried out for patients outside the government healthcar
e system by both government and private institutions.</font></p>     ^cY#v33n1a1
9.htm##
00545000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704031300073002001300386#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#68#64#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">3. The ABHH will participate to develop
 educational programs to guarantee the minimum required qualifications in underg
raduate, postgraduate and professional courses for physicians and other professi
onals working in the specialty.</font></p>     ^cY#v33n1a19.htm##
00453000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704022100073002001300294#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#69#65#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">4. The ABHH will create training progra
ms to qualify non-specialist physicians to act as technically responsible for tr
ansfusion agencies.</font></p>     ^cY#v33n1a19.htm##
00481000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704024900073002001300322#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#70#66#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">5. The ABHH will send a document to tra
nsfusion services reinforcing the need of a specialist title in transfusion medi
cine for all physicians working in the service.</font></p>     ^cY#v33n1a19.htm#
#
00433000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704020100073002001300274#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#71#67#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">6. The ABHH will review the minimum cri
teria to obtain the title of specialist in hematology and transfusion medicine.<
/font></p>     ^cY#v33n1a19.htm##
00440000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704020800073002001300281#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#72#68#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">7. The ABHH is currently in the process
 of developing and implementing a quality certification program jointly with the
 AABB.</font></p>     ^cY#v33n1a19.htm##
00442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704021000073002001300283#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#73#69#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">8. The ABHH proposed to the AABB to tra
nslate the "standards" of the AABB, with appropriate adaptations to the needs of
 Brazil.</font></p>     ^cY#v33n1a19.htm##
00515000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704028300073002001300356#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#74#70#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">9. The ABHH will request that hematolog
y and transfusion medicine coordinators on technical commissions of Federal and 
Regional Medical Councils and their substitutes are indicated by the ABHH itself
.</font></p>     ^cY#v33n1a19.htm##
00622000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704039000073002001300463#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#75#71#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">10. The ABHH will request that the Nati
onal Agency for Sanitary Surveillance (ANVISA) and General Coordination of Blood
 and Blood Products (CGSH) participate in discussions in respect to technical ma
tters and policies, including the incorporation of new technologies and procedur
es in the scope of the ABHH.</font></p>     ^cY#v33n1a19.htm##
00528000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704029600073002001300369#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#76#72#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">11. The ABHH will increase its particip
ation in the Brazilian Medical Association (AMA) to defend the professional inte
rests of the specialty in national health agencies, healthcare plans and medical
 cooperatives.</font></p>     ^cY#v33n1a19.htm##
00687000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704045500073002001300528#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#77#73#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">12. The ABHH will standardize scientifi
cally-proven procedures which are regarded as the exclusive realm of transfusion
 medicine (e.g. the use of platelet rich plasma (PRP) for purposes not related t
o transfusions) and request that these norms are incorporated into the technical
 standards used by health surveillance institutions during inspections of medica
l facilities.</font></p>     ^cY#v33n1a19.htm##
00799000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704056700073002001300640#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#78#74#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">13. The ABHH considers nucleic acid amp
lification technique (NAT) for blood-borne infectious agents should be obligator
y. Thus the ABHH has accepted the responsibility together with a representative 
of state public prosecutor office (Sao Paulo) to draft a technical paper on secu
rity issues related to NAT assays, which will be forwarded to federal public pro
secutors, to propose measures to establish a legal requirement to immediately pe
rform these tests and to define remuneration.</font></p>     ^cY#v33n1a19.htm##
00429000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704019700073002001300270#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#79#75#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">14. The ABHH believes tests to detect b
acterial contamination in units of platelet concentrates must be mandatory.</fon
t></p>     ^cY#v33n1a19.htm##
00634000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704040200073002001300475#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#80#76#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">15. The ABHH believes that remuneration
 of transfusion therapy must reflect the complexity, responsibility and costs in
volved or risk prejudicing the quality. The ABHH believes that remuneration paym
ents of 20% less than the CBHPM price is demeaning and unethical and will denoun
ce situations that employ this practice.</font></p>     ^cY#v33n1a19.htm##
00660000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704042800073002001300501#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#81#77#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">16. The ABHH believes that cell therapy
 is a transfusion medicine procedure and together with the Brazilian Medical Ass
ociation proposes that the term "cell therapy" should be officially incorporated
 in the name of the Association, which will now be called the "Associa&ccedil;&a
tilde;o Brasileira de Hematologia, Hemoterapia e Terapia Celular".</font></p>   
  ^cY#v33n1a19.htm##
00365000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704013300073002001300206#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#82#78#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">17. The ABHH will draw up a pricelist o
f items in-</font></p>     ^cY#v33n1a19.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704010200073002001300175#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#83#79#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><b>Coordinators</b></font></p>     ^cY#
v33n1a19.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704012100073002001300194#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#84#80#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">C&aacute;rmino Ant&ocirc;nio de Souza <
/font></p>     ^cY#v33n1a19.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704011100073002001300184#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#85#81#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Dante M&aacute;rio Langhi Jr</font></p>
     ^cY#v33n1a19.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704010100073002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#86#82#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Dimas Tadeu Covas </font></p>     ^cY#v
33n1a19.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704011400073002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#87#83#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Jo&atilde;o Carlos Pina Saraiva</font><
/p>     ^cY#v33n1a19.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704011000073002001300183#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#88#84#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Jos&eacute; Orlando Bordin </font></p> 
    ^cY#v33n1a19.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704010100073002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#89#85#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><b>Secretaries</b></font></p>     ^cY#v
33n1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704010700073002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#90#86#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Ant&ocirc;nio Fabron Jr </font></p>    
 ^cY#v33n1a19.htm##
00369000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704013700073002001300210#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#91#87#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Jos&eacute; Francisco Comenalli Marques
 J&uacute;nior </font></p>     ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704010900073002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#92#88#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Jos&eacute; Roberto Luzzi </font></p>  
   ^cY#v33n1a19.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704010100073002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#93#89#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><b>Rapporteurs</b></font></p>     ^cY#v
33n1a19.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704010000073002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#94#90#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Alfredo Mendrone </font></p>     ^cY#v3
3n1a19.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704010500073002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#95#91#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Eugenia Amorim Ubiali </font></p>     ^
cY#v33n1a19.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704011700073002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#96#92#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Jo&atilde;o Pedro Marques Pereira </fon
t></p>     ^cY#v33n1a19.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704010800073002001300181#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#97#93#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Jos&eacute; Mauro Kutner </font></p>   
  ^cY#v33n1a19.htm##
00327000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704009500073002001300168#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#98#94#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Luiz Amorim </font></p>     ^cY#v33n1a1
9.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000400069704010500073002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#99#95#text#320#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Mar&iacute;lia Rugani </font></p>     ^
cY#v33n1a19.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000500065708000400070704010200074002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#100#96#text#320#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Participants</b></font></p>     ^cY
#v33n1a19.htm##
00354000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000500065708000400070704012100074002001300195#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#101#97#text#320#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Acacira Oliveira Bezerra Ara&uacute;jo
</font></p>     ^cY#v33n1a19.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000500065708000400070704009700074002001300171#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#102#98#text#320#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Adriana Parodi</font></p>     ^cY#v33n
1a19.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000500065708000400070704009800074002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#103#99#text#320#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Adriano Pereira</font></p>     ^cY#v33
n1a19.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010800075002001300183#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#104#100#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Adrieli de Souza Loureiro</font></p> 
    ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#105#101#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Alessandra Quinto Bentes</font></p>  
   ^cY#v33n1a19.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010900075002001300184#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#106#102#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Alessandra Takatu Vacarini</font></p>
     ^cY#v33n1a19.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010000075002001300175#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#107#103#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Alexandre Pereira</font></p>     ^cY#
v33n1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#108#104#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Alien dos Santos Borgo</font></p>    
 ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#109#105#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Aline de Freitas Pereira</font></p>  
   ^cY#v33n1a19.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#110#106#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Aline Sampaio Fernandes</font></p>   
  ^cY#v33n1a19.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011700075002001300192#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#111#107#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">&Aacute;lvaro Augusto D' Alincourt</f
ont></p>     ^cY#v33n1a19.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#112#108#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Alvaro Augusto Passos</font></p>     
^cY#v33n1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#113#109#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Amauri Antiquera Leite</font></p>    
 ^cY#v33n1a19.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#114#110#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Amile Martins Massucato</font></p>   
  ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#115#111#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ana Cynira Franco Marret</font></p>  
   ^cY#v33n1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#116#112#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ana Lucia Cornacchione</font></p>    
 ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#117#113#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ana L&uacute;cia Girello</font></p>  
   ^cY#v33n1a19.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010300075002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#118#114#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ana Maria Zimmermann</font></p>     ^
cY#v33n1a19.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009400075002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#119#115#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ana Orlando</font></p>     ^cY#v33n1a
19.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#120#116#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ana Suely Leite Saraiva</font></p>   
  ^cY#v33n1a19.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009800075002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#121#117#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Andre de Macedo</font></p>     ^cY#v3
3n1a19.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011000075002001300185#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#122#118#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Andr&eacute; Malzoni Langhi</font></p
>     ^cY#v33n1a19.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011000075002001300185#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#123#119#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Andr&eacute; Netel de Mello</font></p
>     ^cY#v33n1a19.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010100075002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#124#120#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Andre Norio Yamada</font></p>     ^cY
#v33n1a19.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011100075002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#125#121#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Andrea Carla Caffaro Copello</font></
p>     ^cY#v33n1a19.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009500075002001300170#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#126#122#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Andrea Frenk</font></p>     ^cY#v33n1
a19.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011200075002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#127#123#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Angela Maria de Melo Ferreira</font><
/p>     ^cY#v33n1a19.htm##
00365000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704013100075002001300206#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#128#124#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Anna B&aacute;rbara de Freitas Carnei
ro Proietti</font></p>     ^cY#v33n1a19.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011800075002001300193#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#129#125#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ant&ocirc;nio C&eacute;sar Teixeira</
font></p>     ^cY#v33n1a19.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010300075002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#130#126#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Antonio Condino Neto</font></p>     ^
cY#v33n1a19.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011100075002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#131#127#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Antonio Gomes Pinto Ferreira</font></
p>     ^cY#v33n1a19.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010300075002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#132#128#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Audrey Akiko Hirano </font></p>     ^
cY#v33n1a19.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#133#129#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Auristela Maciel Lins</font></p>     
^cY#v33n1a19.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011300075002001300188#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#134#130#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Barbara de Jesus Sim&otilde;es</font>
</p>     ^cY#v33n1a19.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704012200075002001300197#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#135#131#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Beatriz Helena Cermaria Soares da Sil
va</font></p>     ^cY#v33n1a19.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011300075002001300188#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#136#132#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Beatriz Tavares Costa Carvalho</font>
</p>     ^cY#v33n1a19.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010000075002001300175#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#137#133#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Bruna Pessoa Cruz</font></p>     ^cY#
v33n1a19.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010200075002001300177#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#138#134#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Carla Luana Dinardo</font></p>     ^c
Y#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#139#135#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Carlos Alberto de Macedo</font></p>  
   ^cY#v33n1a19.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011600075002001300191#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#140#136#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Carlos Alexandre Monteiro Mesiano</fo
nt></p>     ^cY#v33n1a19.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010100075002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#141#137#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Carlos Gama Sauaia</font></p>     ^cY
#v33n1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#142#138#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Carlos Henrique Maciel</font></p>    
 ^cY#v33n1a19.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704012200075002001300197#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#143#139#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">C&eacute;sar Gustavo Leal Galv&atilde
;o</font></p>     ^cY#v33n1a19.htm##
00361000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704012700075002001300202#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#144#140#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Cinthya Pereira Leite Costa de Ara&ua
cute;jo</font></p>     ^cY#v33n1a19.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011200075002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#145#141#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Clarisse Lopes de Castro Lobo</font><
/p>     ^cY#v33n1a19.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#146#142#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Claudia Cristina Naufel Terzian</font
></p>     ^cY#v33n1a19.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010900075002001300184#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#147#143#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Claudia Regina Abreu Silva</font></p>
     ^cY#v33n1a19.htm##
00364000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704013000075002001300205#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#148#144#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Cl&aacute;udia Regina de Ara&uacute;j
o Monteiro</font></p>     ^cY#v33n1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#149#145#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Claudio Carneiro Borba</font></p>    
 ^cY#v33n1a19.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011600075002001300191#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#150#146#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Claudio Marcelo Tavares Pessoa de</fo
nt></p>     ^cY#v33n1a19.htm##
00321000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704008700075002001300162#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#151#147#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Melo</font></p>     ^cY#v33n1a19.htm#
#
00333000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009900075002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#152#148#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Claudio Siqueira</font></p>     ^cY#v
33n1a19.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011800075002001300193#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#153#149#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Clever Rodolfo Carvalho Vasconcelos</
font></p>     ^cY#v33n1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#154#150#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Cristina Pontes Langhi</font></p>    
 ^cY#v33n1a19.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#155#151#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Daniel Teles Galdiano</font></p>     
^cY#v33n1a19.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010100075002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#156#152#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Daniela Calminatti</font></p>     ^cY
#v33n1a19.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009900075002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#157#153#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Daniela Jinzenji</font></p>     ^cY#v
33n1a19.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011900075002001300194#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#158#154#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Danila Augusta Accioly Varella Barca<
/font></p>     ^cY#v33n1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#159#155#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Dario Garcia Adomaitis</font></p>    
 ^cY#v33n1a19.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#160#156#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Doralice Marvulle Tan</font></p>     
^cY#v33n1a19.htm##
00354000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704012000075002001300195#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#161#157#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Edilene Cristina Sampaio R. Fernandes
</font></p>     ^cY#v33n1a19.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009700075002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#162#158#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Eduardo Takatu</font></p>     ^cY#v33
n1a19.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011000075002001300185#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#163#159#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Edvis Santos Soares Serafim</font></p
>     ^cY#v33n1a19.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010800075002001300183#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#164#160#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Elaine Veloso Rocha Urias</font></p> 
    ^cY#v33n1a19.htm##
00416000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704018200075002001300257#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#165#161#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Elizabeth Ang&eacute;lica Leme Martin
s</font></p> <font size="2" face="Verdana, Arial, Helvetica, sans-serif">     ^c
Y#v33n1a19.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704002300075002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#166#162#text#320#<blockquote>       ^
cY#v33n1a19.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704005400075002001300129#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#167#163#text#320#<p>Ellen Cristina Ba
rros Lima de Souza </p>       ^cY#v33n1a19.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704002400075002001300099#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#168#164#text#320#<p>Bastos</p>       
^cY#v33n1a19.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004400075002001300119#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#169#165#text#320#<p>Emanuel Borges Vi
tor Anjos</p>       ^cY#v33n1a19.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004800075002001300123#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#170#166#text#320#<p>Fabiana Chagas Ca
margos Piassi</p>       ^cY#v33n1a19.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003800075002001300113#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#171#167#text#320#<p>Fernanda Horn Raz
ouk</p>       ^cY#v33n1a19.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#172#168#text#320#<p>Fernando Ghilardi
</p>       ^cY#v33n1a19.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004200075002001300117#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#173#169#text#320#<p>Flavia Gonzalez d
a Costa</p>       ^cY#v33n1a19.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004100075002001300116#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#174#170#text#320#<p>Fortun&eacute;e M
eyohas</p>       ^cY#v33n1a19.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004900075002001300124#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#175#171#text#320#<p>Francisco Guilher
me Fujita Neto</p>       ^cY#v33n1a19.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704005300075002001300128#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#176#172#text#320#<p>Francisco Ludovic
o de Almeida Filho</p>       ^cY#v33n1a19.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004100075002001300116#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#177#173#text#320#<p>Frederico Carbone
 Filho</p>       ^cY#v33n1a19.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004200075002001300117#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#178#174#text#320#<p>Gabriel Alves dos
 Santos</p>       ^cY#v33n1a19.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704005300075002001300128#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#179#175#text#320#<p>Gabriela Macedo d
e Freitas Oliveira</p>       ^cY#v33n1a19.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704005000075002001300125#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#180#176#text#320#<p>Geny Aparecida de
 Oliveira Barna</p>       ^cY#v33n1a19.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704005600075002001300131#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#181#177#text#320#<p>Geraldo Sant&acut
e;Ana da Cunha Junior</p>       ^cY#v33n1a19.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004900075002001300124#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#182#178#text#320#<p>Gl&aacute;ucia Co
sta Esmanhotto</p>       ^cY#v33n1a19.htm##
00264000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003000075002001300105#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#183#179#text#320#<p>Glauco Plens</p> 
      ^cY#v33n1a19.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003400075002001300109#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#184#180#text#320#<p>Gleice Fernandes<
/p>       ^cY#v33n1a19.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003700075002001300112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#185#181#text#320#<p>Helder Texeira Me
lo</p>       ^cY#v33n1a19.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004600075002001300121#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#186#182#text#320#<p>H&eacute;lio Mora
es de Souza</p>       ^cY#v33n1a19.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004600075002001300121#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#187#183#text#320#<p>Iara de Jesus Fer
reira Motta</p>       ^cY#v33n1a19.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004800075002001300123#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#188#184#text#320#<p>Iracema Marques V
ieira Hirtsch</p>       ^cY#v33n1a19.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004000075002001300115#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#189#185#text#320#<p>Jane Terezinha Ma
rtins</p>       ^cY#v33n1a19.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003500075002001300110#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#190#186#text#320#<p>Jefferson Cardoso
</p>       ^cY#v33n1a19.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003700075002001300112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#191#187#text#320#<p>Joana Darc S. Ram
os</p>       ^cY#v33n1a19.htm##
00281000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004700075002001300122#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#192#188#text#320#<p>Jo&atilde;o Carlo
s Pina Faria</p>       ^cY#v33n1a19.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704005000075002001300125#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#193#189#text#320#<p>Jo&atilde;o Paulo
 Baccara Araujo</p>       ^cY#v33n1a19.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003100075002001300106#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#194#190#text#320#<p>Joel da Cunha</p>
       ^cY#v33n1a19.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004600075002001300121#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#195#191#text#320#<p>Joice Arag&atilde
;o de Jesus</p>       ^cY#v33n1a19.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003800075002001300113#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#196#192#text#320#<p>Jorge Luiz de Aqu
ino</p>       ^cY#v33n1a19.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004200075002001300117#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#197#193#text#320#<p>Jos&eacute; Antom
io Rosa</p>       ^cY#v33n1a19.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004200075002001300117#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#198#194#text#320#<p>Jos&eacute; Eduar
do Levi</p>       ^cY#v33n1a19.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704005600075002001300131#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#199#195#text#320#<p>Jos&eacute; Guilh
erme Pereira de Souza</p>       ^cY#v33n1a19.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704005400075002001300129#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#200#196#text#320#<p>Jos&eacute; Linde
mberg da Costa Lima</p>       ^cY#v33n1a19.htm##
00277000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004300075002001300118#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#201#197#text#320#<p>Jos&eacute; Mauro
 Zarnini</p>       ^cY#v33n1a19.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003300075002001300108#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#202#198#text#320#<p>Juarez Pappiani</
p>       ^cY#v33n1a19.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004900075002001300124#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#203#199#text#320#<p>Juliane de Campos
 In&aacute;cio</p>       ^cY#v33n1a19.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003700075002001300112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#204#200#text#320#<p>Leandra C. N. Sil
va</p>       ^cY#v33n1a19.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003700075002001300112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#205#201#text#320#<p>Leandro Celso Gri
lo</p>       ^cY#v33n1a19.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004200075002001300117#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#206#202#text#320#<p>Leila Manfredini 
Feitosa</p>       ^cY#v33n1a19.htm##
00291000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704005700075002001300132#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#207#203#text#320#<p>Leila Maria Magal
h&atilde;es Pessoa de </p>       ^cY#v33n1a19.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#208#204#text#320#<p>Melo</p>       ^c
Y#v33n1a19.htm##
00264000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003000075002001300105#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#209#205#text#320#<p>Leila Minari</p> 
      ^cY#v33n1a19.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004100075002001300116#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#210#206#text#320#<p>Leonardo Antunes 
Amorim</p>       ^cY#v33n1a19.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003700075002001300112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#211#207#text#320#<p>Levy S. Rocha Pir
es</p>       ^cY#v33n1a19.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004500075002001300120#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#212#208#text#320#<p>Lucas de Menezes 
dos Santos</p>       ^cY#v33n1a19.htm##
00281000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004700075002001300122#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#213#209#text#320#<p>Luciana Campos C.
 Machado de </p>       ^cY#v33n1a19.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704002300075002001300098#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#214#210#text#320#<p>Souza</p>       ^
cY#v33n1a19.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704003300075002001300108#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#215#211#text#320#<p>Lucimara Aguiar</
p>       ^cY#v33n1a19.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004100075002001300116#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#216#212#text#320#<p>Luiza Vasconcello
s Lang</p>       ^cY#v33n1a19.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704007200075002001300147#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#217#213#text#320#<p>Lydia M&aacute;rc
ia de Melo Franca</p> </blockquote> </font>     ^cY#v33n1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#218#214#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Manuela Zubaran Santos</font></p>    
 ^cY#v33n1a19.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009500075002001300170#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#219#215#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Marcel Inada</font></p>     ^cY#v33n1
a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#220#216#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Marcelo Addas Carvalho</font></p>    
 ^cY#v33n1a19.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010800075002001300183#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#221#217#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Marcelo de Carvalho Braga</font></p> 
    ^cY#v33n1a19.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010800075002001300183#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#222#218#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Marcelo Tha Aciioly Veiga</font></p> 
    ^cY#v33n1a19.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011100075002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#223#219#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Marcia B. de Carvalho Polite</font></
p>     ^cY#v33n1a19.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011300075002001300188#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#224#220#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Marcia Cristina Zago Novaretti</font>
</p>     ^cY#v33n1a19.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009400075002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#225#221#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Marcia Otta</font></p>     ^cY#v33n1a
19.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011200075002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#226#222#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">M&aacute;rcia Vaz Mo&ccedil;o</font><
/p>     ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#227#223#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">M&aacute;rcia Villa Nova</font></p>  
   ^cY#v33n1a19.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#228#224#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Maria Angelica de Camargo Soares</fon
t></p>     ^cY#v33n1a19.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011100075002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#229#225#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Maria Aparecida E. Felicetti</font></
p>     ^cY#v33n1a19.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011000075002001300185#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#230#226#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Maria Cristina Albe Olivato</font></p
>     ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#231#227#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Maria Cristina Balestrin</font></p>  
   ^cY#v33n1a19.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704012100075002001300196#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#232#228#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Maria de F&aacute;tima Alves Fernande
s</font></p>     ^cY#v33n1a19.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011300075002001300188#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#233#229#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Maria de Fatima Pombo Montoril</font>
</p>     ^cY#v33n1a19.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704012500075002001300200#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#234#230#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Maria do Ros&aacute;rio Leal Galv&ati
lde;o</font></p>     ^cY#v33n1a19.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010200075002001300177#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#235#231#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Maria Esther Duarte</font></p>     ^c
Y#v33n1a19.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010800075002001300183#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#236#232#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Maria Jos&eacute; Furquim</font></p> 
    ^cY#v33n1a19.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#237#233#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Maria Odila Jacob de Assis Moura</fon
t></p>     ^cY#v33n1a19.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#238#234#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Mariana Sartori Magnoni</font></p>   
  ^cY#v33n1a19.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010100075002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#239#235#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Mariangela Moschen</font></p>     ^cY
#v33n1a19.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009500075002001300170#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#240#236#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Mariza Saito</font></p>     ^cY#v33n1
a19.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#241#237#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Marta Auxiliadora Ferreira Reis</font
></p>     ^cY#v33n1a19.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009500075002001300170#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#242#238#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Mauro Avanzi</font></p>     ^cY#v33n1
a19.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009900075002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#243#239#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Maza Alves Jacob</font></p>     ^cY#v
33n1a19.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009800075002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#244#240#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Merula Steagall</font></p>     ^cY#v3
3n1a19.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704012400075002001300199#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#245#241#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Moema de Oliveira Pess&ocirc;a dos Sa
ntos</font></p>     ^cY#v33n1a19.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010900075002001300184#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#246#242#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Monica Nascimento dos Reis</font></p>
     ^cY#v33n1a19.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011000075002001300185#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#247#243#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">M&ocirc;nica Torres Rifeiro</font></p
>     ^cY#v33n1a19.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010100075002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#248#244#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Nanci Alves Salles</font></p>     ^cY
#v33n1a19.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010300075002001300178#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#249#245#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Nixon Ramos da Silva</font></p>     ^
cY#v33n1a19.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010900075002001300184#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#250#246#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Noemi &Eacute;lidi Martins</font></p>
     ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#251#247#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Olga Maria diniz Pereira</font></p>  
   ^cY#v33n1a19.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#252#248#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Osnei Okumoto</font></p>     ^cY#v33n
1a19.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#253#249#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Osvaldo Antonio Donnini</font></p>   
  ^cY#v33n1a19.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011800075002001300193#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#254#250#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Patricia Alvarez Baptista Brindeiro</
font></p>     ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#255#251#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Patricia Cressoni Sierra</font></p>  
   ^cY#v33n1a19.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010800075002001300183#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#256#252#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Patricia da Paix&atilde;o</font></p> 
    ^cY#v33n1a19.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009900075002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#257#253#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Patricia Dadario</font></p>     ^cY#v
33n1a19.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009700075002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#258#254#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Paula Loureiro</font></p>     ^cY#v33
n1a19.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011700075002001300192#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#259#255#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Paula Renata Domeneghetti Teixeira</f
ont></p>     ^cY#v33n1a19.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009400075002001300169#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#260#256#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Paulo Silva</font></p>     ^cY#v33n1a
19.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#261#257#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Paulo Tadeu Rodrigues De Almeida</fon
t></p>     ^cY#v33n1a19.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009500075002001300170#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#262#258#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Paulo Vargas</font></p>     ^cY#v33n1
a19.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011100075002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#263#259#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Pedro Clovis Junqueira Filho</font></
p>     ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#264#260#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Perla Risette Alves Lima</font></p>  
   ^cY#v33n1a19.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011100075002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#265#261#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Poliana Cristina Carvalheiro</font></
p>     ^cY#v33n1a19.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#266#262#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Priscila Ferreira Silva</font></p>   
  ^cY#v33n1a19.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#267#263#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Rafael Souza </font></p>     ^cY#v33n
1a19.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010100075002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#268#264#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Regiane de Freitas</font></p>     ^cY
#v33n1a19.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011200075002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#269#265#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Regina A. Pereira Moraes Dias</font><
/p>     ^cY#v33n1a19.htm##
00354000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704012000075002001300195#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#270#266#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Regina Lucia Azevedo de Castro Mendes
</font></p>     ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#271#267#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Regina Rita Dutra Dantas</font></p>  
   ^cY#v33n1a19.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009700075002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#272#268#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ricardo Haddad</font></p>     ^cY#v33
n1a19.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#273#269#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ricardo Omoto</font></p>     ^cY#v33n
1a19.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009900075002001300174#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#274#270#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ricardo S. Abreu</font></p>     ^cY#v
33n1a19.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009800075002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#275#271#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Rita Cavalheiro</font></p>     ^cY#v3
3n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#276#272#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Roberto Saturnino Chaves</font></p>  
   ^cY#v33n1a19.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010900075002001300184#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#277#273#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Roberto Soares Schlindwein</font></p>
     ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#278#274#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Robson Pereira da Silva </font></p>  
   ^cY#v33n1a19.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010200075002001300177#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#279#275#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Rodrigo Barbosa Gil</font></p>     ^c
Y#v33n1a19.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#280#276#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Rodrigo Jos&eacute; Nunes Lisboa</fon
t></p>     ^cY#v33n1a19.htm##
00354000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704012000075002001300195#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#281#277#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Romeika Maria de Souza Bezerra Nelson
</font></p>     ^cY#v33n1a19.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010800075002001300183#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#282#278#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Romeu Ibrahim de Carvalho</font></p> 
    ^cY#v33n1a19.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#283#279#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ronalda Ara&uacute;jo</font></p>     
^cY#v33n1a19.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011500075002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#284#280#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Rosane Resende de Sousa Giuliani</fon
t></p>     ^cY#v33n1a19.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009800075002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#285#281#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Samuel Mauricio</font></p>     ^cY#v3
3n1a19.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011200075002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#286#282#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">S&eacute;rgio Augusto Pereira</font><
/p>     ^cY#v33n1a19.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011200075002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#287#283#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">S&eacute;rgio Barroca Mesiano</font><
/p>     ^cY#v33n1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#288#284#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Sergio Domingos Vieira</font></p>    
 ^cY#v33n1a19.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010800075002001300183#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#289#285#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Silma Maria Alves de Melo</font></p> 
    ^cY#v33n1a19.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#290#286#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Silvana Regina Matana</font></p>     
^cY#v33n1a19.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009700075002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#291#287#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Silvano Wendel</font></p>     ^cY#v33
n1a19.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704012400075002001300199#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#292#288#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Silvia Helena da Silva S&aacute; Teix
eira</font></p>     ^cY#v33n1a19.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009700075002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#293#289#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Silvia Pereira</font></p>     ^cY#v33
n1a19.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010000075002001300175#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#294#290#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Silvio Ferrari Jr</font></p>     ^cY#
v33n1a19.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011200075002001300187#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#295#291#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Silvio Lemos Gon&ccedil;alves</font><
/p>     ^cY#v33n1a19.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009800075002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#296#292#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Simone Silveira</font></p>     ^cY#v3
3n1a19.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#297#293#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Simone Tcherniakovsky</font></p>     
^cY#v33n1a19.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010100075002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#298#294#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">S&ocirc;nia Bastos</font></p>     ^cY
#v33n1a19.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011000075002001300185#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#299#295#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Sonia Maria Nunes de Barros</font></p
>     ^cY#v33n1a19.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#300#296#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Suely Chinenn</font></p>     ^cY#v33n
1a19.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010500075002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#301#297#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Suely Meireles Rezende</font></p>    
 ^cY#v33n1a19.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009700075002001300172#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#302#298#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Sylvie Boechat</font></p>     ^cY#v33
n1a19.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011100075002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#303#299#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Tania Maria Onzi Pietrobelli</font></
p>     ^cY#v33n1a19.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010600075002001300181#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#304#300#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Thiago Batista da Silva</font></p>   
  ^cY#v33n1a19.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010700075002001300182#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#305#301#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Thiago Vilarinho Tavares</font></p>  
   ^cY#v33n1a19.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009600075002001300171#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#306#302#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Tsutomu Oguro</font></p>     ^cY#v33n
1a19.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704010400075002001300179#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#307#303#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Valdir Santana Lisboa</font></p>     
^cY#v33n1a19.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011100075002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#308#304#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Valnei Canutti J&uacute;nior</font></
p>     ^cY#v33n1a19.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704011400075002001300189#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#309#305#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Valnia Brand&atilde;o Wanderley</font
></p>     ^cY#v33n1a19.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#310#306#text#320#<p>&nbsp;</p>     ^c
Y#v33n1a19.htm##
00392000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704015800075002001300233#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#311#307#text#320#<p align="center"><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="/img/revistas
/rbhh/v33n1/a19fig01.jpg">Figure 1</a></font></p>     ^cY#v33n1a19.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#312#308#text#320#<p>&nbsp;</p>     ^c
Y#v33n1a19.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#313#309#text#320#<p>&nbsp;</p>     ^c
Y#v33n1a19.htm##
00393000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704015900075002001300234#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#314#310#text#320#<p align="center"><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif"> <a href="/img/revista
s/rbhh/v33n1/a19fig02.jpg">Figure 2</a></font></p>     ^cY#v33n1a19.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#315#311#text#320#<p>&nbsp;</p>     ^c
Y#v33n1a19.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#316#312#text#320#<p>&nbsp;</p>     ^c
Y#v33n1a19.htm##
00420000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704018600075002001300261#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#317#313#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img 
src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b>  
  ^cY#v33n1a19.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704007900075002001300154#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#318#314#text#320#<br>   Associa&ccedi
l;&atilde;o Brasileira de Hematologia e Hemoterapia    ^cY#v33n1a19.htm##
00295000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704006100075002001300136#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#319#315#text#320#<br>   Rua da Assemb
l&eacute;ia, 10 Gr. 1407 - Centro    ^cY#v33n1a19.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704005400075002001300129#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#320#316#text#320#<br>   Rio de Janeir
o (RJ), Brazil</font></p>     ^cY#v33n1a19.htm##
00325000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704009100075002001300166#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#321#317#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Submitted: 1/10/2011    ^cY#v33n1a19.
htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704004600075002001300121#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#322#318#text#320#<br>   Accepted: 1/2
1/2011</font></p>     ^cY#v33n1a19.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#323#319#text#320#<p>&nbsp;</p>     ^c
Y#v33n1a19.htm##
00458000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000500066708000400071704022400075002001300299#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a19.htm#S#p#324#320#text#320#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"> <a href="http://www.rbhh.org" target
="_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_blank
">www.scielo.br/rbhh</a></font></p>     ^cY#v33n1a19.htm##
00274000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00300101#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a20.htm#S#o#1#1#article#1
#20110411#115607#v33n1a20.htm#38##
01297000000000481000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030002900109
03100030013803200020014106500090014301400090015203500100016123700270017101200670
01980100031002650100028002960100025003240100032003490700110003810700075004910830
16400566085001000730085002900740085002500769117000600794072000200800002001300802
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a20.htm#S#h#2#1#article#1#oa#en#b
r1.1#1#4.0#ILUS#20#RBHH160#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f82^l8
2#1516-8484#10.5581/1516-8484.20110020#Multiple myeloma with cells typically see
n in storage diseases^len#^rND^1A01^nEdmir^sBoturão Neto#^rND^1A01^nMihoko^sYama
moto#^rND^1A02^nYara^sMenezes#^rND^1A01^nJosé Orlando^sBordin#Universidade Feder
al de São Paulo^iA01^1Hematology and Transfusion Medicine Department^cSão Paulo^
sSP^pBrazil#Hospital Alemão Oswaldo Cruz^iA02^1CICAP Laboratory^cSão Paulo^sSP^p
Brazil#^len^aWe report on a rare case of multiple myeloma with atypically large 
cells containing a great amount of azurophilic inclusions usually seen in storag
e diseases#^ddecs^i1#^tm^len^kMultiple myeloma^i1#^tm^len^kPlasma cells^i1#other
#1#v33n1a20.htm##
01304000000000481000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030002900109
03100030013803200020014106500090014301400090015203500100016123700270017101200740
01980100031002720100028003030100025003310100032003560700110003880700075004980830
16400573085001000737085002900747085002500776117000600801072000200807002001300809
#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a20.htm#S#f#3#1#article#1#oa#en#b
r1.1#1#4.0#ILUS#20#RBHH160#nd#Rev. Bras. Hematol. Hemoter.#33#1#20110200#^f82^l8
2#1516-8484#10.5581/1516-8484.20110020#<b>Multiple myeloma with cells typically 
seen in storage diseases</b>^len#^rND^1A01^nEdmir^sBoturão Neto#^rND^1A01^nMihok
o^sYamamoto#^rND^1A02^nYara^sMenezes#^rND^1A01^nJosé Orlando^sBordin#Universidad
e Federal de São Paulo^iA01^1Hematology and Transfusion Medicine Department^cSão
 Paulo^sSP^pBrazil#Hospital Alemão Oswaldo Cruz^iA02^1CICAP Laboratory^cSão Paul
o^sSP^pBrazil#^len^aWe report on a rare case of multiple myeloma with atypically
 large cells containing a great amount of azurophilic inclusions usually seen in
 storage diseases#^ddecs^i1#^tm^len^kMultiple myeloma^i1#^tm^len^kPlasma cells^i
1#other#1#v33n1a20.htm##
01426000000000505000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103121000300108049000800111158000300119
03000280012203100030015003200020015306500090015501400090016403500100017323700270
01830120067002100100031002770100028003080100025003360100032003610700112003930700
07700505083016400582085001000746085002900756085002500785117000600810072000200816
002001300818008008900831#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a20.htm#S
#l#4#1#article#1#^mFeb.^a2011#oa#en#br1.1#1#4.0#ilus#20#RBHH160#nd#Rev. bras. he
matol. hemoter#33#1#20110200#^f82^l82#1516-8484#10.5581/1516-8484.20110020#Multi
ple myeloma with cells typically seen in storage diseases^len#^rND^1A01^nEdmir^s
Boturão Neto#^rND^1A01^nMihoko^sYamamoto#^rND^1A02^nYara^sMenezes#^rND^1A01^nJos
é Orlando^sBordin#^iA01^1Universidade Federal de São Paulo^2Hematology and Trans
fusion Medicine Department^cSão Paulo^sSP^pBrazil#^iA02^1Hospital Alemão Oswaldo
 Cruz^2CICAP Laboratory^cSão Paulo^sSP^pBrazil#^len^aWe report on a rare case of
 multiple myeloma with atypically large cells containing a great amount of azuro
philic inclusions usually seen in storage diseases#^ddecs^i1#^tm^len^kMultiple m
yeloma^i1#^tm^len^kPlasma cells^i1#other#1#v33n1a20.htm#Internet^ihttp://www.sci
elo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100020##
00365000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704013300073002001300206#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#5#1#article#33#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>IMAGES IN CLINICAL HEM
ATOLOGY</b></font></p>     ^cY#v33n1a20.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#6#2#article#33#<p>&nbsp;</p>     ^cY#
v33n1a20.htm##
00402000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704017000073002001300243#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#7#3#article#33#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Multiple myeloma w
ith cells typically seen in storage diseases</b></font></p>     ^cY#v33n1a20.htm
##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#8#4#article#33#<p>&nbsp;</p>     ^cY#
v33n1a20.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#9#5#article#33#<p>&nbsp;</p>     ^cY#
v33n1a20.htm##
00456000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704022300074002001300297#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#10#6#article#33#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Edmir Botur&atilde;o Neto<sup>I</su
p>; Mihoko Yamamoto<sup>I</sup>; Yara Menezes<sup>II</sup>; Jos&eacute; Orlando 
Bordin<sup>I</sup></b></font></p>     ^cY#v33n1a20.htm##
00445000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704021200074002001300286#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#11#7#article#33#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Hematology and Transfusion
 Medicine Department, Universidade Federal de S&atilde;o Paulo - UNIFESP, S&atil
de;o Paulo (SP), Brazil    ^cY#v33n1a20.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704012500074002001300199#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#12#8#article#33#<br>   <sup>II</sup>C
ICAP Laboratory, Hospital Alem&atilde;o Oswaldo Cruz, S&atilde;o Paulo, (SP) Bra
zil </font></p>     ^cY#v33n1a20.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704011500074002001300189#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#13#9#article#33#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></font
></p>     ^cY#v33n1a20.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#14#10#article#33#<p>&nbsp;</p>     ^c
Y#v33n1a20.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004400075002001300119#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#15#11#article#33#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v33n1a20.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009800075002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#16#12#article#33#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v3
3n1a20.htm##
00475000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704024100075002001300316#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#17#13#article#33#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">We report on a rare case of multiple 
myeloma with atypically large cells containing a great amount of azurophilic inc
lusions usually seen in storage diseases.</font></p>     ^cY#v33n1a20.htm##
00386000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704015200075002001300227#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#18#14#article#33#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Multiple myeloma; Pl
asma cells</font></p> <hr size="1" noshade>     ^cY#v33n1a20.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#19#15#article#33#<p>&nbsp;</p>     ^c
Y#v33n1a20.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#20#16#article#33#<p>&nbsp;</p>     ^c
Y#v33n1a20.htm##
01361000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704112700075002001301202#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#21#17#article#33#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A 45-year-old Brazilian black woman w
as experiencing weakness and back pain, as well as mucosal pallor. The complete 
blood count showed a white blood cell count of 9.7 x 10<sup>9</sup>/L, red blood
 cell count of 3.00 x 10<sup>12</sup>/L, hemoglobin level of 91 g/L and platelet
 count of 372 x 10<sup>9</sup>/L. Rouleaux formation was noticed. Serum protein 
electrophoresis revealed an M-protein spike of 33.3 g/L in the beta region. The 
concentrations of the IgG, IgA and IgM immunoglobulins were 52.90 g/L, 0.23 g/L 
and 0.15 g/L, respectively. The beta2-microglobulin level was 3.99 mg/L. No rena
l function or calcium metabolism abnormalities were noted as per the following r
esults: creatinine 114.9 &#181;mol/L, serum calcium 2.02 mmol/L and ionized calc
ium 1.06 mmol/L. There were no skeletal lesions identified by bone radiography, 
scintigraphy or magnetic resonance imaging. Using an immunochemical method, 40% 
of free kappa light chain was detected in 1.29 g/24-hour urine protein, which al
so presented an IgG kappa monoclonal component.</font></p>     ^cY#v33n1a20.htm#
#
02282000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704204800075002001302123#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#22#18#article#33#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">May-Gr&uuml;nwald-Giemsa stained bone
 marrow aspirate smears showed 7 per cent of typical myeloma plasma cells and 20
% of atypical large cells containing a great amount of azurophilic inclusions us
ually seen in storage diseases (<a href="/img/revistas/rbhh/v33n1/a20fig01.jpg">
Figure 1A</a> and <a href="/img/revistas/rbhh/v33n1/a20fig01.jpg">1B</a>). Flow 
cytometric analysis revealed 6.5% of neoplastic plasma cells expressing the foll
owing phenotypes: CD19-, CD56-, CD38+++, CD138+++, CD45+, CD117+ and kappa light
 chain restriction. Cells in the high granularity (SSC) and large size (FLC) reg
ion showed the same immunophenotypes. Although no karyotype abnormality was iden
tified by conventional cytogenetic methods, the heterozygous deletion of 13q14.3
 was detected using fluorescence in situ hybridization. Hematoxylin-eosin-staine
d sections in a bone marrow biopsy demonstrated partial replacement with atypica
l large cells, which accounted for approximately 30% of the nucleated marrow cel
ls. These cells displayed a round, eccentric nucleus and large granular cytoplas
m resembling histiocytic cells seen in deposit disease (<a href="/img/revistas/r
bhh/v33n1/a20fig01.jpg">Figure 1C</a> and <a href="/img/revistas/rbhh/v33n1/a20f
ig01.jpg">1D</a>). The immunohistochemical study demonstrated a weak reaction fo
r CD68 and a strong positive kappa light chain reaction on the large cells, whil
e lambda light chain reaction was positive only in a few normal plasma cells (<a
 href="/img/revistas/rbhh/v33n1/a20fig01.jpg">Figure 1E</a> and <a href="/img/re
vistas/rbhh/v33n1/a20fig01.jpg">1F</a>). This type of inclusion is rare in multi
ple myeloma cells with most of the reported cases being IgA or IgG myeloma but w
ith all having kappa light chains.<sup>(1)</sup> Our patient achieved complete r
emission after treatment with VAD-regimen chemotherapy followed by autologous pe
ripheral blood stem cell transplantation and remains event-free at more than fiv
e years.</font></p>     ^cY#v33n1a20.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#23#19#article#33#<p>&nbsp;</p>     ^c
Y#v33n1a20.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010000075002001300175#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#24#20#article#33#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>     ^cY#
v33n1a20.htm##
00442000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704019400077002001300271#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#25#21#article#33#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Frotscher B, Saligna
c S, Lecompte T. Multiple myeloma with unusual inclusions. Brt J Haematol. 2009;
144(1):1</font></p>     ^cY#v33n1a20.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#26#22#article#33#<p>&nbsp;</p>     ^c
Y#v33n1a20.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#27#23#article#33#<p>&nbsp;</p>     ^c
Y#v33n1a20.htm##
00420000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704018600075002001300261#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#28#24#article#33#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img 
src="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b>  
  ^cY#v33n1a20.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004200075002001300117#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#29#25#article#33#<br>   Edmir Botur&a
tilde;o-Neto,     ^cY#v33n1a20.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009800075002001300173#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#30#26#article#33#<br>   Disciplina de
 Hematologia e Hemoterapia , Universidade Federal de S&atilde;o Paulo     ^cY#v3
3n1a20.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003200075002001300107#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#31#27#article#33#<br>   Rua Botucatu,
 740    ^cY#v33n1a20.htm##
00291000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704005700075002001300132#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#32#28#article#33#<br>   04023-092  - 
S&atilde;o Paulo (SP), Brazil    ^cY#v33n1a20.htm##
00292000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704005800075002001300133#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#33#29#article#33#<br>   Phone: 55 11 
5579-1550 Fax: 55 11 5571-8806    ^cY#v33n1a20.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009500075002001300170#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#34#30#article#33#<br>   <a href="mail
to:edmirboturao@uol.com.br">edmirboturao@uol.com.br</a></font></p>     ^cY#v33n1
a20.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#35#31#article#33#<p>&nbsp;</p>     ^c
Y#v33n1a20.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#36#32#article#33#<p>&nbsp;</p>     ^c
Y#v33n1a20.htm##
00457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704022300075002001300298#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a20.htm#S#p#37#33#article#33#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" target=
"_blank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_blank"
>www.scielo.br/rbhh</a></font></p>     ^cY#v33n1a20.htm##
00526000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080002000711180002000730100019000750100018000940100
01800112012004500130030001500175710000200190065000900192064000500201031000400206
032000200210020000200212865000900214002001300223#v33n1#V:\SciELO\serial\rbhh\v33
n1\markup\v33n1a20.htm#S#c#38#1#article#1#1#^rND^sFrotscher^nB#^rND^sSalignac^nS
#^rND^sLecompte^nT#Multiple myeloma with unusual inclusions^len#Brt J Haematol#2
#20090000#2009#144#1#1#20110200#v33n1a20.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a21.htm#S#o#1#1#text#1#20
110411#115607#v33n1a21.htm#46##
00673000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030002900106
03100030013503200020013806500090014001400090014903500100015812300020016823700270
0170012002300197010002700220070003900247002001300286#v33n1#V:\SciELO\serial\rbhh
\v33n1\markup\v33n1a21.htm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ILUS#22#RBHH370#nd#R
ev. Bras. Hematol. Hemoter.#33#1#20110200#^f85^l85#1516-8484#1#10.5581/1516-8484
.20110021#Santiago Pavlovsky^len#^rND^1A01^nJorge H^sMilone#Sociedad Argentina d
e Hematología^iA01#v33n1a21.htm##
00680000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030002900106
03100030013503200020013806500090014001400090014903500100015812300020016823700270
0170012003000197010002700227070003900254002001300293#v33n1#V:\SciELO\serial\rbhh
\v33n1\markup\v33n1a21.htm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ILUS#22#RBHH370#nd#R
ev. Bras. Hematol. Hemoter.#33#1#20110200#^f85^l85#1516-8484#1#10.5581/1516-8484
.20110021#<b>Santiago Pavlovsky</b>^len#^rND^1A01^nJorge H^sMilone#Sociedad Arge
ntina de Hematología^iA01#v33n1a21.htm##
00800000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000800108158000300116
03000280011903100030014703200020015006500090015201400090016103500100017012300020
0180237002700182012002300209010002700232070004100259002001300300008008900313#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a21.htm#S#l#4#1#text#1#^mFeb.^a2011#o
a#en#br1.1#1#4.0#ilus#22#RBHH370#nd#Rev. bras. hematol. hemoter#33#1#20110200#^f
85^l85#1516-8484#1#10.5581/1516-8484.20110021#Santiago Pavlovsky^len#^rND^1A01^n
Jorge H^sMilone#^iA01^1Sociedad Argentina de Hematología#v33n1a21.htm#Internet^i
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100022##
00349000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012000070002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#5#1#text#42#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>MEMORIAL LECTURE</b></fon
t></p>     ^cY#v33n1a21.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#6#2#text#42#<p>&nbsp;</p>     ^cY#v33
n1a21.htm##
00376000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704014700070002001300217#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#7#3#text#42#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Professor Pedro Cl&oa
cute;vis Junqueira</b></font></p>     ^cY#v33n1a21.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#8#4#text#42#<p>&nbsp;</p>     ^cY#v33
n1a21.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#9#5#text#42#<p>&nbsp;</p>     ^cY#v33
n1a21.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704010900071002001300180#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#10#6#text#42#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Nelson Hamerschlak </b></font></p>    
 ^cY#v33n1a21.htm##
00401000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704017100071002001300242#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#11#7#text#42#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Instituto Israelita de Ensino e Pesquisa 
Albert Einstein  IIEPAE São Paulo, (SP) Brazil</font></p>     ^cY#v33n1a21.htm#
#
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011500071002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#12#8#text#42#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></font></
p>     ^cY#v33n1a21.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#13#9#text#42#<p>&nbsp;</p>     ^cY#v3
3n1a21.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#14#10#text#42#<p>&nbsp;</p>     ^cY#v
33n1a21.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008000072002001300152#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#15#11#text#42#<p align="center"><img 
src="/img/revistas/rbhh/v33n1/a21img01.jpg"></p>     ^cY#v33n1a21.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#16#12#text#42#<p>&nbsp;</p>     ^cY#v
33n1a21.htm##
01653000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704142200072002001301494#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#17#13#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Clovis Pedro Junqueira, considered a liv
ing legend in transfusion medicine in Brazil died on October 2, 2011, at the age
 of 94 years. Until about 1 or 2 years ago, Professor Junqueira was still active
, receiving honors and being interviewed and consulted about the future of hemot
herapy in Brazil. He was seen in the library that bears his name at the headquar
ters of the Brazilian Society of Hematology and Hemotherapy (SBHH), studying, co
nsulting international journals and the internet in order to keep himself up to 
date. It could not have been different: all his lifetime, Professor Junqueira de
voted himself to transfusion medicine in Brazil; he scientifically and personall
y influenced several generations. The library of the SBHH should now receive in 
its collection, the books of this illustrious visitor, in fact many rare books i
n perfect condition were already donated while he was alive. Hematology will alw
ays have the works that he edited: 'the Essentials of Blood Transfusion', 'Peri-
Natal Hemolytic Disease' and last year with Jacob Rosenblit and myself, 'Clinica
l Transfusion Medicine', a book that summarizes his philosophy of changing the t
ransfusion medicine specialist inside the blood bank from someone who follows pr
escriptions to being active with colleagues of other specialties, and especially
 with his patients.</font></p>     ^cY#v33n1a21.htm##
00894000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704066300072002001300735#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#18#14#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Born in Sao Luiz, Maranh&atilde;o on Jun
e 1, 1916, he was still a child he moved with his family to Rio de Janeiro, the 
then capital of the country. His Portuguese father was hoping to find opportunit
ies in trade, but he became attracted to medicine and in 1939 he graduated at th
e National Medicine School of Brazil in Rio de Janeiro. He was a disciple of Wal
ter Oswaldo Cruz and his training included stints in England, Germany, Holland, 
France, Argentina and the United States, as he passed in first place in the Post
graduate Course in Hematology at the Oswaldo Cruz Institute.</font></p>     ^cY#
v33n1a21.htm##
00537000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704030600072002001300378#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#19#15#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In 1945, he began to devote himself to t
ransfusion medicine and founded a service in Rio de Janeiro. Later, he joined Pr
of. Dr. Hildebrando Monteiro Marinho, merging hematology and transfusion medicin
e into one single unit.</font></p>     ^cY#v33n1a21.htm##
00651000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704042000072002001300492#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#20#16#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">With Walter Oswaldo Cruz he gave the fir
st course of specialization in hematology in Manguinhos in 1949. In the same yea
r, he was one of the organizers of the First Paulista Congress of Hematology. Th
e event started on June 8, lasted four days and produced 30 recommendations, inc
luding the establishment of the First Brazilian Congress.</font></p>     ^cY#v33
n1a21.htm##
00942000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704071100072002001300783#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#21#17#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Along with Carlos da Silva Lacaz, Oswald
o Mellone and Michel Abu Jamra, he founded the Sociedade Brasileira de Hematolog
ia e Hemoterapia (Brazilian Society of Hematology and Hematology), scheduling th
e First Brazilian Hematology Congress for the 21 to 26 of May 1950, at which tim
e the society became official. Besides Pedro Junqueira Clovis, the organizing co
mmittee included Walter Oswaldo Cruz, Heraldo Maciel, Artur Cavalcante, Jo&atild
e;o Maia Mendon&ccedil;a, Frederico Ottensooser, Oswaldo Mellone, Michel Abu Jam
ra, Ruy Faria, Carlos da Silva Lacaz, Menandro Novaes, C&ocirc;rtes Villela and 
Carlos Estev&atilde;o Frimm.</font></p>     ^cY#v33n1a21.htm##
00797000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704056600072002001300638#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#22#18#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In 1951, Professor Junqueira presented p
apers on blood groups in Brazilian Indians in two international conferences in P
ortugal and Italy. In the same year, he participated in the creation of the Huma
n Genetics Commission of the Brazilian Society of Genetics. In 1954 he led the B
razilian delegation to the Fifth Congress of the International Society of Blood 
Transfusion held at the Sorbonne in Paris. That same year, he worked on projects
 together with Jean Dausset and AE Mourant.</font></p>     ^cY#v33n1a21.htm##
00682000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704045100072002001300523#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#23#19#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Professor Junqueira was elected presiden
t of the Brazilian Society of Hematology and Hemotherapy for two consecutive ter
ms; he worked very hard for the recognition of the specialty and was responsible
 for the acquisition of the Society's own headquarters. He was awarded honorary 
professor and honorary president of the Brazilian Society of Hematology and Hemo
therapy.</font></p>     ^cY#v33n1a21.htm##
00879000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704064800072002001300720#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#24#20#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">He also participated in several scientif
ic societies and other entities, as full member of the Brazilian College of Surg
eons, president of the Brazilian Society of Clinical Pathology, a member of the 
Advisory Board of the International Society of Blood Transfusion, member of the 
Human Genetics Commission of the Brazilian Society of Genetics, director of the 
Physician Continuous Education Center of the Department of Health, president of 
the Latin American Society of Hematology and a member of the Technical Division 
of Hematology of the National Health Council.</font></p>     ^cY#v33n1a21.htm##
01084000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704085300072002001300925#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#25#21#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Post-graduation professor of Hematology 
of PUC-RJ and former Regent Professor of Genetics, he gave six postgraduate cour
ses, 20 courses on hematology, more than 170 classes, with more than 42 courses 
in his curriculum. Additionally, he published more than 40 scientific papers in 
prominent journals. It is important to note that Professor Junqueira is one of t
he few Brazilians with publications in the journal Nature in which he published 
three papers. He wrote and translated books, wrote chapters in books and several
 monographs. He participated in 70 national and 27 international conferences, in
cluding 24 meetings of the American Association of Blood Banks. In these confere
nces, he presented a hundred papers, participated in 85 round tables and gave 35
 lectures.</font></p>     ^cY#v33n1a21.htm##
00809000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704057800072002001300650#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#26#22#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Throughout his career, he also received 
several other awards, including the Laboratory Prize of the Academic Society of 
Medicine and Surgery of Rio de Janeiro in 1939, the "Merit. Prof. Clementino Fra
ga" medal awarded by the Governor of Guanabara in 1974, Diploma of Great homage 
given by the Brazilian Society of Clinical Pathology, the title of Professor Eme
ritus of the Medical School of Teres&oacute;polis in 1987 and the Alfred Juazyko
wski Award by the National Academy of Medicine in 1998.</font></p>     ^cY#v33n1
a21.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704019500072002001300267#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#27#23#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In 1992, with a wonderful monograph on a
uto transfusion, he became a member of the National Academy of Medicine.</font><
/p>     ^cY#v33n1a21.htm##
00610000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704037900072002001300451#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#28#24#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In 2000, he was chairman of the XXIV Bra
zilian Congress of Hematology, celebrating the fiftieth anniversary of the Brazi
lian Society of Hematology and Hemotherapy. The competence and care, characteris
tics of Professor Junqueira were apparent in every detail of the scientific and 
social programs.</font></p>     ^cY#v33n1a21.htm##
00520000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704028900072002001300361#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#29#25#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">His contribution to Brazilian transfusio
n medicine was so important that, at this time, he was honored by our colleague 
Marcos Pimentel Alfredo with a book about his life called: The Trajectory of a M
aster.</font></p>     ^cY#v33n1a21.htm##
00654000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704042300072002001300495#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#30#26#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In 2008, during a hospital stay, he beca
me enthusiastic when he heard about the merger between the SBHH and the Brazilia
n College of Hematology to form the Brazilian Association of Hematology (ABHH). 
Even when Professor Junqueira was recovering from health problems, he did not fo
rget and even continued to influence decisions in his field.</font></p>     ^cY#
v33n1a21.htm##
00811000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704058000072002001300652#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#31#27#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">More important than everything else, mor
e important than any title or award, he was human; Clovis Pedro Junqueira, or Pi
erre Clochard as he liked to be called. Father, grandfather, loyal friend and wo
nderful husband, an enviable man of culture, fond of all the causes he embraced,
 he was an example and encouragement to us all. A fanatical supporter of Flameng
o Football Club, admirer of a good whiskey and fine wine, Mr. Junqueira was marr
ied to Norma, the secret to his everlasting youthfulness.</font></p>     ^cY#v33
n1a21.htm##
00457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022600072002001300298#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#32#28#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Professor Junqueira will always be remem
bered for his professional competence, wisdom, intellect, simplicity, humility a
nd his "joie de vivre."</font></p>     ^cY#v33n1a21.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#33#29#text#42#<p>&nbsp;</p>     ^cY#v
33n1a21.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#34#30#text#42#<p>&nbsp;</p>     ^cY#v
33n1a21.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018600072002001300258#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#35#31#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img src
="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b>    ^
cY#v33n1a21.htm##
00262000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003100072002001300103#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#36#32#text#42#<br> Nelson Hamerschlak
    ^cY#v33n1a21.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005900072002001300131#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#37#33#text#42#<br> Instituto de Ensin
o e Pesquisa Albert Einstein    ^cY#v33n1a21.htm##
00285000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005400072002001300126#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#38#34#text#42#<br> Av Albert Einstein
 627 sala 1203, Morumbi    ^cY#v33n1a21.htm##
00286000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005500072002001300127#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#39#35#text#42#<br> 05651-901 - S&atil
de;o Paulo (SP),  Brazil    ^cY#v33n1a21.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003400072002001300106#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#40#36#text#42#<br> Phone 55 11 3747-3
203    ^cY#v33n1a21.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008100072002001300153#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#41#37#text#42#<br> <a href="mailto:ha
mer@einstein.br">hamer@einstein.br</a></font></p>     ^cY#v33n1a21.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009100072002001300163#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#42#38#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Submitted: 1/24/2011    ^cY#v33n1a21.htm
##
00276000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004500072002001300117#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#43#39#text#42#<br> Accepted: 1/25/201
1 </font></p>     ^cY#v33n1a21.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#44#40#text#42#<p>&nbsp;</p>     ^cY#v
33n1a21.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#45#41#text#42#<p>&nbsp;</p>     ^cY#v
33n1a21.htm##
00454000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022300072002001300295#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a21.htm#S#p#46#42#text#42#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" target="_b
lank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_blank">ww
w.scielo.br/rbhh</a></font></p>     ^cY#v33n1a21.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v33n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a22.htm#S#o#1#1#text#1#20
110411#115608#v33n1a22.htm#40##
00737000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030002900106
03100030013503200020013806500090014001400090014903500100015812300020016823700270
0170012003700197010003100234070008500265002001300350#v33n1#V:\SciELO\serial\rbhh
\v33n1\markup\v33n1a22.htm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ILUS#21#RBHH370#nd#R
ev. Bras. Hematol. Hemoter.#33#1#20110200#^f82^l83#1516-8484#1#10.5581/1516-8484
.20110022#Professor Pedro Clóvis Junqueira^len#^rND^1A01^nNelson^sHamerschlak#In
stituto Israelita de Ensino e Pesquisa Albert Einstein^iA01^cSão Paulo^sSP^pBraz
il#v33n1a22.htm##
00744000000000373000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030002900106
03100030013503200020013806500090014001400090014903500100015812300020016823700270
0170012004400197010003100241070008500272002001300357#v33n1#V:\SciELO\serial\rbhh
\v33n1\markup\v33n1a22.htm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ILUS#21#RBHH370#nd#R
ev. Bras. Hematol. Hemoter.#33#1#20110200#^f82^l83#1516-8484#1#10.5581/1516-8484
.20110022#<b>Professor Pedro Clóvis Junqueira</b>^len#^rND^1A01^nNelson^sHamersc
hlak#Instituto Israelita de Ensino e Pesquisa Albert Einstein^iA01^cSão Paulo^sS
P^pBrazil#v33n1a22.htm##
00864000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000800108158000300116
03000280011903100030014703200020015006500090015201400090016103500100017012300020
0180237002700182012003700209010003100246070008700277002001300364008008900377#v33
n1#V:\SciELO\serial\rbhh\v33n1\markup\v33n1a22.htm#S#l#4#1#text#1#^mFeb.^a2011#o
a#en#br1.1#1#4.0#ilus#21#RBHH370#nd#Rev. bras. hematol. hemoter#33#1#20110200#^f
82^l83#1516-8484#1#10.5581/1516-8484.20110022#Professor Pedro Clóvis Junqueira^l
en#^rND^1A01^nNelson^sHamerschlak#^iA01^1Instituto Israelita de Ensino e Pesquis
a Albert Einstein^cSão Paulo^sSP^pBrazil#v33n1a22.htm#Internet^ihttp://www.sciel
o.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100021##
00349000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012000070002001300190#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#5#1#text#36#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>MEMORIAL LECTURE</b></fon
t></p>     ^cY#v33n1a22.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#6#2#text#36#<p>&nbsp;</p>     ^cY#v33
n1a22.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012600070002001300196#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#7#3#text#36#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Santiago Pavlovsky</b
></font></p>     ^cY#v33n1a22.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#8#4#text#36#<p>&nbsp;</p>     ^cY#v33
n1a22.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#9#5#text#36#<p>&nbsp;</p>     ^cY#v33
n1a22.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704010500071002001300176#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#10#6#text#36#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Jorge H. Milone</b></font></p>     ^cY
#v33n1a22.htm##
00364000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704013400071002001300205#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#11#7#text#36#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">President, Sociedad Argentina de Hematolo
g&iacute;a</font></p>     ^cY#v33n1a22.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011500071002001300186#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#12#8#text#36#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence</a></font></
p>     ^cY#v33n1a22.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#13#9#text#36#<p>&nbsp;</p>     ^cY#v3
3n1a22.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#14#10#text#36#<p>&nbsp;</p>     ^cY#v
33n1a22.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008000072002001300152#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#15#11#text#36#<p align="center"><img 
src="/img/revistas/rbhh/v33n1/a22img01.jpg"></p>     ^cY#v33n1a22.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#16#12#text#36#<p>&nbsp;</p>     ^cY#v
33n1a22.htm##
00514000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704028300072002001300355#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#17#13#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">A tireless worker, he promoted clinical 
research in Argentina and was well aware of how to accomplish and transmit warmt
h in medical treatment and excellence in scientific production to his disciples.
</font></p>     ^cY#v33n1a22.htm##
00548000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704031700072002001300389#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#18#14#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Born into a family of outstanding hemato
logists, Santiago graduated as a Medical Doctor at the University of Buenos Aire
s in 1964, and completed his postgraduate degree at the Hospital Saint Louis of 
Paris with Professor Jean Bernard.</font></p>     ^cY#v33n1a22.htm##
00749000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704051800072002001300590#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#19#15#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Once he returned to Argentina, after wor
king at the Instituto de Investigaciones Hematol&oacute;gicas, Academia Nacional
 de Medicina, he created the GATLA, Argentine Group for the treatment of Acute L
eukemia, a pioneering group in clinical research in Latin America, through which
 he made innovative worldwide contributions about Hodgkin's disease; improving c
are of patients in our country through the creation of treatment protocols.</fon
t></p>     ^cY#v33n1a22.htm##
00490000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704025900072002001300331#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#20#16#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">From 1983 to 1986, he coordinated from W
ashington the Collaborative Cancer Treatment Research Program of the National Ca
ncer Institute and the Pan American Health Organization.</font></p>     ^cY#v33n
1a22.htm##
00449000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704021800072002001300290#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#21#17#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">He was a Coordinator of International Af
fairs for the American Society of Clinical Oncology (ASCO) and the European Scho
ol of Oncology.</font></p>     ^cY#v33n1a22.htm##
00445000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704021400072002001300286#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#22#18#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Since 1989, he was the medical director 
of Fundaci&oacute;n para Combatir la Leucemia (Fundaleu), and then the scientifi
c director.</font></p>     ^cY#v33n1a22.htm##
00448000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704021700072002001300289#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#23#19#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Doctor Pavlovsky was an outstanding scie
ntist, who was a member of the most important medical societies of his specialty
 in the world.</font></p>     ^cY#v33n1a22.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704013900072002001300211#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#24#20#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">He published 144 scientific papers and 7
6 book chapters.</font></p>     ^cY#v33n1a22.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012200072002001300194#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#25#21#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">He was "Physician of the Year" in 2000.<
/font></p>     ^cY#v33n1a22.htm##
00615000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704038400072002001300456#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#26#22#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Disregarding his high academic level, he
 always managed to be not only side by side with his patients at his practice or
 through hospitalization, relieving and curing them, but also with his colleague
s and disciples, encouraging them to continuously surpass the struggle against m
alignant hemopathies.</font></p>     ^cY#v33n1a22.htm##
00485000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704025400072002001300326#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#27#23#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">He died last September 19<sup>th</sup>. 
The Argentinean hematological community will always remember him as one of the s
pecial figures in the development of the specialty.</font></p>     ^cY#v33n1a22.
htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#28#24#text#36#<p>&nbsp;</p>     ^cY#v
33n1a22.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#29#25#text#36#<p>&nbsp;</p>     ^cY#v
33n1a22.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018600072002001300258#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#30#26#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img src
="/img/revistas/rbhh/v33n1/seta.jpg" border="0"></a> <b>Correspondence:</b>    ^
cY#v33n1a22.htm##
00261000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003000072002001300102#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#31#27#text#36#<br>   Jorge H. Milone 
   ^cY#v33n1a22.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005300072002001300125#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#32#28#text#36#<br> Sociedad Argentina
 de Hematolog&iacute;a    ^cY#v33n1a22.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007500072002001300147#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#33#29#text#36#<br> Julian Alvarez 146
  Ciudad Aut&oacute;noma de BS As  Argentina    ^cY#v33n1a22.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004000072002001300112#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#34#30#text#36#<br> Phone: 54 11 4855 
2452/2485    ^cY#v33n1a22.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007900072002001300151#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#35#31#text#36#<br> <a href="mailto:it
no@netverk.com">itno@netverk.com</a></font></p>     ^cY#v33n1a22.htm##
00323000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009200072002001300164#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#36#32#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Submitted: 12/27/2010    ^cY#v33n1a22.ht
m##
00277000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004600072002001300118#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#37#33#text#36#<br> Accepted: 12/28/20
10 </font></p>     ^cY#v33n1a22.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#38#34#text#36#<p>&nbsp;</p>     ^cY#v
33n1a22.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#39#35#text#36#<p>&nbsp;</p>     ^cY#v
33n1a22.htm##
00455000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704022400072002001300296#v33n1#V:\SciELO
\serial\rbhh\v33n1\markup\v33n1a22.htm#S#p#40#36#text#36#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a href="http://www.rbhh.org" target="_b
lank">www.rbhh.org</a> or <a href="http://www.scielo.br/rbhh" target="_blank">ww
w.scielo.br/rbhh</a> </font></p>     ^cY#v33n1a22.htm##
